PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dunn, DE; Tanawattanacharoen, P; Boccuni, P; Nagakura, S; Green, SW; Kirby, MR; Kumar, MSA; Rosenfeld, S; Young, NS				Dunn, DE; Tanawattanacharoen, P; Boccuni, P; Nagakura, S; Green, SW; Kirby, MR; Kumar, MSA; Rosenfeld, S; Young, NS			Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED APLASTIC-ANEMIA; MYELODYSPLASTIC SYNDROMES; FLOW-CYTOMETRY; MONOCLONAL-ANTIBODIES; ANCHORED PROTEINS; PATHOGENETIC LINK; PNH PHENOTYPE; DEFICIENCY; DIAGNOSIS; DISEASE	Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem-cell disorder in which the affected cells are deficient in glycosylphosphatidylinositol (GPI)-anchored proteins. Paroxysmal nocturnal hemoglobinuria is frequently associated with aplastic anemia, although the basis of this relation is unknown. Objective: To assess the PNH status of patients with diverse marrow failure syndromes. Design: Correlation of cytofluorometric data with clinical features. Setting: Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland. Patients: 115 patients with aplastic anemia, 39 patients with myelodysplasia, 28 patients who had recently undergone bone marrow transplantation, 18 patients with cancer that was treated with chemotherapy, 13 patients with large granular lymphocytosis, 20 controls who had received renal allografts, and 21 healthy participants. Intervention: Patients with aplastic anemia, myelodysplasia, or renal allografts received antithymocyte globulin. Measurements: Flow cytometry was used to assess expression of GPI-anchored proteins on granulocytes. Results: Evidence of PNH was found in 25 of 115 (22%) patients with aplastic anemia. No patient with normal CPI-anchored protein expression at presentation developed PNH after therapy (n = 16). Nine of 39 (23%) patients with myelodysplasia had CPI-anchored protein-deficient cells. Abnormal cells were not detected in patients with constitutional or other forms of bone marrow failure or in renal allograft recipients who had received antithymocyte globulin. Aplastic anemia is known to respond to immunosuppressive therapy; in myelodysplasia, the presence of a PNH population was strongly correlated with hematologic improvement after administration of antithymocyte globulin (P = 0.0015). Conclusions: Flow cytometric analysis is superior to the Ham test and permits concomitant diagnosis of PNH in about 20% of patients with myelodysplasia (a rate similar to that seen in patients with aplastic anemia). The presence of GPI-anchored protein-deficient cells in myelodysplasia predicts responsiveness to immunosuppressive therapy. Early emergence of GPI-anchored protein-deficient hematopoiesis in a patient with marrow failure may point to an underlying immune pathogenesis.	NHLBI, Bethesda, MD 20892 USA; MCP Hahnemann Univ Hosp, Philadelphia, PA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Drexel University	Dunn, DE (corresponding author), 309 E Osceola St,Suite 208, Stuart, FL 34994 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002315, ZIAHL002315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfinito F, 1996, LEUKEMIA, V10, P1326; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Aul C, 1998, LEUKEMIA RES, V22, P93, DOI 10.1016/S0145-2126(97)00089-1; CONRAD ME, 1979, AM J HEMATOL, V7, P61, DOI 10.1002/ajh.2830070108; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; Dunn DE, 1997, BLOOD, V90, P1811; GRAHAM DL, 1992, AM J MED, V93, P671, DOI 10.1016/0002-9343(92)90201-L; GRISCELLIBENNACEUR A, 1995, BLOOD, V85, P1354, DOI 10.1182/blood.V85.5.1354.bloodjournal8551354; Hall SE, 1996, BLOOD, V87, P5332, DOI 10.1182/blood.V87.12.5332.bloodjournal87125332; HERTENSTEIN B, 1995, BLOOD, V86, P1487, DOI 10.1182/blood.V86.4.1487.bloodjournal8641487; IWAMOTO N, 1995, BLOOD, V85, P2228, DOI 10.1182/blood.V85.8.2228.bloodjournal8582228; Iwanaga M, 1998, BRIT J HAEMATOL, V102, P465, DOI 10.1046/j.1365-2141.1998.00794.x; Jonasova A, 1998, BRIT J HAEMATOL, V100, P304, DOI 10.1046/j.1365-2141.1998.00551.x; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1996, ANNU REV MED, V47, P1; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOUGHRAN TP, 1993, BLOOD, V82, P1; Luzzatto L, 1996, Curr Opin Hematol, V3, P101; Molldrem JJ, 1997, BRIT J HAEMATOL, V99, P699, DOI 10.1046/j.1365-2141.1997.4423249.x; Nagakura S, 1997, INT J HEMATOL, V65, P187; NAKAKUMA H, 1995, BLOOD, V85, P1371, DOI 10.1182/blood.V85.5.1371.bloodjournal8551371; NISSEN C, 1986, BRIT J HAEMATOL, V64, P355, DOI 10.1111/j.1365-2141.1986.tb04129.x; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; Raza A, 1996, LEUKEMIA, V10, P1648; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Rosti V, 1997, J CLIN INVEST, V100, P1028, DOI 10.1172/JCI119613; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; SCHREZENMEIER H, 1995, EXP HEMATOL, V23, P81; SCHUBERT J, 1991, BRIT J HAEMATOL, V79, P487, DOI 10.1111/j.1365-2141.1991.tb08060.x; SHICHISHIMA T, 1993, BRIT J HAEMATOL, V85, P378, DOI 10.1111/j.1365-2141.1993.tb03182.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; TERSTAPPEN LWMM, 1992, J LEUKOCYTE BIOL, V52, P652, DOI 10.1002/jlb.52.6.652; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; VANKAMP H, 1994, BRIT J HAEMATOL, V87, P399, DOI 10.1111/j.1365-2141.1994.tb04929.x; WARE RE, 1991, NEW ENGL J MED, V325, P991, DOI 10.1056/NEJM199110033251403; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Young NS, 1999, JAMA-J AM MED ASSOC, V282, P271, DOI 10.1001/jama.282.3.271; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385	41	210	219	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					401	408		10.7326/0003-4819-131-6-199909210-00002	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498555				2022-12-28	WOS:000082641100001
J	Treasure, T				Treasure, T			Rethink on biological aortic valves for the elderly	LANCET			English	Editorial Material							HEART-VALVE		Univ London St Georges Hosp, Cardiothorac Unit, London SW17 0QT, England	St Georges University London	Treasure, T (corresponding author), Univ London St Georges Hosp, Cardiothorac Unit, London SW17 0QT, England.							BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; Bouma BJ, 1999, HEART, V82, P143, DOI 10.1136/hrt.82.2.143; Gilbert T, 1999, HEART, V82, P138, DOI 10.1136/hrt.82.2.138; HAMMERMEISTER KE, 1993, NEW ENGL J MED, V328, P1289, DOI 10.1056/NEJM199305063281801; HUYSMANS HA, 1999, STENTLESS BIOPROSTHE; Peterseim DS, 1999, J THORAC CARDIOV SUR, V117, P890, DOI 10.1016/S0022-5223(99)70368-5; Senthilnathan V, 1999, CARDIOVASC SURG, V7, P393, DOI 10.1016/S0967-2109(99)00026-5; TREASURE T, 1990, LANCET, V336, P1115, DOI 10.1016/0140-6736(90)92583-4; TREASURE T, 1995, CURR OPIN CARDIOL, V10, P144, DOI 10.1097/00001573-199503000-00008; *UK HEART VALV REG, 1999, UK HEART VALV REG RE	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					964	965		10.1016/S0140-6736(99)00198-1	http://dx.doi.org/10.1016/S0140-6736(99)00198-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501351				2022-12-28	WOS:000082596000002
J	Huang, ZJ; Kirkwood, A; Pizzorusso, T; Porciatti, V; Morales, B; Bear, MF; Maffei, L; Tonegawa, S				Huang, ZJ; Kirkwood, A; Pizzorusso, T; Porciatti, V; Morales, B; Bear, MF; Maffei, L; Tonegawa, S			BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex	CELL			English	Article							LONG-TERM POTENTIATION; GAMMA-AMINOBUTYRIC-ACID; NERVE GROWTH-FACTOR; DEVELOPING NEUROMUSCULAR SYNAPSES; EXPERIENCE-DEPENDENT PLASTICITY; NEUROTROPHIC FACTOR; MONOCULAR DEPRIVATION; SYNAPTIC PLASTICITY; MESSENGER-RNA; RAT-BRAIN	Maturation of the visual cortex is influenced by visual experience during an early postnatal period. The factors that regulate such a critical period remain unclear. We examined the maturation and plasticity of the visual cortex in transgenic mice in which the postnatal rise of brain-derived neurotrophic factor (BDNF) was accelerated. In these mice, the maturation of GABAergic innervation and inhibition was accelerated. Furthermore, the age-dependent decline of cortical longterm potentiation induced by white matter stimulation, a form of synaptic plasticity sensitive to cortical inhibition, occurred earlier. Finally, transgenic mice showed a precocious development of visual acuity and an earlier termination of the critical period for ocular dominance plasticity. We propose that BDNF promotes the maturation of cortical inhibition during early postnatal life, thereby regulating the critical period for visual cortical plasticity.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA; CNR, Ist Neurofisiol, I-56127 Pisa, Italy; Scuola Normale Super Pisa, I-56127 Pisa, Italy; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Scuola Normale Superiore di Pisa; Brown University	Tonegawa, S (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.	tonegawa@mit.edu	Pizzorusso, Tommaso/D-1399-2013	Pizzorusso, Tommaso/0000-0001-5614-0668; Porciatti, Vittorio/0000-0002-1592-3532; Bear, Mark/0000-0002-9903-2541; Huang, Z. Josh/0000-0003-0592-028X	NATIONAL EYE INSTITUTE [R01EY012124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY12124-01] Funding Source: Medline; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaneya Y, 1997, J NEUROSCI, V17, P6707; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BENEVENTO LA, 1992, BRAIN RES, V572, P198, DOI 10.1016/0006-8993(92)90470-T; BENEVENTO LA, 1995, BRAIN RES, V689, P172, DOI 10.1016/0006-8993(95)00553-3; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BIRCH D, 1979, VISION RES, V19, P933, DOI 10.1016/0042-6989(79)90029-4; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOOTHE RG, 1985, ANNU REV NEUROSCI, V8, P495, DOI 10.1146/annurev.ne.08.030185.002431; BOZZI Y, 1995, NEUROSCIENCE, V69, P1133, DOI 10.1016/0306-4522(95)00321-9; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CAMPBELL FW, 1965, J PHYSIOL-LONDON, V181, P576, DOI 10.1113/jphysiol.1965.sp007784; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; Cellerino A, 1996, EUR J NEUROSCI, V8, P1190, DOI 10.1111/j.1460-9568.1996.tb01287.x; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; COHENCORY S, 1991, J NEUROSCI, V11, P462; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DELRIO JA, 1994, DEV BRAIN RES, V81, P247, DOI 10.1016/0165-3806(94)90311-5; DELRIO JA, 1992, J COMP NEUROL, V326, P501, DOI 10.1002/cne.903260403; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DRAGER UC, 1975, J COMP NEUROL, V160, P269, DOI 10.1002/cne.901600302; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; Dupuy ST, 1996, J NEUROSCI, V16, P6919; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834, DOI 10.1523/JNEUROSCI.14-03-01834.1994; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREEMAN DN, 1975, NATURE, V254, P614, DOI 10.1038/254614a0; Galuske RAW, 1996, EUR J NEUROSCI, V8, P1554, DOI 10.1111/j.1460-9568.1996.tb01618.x; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gianfranceschi L, 1999, VISION RES, V39, P569, DOI 10.1016/S0042-6989(98)00169-2; Gonchar Y, 1997, CEREB CORTEX, V7, P347, DOI 10.1093/cercor/7.4.347; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gorba T, 1999, EUR J NEUROSCI, V11, P1179, DOI 10.1046/j.1460-9568.1999.00551.x; Gordon JA, 1996, J NEUROSCI, V16, P3274; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; HICKS TP, 1983, BRAIN RES, V274, P160, DOI 10.1016/0006-8993(83)90533-4; Huber KM, 1998, NEUROPHARMACOLOGY, V37, P571, DOI 10.1016/S0028-3908(98)00050-1; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; Liu XB, 1996, P NATL ACAD SCI USA, V93, P7332, DOI 10.1073/pnas.93.14.7332; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; Marty S, 1996, J NEUROSCI, V16, P675; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Micheva KD, 1997, CAN J PHYSIOL PHARM, V75, P470, DOI 10.1139/cjpp-75-5-470; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; NAWA H, 1994, J NEUROSCI, V14, P3751; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; PERKINS AT, 1988, BRAIN RES, V439, P222; PORCIATTI V, 1999, IN PRESS VISION RES; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SILLITO AM, 1979, J PHYSIOL-LONDON, V289, P33, DOI 10.1113/jphysiol.1979.sp012723; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG T, 1995, J NEUROSCI, V15, P4796; WIDMER HR, 1994, DEV BRAIN RES, V80, P279, DOI 10.1016/0165-3806(94)90114-7; WOLFF JR, 1984, NEUROSCI LETT, V47, P207, DOI 10.1016/0304-3940(84)90515-9; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	86	896	904	2	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					739	755		10.1016/S0092-8674(00)81509-3	http://dx.doi.org/10.1016/S0092-8674(00)81509-3			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499792	Bronze			2022-12-28	WOS:000082679200002
J	Moore, T				Moore, T			Shape representations and visual guidance sf saccadic eye movements	SCIENCE			English	Article							CORTEX; MACAQUE; CONNECTIONS; POSITION; FIELD	One hallmark of primate vision is that the direction of gaze is constantly shifting to position objects of interest appropriately on the fovea, where visual acuity is greatest. This process most involve the close cooperation of oculomotor and Visual recognition mechanisms because visual details must be translated into specific motor commands. This paper describes the correspondence between the presaccadic activity of V4 neurons and the degree of visual guidance of saccadic eye movements to objects of different form. The results suggest that neurons that participate in coding visual stimuli are also involved in guiding the eyes to prominent features of objects.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Moore, T (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	tirin@princeton.edu			NEI NIH HHS [EY0067] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1980, BRAIN RES, V184, P41, DOI 10.1016/0006-8993(80)90586-7; FISCHER B, 1981, EXP BRAIN RES, V44, P129; FRIES W, 1984, J COMP NEUROL, V230, P55, DOI 10.1002/cne.902300106; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Groh JM, 1997, J NEUROSCI, V17, P4312; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Moore T, 1998, P NATL ACAD SCI USA, V95, P8981, DOI 10.1073/pnas.95.15.8981; ROBINSON DA, 1964, J PHYSIOL-LONDON, V174, P245, DOI 10.1113/jphysiol.1964.sp007485; SCHALL JD, 1995, J NEUROSCI, V15, P4464; Thier P, 1998, J NEUROPHYSIOL, V80, P1713, DOI 10.1152/jn.1998.80.4.1713; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; VITU F, 1990, PERCEPT PSYCHOPHYS, V47, P583, DOI 10.3758/BF03203111; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; Zipser K, 1996, J NEUROSCI, V16, P7376	18	67	67	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1914	1917		10.1126/science.285.5435.1914	http://dx.doi.org/10.1126/science.285.5435.1914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489371				2022-12-28	WOS:000082638300051
J	Lijmer, JG; Mol, BW; Heisterkamp, S; Bonsel, GJ; Prins, MH; van der Meulen, JHP; Bossuyt, PMM				Lijmer, JG; Mol, BW; Heisterkamp, S; Bonsel, GJ; Prins, MH; van der Meulen, JHP; Bossuyt, PMM			Empirical evidence of design-related bias in studies of diagnostic tests	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIPHERAL ARTERIAL-DISEASE; MEDICAL LITERATURE; SCREENING-TESTS; TEST ACCURACY; USERS GUIDES; ROC ANALYSIS; METAANALYSIS; VERIFICATION; ARTICLE; QUALITY	Context The literature contains a large number of potential biases in the evaluation of diagnostic tests. Strict application of appropriate methodological criteria would invalidate the clinical application of most study results. Objective To empirically determine the quantitative effect of study design shortcomings on estimates of diagnostic accuracy. Design and Setting Observational study of the methodological features of 184 original studies evaluating 218 diagnostic tests. Meta-analyses on diagnostic tests were identified through a systematic search of the literature using MEDLINE, EMBASE, and DARE databases and the Cochrane Library (1996-1997). Associations between study characteristics and estimates of diagnostic accuracy were evaluated with a regression model. Main Outcome Measures Relative diagnostic odds ratio (RDOR), which compared the diagnostic odds ratios of studies of a given test that lacked a particular methodological feature with those without the corresponding shortcomings in design. Results Fifteen (6.8%) of 218 evaluations met all 8 criteria; 64 (30%) met 6 or more. Studies evaluating tests in a diseased population and a separate control group overestimated the diagnostic performance compared with studies that used a clinical population (RDOR, 3.0; 95% confidence interval [CI], 2.0-4.5), Studies in which different reference tests were used for positive and negative results of the test under study overestimated the diagnostic performance compared with studies using a single reference test for all patients (RDOR, 2.2; 95% CI, 1.5-3.3). Diagnostic performance was also overestimated when the reference test was interpreted with knowledge of the test result (RDOR, 1.3;95% CI, 1.0-1.9), when no criteria for the test were described (RDOR, 1.7, 95% CI, 1.1-2.5), and when no description of the population under study was provided (RDOR, 1.4; 95% CI, 1.1-1.7). Conclusion These data provide empirical evidence that diagnostic studies with methodological shortcomings may overestimate the accuracy of a diagnostic test, particularly those including nonrepresentative patients or applying different reference standards.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Lijmer, JG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Mol, Ben/I-4526-2012; Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; van der Meulen, Jan/0000-0002-9451-2335				Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; DETRANO R, 1989, PROG CARDIOVASC DIS, V32, P173, DOI 10.1016/0033-0620(89)90025-X; deVries SO, 1996, ACAD RADIOL, V3, P361, DOI 10.1016/S1076-6332(96)80257-1; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P597; Greenhalgh T, 1997, BRIT MED J, V315, P540, DOI 10.1136/bmj.315.7107.540; Griner P F, 1981, Ann Intern Med, V94, P557; HALDANE JBS, 1955, ANN HUM GENET, V20, P309; HALLER DG, 1996, P AN M AM SOC CLIN, V15, P486; Huicho L, 1996, PEDIATR INFECT DIS J, V15, P486, DOI 10.1097/00006454-199606000-00004; HUNINK MGM, 1990, MED DECIS MAKING, V10, P201, DOI 10.1177/0272989X9001000307; IRWIG L, 1995, J CLIN EPIDEMIOL, V48, P119, DOI 10.1016/0895-4356(94)00099-C; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Kraemer HC., 1992, EVALUATING MED TESTS, P103; Lijmer JG, 1996, ULTRASOUND MED BIOL, V22, P391, DOI 10.1016/0301-5629(96)00036-1; LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408; Mirvis SE, 1996, RADIOLOGY, V200, P413, DOI 10.1148/radiology.200.2.8685335; Mol BWJ, 1997, FERTIL STERIL, V67, P1031, DOI 10.1016/S0015-0282(97)81435-5; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MULROW CD, 1989, J GEN INTERN MED, V4, P288, DOI 10.1007/BF02597398; PANZER RJ, 1987, MED DECIS MAKING, V7, P115, DOI 10.1177/0272989X8700700209; QUINN MF, 1989, MED DECIS MAKING, V9, P196, DOI 10.1177/0272989X8900900308; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Reed WW, 1996, WESTERN J MED, V165, P197; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; SACKETT DL, 1991, CLIN EPIDEMIOLOGY, P47; Scheidler J, 1997, JAMA-J AM MED ASSOC, V278, P1096, DOI 10.1001/jama.278.13.1096; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SiegmanIgra Y, 1997, J CLIN MICROBIOL, V35, P928, DOI 10.1128/JCM.35.4.928-936.1997; Smith ER, 1996, CLIN LAB MAN REV, V10, P176; Stoffers HEJH, 1996, J CLIN EPIDEMIOL, V49, P1401, DOI 10.1016/S0895-4356(96)00275-2; VANDERSCHOUW YT, 1995, INVEST RADIOL, V30, P334, DOI 10.1097/00004424-199506000-00002; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	38	1332	1354	2	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1061	1066		10.1001/jama.282.11.1061	http://dx.doi.org/10.1001/jama.282.11.1061			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493205	Bronze			2022-12-28	WOS:000082512300030
J	Sabapathy, PB; Sharma, AK				Sabapathy, PB; Sharma, AK			Our most unforgettable error - Always take a proper drug history	BRITISH MEDICAL JOURNAL			English	Article													Sharma, Ajay Kumar/HHC-1334-2022						0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					696	696		10.1136/bmj.319.7211.696	http://dx.doi.org/10.1136/bmj.319.7211.696			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480830	Green Published			2022-12-28	WOS:000082636800029
J	Rubenfire, M				Rubenfire, M			Update in cardiology	ANNALS OF INTERNAL MEDICINE			English	Article							PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; CORONARY HEART-DISEASE; C-REACTIVE PROTEIN; CHOLESTEROL; RISK; PREVENTION; WOMEN; MEN; HDL		Univ Michigan, Ann Arbor, MI 48106 USA	University of Michigan System; University of Michigan	Rubenfire, M (corresponding author), Univ Michigan, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA.							Altkorn D, 1999, ANN INTERN MED, V131, P199, DOI 10.7326/0003-4819-131-3-199908030-00007; Bonow RO, 1998, CIRCULATION, V98, P1949, DOI 10.1161/01.CIR.98.18.1949; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Strom BL, 1998, ANN INTERN MED, V129, P761, DOI 10.7326/0003-4819-129-10-199811150-00002; Superko HR, 1996, CIRCULATION, V94, P2351, DOI 10.1161/01.CIR.94.10.2351; Topol E, 1998, NEW ENGL J MED, V339, P436; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293	16	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					356	362		10.7326/0003-4819-131-5-199909070-00007	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475889				2022-12-28	WOS:000082458500006
J	Chappell, LC; Seed, PT; Briley, AL; Kelly, FJ; Lee, R; Hunt, BJ; Parmar, K; Bewley, SJ; Shennan, AH; Steer, PJ; Poston, L				Chappell, LC; Seed, PT; Briley, AL; Kelly, FJ; Lee, R; Hunt, BJ; Parmar, K; Bewley, SJ; Shennan, AH; Steer, PJ; Poston, L			Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; VITAMIN-E; ALPHA-TOCOPHEROL; ASCORBIC-ACID; NORMAL PREGNANCIES; DIASTOLIC NOTCH; PLACENTAL BED; PREECLAMPSIA; SUPPLEMENTATION; OXIDATION	Background Oxidative stress has been implicated in the pathophysiology of preeclampsia. This randomised controlled trial investigated the effect of supplementation with vitamins 0 and E in women at increased risk of the disorder on plasma markers of vascular endothelial activation and placental insufficiency and the occurrence of pre-eclampsia. Methods 283 women were identified as being at increased risk of preeclampsia by abnormal two-stage uterine-artety doppler analysis or a previous history of the disorder and were randomly assigned vitamin C (1000 mg/day) and vitamin E (400 IU/day) or placebo at 16-22 weeks' gestation. Plasma markers of endothelial activation (plasminogen-activator inhibitor 1 [PAI-1]) and placental dysfunction (PAI-2) were measured every month until delivery. Preeclampsia was assessed by the development of proteinuric hypertension. Analyses were done by intention to treat, and in the cohort who completed the study. Findings Supplementation with vitamins C and E was associated with a 21% decrease in the PAI-1/PAI-2 ratio during gestation (95% CI 4-35, p=0.015). In the intention-to-treat cohort, preeclampsia occurred in 24 (17%) of 142 women in the placebo group and 11 (8%) of 141 in the vitamin group (adjusted odds ratio 0.39 [0.17-0.90], p=0.02). In the cohort who completed the study (81 placebo group, 79 vitamin group), the odds ratio for preeclampsia was 0 24 (0.08-0.70, p=0.002). Interpretation Supplementation with vitamins C and E may be beneficial in the prevention of preeclampsia in women at increased risk of the disease. Multicentre trials are needed to show whether vitamin supplementation affects the occurrence of preeclampsia in low-risk women and to confirm our results in larger groups of high-risk women from different populations.	St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Obstet & Gynaecol, Fetal Hlth Res Grp, London SE1 7EH, England; St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Haematol, London SE1 7EH, England; St Thomas Hosp, Guys Kings & St Thomas Sch Med, Ctr Cardiovasc Biol & Med, London SE1 7EH, England; St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 7EH, England; Chelsea & Westminster Hosp, Imperial Coll Sch Med, Dept Maternal Fetal Med, London, England; Guys & St Thomas Hosp, Dept Obstet, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Poston, L (corresponding author), St Thomas Hosp, Guys Kings & St Thomas Sch Med, Dept Obstet & Gynaecol, Fetal Hlth Res Grp, London SE1 7EH, England.		Kelly, Frank J/C-6125-2009; Briley, Annette/N-1704-2019; Seed, Paul T/C-4435-2008; Briley, Annette/AAZ-5305-2020	Kelly, Frank J/0000-0003-2558-8392; Seed, Paul T/0000-0001-7904-7933; Briley, Annette/0000-0002-4266-920X; Shennan, Andrew/0000-0001-5273-3132; bewley, susan/0000-0001-8064-652X				ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; Barden A, 1996, CLIN SCI, V91, P711, DOI 10.1042/cs0910711; BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; BOWER S, 1993, OBSTET GYNECOL, V82, P78; BROWN RK, 1994, PEDIATR RES, V36, P487, DOI 10.1203/00006450-199410000-00013; CAMPBELL DM, 1985, BRIT J OBSTET GYNAEC, V92, P131, DOI 10.1111/j.1471-0528.1985.tb01064.x; Caritis S, 1998, AM J OBSTET GYNECOL, V179, P946, DOI 10.1016/S0002-9378(98)70194-2; CHAN AC, 1993, CAN J PHYSIOL PHARM, V71, P725, DOI 10.1139/y93-109; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Davidge ST, 1998, SEMIN REPROD ENDOCR, V16, P65, DOI 10.1055/s-2007-1016254; Dekker GA, 1998, AM J OBSTET GYNECOL, V179, P1359, DOI 10.1016/S0002-9378(98)70160-7; Devaraj S, 1997, ARTERIOSCL THROM VAS, V17, P2273, DOI 10.1161/01.ATV.17.10.2273; Fuller CJ, 1996, ATHEROSCLEROSIS, V119, P139, DOI 10.1016/0021-9150(95)05659-9; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Gulmezoglu AM, 1997, BRIT J OBSTET GYNAEC, V104, P689, DOI 10.1111/j.1471-0528.1997.tb11979.x; HALLIGAN A, 1994, BRIT J OBSTET GYNAEC, V101, P488, DOI 10.1111/j.1471-0528.1994.tb13147.x; Higgins JR, 1997, BRIT J OBSTET GYNAEC, V104, P356, DOI 10.1111/j.1471-0528.1997.tb11468.x; Hubel CA, 1996, AM J OBSTET GYNECOL, V174, P975, DOI 10.1016/S0002-9378(96)70336-8; JIALAL I, 1992, J LIPID RES, V33, P899; JOHNSON L, 1995, J PEDIATR-US, V127, P632, DOI 10.1016/S0022-3476(95)70129-X; KELLY FJ, 1990, BRIT J NUTR, V63, P631, DOI 10.1079/BJN19900149; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; LEWIS G, 1998, WHY MOTHERS DIE REPO; Lie RT, 1998, BRIT MED J, V316, P1343, DOI 10.1136/bmj.316.7141.1343; LIN S, 1995, OBSTET GYNECOL, V85, P760, DOI 10.1016/0029-7844(95)00020-R; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; MEEKINS JW, 1994, BRIT J OBSTET GYNAEC, V101, P669, DOI 10.1111/j.1471-0528.1994.tb13182.x; Meis PJ, 1998, AM J OBSTET GYNECOL, V178, P562, DOI 10.1016/S0002-9378(98)70439-9; MIKHAIL MS, 1994, AM J OBSTET GYNECOL, V171, P150, DOI 10.1016/0002-9378(94)90462-6; MINO M, 1973, J NUTR SCI VITAMINOL, V19, P475, DOI 10.3177/jnsv.19.475; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; Ochi H, 1998, BRIT J OBSTET GYNAEC, V105, P1118, DOI 10.1111/j.1471-0528.1998.tb09946.x; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; REITH A, 1993, BRIT J OBSTET GYNAEC, V100, P370, DOI 10.1111/j.1471-0528.1993.tb12982.x; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P1024, DOI 10.1016/S0002-9378(96)80046-9; SENN SJ, 1989, STAT MED, V8, P797; Sibai BM, 1998, AM J OBSTET GYNECOL, V179, P1275, DOI 10.1016/S0002-9378(98)70146-2; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STRATTA P, 1994, GYNECOL OBSTET INVES, V37, P246, DOI 10.1159/000292570; Wang YP, 1996, J SOC GYNECOL INVEST, V3, P179, DOI 10.1016/1071-5576(96)00015-9	44	596	624	2	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					810	816		10.1016/S0140-6736(99)80010-5	http://dx.doi.org/10.1016/S0140-6736(99)80010-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485722				2022-12-28	WOS:000082400700009
J	Roberts, JM; Hubel, CA				Roberts, JM; Hubel, CA			Is oxidative stress the link in the two-stage model of pre-eclampsia?	LANCET			English	Editorial Material							PREGNANCY; HYPERTENSION; PREECLAMPSIA		Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Roberts, JM (corresponding author), Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15213 USA.							Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585, DOI 10.1016/0002-9378(93)90499-9; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; HUBEL CA, 1997, FETAL MATERNAL MED R, V9, P73; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Ness RB, 1996, AM J OBSTET GYNECOL, V175, P1365, DOI 10.1016/S0002-9378(96)70056-X; Page EW, 1939, AM J OBSTET GYNECOL, V37, P291; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5	11	280	290	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					788	789		10.1016/S0140-6736(99)80002-6	http://dx.doi.org/10.1016/S0140-6736(99)80002-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485715				2022-12-28	WOS:000082400700002
J	Cregan, RF; Mangan, BJ; Knight, JC; Birks, TA; Russell, PS; Roberts, PJ; Allan, DC				Cregan, RF; Mangan, BJ; Knight, JC; Birks, TA; Russell, PS; Roberts, PJ; Allan, DC			Single-mode photonic band gap guidance of light in air	SCIENCE			English	Article							OPTICAL-FIBER; GLASS	The confinement of light within a hollow core;(a Large air hole) in a silica-air photonic crystal fiber is demonstrated. Only certain wavelength bands are confined and guided down the fiber, each band corresponding to the presence of a full two-dimensional band gap in the photonic crystal cladding. Single-mode vacuum waveguides have a multitude of potential applications from ultrahigh-power transmission to the guiding of cold atoms.	Univ Bath, Optoelect Grp, Bath BA2 7AY, Avon, England; Def Evaluat & Res Agcy, Malvern WR14 7HR, Worcs, England; Corning Inc, Corning, NY 14831 USA	University of Bath; Corning Inc; State University of New York (SUNY) System; SUNY Community College	Russell, PS (corresponding author), Univ Bath, Optoelect Grp, Bath BA2 7AY, Avon, England.	pyspsjr@bath.ac.uk	Knight, Jonathan C/D-3879-2011; Birks, Tim A/GNW-3099-2022; Russell, Philip St.J./G-5132-2012	Knight, Jonathan C/0000-0002-0802-8804; Russell, Philip St.J./0000-0002-8972-2477; Birks, Tim/0000-0001-7984-4932				Birks TA, 1997, OPT LETT, V22, P961, DOI 10.1364/OL.22.000961; BIRKS TA, 1995, ELECTRON LETT, V31, P1941, DOI 10.1049/el:19951306; Birks TA, 1996, NATO ADV SCI INST SE, V315, P437; Dai JW, 1997, APPL OPTICS, V36, P5072, DOI 10.1364/AO.36.005072; Knight JC, 1998, SCIENCE, V282, P1476, DOI 10.1126/science.282.5393.1476; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Knight JC, 1997, OPT LETT, V22, P484, DOI 10.1364/OL.22.000484; MARCATILI EAJ, 1964, AT&T TECH J, V43, P1783, DOI 10.1002/j.1538-7305.1964.tb04108.x; RUSSELL RS, 1995, CONFINED ELECT PHOTO, P585; Schnurer M, 1998, APPL PHYS B-LASERS O, V67, P263, DOI 10.1007/s003400050504; Snyder A. W., 1983, WAVEGUIDE THEORY; TONUCCI RJ, 1992, SCIENCE, V258, P783, DOI 10.1126/science.258.5083.783	12	1510	1730	22	355	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1537	1539		10.1126/science.285.5433.1537	http://dx.doi.org/10.1126/science.285.5433.1537			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477511				2022-12-28	WOS:000082359500056
J	Marshall, CA; Largo, HR				Marshall, CA; Largo, HR			Disability and rehabilitation: a context for understanding the American Indian experience	LANCET			English	Article									No Arizona Univ, Amer Indian Rehabil Res & Training Ctr, Flagstaff, AZ 86011 USA	Northern Arizona University	Marshall, CA (corresponding author), 4043 E Alhambra Pl, Tucson, AZ 85711 USA.							*CAP TRAB, 1996, C MEX US DEP ED AUG; MARSHALL CA, 1992, J REHABIL, V58, P13; MARSHALL CA, 1998, EVALUATION COUNSELOR; MARSHALL CA, 1998, VECINOS REHABILITATI; MARSHALL CA, 1994, AM INDIAN FAMILY SUP; MARSHALL CA, 1993, J VOCATIONAL REHABIL, V3, P12; MARSHALL CA, 1992, REPLICATION MODEL DE; Triandis HC, 1996, AM PSYCHOL, V51, P407, DOI 10.1037/0003-066X.51.4.407; *US CENS BUR, 1997, CENS FACTS NAT AM MO; Wheaton JE, 1996, REHABIL COUNS BULL, V40, P116; Will JC, 1999, AM J PUBLIC HEALTH, V89, P395, DOI 10.2105/AJPH.89.3.395	11	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					758	760		10.1016/S0140-6736(99)06050-X	http://dx.doi.org/10.1016/S0140-6736(99)06050-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	230BY	10475205				2022-12-28	WOS:000082233000043
J	Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH				Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH			Mice with reduced NMDA receptor expression display behaviors related to schizophrenia	CELL			English	Article							DOPAMINE-RECEPTORS; ANTIPSYCHOTIC AGENTS; TARGETED DISRUPTION; LOCOMOTOR-ACTIVITY; NUCLEUS-ACCUMBENS; NEONATAL DEATH; PCP SITE-2; PHENCYCLIDINE; AMPHETAMINE; SUBUNIT	N-methyl-D-aspartate receptors (NMDARs) represent a subclass of glutamate receptors that play a critical role in neuronal development and physiology. We report here the generation of mice expressing only 5% of normal levels of the essential NMDAR1 (NR1) subunit. Unlike NR1 null mice, these mice survive to adulthood and display behavioral abnormalities, including increased motor activity and stereotypy and deficits in social and sexual interactions. These behavioral alterations are similar to those observed in pharmacologically induced animal models of schizophrenia and can be ameliorated by treatment with haloperidol or clozapine, antipsychotic drugs that antagonize dopaminergic and serotonergic receptors. These findings support a model in which reduced NMDA receptor activity results in schizophrenic-like behavior and reveals how pharmacological manipulation of monoaminergic pathways can affect this phenotype.	Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol & Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Koller, BH (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.	treawouns@aol.com	Gainetdinov, Raul R/G-5875-2011	Gainetdinov, Raul R/0000-0003-2951-6038; Ramsey, Amy/0000-0002-2717-5279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07092] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abi-Saab WM, 1998, PHARMACOPSYCHIATRY, V31, P104, DOI 10.1055/s-2007-979354; AKUNNE HC, 1992, NEUROCHEM RES, V17, P261, DOI 10.1007/BF00966668; ANDEN NE, 1970, EUR J PHARMACOL, V11, P303, DOI 10.1016/0014-2999(70)90006-3; ANGRIST B, 1974, J PSYCHIAT RES, V11, P13, DOI 10.1016/0022-3956(74)90064-8; BAN TA, 1984, PSYCHIAT DEV, V2, P179; *BRANB C GEN BACKG, 1997, NEURON, V20, P755; Carlsson A, 1997, LIFE SCI, V61, P75, DOI 10.1016/S0024-3205(97)00228-2; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; CORBETT R, 1995, PSYCHOPHARMACOLOGY, V120, P67, DOI 10.1007/BF02246146; CORBETT R, 1993, PHARMACOL BIOCHEM BE, V45, P9, DOI 10.1016/0091-3057(93)90079-9; Coyle JT, 1996, HARVARD REV PSYCHIAT, V3, P241, DOI 10.3109/10673229609017192; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; DIXON AK, 1994, J CLIN PSYCHIAT, V55, P4; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Druhan JP, 1996, SYNAPSE, V24, P135, DOI 10.1002/(SICI)1098-2396(199610)24:2<135::AID-SYN5>3.0.CO;2-G; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; ELLISON G, 1995, BRAIN RES REV, V20, P250, DOI 10.1016/0165-0173(94)00014-G; ERESHEFSKY L, 1989, CLIN PHARMACY, V8, P691; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Franklin K. B. J., 1996, MOUSE BRAIN STEREOTA; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gleason SD, 1997, PSYCHOPHARMACOLOGY, V129, P79, DOI 10.1007/s002130050165; Goff DC, 1997, SCHIZOPHR RES, V27, P157, DOI 10.1016/S0920-9964(97)00079-0; GRIFFITH JD, 1972, ARCH GEN PSYCHIAT, V26, P97; HOFFMAN DC, 1995, PSYCHOPHARMACOLOGY, V120, P128, DOI 10.1007/BF02246184; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HYTTEL J, 1978, PSYCHOPHARMACOLOGY, V59, P211, DOI 10.1007/BF00426624; IKEDA K, 1995, MOL BRAIN RES, V33, P61, DOI 10.1016/0169-328X(95)00107-4; IMPERATO A, 1990, EUR J PHARMACOL, V187, P555, DOI 10.1016/0014-2999(90)90387-L; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Kelly MA, 1998, J NEUROSCI, V18, P3470; KNABLE MB, 1994, BIOL PSYCHIAT, V36, P827, DOI 10.1016/0006-3223(94)90593-2; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lahti RA, 1996, NEUROREPORT, V7, P1945, DOI 10.1097/00001756-199608120-00016; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Martin P, 1998, J NEURAL TRANSM, V105, P365, DOI 10.1007/s007020050064; Masters WG, 1996, LAB ANIM SCI, V46, P663; MELTZER HY, 1991, SCHIZOPHRENIA BULL, V17, P263, DOI 10.1093/schbul/17.2.263; Miller DW, 1996, BRAIN RES BULL, V40, P57, DOI 10.1016/0361-9230(95)02144-2; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; MOHN AR, 1995, DNA CLONING, V4, P141; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nankai M, 1996, NEUROCHEM INT, V29, P529, DOI 10.1016/0197-0186(96)00010-1; Nieoullon A., 1983, EXP BRAIN RES S, V7, P54; Nimgaonkar VL, 1997, ACTA PSYCHIAT SCAND, V95, P364, DOI 10.1111/j.1600-0447.1997.tb09647.x; ODEGARD O, 1980, ACTA PSYCHIAT SCAND, V62, P212, DOI 10.1111/j.1600-0447.1980.tb00609.x; Pierce RC, 1997, PSYCHOPHARMACOLOGY, V133, P188, DOI 10.1007/s002130050390; ROSENBAUER K A, 1980, Folia Morphologica (Prague), V28, P126; ROTHMAN RB, 1994, NEUROTOXICOL TERATOL, V16, P343, DOI 10.1016/0892-0362(94)90022-1; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SAUGSTAD LF, 1989, SCHIZOPHRENIA BULL, V15, P9, DOI 10.1093/schbul/15.1.9; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5	62	826	869	0	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					427	436		10.1016/S0092-8674(00)81972-8	http://dx.doi.org/10.1016/S0092-8674(00)81972-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481908	Bronze			2022-12-28	WOS:000082174900004
J	Oddy, WH; Holt, PG; Sly, PD; Read, AW; Landau, LI; Stanley, FJ; Kendall, GE; Burton, PR				Oddy, WH; Holt, PG; Sly, PD; Read, AW; Landau, LI; Stanley, FJ; Kendall, GE; Burton, PR			Association between breast feeding and asthma in 6 year old children: findings of a prospective birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE FOLLOW-UP; ATOPIC DISEASE; HUMAN-MILK; CHILDHOOD; ALLERGY; INFANTS; PROPHYLAXIS; LIFE; AGE	Objectives To investigate the association between the duration of exclusive breast feeding and the development of asthma related outcomes in children at age 6 years. Design Prospective cohort study, Setting Western Australia. Subjects 2187 children ascertained through antenatal clinics at the major tertiary obstetric hospital in Perth and followed to age 6 years. Main outcome measures Unconditional logistic regression to model the association between duration of exclusive breast feeding and outcomes related ro asthma or atopy at 6 years of age, allowing for several important confounders: sex, gestational age, smoking in the household, and early childcare, Results. After adjustment for confounders, the introduction of milk other than breast milli before ii months of age was a significant risk factor for all asthma and atopy related outcomes in children aged 6) ears: asthma diagnosed by a doctor (odds ratio 1.25, 95% confidence interval 1.02 to 1.52); wheeze three or more rimes since 1 year bf age (1.41, 1.14 to 1.76); wheeze in the past year (1.31, 1.05 to 1.64); sleep disturbance due to wheeze within the past year (1.42, 1.07 to 1.89), age when doctor diagnosed asthma (hazard ratio 1.22, 1.03 to 1.43); age at first wheeze (1.36, 1.17 to 1.59); and positive skin prick test reaction to at least one common aeroallergen (1.30, 1.04 to 1.61). Conclusion A significant reduction in the risk of childhood asthma at age 6 years occurs if exclusive breast feeding is continued for at least the 4 months after birth. These findings are important for our understanding of the cause of childhood asthma and suggest that public health interventions to optimise breast feeding may help to reduce the community burden of childhood asthma and its associated traits.	TVW Telethon, Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Fac Med & Dent, Nedlands, WA 6009, Australia; Univ Western Australia, Princess Margaret Hosp Children, Dept Paediat, Div Biostat & Genet Epidemiol, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Oddy, WH (corresponding author), TVW Telethon, Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	Wendyo@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Study, Raine/K-4517-2013; Sly, Peter D/F-1486-2010; Burton, Paul R/H-7527-2016	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Golding J, 1997, EARLY HUM DEV, V49, pS121, DOI 10.1016/S0378-3782(97)00058-3; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; Hamosh M, 1998, BIOL NEONATE, V74, P163, DOI 10.1159/000014021; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; Hide D W, 1991, Adv Exp Med Biol, V310, P475; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Juvonen P, 1996, ACTA PAEDIATR, V85, P1047, DOI 10.1111/j.1651-2227.1996.tb14215.x; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Pabst HF, 1997, PEDIATR INFECT DIS J, V16, P991, DOI 10.1097/00006454-199710000-00017; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Strachan DP, 1995, LANCET, V346, P1714, DOI 10.1016/S0140-6736(95)92884-7; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758, DOI 10.1001/archpedi.1995.02170200048006; Xanthou M, 1998, BIOL NEONATE, V74, P121, DOI 10.1159/000014018	24	357	367	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					815	819		10.1136/bmj.319.7213.815	http://dx.doi.org/10.1136/bmj.319.7213.815			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496824	Green Published, Bronze			2022-12-28	WOS:000082865200022
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Users and practitioners of complementary medicine	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									COWARD R, 1989, WHOLE TRUTH; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FURNHAM A, 1998, COMPLEMENTARY MED OB, P71; Mills S., 1997, PROFESSIONAL ORG COM; *RES COUNC COMPL M, 1998, PUBL US COMPL MED OV; SHARMA U, 1995, COMPLEMENTARY MED TO; THOMAS K, 1995, NATL SUVEY ACCESS CO; Thomas KJ, 1993, METHODOLOGICAL STUDY; Wearn AM, 1998, J ROY SOC MED, V91, P465, DOI 10.1177/014107689809100904	9	127	132	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					836	838		10.1136/bmj.319.7213.836	http://dx.doi.org/10.1136/bmj.319.7213.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496832	Green Published			2022-12-28	WOS:000082865200030
J	Battaglia, M; Roberts, C; Segall, P				Battaglia, M; Roberts, C; Segall, P			Magma intrusion beneath Long Valley caldera confirmed by temporal changes in gravity	SCIENCE			English	Article							CAMPI-FLEGREI CALDERA; YELLOWSTONE CALDERA; CALIFORNIA; UNREST; DEFORMATION; MECHANISMS	Precise relative gravity measurements conducted in Long Valley (California) in 1982 and 1998 reveal a decrease in gravity of as much as -107 +/- 6 microgals (1 microgal = 10(-8) meters per square second) centered on the uplifting resurgent dome. A positive residual gravity change of up to 64 +/- 15 microgals was found after correcting for the effects of uplift and water table fluctuations. Assuming a point source of intrusion, the density of the intruding material is 2.7 X 10(3) to 4.1 X 10(3) kilograms per cubic meter at 95 percent confidence. The gravity results require intrusion of silicate magma and exclude in situ thermal expansion or pressurization of the hydrothermal system as the cause of uplift and seismicity.	Stanford Univ, Dept Geophys, Stanford, CA 94305 USA; US Geol Survey, Menlo Park, CA 94025 USA	Stanford University; United States Department of the Interior; United States Geological Survey	Battaglia, M (corresponding author), Stanford Univ, Dept Geophys, Stanford, CA 94305 USA.		Battaglia, Maurizio/I-7288-2019	Battaglia, Maurizio/0000-0003-4726-5287				[Anonymous], 1989, VOLCANIC HAZARDS; Arnet F, 1997, GEOPHYS RES LETT, V24, P2741, DOI 10.1029/97GL02801; BAILEY RA, 1990, GEOSCI CAN, V17, P175; Barberi F., 1996, MONITORING MITIGATIO, P771; BERRINO G, 1992, J VOLCANOL GEOTH RES, V53, P11, DOI 10.1016/0377-0273(92)90071-K; BERRINO G, 1994, J VOLCANOL GEOTH RES, V61, P293, DOI 10.1016/0377-0273(94)90010-8; CHARMICHAEL RS, 1984, HDB PHYSICAL ROCK PR, V3; DENATALE G, 1991, J VOLCANOL GEOTH RES, V48, P199, DOI 10.1016/0377-0273(91)90043-Y; DZURISIN D, 1994, B VOLCANOL, V56, P261, DOI 10.1007/BF00302079; DZURISIN D, COMMUNICATION; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; EGGERS AA, 1987, J VOLCANOL GEOTH RES, V33, P201, DOI 10.1016/0377-0273(87)90062-X; FARRAR CD, 1995, NATURE, V376, P675, DOI 10.1038/376675a0; Goovaerts P., 1997, GEOSTATISTICS NATURA, P137; HOWLE JF, 1996, 96382 US GEOL SURV; Jachens R. C., 1981, The 1980 eruptions of Mount St. Helens, Washington, P175; JACHENS RC, 1985, J GEOPHYS RES-SOLID, V90, P1210, DOI 10.1029/JB090iB13p11210; JULIAN BR, 1983, NATURE, V303, P323, DOI 10.1038/303323a0; LANGBEIN J, 1995, J GEOPHYS RES-SOL EA, V100, P12487, DOI 10.1029/95JB01052; ROBERTS CW, 1988, 8850 US GEOL SURV; ROUHANI S, 1990, MATH GEOL, V22, P611, DOI 10.1007/BF00890508; RUNDLE JB, 1986, J GEOPHYS RES-SOLID, V91, P2675, DOI 10.1029/JB091iB12p12675; Smith R.L., 1968, STUDIES VOLCANOLOGY, V116, P613, DOI DOI 10.1130/MEM116-P613; SOREY ML, 1995, J GEOPHYS RES-SOL EA, V100, P12475, DOI 10.1029/95JB00955; SOREY ML, 1978, 1044A US GEOL SURV; TALAI B, 1997, B GLOBAL VOLCANISM N, V22; TILLING RI, 1993, NATURE, V363, P125, DOI 10.1038/363125a0; WALSH JB, 1979, J GEOPHYS RES, V84, P165, DOI 10.1029/JB084iB01p00165; WEILAND CM, 1995, J GEOPHYS RES-SOL EA, V100, P20379, DOI 10.1029/95JB01147; Wicks C, 1998, SCIENCE, V282, P458, DOI 10.1126/science.282.5388.458	31	94	95	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2119	2122		10.1126/science.285.5436.2119	http://dx.doi.org/10.1126/science.285.5436.2119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497128	Green Submitted			2022-12-28	WOS:000082734300040
J	Valla, T; Fedorov, AV; Johnson, PD; Wells, BO; Hulbert, SL; Li, Q; Gu, GD; Koshizuka, N				Valla, T; Fedorov, AV; Johnson, PD; Wells, BO; Hulbert, SL; Li, Q; Gu, GD; Koshizuka, N			Evidence for quantum critical behavior in the optimally doped cuprate Bi2Sr2CaCu2O8+delta	SCIENCE			English	Article							ANGLE-RESOLVED PHOTOEMISSION; T-C SUPERCONDUCTORS; NORMAL-STATE; ELECTRONIC-STRUCTURE; GAP ANISOTROPY; PSEUDOGAP	The photoemission Line shapes of the optimally doped cuprate Bi2Sr2CaCu2O8+delta were studied in the direction of a node in the superconducting order parameter by means of very high resolution photoemission spectroscopy. The peak width or inverse lifetime of the excitation displays a Linear temperature dependence, independent of: binding energy, for small energies, and a Linear energy dependence, independent of temperature, for Large binding energies. This behavior is unaffected by the superconducting transition, which is an indication that the nodal states play no role in the superconductivity. Temperature-dependent scaling suggests that the system displays quantum critical behavior.	Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA; Brookhaven Natl Lab, Div Mat Sci, Upton, NY 11973 USA; Univ Connecticut, Dept Phys, Storrs, CT 06269 USA; Univ New S Wales, Sch Phys, Kensington, NSW 2033, Australia; ISTEC, Superconduct Res Lab, Koto Ku, Tokyo 135, Japan	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Connecticut; University of New South Wales Sydney; International Superconductivity Technology Center (ISTEC)	Valla, T (corresponding author), Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA.		Valla, Tonica/ABD-7811-2021	Valla, Tonica/0000-0002-3237-9102; Fedorov, Alexei/0000-0003-3510-3117				AEPPLI G, 1997, SCIENCE, V278, P21; Allen P. B., 1996, Quantum theory of real materials, P219; Anderson P. W., 1997, THEORY SUPERCONDUCTI; ANDERSON PW, 1987, FRONTIERS BORDERLINE; Ashcroft N.W., 1976, SOLID STATE PHYS; CAMPUZANO JC, 1990, PHYS REV LETT, V64, P2308, DOI 10.1103/PhysRevLett.64.2308; CASTELLANI C, 1995, PHYS REV LETT, V75, P4650, DOI 10.1103/PhysRevLett.75.4650; CHAKRAVARTY S, 1989, PHYS REV B, V39, P2344, DOI 10.1103/PhysRevB.39.2344; Ding H, 1996, PHYS REV B, V54, pR9678, DOI 10.1103/PhysRevB.54.R9678; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; EMERY VJ, 1993, PHYS REV LETT, V71, P3701, DOI 10.1103/PhysRevLett.71.3701; Fedorov AV, 1999, PHYS REV LETT, V82, P2179, DOI 10.1103/PhysRevLett.82.2179; Grimvall G., 1981, ELECT PHONON INTERAC; GU GD, 1993, J CRYST GROWTH, V130, P325, DOI 10.1016/0022-0248(93)90872-T; GURVITCH M, 1987, PHYS REV LETT, V59, P1337, DOI 10.1103/PhysRevLett.59.1337; INGLESFIELD JE, 1992, ANGLE RESOLVED PHOTO; KRAKAUER H, 1988, PHYS REV LETT, V60, P1665, DOI 10.1103/PhysRevLett.60.1665; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; OLSON CG, 1990, PHYS REV B, V42, P381, DOI 10.1103/PhysRevB.42.381; PINES D, 1969, THEORY QUANTUM LIQUI; Puchkov AV, 1996, J PHYS-CONDENS MAT, V8, P10049, DOI 10.1088/0953-8984/8/48/023; SACHDEV S, 1992, PHYS REV LETT, V69, P2411, DOI 10.1103/PhysRevLett.69.2411; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; SOKOL A, 1993, PHYS REV LETT, V71, P2813, DOI 10.1103/PhysRevLett.71.2813; Valla T, 1999, PHYS REV LETT, V83, P2085, DOI 10.1103/PhysRevLett.83.2085; Varma CM, 1997, PHYS REV B, V55, P14554, DOI 10.1103/PhysRevB.55.14554; VARMA CM, 1989, PHYS REV LETT, V63, P1936; WELLS BO, 1992, PHYS REV B, V46, P11830, DOI 10.1103/PhysRevB.46.11830	28	468	471	3	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2110	2113		10.1126/science.285.5436.2110	http://dx.doi.org/10.1126/science.285.5436.2110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497125				2022-12-28	WOS:000082734300037
J	Delbanco, T; Hartman, E				Delbanco, T; Hartman, E			An asymptomatic 41-year-old man with HIV infection, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Makadon HJ, 1999, JAMA-J AM MED ASSOC, V281, P739, DOI 10.1001/jama.281.8.739	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1176	1176		10.1001/jama.282.12.1176	http://dx.doi.org/10.1001/jama.282.12.1176			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501122				2022-12-28	WOS:000082596200034
J	Shiflett, MB; Foley, HC				Shiflett, MB; Foley, HC			Ultrasonic deposition of high-selectivity nanoporous carbon membranes	SCIENCE			English	Article							CARBOGENIC MOLECULAR-SIEVES; CATALYTIC INORGANIC MEMBRANE; SILICA MEMBRANES; AIR SEPARATION; PERMEATION; PERMEABILITY; ADSORPTION	Ultrasonic deposition creates a thin film of polymer on a tubular, macroporous, stainless steel support. Using polyfurfuryl alcohol as the nanoporous carbon precursor and a pyrolysis temperature of 723 kelvin, a membrane was prepared with the following permeances, measured in moles per square meter per Pascal per second: nitrogen, 1.8 X 10(-12); oxygen, 5.6 X 10(-11); helium, 3.3 X 10(-10); and hydrogen, 6.1 X 10(-10). The ideal separation factors as compared to that for nitrogen are 30:1, 178:1, and 331:1 for oxygen, helium, and hydrogen, respectively.	Dupont Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA; Univ Delaware, Ctr Catalyt Sci & Technol, Dept Chem Engn, Newark, DE 19716 USA	DuPont; University of Delaware	Shiflett, MB (corresponding author), Dupont Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA.							Acharya M, 1997, IND ENG CHEM RES, V36, P2924, DOI 10.1021/ie960769d; ARMOR JN, 1995, ADV CHEM SER, V245, P321; Armor JN, 1998, J MEMBRANE SCI, V147, P217, DOI 10.1016/S0376-7388(98)00124-0; Bakker WJW, 1996, J MEMBRANE SCI, V117, P57, DOI 10.1016/0376-7388(96)00035-X; Boudreau LC, 1999, J MEMBRANE SCI, V152, P41, DOI 10.1016/S0376-7388(98)00166-5; BRAYMER TA, 1994, CARBON, V32, P445, DOI 10.1016/0008-6223(94)90165-1; CHEN YD, 1994, IND ENG CHEM RES, V33, P3146, DOI 10.1021/ie00036a033; de Vos RM, 1998, SCIENCE, V279, P1710, DOI 10.1126/science.279.5357.1710; FOLEY HC, 1995, MICROPOROUS MATER, V4, P407, DOI 10.1016/0927-6513(95)00014-Z; Funke HH, 1997, J MEMBRANE SCI, V129, P77, DOI 10.1016/S0376-7388(96)00333-X; Gaffney TR, 1996, CURR OPIN SOLID ST M, V1, P69, DOI 10.1016/S1359-0286(96)80013-1; Geiszler VC, 1996, IND ENG CHEM RES, V35, P2999, DOI 10.1021/ie950746j; Harold MP, 1997, CHEM ENG SCI, V52, P1923, DOI 10.1016/S0009-2509(97)00024-9; HUTCHINSON JW, 1992, ADV APPL MECH, V29, P63, DOI 10.1016/s0065-2156(08)70164-9; Kane MS, 1996, CHEM MATER, V8, P2159, DOI 10.1021/cm960085w; KORESH JE, 1987, SEPAR SCI TECHNOL, V22, P973, DOI 10.1080/01496398708068993; KORESH JE, 1986, J CHEM SOC FARAD T 1, V82, P2057, DOI 10.1039/f19868202057; Li YG, 1998, MATER LETT, V37, P221, DOI 10.1016/S0167-577X(98)00095-0; MARIWALA RK, 1994, IND ENG CHEM RES, V33, P2314, DOI 10.1021/ie00034a009; MARIWALA RK, 1994, IND ENG CHEM RES, V33, P607, DOI 10.1021/ie00027a018; Nair BN, 1997, J MEMBRANE SCI, V135, P237, DOI 10.1016/S0376-7388(97)00137-3; Ohya H, 1998, J MEMBRANE SCI, V146, P9, DOI 10.1016/S0376-7388(98)00084-2; RAO MB, 1996, J MEMBRANE SCI, V110, P10; Reid R.C., 1987, PROPERTIES GASES LIQ; ROBESON LM, 1991, J MEMBRANE SCI, V62, P165, DOI 10.1016/0376-7388(91)80060-J; Yan YS, 1997, J MEMBRANE SCI, V123, P95, DOI 10.1016/S0376-7388(96)00206-2	26	303	320	5	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1902	1905		10.1126/science.285.5435.1902	http://dx.doi.org/10.1126/science.285.5435.1902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489366				2022-12-28	WOS:000082638300046
J	Esteban, CR; Capdevila, J; Economides, AN; Pascual, J; Ortiz, A; Belmonte, JCI				Esteban, CR; Capdevila, J; Economides, AN; Pascual, J; Ortiz, A; Belmonte, JCI			The novel Cer-like protein Caronte mediates the establishment of embryonic left-right asymmetry	NATURE			English	Article							HOMEOBOX GENE; NEURALIZING ACTIVITY; CHICK EMBRYOGENESIS; HEART DEVELOPMENT; NODAL EXPRESSION; SECRETED FACTOR; ORGANIZER; CERBERUS; PATHWAY; CELLS	In the chick embryo, left-right asymmetric patterns of gene expression in the lateral plate mesoderm are initiated by signals located in and around Hensen's node, Here we show that Caronte (Gar), a secreted protein encoded by a member of the Cerberus/Dan gene family, mediates the Sonic hedgehog (Shh)-dependent induction of left-specific genes in the lateral plate mesoderm, Car is induced by Shh and repressed by fibroblast growth factor-8 (FGF-8), Car activates the expression of Nodal by antagonizing a repressive activity of bone morphogenic proteins (BMPs), Our results define a complex network of antagonistic molecular interactions between Activin, FGF-8, Lefty-1, Nodal, BMPs and Car that cooperate to control left-right asymmetry in the chick embryo.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Salk Institute; Regeneron; Scripps Research Institute	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu	pascual, jaime/D-4566-2009	pascual, jaime/0000-0001-8992-7475; Economides, Aris/0000-0002-6508-8942				Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Campione M, 1999, DEVELOPMENT, V126, P1225; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; King T, 1999, CURR BIOL, V9, pR18, DOI 10.1016/S0960-9822(99)80036-0; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Merino R, 1999, DEV BIOL, V206, P33, DOI 10.1006/dbio.1998.9129; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pizette S, 1999, DEVELOPMENT, V126, P883; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Schneider A, 1999, CURR BIOL, V9, P911, DOI 10.1016/S0960-9822(99)80397-2; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; STANLEY E, MECH DEV, V77, P173; Streit A, 1998, DEVELOPMENT, V125, P507; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Thisse C, 1999, DEVELOPMENT, V126, P229; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; TSUKUI T, IN PRESS P NATL ACAD; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; YOKOUCHI Y, IN PRESS CELL; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Zhu L, 1999, CURR BIOL, V9, P931, DOI 10.1016/S0960-9822(99)80419-9; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	168	175	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					243	251		10.1038/45738	http://dx.doi.org/10.1038/45738			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499580				2022-12-28	WOS:000082678400044
J	van Herten, LM; van de Water, HPA				van Herten, LM; van de Water, HPA			New global Health for All targets	BRITISH MEDICAL JOURNAL			English	Article							SURVEILLANCE		Netherlands Org Appl Sci Res Prevent & Hlth, NL-2301 CE Leiden, Netherlands	Netherlands Organization Applied Science Research	van Herten, LM (corresponding author), Netherlands Org Appl Sci Res Prevent & Hlth, POB 2215, NL-2301 CE Leiden, Netherlands.							*AD HOCK COMM HLTH, 1996, TDRGEN961 AD HOC COM; [Anonymous], [No title captured]; ERKENS C, 1996, COST EFFECTIVENESS S; FRERICHS RR, 1991, ANNU REV PUBL HEALTH, V12, P257, DOI 10.1146/annurev.pu.12.050191.001353; Murray C. J. L., 1996, GLOBAL BURDEN DIS; TAYLOR CE, 1992, INT J EPIDEMIOL, V21, P1043, DOI 10.1093/ije/21.6.1043; *UN, 1998, WORLD POP PROSP; *UN DEV PROGR, 1997, HUM DEV REP 1997N; VANDEWATER HPA, 1999, NEVER CHANGE WINNING; VANDEWATER HPA, 1996, BULLS EYE ACHILLES H; VANDEWATER HPA, 1998, HLTH POLICIES TARGET; Visschedijk Jan, 1998, World Health Statistics Quarterly, V51, P56; *WHO, 1996, EMC ANN REP 1996; *WHO, 1999, IN PRESS 3 EV HLTH A; *WHO, 1998, M 17 19 NOV 1997 HEL; *WHO, 1997, 1997 CONQ SUFF ENR H; WHO, 1997, GLOB DAT CHILD GROWT; World Bank, 1996, POV RED WORLD BANK P; World Health Organization, 1995, WHO TECHN REP SER, V834; World Health Organization, 1995, BRIDG GAPS; *WORLD HLTH ASS, 1998, HLTH 21 CENT; *WORLD HLTH ASS, 1981, WHO HLTH ALL SER, V3	22	10	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					700	703		10.1136/bmj.319.7211.700	http://dx.doi.org/10.1136/bmj.319.7211.700			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480832	Green Published			2022-12-28	WOS:000082636800032
J	Tibuleac, IM; Herrin, E				Tibuleac, IM; Herrin, E			Lower mantle lateral heterogeneity beneath the Caribbean Sea	SCIENCE			English	Article							SEISMIC EVIDENCE; BOUNDARY	Seismic wave reflections from Earth's core recorded at seismic arrays in North America from events in the Caribbean Islands, Venezuela, and the Mid-Atlantic Ridge have observed slownesses more than 64 percent greater than predicted by the IASPEI91 standard Earth model. P waves turning in the Lowermost mantle beneath the same region also have anomalous slowness. The slowness anomalies are not accompanied by significant travel time residuals and appear to be caused by lateral inhomogeneities in the velocity structure of the Lower mantle.	So Methodist Univ, Dept Geol Sci, Dallas, TX 75275 USA	Southern Methodist University	Tibuleac, IM (corresponding author), So Methodist Univ, Dept Geol Sci, Dallas, TX 75275 USA.	ileana@passion.isem.sum.edu; herrin@passion.isem.smu.edu						Aki K., 1980, QUANTITATIVE SEISMOL; BURDICK LJ, 1980, J GEOPHYS RES, V85, P3845, DOI 10.1029/JB085iB07p03845; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; Grand SP., 1997, GSA TODAY, V7, P1; Helmberger DV, 1998, NATURE, V396, P251, DOI 10.1038/24357; JOHNSON LR, 1969, B SEISMOL SOC AM, V59, P973; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KENNETT BLN, 1991, IASEPEI 1991 SEISMOL; Koch K, 1997, B SEISMOL SOC AM, V87, P1576; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Liu XF, 1998, EARTH PLANET SC LETT, V160, P343, DOI 10.1016/S0012-821X(98)00095-8; POWELL C, 1975, NATURE, V254, P40, DOI 10.1038/254040a0; PULLIAM RJ, 1993, J GEOPHYS RES-SOL EA, V98, P699, DOI 10.1029/92JB01053; TIBULEAC I, 1997, SEISMOL RES LETT, V68, P353; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; Wen LX, 1998, SCIENCE, V279, P1701, DOI 10.1126/science.279.5357.1701; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; WRIGHT C, 1973, J GEOPHYS RES, V78, P4965, DOI 10.1029/JB078i023p04965	19	7	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1711	1715		10.1126/science.285.5434.1711	http://dx.doi.org/10.1126/science.285.5434.1711			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481003				2022-12-28	WOS:000082472600029
J	Zhang, Y; Ichihashi, T; Landree, E; Nihey, F; Iijima, S				Zhang, Y; Ichihashi, T; Landree, E; Nihey, F; Iijima, S			Heterostructures of single-walled carbon nanotubes and carbide nanorods	SCIENCE			English	Article							SILICON SURFACES; GROWTH-MECHANISM; FILM GROWTH; C-60 FILMS; CARBONIZATION	A method based on a controlled solid-solid reaction was used to fabricate heterostructures between single-walled carbon nanotubes (SWCNTs) and nanorods or particles of silicon carbide and transition metal carbides. Characterization by high-resolution transmission electron microscopy and electron diffraction indicates that the heterostructures have well-defined crystalline interfaces. The SWCNT/carbide interface, with a nanometer-scale area defined by the cross section of a SWCNT bundle or of a single nanotube, represents the smallest heterojunction that can be achieved using carbon nanotubes, and it can be expected to play an important role in the future fabrication of hybrid nanodevices.	NEC Corp Ltd, Fundamental Res Labs, Tsukuba, Ibaraki 3058501, Japan; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; Meijo Univ, Japan Sci & Technol Corp, Dept Phys, Tenpaku Ku, Nagoya, Aichi 4688502, Japan	NEC Corporation; Northwestern University; Japan Science & Technology Agency (JST); Meijo University	Zhang, Y (corresponding author), NEC Corp Ltd, Fundamental Res Labs, 34 Miyukigaoka, Tsukuba, Ibaraki 3058501, Japan.		Zhang, Y/E-6600-2011	Zhang, Y/0000-0003-0344-8399; Nihey, Fumiyuki/0000-0002-2466-3066				BECKER JP, 1994, J VAC SCI TECHNOL A, V12, P174, DOI 10.1116/1.578916; Chen D, 1995, SURF SCI, V344, P23, DOI 10.1016/0039-6028(95)00840-3; DIA H, 1995, NATURE, V375, P769; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; GRAUL J, 1972, APPL PHYS LETT, V21, P67, DOI 10.1063/1.1654282; GUO T, 1995, CHEM PHYS LETT, V243, P49, DOI 10.1016/0009-2614(95)00825-O; HAMZA AV, 1994, SURF SCI, V317, pL1129, DOI 10.1016/0039-6028(94)90279-8; Han WQ, 1997, CHEM PHYS LETT, V265, P374, DOI 10.1016/S0009-2614(96)01441-8; Harris GL, 1995, PROPERTIES SILICON C; HENDERSON RC, 1971, J APPL PHYS, V42, P1208, DOI 10.1063/1.1660168; Hu JT, 1999, NATURE, V399, P48, DOI 10.1038/19941; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; LI JP, 1995, J ELECTROCHEM SOC, V142, P634, DOI 10.1149/1.2044113; MOGAB CJ, 1974, J APPL PHYS, V45, P1075, DOI 10.1063/1.1663370; Moro L, 1997, J APPL PHYS, V81, P6141, DOI 10.1063/1.364395; Moro L, 1997, APPL SURF SCI, V119, P76, DOI 10.1016/S0169-4332(96)01086-0; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; SAMSONOV GV, 1980, HDB REFRACTORY COMPO, P222; Schmidt J, 1997, PHYS REV B, V56, P9918, DOI 10.1103/PhysRevB.56.9918; Toth L., 1971, TRANSITION METAL CAR; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Williams WS, 1997, JOM-J MIN MET MAT S, V49, P38, DOI 10.1007/BF02914655; Zhang Y, 1998, PHIL MAG LETT, V78, P139, DOI 10.1080/095008398178129; ZHOU D, 1994, CHEM PHYS LETT, V222, P233, DOI 10.1016/0009-2614(94)00342-4	24	384	434	5	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1719	1722		10.1126/science.285.5434.1719	http://dx.doi.org/10.1126/science.285.5434.1719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481005				2022-12-28	WOS:000082472600031
J	Samama, MM; Cohen, AT; Darmon, JY; Desjardins, L; Eldor, A; Janbon, C; Leizorovicz, A; Nguyen, H; Olsson, CG; Turpie, AG; Weisslinger, N				Samama, MM; Cohen, AT; Darmon, JY; Desjardins, L; Eldor, A; Janbon, C; Leizorovicz, A; Nguyen, H; Olsson, CG; Turpie, AG; Weisslinger, N		Enoxaparin Study Grp	A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; COST-EFFECTIVENESS ANALYSIS; FATAL PULMONARY-EMBOLISM; TOTAL HIP-REPLACEMENT; LOW-DOSE HEPARIN; DOUBLE-BLIND; UNFRACTIONATED HEPARIN; ORTHOPEDIC-SURGERY; RANDOMIZED TRIALS	Background The efficacy and safety of thromboprophylaxis in patients with acute medical illnesses who may be at risk for venous thromboembolism have not been determined in adequately designed trials. Methods In a double-blind study, we randomly assigned 1102 hospitalized patients older than 40 years to receive 40 mg of enoxaparin, 20 mg of enoxaparin, or placebo subcutaneously once daily for 6 to 14 days. Most patients were not in an intensive care unit. The primary outcome was venous thromboembolism between days 1 and 14, defined as deep-vein thrombosis detected by bilateral venography (or duplex ultrasonography) between days 6 and 14 (or earlier if clinically indicated) or documented pulmonary embolism. The duration of follow-up was three months. Results The primary outcome could be assessed in 866 patients. The incidence of venous thromboembolism was significantly lower in the group that received 40 mg of enoxaparin (5.5 percent [16 of 291 patients]) than in the group that received placebo (14.9 percent [43 of 288 patients]) (relative risk, 0.37; 97.6 percent confidence interval, 0.22 to 0.63; P< 0.001). The benefit observed with 40 mg of enoxaparin was maintained at three months. There was no significant difference in the incidence of venous thromboembolism between the group that received 20 mg of enoxaparin (15.0 percent [43 of 287 patients]) and the placebo group. The incidence of adverse effects did not differ significantly between the placebo group and either enoxaparin group. By day 110, 50 patients in the placebo group had died (13.9 percent), 51 in the 20-mg group had died (14.7 percent), and 41 in the 40-mg group had died (11.4 per cent); the differences were not significant. Conclusions Prophylactic treatment with 40 mg per day of enoxaparin subcutaneously safely reduces the risk of venous thromboembolism in patients with acute medical illnesses. (N Engl J Med 1999;341: 793-800.) (C)1999, Massachusetts Medical Society.	Hop Hotel Dieu, Dept Hematol Biol, F-75181 Paris 04, France; Guys Kings & St Thomas Sch Med, Acad Dept Med, London, England; Labs Rhone Poulenc Rorer, Dept Cardiovasc, Montrouge, France; Ctr Hosp Univ Quebec, Serv Hematol, Quebec City, PQ, Canada; Ichilov Hosp, Sourasky Med Ctr, Inst Hematol, IL-64239 Tel Aviv, Israel; Ctr Hosp Univ Hop St Eloi, Serv Med Interne, Montpellier, France; Univ Lyons, Serv Pharmacol Clin, Lyon, France; Univ Lund Hosp, Dept Internal Med, S-22185 Lund, Sweden; Hamilton Hlth Sci Corp Gen Div, Dept Med, Hamilton, ON, Canada	University of London; King's College London; Sanofi-Aventis; Laval University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Universite de Montpellier; Lund University; Skane University Hospital; McMaster University	Samama, MM (corresponding author), Hop Hotel Dieu, Dept Hematol Biol, 1 Pl Parvis Notre Dame, F-75181 Paris 04, France.							ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; Armitage P, 1987, STATISTICAL METHODS, P455; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; Bergmann JF, 1996, LANCET, V348, P205, DOI 10.1016/S0140-6736(05)66160-0; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; BERGQVIST D, 1990, ACTA CHIR SCAND, P36; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; CADE JF, 1982, CRIT CARE MED, V10, P448, DOI 10.1097/00003246-198207000-00006; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DAHAN R, 1986, HAEMOSTASIS, V16, P159; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; Gardlund B, 1996, LANCET, V347, P1357; GAZZANIGA GM, 1993, INT SURG, V78, P271; GOLDHABER SZ, 1992, JAMA-J AM MED ASSOC, V268, P1727, DOI 10.1001/jama.268.13.1727; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; HIRSH J, 1994, CIRCULATION, V89, P1449, DOI 10.1161/01.CIR.89.3.1449; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; KELLER F, 1995, THROMB HAEMOSTASIS, V73, P1106; Kleber F. X., 1998, Annals of Hematology, V76, pA93; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; LOWE GDO, 1992, BMJ-BRIT MED J, V305, P567; NICOLAIDES AN, 1992, INT ANGIOL, V11, P151; Nicolaides AN, 1997, INT ANGIOL, V16, P3; NURMOHAMED MT, 1995, AM J SURG, V169, P567, DOI 10.1016/S0002-9610(99)80222-0; OSTER G, 1987, AM J MED, V82, P889, DOI 10.1016/0002-9343(87)90149-5; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; SAMAMA M, 1988, BRIT J SURG, V75, P128, DOI 10.1002/bjs.1800750213; SAMAMA MM, 1993, THROMB HAEMOSTASIS, V69, P763; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	40	1220	1279	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					793	800		10.1056/NEJM199909093411103	http://dx.doi.org/10.1056/NEJM199909093411103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477777				2022-12-28	WOS:000082534000003
J	Wiesmann, C; Ultsch, MH; Bass, SH; de Vos, AM				Wiesmann, C; Ultsch, MH; Bass, SH; de Vos, AM			Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; TYROSINE KINASE RECEPTORS; LEUCINE-RICH MOTIF; NEUROTROPHIN RECEPTORS; AFFINITY RECEPTOR; NGF; RESOLUTION; SITE; DIFFERENTIATION; SPECIFICITY	Nerve growth factor (NGF) is involved in a variety of processes involving signalling, such as cell differentiation and survival, growth cessation and apoptosis of neurons'. These events are mediated by NGF as a result of binding to its two cell-surface receptors,TrkA and p75 (ref. 2). TrkA is a receptor with tyrosine kinase activity that forms a high-affinity binding site for NGF(3). Of the five domains comprising its extracellular portion, the immunoglobulin-like domain proximal to the membrane (TrkA-d5 domain) is necessary and sufficient for NGF binding(4). Here we present the crystal structure of human NGF in complex with human TrkA-d5 at 2.2 Angstrom resolution. The ligand-receptor interface consists of two patches of similar size. One patch involves the central beta-sheet that forms the core of the homodimeric NGF molecule and the loops at the carboxy-terminal pole of TrkA-d5. The second patch comprises the amino-terminal resudes of NGF, which adopt a helical conformation upon complex formation, packing against the 'ABED' sheet of TrkA-d5. The structure is consistent with results from mutagenesis experiments for all neurotrophins, and indicates that the first patch may constitute a conserved binding motif for all family members, whereas the second patch is specific for the interaction between NGF and TrkA.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	de Vos, AM (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.			Wiesmann, Christian/0000-0002-4092-9880				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DECHANT G, 1997, J NEUROSCI, V17, P5271; GOTZ R, 1994, NATURE, V372, P366; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Ryden M, 1997, J BIOL CHEM, V272, P33085, DOI 10.1074/jbc.272.52.33085; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; Urfer R, 1998, J BIOL CHEM, V273, P5829, DOI 10.1074/jbc.273.10.5829; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	30	303	331	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					184	188		10.1038/43705	http://dx.doi.org/10.1038/43705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490030				2022-12-28	WOS:000082458800059
J	Henney, JE				Henney, JE			Endotoxin-like reactions to gentamicin sulfate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-28	WOS:000082335900006
J	Rice, TW				Rice, TW			Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy?	LANCET			English	Editorial Material									Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Rice, TW (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA.							CHRISTIE NA, IN PRESS J THORAC CA; Matsubara T, 1999, BRIT J SURG, V86, P669, DOI 10.1046/j.1365-2168.1999.01067.x; Nigro JJ, 1999, J THORAC CARDIOV SUR, V117, P16, DOI 10.1016/S0022-5223(99)70464-2; Rice TW, 1998, ANN THORAC SURG, V65, P787, DOI 10.1016/S0003-4975(97)01387-8	4	45	47	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					792	794						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485718				2022-12-28	WOS:000082400700005
J	Facsko, S; Dekorsy, T; Koerdt, C; Trappe, C; Kurz, H; Vogt, A; Hartnagel, HL				Facsko, S; Dekorsy, T; Koerdt, C; Trappe, C; Kurz, H; Vogt, A; Hartnagel, HL			Formation of ordered nanoscale semiconductor dots by ion sputtering	SCIENCE			English	Article							ROUGHENING INSTABILITY; RIPPLE FORMATION; SURFACES; TOPOGRAPHY; EVOLUTION; EROSION; GROWTH	A formation process for semiconductor quantum dots based on a surface instability induced by ion sputtering under normal incidence is presented. Crystalline dots 35 nanometers in diameter and arranged in a regular hexagonal Lattice were produced on gallium antimonide surfaces. The formation mechanism relies on a natural self-organization mechanism that occurs during the erosion of surfaces, which is based on the interplay between roughening induced by ion sputtering and smoothing due to surface diffusion.	Rhein Westfal TH Aachen, Inst Semicond Elect, D-52074 Aachen, Germany; TU Darmstadt, Inst Hochfrequenztech, D-64283 Darmstadt, Germany	RWTH Aachen University; Technical University of Darmstadt	Facsko, S (corresponding author), Rhein Westfal TH Aachen, Inst Semicond Elect, Sommerfeldstr 24, D-52074 Aachen, Germany.		Dekorsy, Thomas/A-6152-2008; Facsko, Stefan/B-7312-2009	Dekorsy, Thomas/0000-0003-2257-2854; Facsko, Stefan/0000-0003-3698-3793				BALES GS, 1990, SCIENCE, V249, P264, DOI 10.1126/science.249.4966.264; BRADLEY RM, 1988, J VAC SCI TECHNOL A, V6, P2390, DOI 10.1116/1.575561; Carter G, 1996, PHYS REV B, V54, P17647, DOI 10.1103/PhysRevB.54.17647; CARTER G, 1993, SURF INTERFACE ANAL, V20, P90, DOI 10.1002/sia.740200113; Carter  G., 1991, TOP APPL PHYS, V64, P231; CHASON E, 1994, PHYS REV LETT, V72, P3040, DOI 10.1103/PhysRevLett.72.3040; CUERNO R, 1995, PHYS REV LETT, V74, P4746, DOI 10.1103/PhysRevLett.74.4746; Glaser ER, 1996, APPL PHYS LETT, V68, P3614, DOI 10.1063/1.115747; GRUNDMANN M, 1995, PHYS REV LETT, V74, P4043, DOI 10.1103/PhysRevLett.74.4043; Koponen I, 1997, PHYS REV LETT, V78, P2612, DOI 10.1103/PhysRevLett.78.2612; MACLAREN SW, 1992, J VAC SCI TECHNOL A, V10, P468, DOI 10.1116/1.578173; MAYER TM, 1994, J APPL PHYS, V76, P1633, DOI 10.1063/1.357748; NAVEZ M, 1962, CR HEBD ACAD SCI, V254, P240; Rusponi S, 1998, PHYS REV LETT, V81, P4184, DOI 10.1103/PhysRevLett.81.4184; Rusponi S, 1997, PHYS REV LETT, V78, P2795, DOI 10.1103/PhysRevLett.78.2795; Springholz G, 1998, SCIENCE, V282, P734, DOI 10.1126/science.282.5389.734	16	749	760	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1551	1553		10.1126/science.285.5433.1551	http://dx.doi.org/10.1126/science.285.5433.1551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477516	Green Submitted			2022-12-28	WOS:000082359500061
J	Lin, JY; Qi, R; Aston, C; Jing, JP; Anantharaman, TS; Mishra, B; White, O; Daly, MJ; Minton, KW; Venter, JC; Schwartz, DC				Lin, JY; Qi, R; Aston, C; Jing, JP; Anantharaman, TS; Mishra, B; White, O; Daly, MJ; Minton, KW; Venter, JC; Schwartz, DC			Whole-genome shotgun optical mapping of Deinococcus radiodurans	SCIENCE			English	Article							ORDERED RESTRICTION MAPS; IONIZING-RADIATION; FORCE MICROSCOPY; DNA-MOLECULES; PHYSICAL MAP; CHROMOSOME; RECOMBINATION; SURFACES; REPAIR	A whole-genome restriction map of Deinococcus radiodurans, a radiation-resistant bacterium able to survive up to 15,000 grays of ionizing radiation, was constructed without using DNA Libraries, the polymerase chain reaction, or electrophoresis. Very Large, randomly sheared, genomic DNA fragments were used to construct maps from individual DNA molecules that were assembled into two circular overlapping maps (2.6 and 0.415 megabases), without gaps. A third smaller chromosome (176 kilobases) was identified and characterized. Aberrant nonlinear DNA structures that may define chromosome structure and organization, as well as intermediates in DNA repair, were directly visualized by optical mapping techniques after gamma irradiation.	NYU, Dept Chem, WM Keck Lab Biomol Imaging, New York, NY 10003 USA; NYU, Courant Inst Math Sci, Dept Comp Sci, New York, NY 10012 USA; Inst Genome Res, Rockville, MD 20850 USA; Celera Genom, Rockville, MD 20850 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	New York University; New York University; J. Craig Venter Institute; Uniformed Services University of the Health Sciences - USA	Schwartz, DC (corresponding author), Univ Wisconsin, Ctr Biotechnol, Dept Chem, 425 Henry Mall, Madison, WI 53706 USA.				NHGRI NIH HHS [HG0025-08] Funding Source: Medline; NIGMS NIH HHS [GM 39933] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman TS, 1997, J COMPUT BIOL, V4, P91, DOI 10.1089/cmb.1997.4.91; ANANTHARAMAN TS, IN PRESS 7 INT C INT; ANANTHARAMAN TS, 1998, 760 NEW YORK U COUR; Aston C, 1999, METHOD ENZYMOL, V303, P55; BAUTSCH W, 1997, GENOME MAPPING PRACT, P281; BEDERSON BB, 1998, HUMAN FACTORS WEB DE, P255; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLATTNER FR, UNPUB; CAI WW, 1995, P NATL ACAD SCI USA, V92, P5164, DOI 10.1073/pnas.92.11.5164; Cai WW, 1998, P NATL ACAD SCI USA, V95, P3390, DOI 10.1073/pnas.95.7.3390; Daly MJ, 1997, GENE, V187, P225, DOI 10.1016/S0378-1119(96)00755-X; DALY MJ, 1995, SCIENCE, V270, P1318, DOI 10.1126/science.270.5240.1318; Daly MJ, 1996, J BACTERIOL, V178, P4461, DOI 10.1128/jb.178.15.4461-4471.1996; DALY MJ, 1995, J BACTERIOL, V177, P5505; DALY MM, UNPUB; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HANSEN MT, 1978, J BACTERIOL, V134, P71, DOI 10.1128/JB.134.1.71-75.1978; Jing JP, 1999, GENOME RES, V9, P175; KIKUCHI M, 1994, RADIAT RES, V139, P123, DOI 10.2307/3578742; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAI Z, UNPUB; Lee E, UNPUB; LINK AJ, 1991, GENETICS, V127, P681; LIOUTAS C, 1995, EXP PARASITOL, V80, P349, DOI 10.1006/expr.1995.1045; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; Minton KW, 1996, MUTAT RES-DNA REPAIR, V363, P1, DOI 10.1016/0921-8777(95)00014-3; MINTON KW, 1995, BIOESSAYS, V17, P457, DOI 10.1002/bies.950170514; Reed J, 1998, ANAL BIOCHEM, V259, P80, DOI 10.1006/abio.1998.2640; SAMAD AH, 1995, NATURE, V378, P516, DOI 10.1038/378516a0; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; Schwartz DC, 1997, CURR OPIN BIOTECH, V8, P70, DOI 10.1016/S0958-1669(97)80160-7; Wang WN, 1998, BIOPHYS J, V75, P513, DOI 10.1016/S0006-3495(98)77540-X; WHITE O, UNPUB	35	143	167	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1558	1562		10.1126/science.285.5433.1558	http://dx.doi.org/10.1126/science.285.5433.1558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477518				2022-12-28	WOS:000082359500063
J	Chemelli, RM; Willie, JT; Sinton, CM; Elmquist, JK; Scammell, T; Lee, C; Richardson, JA; Williams, SC; Xiong, YM; Kisanuki, Y; Fitch, TE; Nakazato, M; Hammer, RE; Saper, CB; Yanagisawa, M				Chemelli, RM; Willie, JT; Sinton, CM; Elmquist, JK; Scammell, T; Lee, C; Richardson, JA; Williams, SC; Xiong, YM; Kisanuki, Y; Fitch, TE; Nakazato, M; Hammer, RE; Saper, CB; Yanagisawa, M			Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation	CELL			English	Article							LATERAL HYPOTHALAMIC AREA; CANINE NARCOLEPSY; INTERMEDIATE STAGE; PARADOXICAL SLEEP; NORMAL DOGS; NEURONS; NUCLEI; CYCLE; PROJECTIONS; DISRUPTION	Neurons containing the neuropeptide orexin (hypocretin) are located exclusively in the lateral hypothalamus and send axons to numerous regions throughout the central nervous system, including the major nuclei implicated in sleep regulation, Here, we report that, by behavioral and electroencephalographic criteria, orexin knockout mice exhibit a phenotype strikingly similar to human narcolepsy patients, as well as canarc-1 mutant dogs, the only known monogenic model of narcolepsy. Moreover, modafinil, an anti-narcoleptic drug with ill-defined mechanisms of action, activates orexin-containing neurons. We propose that orexin regulates sleep/wakefulness states, and that orexin knockout mice are a model of human narcolepsy, a disorder characterized primarily by rapid eye movement (REM) sleep dysregulation.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Beth Israel Deaconess Medical Center; University of Miyazaki	Yanagisawa, M (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	afcsushi@aol.com	Saper, Clifford/L-3815-2019; Kisanuki, Yasushi/E-3393-2011	Hammer, Robert E./0000-0001-5487-7551	NIDDK NIH HHS [DK53301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ASTONJONES G, 1981, J NEUROSCI, V1, P876; BAKER TL, 1986, SLEEP, V9, P232, DOI 10.1093/sleep/9.1.232; BAKER TL, 1982, EXP NEUROL, V75, P729, DOI 10.1016/0014-4886(82)90038-3; BARONE FC, 1981, BRAIN RES BULL, V7, P75, DOI 10.1016/0361-9230(81)90101-5; Bassetti C, 1996, NEUROL CLIN, V14, P545, DOI 10.1016/S0733-8619(05)70273-5; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Ellis CM, 1998, NEUROLOGY, V50, pS23, DOI 10.1212/WNL.50.2_Suppl_1.S23; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; GLIN L, 1991, PHYSIOL BEHAV, V50, P951, DOI 10.1016/0031-9384(91)90420-S; Gottesmann C, 1996, NEUROSCI BIOBEHAV R, V20, P367, DOI 10.1016/0149-7634(95)00055-0; Guilleminault C, 1998, NEUROLOGY, V50, pS8, DOI 10.1212/WNL.50.2_Suppl_1.S8; HISHIKAWA Y, 1976, ELECTROEN CLIN NEURO, V41, P1, DOI 10.1016/0013-4694(76)90210-8; Honda Y., 1988, HLA NARCOLEPSY, P24, DOI [10.1007/978-3-642-83387-8_3, DOI 10.1007/978-3-642-83387-8_3]; Jones B E, 1998, Adv Neurol, V77, P75; Kadotani H, 1998, GENOME RES, V8, P427, DOI 10.1101/gr.8.5.427; KOIZUMI K, 1976, J PHYSIOL-LONDON, V263, P331, DOI 10.1113/jphysiol.1976.sp011634; Konigsmark B., 1970, CONT RES METHODS NEU, P315, DOI DOI 10.1007/978-3-642-85986-1_14; KUSHIDA CA, 1985, ELECTROEN CLIN NEURO, V61, P61, DOI 10.1016/0013-4694(85)91073-9; Lin JS, 1996, P NATL ACAD SCI USA, V93, P14128, DOI 10.1073/pnas.93.24.14128; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; LUCAS EA, 1979, PHYSIOL BEHAV, V23, P737, DOI 10.1016/0031-9384(79)90168-9; MCGINTY DJ, 1976, BRAIN RES, V101, P569, DOI 10.1016/0006-8993(76)90480-7; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; MIKKELSEN JD, 1990, NEUROSCI LETT, V116, P58, DOI 10.1016/0304-3940(90)90386-N; MITLER MM, 1977, ELECTROEN CLIN NEURO, V43, P691, DOI 10.1016/0013-4694(77)90084-0; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; MONTPLAISIR J, 1978, BIOL PSYCHIAT, V13, P73; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; NISHINO S, 1995, J NEUROSCI, V15, P4806; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; Peyron C, 1998, J NEUROSCI, V18, P9996; RADULOVACKI M, 1984, J PHARMACOL EXP THER, V228, P268; Riehl J, 1998, EXP NEUROL, V152, P292, DOI 10.1006/exnr.1998.6847; Risold PY, 1999, NEUROSCI LETT, V259, P153, DOI 10.1016/S0304-3940(98)00906-9; Rye DB, 1997, SLEEP, V20, P757, DOI 10.1093/sleep/20.9.757; Sakurai T, 1999, J BIOL CHEM, V274, P17771, DOI 10.1074/jbc.274.25.17771; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; STERIADE M, 1990, J NEUROSCI, V10, P2541; Tafti M, 1997, NEUROREPORT, V8, P3755, DOI 10.1097/00001756-199712010-00019; THORPY MJ, 1990, INT CALSSIFICATION S; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171; VANNIMERCIER G, 1984, CR ACAD SCI III-VIE, V298, P195; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; ZORICK F, 1982, SLEEP, V5, pS165, DOI 10.1093/sleep/5.S2.S165	54	2267	2428	4	198	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					437	451		10.1016/S0092-8674(00)81973-X	http://dx.doi.org/10.1016/S0092-8674(00)81973-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481909	Bronze			2022-12-28	WOS:000082174900005
J	Di Cristofano, A; Kotsi, P; Peng, YF; Cordon-Cardo, C; Elkon, KB; Pandolfi, PP				Di Cristofano, A; Kotsi, P; Peng, YF; Cordon-Cardo, C; Elkon, KB; Pandolfi, PP			Impaired Fas response and autoimmunity in Pten(+/-) mice	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; COWDEN-DISEASE; CELL-DEATH; PTEN GENE; PTEN/MMAC1; MUTATIONS; APOPTOSIS; BREAST; FREQUENT	Inactivating mutations in the PTEN tumor suppressor gene, encoding a phosphatase, occur in three related human autosomal dominant disorders characterized by tumor Susceptibility. Here it is shown that Pten heterozygous (Pten(+/-)) mutants develop a lethal polyclonal autoimmune disorder with features reminiscent of those observed in Fas-deficient mutants. Fas-mediated apoptosis was impaired in Pten(+/-) mice, and T Lymphocytes from these mice show reduced activation-induced cell death and increased proliferation upon activation. Phosphatidylinositol (PI) 3-kinase inhibitors restored Fas responsiveness in Pten(+/-) cells. These results indicate that Pten is an essential mediator of the Fas response and a repressor of autoimmunity and thus implicate the PI 3-kinase/Akt pathway in Fas-mediated apoptosis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Hosp Special Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020; kotsi, paraskevi/GRR-7445-2022	di cristofano, antonio/0000-0003-2537-3228; kotsi, paraskevi/0000-0003-3696-6731	NATIONAL CANCER INSTITUTE [R01CA082328, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045482] Funding Source: NIH RePORTER; NCI NIH HHS [CA-82328, CA-08748] Funding Source: Medline; NIAMS NIH HHS [AR45482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Cairns P, 1997, CANCER RES, V57, P4997; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Elkon KB, 1996, CURR OPIN IMMUNOL, V8, P852, DOI 10.1016/S0952-7915(96)80015-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Levine JS, 1999, SEMIN NEPHROL, V19, P34; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; Rhei E, 1997, CANCER RES, V57, P3657; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tashiro H, 1997, CANCER RES, V57, P3935; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weintraub JP, 1997, J IMMUNOL, V159, P4117; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	33	439	452	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2122	2125		10.1126/science.285.5436.2122	http://dx.doi.org/10.1126/science.285.5436.2122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497129				2022-12-28	WOS:000082734300041
J	Jadad, AR				Jadad, AR			Promoting partnerships: challenges for the internet age	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL INFORMATION; HEALTH-CARE; MAIL		McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada	McMaster University	Jadad, AR (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada.	jadada@fhs.mcmaster.ca						Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Benjamin I, 1996, Proc AMIA Annu Fall Symp, P398; BENNAHUM DS, 1999, WIRED, V7, P100; BURBEY I, 1999, UBIQUITOUS INTERNET; *CAN MED ASS, 1999, 1998 CAN MED ASS PHY; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Finkelstein J, 1998, J AM MED INFORM ASSN, P336; Frisse ME, 1996, ACAD MED, V71, P1064, DOI 10.1097/00001888-199610000-00012; GARRIOT GL, 1999, LOW EARTH ORBITING S; Goodman KW, 1999, M D COMPUT, V16, P24; HARROW JR, 1998, BANDWIDTH SILICON 21; Haynes RB, 1997, CAN MED ASSOC J, V157, P1718; Haynes RB, 1996, EVIDENCE BASED MED, V1, P196; *HEALTH CORP, 1999, DRAM INCR NUMB MED O; Hersh W, 1999, ACAD MED, V74, P240, DOI 10.1097/00001888-199903000-00012; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Jadad AR, 1998, RANDOMISED CONTROLLE; JADAD AR, IN PRESS CAN MED ASS; Kim P, 1999, BMJ-BRIT MED J, V318, P647, DOI 10.1136/bmj.318.7184.647; Kurzweil R., 1999, AGE SPIRITUAL MACHIN; MANN S, 1999, WEARABLE COMPUTER SY; McNamee D, 1998, LANCET, V351, P772, DOI 10.1016/S0140-6736(05)78927-3; *NAT SCI FDN, 1999, SCI ENG IND 1998 IT; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; Nisbett R. E., 1980, HUMAN INFERENCE STRA; Norman GR, 1998, CAN MED ASSOC J, V158, P177; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; PERAINO V, 1999, WIRED, V7, P136; PLATT C, 1999, WIRED, V7, P150; Smith J, 1998, J NATL CANCER I, V90, P1695, DOI 10.1093/jnci/90.22.1695; Spielberg AR, 1998, JAMA-J AM MED ASSOC, V280, P1353, DOI 10.1001/jama.280.15.1353; United Nations Development Programme, 1999, HUM DEV REP; Weiser M., 1999, UBIQUITOUS COMPUTING; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; 1999, ECONOMIST       0501, P15	37	112	114	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					761	764		10.1136/bmj.319.7212.761	http://dx.doi.org/10.1136/bmj.319.7212.761			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488008	Green Published			2022-12-28	WOS:000082701500025
J	Someya, T; Werner, R; Forchel, A; Catalano, M; Cingolani, R; Arakawa, Y				Someya, T; Werner, R; Forchel, A; Catalano, M; Cingolani, R; Arakawa, Y			Room temperature lasing at blue wavelengths in gallium nitride microcavities	SCIENCE			English	Article							STRUCTURE LASER-DIODES; PULSED OPERATION	Lasing action has been demonstrated at blue wavelengths in vertical cavity surface-emitting Lasers at room temperature. The microcavity was formed by sandwiching indium gallium nitride multiple quantum wells between nitride-based and oxide-based quarter-wave reflectors. Lasing action was observed at a wavelength of 399 nanometers under optical excitation and confirmed by a narrowing of the Linewidth in the emission spectra from 0.8 nanometer below threshold to Less than 0.1 nanometer (resolution limit) above threshold. The result suggests that practical blue vertical cavity surface-emitting lasers can be realized in gallium-nitride-based material systems.	Univ Tokyo, Inst Ind Sci, Minato Ku, Tokyo 1068558, Japan; Univ Wurzburg, Lehrstuhl Tech Phys, D-97074 Wurzburg, Germany; Univ Lecce, CNR, Ist Studio Mat Elettr, I-73100 Lecce, Italy; Univ Lecce, Ist Nazl Fis Mat, Dipartimento Ingn Innovaz, I-73100 Lecce, Italy	University of Tokyo; University of Wurzburg; Consiglio Nazionale delle Ricerche (CNR); University of Salento; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Salento	Someya, T (corresponding author), Univ Tokyo, Inst Ind Sci, Minato Ku, 7-22-1 Roppongi, Tokyo 1068558, Japan.		Prados, Michael/N-5220-2019; Kesari, Santosh/E-8461-2013; Cingolani, Roberto/B-9191-2011; Someya, Takao/H-3052-2015; Catalano, Massimo/AAA-9366-2019	Someya, Takao/0000-0003-3051-1138; Catalano, Massimo/0000-0001-9218-1133; Forchel, Alfred/0000-0002-9377-9935				Akasaki I, 1996, ELECTRON LETT, V32, P1105, DOI 10.1049/el:19960743; BLUMAN GE, 1997, ELECTRON LETT, V33, P1556; Coldren L.A., 1995, DIODE LASERS PHOTONI; FRITZ IJ, 1995, ELECTRON LETT, V31, P68, DOI 10.1049/el:19950020; IGA K, 1996, P 1 INT S BLUE LAS L; Itaya K, 1996, JPN J APPL PHYS 2, V35, pL1315, DOI 10.1143/JJAP.35.L1315; Katoh H, 1998, JPN J APPL PHYS 2, V37, pL444, DOI 10.1143/JJAP.37.L444; Kimura Y, 1998, JPN J APPL PHYS 2, V37, pL1231, DOI 10.1143/JJAP.37.L1231; Kuramata A, 1997, JPN J APPL PHYS 2, V36, pL1130, DOI 10.1143/JJAP.36.L1130; Mack MP, 1997, MRS INTERNET J N S R, V2, part. no.; Nakamura S, 1998, JPN J APPL PHYS 2, V37, pL309, DOI 10.1143/JJAP.37.L309; Nakamura S, 1998, SCIENCE, V281, P956, DOI 10.1126/science.281.5379.956; Nakamura S, 1996, JPN J APPL PHYS 2, V35, pL74, DOI 10.1143/JJAP.35.L74; Nakamura S, 1996, APPL PHYS LETT, V69, P4056, DOI 10.1063/1.117816; Nakamura S, 1998, JPN J APPL PHYS 2, V37, pL1020, DOI 10.1143/JJAP.37.L1020; Nakamura S., 1997, BLUE LASER DIODE GAN; Redwing JM, 1996, APPL PHYS LETT, V69, P1, DOI 10.1063/1.118104; Shirasawa T, 1998, J CRYST GROWTH, V189, P124, DOI 10.1016/S0022-0248(98)00184-5; Someya T, 1998, APPL PHYS LETT, V73, P3653, DOI 10.1063/1.122852; Someya T, 1998, JPN J APPL PHYS 2, V37, pL1424, DOI 10.1143/JJAP.37.L1424; STRITE S, 1992, J VAC SCI TECHNOL B, V10, P1237, DOI 10.1116/1.585897	21	231	247	3	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1905	1906		10.1126/science.285.5435.1905	http://dx.doi.org/10.1126/science.285.5435.1905			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489367	Green Submitted			2022-12-28	WOS:000082638300047
J	Randel, WJ; Stolarski, RS; Cunnold, DM; Logan, JA; Newchurch, MJ; Zawodny, JM				Randel, WJ; Stolarski, RS; Cunnold, DM; Logan, JA; Newchurch, MJ; Zawodny, JM			Atmosphere - Trends in the vertical distribution of ozone	SCIENCE			English	Review								Analyses of satellite, ground-based, and balloon measurements allow updated estimates of trends in the vertical profile of ozone since 1979. The results show overall consistency among several independent measurement systems, particularly for northern hemisphere midlatitudes where most balloon and ground-based measurements are made. Combined trend estimates over these Latitudes for the period 1979-96 show statistically significant negative trends at all altitudes between 10 and 45 km, with two Local extremes: -7.4 +/- 2.0% per decade at 40 km and -7.3 +/- 4.6% per decade at 15 km altitude. There is a strong seasonal variation in trends over northern midlatitudes in the altitude range of 10 to 18 km, with the Largest ozone loss during winter and spring. The profile trends are in quantitative agreement with independently measured trends in column ozone, the amount of ozone in a column above the surface. The vertical profiles of ozone trends provide a fingerprint for the mechanisms of ozone depletion over the last two decades.	Natl Ctr Atmospher Res, Boulder, CO 80307 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Georgia Inst Technol, Atlanta, GA 30332 USA; Harvard Univ, Cambridge, MA 02138 USA; Univ Alabama, Huntsville, AL 35899 USA; NASA, Langley Res Ctr, Hampton, VA 23681 USA	National Center Atmospheric Research (NCAR) - USA; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Georgia; Georgia Institute of Technology; Harvard University; University of Alabama System; University of Alabama Huntsville; National Aeronautics & Space Administration (NASA); NASA Langley Research Center	Randel, WJ (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.		Stolarski, Richard/B-8499-2013; Randel, William J/K-3267-2016; Logan, Jennifer A/B-7323-2014	Stolarski, Richard/0000-0001-8722-4012; Randel, William J/0000-0002-5999-7162; 				BEKKI S, 1994, NATURE, V371, P595, DOI 10.1038/371595a0; BRASSEUR Y, 1986, AERONOMY MIDDLE ATMO; FUGLESTVEDT JS, 1994, TELLUS B, V46, P172, DOI 10.1034/j.1600-0889.1992.t01-3-00001.x-i1; Fusco AC, 1999, J CLIMATE, V12, P1619, DOI 10.1175/1520-0442(1999)012<1619:IVOTOA>2.0.CO;2; HOFMANN DJ, 1999, 44 WMO GLOB OZ RES M, pCH12; Hood LL, 1997, J GEOPHYS RES-ATMOS, V102, P13079, DOI 10.1029/97JD00423; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P465, DOI 10.1029/92GL00378; MCCORMICK MP, 1989, PLANET SPACE SCI, V37, P1567, DOI 10.1016/0032-0633(89)90146-3; McPeters RD, 1996, GEOPHYS RES LETT, V23, P3699, DOI 10.1029/96GL03540; MULLER R, 1999, SCI ASSESSMENT OZONE, pCH6; PENTZOLDT K, 1999, ANN GEOPHYS, V17, P231	11	90	97	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1689	1692		10.1126/science.285.5434.1689	http://dx.doi.org/10.1126/science.285.5434.1689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10480999	Green Submitted			2022-12-28	WOS:000082472600025
J	Kelly, TR; De Silva, H; Silva, RA				Kelly, TR; De Silva, H; Silva, RA			Unidirectional rotary motion in a molecular system	NATURE			English	Article							MOTORS; MUSCLE; F1-ATPASE; MACHINES; SHUTTLE; COMPLEX; RATCHET; SEARCH; WORK	The conversion of energy into controlled motion plays an important role in both man-made devices and biological systems. The principles of operation of conventional motors are well established, but the molecular processes used by 'biological motors' such as muscle fibres, flagella and cilia(1-9) to convert chemical energy into co-ordinated movement remain poorly understood(10-12). Although Brownian ratchets'(13-16) are known to permit thermally activated motion in one direction only, the concept of channelling random thermal energy into controlled motion has not pet been extended to the molecular level. Here we describe a molecule that uses chemical energy to activate and bias a thermally induced isomerization reaction, and thereby achieve unidirectional intramolecular rotary motion. The motion consists of a 120 degrees rotation around a single bond connecting a three-bladed subunit to the bulky remainder of the molecule, and unidirectional motion is achieved by reversibly introducing a tether between the two units to energetically favour one of the two possible rotation directions. Although our system does not achieve continuous and fast rotation, the design principles that we have used may prove relevant for a better understanding of biological and synthetic molecular motors producing unidirectional rotary motion.	Boston Coll, Dept Chem, EF Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Kelly, TR (corresponding author), Boston Coll, Dept Chem, EF Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BENNISTON AC, 1993, ANGEW CHEM INT EDIT, V32, P1459, DOI 10.1002/anie.199314591; Berg HC, 1998, NATURE, V394, P324, DOI 10.1038/28506; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Block SM, 1997, NATURE, V386, P217, DOI 10.1038/386217a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Huxley A, 1998, NATURE, V391, P239, DOI 10.1038/34567; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; KELLY TR, 1994, J AM CHEM SOC, V116, P3657, DOI 10.1021/ja00087a085; Kelly TR, 1998, J ORG CHEM, V63, P3655, DOI 10.1021/jo9723218; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Mislow K, 1988, CHEMTRACTS ORG CHEM, V2, P151; Musser G, 1999, SCI AM, V280, P24; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; STRYER L, 1995, BIOCHEMISTRY-US, pCH15; TRAVIS J, 1995, SCIENCE, V267, P1593, DOI 10.1126/science.267.5204.1593; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I	28	679	691	2	201	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					150	152		10.1038/43639	http://dx.doi.org/10.1038/43639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490021				2022-12-28	WOS:000082458800049
J	Koumura, N; Zijlstra, RWJ; van Delden, RA; Harada, N; Feringa, BL				Koumura, N; Zijlstra, RWJ; van Delden, RA; Harada, N; Feringa, BL			Light-driven monodirectional molecular rotor	NATURE			English	Article							UNIQUE CHIRAL OLEFINS; ABSOLUTE STEREOCHEMISTRY; ROTATION; TRANS-1,1',2,2',3,3',4,4'-OCTAHYDRO-3,3'-DIMETHYL-4,4'-BIPHENANTHRYLIDENE; CIS-1,1',2,2',3,3',4,4'-OCTAHYDRO-3,3'-DIMETHYL-4,4'-BIPHENANTHRYLIDENE; MACHINES	Attempts to fabricate mechanical devices on the molecular level(1,2) have yielded analogues of rotors(3), gears(4) switches(5), shuttles(6,7), turnstiles(8) and ratchets(9). Molecular motors, however, have not yet been made, even though they are common in biological systems(10) Rotary motion as such has been induced in interlocked systems(11-13) and directly visualized for single molecules(14), but the controlled conversion of energy into unidirectional rotary motion has remained difficult to achieve. Here we report repetitive, monodirectional rotation around a central carbon-carbon double bond in a chiral, helical alkene, with each 360 degrees rotation involving four discrete isomerization steps activated by ultraviolet light or a change in the temperature of the system. We find that axial chirality and the presence of two chiral centres are essential for the observed monodirectional behaviour of the molecular motor. Two light-induced cis-trans isomerizations are each associated with a 180 degrees rotation around the carbon-carbon double bond and are each followed by thermally controlled helicity inversions, which effectively block reverse rotation and thus ensure that the four individual steps add up to one full rotation in one direction only. As the energy barriers of the helicity inversion steps can be adjusted by structural modifications, chiral alkenes based on our system may find use as basic components for 'molecular machinery' driven by light.	Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, NL-9747 AG Groningen, Netherlands; Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	University of Groningen; Tohoku University	Feringa, BL (corresponding author), Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Feringa, Ben L./C-1665-2013; Koumura, Nagatoshi/M-4947-2018	Koumura, Nagatoshi/0000-0002-2141-0741				Armaroli N, 1999, J AM CHEM SOC, V121, P4397, DOI 10.1021/ja984051w; Ashton PR, 1998, J AM CHEM SOC, V120, P11932, DOI 10.1021/ja982167m; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Clayden J, 1998, ANGEW CHEM INT EDIT, V37, P1937, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14<1937::AID-ANIE1937>3.0.CO;2-4; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Drexler K.E., 1992, NANOSYSTEMS MOL MACH; Feynman RP, 1961, MINIATURIZATION; Gimzewski JK, 1998, SCIENCE, V281, P531, DOI 10.1126/science.281.5376.531; Harada N, 1997, J AM CHEM SOC, V119, P7256, DOI 10.1021/ja970669e; Huck NPM, 1996, SCIENCE, V273, P1686, DOI 10.1126/science.273.5282.1686; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; Koumura N, 1998, CHEM LETT, P1151, DOI 10.1246/cl.1998.1151; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Schoevaars AM, 1997, J ORG CHEM, V62, P4943, DOI 10.1021/jo962210t	17	1386	1400	26	925	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					152	155		10.1038/43646	http://dx.doi.org/10.1038/43646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490022	Green Submitted			2022-12-28	WOS:000082458800050
J	Delpre, G; Stark, P; Niv, Y				Delpre, G; Stark, P; Niv, Y			Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation	LANCET			English	Article								Effectiveness of sublingual cobalamin-replacement therapy was studied in 18 people with cobalamin deficiency. Administration was efficacious and convenient, and compliance was high.	Rabin Med Ctr, Dept Gastroenterol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Inst Haematol, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Delpre, G (corresponding author), Rabin Med Ctr, Dept Gastroenterol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							Elia M, 1998, LANCET, V352, P1721, DOI 10.1016/S0140-6736(05)79821-4; Kuzminski AM, 1998, BLOOD, V92, P1191, DOI 10.1182/blood.V92.4.1191.416k15_1191_1198; LEDERLE FA, 1991, JAMA-J AM MED ASSOC, V265, P94, DOI 10.1001/jama.265.1.94; MURRAY MT, 1996, AM J NAT MED, V3, P10; Verhaeverbeke I, 1997, J AM GERIATR SOC, V45, P124, DOI 10.1111/j.1532-5415.1997.tb01000.x	5	34	34	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					740	741		10.1016/S0140-6736(99)02479-4	http://dx.doi.org/10.1016/S0140-6736(99)02479-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475189				2022-12-28	WOS:000082233000017
J	Grum, VL; Li, DN; MacDonald, RI; Mondragon, A				Grum, VL; Li, DN; MacDonald, RI; Mondragon, A			Structures of two repeats of spectrin suggest models of flexibility	CELL			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; MEMBRANE SKELETON; CRYSTAL-STRUCTURE; ALPHA-SPECTRIN; TEMPERATURE-DEPENDENCE; CONFORMATIONAL UNIT; MOLECULAR-STRUCTURE; PLASMA-MEMBRANE; CELL MEMBRANE; SITE	Spectrin is a vital component of the cytoskeleton, conferring flexibility on cells and providing a scaffold for a variety of proteins. It is composed of tandem, antiparallel coiled-coil repeats. We report four related crystal structures at 1.45 Angstrom, 2.0 Angstrom 3.1 Angstrom and 4.0 Angstrom resolution of two connected repeats of chicken brain a-spectrin. In all of the structures, the linker region between adjacent units is or-helical without breaks, kinks, or obvious boundaries. Two features observed in the structures are (1) conformational rearrangement in one repeat, resulting in movement of the position of a loop, and (2) varying degrees of bending at the linker region. These features form the basis of two different models of flexibility: a conformational rearrangement and a bending model. These models provide novel atomic details of spectrin flexibility.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	a-mondragon@nwu.edu			NIGMS NIH HHS [GM57692, GM51350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057692, R01GM051350] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BABCOCK MS, 1994, J MOL BIOL, V237, P125, DOI 10.1006/jmbi.1994.1213; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLOCH R J, 1992, Trends in Cell Biology, V2, P186, DOI 10.1016/0962-8924(92)90231-B; Brown JH, 1996, PROTEINS, V26, P134; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P3898, DOI 10.1021/bi00468a016; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DeSilva TM, 1997, BIOCHEMISTRY-US, V36, P3991, DOI 10.1021/bi962412j; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dubreuil RR, 1996, CURR TOP MEMBR, V43, P147; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUNG LWM, 1989, LIFE SCI, V44, P735, DOI 10.1016/0024-3205(89)90385-8; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GRUM VL, 1998, THESIS NW U EVANSTON; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEARMONTH RP, 1989, BIOCHIM BIOPHYS ACTA, V987, P124, DOI 10.1016/0005-2736(89)90463-X; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; Lusitani D, 1998, BIOCHEMISTRY-US, V37, P16546, DOI 10.1021/bi9811462; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MARCHESI SL, 1991, CURR TOP MEMBR, V38, P155; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKKELSEN A, 1981, BIOCHIM BIOPHYS ACTA, V668, P74, DOI 10.1016/0005-2795(81)90150-1; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 1998, BIOCHEM J, V332, P81, DOI 10.1042/bj3320081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantazatos DP, 1997, J BIOL CHEM, V272, P21052, DOI 10.1074/jbc.272.34.21052; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Repasky EA, 1996, CURR TOP MEMBR, V43, P313; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Steck T. L., 1989, CELL SHAPE DETERMINA, P205; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P111, DOI 10.1016/0005-2736(85)90399-2; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P102, DOI 10.1016/0005-2736(85)90398-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WAUGH RE, 1982, BIOPHYS J, V39, P273, DOI 10.1016/S0006-3495(82)84517-7; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	72	213	214	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					523	535		10.1016/S0092-8674(00)81980-7	http://dx.doi.org/10.1016/S0092-8674(00)81980-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481916	Bronze			2022-12-28	WOS:000082174900012
J	Weitering, HH; Carpinelli, JM; Melechko, AP; Zhang, JD; Bartkowiak, M; Plummer, EW				Weitering, HH; Carpinelli, JM; Melechko, AP; Zhang, JD; Bartkowiak, M; Plummer, EW			Defect-mediated condensation of a charge density wave	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; TRANSITION; PHASE; SURFACE; INTERFACE; DISORDER; SYSTEMS	Symmetry, dimensionality, and disorder play a pivotal role in critical phenomena. The atomic imaging capabilities of the scanning tunneling microscope were used to directly visualize the interaction between charge density oscillations and Lattice defects in a two-dimensional charge density wave (CDW) system, point defects act as nucleation centers of the CDW, which, as the temperature is Lowered, results in the formation of pinned CDW domains that are separated by atomically abrupt charge boundaries. Incomplete freezing of substitutional disorder at low temperature indicates a novel CDW-mediated hopping of pinning centers.	Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA; Oak Ridge Natl Lab, Div Solid State, Oak Ridge, TN 37831 USA; Florida Int Univ, Dept Phys, Miami, FL 33199 USA	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; State University System of Florida; Florida International University	Weitering, HH (corresponding author), Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA.		Melechko, Anatoli/B-8820-2008; Weitering, Hanno H/I-2884-2017	Weitering, Hanno H/0000-0001-6770-9039				AIZENMAN M, 1989, PHYS REV LETT, V62, P2503, DOI 10.1103/PhysRevLett.62.2503; ALEXANDER S, 1975, PHYS LETT A, V54, P353, DOI 10.1016/0375-9601(75)90766-5; Avila J, 1999, PHYS REV LETT, V82, P442, DOI 10.1103/PhysRevLett.82.442; BARTKOWIAK M, UNPUB; Cardy J, 1999, PHYSICA A, V263, P215, DOI 10.1016/S0378-4371(98)00489-0; Carpinelli JM, 1998, SURF SCI, V401, pL457, DOI 10.1016/S0039-6028(98)00146-0; Carpinelli JM, 1997, PHYS REV LETT, V79, P2859, DOI 10.1103/PhysRevLett.79.2859; Carpinelli JM, 1996, NATURE, V381, P398, DOI 10.1038/381398a0; DUMAS J, 1984, PHYS REV B, V30, P2249, DOI 10.1103/PhysRevB.30.2249; FISHER DS, 1988, PHYS TODAY, V41, P56, DOI 10.1063/1.881141; GIAMBATTISTA B, 1990, PHYS REV B, V41, P10082, DOI 10.1103/PhysRevB.41.10082; Gruner G., 1994, DENSITY WAVES SOLIDS; HUI K, 1989, PHYS REV LETT, V62, P2507, DOI 10.1103/PhysRevLett.62.2507; INOUE K, 1994, PHYS REV B, V49, P14774, DOI 10.1103/PhysRevB.49.14774; MELECHKO AV, UNPUB; METOIS JJ, 1983, SURF SCI, V133, P422, DOI 10.1016/0039-6028(83)90011-0; SCHICK M, 1977, PHYS REV B, V16, P2205, DOI 10.1103/PhysRevB.16.2205; Stumpf RR, 1999, PHYS REV B, V59, P15779, DOI 10.1103/PhysRevB.59.15779; WEAIRE D, 1984, CONTEMP PHYS, V25, P59, DOI 10.1080/00107518408210979; WEAKLIEM PC, 1990, SURF SCI, V232, pL219, DOI 10.1016/0039-6028(90)90112-L; WILSON JA, 1975, ADV PHYS, V24, P117, DOI 10.1080/00018737500101391; WU XL, 1990, PHYS REV B, V41, P1239, DOI 10.1103/PhysRevB.41.1239	22	99	100	4	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2107	2110		10.1126/science.285.5436.2107	http://dx.doi.org/10.1126/science.285.5436.2107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497124				2022-12-28	WOS:000082734300036
J	Kalb, PE				Kalb, PE			Health care fraud and abuse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In recent years, health care fraud and abuse have become major issues, in part because of the rising cost of health care, industry consolidation, the emergence of private "whistle-blowers," and a change in the concept of fraud to include an emerging concern about quality of care. The 3 types of conduct that are generally prohibited by hearth care fraud laws are false claims, kickbacks, and self-referrals. False claims are subject to several criminal, civil, and administrative prohibitions, notably the federal civil False Claims Act. Kickbacks, or inducements with the intent to influence the purchase or sale of health care-related goods or services, are prohibited under the federal Anti-Kickback statute as well as by state laws. Finally, self-referrals-the referral of patients to an entity with which the referring physician has a financial relationship-are outlawed by the Ethics in Patient Referral Act as well as numerous state statutes. Consequences of violations of these laws can include, in addition to imprisonment and fines, civil monetary penalties, loss of licensure, loss of staff privileges, and exclusion from participation in federal health care programs. Federal criminal and civil statutes are enforced by the US Department of Justice; administrative actions are pursued by the Department of Health and Human Services' Office of Inspector General; and ail state actions are pursued by the individual states. In addition, private whistle-blowers may, acting in the name of the United States, file suit against an entity under the False Claims Act. Enforcement of health care fraud and abuse laws has become increasingly commonplace and now affects many mainstream providers. This trend is likely to continue.	Sidley & Austin, Washington, DC USA		Kalb, PE (corresponding author), 1722 Eye St NW, Washington, DC 20006 USA.	pkalb@sidley.com						Altschuler AM, 1998, AM CRIM LAW REV, V35, P841; *AM HLTH LAW ASS, 1999, 199 ANN REP STAT HLT; BELUCK P, 1995, NY TIMES        1222, P32; BETZ K, 1999, BNA HLTH CARE FRAUD, V3, P362; BUYC P, 1999, HLTH CARE FRAUD CRIM; *DEP HLTH HUM SERV, 1999, HLTH CAR FRAUD AB CO; EICHENWALD K, 1998, NY TIMES        1231, pC1; HOFFMAN DR, 1996, FALSE CLAIMS ACT QUI, V6, P17; MANIER J, 1999, CHICAGO TRIBUNE 0117, P1; MCADAMS RW, 1998, STATE FEDERAL PROHIB; MITKA M, 1996, AM MED NEWS     1209, P3; MOORE JD, 1999, MODERN HEALTHCA 0412, P2; *OFF INSP GEN, 1997, OV PHYS TEACH HOSP I; Pear Robert, 1999, N Y Times Web, pA20; SHEEHAN JG, 1998, HLTH CARE FRAUD 1998, pH11; TANOUYE E, 1997, WALL STREET J   0225, pB6; TOP DOJ, 1999, BNA HLTH CARE FRAUD, V3, P385; *US DEP JUST, 1996, HLTH CAR FRAUD REP F; *US DEP JUST, 1997, HLTH CARE FRAUD REP, P14; *US GEN ACC, 1992, HLTH INS VULN PAY LO; *US GEN ACC OFF, 1998, US GEN ACC OFF PUBL	21	39	42	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1163	1168		10.1001/jama.282.12.1163	http://dx.doi.org/10.1001/jama.282.12.1163			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501120				2022-12-28	WOS:000082596200032
J	Little, SJ; Daar, ES; D'Aquila, RT; Keiser, PH; Connick, E; Whitcomb, JM; Hellmann, NS; Petropoulos, CJ; Sutton, L; Pitt, JA; Rosenberg, ES; Koup, RA; Walker, BD; Richman, DD				Little, SJ; Daar, ES; D'Aquila, RT; Keiser, PH; Connick, E; Whitcomb, JM; Hellmann, NS; Petropoulos, CJ; Sutton, L; Pitt, JA; Rosenberg, ES; Koup, RA; Walker, BD; Richman, DD			Reduced antiretroviral drug susceptibility among patients with primary HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE RESISTANCE; REVERSE-TRANSCRIPTASE; NUCLEOSIDE ANALOGS; THERAPY; LAMIVUDINE; TRANSMISSION; NEVIRAPINE; INDINAVIR; VIREMIA	Context The transmission of drug-resistant hu man immunodeficiency virus (HIV) has been documented, but the prevalence of such transmission is unknown. Objective To assess the spectrum and frequency of antiretroviral susceptibility among subjects with primary HIV infection. Design, Setting, and Patients Retrospective analysis of 141 subjects identified from clinical research centers in 5 major metropolitan areas, enrolled from 1989 to 1998, with HIV seroconversion within the preceding 12 months and no more than 7 days' prior antiretroviral (ARV) therapy. Main Outcome Measures Phenotypic and genotypic ARV susceptibility of HIV from plasma samples. Results The transmission of drug-resistant HIV as assessed by a greater than 10-fold reduction in ARV susceptibility to 1 or more drugs was observed in 3 (2%) of 141 subjects, including to a nonnucleoside reverse transcriptase inhibitor in 1 patient and to a nucleoside reverse transcriptase inhibitor and a protease inhibitor in 2 patients. Population-based sequence analysis of these 3 samples identified multidrug-resistance mutations in reverse transcriptase (M184V, T215Y, K219K/R) and protease (L10I/V, K20R, M36I, M46I, G48V, L63P, A71T, V77I, V82T, I84V, L90M) in the 2 latter patient samples, along with numerous polymorphisms. A reduction in susceptibility of greater than 2.5- to 10-fold to 1 or more drugs was observed in viral isolates from 36 patients (26%). Sequence analysis of these 36 samples identified well-characterized drug resistance mutation in reverse transcriptase and protease in only 1 of these patients. Conclusions Reductions in drug susceptibility of more than 10-fold were rare among this cohort of recently HIV-infected subjects and were distributed among each of the 3 major classes of ARV drugs tested. Reductions in susceptibility of more than 2.5- to 10-fold to certain ARV drugs of unknown clinical significance were highly prevalent among newly infected patients. Resistance testing may be warranted to monitor the frequency of drug resistance over time and to assess the potential for geographic variability.	Univ Calif San Diego, Treatment Ctr, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Dept Vet Affairs Med Ctr, San Diego, CA USA; Cedars Sinai Burns & Allen Res Inst, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Dept Vet Affairs Med Ctr, Denver, CO USA; ViroLog Inc, San Francisco, CA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Merck & Co Inc, Blue Bell, PA USA; Bristol Myers Squibb Co, Glaxo Wellcome, Princeton, NJ USA; Agouron Inst, La Jolla, CA 92037 USA; Roxane, Columbus, OH USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Massachusetts General Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; GlaxoSmithKline; Merck & Company; Bristol-Myers Squibb; GlaxoSmithKline	Little, SJ (corresponding author), Univ Calif San Diego, Treatment Ctr, Dept Med, 2760 5th Ave,Suite 300, San Diego, CA 92103 USA.	slittle@ucsd.edu	Little, Susan/AAA-6116-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001541, P30AI036214, U01AI027670] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Conway B, 1999, CLIN INFECT DIS, V28, P910, DOI 10.1086/515225; DAAR E, 1999, 6 C RETR OPP INF JAN; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1998, J VIROL, V72, P3773, DOI 10.1128/JVI.72.5.3773-3778.1998; HARRIGAN R, 1998, 38 INT C ANT AG CHEM; HECHT F, 1998, 12 INT C AIDS JUN 28; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HELLMAN N, 1999, 3 INT WORKSH DRUG RE; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HUANG W, 1999, 3 INT WORKSH DRUG RE; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Imrie A, 1996, J INFECT DIS, V174, P195, DOI 10.1093/infdis/174.1.195; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; MILLER MD, 1999, 3 INT WORKSH DRUG RE; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Parkin NT, 1999, J INFECT DIS, V180, P865, DOI 10.1086/314928; PARKIN NT, 1999, 3 INT WORKSH DRUG RE; Piketty C, 1999, AIDS, V13, pF71, DOI 10.1097/00002030-199907300-00001; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SKOWRON G, 1999, 3 INT WORKSH DRUG RE; Vanhems P, 1997, CLIN INFECT DIS, V24, P965, DOI 10.1093/clinids/24.5.965; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; YERLY S, 1998, 12 INT C AIDS JUN 26	39	266	275	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1142	1149		10.1001/jama.282.12.1142	http://dx.doi.org/10.1001/jama.282.12.1142			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501117	Bronze			2022-12-28	WOS:000082596200029
J	Bechinger, C; Giebel, KF; Schnell, M; Leiderer, P; Deising, HB; Bastmeyer, M				Bechinger, C; Giebel, KF; Schnell, M; Leiderer, P; Deising, HB; Bastmeyer, M			Optical measurements of invasive forces exerted by appressoria of a plant pathogenic fungus	SCIENCE			English	Article							TURGOR PRESSURE; RICE BLAST; PENETRATION; MICROSCOPY	Many plant pathogenic fungi, such as the cereal pathogen Colletotrichum graminicola, differentiate highly specialized infection structures called appressoria, which send a penetration peg into the underlying plant cell. Appressoria have been shown to generate enormous turgor pressure, but direct evidence for mechanical infection of plants by fungi is Lacking. A microscopic method was developed that uses elastic optical waveguides to visualize and measure forces Locally exerted by single appressoria. By this method, the force exerted-by appressoria of C. graminicola was found to be about 17 micronewtons.	Univ Halle Wittenberg, Fac Agr Phytopathol & Plant Protect, D-06099 Halle, Saale, Germany; Univ Konstanz, Fac Phys, D-78457 Constance, Germany; Univ Konstanz, Fac Biol, D-78457 Constance, Germany	Martin Luther University Halle Wittenberg; University of Konstanz; University of Konstanz	Deising, HB (corresponding author), Univ Halle Wittenberg, Fac Agr Phytopathol & Plant Protect, Ludwig Wucherer Str 2, D-06099 Halle, Saale, Germany.		Bastmeyer, Martin/H-9342-2013	Bastmeyer, Martin/0000-0003-3471-8400; Deising, Holger Bruno/0000-0001-5789-4269				deJong JC, 1997, NATURE, V389, P244, DOI 10.1038/38418; Herminghaus S, 1997, APPL PHYS LETT, V70, P22, DOI 10.1063/1.119292; HERMINGHAUS S, 1994, OPT COMMUN, V112, P16, DOI 10.1016/0030-4018(94)90072-8; HERMINGHAUS S, 1989, APPL PHYS LETT, V54, P99, DOI 10.1063/1.101201; HICKEL W, 1989, ACTA METALL MATER, V37, P2141, DOI 10.1016/0001-6160(89)90139-9; HOWARD RJ, 1991, P NATL ACAD SCI USA, V88, P11281, DOI 10.1073/pnas.88.24.11281; Howard RJ, 1996, ANNU REV MICROBIOL, V50, P491, DOI 10.1146/annurev.micro.50.1.491; KRETSCHM.E, 1968, Z NATURFORSCH PT A, VA 23, P2135, DOI 10.1515/zna-1968-1247; Kubo Y, 1996, APPL ENVIRON MICROB, V62, P4340, DOI 10.1128/AEM.62.12.4340-4344.1996; Lavers CR, 1996, THIN SOLID FILMS, V289, P133, DOI 10.1016/S0040-6090(96)08885-2; Mendgen K, 1996, ANNU REV PHYTOPATHOL, V34, P367, DOI 10.1146/annurev.phyto.34.1.367; MONEY NP, 1995, CAN J BOT, V73, pS96, DOI 10.1139/b95-231; Money NP, 1996, FUNGAL GENET BIOL, V20, P217, DOI 10.1006/fgbi.1996.0037; Oerke EC., 1994, CROP PRODUCTION CROP; OTTO A, 1968, PHYS STATUS SOLIDI, V26, pK99, DOI 10.1002/pssb.19680260246; POLITIS DJ, 1973, PHYSIOL PLANT PATHOL, V3, P465, DOI 10.1016/0048-4059(73)90056-8; SAMBLES JR, 1991, CONTEMP PHYS, V32, P173, DOI 10.1080/00107519108211048; WALTON JD, 1994, PLANT PHYSIOL, V104, P1113, DOI 10.1104/pp.104.4.1113	18	193	213	5	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1896	1899		10.1126/science.285.5435.1896	http://dx.doi.org/10.1126/science.285.5435.1896			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489364	Green Submitted			2022-12-28	WOS:000082638300044
J	Cao, TT; Deacon, HW; Reczek, D; Bretscher, A; von Zastrow, M				Cao, TT; Deacon, HW; Reczek, D; Bretscher, A; von Zastrow, M			A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta 2-adrenergic receptor	NATURE			English	Article							BETA(2)-ADRENERGIC RECEPTOR; NA+/H+-EXCHANGER; PHOSPHORYLATION SITES; PROTEIN; MEMBRANE; DESENSITIZATION; BINDING; RESENSITIZATION; INTERNALIZATION; IDENTIFICATION	A fundamental question in cell biology is how membrane proteins are sorted in the endocytic pathway, The sorting of internalized beta 2-adrenergic receptors between recycling endosomes and lysosomes is responsible for opposite effects on signal transduction and is regulated by physiological stimuli(1,2). Here we describe a mechanism that controls this sorting operation, which is mediated by a family of conserved protein-interaction modules called PDZ domains(3). The phosphoprotein EBP50 (for ezrin-radixin-moesin(ERM)-binding phosphoprotein-50)(4) binds to the cytoplasmic tail of the beta 2-adrenergic receptor through a PDZ domain and to the cortical actin cytoskeleton through an ERM-binding domain. Disrupting the interaction of EBP50 with either domain or depolymerization of the actin cytoskeleton itself causes missorting of endocytosed beta 2-adrenergic receptors but does not affect the recycling of transferrin receptors. A serine residue at position 411 in the tail of the beta 2-adrenergic receptor is a substrate for phosphorylation by GRK-5 (for G-protein-coupled-receptor kinase-5) (ref. 5) and is required for interaction with EBP50 and for proper recycling of the receptor. Our results identify a new role for PDZ-domain-mediated protein interactions and for the actin cytoskeleton in endocytic sorting, and suggest a mechanism by which GRK-mediated phosphorylation could regulate membrane trafficking of G-protein-coupled receptors after endocytosis.	Univ Calif San Francisco, Program Cell Biol Cellular & Mol Pharmacol & Psyc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University	von Zastrow, M (corresponding author), Univ Calif San Francisco, Program Cell Biol Cellular & Mol Pharmacol & Psyc, San Francisco, CA 94143 USA.							Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durrbach A, 1996, J CELL SCI, V109, P457; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	26	551	558	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					286	290		10.1038/45816	http://dx.doi.org/10.1038/45816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499588				2022-12-28	WOS:000082678400056
J	Llewellyn-Jones, RH; Baikie, KA; Smithers, H; Cohen, J; Snowdon, J; Tennant, CC				Llewellyn-Jones, RH; Baikie, KA; Smithers, H; Cohen, J; Snowdon, J; Tennant, CC			Multifaceted shared care intervention for late life depression in residential care: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PEOPLE; MAJOR DEPRESSION; NURSING-HOME; MENTAL-HEALTH; VALIDATION; MORTALITY; SYMPTOMS; RATES	Objective To evaluate the effectiveness of a population based, multifaceted shared care intervention for late life depression in residential care. Design Randomised controlled trial, with control and intervention groups studied one after the other and blind follow up after 9.5 months. Setting Population of residential facility in Sydney living in self care units and hostels. Participants 220 depressed residents aged greater than or equal to 65 without severe cognitive impairment. Intervention The shared care intervention included: (a) multidisciplinary consultation and collaboration, (b) training of general practitioners and carers in detection and management of depression, and (c) depression related health education and activity programmes for residents. The control group received routine care. Main outcome measure Geriatric depression scale. Results Intention to treat analysis was used. There was significantly more movement to "less depressed" levels of depression at follow up in the intervention than control group (Mantel-Haenszel stratification test, P = 0.0125). Multiple linear regression analysis found a significant intervention effect after controlling for possible confounders, with the intervention group showing an average improvement of 1.87 points on the geriatric depression scale compared with the control group (95% confidence interval 0.76 to 2.97, P = 0.0011). Conclusions The outcome of depression among elderly people in residential care can be improved by multidisciplinary collaboration, by enhancing the clinical skills of general practitioners and care staff, and by providing depression related health education and activity programmes for residents.	Univ Sydney, Dept Psychol Med, Sydney, NSW 2006, Australia	University of Sydney	Llewellyn-Jones, RH (corresponding author), Hornsby Ku Ring Gai Hosp, Healthy Aging Res Unit, Palmerston Rd, Sydney, NSW 2077, Australia.	rljones@mail.usyd.edu.au						ALTMAN DG, 1985, STATISTICIAN, V34, P125; AMES D, 1990, BRIT J PSYCHIAT, V156, P667, DOI 10.1192/bjp.156.5.667; AMES D, 1993, AUST NZ J PSYCHIAT, V27, P379, DOI 10.3109/00048679309075793; Armitage P., 2001, STAT METHODS MED RES; Banerjee S, 1996, BRIT MED J, V313, P1058; BELLOC NB, 1971, AM J EPIDEMIOL, V93, P328, DOI 10.1093/oxfordjournals.aje.a121265; BLANCHARD MR, 1995, INT J GERIATR PSYCH, V10, P289, DOI 10.1002/gps.930100405; Brown GW, 1989, LIFE EVENTS ILLNESS; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P833, DOI 10.1111/j.1532-5415.1994.tb06554.x; CASSEL CK, 1994, BRIT MED J, V308, P1655, DOI 10.1136/bmj.308.6945.1655; Daniel A.E., 1983, POWER PRIVILEGE PRES; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FERNANDEZBALLESTEROS R, 1988, PERCEPT MOTOR SKILL, V66, P923, DOI 10.2466/pms.1988.66.3.923; Flaherty JH, 1998, J AM GERIATR SOC, V46, P31, DOI 10.1111/j.1532-5415.1998.tb01010.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; GREENOUGH HP, 1997, CRYPTOLOGIA, V21, P353; Henderson, 1981, NEUROSIS SOCIAL ENV; HESTON LL, 1992, J AM GERIATR SOC, V40, P1117, DOI 10.1111/j.1532-5415.1992.tb01800.x; Hooper SC, 1996, MED J AUSTRALIA, V165, P416, DOI 10.5694/j.1326-5377.1996.tb138576.x; Howell DC, 1987, STAT METHODS PSYCHOL; JORM AF, 1989, PSYCHOL MED, V19, P487, DOI 10.1017/S0033291700012514; KATONA CLE, 1994, DEPRESSION OLD AGE; KATZ IR, 1990, J CLIN PSYCHIAT, V51, P41; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186; MCGIVNEY SA, 1994, J AM GERIATR SOC, V42, P490, DOI 10.1111/j.1532-5415.1994.tb04969.x; MCMURDO MET, 1993, AGE AGEING, V22, P11, DOI 10.1093/ageing/22.1.11; Montorio I, 1996, Int Psychogeriatr, V8, P103, DOI 10.1017/S1041610296002505; MORRIS RG, 1991, INT J GERIATR PSYCH, V6, P407, DOI 10.1002/gps.930060612; Mossey JM, 1996, J GERONTOL A-BIOL, V51, pM172, DOI 10.1093/gerona/51A.4.M172; MURPHY E, 1988, BRIT J PSYCHIAT, V152, P347, DOI 10.1192/bjp.152.3.347; OUSLANDER J, 1991, MED CARE NURSING HOM; Parmelee PA, 1989, PSYCHOL ASSESSMENT J, V1, P331, DOI DOI 10.1037/1040-3590.1.4.331; RATTENBURY C, 1989, GERONTOLOGIST, V29, P768, DOI 10.1093/geront/29.6.768; Rose G., 1992, STRATEGY PREVENTIVE; Rosen J, 1997, AM J GERIAT PSYCHIAT, V5, P247, DOI 10.1097/00019442-199700530-00009; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; SCHIFANO F, 1990, ACTA PSYCHIAT SCAND, V81, P289, DOI 10.1111/j.1600-0447.1990.tb06499.x; Spreen O., 1991, PROFILE TEST RESULTS; Stolee P, 1996, J AM GERIATR SOC, V44, P314; *VICT MED POSTGR F, 1995, PSYCH DRUG GUID 1996; WAXMAN HM, 1984, GERONTOLOGIST, V24, P23, DOI 10.1093/geront/24.1.23; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	47	90	91	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	1999	319	7211					676	682		10.1136/bmj.319.7211.676	http://dx.doi.org/10.1136/bmj.319.7211.676			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	237CH	10480824	Green Published, Bronze			2022-12-28	WOS:000082636800023
J	Weil, O; Fernandez, H				Weil, O; Fernandez, H			Is safe motherhood an orphan initiative?	LANCET			English	Editorial Material							MATERNAL MORTALITY; MATLAB; BANGLADESH; MORBIDITY; DECLINE; AFRICA; CARE		Hop Antoine Beclere, Dept Obstet & Gynecol, F-92140 Clamart, France; Ctr Rech & Etud Dev Sante, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Fernandez, H (corresponding author), Hop Antoine Beclere, Dept Obstet & Gynecol, 157 Rue Porte Trivaux, F-92140 Clamart, France.							Benson J, 1996, HEALTH POLICY PLANN, V11, P117, DOI 10.1093/heapol/11.2.117; BOERMA JT, 1997, SOC SCI MED, V24, P551; FAUVEAU V, 1991, LANCET, V338, P345; FORTNEY J, 1995, INT J GYNECOL OBSTET, V50, P53; FORTNEY JA, 1987, STUD FAMILY PLANN, V18, P109, DOI 10.2307/1966702; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; GREENWOOD AM, 1987, B WORLD HEALTH ORGAN, V65, P635; HALL MH, 1990, BAILLIERE CLIN OB GY, V4, P65, DOI 10.1016/S0950-3552(05)80212-3; Harrison KA, 1997, LANCET, V349, P644, DOI 10.1016/S0140-6736(97)02192-2; Interagency group for safe motherhood, 1997, SAF MOTH ACT AG PRIO; KAUNITZ AM, 1984, AM J OBSTET GYNECOL, V150, P826, DOI 10.1016/0002-9378(84)90457-5; LOUDON I, 1992, DEATH CHILD BIRTH IN; MAHLER H, 1987, LANCET, V1, P668; Maine D, 1996, STUD FAMILY PLANN, V27, P179, DOI 10.2307/2137952; Maine D, 1991, SAFE MOTHERHOOD PROG; McDonagh M, 1996, HEALTH POLICY PLANN, V11, P1, DOI 10.1093/heapol/11.1.1; MHANGO C, 1986, STUD FAMILY PLANN, V17, P243, DOI 10.2307/1966974; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; OAKLEY A, 1984, CAPTURE WOMB HIST ME; Reynolds FN, 1934, LANCET, V2, P1474; Ronsmans C, 1998, STUD FAMILY PLANN, V29, P282, DOI 10.2307/172274; Ronsmans C, 1997, LANCET, V350, P1810, DOI 10.1016/S0140-6736(97)08012-4; ROONEY C, 1992, WHOMSM92; ROSENFIELD A, 1985, LANCET, V2, P83; STARRS A, 1987, INT SAF MOTH C NAIR, P56; SUMMERS L, 1992, SCI AM, V64, P108; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; The Lancet, 1997, LANCET, V349, P815; TINKER A, 1993, WORLD BANK DISCUSSIO, V202, P143; World Health Organization, 1996, WHOFRHMSM967 MAT HLT, P16	30	60	61	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					940	943		10.1016/S0140-6736(99)02369-7	http://dx.doi.org/10.1016/S0140-6736(99)02369-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489970				2022-12-28	WOS:000082511800043
J	Wan, JJ; Poo, MM				Wan, JJ; Poo, MM			Activity-induced potentiation of developing neuromuscular synapses	SCIENCE			English	Article							LONG-TERM POTENTIATION; CALCIUM-RELEASE CHANNEL; HETEROSYNAPTIC SUPPRESSION; SARCOPLASMIC-RETICULUM; SYNAPTIC TRANSMISSION; SILENT SYNAPSES; SKELETAL-MUSCLE; DEPRESSION; CALMODULIN; PROTEIN	Electrical activity plays a critical role in shaping the structure and function of synaptic connections in the nervous system. In Xenopus nerve-muscle cultures, a brief burst of action potentials in the presynaptic neuron induced a persistent potentiation of neuromuscular synapses that exhibit immature synaptic functions. Induction of potentiation required an elevation of postsynaptic Ca2+ and expression of potentiation appeared to involve an increased probability of transmitter secretion from the presynaptic nerve terminal. Thus, activity-dependent persistent synaptic enhancement may reflect properties characteristic of immature synaptic connections, and bursting activity in developing spinal neurons may promote functional maturation of the neuromuscular synapse.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CHOW I, 1985, J NEUROSCI, V5, P1076; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; EVERS J, 1989, J NEUROSCI, V9, P1523; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KIDOKORO Y, 1982, P NATL ACAD SCI-BIOL, V79, P6727, DOI 10.1073/pnas.79.21.6727; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KULLBERG RW, 1977, DEV BIOL, V60, P101, DOI 10.1016/0012-1606(77)90113-0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LANDMESSER LT, 1984, J PHYSIOL-LONDON, V347, P189, DOI 10.1113/jphysiol.1984.sp015061; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Donovan MJ, 1998, ANN NY ACAD SCI, V860, P130; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; Tabti N, 1998, CULTURING NERVE CELL, P237; WAN J, UNPUB; XIE Z, 1986, P NATL ACAD SCI USA, V83, P4069; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	35	30	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1725	1728		10.1126/science.285.5434.1725	http://dx.doi.org/10.1126/science.285.5434.1725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481007				2022-12-28	WOS:000082472600033
J	Powell, JW; Barber-Foss, KD				Powell, JW; Barber-Foss, KD			Traumatic brain injury in high school athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOTBALL PLAYERS; CONCUSSION	Context The potential seriousness of mild traumatic brain injury (MTBI) is increasingly recognized; however, information on the frequency of MTBI among high school athletes is limited. Objective To identify the type, frequency, and severity of MTBI in selected high school sports activities. Design Observational cohort study.. Setting and Participants Two hundred forty-six certified athletic trainers recorded injury and exposure data for high school varsity athletes participating in boys' football, wrestling, baseball and field hockey, girls' volleyball and softball, boys' and girls' basketball, and boys' and girls' soccer at 235 US high schools during 1 or more of the 1995-1997 academic years. Main Outcome Measures Rates of reported MTBI, defined as a head-injured player who was removed from participation and evaluated by an athletic trainer or physician prior to returning to participation. National incidence figures for MTBI also were estimated. Results Of 23 566 reported injuries in the 10 sports during the 3-year study period, 1219 (5.5 %) were MTBIs. Of the MTBIs, football accounted for 773 (63.4%) of cases; wrestling, 128 (10.5%); girls' soccer, 76 (6.2%); boys' soccer, 69 (5.7%); girls' basketball, 63 (5.2%); boys' basketball, 51 (4.2%); softball, 25 (2.1%); baseball, 15 (1.2%); field hockey, 13 (1.1%); and volleyball, 6 (0.5%). The injury rates per 100 player-seasons were 3.66 for football, 1.58 for wrestling, 1.14 for girls' soccer, 1.04 for girls' basketball, 0.92 for boys' soccer, 0.75 for boys' basketball, 0.46 for softball, 0.46 for field hockey, 0.23 for baseball, and 0.14 for volleyball. The median time lost from participation for all MTBIs was 3 days. There were 6 cases of subdural hematoma and intracranial injury reported in football. Based on these data, an estimated 62 816 cases of MTBI occur annually among high school varsity athletes participating in these sports, with football accounting for about 63 % of cases. Conclusions Rates of MTBI vary among sports and none of the 10 popular high school sports we studied is without the occurrence of an MTBI. Continued involvement of high school sports sponsors, researchers, medical professionals, coaches, and sports participants is essential to help minimize the risk of MTBI.	Med Sports Syst, Iowa City, IA USA		Powell, JW (corresponding author), Michigan State Univ, Dept Kinesiol, IM Sports Circle, E Lansing, MI 48824 USA.							Barth J.T., 1989, MILD HEAD INJURY, P257; BUCKLEY WE, 1985, THESIS PENNSYLVANIA; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; CLARKE KS, 1979, MED SCI SPORTS EXERC, V2, P138; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; GAHLINGER PM, 1993, RATRES2 VERSION 1 4C; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *NAT ATHL TRAIN AS, 1991, P MILD BRAIN INJ NAT; *NAT CTR ED STAT, 1994, US DHEW NCES PUBL; Powell JW, 1999, J ATHL TRAINING, V34, P277; POWELL JW, 1988, AM J SPORTS MED S, V16, P134; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1	21	408	413	0	59	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					958	963		10.1001/jama.282.10.958	http://dx.doi.org/10.1001/jama.282.10.958			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485681				2022-12-28	WOS:000082335900034
J	Chen, CC; Luo, CL; Wang, SJ; Chern, CM; Fuh, JL; Lin, SH; Hu, HH				Chen, CC; Luo, CL; Wang, SJ; Chern, CM; Fuh, JL; Lin, SH; Hu, HH			Colour doppler imaging for diagnosis of intracranial hypotension	LANCET			English	Article							BLOOD-FLOW; ENHANCEMENT; HEADACHES; ANATOMY; ORBIT	Background Measurement of CSF pressure is the only known way to confirm the diagnosis of intracranial hypotension. We aimed to assess colour doppler flow imaging (CDFI) for measurement of blood flow of the superior ophthalmic vein for the diagnosis of intracranial hypotension. Methods We enrolled 25 consecutive patients with orthostatic headache who had clinical features of intracranial hypotension. We defined low-pressure headache as cerebrospinal-fluid pressure below 60 mm H2O. We used CDFI to measure the diameter and maximum flow velocity of the superior ophthalmic vein in all patients. Magnetic resonance imaging of the brain and lumbar puncture with measurement of cerebrospinal-fluid pressure within 24 h were also done after sonographic examination. The control group comprised 13 healthy individuals of a similar age; in addition, those patients who had orthostatic headache without low pressure served as a control group for the patients. Findings Of the 25 patients recruited for this study, 13 satisfied the criteria for low-pressure headache. The remaining 12 patients with normal cerebrospinal-fluid pressure had transformed migraine (five patients) or chronic tension-type headache (seven patients), and therefore served as the control group for the patients. The mean diameter of the superior ophthalmic vein was substantially larger in the patients with intracranial hypotension (3.9 [SD 0.2] mm) than in the healthy controls (2.6 [0.4] mm) and the controls from the patients' group (2.7 [0.2] mm) (p<0.0001). The mean maximum flow velocity was significantly higher in the intracranial-hypotension group (17.0 [SD 3.4] cm/s) than in the healthy controls (7.9 [1.1] cm/s) and the other patients (7.3 [1.7] cm/s) (p<0.0001). Seven patients with intracranial hypotension were reassessed after treatment with epidural blood patch. After this treatment the clinical symptoms were relieved and there was a striking reversal of the superior ophthalmic vein flow. Interpretation CDFI to measure blood flow of the superior ophthalmic vein provides a practical, simple, and non-invasive diagnostic method for suspected intracranial hypotension.	Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Anesthesiol, Taipei, Taiwan	National Yang Ming Chiao Tung University	Hu, HH (corresponding author), Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan.			Fuh, Jong-Ling/0000-0001-9135-3351				Benzon HT, 1996, ANESTHESIOLOGY, V85, P920, DOI 10.1097/00000542-199610000-00029; Blank SC, 1997, CLIN NEUROL NEUROSUR, V99, P199, DOI 10.1016/S0303-8467(97)00015-2; CARRIE LES, 1993, BRIT J ANAESTH, V71, P179, DOI 10.1093/bja/71.2.179; Costa VP, 1997, J CLIN ULTRASOUND, V25, P448, DOI 10.1002/(SICI)1097-0096(199710)25:8<448::AID-JCU7>3.0.CO;2-J; ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264; Ettl A, 1997, OPHTHALMOLOGY, V104, P869, DOI 10.1016/S0161-6420(97)30219-X; FISHMAN RA, 1993, NEUROLOGY, V43, P609, DOI 10.1212/WNL.43.3_Part_1.609; Fishman RA, 1992, CEREBROSPINAL FLUID, P71; GUILIONI M, 1988, NEUROSURGERY, V22, P807; HIRASHITA M, 1992, EUR J APPL PHYSIOL, V64, P92, DOI 10.1007/BF00376447; HU HH, 1993, STROKE, V24, P1196, DOI 10.1161/01.STR.24.8.1196; Khanna RK, 1997, J NEUROSURG, V86, P893, DOI 10.3171/jns.1997.86.5.0893; Klotzsch C, 1996, NEURORADIOLOGY, V38, P555; LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036; MOKRI B, 1995, NEUROLOGY, V45, P1801, DOI 10.1212/WNL.45.10.1801; Mokri B, 1997, MAYO CLIN PROC, V72, P400, DOI 10.4065/72.5.400; Mokri B, 1998, NEUROLOGY, V51, P786, DOI 10.1212/WNL.51.3.786; POMERANZ S, 1993, ACTA NEUROCHIR, V122, P113, DOI 10.1007/BF01446996; Schievink WI, 1996, J NEUROSURG, V84, P598, DOI 10.3171/jns.1996.84.4.0598; Silberstein SD, 1996, NEUROLOGY, V47, P871, DOI 10.1212/WNL.47.4.871; Spektor S, 1997, NEUROSURGERY, V40, P532, DOI 10.1097/00006123-199703000-00022	21	31	32	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					826	829						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485725				2022-12-28	WOS:000082400700012
J	Krishnamurti, TN; Kishtawal, CM; LaRow, TE; Bachiochi, DR; Zhang, Z; Williford, CE; Gadgil, S; Surendran, S				Krishnamurti, TN; Kishtawal, CM; LaRow, TE; Bachiochi, DR; Zhang, Z; Williford, CE; Gadgil, S; Surendran, S			Improved weather and seasonal climate forecasts from multimodel superensemble	SCIENCE			English	Article								A method for improving weather and climate forecast skill has been developed. It is called a superensemble, and it arose from a study of the statistical properties of a low-order spectral model. Multiple regression was used to determine coefficients from multimodel forecasts and observations. The coefficients were then used in the superensemble technique. The superensemble was shown to outperform all model forecasts for multiseasonal, medium-range weather and hurricane forecasts. In addition, the superensemble was shown to have higher skill than forecasts based solely on ensemble averaging.	Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA; Indian Inst Sci, Ctr Atmospher & Ocean Sci, Bangalore, Karnataka, India	State University System of Florida; Florida State University; Indian Institute of Science (IISC) - Bangalore	Krishnamurti, TN (corresponding author), Florida State Univ, Dept Meteorol, Tallahassee, FL 32306 USA.		Surendran, Sajani/C-3339-2009	Surendran, Sajani/0000-0003-2734-2097				Gates WL, 1999, B AM METEOROL SOC, V80, P29, DOI 10.1175/1520-0477(1999)080<0029:AOOTRO>2.0.CO;2; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; PHILIPS TJ, 1994, 18 PCMDI L LIV NAT L; Phillips TJ, 1996, B AM METEOROL SOC, V77, P1191, DOI 10.1175/1520-0477(1996)077<1191:DOTAMO>2.0.CO;2	4	632	708	4	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1548	1550		10.1126/science.285.5433.1548	http://dx.doi.org/10.1126/science.285.5433.1548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477515	Green Accepted			2022-12-28	WOS:000082359500060
J	Ridley, RG				Ridley, RG			Perspectives: Biomedicine - Planting the seeds of new antimalarial drugs	SCIENCE			English	Editorial Material							APICOMPLEXAN PARASITES; PLASMODIUM-FALCIPARUM; TARGET		WHO, Special Programme Res Dev & Res Training Huma, Drug Discovery Res & New Med Malaria Venture, CH-1211 Geneva 27, Switzerland	World Health Organization	Ridley, RG (corresponding author), WHO, Special Programme Res Dev & Res Training Huma, Drug Discovery Res & New Med Malaria Venture, CH-1211 Geneva 27, Switzerland.							Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Ridley RG, 1998, NAT MED, V4, P894, DOI 10.1038/nm0898-894; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	7	40	44	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1502	1503		10.1126/science.285.5433.1502	http://dx.doi.org/10.1126/science.285.5433.1502			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10498534				2022-12-28	WOS:000082359500037
J	Tang, YP; Shimizu, E; Dube, GR; Rampon, C; Kerchner, GA; Zhuo, M; Liu, GS; Tsien, JZ				Tang, YP; Shimizu, E; Dube, GR; Rampon, C; Kerchner, GA; Zhuo, M; Liu, GS; Tsien, JZ			Genetic enhancement of learning and memory in mice	NATURE			English	Article							LONG-TERM POTENTIATION; HETEROMERIC NMDA RECEPTORS; SYNAPTIC PLASTICITY; GLUTAMATE RECEPTORS; VISUAL-CORTEX; HIPPOCAMPUS; BRAIN; FEAR; ANTAGONIST; AMYGDALA	Hebb's rule (1949) states that learning and memory are based on modifications of synaptic strength among neurons that are simultaneously active. This implies that enhanced synaptic coincidence detection would lead to better learning and memory. If the NMDA (N-methyl-D-aspartate) receptor, a synaptic coincidence detector(1-4), acts as a graded switch for memory formation, enhanced signal detection by NMDA receptors should enhance learning and memory. Here we show that overexpression of NMDA receptor 2B (NR2B) in the forebrains of transgenic mice leads to enhanced activation of NMDA receptors, facilitating synaptic potentiation in response to stimulation at 10-100 Hz. These mice exhibit superior ability in learning and memory in various behavioural tasks, showing that NR2B is critical in gating the age-dependent threshold for plasticity and memory formation. NMDA-receptor-dependent modifications of synaptic efficacy, therefore, represent a unifying mechanism for associative learning and memory. Our results suggest that genetic enhancement of mental and cognitive attributes such as intelligence and memory in mammals is feasible.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; MIT, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurobiol, St Louis, MO 63110 USA	Princeton University; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); Washington University (WUSTL)	Tsien, JZ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Tang, Ya-Ping/A-1035-2011; Zhuo, Min/A-2072-2008; Shimizu, Eiji/K-4637-2017	Zhuo, Min/0000-0001-9062-3241; Shimizu, Eiji/0000-0002-6741-9338; Tang, Ya-Ping/0000-0002-0445-4072; rampon, claire/0000-0001-8551-8682				Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; DAVIS M, 1987, PSYCHOL LEARNING MEM; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FALLS WA, 1992, J NEUROSCI, V12, P854; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; KONISHI M, 1989, NEURON, V3, P541, DOI 10.1016/0896-6273(89)90264-X; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Morris RG, 1982, NATURE, V2, P681; Mumby DG, 1996, BEHAV NEUROSCI, V110, P266, DOI 10.1037/0735-7044.110.2.266; MYHRER T, 1988, BEHAV NEUROSCI, V102, P356, DOI 10.1037/0735-7044.102.3.356; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Okabe S, 1998, J NEUROSCI, V18, P4177; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Reed JM, 1997, BEHAV NEUROSCI, V111, P667, DOI 10.1037/0735-7044.111.4.667; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Stevens CF, 1998, CURR BIOL, V8, pR151, DOI 10.1016/S0960-9822(98)70097-1; STUBLI U, 1996, J NEUROSCI, V16, P853; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7	30	1434	1541	4	191	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					63	69		10.1038/43432	http://dx.doi.org/10.1038/43432			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485705				2022-12-28	WOS:000082374400041
J	Clemons, WM; May, JLC; Wimberly, BT; McCutcheon, JP; Capel, MS; Ramakrishnan, V				Clemons, WM; May, JLC; Wimberly, BT; McCutcheon, JP; Capel, MS; Ramakrishnan, V			Structure of a bacterial 30S ribosomal subunit at 5.5 angstrom resolution	NATURE			English	Article							RNA-BINDING-SITE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; PROTEIN S15; CRYSTAL-STRUCTURE; BACILLUS-STEAROTHERMOPHILUS; NMR-SPECTROSCOPY; CROSS-LINKING; MESSENGER-RNA; 16S RNA	The 30S ribosomal subunit binds messenger RNA and the anticodon stem-loop of transfer RNA during protein synthesis. A crystallographic analysis of the structure of the subunit from the bacterium Thermos thermophilus is presented, At a resolution of 5.5 Angstrom, the phosphate backbone of the ribosomal RNA is visible, as are the cu-helices of the ribosomal proteins, enabling double-helical regions of RNA to be identified throughout the subunit, all seven of the small-subunit proteins of known crystal structure to be positioned in the electron density map, and the fold of the entire central domain of the small-subunit ribosomal RNA to be determined.	MRC, Mol Biol Lab, Structural Studies Div, Cambridge CB2 2QH, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84103 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	MRC Laboratory Molecular Biology; Utah System of Higher Education; University of Utah; United States Department of Energy (DOE); Brookhaven National Laboratory	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Structural Studies Div, Hills Rd, Cambridge CB2 2QH, England.		Clemons, William M/D-1026-2009	Clemons, William M/0000-0002-0021-889X; Ramakrishnan, V/0000-0002-4699-2194; McCutcheon, John/0000-0002-5489-6039	NIGMS NIH HHS [F31 GM019384] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM019384] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agafonov DE, 1997, P NATL ACAD SCI USA, V94, P12892, DOI 10.1073/pnas.94.24.12892; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Alberts B, 1995, MOL BIOL CELL; ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; ALLEN G, 1979, J BIOL CHEM, V254, P9800; ATMADJA J, 1986, NUCLEIC ACIDS RES, V14, P659, DOI 10.1093/nar/14.2.659; Batey RT, 1996, J MOL BIOL, V261, P536, DOI 10.1006/jmbi.1996.0481; Berglund H, 1997, NAT STRUCT BIOL, V4, P20, DOI 10.1038/nsb0197-20; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; Davies C, 1996, STRUCTURE, V4, P1093, DOI 10.1016/S0969-2126(96)00115-3; GREGORY RJ, 1984, J MOL BIOL, V178, P287, DOI 10.1016/0022-2836(84)90145-1; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; Jaishree TN, 1996, BIOCHEMISTRY-US, V35, P2845, DOI 10.1021/bi951062i; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kalurachchi K, 1997, P NATL ACAD SCI USA, V94, P2139, DOI 10.1073/pnas.94.6.2139; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Lee KS, 1997, J MOL BIOL, V269, P732, DOI 10.1006/jmbi.1997.1092; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Markus MA, 1998, EMBO J, V17, P4559, DOI 10.1093/emboj/17.16.4559; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Moine H, 1997, RNA, V3, P255; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Nevskaya N, 1998, J MOL BIOL, V279, P233, DOI 10.1006/jmbi.1998.1758; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POWERS T, 1995, RNA, V1, P194; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; RAMAKRISHNAN VR, 1981, J MOL BIOL, V153, P739, DOI 10.1016/0022-2836(81)90416-2; Serganov AA, 1996, RNA, V2, P1124; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRAKHANOV SD, 1987, FEBS LETT, V220, P319, DOI 10.1016/0014-5793(87)80838-4; UNGEWICKELL E, 1975, EUR J BIOCHEM, V51, P165, DOI 10.1111/j.1432-1033.1975.tb03917.x; Urlaub H, 1997, J BIOL CHEM, V272, P14547, DOI 10.1074/jbc.272.23.14547; VANACKEN U, 1975, MOL GEN GENET, V140, P61, DOI 10.1007/BF00268989; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WINBERLY BT, 1997, STRUCTURE, V5, P1187; WITTMANNLIEBOLD B, 1978, FEBS LETT, V95, P91, DOI 10.1016/0014-5793(78)80059-3; WU H, 1994, NUCLEIC ACIDS RES, V22, P1687, DOI 10.1093/nar/22.9.1687; YONATH A, 1988, J MOL BIOL, V203, P831, DOI 10.1016/0022-2836(88)90216-1; Yonath A, 1998, ACTA CRYSTALLOGR A, V54, P945, DOI 10.1107/S010876739800991X; YUSUPOV MM, 1988, FEBS LETT, V238, P113, DOI 10.1016/0014-5793(88)80237-0	50	305	328	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					833	840		10.1038/23631	http://dx.doi.org/10.1038/23631			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476960				2022-12-28	WOS:000082233200035
J	Forrester, WC; Dell, M; Perens, E; Garriga, G				Forrester, WC; Dell, M; Perens, E; Garriga, G			A C-elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NEUROMUSCULAR-JUNCTION; GENES; MIGRATION; LINEAGE; FAMILY; MUSK	Ror kinases are a family of orphan receptors with tyrosine kinase activity that are related to muscle specific kinase (MuSK), a receptor tyrosine kinase that assembles acetylcholine receptors at the neuromuscular junction(1,2). Although the functions of Ror kinases are unknown, similarities between Ror and MuSK kinases have led to speculation that Ror kinases regulate synaptic development. Here we show that the Caenorhabditis elegans gene cam-1 encodes a member of the Ror kinase family that guides migrating cells and orients the polarity of asymmetric cell divisions and axon outgrowth. We find that tyrosine kinase activity is required for some of the functions of CAM-1, but not for its role in cell migration. CAM-1 is expressed in cells that require its function, and acts cell autonomously in migrating neurons. Overexpression and loss of cam-1 function result in reciprocal cell-migration phenotypes, indicating that levels of CAM-1 influence the final positions of migrating cells. Our results raise the possibility that Ror kinases regulate cell motility and asymmetric cell division in organisms as diverse as nematodes and mammals.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Garriga, G (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.			Perens, Elliot/0000-0003-3377-7708				Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Forrester WC, 1997, DEVELOPMENT, V124, P1831; Forrester WC, 1998, GENETICS, V148, P151; HANKS SK, 1988, SCIENCE, V241, P47; Hawkins N, 1998, GENE DEV, V12, P3625, DOI 10.1101/gad.12.23.3625; HEDECOCK EM, 1995, GENETICS, V141, P989; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HERMAN RK, 1984, GENETICS, V108, P165; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	25	130	135	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					881	885		10.1038/23722	http://dx.doi.org/10.1038/23722			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476968				2022-12-28	WOS:000082233200048
J	Altmann, P; Cunningham, J; Dhanesha, U; Ballard, M; Thompson, J; Marsh, F				Altmann, P; Cunningham, J; Dhanesha, U; Ballard, M; Thompson, J; Marsh, F			Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: retrospective study of the Camelford water incident	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; GASTROINTESTINAL ABSORPTION; DIALYSIS ENCEPHALOPATHY; ENVIRONMENTAL ALUMINUM; HEMODIALYSIS-PATIENTS; CEREBROSPINAL-FLUID; PRESENILE-DEMENTIA; NORTH CORNWALL; METABOLISM; POLLUTION	Objective To establish whether people exposed to drinking water contaminated with 20 tonnes of aluminium sulphate in the Camelford area of Cornwall in the south west of England in July 1988 had suffered organic brain damage as opposed to psychological trauma only. Design Retrospective study of affected people. Participants 55 affected people and 15 siblings nearest in age to one of the group but who had not been exposed to the contaminated water were studied. Main outcome measures Various clinical and psychological tests to determine medical condition and anxiety levels in affected people. Assessment of premorbid IQ (pFSIQ) with the national adult reading test, a computerised battery of psychomotor testing, and measurement of the difference in latencies between the flash and pattern visual evoked potentials in all participants. Results The mean (SE) pFSIQ was above average at 114.4 (1.1). The most sensitive of the psychomotor tests for organic brain disease was the symbol digit coding (SDC) test (normal score 100, abnormal <85). Participants performed less well on this test (54.5 (6.0)) than expected from their pFSIQ (P < 0.0001) and a little less poorly on the averaged less discriminating tests within the battery (86.1 (2.5), P < 0.0001). In a comparison with the 15 sibling pairs (affected people's age 41.0 (3.3) years v sibling age of 42.7 (3.1) years (P = 0.36) the exposed people had similar pFSIQ (114.7 (2.1)) to their siblings (116.3 (2.1), (P = 0.59) but performed badly on the symbol digit coding test (51.8 (16.6)) v (87.5 (4.9) for siblings, P = 0.03), The flash-pattern differences in exposed people were greater than in 42 unrelated control subjects of similar age (27.33 (1.64) ms v 18.57 (1.47) ms, P = 0.0002). The 15 unexposed siblings had significantly better flash-pattern differences than their affected siblings (13.4 (2.4) ms v 29.6 (2.9) ms, P = 0.0002). No effect of anxiety could be shown on these measurements from the analysis of the anxiety scores of exposed people. Conclusion People who were exposed to the contaminated water at Camelford suffered considerable damage to cerebral function, which was not related to anxiety. Follow up studies would be required to determine the longer term prognosis for affected individuals.	Oxford Radcliffe Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England; Royal London Hosp, London E1 1BB, England; Coventry & Warwickshire Hosp, Paybody Eye Unit, Coventry CV1 4FH, W Midlands, England; Priory Hosp, London SW15 5JJ, England; UCL, Sch Med, London W1N 8AA, England	University of Oxford; Barts Health NHS Trust; Royal London Hospital; University of London; University College London; UCL Medical School	Altmann, P (corresponding author), Oxford Radcliffe Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England.	paul.altmann@orh.anglox.nhs.uk						ACKER W, 1982, B MAUDSLEY AUTOMATED; Acker W., 1982, BEXLEY MAUDSLEY AUTO; ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402; ALLEN WM, 1989, VET REC, V124, P479, DOI 10.1136/vr.124.18.479; ALTMANN P, 1989, LANCET, V2, P7, DOI 10.1016/S0140-6736(89)90254-7; ALTMANN P, 1987, KIDNEY INT, V32, P710, DOI 10.1038/ki.1987.264; ALTMANN P, 1987, NEW ENGL J MED, V317, P80, DOI 10.1056/NEJM198707093170204; ALTMANN P, 1991, THESIS U LONDON LOND; BARLOW PJ, 1986, J ROY SOC MED, V79, P581, DOI 10.1177/014107688607901007; BASUN H, 1991, J NEURAL TRANSM-PARK, V3, P231; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRUN A, 1981, ACTA PATH MICRO IM A, V89, P193; Cacabelos R, 1996, ACTA NEUROL SCAND, V93, P72; CLAYTON B, 1991, WATER POLLUTION LOWE; Clayton B., 1989, WATER POLLUTION LOWE; COGGON D, 1991, BRIT MED J, V303, P1280, DOI 10.1136/bmj.303.6813.1280; CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; DELABAR JM, 1987, SCIENCE, V235, P1390, DOI 10.1126/science.2950593; DEROGATIS LR, 1977, S CHECKL 90 R ADM SC; DHAESE PC, 1985, CLIN CHEM, V31, P24; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; ELLIOTT HL, 1978, BRIT MED J, V1, P1101, DOI 10.1136/bmj.1.6120.1101; Exley C, 1996, J TOXICOL ENV HEALTH, V48, P569, DOI 10.1080/009841096161078; FARRAR G, 1990, LANCET, V335, P747, DOI 10.1016/0140-6736(90)90868-6; Flaten TP, 1996, J TOXICOL ENV HEALTH, V48, P527, DOI 10.1080/009841096161050; GURLING HMD, 1980, 3 INT C TWIN STUD JE; GURLING HMD, 1980, 3 INT C TWIN STUD; HANTSON P, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90446-4; Haycock KH, 1992, STATVIEW; JACQMIN H, 1994, AM J EPIDEMIOL, V139, P48, DOI 10.1093/oxfordjournals.aje.a116934; KAEHNY WD, 1977, NEW ENGL J MED, V296, P1389, DOI 10.1056/NEJM197706162962407; KAPAKI EN, 1993, BIOL PSYCHIAT, V33, P679, DOI 10.1016/0006-3223(93)90114-S; KELLETT JM, 1986, LANCET, V1, P682; Lezak M., 1976, NEUROPSYCHOLOGICAL A; MARTYN CN, 1989, LANCET, V1, P59; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MAYONWHITE RT, 1993, BRIT MED J, V307, P398, DOI 10.1136/bmj.307.6901.398; MCMILLAN TM, 1993, HUM EXP TOXICOL, V12, P37, DOI 10.1177/096032719301200108; MCMILLAN TM, 1993, J CHILD PSYCHOL PSYC, V34, P1449, DOI 10.1111/j.1469-7610.1993.tb02102.x; MEHTA RP, 1979, CAN MED ASSOC J, V120, P1112; MICHEL P, 1990, NEUROBIOL AGING, V11, P264; Mjoberg B, 1997, ACTA ORTHOP SCAND, V68, P511, DOI 10.3109/17453679708999016; Moore PB, 1997, BIOL PSYCHIAT, V41, P488, DOI 10.1016/S0006-3223(96)00045-5; Nelson HE., 1982, NATL ADULT READING T; OWEN PJ, 1995, J PUBLIC HEALTH MED, V17, P200, DOI 10.1093/oxfordjournals.pubmed.a043093; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; PLATTS MM, 1981, CLIN NEPHROL, V15, P223; PLATTS MM, 1977, BRIT MED J, V2, P657, DOI 10.1136/bmj.2.6088.657; POWELL JJ, 1995, ANALYST, V120, P793, DOI 10.1039/an9952000793; Priest ND, 1996, BIOMETALS, V9, P221, DOI 10.1007/BF00817919; PRIEST ND, 1995, HUM EXP TOXICOL, V14, P287, DOI 10.1177/096032719501400309; PRIEST ND, 1993, P NUTR SOC, V52, P231, DOI 10.1079/PNS19930055; RIFAT SL, 1990, LANCET, V336, P1162, DOI 10.1016/0140-6736(90)92775-D; SHARP CA, 1993, EUR J CLIN INVEST, V23, P554, DOI 10.1111/j.1365-2362.1993.tb00965.x; Spofforth J, 1921, LANCET, V1, P1301; TALBOT RJ, 1995, HUM EXP TOXICOL, V14, P595, DOI 10.1177/096032719501400707; TAYLOR GA, 1992, AGE AGEING, V21, P81, DOI 10.1093/ageing/21.2.81; TERRY RD, 1965, NEUROPATHOL EXP NEUR, V23, P200; VONDOLLKEN, 1897, ARCH EXP PATHOL PH, V40, P98; WHALLEY LJ, 1985, LANCET, V1, P578; WHITE DM, 1992, ARCH INTERN MED, V152, P1443, DOI 10.1001/archinte.152.7.1443; WHITE DM, 1992, ARCH INTERN MED, V153, P2796; WRIGHT CE, 1984, ELECTROEN CLIN NEURO, V57, P405, DOI 10.1016/0013-4694(84)90069-5; ZAPATERO MD, 1995, BIOL TRACE ELEM RES, V47, P235, DOI 10.1007/BF02790122	66	82	88	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					807	+		10.1136/bmj.319.7213.807	http://dx.doi.org/10.1136/bmj.319.7213.807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241CR	10496822	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000082865200020
J	Shumway, N				Shumway, N			Clarence Walton Lillehei - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					856	856		10.1136/bmj.319.7213.856	http://dx.doi.org/10.1136/bmj.319.7213.856			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496852	Green Published			2022-12-28	WOS:000082865200057
J	Wade, DT; Johnston, C				Wade, DT; Johnston, C			The permanent vegetative state: practical guidance on diagnosis and management	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPROVEMENT		Rivermead Rehabil Ctr, Oxford OX1 4XD, England; Supreme Court, London W2A 1DD, England		Wade, DT (corresponding author), Rivermead Rehabil Ctr, Oxford OX1 4XD, England.	derick.wade@dial.pipex.com		Wade, Derick/0000-0002-1188-8442				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; [Anonymous], 1995, Neurology, V45, P1012; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; HARRIS P, 1996, FAM LAW REP, V2, P375; HINCHCLIFFE M, 1996, NEW LAW J, P1579; Jennett B, 1997, BMJ-BRIT MED J, V314, P1621, DOI 10.1136/bmj.314.7094.1621; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; LIU GT, 1992, J CLIN NEURO-OPHTHAL, V12, P47; McMillan TM, 1997, BRAIN INJURY, V11, P483, DOI 10.1080/713802184; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; *ROYAL HOSP NEUR, 1996, INT WORK PART REP VE; Shiel A, 1998, BRAIN INJURY, V12, P809, DOI 10.1080/026990598122043	18	46	47	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					841	844		10.1136/bmj.319.7213.841	http://dx.doi.org/10.1136/bmj.319.7213.841			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496834	Green Published			2022-12-28	WOS:000082865200032
J	Dixon-Woods, M; Young, B; Heney, D				Dixon-Woods, M; Young, B; Heney, D			Partnerships with children	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		Univ Leicester, Fac Med & Biol Sci, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm NHS Trust, Childrens Hosp, Leicester LE1 5WW, Leics, England	University of Leicester	Dixon-Woods, M (corresponding author), Univ Leicester, Fac Med & Biol Sci, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Young, Bridget/A-2184-2014	Dixon-Woods, Mary/0000-0002-5915-0041; Young, Bridget/0000-0001-6041-9901				Alderson P, 1996, HLTH CARE CHOICES MA; BREWSTER AB, 1982, PEDIATRICS, V69, P355; Dyer C, 1999, BRIT MED J, V319, P209, DOI 10.1136/bmj.319.7204.209; Hart C, 1998, BRIT MED J, V316, P1600, DOI 10.1136/bmj.316.7144.1600; *HC HLTH COMM, 1997, SPEC NEEDS CHILDR YO, V1; *HC HLTH COMM, 1997, HOSP SERV CHILDR YOU; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KOHRMAN A, 1995, PEDIATRICS, V95, P314; Lansdown R, 1998, J ROY SOC MED, V91, P457, DOI 10.1177/014107689809100902; MAYALL B, 1995, HLTH OUR CHILDREN S; OAKLEY A, 1995, BRIT MED J, V310, P1029, DOI 10.1136/bmj.310.6986.1029; Ross LF, 1997, HASTINGS CENT REP, V27, P41, DOI 10.2307/3527717; *ROYAL COLL PAED C, 1998, CHILDR HLTH SERV; Rylance G, 1996, BRIT MED J, V312, P794; SHUCKSMITH J, 1998, HLTH ISSUES ADOLESCE; Silverman D., 1987, COMMUNICATION MED PR; UN, 1989, CONV RIGHTS CHILD	17	46	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					778	780		10.1136/bmj.319.7212.778	http://dx.doi.org/10.1136/bmj.319.7212.778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488013	Green Published			2022-12-28	WOS:000082701500032
J	Spruck, CH; Won, KA; Reed, SI				Spruck, CH; Won, KA; Reed, SI			Deregulated cyclin E induces chromosome instability	NATURE			English	Article							BREAST-CANCER; CELL-CYCLE; DNA-REPLICATION; S-PHASE; EXPRESSION; KINASE; PROLIFERATION; CARCINOMAS; ACTIVATION; INDUCTION	Cyclin E, a regulatory subunit of cyclin-dependent kinase 2 (Cdk2), is an important regulator of entry into S phase in the mammalian cell cycle. In normal dividing cells, cyclin E accumulates at the G(1)/S-phase boundary and is degraded as cells progress through S phase(1,2). However, in many human tumours cyclin E is overexpressed(3) and the levels of protein and kinase activity are often deregulated relative to the cell cycle(4-7). It is not understood how alterations in expression of cyclin E contribute to tumorigenesis. Here we show that constitutive cyclin-E overexpression in both immortalized rat embryo fibroblasts and human breast epithelial cells results in chromosome instability (CIN). In contrast, analogous expression of cyclin D1 or A does not increase the frequency of GIN. Cyclin-E-expressing cells that exhibit CIN have normal centrosome numbers. However, constitutive overexpression of cyclin E impairs S-phase progression, indicating that aberrant regulation of this process may be responsible for the CIN observed. These results indicate that downregulation of cyclin-E/Cdk2 kinase activity following the G(1)/S-phase transition may be necessary for the maintenance of karyotypic stability.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bito T, 1997, J CUTAN PATHOL, V24, P305, DOI 10.1111/j.1600-0560.1997.tb00796.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; ELBLE R, 1992, MOL BIOL CELL, V3, P971, DOI 10.1091/mbc.3.9.971; Erlanson M, 1998, BLOOD, V92, P770; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mumberg D, 1996, ONCOGENE, V13, P2493; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; Pihan GA, 1998, CANCER RES, V58, P3974; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B; Simpson G. G., 1960, QUANTITATIVE ZOOLOGY; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	28	587	606	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					297	300		10.1038/45836	http://dx.doi.org/10.1038/45836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499591				2022-12-28	WOS:000082678400059
J	Whitten, W				Whitten, W			Reproductive biology - Pheromones and regulation of ovulation	NATURE			English	Article							MENSTRUAL SYNCHRONY		Australian Natl Univ, Dept Mol Med, Canberra, ACT 2601, Australia	Australian National University	Whitten, W (corresponding author), Australian Natl Univ, Dept Mol Med, POB 334, Canberra, ACT 2601, Australia.							CUTLER WB, 1979, PSYCHONEUROENDOCRINO, V4, P297, DOI 10.1016/0306-4530(79)90014-3; CUTLER WB, 1980, AM J OBSTET GYNECOL, V137, P834, DOI 10.1016/0002-9378(80)90895-9; MCCLINTOCK MK, 1971, NATURE, V229, P244, DOI 10.1038/229244a0; SCHANK JC, 1992, J THEOR BIOL, V157, P317, DOI 10.1016/S0022-5193(05)80614-9; Stern K, 1998, NATURE, V392, P177, DOI 10.1038/32408; Strassmann BI, 1997, CURR ANTHROPOL, V38, P123, DOI 10.1086/204592; TREVATHAN WR, 1993, PSYCHONEUROENDOCRINO, V18, P425, DOI 10.1016/0306-4530(93)90017-F; WILSON HC, 1992, PSYCHONEUROENDOCRINO, V17, P565, DOI 10.1016/0306-4530(92)90016-Z	8	10	11	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					232	232		10.1038/45720	http://dx.doi.org/10.1038/45720			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499577	Bronze			2022-12-28	WOS:000082678400039
J	Juni, P; Witschi, A; Bloch, R; Egger, M				Juni, P; Witschi, A; Bloch, R; Egger, M			The hazards of scoring the quality of clinical trials for meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIALS; MOLECULAR-WEIGHT HEPARIN; CRITERIA-BASED METAANALYSIS; UNFRACTIONATED HEPARIN; METHODOLOGICAL QUALITY; SYSTEMATIC REVIEWS; BIAS; THROMBOSIS; PAIN; INTERVENTION	Context Although it is widely recommended that clinical trials undergo some type of quality review, the number and variety of quality assessment scales that exist make it unclear how to achieve the best assessment. Objective To determine whether the type of quality assessment scale used affects the conclusions of meta-analytic studies. Design and Setting Meta-analysis of 17 trials comparing low-molecular-weight heparin (LMWH) with standard heparin for prevention of postoperative thrombosis using 25 different scales to identify high-quality trials. The association between treatment effect and summary scores and the association with 3 key domains (concealment of treatment allocation, blinding of outcome assessment, and handling of withdrawals) were examined in regression models. Main Outcome Measure Pooled relative risks of deep vein thrombosis with LMWH vs standard heparin in high-quality vs low-quality trials as determined by 25 quality scales. Results Pooled relative risks from high-quality trials ranged from 0.63 (95% confidence interval [CI], 0.44-0.90) to 0.90 (95% CI, 0.67-1.21) vs 0.52 (95% CI, 0.24-1.09) to 1.13 (95% CI, 0.70-1.82) for low-quality trials. For 6 scales, relative risks of high-quality trials were close to unity, indicating that LMWH was not significantly superior to standard heparin, whereas low-quality trials showed better protection with LMWH (P<.05). Seven scales showed the opposite: high quality trials showed an effect whereas low quality trials did not. For the remaining 12 scales, effect estimates were similar in the 2 quality strata. In regression analysis, summary quality scores were not significantly associated with treatment effects. There was no significant association of treatment effects with allocation concealment and handling of withdrawals. Open outcome assessment, however, influenced effect size with the effect of LMWH, on average, being exaggerated by 35% (95% CI, 1%-57%; P=.046). Conclusions Our data indicate that the use of summary scores to identify trials of high quality is problematic. Relevant methodological aspects should be assessed individually and their influence on effect sizes explored.	Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol B8S 2PR, Avon, England; Clin Epidemiol Study Grp, Bern, Switzerland; Univ Bern, Inst Med Educ, CH-3012 Bern, Switzerland	University of Bristol; University of Bern	Egger, M (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Canynge Hall,Whiteladies Rd, Bristol B8S 2PR, Avon, England.	m.egger@bristol.ac.uk	Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Egger, Matthias/0000-0001-7462-5132				ANDREW E, 1984, ACTA RADIOL DIAGN, V25, P55, DOI 10.1177/028418518402500111; BECKERMAN H, 1992, PHYS THER, V72, P483, DOI 10.1093/ptj/72.7.483; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BROWN SA, 1991, NURS RES, V40, P352; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS I, 1995, J CLIN EPIDEMIOL, V48, P67, DOI 10.1016/0895-4356(94)00105-Y; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EVANS M, 1985, BRIT J SURG, V72, P256, DOI 10.1002/bjs.1800720403; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P300, DOI 10.1093/oxfordjournals.aje.a117250; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; LEVINE J, 1991, GUIDE CLIN TRIALS, P780; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; MAY GS, 1981, CIRCULATION, V64, P669, DOI 10.1161/01.CIR.64.4.669; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; MULROW CD, 1998, COCHRANE COLLABORATI; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; ONGHENA P, 1992, PAIN, V49, P205, DOI 10.1016/0304-3959(92)90144-Z; PEDUZZI P, 1993, STAT MED, V12, P1185, DOI 10.1002/sim.4780121102; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; POYNARD T, 1988, PRESSE MED, V17, P315; REISCH JS, 1989, PEDIATRICS, V84, P815; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sharp S, 1998, STATA TECH B, V7, DOI DOI 10.1002/SIM.1187/FULL); SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SMITH K, 1992, AM REV RESPIR DIS, V145, P533, DOI 10.1164/ajrccm/145.3.533; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; THOMPSON SG, IN PRESS STAT MED; VERARDI S, 1989, CURR THER RES CLIN E, V46, P366; VERARDI S, 1988, INT ANGIOL, V7, P19; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007	61	1428	1437	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1054	1060		10.1001/jama.282.11.1054	http://dx.doi.org/10.1001/jama.282.11.1054			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493204	Bronze			2022-12-28	WOS:000082512300029
J	Bradley, JP; Keller, LP; Snow, TP; Hanner, MS; Flynn, GJ; Gezo, JC; Clemett, SJ; Brownlee, DE; Bowey, JE				Bradley, JP; Keller, LP; Snow, TP; Hanner, MS; Flynn, GJ; Gezo, JC; Clemett, SJ; Brownlee, DE; Bowey, JE			An infrared spectral match between GEMS and interstellar grains	SCIENCE			English	Article							INTERPLANETARY DUST PARTICLES; SILICATE MINERALOGY; FEATURES; CLOUD; STEPS; STARS	Infrared spectral properties of silicate grains in interplanetary dust particles (IDPs) were compared with those of astronomical silicates. The similar to 10-micrometer silicon-oxygen stretch bands of IDPs containing enstatite (MgSiO3), forsterite (Mg2SiO4), and glass with embedded metal and sulfides (GEMS) exhibit fine structure and bandwidths similar to those of solar system comets and some pre-main sequence Herbig Ae/Be stars. Some GEMS exhibit a broad, featureless silicon-oxygen stretch band similar to those observed in interstellar molecular clouds and young stellar objects. These GEMS provide a spectral match to astronomical "amorphous" silicates, one of the fundamental building blocks from which the solar system is presumed to have formed.	MVA Inc, Norcross, GA 30093 USA; Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA; Univ Colorado, Ctr Astrophys & Space Astron, Boulder, CO 80309 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Washington, Dept Astron, Seattle, WA 98195 USA; SUNY Coll Plattsburgh, Plattsburgh, NY 12901 USA; Queen Mary Univ London, Dept Phys, London E1 4NS, England	University System of Georgia; Georgia Institute of Technology; University of Colorado System; University of Colorado Boulder; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Washington; University of Washington Seattle; State University of New York (SUNY) System; SUNY Plattsburgh; University of London; Queen Mary University London	Bradley, JP (corresponding author), MVA Inc, Norcross, GA 30093 USA.		Bowey, Janet/AAL-5809-2021	Bowey, Janet/0000-0003-3738-8857				AITKEN DK, 1988, MON NOT R ASTRON SOC, V230, P629, DOI 10.1093/mnras/230.4.629; Bowey JE, 1998, MON NOT R ASTRON SOC, V298, P131, DOI 10.1046/j.1365-8711.1998.01640.x; BOWEY JE, 1997, THESIS U CENTRAL LAN; Bradley J, 1996, ASTR SOC P, V104, P275; BRADLEY JP, 1992, ASTROPHYS J, V394, P643, DOI 10.1086/171618; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; BRADLEY JP, 1983, NATURE, V301, P473, DOI 10.1038/301473a0; BRADLEY JP, 1986, SCIENCE, V231, P1542, DOI 10.1126/science.231.4745.1542; BRADLEY JP, 1999, LUNAR PLANET SCI C, V30, P1835; BRADLEY JP, 1996, LUNAR PLANET SCI, V27, P149; BRADLEY JP, 1998, LPS, V29, P1737; BRADLEY JP, 1999, SOLID INTERSTELLAR M, P298; BRADLEY JP, 1993, LUNAR PLANET SCI, V24, P173; BREGMAN JD, 1987, ASTRON ASTROPHYS, V187, P616; BROWNLEE DE, 1985, ANNU REV EARTH PL SC, V13, P147, DOI 10.1146/annurev.ea.13.050185.001051; BROWNLEE DE, 1994, LUNAR PLANET SCI, V25, P185; BROWNLEE DE, 1999, LUNAR PLANET SCI C, V30, P2031; CAMPINS H, 1989, ASTROPHYS J, V341, P1059, DOI 10.1086/167563; CARR GL, 1995, REV SCI INSTRUM, V66, P1490, DOI 10.1063/1.1145951; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; DERMOTT SF, 1994, NATURE, V369, P719, DOI 10.1038/369719a0; DORSCHNER J, 1995, ASTRON ASTROPHYS, V300, P503; FLYNN GJ, 1994, NATURE, V371, P287, DOI 10.1038/371287a0; GOODMAN AA, 1995, ASTROPHYS J, V455, pL181, DOI 10.1086/309840; Greenberg J., 1982, COMETS, P131; GURTLER J, 1989, ASTRON NACHR, V310, P319, DOI 10.1002/asna.2113100419; HANNER MS, 1995, ASTROPHYS J, V438, P250, DOI 10.1086/175069; Hanner MS, 1998, ASTROPHYS J, V502, P871, DOI 10.1086/305939; HANNER MS, IN PRESS EARTH MOON; HENNING T, 1993, ASTRON ASTROPHYS, V280, P609; Jager C, 1998, ASTRON ASTROPHYS, V339, P904; JANSEN DJ, 1994, ASTRON ASTROPHYS, V282, P605; JESSBERGER EK, 1988, NATURE, V332, P691, DOI 10.1038/332691a0; JONES RV, 1967, ASTROPHYS J, V147, P943, DOI 10.1086/149086; KELLER LP, 1997, LUNAR PLANET SCI C, V28, P707; KIM SH, 1994, ASTROPHYS J, V422, P164, DOI 10.1086/173714; MADON M, 1989, J GEOPHYS RES-SOLID, V94, P15687, DOI 10.1029/JB094iB11p15687; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; MARTIN PG, 1995, ASTROPHYS J, V445, pL63, DOI 10.1086/187890; MESSENGER S, 1997, AIP C P, V402, P545; MILLAR TJ, 1980, MON NOT R ASTRON SOC, V191, P641, DOI 10.1093/mnras/191.3.641; Nuth J. A., 1988, METEORITES EARLY SOL, P984; REFFNER J, 1994, SYNCH RAD NEWS, V7, P30; Sandford S. A., 1987, Fundamentals of Cosmic Physics, V12, P1; SANDFORD SA, 1985, ASTROPHYS J, V291, P838, DOI 10.1086/163120; SANDFORD SA, 1989, ICARUS, V82, P146, DOI 10.1016/0019-1035(89)90028-6; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; SIMPSON JP, 1991, ASTROPHYS J, V368, P570, DOI 10.1086/169721; Sitko ML, 1999, ASTROPHYS J, V510, P408, DOI 10.1086/306586; Snow TP, 1996, ASTROPHYS J, V468, pL65, DOI 10.1086/310225; SOFIA UJ, 1994, ASTROPHYS J, V430, P650, DOI 10.1086/174438; SPITZER L, 1993, ASTROPHYS J, V409, P299, DOI 10.1086/172664; STADERMANN FJ, 1999, LUNAR PLANET SCI C, V30, P1407; STEPHENS JR, 1979, ASTROPHYS J, V228, P780, DOI 10.1086/156904; THIEL K, 1988, NUCL TRACKS RAD MEAS, V15, P685; THOMAS KL, 1993, GEOCHIM COSMOCHIM AC, V57, P1551, DOI 10.1016/0016-7037(93)90012-L; Waelkens C, 1996, ASTRON ASTROPHYS, V315, pL245; Waters LBFM, 1998, NATURE, V391, P868, DOI 10.1038/36052; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; Wooden DH, 1999, ASTROPHYS J, V517, P1034, DOI 10.1086/307206	60	195	196	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1716	1718		10.1126/science.285.5434.1716	http://dx.doi.org/10.1126/science.285.5434.1716			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481004				2022-12-28	WOS:000082472600030
J	Romashkova, JA; Makarov, SS				Romashkova, JA; Makarov, SS			NF-kappa B is a target of AKT in anti-apoptotic PDGF signalling	NATURE			English	Article							KINASE-C-ZETA; GROWTH-FACTOR; CELL-DEATH; PROTEIN; ACTIVATION; PHOSPHORYLATION; FIBROBLASTS; INDUCTION; RAS; TRANSDUCTION	The mechanisms of cell proliferation and transformation are intrinsically linked to the process of apoptosis: the default of proliferating cells is to die unless specific survival signals are provided(1,2). Platelet-derived growth factor (PDGF) is a principal survival factor that inhibits apoptosis and promotes proliferation(1), but the mechanisms mediating its anti-apoptotic properties are not completely understood. Here we show that the transcription factor NF-kappa B3-5 is important in PDGF signalling. NF-kappa B transmits two signals: one is required for the induction of proto-oncogene c-myc and proliferation, and the second, an anti-apoptotic signal, counterbalances c-Myc cytotoxicity. We have traced a putative pathway whereby PDGF activates NF-kappa B through pas and phospatidylinositol-3-kinase (PI(3)K) to the PKB/Akt protein kinase and the I kappa B kinase (IKK); NF-kappa B thus appears to be a target of the anti-apoptotic Ras/PI(3)K/Akt pathway(6,7). We show that, upon PDGF stimulation, Akt transiently associates in vivo with IKK and induces IKK activation. These findings establish a role for NF-kappa B in growth factor signalling and define an anti-apoptotic Ras/PI(3)K/Akt/IKK/NF-kappa B pathway, thus linking anti-apoptotic signalling with transcription machinery.	Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Makarov, SS (corresponding author), Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Firestein GS, 1999, ARTHRITIS RHEUM-US, V42, P609, DOI 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I; Foo SY, 1999, TRENDS GENET, V15, P229; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARRIS CC, 1994, CANCER EPIDEM BIOMAR, V3, P1; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Makarov SS, 1996, P NATL ACAD SCI USA, V93, P402, DOI 10.1073/pnas.93.1.402; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296	30	1620	1672	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					86	90		10.1038/43474	http://dx.doi.org/10.1038/43474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485711				2022-12-28	WOS:000082374400047
J	Breen, LM				Breen, LM			What should I do if my patient does not speak English?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EMERGENCY; INTERPRETERS		Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Virginia Commonwealth University	Breen, LM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA.							Baker DW, 1996, JAMA-J AM MED ASSOC, V275, P783, DOI 10.1001/jama.275.10.783; BAL P, 1981, BRIT MED J, V283, P368, DOI 10.1136/bmj.283.6287.368; EBDEN P, 1988, LANCET, V1, P347, DOI 10.1016/S0140-6736(88)91133-6; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; PRINCE D, 1995, ACAD EMERG MED, V2, P32, DOI 10.1111/j.1553-2712.1995.tb03076.x; PUTSCH RW, 1985, JAMA-J AM MED ASSOC, V254, P3344, DOI 10.1001/jama.254.23.3344; *US BUR CENS, 1990, CENS QUEST CONT 1990	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					819	819		10.1001/jama.282.9.819	http://dx.doi.org/10.1001/jama.282.9.819			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478684	hybrid			2022-12-28	WOS:000082272200003
J	Lyons, RA; Sibert, J; McCabe, M				Lyons, RA; Sibert, J; McCabe, M			Sharing data to prevent injuries	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales; Univ Wales Coll Med, Dept Child Hlth, Cardiff CF64 2XX, S Glam, Wales; Morriston Hosp, Swansea NHS Trust, Swansea SA6 6NL, W Glam, Wales	Cardiff University; Morriston Hospital	Lyons, RA (corresponding author), Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				*DEP HLTH, 1998, OUR HLTH NAT CONTR H; Department of Health, 1992, HLTH NAT STRAT HLTH; Lyons R A, 1995, Inj Prev, V1, P173, DOI 10.1136/ip.1.3.173; *WELSH HLTH PLANN, 1992, PROT INV HLTH GAIN I; *WELSH HLTH PLANN, 1989, STRAT INT DIR NHS WA; Welsh Office, 1995, 1992 WELSH SOC SURV	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					372	373		10.1136/bmj.319.7206.372	http://dx.doi.org/10.1136/bmj.319.7206.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490321				2022-12-28	WOS:000082001700027
J	Freeman, TB; Vawter, DE; Leaverton, PE; Godbold, JH; Hauser, RA; Goetz, CG; Olanow, CW				Freeman, TB; Vawter, DE; Leaverton, PE; Godbold, JH; Hauser, RA; Goetz, CG; Olanow, CW			Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FETAL NIGRAL TRANSPLANTATION; LONG-TERM SURVIVAL; DOUBLE-BLIND; DOPAMINERGIC GRAFTS; CLINICAL RESEARCH; GENE-THERAPY; PATIENT; IMPLANTS; LEVODOPA; PET		Univ S Florida, Tampa, FL 33606 USA; Minnesota Ctr Hlth Care Eth, Minneapolis, MN 55454 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	State University System of Florida; University of South Florida; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rush University	Freeman, TB (corresponding author), Univ S Florida, Tampa, FL 33606 USA.		Hauser, Robert/I-5372-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033772] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32842, R01 NS33772] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1998, FED REGISTER, V63, P26744; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; BAUM M, 1999, LANCET S1, V353, pS16, DOI DOI 10.1016/S0140-6736(99)90220-9]; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BONCHEK LI, 1979, NEW ENGL J MED, V301, P44, DOI 10.1056/NEJM197907053010110; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Defer GL, 1996, BRAIN, V119, P41, DOI 10.1093/brain/119.1.41; Delbanco TL, 1996, JAMA-J AM MED ASSOC, V275, P716; DIMOND EG, 1958, CIRCULATION, V18, P712; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Freeman TB, 1997, EXP NEUROL, V144, P47, DOI 10.1006/exnr.1996.6387; GUTTMAN M, 1989, CAN J NEUROL SCI, V16, P305, DOI 10.1017/S0317167100029139; HARBAUGH RE, 1989, J NEUROSURG, V71, P481, DOI 10.3171/jns.1989.71.4.0481; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; HAUSER RA, 1992, SCI BASIS TREATMENT, P275; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; LAW PK, 1991, ACTA CARDIOMIOLOGICA, V3, P281; LEAPE LL, 1991, JRA02 RAND, pR5; LEVINE RJ, 1986, ETHICS REGULATION CL; Levit K R, 1985, Health Care Financ Rev, V7, P1; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Lotz B, 1996, NEUROLOGY, V46, P1244; LOVE JW, 1975, JAMA-J AM MED ASSOC, V232, P37, DOI 10.1001/jama.232.1.37; McCarthy M, 1996, LANCET, V348, P323, DOI 10.1016/S0140-6736(05)64475-3; Moseley JB, 1996, AM J SPORT MED, V24, P28, DOI 10.1177/036354659602400106; Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; OLANOW CW, 1990, ARCH NEUROL-CHICAGO, V47, P1286, DOI 10.1001/archneur.1990.00530120030006; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Prentice Ernest D, 1989, IRB, V11, P6, DOI 10.2307/3563825; Reeves B, 1999, LANCET S1, V353, pS13; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SPODICK DH, 1971, AM HEART J, V81, P149, DOI 10.1016/0002-8703(71)90125-6; STANLEY B, 1988, PSYCHOPHARMACOL BULL, V24, P18; TAYLOR JR, 1995, CELL TRANSPLANT, V4, P13, DOI 10.1016/0963-6897(94)00035-I; THOMSEN J, 1981, ARCH OTOLARYNGOL, V107, P271; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Wagner M, 1996, LANCET, V348, P1394, DOI 10.1016/S0140-6736(05)67494-6; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115	52	174	178	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					988	992		10.1056/NEJM199909233411311	http://dx.doi.org/10.1056/NEJM199909233411311			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498497				2022-12-28	WOS:000082658100011
J	Greenberger, NJ				Greenberger, NJ			Update in gastroenterology	ANNALS OF INTERNAL MEDICINE			English	Article							CROHNS-DISEASE; GASTROESOPHAGEAL REFLUX		Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Greenberger, NJ (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	ngreenbe@kumc.edu						Blustein PK, 1998, AM J GASTROENTEROL, V93, P2508, DOI 10.1016/S0002-9270(98)00475-4; Clave P, 1998, GASTROENTEROLOGY, V115, P597, DOI 10.1016/S0016-5085(98)70139-8; Fine KD, 1998, GASTROENTEROLOGY, V114, P29, DOI 10.1016/S0016-5085(98)70629-8; Friedman LS, 1998, NEW ENGL J MED, V339, P1928, DOI 10.1056/NEJM199812243392611; Greenberger N J, 1998, Ann Intern Med, V129, P309; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; McLeod RS, 1997, GASTROENTEROLOGY, V113, P1823, DOI 10.1016/S0016-5085(97)70001-5; Rockey DC, 1998, NEW ENGL J MED, V339, P153, DOI 10.1056/NEJM199807163390303; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4	11	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					445	452		10.7326/0003-4819-131-6-199909210-00010	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498562				2022-12-28	WOS:000082641100008
J	Charles, C; Whelan, T; Gafni, A				Charles, C; Whelan, T; Gafni, A			What do we mean by partnership in making decisions about treatment?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; BREAST-CANCER; PATIENT; INSTRUMENT		McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Charles, C (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.		Whelan, Timothy/D-3185-2017; Evans, Diane/F-9258-2017	Whelan, Timothy/0000-0001-9844-2023; 				Beisecker A.E., 1993, HEALTH COMMUN, V5, P41; Cahill J, 1996, J ADV NURS, V24, P561, DOI 10.1046/j.1365-2648.1996.22517.x; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DEBER RB, 1994, CAN MED ASSOC J, V151, P171; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HUGHES TE, 1991, MED CARE, V29, P297, DOI 10.1097/00005650-199103000-00011; ISCOE NA, 1994, CAN MED ASSOC J, V150, P345; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; LOMAS J, 1994, WHY ARE SOME PEOPLE, P253; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; WHELAN TJ, 1995, J CLIN ONCOL, V13, P847, DOI 10.1200/JCO.1995.13.4.847	15	383	393	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					780	782		10.1136/bmj.319.7212.780	http://dx.doi.org/10.1136/bmj.319.7212.780			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488014	Green Published			2022-12-28	WOS:000082701500033
J	Liu, SM; Ajani, U; Chae, C; Hennekens, C; Buring, JE; Manson, JE				Liu, SM; Ajani, U; Chae, C; Hennekens, C; Buring, JE; Manson, JE			Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPAIRED GLUCOSE-TOLERANCE; INSULIN ACTION; DIET; ANTIOXIDANT; WOMEN	Context Recent data suggest a protective role of carotenoids in the development of type 2 diabetes mellitus (DM), possibly via an antioxidant effect, but no randomized trial has directly assessed the efficacy of beta-carotene to prevent DM. Objective To determine whether long-term beta-carotene supplementation reduces the risk of developing type 2 DM, Design, Setting, and Participants A total of 22 071 healthy US male physicians aged 40 to 84 years in a randomized, double-blind, placebo-controlled trial, from 1982 to 1995. More than 99% of the participants had complete follow-up (median duration, 12 years). Intervention Subjects were randomly assigned to receive beta-carotene (50 mg on alternate days) or placebo. Main Outcome Measure Incidence of type 2 DM. Results A total of 10 756 subjects were assigned to beta-carotene and 10 712 to placebo. Incidence of type 2 DM did not differ between groups: 396 men in the beta-carotene group and 402 men in the placebo group developed type 2 DM (relative risk, 0.98; 95% confidence interval, 0.85-1.12). The lack of association between beta-carotene supplementation and incidence of type 2 DM persisted despite multivariate adjustment, There was no evidence of benefit when the period of risk was subdivided into years of follow-up or increasing duration of treatment. Conclusion In this trial of apparently healthy men, supplementation with beta-carotene for an average of 12 years had no effect on the risk of subsequent type 2 DM.	Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Liu, SM (corresponding author), Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.		Liu, Simin/I-3689-2014; Liu, Simin/GSN-4159-2022	Liu, Simin/0000-0003-2098-3844; 	NCI NIH HHS [CA34944, CA40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; COLDITZ GA, 1992, AM J CLIN NUTR, V55, P1018, DOI 10.1093/ajcn/55.5.1018; FESKENS EJM, 1995, DIABETES CARE, V18, P1104, DOI 10.2337/diacare.18.8.1104; Ford ES, 1999, AM J EPIDEMIOL, V149, P168, DOI 10.1093/oxfordjournals.aje.a009783; GOLAY A, 1994, DIABETES METAB, V20, P3; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KRINSKY NI, 1993, ANNU REV NUTR, V13, P561, DOI 10.1146/annurev.nutr.13.1.561; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PAOLISSO G, 1993, METABOLISM, V42, P659, DOI 10.1016/0026-0495(93)90228-G; PAOLISSO G, 1993, AM J CLIN NUTR, V57, P650, DOI 10.1093/ajcn/57.5.650; Reunanen A, 1998, EUR J CLIN NUTR, V52, P89, DOI 10.1038/sj.ejcn.1600519; Rock CL, 1997, AM J CLIN NUTR, V65, P844, DOI 10.1093/ajcn/65.3.844; Rothman K., 1998, MODERN EPIDEMIOLOGY; SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8; SNOWDON DA, 1985, AM J PUBLIC HEALTH, V75, P507, DOI 10.2105/AJPH.75.5.507	18	91	94	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1073	1075		10.1001/jama.282.11.1073	http://dx.doi.org/10.1001/jama.282.11.1073			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493207	Bronze			2022-12-28	WOS:000082512300032
J	Kelleher, C; Braude, P				Kelleher, C; Braude, P			Recent advances - Gynaecology	BRITISH MEDICAL JOURNAL			English	Review							LEVONORGESTREL INTRAUTERINE SYSTEM; UTERINE ARTERY EMBOLIZATION; ENDOMETRIAL RESECTION; FECAL INCONTINENCE; URINARY-INCONTINENCE; ECTOPIC PREGNANCY; MENORRHAGIA; MANAGEMENT; FIBROIDS; CHILDBIRTH		St Thomas Hosp, Guys Kings & St Thomass Sch Med, Div Womens & Childerns Hlth, London SE1 7EH, England; St Thomas Hosp, Guys & St Thomass Hosp Trust, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Braude, P (corresponding author), St Thomas Hosp, Guys Kings & St Thomass Sch Med, Div Womens & Childerns Hlth, London SE1 7EH, England.							Amso NN, 1998, BRIT J OBSTET GYNAEC, V105, P517, DOI 10.1111/j.1471-0528.1998.tb10152.x; Barrington JW, 1997, BRIT J OBSTET GYNAEC, V104, P614, DOI 10.1111/j.1471-0528.1997.tb11542.x; BONNAR J, 1997, BRIT MED J, V313, P379; Bradley EA, 1998, BRIT J OBSTET GYNAEC, V105, P235, DOI 10.1111/j.1471-0528.1998.tb10060.x; Coleman M, 1997, AUST NZ J OBSTET GYN, V37, P195, DOI 10.1111/j.1479-828X.1997.tb02253.x; Cook TA, 1998, BRIT J SURG, V85, P293; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1360, DOI 10.1111/j.1471-0528.1997.tb11004.x; COULTER A, 1995, INT J TECHNOL ASSESS, V11, P456, DOI 10.1017/S0266462300008679; COULTER A, 1994, FAM PRACT, V11, P394, DOI 10.1093/fampra/11.4.394; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; Crosignani PG, 1997, OBSTET GYNECOL, V90, P257, DOI 10.1016/S0029-7844(97)00226-3; Dimitry ES, 1996, BRIT J CLIN PRACT, V50, P376; Gerris J, 1996, HORM RES, V45, P279, DOI 10.1159/000184806; Golan A, 1996, HUM REPROD, V11, P33, DOI 10.1093/humrep/11.suppl_3.33; Goodwin SC, 1997, J VASC INTERV RADIOL, V8, P517, DOI 10.1016/S1051-0443(97)70603-1; Hampel C, 1997, UROLOGY, V50, P4, DOI 10.1016/S0090-4295(97)00578-5; Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x; Kelleher CJ, 1997, BRIT J OBSTET GYNAEC, V104, P988, DOI 10.1111/j.1471-0528.1997.tb12054.x; Kelleher CJ, 1997, BRIT J OBSTET GYNAEC, V104, P1374, DOI 10.1111/j.1471-0528.1997.tb11006.x; Korell M, 1997, FERTIL STERIL, V68, P220, DOI 10.1016/S0015-0282(97)81505-1; Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122; Lamping DL, 1998, BRIT J OBSTET GYNAEC, V105, P766, DOI 10.1111/j.1471-0528.1998.tb10209.x; Lindsay PC, 1996, FERTIL STERIL, V65, P342, DOI 10.1016/S0015-0282(16)58096-0; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; OConnor H, 1996, NEW ENGL J MED, V335, P151, DOI 10.1056/NEJM199607183350302; OCONNOR H, 1997, LANCET, V349, P887; Overton C, 1997, BRIT J OBSTET GYNAEC, V104, P1351, DOI 10.1111/j.1471-0528.1997.tb11003.x; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PATTERSONBROWN S, 1998, BRIT MED J, V7156, P462; Pickersgill A, 1998, BRIT J OBSTET GYNAEC, V105, P475, DOI 10.1111/j.1471-0528.1998.tb10146.x; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; PRESTON JT, 1995, BRIT J OBSTET GYNAEC, V102, P401, DOI 10.1111/j.1471-0528.1995.tb11293.x; RAVINA JH, 1995, LANCET, V346, P671, DOI 10.1016/S0140-6736(95)92282-2; STOVALL TG, 1991, OBSTET GYNECOL, V77, P749; Sultan AH, 1997, CURR OPIN OBSTET GYN, V9, P320; Sultan AH, 1997, BRIT J OBSTET GYNAEC, V104, P979; *TASKF IMPR MAN ME, 1997, GEN PRACT SURV MEN; Templeton A, 1996, LANCET, V348, P1402, DOI 10.1016/S0140-6736(96)05291-9; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; Van Steirteghem A, 1998, HUM REPROD, V13, P134, DOI 10.1093/humrep/13.suppl_1.134; Yao ML, 1997, FERTIL STERIL, V67, P421, DOI 10.1016/S0015-0282(97)80064-7	42	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					689	692		10.1136/bmj.319.7211.689	http://dx.doi.org/10.1136/bmj.319.7211.689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480828	Green Published			2022-12-28	WOS:000082636800027
J	Sahara, S; Aoto, M; Eguchi, Y; Imamoto, N; Yoneda, Y; Tsujimoto, Y				Sahara, S; Aoto, M; Eguchi, Y; Imamoto, N; Yoneda, Y; Tsujimoto, Y			Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation	NATURE			English	Article							CASPASE-ACTIVATED DNASE; LAMIN-A; IMPORT; CELLS; FRAGMENTATION; COMPLEX	Apoptosis is defined by several unique morphological nuclear changes, such as chromatin condensation and nuclear fragmentation(1). These changes are triggered by the activation of a family of cysteine proteases called caspases(2,3), and caspase-activated DNase (CAD/DPP40)(4,5) and Iamin protease (caspase-6)(6,7) have been implicated in some of these changes. CAD/DFF40 induces chromatin condensation in purified nuclei, but distinct caspase-activated factor(s) may be responsible for chromatin condensations. Here we use an in vitro system to identify a new nuclear factor, designated Acinus, which induces apoptotic chromatin condensation after cleavage by caspase-3 without inducing DNA fragmentation. Immunodepletion experiments showed that Acinus is essential for apoptotic chromatin condensation in vitro, and an antisense study revealed that Acinus is also important in the induction of apoptotic chromatin condensation in cells.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Anat, Osaka 5650871, Japan; Japan Sci & Technol Corp JST, CREST, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, 202 Yamadaoka, Osaka 5650871, Japan.		Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	26	346	354	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					168	173		10.1038/43678	http://dx.doi.org/10.1038/43678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490026				2022-12-28	WOS:000082458800055
J	Pellegrino, ED; Relman, AS				Pellegrino, ED; Relman, AS			Professional medical associations - Ethical and practical guidelines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA USA	Georgetown University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Pellegrino, ED (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, 4000 Reservoir Rd NW,Room D-238, Washington, DC 20007 USA.								0	89	91	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					984	986		10.1001/jama.282.10.984	http://dx.doi.org/10.1001/jama.282.10.984			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485685				2022-12-28	WOS:000082335900038
J	Harjai, KJ				Harjai, KJ			Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; PRIMARY-PREVENTION TRIAL; LOW-DENSITY-LIPOPROTEIN; ISOLATED SYSTOLIC HYPERTENSION; OCCLUSIVE ARTERIAL-DISEASE; VITAMIN-E CONSUMPTION; APOLIPOPROTEIN-A-I; MIDDLE-AGED MEN; MYOCARDIAL-INFARCTION; PLASMA HOMOCYSTEINE	The 1996 Bethesda Conference acknowledged left ventricular hypertrophy, hyperhomocysteinemia, lipoprotein(a) excess, hypertriglyceridemia. oxidative stress, and hyperfibrinogenemia as possible new cardiac risk factors. This review summarizes the current literature that supports these conditions as cardiac risk factors. Left ventricular hypertrophy is an independent risk factor for vascular disease. Improvement or progression of left ventricular hypertrophy influences subsequent cardiovascular complications. Clinical trials are under way to assess the potential benefit of decreasing homocysteine levels. The role of lipoprotein(a) excess in vascular disease is controversial. The atherogenic potential of lipoprotein(a) seems to be neutralized by effective reduction of low-density lipoprotein cholesterol levels. Increasing evidence supports an independent role of hypertriglyceridemia in cardiovascular disease and a possible clinical benefit from decreasing triglyceride levels. Among antioxidant micronutrients, supplementation with vitamin E has been shown to be beneficial in primary and secondary prevention studies. Data supporting the use of other antioxidants are much weaker. Preliminary evidence suggests that reducing fibrinogen levels in patients with high baseline levels and coronary disease may be beneficial. Despite the potential relation between new risk factors and cardiovascular disease, routine clinical application of these conditions as cardiovascular risk factors would be premature. Evidence is needed that these conditions extend prognostic ability beyond conventional risk factors and that modification of these conditions can reduce the risk for cardiovascular events.	Alton Ochsner Med Fdn & Ochsner Clin, Dept Cardiol, New Orleans, LA 70121 USA	Ochsner Health System	Harjai, KJ (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Cardiol, 1514 Jefferson Highway, New Orleans, LA 70121 USA.	kharjai@ochsner.org						Albers John J., 1994, Current Opinion in Lipidology, V5, P417, DOI 10.1097/00041433-199412000-00004; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; *AM HEART ASS, 1993, HEART STROK FACTS ST; [Anonymous], 1993, JAMA, V269, P505; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BARASCH E, 1995, J CLIN EPIDEMIOL, V48, P757, DOI 10.1016/0895-4356(94)00191-R; BARBIR M, 1992, LANCET, V340, P1500, DOI 10.1016/0140-6736(92)92756-6; Behar S, 1999, Blood Coagul Fibrinolysis, V10 Suppl 1, pS41; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BIKKINA M, 1994, JAMA-J AM MED ASSOC, V272, P33, DOI 10.1001/jama.272.1.33; BLANKENHORN DH, 1990, CIRCULATION, V81, P470, DOI 10.1161/01.CIR.81.2.470; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; BRENNER H, 1990, EUR HEART J, V11, P1054, DOI 10.1093/oxfordjournals.eurheartj.a059642; BROADHURST P, 1990, ATHEROSCLEROSIS, V85, P169, DOI 10.1016/0021-9150(90)90108-U; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; BUDDE T, 1994, ARTERIOSCLER THROMB, V14, P1730, DOI 10.1161/01.ATV.14.11.1730; BURR ML, 1989, LANCET, V2, P757; Cantin B, 1998, J AM COLL CARDIOL, V31, P519, DOI 10.1016/S0735-1097(97)00528-7; Chambless LE, 1996, AM J EPIDEMIOL, V144, P857; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; De Maat M. P. M., 1994, Blood Coagulation and Fibrinolysis, V5, P17; deFaire U, 1996, EUR HEART J, V17, P37, DOI 10.1093/eurheartj/17.suppl_F.37; DESMARAIS RL, 1995, CIRCULATION, V91, P1403, DOI 10.1161/01.CIR.91.5.1403; Devereux RB, 1996, J HYPERTENS, V14, pS95, DOI 10.1097/00004872-199609002-00018; Devereux RB, 1997, J HYPERTENS, V15, P801, DOI 10.1097/00004872-199715080-00002; Devereux RB, 1996, AM J CARDIOL, V78, P61, DOI 10.1016/S0002-9149(96)00228-7; Devereux RB, 1996, JAMA-J AM MED ASSOC, V275, P1517, DOI 10.1001/jama.275.19.1517; Dhawan J, 1996, CURR OPIN LIPIDOL, V7, P196, DOI 10.1097/00041433-199608000-00004; Drouet L., 1994, Blood Coagulation and Fibrinolysis, V5, P18; Durand P, 1997, FASEB J, V11, P1157, DOI 10.1096/fasebj.11.13.9367351; DURRINGTON PN, 1988, LANCET, V1, P1070; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; ERNST E, 1995, EUR HEART J, V16, P47, DOI 10.1093/eurheartj/16.suppl_A.47; Espeland MA, 1998, CIRCULATION, V97, P979; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GANAU A, 1992, J AM COLL CARDIOL, V19, P1550, DOI 10.1016/0735-1097(92)90617-V; GAVISH D, 1991, LANCET, V337, P203, DOI 10.1016/0140-6736(91)92161-T; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GENEST J, 1995, AM J CARDIOL, V76, pA8; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; Ghali Jalal K. 3rd, 1997, Am J Geriatr Cardiol, V6, P38; Giri S, 1998, ATHEROSCLEROSIS, V137, P359, DOI 10.1016/S0021-9150(98)00022-7; Goldbourt U, 1998, EUR HEART J, V19, pH42; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; GRUNDY SM, 1992, ARCH INTERN MED, V152, P28, DOI 10.1001/archinte.152.1.28; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; HANSEN PR, 1994, EUR J CLIN INVEST, V24, P497, DOI 10.1111/j.1365-2362.1994.tb02381.x; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HODIS HN, 1994, J AM COLL CARDIOL, pA481; HODIS HN, 1996, CIRCULATION S1, V94, P1508; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; Jialal I, 1992, CURR OPIN LIPIDOL, V3, P324; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KEILANI T, 1993, ANN INTERN MED, V118, P246, DOI 10.7326/0003-4819-118-4-199302150-00002; Koenig W., 1994, Blood Coagulation and Fibrinolysis, V5, P16; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; Kronenberg F, 1996, ARTERIOSCL THROM VAS, V16, P1568, DOI 10.1161/01.ATV.16.12.1568; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; LaRosa JC, 1997, ARCH INTERN MED, V157, P961, DOI 10.1001/archinte.157.9.961; LEE AJ, 1993, BRIT HEART J, V69, P338; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; LOWE GDO, 1980, BRIT MED J, V280, P673, DOI 10.1136/bmj.280.6215.673; Mack WJ, 1996, ARTERIOSCL THROM VAS, V16, P697, DOI 10.1161/01.ATV.16.5.697; MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7; Marcovina SM, 1999, ARTERIOSCL THROM VAS, V19, P1250, DOI 10.1161/01.ATV.19.5.1250; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Mijatovic V, 1998, FERTIL STERIL, V69, P876, DOI 10.1016/S0015-0282(98)00041-7; MOLITERNO DJ, 1995, ARTERIOSCL THROM VAS, V15, P850, DOI 10.1161/01.ATV.15.7.850; MONTALESCOT G, 1995, CIRCULATION, V92, P31, DOI 10.1161/01.CIR.92.1.31; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; MULDOON MF, 1995, ARCH INTERN MED, V155, P615, DOI 10.1001/archinte.155.6.615; NARUSZEWICZ M, 1992, METABOLISM, V41, P1215, DOI 10.1016/0026-0495(92)90012-Y; NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3; NIORT G, 1988, ATHEROSCLEROSIS, V71, P113, DOI 10.1016/0021-9150(88)90135-9; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Ofili EO, 1998, JAMA-J AM MED ASSOC, V279, P778, DOI 10.1001/jama.279.10.778; OLIVER MF, 1994, LANCET, V344, P633; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; OrthGomer K, 1997, CIRCULATION, V95, P329; OTTO C, 1994, BLOOD COAGUL FIBRI S, V5, P11; Pasternak RC, 1996, J AM COLL CARDIOL, V27, P978, DOI 10.1016/0735-1097(96)87731-X; PAZZUCCONI F, 1992, EUR J CLIN PHARMACOL, V43, P219; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P422, DOI 10.1016/S0735-1097(10)80109-3; Poon M, 1997, CIRCULATION, V96, P2514, DOI 10.1161/01.CIR.96.8.2514; Post WS, 1997, HYPERTENSION, V30, P1025, DOI 10.1161/01.HYP.30.5.1025; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAPP JH, 1991, ARTERIOSCLER THROMB, V11, P903, DOI 10.1161/01.ATV.11.4.903; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; Ridker PM, 1999, ANN INTERN MED, V130, P933, DOI 10.7326/0003-4819-130-11-199906010-00018; RIDKER PM, 1995, JAMA-J AM MED ASSOC, V273, P1269, DOI 10.1001/jama.273.16.1269; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rosengren A, 1996, J INTERN MED, V239, P499, DOI 10.1046/j.1365-2796.1996.485821000.x; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SAVAGE DD, 1987, CIRCULATION, V75, P26; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SCHMIEDER RE, 1988, CIRCULATION, V78, P951, DOI 10.1161/01.CIR.78.4.951; Schreiner Pamela J., 1994, Annals of Epidemiology, V4, P351; Schreiner PJ, 1996, ARTERIOSCL THROM VAS, V16, P471, DOI 10.1161/01.ATV.16.3.471; SMITH EB, 1994, THROMB RES, V73, P1, DOI 10.1016/0049-3848(94)90049-3; SMITH EB, 1991, ATHEROSCLEROSIS, V89, P127, DOI 10.1016/0021-9150(91)90052-5; SOLYMOSS BC, 1993, CAN J CARDIOL, V9, P80; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Sunayama S, 1996, CIRCULATION, V94, P1263, DOI 10.1161/01.CIR.94.6.1263; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Tato F, 1997, ARTERIOSCL THROM VAS, V17, P56, DOI 10.1161/01.ATV.17.1.56; Temme EHM, 1996, AM J CLIN NUTR, V63, P897, DOI 10.1093/ajcn/63.6.897; Thomas TR, 1997, METABOLISM, V46, P1178, DOI 10.1016/S0026-0495(97)90213-4; Toss H, 1997, CIRCULATION, V96, P4204; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Ubbink JB, 1997, J INHERIT METAB DIS, V20, P316, DOI 10.1023/A:1005329427711; vanKooten F, 1996, STROKE, V27, P1231, DOI 10.1161/01.STR.27.7.1231; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; *WOM HLTH STUD RES, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Woo KS, 1997, CIRCULATION, V96, P2542, DOI 10.1161/01.CIR.96.8.2542; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; Yokoi H, 1997, J AM COLL CARDIOL, V30, P855, DOI 10.1016/S0735-1097(97)00270-2; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942	168	118	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					376	386		10.7326/0003-4819-131-5-199909070-00009	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475891				2022-12-28	WOS:000082458500008
J	Horton, R				Horton, R			Future of European cardiology: continentally isolated or globally integrated?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							Chockalingam A, 1999, IMPENDING GLOBAL PAN; de Luna AB, 1999, J AM COLL CARDIOL, V33, P1427; De Luna AB, 1999, EUR HEART J, V20, P562, DOI 10.1053/euhj.1998.1392; Fuster V, 1999, CIRCULATION, V99, P1132, DOI 10.1161/01.CIR.99.9.1132; Institute of Medicine, 1998, CONTR CARD DIS DEV C; King SB, 1998, J AM COLL CARDIOL, V32, P2100; Lechat P, 1999, LANCET, V353, P9; Masera G, 1998, LANCET, V352, P1923, DOI 10.1016/S0140-6736(98)07077-9; Ryden L, 1999, EUR HEART J, V20, P319; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0	10	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					791	792						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485717				2022-12-28	WOS:000082400700004
J	Joubin, K; Stern, CD				Joubin, K; Stern, CD			Molecular interactions continuously define the organizer during the cell movements of gastrulation	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; PRIMITIVE STREAK FORMATION; EARLY XENOPUS DEVELOPMENT; EARLY CHICK-EMBRYO; NEURAL INDUCTION; SPEMANNS ORGANIZER; MESODERM INDUCTION; MARGINAL ZONE; AVIAN EMBRYOS; HENSENS NODE	The organizer is a unique region in the gastrulating embryo that induces and patterns the body axis. It arises before gastrulation under the influence of the Nieuwkoop center. We show that during gastrulation, cell movements bring cells into and out of the chick organizer, Hensen's node. During these movements, cells acquire and lose organizer properties according to their position. A "node inducing center," which emits Vg1 and Wnt8C, is located in the middle of the primitive streak. Its activity is inhibited by ADMP produced by the node and by BMPs at the periphery. These interactions define the organizer as a position in the embryo, whose cellular makeup is constantly changing, and explain the phenomenon of organizer regeneration.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University	Stern, CD (corresponding author), Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.	cds20@columbia.edu	Stern, Claudio D/C-6265-2008; Stern, Claudio/AAZ-7381-2021	Stern, Claudio D/0000-0002-9907-889X; Stern, Claudio/0000-0002-9907-889X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053456] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53456] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1954, J EMBRYOL EXP MORPH, V2, P55; ALTABA AR, 1995, DEV BIOL, V170, P299; Bachvarova RF, 1998, DEVELOPMENT, V125, P3521; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BUTROS J, 1967, J EMBRYOL EXP MORPH, V17, P119; Connolly DJ, 1997, INT J DEV BIOL, V41, P389; CONNOLLY DJ, 1995, DEV GENET, V17, P65, DOI 10.1002/dvg.1020170108; COOKE J, 1973, J EMBRYOL EXP MORPH, V30, P283; COOKE J, 1975, J EMBRYOL EXP MORPH, V33, P147; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; DALE L, 1992, DEVELOPMENT, V115, P573; DU SJ, 1995, MOL CELL BIOL, V15, P2625; GALLERA J, 1974, EXPERIENTIA, V30, P183, DOI 10.1007/BF01927723; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GRABOWSKI CT, 1956, J EXP ZOOL, V133, P301, DOI 10.1002/jez.1401330207; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, ORG MILESTONE HALF C, P221; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATADA Y, 1994, DEVELOPMENT, V120, P2879; Hoang BH, 1998, DEV DYNAM, V212, P364, DOI 10.1002/(SICI)1097-0177(199807)212:3<364::AID-AJA4>3.0.CO;2-F; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HUME CR, 1993, DEVELOPMENT, V119, P1147; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jones CM, 1996, DEVELOPMENT, V122, P1545; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Kodjabachian L, 1998, CURR BIOL, V8, pR918, DOI 10.1016/S0960-9822(98)00009-8; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Moos M, 1995, DEVELOPMENT, V121, P4293; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Nicholas JS, 1942, J EXP ZOOL, V90, P127, DOI 10.1002/jez.1400900108; Nicolas JF, 1996, DEVELOPMENT, V122, P2933; NICOLET G, 1970, Journal of Embryology and Experimental Morphology, V23, P79; Nicolet G., 1971, Adv Morphogen, V9, P231; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; Pannett CA, 1924, LANCET, V1, P381; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Psychoyos D, 1996, DEVELOPMENT, V122, P1523; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Seleiro EAP, 1996, CURR BIOL, V6, P1476, DOI 10.1016/S0960-9822(96)00752-X; SELLECK MAJ, 1992, NATO ADV SCI I A-LIF, V231, P23; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; Shah SB, 1997, DEVELOPMENT, V124, P5127; Shih J, 1996, DEVELOPMENT, V122, P1313; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smith JL, 1998, CURR TOP DEV BIOL, V40, P79, DOI 10.1016/S0070-2153(08)60365-8; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; STERN CD, 1981, ANAT EMBRYOL, V163, P245, DOI 10.1007/BF00315703; STOREY KG, 1995, DEVELOPMENT, V121, P417; Streit A, 1997, DEVELOPMENT, V124, P1191; Streit A, 1998, DEVELOPMENT, V125, P507; Streit A, 1999, MECH DEVELOP, V82, P51, DOI 10.1016/S0925-4773(99)00013-1; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tonegawa A, 1997, DEVELOPMENT, V124, P1975; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang SW, 1997, BIOCHEM BIOPH RES CO, V236, P502, DOI 10.1006/bbrc.1997.6995; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WU M, 1991, METHOD CELL BIOL, V36, P3; YUAN SP, 1995, DEV GENET, V17, P38, DOI 10.1002/dvg.1020170106; Yuan SP, 1999, DEVELOPMENT, V126, P2461; Yuan SP, 1998, DEVELOPMENT, V125, P201; Yuan SP, 1995, DEV BIOL, V172, P567, DOI 10.1006/dbio.1995.8064; ZOM AM, 1999, DEV BIOL, V209, P282	85	119	122	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					559	571		10.1016/S0092-8674(00)80044-6	http://dx.doi.org/10.1016/S0092-8674(00)80044-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490096	hybrid			2022-12-28	WOS:000082433500004
J	Oldstone, MBA; Lewicki, H; Thomas, D; Tishon, A; Dales, S; Patterson, J; Manchester, M; Homann, D; Naniche, D; Holz, A				Oldstone, MBA; Lewicki, H; Thomas, D; Tishon, A; Dales, S; Patterson, J; Manchester, M; Homann, D; Naniche, D; Holz, A			Measles virus infection in a transgenic model: Virus-induced immunosuppression and central nervous system disease	CELL			English	Article							DEPENDENT DIABETES-MELLITUS; SINDBIS VIRUS; MOUSE MODEL; T-CELLS; PROTEIN; MICE; CD46; EXPRESSION; RECEPTOR; STRAIN	Measles virus (MV) infects 40 million persons and kills one million per year primarily by suppressing the immune system and afflicting the central nervous system (CNS). The lack of a suitable small animal model has impeded progress of understanding how MV causes disease and the development of novel therapies and improved vaccines. We tested a transgenic mouse line in which expression of the MV receptor CD46 closely mimicked the location and amount of CD46 found in humans. Virus replicated in and was recovered from these animals' immune systems and was associated with suppression of humoral and cellular immune responses. infectious virus was recovered from the CNS, replicated primarily in neurons, and spread to distal sites presumably by fast axonal transport. Thus, a small animal model is available for analysis of MV pathogenesis.	Scripps Res Inst, Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Rockefeller Univ, Dept Cell Biol, New York, NY 10024 USA	Scripps Research Institute; Rockefeller University	Oldstone, MBA (corresponding author), Scripps Res Inst, Res Inst, Dept Neuropharmacol, Div Virol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mbaobo@scripps.edu	Naniche, Denise S/S-1814-2018	Naniche, Denise S/0000-0002-4495-6325; Holz, Andreas/0000-0002-8886-0915; Homann, Dirk/0000-0002-7622-5754	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019185] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36222] Funding Source: Medline; NIA NIH HHS [AG00080] Funding Source: Medline; NIMH NIH HHS [MH19185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; Blixenkrone-Moller M, 1998, VIROLOGY, V249, P238, DOI 10.1006/viro.1998.9301; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; EASTMAN CL, 1994, EXP NEUROL, V125, P119, DOI 10.1006/exnr.1994.1015; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; Griffin DE, 1999, TRENDS MICROBIOL, V7, P155, DOI 10.1016/S0966-842X(99)01470-5; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Holz A, 1996, J NEUROSCI, V16, P467; Homann D, 1998, J VIROL, V72, P9208, DOI 10.1128/JVI.72.11.9208-9216.1998; Horvat B, 1996, J VIROL, V70, P6673, DOI 10.1128/JVI.70.10.6673-6681.1996; Horwitz MS, 1999, LAB INVEST, V79, P235; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; Lawrence DMP, 1999, J VIROL, V73, P1795, DOI 10.1128/JVI.73.3.1795-1801.1999; LIEBERT UG, 1995, CURR TOP MICROBIOL, V191, P149; LIPKIN WI, 1989, CURR TOP MICROBIOL, V143, P33; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LONG EO, 1989, IMMUNOL TODAY, V10, P45, DOI 10.1016/0167-5699(89)90303-4; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Markowitz LE, 1994, VACCINES, P229; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MOSIER DE, 1974, J IMMUNOL, V112, P305; Mrkic B, 1998, J VIROL, V72, P7420, DOI 10.1128/JVI.72.9.7420-7427.1998; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OLDSTONE MB, 1973, J IMMUNOL, V110, P1268; Oldstone MBA, 1997, VIROLOGY, V234, P179, DOI 10.1006/viro.1997.8674; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OLDSTONE MBA, 1998, VIRUSES PLAGUES HIST, P73; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Rall GF, 1997, P NATL ACAD SCI USA, V94, P4659, DOI 10.1073/pnas.94.9.4659; RIMA BK, 1995, CURR TOP MICROBIOL, V191, P65; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROZENBLATT S, 1979, J VIROL, V32, P329, DOI 10.1128/JVI.32.1.329-333.1979; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; Schnorr JJ, 1997, P NATL ACAD SCI USA, V94, P5326, DOI 10.1073/pnas.94.10.5326; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; TERMEULEN V, 1983, COMPR VIROL, V18, P105; Thorley BR, 1997, EUR J IMMUNOL, V27, P726, DOI 10.1002/eji.1830270322; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TISHON A, 1988, J IMMUNOL, V140, P1280; Trgovcich J, 1997, VIROLOGY, V227, P234, DOI 10.1006/viro.1996.8289; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; Yannoutsos N, 1996, GENES CELLS, V1, P409, DOI 10.1046/j.1365-2443.1996.d01-244.x; Zingoni A, 1998, J IMMUNOL, V161, P547	51	125	127	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					629	640		10.1016/S0092-8674(00)80050-1	http://dx.doi.org/10.1016/S0092-8674(00)80050-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490102	Bronze			2022-12-28	WOS:000082433500010
J	Schacter, DL; Wagner, AD				Schacter, DL; Wagner, AD			Perspectives: Neuroscience - Remembrance of things past	SCIENCE			English	Editorial Material							SEMANTIC MEMORY; BRAIN ACTIVITY		Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Nucl Magnet Resonance Ctr, Boston, MA 02129 USA	Harvard University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Schacter, DL (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.			Wagner, Anthony/0000-0003-0624-4543	NIA NIH HHS [AG05778, AG08441] Funding Source: Medline; NIMH NIH HHS [MH57915] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG008441, R01AG008441] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGGLETON JP, IN PRESS BEHAV BRAIN; Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; Fernandez G, 1999, SCIENCE, V285, P1582, DOI 10.1126/science.285.5433.1582; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; NEVILLE HJ, 1986, J MEM LANG, V25, P75, DOI 10.1016/0749-596X(86)90022-7; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; Schacter D. L., 1982, HUMAN MEMORY AMNESIA, P1; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; Teng E, 1999, NATURE, V400, P675, DOI 10.1038/23276; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; WAGNER AD, 1999, PHILOS T R SOC LON B, V354, P1283	19	22	22	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1503	1504		10.1126/science.285.5433.1503	http://dx.doi.org/10.1126/science.285.5433.1503			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10498535	Green Submitted			2022-12-28	WOS:000082359500038
J	Boekema, EJ; van Breemen, JFL; Brisson, A; Ubbink-Kok, T; Konings, WN; Lolkema, JS				Boekema, EJ; van Breemen, JFL; Brisson, A; Ubbink-Kok, T; Konings, WN; Lolkema, JS			Biological motors - Connecting stalks in V-type ATPase	NATURE			English	Article							ROTATIONAL CATALYSIS; ELECTRON-MICROSCOPY; SYNTHASE		Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands	University of Groningen	Boekema, EJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands.		Konings, Wilhelmus N./C-7063-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOYER PD, 1995, FASEB J, V9, P559, DOI 10.1096/fasebj.9.7.7737466; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	10	76	76	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					37	38		10.1038/43369	http://dx.doi.org/10.1038/43369			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485704	Green Published			2022-12-28	WOS:000082374400031
J	Aziz, I; Kastelik, JA; Meigh, RE; Morice, AH				Aziz, I; Kastelik, JA; Meigh, RE; Morice, AH			Collapse with a streptococcal infection	LANCET			English	Article							ENDOCARDITIS		Univ Hull, Castle Hill Hosp, Acad Dept Med, Cottingham HU16 5JQ, England; Castle Hill Hosp, Publ Hlth Lab Serv, Cottingham, England	University of Hull; University of Hull	Aziz, I (corresponding author), Univ Hull, Castle Hill Hosp, Acad Dept Med, Castle Rd, Cottingham HU16 5JQ, England.							GALLAGHER PG, 1986, REV INFECT DIS, V8, P175; Lancefield RC, 1935, J EXP MED, V61, P335, DOI 10.1084/jem.61.3.335; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; SCULLY BE, 1987, INFECTION, V15, P169, DOI 10.1007/BF01646041; SLEDGE D, 1994, CLIN INFECT DIS, V19, P166, DOI 10.1093/clinids/19.1.166	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					738	738		10.1016/S0140-6736(99)04422-0	http://dx.doi.org/10.1016/S0140-6736(99)04422-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475186				2022-12-28	WOS:000082233000014
J	Sinha, A; Sazawal, S; Kumar, R; Sood, S; Reddaiah, VP; Singh, B; Rao, M; Naficy, A; Clemens, JD; Bhan, MK				Sinha, A; Sazawal, S; Kumar, R; Sood, S; Reddaiah, VP; Singh, B; Rao, M; Naficy, A; Clemens, JD; Bhan, MK			Typhoid fever in children aged less than 5 years	LANCET			English	Article							VI-CAPSULAR POLYSACCHARIDE; SALMONELLA-TYPHI; VACCINE; YOUNGER	Background Calculation of the incidence of typhoid fever during preschool years is important to define the optimum age of immunisation and the choice of vaccines for public-health programmes in developing countries. Hospital-based studies have suggested that children younger than 5 years do not need vaccination against typhoid fever, but this view needs to be re-examined in community-based longitudinal studies. We undertook a prospective follow-up study of residents of a low-income urban area of Delhi, India, with active surveillance for case detection. Methods A baseline census was undertaken in 1995, Between Nov 1, 1995, and Oct 31, 1996, we visited 8172 residents of 1820 households in Kalkaji, Delhi, twice weekly to detect febrile cases. Blood samples were obtained from febrile patients, and those who tested positive for Salmonella typhi were treated with ciprofloxacin, Findings 63 culture-positive typhoid fever cases were detected. Of these, 28 (44%) were in children aged under 5 years. The incidence rate of typhoid per 1000 person-years was 27.3 at age under 5 years, 11.7 at 5-19 years, and 1.1 between 19 and 40 years. The difference in the incidence of typhoid fever between those under 5 years and those aged 5-19 years (15.6 per 1000 person-years [95% CI 4.7-26.5]), and those aged 19-40 years (26.2 [16.0-36.3]) was significant (p<0.001 for both). The difference between the incidence of typhoid at 5-19 years and the incidence at 19-40 years was also significant (10.6 [6.3-14.8], p<0.001). Morbidity in those under 5 and in older people was similar in terms of duration of fever, signs and symptoms, and need for hospital admission. Interpretation Our findings challenge the common view that typhoid fever is a disorder of school-age children and of adults. Typhoid is a common and significant cause of morbidity between 1 and 5 years of age. The optimum age of typhoid immunisation and the choice of vaccines needs to be reassessed.	All India Inst Med Sci, Dept Pediat, Div Paediat Gastroenterol, Adv Ctr Diarrhoeal Dis Res,Indian Council Med Res, New Delhi 110029, India; All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India; All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; NICHHD, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Council of Medical Research (ICMR); All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bhan, MK (corresponding author), All India Inst Med Sci, Dept Pediat, Div Paediat Gastroenterol, Adv Ctr Diarrhoeal Dis Res,Indian Council Med Res, New Delhi 110029, India.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002528] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; ARORA R K, 1992, Indian Pediatrics, V29, P61; CHUTTANI CS, 1972, INT J EPIDEMIOL, V1, P39, DOI 10.1093/ije/1.1.39; EDELMAN R, 1986, REV INFECT DIS, V8, P329; FERRECCIO C, 1984, J PEDIATR-US, V104, P899, DOI 10.1016/S0022-3476(84)80492-8; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; Gupta A, 1994, Indian J Pediatr, V61, P321, DOI 10.1007/BF02751884; HACKETT J, 1990, VACCINE, V8, P5, DOI 10.1016/0264-410X(90)90169-M; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; KAPOOR J P, 1985, Indian Pediatrics, V22, P811; KLUGMAN KP, 1987, LANCET, V2, P1165; LEVINE MM, 1997, NEW GENERATION VACCI, P437; LEVINE MM, 1994, VACCINES, P601; MAHLE WT, 1993, PEDIATR INFECT DIS J, V12, P627, DOI 10.1097/00006454-199308000-00001; MIDDELKAMP J N, 1965, Med Times, V93, P956; MISHRA S, 1991, Indian Pediatrics, V28, P1171; MULLIGAN TO, 1971, BRIT MED J, V4, P665, DOI 10.1136/bmj.4.5788.665; PATNAIK KC, 1967, INDIAN J MED RES, V55, P228; PLOTKIN SA, 1995, ARCH INTERN MED, V155, P2293, DOI 10.1001/archinte.155.21.2293; Sen S K, 1972, Indian J Pediatr, V39, P354, DOI 10.1007/BF02753167; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; SMITH PG, 1991, METHODS FIELDS TRIAL, P292	22	285	291	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					734	737		10.1016/S0140-6736(98)09001-1	http://dx.doi.org/10.1016/S0140-6736(98)09001-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475185				2022-12-28	WOS:000082233000013
J	Fuller, BP; Kahn, MJE; Barr, PA; Biesecker, L; Crowley, E; Garber, J; Mansoura, MK; Murphy, P; Murray, J; Phillips, J; Rothenberg, K; Rothstein, M; Stopfer, J; Swergold, G; Weber, B; Collins, FS; Hudson, KL				Fuller, BP; Kahn, MJE; Barr, PA; Biesecker, L; Crowley, E; Garber, J; Mansoura, MK; Murphy, P; Murray, J; Phillips, J; Rothenberg, K; Rothstein, M; Stopfer, J; Swergold, G; Weber, B; Collins, FS; Hudson, KL			Policy forum: Ethics - Privacy in genetics research	SCIENCE			English	Editorial Material							INFORMATION						Biesecker, Leslie/AAG-2526-2021		NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000009, Z01HG000091, Z01HG000043, Z01HG000139] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bernstein T, 1994, RADON RENTAL HOUSING; *DEP LAB, 1998, GEN INF WORKPL; EARLEY CL, 1995, AM J HUM GENET, V57, P727; Geller Lisa N, 1996, Sci Eng Ethics, V2, P71, DOI 10.1007/BF02639319; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; *MAYO CLIN, 1998, I REV BOARD POL REG; *NIH DEP EN TASK F, 1997, PROM SAF EFF GEN TES; *OFF PROT RES RISK, 1993, I REV BOARD GUID, P3; OHARROW R, 1998, WASH POST       0308, pA1; *PRIV PROT STUD CO, 1977, PERS PRIV INF SOC, P579; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; SHALALA D, 1997, REPORT SECRETARY PRE; *US GEN ACC OFF, 1999, MED REC PRIV ACC NEE; 1999, FED REG         0618, V56	15	50	52	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1359	+		10.1126/science.285.5432.1359	http://dx.doi.org/10.1126/science.285.5432.1359			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10490410				2022-12-28	WOS:000082233500026
J	Mach, B				Mach, B			Perspectives: Immunology - Regulating the regulator	SCIENCE			English	Editorial Material							CLASS-II TRANSACTIVATOR; BINDING; CIITA; DEFICIENCY; EXPRESSION; COMPLEX; MOTIF		Univ Geneva, Sch Med, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	University of Geneva	Mach, B (corresponding author), Univ Geneva, Sch Med, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland.							Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; STEIMLE V, 1995, GENE DEV, V9, P10221	14	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1367	1367		10.1126/science.285.5432.1367	http://dx.doi.org/10.1126/science.285.5432.1367			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10490413				2022-12-28	WOS:000082233500031
J	Djinovic-Carugo, K; Young, P; Gautel, M; Saraste, M				Djinovic-Carugo, K; Young, P; Gautel, M; Saraste, M			Structure of the alpha-actinin rod: Molecular basis for cross-linking of actin filaments	CELL			English	Article							SPECTRIN-LIKE REPEATS; MAXIMUM-LIKELIHOOD; CYTOPLASMIC DOMAIN; DIFFRACTION DATA; COILED-COIL; ION-PAIRS; PROTEIN; ASSOCIATION; ALIGNMENT; ADHESION	We have determined the crystal structure of the two central repeats in the alpha-actinin rod at 2.5 Angstrom resolution. The repeats are connected by a helical linker and form a symmetric, antiparallel dimer in which the repeats are aligned rather than staggered. Using this structure, which reveals the structural principle that governs the architecture of alpha-actinin, we have devised a plausible model of the entire alpha-actinin rod. The electrostatic properties explain how the two alpha-actinin subunits assemble in an antiparallel fashion, placing the actin-binding sites at both ends of the rod. This molecular architecture results in a protein that is able to form cross-links between actin filaments.	European Mol Biol Lab, Struct Biol Programme, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Saraste, M (corresponding author), European Mol Biol Lab, Struct Biol Programme, Postfach 10-2209, D-69012 Heidelberg, Germany.	saraste@embl-heidelberg.de	Young, Paul/A-4874-2015; Djinovic-Carugo, Kristina/AAW-1167-2021; Gautel, Mathias/AAB-9860-2019	Young, Paul/0000-0002-1307-0249; Djinovic-Carugo, Kristina/0000-0003-0252-2972; Gautel, Mathias/0000-0003-4027-9803				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Carugo O, 1999, ACTA CRYSTALLOGR D, V55, P479, DOI 10.1107/S0907444998012086; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; Flood G, 1997, EUR BIOPHYS J BIOPHY, V25, P431, DOI 10.1007/s002490050057; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAHANA E, 1991, CELL MOTIL CYTOSKEL, V20, P242, DOI 10.1002/cm.970200307; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA M, 1994, BBA-PROTEIN STRUCT M, V1205, P97, DOI 10.1016/0167-4838(94)90097-3; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LYU PCC, 1992, J MOL BIOL, V223, P343, DOI 10.1016/0022-2836(92)90735-3; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohtsuka H, 1997, BIOCHEM BIOPH RES CO, V235, P1, DOI 10.1006/bbrc.1997.6534; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; TAYLOR KA, 1993, J MOL BIOL, V230, P196, DOI 10.1006/jmbi.1993.1136; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; Winkler J, 1997, EUR J BIOCHEM, V248, P193, DOI 10.1111/j.1432-1033.1997.00193.x; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614	61	203	206	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					537	546		10.1016/S0092-8674(00)81981-9	http://dx.doi.org/10.1016/S0092-8674(00)81981-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481917	Bronze			2022-12-28	WOS:000082174900013
J	Dyer, C				Dyer, C			Study identifies why child heart operations go wrong	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					803	803		10.1136/bmj.319.7213.803	http://dx.doi.org/10.1136/bmj.319.7213.803			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496812	Green Published			2022-12-28	WOS:000082865200011
J	Curtis, JR				Curtis, JR			Learning medicine through the closet door	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Curtis, JR (corresponding author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Box 359762,325 9th Ave, Seattle, WA 98104 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					470	471		10.7326/0003-4819-131-6-199909210-00014	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498566				2022-12-28	WOS:000082641100012
J	Roose, J; Huls, G; van Beest, M; Moerer, P; van der Horn, K; Goldschmeding, R; Logtenberg, T; Clevers, H				Roose, J; Huls, G; van Beest, M; Moerer, P; van der Horn, K; Goldschmeding, R; Logtenberg, T; Clevers, H			Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1	SCIENCE			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; COLORECTAL-CANCER; AXIS FORMATION; FUNCTIONAL INTERACTION; XENOPUS EMBRYOS; TRANSCRIPTION; GENE; ASSOCIATION; ACTIVATION	Mutations in APC or beta-catenin inappropriately activate the transcription factor Tcf4, thereby transforming intestinal epithelial cells. Here it is shown that one of the target genes of Tcf4 in epithelial cells is Tcf1, The most abundant Tcf1 isoforms Lack a beta-catenin interaction domain. Tcf1(-/-) mice develop adenomas in the gut and mammary glands. Introduction of a mutant APC allele into these mice substantially increases the number of these adenomas. Tcf1 may act as a feedback repressor of beta-catenin-Tcf4 target genes and thus may cooperate with APC to suppress malignant transformation of epithelial cells.	Univ Utrecht, Med Ctr, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Clevers, H (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol, POB 85500, NL-3508 GA Utrecht, Netherlands.	h.clevers@lab.azu.nl	Goldschmeding, Roel/I-1723-2014					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BAKRER N, 1999, AM J PATHOL, V154, P29; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JEN J, 1994, CANCER RES, V54, P5523; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mayer K, 1997, INT J CANCER, V72, P625, DOI 10.1002/(SICI)1097-0215(19970807)72:4<625::AID-IJC13>3.0.CO;2-A; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schilham MW, 1998, J IMMUNOL, V161, P3984; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANBEEST M, UNPUB; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	392	417	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1923	1926		10.1126/science.285.5435.1923	http://dx.doi.org/10.1126/science.285.5435.1923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489374				2022-12-28	WOS:000082638300054
J	Pena, BMG; Mandl, KD; Kraus, SJ; Fischer, AC; Fleisher, GR; Lund, DP; Taylor, GA				Pena, BMG; Mandl, KD; Kraus, SJ; Fischer, AC; Fleisher, GR; Lund, DP; Taylor, GA			Ultrasonography and limited computed tomography in the diagnosis and management of appendicitis in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ABDOMINAL-PAIN; SUSPECTED APPENDICITIS; CHILDHOOD APPENDICITIS; CT TECHNIQUE; US; PERFORATION; ULTRASOUND; APPEARANCE	Context Limited computed tomography with rectal contrast (CTRC) has been shown to be 98% accurate in the diagnosis of appendicitis in the adult population, but data are lacking regarding the accuracy and effectiveness of this technique in diagnosing pediatric appendicitis. Objective To determine the diagnostic value of a protocol involving ultrasonography and CTRC in the diagnosis and management of appendicitis in children and adolescents, Design, Setting, and Participants Prospective cohort study of 139 children and adolescents aged 3 to 21 years (2 patients were older than 18 years) who had equivocal clinical findings for acute appendicitis and who presented to the emergency department of a large, urban, pediatric teaching hospital between July and December 1998. Interventions Children were first evaluated with pelvic ultrasonography. If the result was definitive for appendicitis, laparotomy was performed; if ultrasonography was negative or inconclusive, CTRC was obtained. Patients who did not undergo laparotomy had telephone follow-up at 2 weeks and medical records of all patients were reviewed 4 to 6 months after study completion. Main Outcome Measures Specificity, sensitivity, positive predictive value, negative predictive value, and accuracy of tests based on final diagnoses; surgeons' estimated likelihood of appendicitis on a scale of 1 to 10 for each case and their case management plans before imaging, after ultrasonography, and after CTRC. Results A total of 108 patients underwent both ultrasonography and CTRC examinations. The protocol had a sensitivity of 94%, specificity of 94%, positive predictive value of 90%, negative predictive Value of 97%, and accuracy of 94%. A normal appendix was identified by ultrasonography in 2 (2.4%) of 83 patients without appendicitis and by CTRC in 62 (84%) of 74 patients. A negative ultrasonography result did not change the surgeons' clinical confidence level in excluding appendicitis (P =.06), while a negative CTRC result did have a significant effect (P<.001). Positive results obtained for either ultrasonography or CTRC significantly affected surgeons' estimated likelihood of appendicitis (P=.001 and P<.001, respectively). Ultrasonography resulted in a beneficial change in patient management in 26 (18.7%) of 139 children while CTRC correctly changed management in 79 (73.1%) of 108. Conclusions These data show that CTRC following a negative or indeterminate ultrasonography result is highly accurate in the diagnosis of appendicitis in children.	Harvard Univ, Childrens Hosp, Sch Med, Dept Med,Div Emergency Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Pena, BMG (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Med,Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.			Fleisher, Gary/0000-0002-4819-1710				BALTHAZAR EJ, 1994, RADIOLOGY, V190, P31, DOI 10.1148/radiology.190.1.8259423; BALTHAZAR EJ, 1991, RADIOLOGY, V180, P21, DOI 10.1148/radiology.180.1.2052696; BIRNBAUM BA, 1997, RADIOLOGICAL SOC N A, P199; BRENDER JD, 1985, PEDIATRICS, V76, P301; CRADY SK, 1993, ANN EMERG MED, V22, P1125, DOI 10.1016/S0196-0644(05)80976-X; DISON JM, 1991, BRIT MED J, V302, P386; Fenyo G, 1997, EUR J SURG, V163, P831; GAMAL R, 1990, AM J SURG, V159, P589, DOI 10.1016/S0002-9610(06)80073-5; HOROWITZ JR, 1997, AM J SURG, V173, P80; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; LUND DP, 1994, J PEDIATR SURG, V29, P1130, DOI 10.1016/0022-3468(94)90294-1; Lund DP, 1996, PEDIAT GASTROINTESTI, P907; Pena BMG, 1999, PEDIATRICS, V104, P440, DOI 10.1542/peds.104.3.440; PUTNAM TC, 1990, SURG GYNECOL OBSTET, V170, P527; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; PUYLAERT JBCM, 1986, RADIOLOGY, V158, P355, DOI 10.1148/radiology.158.2.2934762; Rao PM, 1998, AM J EMERG MED, V16, P26, DOI 10.1016/S0735-6757(98)90060-2; Rao PM, 1997, RADIOLOGY, V202, P139, DOI 10.1148/radiology.202.1.8988203; Rao PM, 1997, AM J ROENTGENOL, V169, P1275, DOI 10.2214/ajr.169.5.9353441; Rao PM, 1997, J COMPUT ASSIST TOMO, V21, P686, DOI 10.1097/00004728-199709000-00002; Rao PM, 1997, CLIN RADIOL, V52, P750, DOI 10.1016/S0009-9260(97)80153-5; Rao PM, 1998, NEW ENGL J MED, V338, P141, DOI 10.1056/NEJM199801153380301; RAPPAPORT WD, 1989, AM SURGEON, V55, P602; Rhea JT, 1997, AM J ROENTGENOL, V169, P113, DOI 10.2214/ajr.169.1.9207509; Roosevelt GE, 1998, ACAD EMERG MED, V5, P1071, DOI 10.1111/j.1553-2712.1998.tb02664.x; ROTHROCK SG, 1991, ANN EMERG MED, V20, P45, DOI 10.1016/S0196-0644(05)81117-5; RUBIN SZ, 1990, J PEDIATR SURG, V25, P737, DOI 10.1016/S0022-3468(05)80008-9; Scholer SJ, 1996, PEDIATRICS, V98, P680; SIEGEL MJ, 1991, JAMA-J AM MED ASSOC, V266, P1987, DOI 10.1001/jama.266.14.1987; SIVIT CJ, 1992, RADIOLOGY, V185, P549, DOI 10.1148/radiology.185.2.1410371; Skaane P, 1997, AM SURGEON, V63, P937; TAOUREL P, 1992, GASTROINTEST RADIOL, V17, P287, DOI 10.1007/BF01888571; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039; Wagner JM, 1996, JAMA-J AM MED ASSOC, V276, P1589, DOI 10.1001/jama.276.19.1589; Wilcox RT, 1997, SURG CLIN N AM, V77, P1355, DOI 10.1016/S0039-6109(05)70622-8; WILSON DH, 1977, BRIT J SURG, V64, P250, DOI 10.1002/bjs.1800640407	36	212	214	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1041	1046		10.1001/jama.282.11.1041	http://dx.doi.org/10.1001/jama.282.11.1041			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493202	Bronze			2022-12-28	WOS:000082512300027
J	Dixon, TC; Meselson, M; Guillemin, J; Hanna, PC				Dixon, TC; Meselson, M; Guillemin, J; Hanna, PC			Anthrax	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; CUTANEOUS ANTHRAX; LETHAL FACTOR; MOLECULAR CHARACTERIZATION; INHALATION ANTHRAX; ADENYLATE-CYCLASE; EUKARYOTIC CELLS; TOXIN COMPONENTS; SPORE CHALLENGE		Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48104 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Boston Coll, Dept Sociol, Chestnut Hill, MA 02167 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Duke University; Harvard University; Boston College; University of Michigan System; University of Michigan	Hanna, PC (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 1150 W Med,5641 MS 2, Ann Arbor, MI 48104 USA.	dixont@umich.edu			NIAID NIH HHS [AI-40644, AI-08649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; AKSARAY N, 1990, TROP GEOGR MED, V42, P168; ALBRINK WS, 1961, BACTERIOL REV, V25, P268, DOI 10.1128/MMBR.25.3.268-273.1961; ALBRINK WS, 1960, AM J PATHOL, V36, P457; ALEXEYEV OA, 1994, INFECTION, V22, P281, DOI 10.1007/BF01739917; ALIZAD A, 1995, PEDIATR INFECT DIS J, V14, P394, DOI 10.1097/00006454-199505000-00013; Andersen GL, 1996, J BACTERIOL, V178, P377, DOI 10.1128/jb.178.2.377-384.1996; Baillie L, 1998, J APPL MICROBIOL, V84, P741; Baillie LWJ, 1998, FEMS MICROBIOL LETT, V163, P43; BATYKIN V, 1929, J HYG EPIDEMIOL, V1, P25; BIRENSVIGE A, 1992, INHALATION HAZARD RE; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; BRACHMAN PS, 1966, BACTERIOL REV, V30, P646, DOI 10.1128/MMBR.30.3.646-659.1966; BRACHMAN PS, 1970, ANN NY ACAD SCI, V174, P577, DOI 10.1111/j.1749-6632.1970.tb45583.x; BRADARIC N, 1992, LANCET, V340, P306, DOI 10.1016/0140-6736(92)92395-V; CATALDI A, 1990, MOL MICROBIOL, V4, P1111, DOI 10.1111/j.1365-2958.1990.tb00685.x; Claus D., 1986, BERGEYS MANUAL SYSTE, P1105, DOI DOI 10.1016/0922-338X(92)90270-5; COULSON NM, 1994, VACCINE, V12, P1395, DOI 10.1016/0264-410X(94)90148-1; DAHLGREN CM, 1960, AM J HYG, V72, P24, DOI 10.1093/oxfordjournals.aje.a120131; Dai ZH, 1997, INFECT IMMUN, V65, P2576, DOI 10.1128/IAI.65.7.2576-2582.1997; DAI ZH, 1995, MOL MICROBIOL, V16, P1171, DOI 10.1111/j.1365-2958.1995.tb02340.x; Davids D, 1981, SECONDARY AEROSOL HA; DELALLA F, 1992, EUR J CLIN MICROBIOL, V11, P839, DOI 10.1007/BF01960887; DIRCKX JH, 1981, AM J DERMATOPATH, V3, P191, DOI 10.1097/00000372-198100320-00012; DOGANAY M, 1987, BRIT J DERMATOL, V117, P659, DOI 10.1111/j.1365-2133.1987.tb07500.x; DOGANAY M, 1994, J INFECTION, V28, P311, DOI 10.1016/S0163-4453(94)91993-3; DOUST JY, 1968, DIS CHEST, V53, P773; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; DUTZ W, 1970, GUT, V11, P352, DOI 10.1136/gut.11.4.352; DUTZ W, 1981, INT J DERMATOL, V20, P203, DOI 10.1111/j.1365-4362.1981.tb00461.x; Dutz W, 1971, Pathol Annu, V6, P209; EDWARDS MS, 1992, TXB PEDIAT INFECT DI, P1053; Ember LR, 1999, CHEM ENG NEWS, V77, P8, DOI 10.1021/cen-v077n027.p008; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; GOLD H, 1967, FED PROC, V26, P1563; GREEN BD, 1985, INFECT IMMUN, V49, P291, DOI 10.1128/IAI.49.2.291-297.1985; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; GUILLEMIN J, IN PRESS ANTRAX INVE; Hammond SE, 1998, INFECT IMMUN, V66, P2374, DOI 10.1128/IAI.66.5.2374-2378.1998; Hanna P, 1998, SCIENCE, V280, P1671; Hanna P, 1998, CURR TOP MICROBIOL, V225, P13; HANNA PC, 1992, MOL BIOL CELL, V3, P1269, DOI 10.1091/mbc.3.11.1269; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; HANNA PC, 1994, MOL MED, V1, P7; Harris Sheldon, 1994, FACTORIES DEATH JAPA; HARRISON LH, 1989, J INFECT DIS, V160, P706, DOI 10.1093/infdis/160.4.706; HENDERSON D. W., 1956, JOUR HYG, V54, P28; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Ivins B.E., 1996, SALISBURY MED B, V87, P125; IVINS BE, 1992, INFECT IMMUN, V60, P662, DOI 10.1128/IAI.60.2.662-668.1992; IVINS BE, 1990, INFECT IMMUN, V58, P303, DOI 10.1128/IAI.58.2.303-308.1990; IVINS BE, 1994, VACCINE, V12, P872, DOI 10.1016/0264-410X(94)90027-2; Jackson PJ, 1997, APPL ENVIRON MICROB, V63, P1400, DOI 10.1128/AEM.63.4.1400-1405.1997; Jackson PJ, 1998, P NATL ACAD SCI USA, V95, P1224, DOI 10.1073/pnas.95.3.1224; JOHNSONWINEGAR A, 1984, J CLIN MICROBIOL, V20, P357, DOI 10.1128/JCM.20.3.357-361.1984; Keim P, 1997, J BACTERIOL, V179, P818, DOI 10.1128/jb.179.3.818-824.1997; KLEVYTSKYA A, 1998, 3 INT C ANTHR PLYM E; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KNISELY RF, 1966, J BACTERIOL, V92, P784, DOI 10.1128/JB.92.3.784-786.1966; KNUDSON GB, 1986, MIL MED, V151, P71, DOI 10.1093/milmed/151.2.71; Koch R., 1877, BEIRT BIOL PFLANZ, V2, P277; KUTLUK MT, 1987, CUTIS, V40, P117; LAFORCE FM, 1994, CLIN INFECT DIS, V19, P1009, DOI 10.1093/clinids/19.6.1009; Lalitha MK, 1997, LANCET, V349, P1522, DOI 10.1016/S0140-6736(05)62103-4; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LITTLE SF, 1986, INFECT IMMUN, V52, P509, DOI 10.1128/IAI.52.2.509-512.1986; LOGAN NA, 1985, J MED MICROBIOL, V20, P75, DOI 10.1099/00222615-20-1-75; MAKINO S, 1989, J BACTERIOL, V171, P722, DOI 10.1128/jb.171.2.722-730.1989; MAKINO S, 1988, MOL MICROBIOL, V2, P371, DOI 10.1111/j.1365-2958.1988.tb00041.x; Mallon E, 1997, AM J DERMATOPATH, V19, P79, DOI 10.1097/00000372-199702000-00014; MANCHEE RJ, 1982, NATURE, V296, P598, DOI 10.1038/296598b0; MANCHEE RJ, 1981, NATURE, V294, P254, DOI 10.1038/294254a0; MANCHEE RJ, 1994, APPL ENVIRON MICROB, V60, P4167, DOI 10.1128/AEM.60.11.4167-4171.1994; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Metchnikoff E., 1905, IMMUNITY INFECT DIS; Miller J, 1998, LETT APPL MICROBIOL, V26, P56, DOI 10.1046/j.1472-765X.1998.00274.x; *MMWR, 1988, MMWR-MORBID MORTAL W, V37, P413; *MMWR, 1987, JAMA-J AM MED ASSOC, V260, P616; NALIN DR, 1977, AM J MED, V62, P130, DOI 10.1016/0002-9343(77)90358-8; OBRIEN J, 1985, INFECT IMMUN, V47, P306, DOI 10.1128/IAI.47.1.306-310.1985; Parry J. M., 1983, A colour atlas of Bacillus species [with reference to Bacillus anthracis, B. cereus and B. subtilis].; Pasteur L., 1881, C R ACAD SCI AGR BUL, V92, P429; Patra G, 1996, FEMS IMMUNOL MED MIC, V15, P223; Patra G, 1998, J CLIN MICROBIOL, V36, P3412, DOI 10.1128/JCM.36.11.3412-3414.1998; PAULET R, 1994, PRESSE MED, V23, P477; Penn C C, 1997, Semin Respir Infect, V12, P28; PENN CC, 1998, INFECT DIS, P1575; PENN CC, 1998, INFECT DIS, P1747; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Pezard C, 1996, Adv Exp Med Biol, V397, P69; PEZARD C, 1995, INFECT IMMUN, V63, P1369, DOI 10.1128/IAI.63.4.1369-1372.1995; PFISTERER RM, 1991, SCHWEIZ MED WSCHR, V121, P813; PLUOT M, 1976, ACTA NEUROPATHOL, V36, P339, DOI 10.1007/BF00699639; Pomerantsev AP, 1997, VACCINE, V15, P1846, DOI 10.1016/S0264-410X(97)00132-1; Price LB, 1999, J BACTERIOL, V181, P2358, DOI 10.1128/JB.181.8.2358-2362.1999; Ramisse V, 1996, FEMS MICROBIOL LETT, V145, P9, DOI 10.1016/0378-1097(96)00358-8; RANGEL RA, 1975, NEUROLOGY, V25, P525, DOI 10.1212/WNL.25.6.525; ROSS JM, 1957, J PATHOL BACTERIOL, V73, P485, DOI 10.1002/path.1700730219; Shlyakhov E, 1997, VACCINE, V15, P631, DOI 10.1016/S0264-410X(96)00286-1; Shlyakhov E, 1996, EUR J CLIN MICROBIOL, V15, P242, DOI 10.1007/BF01591362; SHLYAKHOV EN, 1994, VACCINE, V12, P727, DOI 10.1016/0264-410X(94)90223-2; SIRISANTHANA T, 1988, AM J TROP MED HYG, V39, P575, DOI 10.4269/ajtmh.1988.39.575; Smego RA, 1998, CLIN INFECT DIS, V26, P97; STERNE M, 1982, NATURE, V295, P362, DOI 10.1038/295362c0; TABATABAIE P, 1993, PEDIATR INFECT DIS J, V12, P1035, DOI 10.1097/00006454-199312000-00020; TAHERNIA AC, 1972, PEDIATRICS, V50, P329; TAHERNIA AC, 1967, ARCH DIS CHILD, V42, P181, DOI 10.1136/adc.42.222.181; TAYLOR JP, 1993, SOUTHERN MED J, V86, P1, DOI 10.1097/00007611-199301000-00001; TURELL MJ, 1987, INFECT IMMUN, V55, P1859, DOI 10.1128/IAI.55.8.1859-1861.1987; TURNBULL PCB, 1992, EPIDEMIOL INFECT, V108, P299, DOI 10.1017/S0950268800049773; TURNBULL PCB, 1988, MED MICROBIOL IMMUN, V177, P293, DOI 10.1007/BF00189414; TURNBULL PCB, 1991, MANUAL CLIN MICROBIO, P296; Uchida I, 1997, MOL MICROBIOL, V23, P1229, DOI 10.1046/j.1365-2958.1997.3041667.x; UCHIDA I, 1993, J BACTERIOL, V175, P5329, DOI 10.1128/JB.175.17.5329-5338.1993; VANCURIK J, 1966, FOLIA MICROBIOL, V11, P459, DOI 10.1007/BF02875859; VIETRI NJ, 1995, GENE, V152, P1, DOI 10.1016/0378-1119(94)00662-C; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; WATSON A, 1994, EPIDEMIOL INFECT, V113, P479, DOI 10.1017/S0950268800068497; WHEAT J, 1998, INFECT DIS, P2335; WYNN J, 1982, NATURE, V298, P506, DOI 10.1038/298506b0; YORSTON D, 1989, BRIT J OPHTHALMOL, V73, P809, DOI 10.1136/bjo.73.10.809; YOUNG L S, 1970, Archives of Environmental Health, V20, P400; 1999, MMWR MORB MORTAL WKL, V48, P69; 1998, MED LETT DRUGS THER, V40, P52; 1988, ARCH DERMATOL, V124, P1324; 1965, BMJ, V5464, P717	130	765	863	1	93	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					815	826		10.1056/NEJM199909093411107	http://dx.doi.org/10.1056/NEJM199909093411107			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477781				2022-12-28	WOS:000082534000007
J	Henney, JE				Henney, JE			Approval of TMJ prosthesis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-28	WOS:000082335900007
J	Chen, HW; Lin, RJ; Xie, W; Wilpitz, D; Evans, RM				Chen, HW; Lin, RJ; Xie, W; Wilpitz, D; Evans, RM			Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase	CELL			English	Article							BREAST-CANCER-CELLS; RECEPTOR COACTIVATOR COMPLEX; NUCLEAR-RECEPTOR; ESTROGEN-RECEPTOR; RETINOIC ACID; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ACETYLTRANSFERASE ACTIVITY; CHROMATIN STRUCTURE; LEUKEMIA-CELLS	Nuclear receptors have been postulated to regulate gene expression via their association with histone acetylase (HAT) or deacetylase complexes. We report that hormone induces dramatic hyperacetylation at endogenous target genes through the HAT activity of p300/CBP. Unexpectedly, this hyperacetylation is transient and coincides with attenuation of hormone-induced gene activation. In exploring the underlying mechanism, we found that the acetylase ACTR can be acetylated by p300/CBP. The acetylation neutralizes the positive charges of two lysine residues adjacent to the core LXXLL motif and disrupts the association of HAT coactivator complexes with promoter-bound estrogen receptors. These results provide strong in vivo evidence that histone acetylation plays a key role in hormone-induced gene activation and define cofactor acetylation as a novel regulatory mechanism in hormonal signaling.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Xie, Wen/M-1768-2016; Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880	NIGMS NIH HHS [GM26444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Hyder SM, 1997, CANCER RES, V57, P2547; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JIANG HP, 1994, ONCOGENE, V9, P3397; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pratt MAC, 1996, J BIOL CHEM, V271, P20346, DOI 10.1074/jbc.271.34.20346; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WADE PA, 1997, CURR BIOL, V7, P82; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	63	534	548	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					675	686		10.1016/S0092-8674(00)80054-9	http://dx.doi.org/10.1016/S0092-8674(00)80054-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490106	Bronze			2022-12-28	WOS:000082433500014
J	Redelmeier, DA; Tibshirani, RJ				Redelmeier, DA; Tibshirani, RJ			Why cars in the next lane seem to go faster	NATURE			English	Article							PERCEPTION		Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Stanford University; Stanford University	Redelmeier, DA (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Angrilli A, 1997, PERCEPT PSYCHOPHYS, V59, P972, DOI 10.3758/BF03205512; Feller W., 1966, INTRO PROBABILITY TH, VII; GILOVICH T, 1985, COGNITIVE PSYCHOL, V17, P295, DOI 10.1016/0010-0285(85)90010-6; Helbing D, 1998, NATURE, V396, P738, DOI 10.1038/25499; LARSON RC, 1987, OPER RES, V35, P895, DOI 10.1287/opre.35.6.895; Snowden RJ, 1998, NATURE, V392, P450, DOI 10.1038/33049; TVERSKY A, 1991, Q J ECON, V106, P1039, DOI 10.2307/2937956; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; *US BUR CENS, 1997, STAT ABSTR US 1996; Walton D, 1998, ACCIDENT ANAL PREV, V30, P821, DOI 10.1016/S0001-4575(98)00035-9	10	12	12	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					35	35		10.1038/43360	http://dx.doi.org/10.1038/43360			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	232MK	10485702	Bronze			2022-12-28	WOS:000082374400028
J	Funa, N; Ohnishi, Y; Fujii, I; Shibuya, M; Ebizuka, Y; Horinouchi, S				Funa, N; Ohnishi, Y; Fujii, I; Shibuya, M; Ebizuka, Y; Horinouchi, S			A new pathway for polyketide synthesis in microorganisms	NATURE			English	Article							STREPTOMYCES-GRISEUS; CHALCONE SYNTHASE; GENE; BIOSYNTHESIS; ANTIBIOTICS; VANCOMYCIN; SEQUENCE; SITE	Chalcone synthases, which biosynthesize chalcones (the starting materials for many flavonoids(1,2)), have been believed to be specific to plants. However, the rppA gene from the Gram-positive, soil-living filamentous bacterium Streptomyces griseus encodes a 372-amino-acid protein that shows significant similarity to chalcone synthases'. Several rppA-like genes are known, but their functions and catalytic properties have not been described. Here we show that a homodimer of RppA catalyses polyketide synthesis: it selects malonyl-coenzyme-A as the starter, carries out four successive extensions and releases the resulting pentaketide to cyclize to 1,3,6,8-tetrahydroxynaphthalene (THN). Site-directed mutagenesis revealed that, as in other chalcone synthases(4,5), a cysteine residue is essential for enzyme activity. Disruption of the chromosomal rppA gene in S. griseus abolished melanin production in hyphae, resulting in 'albino' mycelium. THN was readily oxidized to form 2,5,7-trihydroxy-1,4-naphthoquinone(flaviolin), which then randomly polymerized to form various coloured compounds. THN formed by RppA appears to be an intermediate in the biosynthetic pathways for not only melanins but also various secondary metabolites containing a naphthoquinone ring. Therefore, RppA is a chalcone-synthase-related synthase that synthesizes polyketides and is found in the Streptomyces and other bacteria.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.			Ohnishi, Yasuo/0000-0001-7633-9236				Ando N, 1997, MICROBIOL-UK, V143, P2715, DOI 10.1099/00221287-143-8-2715; Bangera MG, 1996, MOL PLANT MICROBE IN, V9, P83, DOI 10.1094/MPMI-9-0083; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BELL AA, 1986, ANNU REV PHYTOPATHOL, V24, P411, DOI 10.1146/annurev.py.24.090186.002211; BLANCO G, 1993, GENE, V130, P107, DOI 10.1016/0378-1119(93)90352-4; DIMROTH P, 1976, EUR J BIOCHEM, V68, P591, DOI 10.1111/j.1432-1033.1976.tb10847.x; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; FUNAYAMA S, 1990, J ORG CHEM, V55, P1132, DOI 10.1021/jo00291a003; HAMMOND SJ, 1982, J CHEM SOC CHEM COMM, P344, DOI 10.1039/c39820000344; Hopwood D.A., 1985, GENETIC MANIPULATION; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LANZ T, 1991, J BIOL CHEM, V266, P9971; Maniatis T., 1982, MOL CLONING LAB MANU; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; PATHIRANA C, 1992, TETRAHEDRON LETT, V33, P7663, DOI 10.1016/0040-4039(93)88010-G; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Schroder J., 1999, COMPREHENSIVE NATURA, V1, P749, DOI DOI 10.1016/b978-0-08-091283-7.00029-1; SHIN-YA K, 1990, Tetrahedron Letters, V31, P6025, DOI 10.1016/S0040-4039(00)98019-5; SHIOMI K, 1986, J ANTIBIOT, V39, P494, DOI 10.7164/antibiotics.39.494; TAKANO Y, 1995, MOL GEN GENET, V249, P162, DOI 10.1007/BF00290362; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; UEDA K, 1995, J ANTIBIOT, V48, P638, DOI 10.7164/antibiotics.48.638; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658	28	230	250	6	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					897	899		10.1038/23748	http://dx.doi.org/10.1038/23748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476972				2022-12-28	WOS:000082233200052
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Folding to green	SCIENCE			English	Article									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Peters, R (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1229	1229		10.1126/science.285.5431.1229	http://dx.doi.org/10.1126/science.285.5431.1229			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10484733				2022-12-28	WOS:000082130200032
J	McLaughlin, DP				McLaughlin, DP			Images in clinical medicine - Pulsus alternans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Martha Jefferson Hosp, Charlottesville, VA 22902 USA		McLaughlin, DP (corresponding author), Martha Jefferson Hosp, Charlottesville, VA 22902 USA.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					955	955		10.1056/NEJM199909233411305	http://dx.doi.org/10.1056/NEJM199909233411305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498491				2022-12-28	WOS:000082658100005
J	Beard, BL; Johnson, CM; Cox, L; Sun, H; Nealson, KH; Aguilar, C				Beard, BL; Johnson, CM; Cox, L; Sun, H; Nealson, KH; Aguilar, C			Iron isotope biosignatures	SCIENCE			English	Article								The Fe-56/Fe-54 of Fe-bearing phases precipitated in sedimentary environments varies by 2.5 per mil (delta(56)Fe values of +0.9 to -1.6 per mil). In contrast, the Fe-56/Fe-54 of Fe-bearing phases in igneous rocks from Earth and the moon does not vary measurably (delta(56)Fe = 0.0 +/- 0.3 per mil). Experiments with dissimilatory Fe-reducing bacteria of the genus Shewanella algae grown on a ferrihydrite substrate indicate that the delta(56)Fe of ferrous Fe in solution is isotopically Lighter than the ferrihydrite substrate by 1.3 per mil. Therefore, the range in delta(56)Fe values of sedimentary rocks may reflect biogenic fractionation, and the isotopic composition of Fe may be used to trace the distribution of microorganisms in modern and ancient Earth.	Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Wisconsin, Inst Great Lakes Study, Milwaukee, WI 53204 USA	University of Wisconsin System; University of Wisconsin Madison; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Wisconsin System; University of Wisconsin Milwaukee	Beard, BL (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.							BEARD BL, IN PRESS GEOCHIM COS; Bullen T.D., 1998, MINERAL MAG A, V62, P255; Bullen T. D., 1997, EOS, V78, pS173; CALDEIRA K, 1990, EXTINCTION EVENTS EA, P333, DOI DOI 10.1007/BFB0011156; DIXON PR, 1992, WATER ROCK INTERACTI, V2, P915; Friedman I., 1977, DATA GEOCHEMISTRY; JOHNSON CM, 1999, INT J MASS SPECTROM, V63, P1653; LIN CF, 1990, ENVIRON SCI TECHNOL, V24, P126, DOI 10.1021/es00071a016; LITTLE B, 1997, CORROSION 97; Marechal CN, 1999, CHEM GEOL, V156, P251, DOI 10.1016/S0009-2541(98)00191-0; Morgan E. H., 1994, IRON METABOLISM HLTH, P63; MYERS CR, 1994, J APPL BACTERIOL, V76, P253, DOI 10.1111/j.1365-2672.1994.tb01624.x; NEALSON KH, 1990, AM J SCI, V290A, P35; Schidlowski M., 1983, P149; Schwertmann U, 1991, IRON OXIDES LAB PREP; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016	16	304	334	6	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1889	1892		10.1126/science.285.5435.1889	http://dx.doi.org/10.1126/science.285.5435.1889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489362				2022-12-28	WOS:000082638300042
J	Benson, SD; Bamford, JKH; Bamford, DH; Burnett, RM				Benson, SD; Bamford, JKH; Bamford, DH; Burnett, RM			Viral evolution revealed by bacteriophage PRD1 and human adenovirus coat protein structures	CELL			English	Article							X-RAY-DIFFRACTION; ELECTRON-MICROSCOPY; INTERNAL MEMBRANE; BACTERIAL-VIRUS; DNA; ORGANIZATION; TOPOLOGY; CRYSTALLOGRAPHY; MACROMOLECULES; REPLICATION	The unusual bacteriophage PRD1 features a membrane beneath its icosahedral protein coat. The crystal structure of the major coat protein, P3, at 1.85 Angstrom resolution reveals a molecule with three interlocking subunits, each with two eight-stranded viral jelly rolls normal to the viral capsid, and putative membrane-interacting regions. Surprisingly, the P3 molecule closely resembles hexon, the equivalent protein in human adenovirus. Both viruses also have similar overall architecture, with identical capsid lattices and attachment proteins at their vertices. Although these two dsDNA viruses infect hosts from very different kingdoms, their striking similarities, from major coat protein through capsid architecture, strongly suggest their evolutionary relationship.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland	The Wistar Institute; University of Helsinki; University of Helsinki	Burnett, RM (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	burnett@wistar.upenn.edu						ALESTROM P, 1982, GENE, V18, P193, DOI 10.1016/0378-1119(82)90117-2; ATHAPPILLY FK, 1994, J MOL BIOL, V242, P430, DOI 10.1006/jmbi.1994.1593; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAMFORD D, 1982, J VIROL, V44, P1031, DOI 10.1128/JVI.44.3.1031-1038.1982; BAMFORD DH, 1981, J GEN VIROL, V57, P365, DOI 10.1099/0022-1317-57-2-365; BAMFORD DH, 1995, ADV VIRUS RES, V45, P281, DOI 10.1016/S0065-3527(08)60064-0; BAMFORD DH, 1984, J VIROL, V50, P309, DOI 10.1128/JVI.50.2.309-315.1984; BAMFORD JKH, 1990, VIROLOGY, V177, P445, DOI 10.1016/0042-6822(90)90508-O; BAMFORD JKH, 1993, VIROLOGY, V197, P652, DOI 10.1006/viro.1993.1640; BAMFORD JKH, 1991, VIROLOGY, V181, P348, DOI 10.1016/0042-6822(91)90501-2; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Butcher SJ, 1995, EMBO J, V14, P6078, DOI 10.1002/j.1460-2075.1995.tb00298.x; CALDENTEY J, 1992, NUCLEIC ACIDS RES, V20, P3971, DOI 10.1093/nar/20.15.3971; CEPKO CL, 1982, CELL, V31, P407, DOI 10.1016/0092-8674(82)90134-9; CHELVANAYAGAM G, 1992, J MOL BIOL, V228, P220, DOI 10.1016/0022-2836(92)90502-B; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; DAVIS TN, 1985, J BIOL CHEM, V260, P663; DESIDERIO SV, 1981, J MOL BIOL, V145, P319, DOI 10.1016/0022-2836(81)90208-4; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FURCINITTI PS, 1989, EMBO J, V8, P3563, DOI 10.1002/j.1460-2075.1989.tb08528.x; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Hanninen AL, 1997, VIROLOGY, V227, P207, DOI 10.1006/viro.1996.8308; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KELLY TJ, 1984, ADENOVIRUSES, P271; KING J, 1997, STRUCTURAL BIOL VIRU, P288; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUO C, 1993, VIROLOGY, V194, P570, DOI 10.1006/viro.1993.1296; LUO C, 1993, VIROLOGY, V194, P564, DOI 10.1006/viro.1993.1295; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MINDICH L, 1982, J VIROL, V44, P1021, DOI 10.1128/JVI.44.3.1021-1030.1982; OLSEN RH, 1974, J VIROL, V14, P689, DOI 10.1128/JVI.14.3.689-699.1974; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Rydman PS, 1999, J MOL BIOL, V291, P575, DOI 10.1006/jmbi.1999.2978; SAVILAHTI H, 1986, GENE, V49, P199, DOI 10.1016/0378-1119(86)90280-5; Shortridge K F, 1970, Arch Gesamte Virusforsch, V29, P1, DOI 10.1007/BF01253875; STEWART PL, 1993, J MOL BIOL, V230, P349, DOI 10.1006/jmbi.1993.1148; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; STIRK HJ, 1992, FEBS LETT, V308, P1, DOI 10.1016/0014-5793(92)81036-L; Tuma R, 1996, J MOL BIOL, V257, P102, DOI 10.1006/jmbi.1996.0150; Tuma R, 1996, J MOL BIOL, V257, P87, DOI 10.1006/jmbi.1996.0149; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E	51	238	248	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					825	833		10.1016/S0092-8674(00)81516-0	http://dx.doi.org/10.1016/S0092-8674(00)81516-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499799	Bronze			2022-12-28	WOS:000082679200009
J	Bernard, A; Hermans, C; Broeckaert, F; De Poorter, G; De Cock, A; Houins, G				Bernard, A; Hermans, C; Broeckaert, F; De Poorter, G; De Cock, A; Houins, G			Food contamination by PCBs and dioxins	NATURE			English	Article							POLYCHLORINATED-BIPHENYLS		Catholic Univ Louvain, Toxicol Unit, B-1200 Brussels, Belgium; Belgian Fed Minist Agr, B-1000 Brussels, Belgium	Universite Catholique Louvain	Bernard, A (corresponding author), Catholic Univ Louvain, Toxicol Unit, 30-54 Clos Chapelle Champs, B-1200 Brussels, Belgium.		BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743				ASPLUND L, 1994, ARCH ENVIRON HEALTH, V49, P477, DOI 10.1080/00039896.1994.9955004; GILBERTSON M, 1991, J TOXICOL ENV HEALTH, V33, P455, DOI 10.1080/15287399109531538; HARRIS JR, 1972, J AM VET MED ASSOC, V161, P1584; KOHANAWA M, 1969, NATL I ANIM HEALTH Q, V9, P220; MASUDA Y, 1994, DIOXINS HLTH, V1, P633; Papke O, 1998, ENVIRON HEALTH PERSP, V106, P723, DOI 10.2307/3433826	6	133	141	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					231	232		10.1038/45717	http://dx.doi.org/10.1038/45717			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499576				2022-12-28	WOS:000082678400038
J	Burkhoff, D; Schmidt, S; Schulman, SP; Myers, J; Resar, J; Becker, LC; Weiss, J; Jones, JW				Burkhoff, D; Schmidt, S; Schulman, SP; Myers, J; Resar, J; Becker, LC; Weiss, J; Jones, JW		ATLANTIC Investigators	Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial	LANCET			English	Article							CANINE MYOCARDIUM; REVASCULARIZATION; CHANNELS; ANGIOGENESIS	Background Transmyocardial revascularisation (TMR) is an operative treatment for refractory angina pectoris when bypass surgery or percutaneous transluminal angioplasty is not indicated, We did a prospective randomised trial to compare TMR with continued medication. Methods We recruited 182 patients from 16 US centres with Canadian Cardiovascular Society Angina (CCSA) score III (38%) or IV (62%), reversible ischaemia, and incomplete response to other therapies. Patients were randomly assigned TMR and continued medication (n=92) or continued medication alone (n=90). Baseline assessments were angina class, exercise tolerance, Seattle angina questionnaire for quality of life, and dipyridamole thallium stress test. We reassessed patients at 3 months, 6 months, and 12 months, with independent masked angina assessment at 12 months. Findings At 12 months, total exercise tolerance increased by a median of 65 s in the TMR group compared with a 46 s decrease in the medication-only group (p<0.0001, median difference 111 s), Independent CCSA score was II or lower in 47.8% in the TMR group compared with 14.3% in the medication-only group (p<0.001). Each Seattle angina questionnaire index increased in the TMR group significantly more than in the medication-only group (p<0.001), Interpretation TMR lowered angina scores, increased exercise tolerance time, and improved patients' perceptions of quality of life. This operative treatment provided clinical benefits in patients with no other therapeutic options.	Columbia Univ, Dept Med, New York, NY USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Johns Hopkins Univ, Baltimore, MD USA; Stanford Univ, Sch Med, Dept Vet Affairs Med Ctr, Palo Alto, CA 94304 USA	Columbia University; Baylor College of Medicine; Johns Hopkins University; Stanford University	Jones, JW (corresponding author), Univ Missouri, Dept Surg, 1 Hosp Dr, Columbia, MO 65212 USA.		Burkhoff, Daniel/D-7674-2011					Burkhoff D, 1999, J AM COLL CARDIOL, V34, P55, DOI 10.1016/S0735-1097(99)00162-X; Burkhoff D, 1997, J THORAC CARDIOV SUR, V114, P497, DOI 10.1016/S0022-5223(97)70202-2; Burkhoff D, 1996, ANN THORAC SURG, V61, P1532, DOI 10.1016/0003-4975(96)00090-2; Cooley DA, 1996, J THORAC CARDIOV SUR, V111, P791, DOI 10.1016/S0022-5223(96)70339-2; COOLEY DA, 1994, TEX HEART I J, V21, P220; Fisher PE, 1997, ANN THORAC SURG, V64, P466, DOI 10.1016/S0003-4975(97)00519-5; FRAZIER OH, 1995, CIRCULATION, V92, P58, DOI 10.1161/01.CIR.92.9.58; HARDY RI, 1987, LASER SURG MED, V6, P563; Horvath KA, 1997, J THORAC CARDIOV SUR, V113, P645, DOI 10.1016/S0022-5223(97)70221-6; HORVATH KA, 1995, J AM COLL CARDIOL, V25, P258, DOI 10.1016/0735-1097(94)00410-R; Horvath KA, 1996, J THORAC CARDIOV SUR, V111, P1047, DOI 10.1016/S0022-5223(96)70381-1; Kohmoto T, 1997, BASIC RES CARDIOL, V92, P45; Kohmoto T, 1997, ANN THORAC SURG, V63, P1275, DOI 10.1016/S0003-4975(97)00102-1; Kohmoto T, 1998, ANN THORAC SURG, V65, P1360, DOI 10.1016/S0003-4975(98)00236-7; Krabatsch T, 1996, J CARDIAC SURG, V11, P326, DOI 10.1111/j.1540-8191.1996.tb00058.x; Kwong KF, 1997, J THORAC CARDIOV SUR, V114, P883, DOI 10.1016/S0022-5223(97)70001-1; MIRHOSEINI M, 1988, ANN THORAC SURG, V45, P415, DOI 10.1016/S0003-4975(98)90015-7; Mirhoseini M, 1990, J Clin Laser Med Surg, V8, P73; PACKER M, 1990, AM HEART J, V120, P1578; PIFARRE R, 1969, J THORAC CARDIOV SUR, V58, P424, DOI 10.1016/S0022-5223(19)42593-2; Schofield PM, 1999, LANCET, V353, P519, DOI 10.1016/S0140-6736(98)11478-2; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158; WITTAKER P, 1993, J AM COLL CARDIOL, V22, P302; Yamamoto N, 1998, J AM COLL CARDIOL, V31, P1426, DOI 10.1016/S0735-1097(98)00086-2; YANO OJ, 1993, ANN THORAC SURG, V56, P46, DOI 10.1016/0003-4975(93)90401-3	25	238	248	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					885	890		10.1016/S0140-6736(99)08113-1	http://dx.doi.org/10.1016/S0140-6736(99)08113-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489946				2022-12-28	WOS:000082511800009
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - What is complementary medicine?	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England		Zollman, C (corresponding author), Res Council Complementary Med, London, England.							ERNST E, 1996, COMPLEMENTARY MED CR; LEWITH G, 1996, COMPLEMENTARY MED IN; VICKERS A, 1998, EXAMINING COMPLEMENT; Vincent C, 1997, COMPLEMENTARY MED RE; WOODHAM A, 1997, ENCY COMPLEMENTARY M	5	183	188	4	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					693	696		10.1136/bmj.319.7211.693	http://dx.doi.org/10.1136/bmj.319.7211.693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480829	Green Published			2022-12-28	WOS:000082636800028
J	Miralles, R; Gerrish, PJ; Moya, A; Elena, SF				Miralles, R; Gerrish, PJ; Moya, A; Elena, SF			Clonal interference and the evolution of RNA viruses	SCIENCE			English	Article							SPONTANEOUS MUTATION; FITNESS; POPULATIONS; ADAPTATION; RATES	In asexual populations, beneficial mutations that occur in different lineages compete with one another. This phenomenon, known as clonal interference, ensures that those beneficial mutations that do achieve fixation are of Large effect. Clonal interference also increases the time between fixations, thereby stowing the adaptation of asexual populations. The effects of clonal interference were measured in the asexual RNA virus vesicular stomatitis virus; rates and average effects of beneficial mutations were quantified.	Univ Valencia, Inst Cavanilles Biodiversitat & Biol Evolut, Valencia 46071, Spain; Univ Valencia, Dept Genet, Valencia 46071, Spain; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	University of Valencia; University of Valencia; Centers for Disease Control & Prevention - USA	Elena, SF (corresponding author), Univ Valencia, Inst Cavanilles Biodiversitat & Biol Evolut, Apartado 22085, Valencia 46071, Spain.		Gerrish, Philip/AAE-7346-2019; Moya, Andrés/A-8190-2008; Elena, Santiago F./A-4191-2011	Moya, Andrés/0000-0002-2867-1119; Elena, Santiago F./0000-0001-8249-5593; Gerrish, Philip/0000-0001-6393-0553				Burch CL, 1999, GENETICS, V151, P921; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; DELATORRE JC, 1990, J VIROL, V64, P6278, DOI 10.1128/JVI.64.12.6278-6281.1990; Drake JW, 1998, GENETICS, V148, P1667; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; Elena SF, 1998, EVOLUTION, V52, P309, DOI 10.1111/j.1558-5646.1998.tb01633.x; Escarmis C, 1999, J MOL BIOL, V285, P495, DOI 10.1006/jmbi.1998.2366; Fisher R.A., 1930, GENETICAL THEORY NAT; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; Hogg R.V., 1995, INTRO MATH STAT; HOLLAND JJ, 1991, J VIROL, V65, P2960, DOI 10.1128/JVI.65.6.2960-2967.1991; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Miralles R, 1999, J GEN VIROL, V80, P2051, DOI 10.1099/0022-1317-80-8-2051; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Novella IS, 1996, MOL GEN GENET, V252, P733, DOI 10.1007/BF02173980; Novella IS, 1999, J VIROL, V73, P1668, DOI 10.1128/JVI.73.2.1668-1671.1999; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; NOVELLA IS, 1995, J VIROL, V69, P2869, DOI 10.1128/JVI.69.5.2869-2872.1995; Orr HA, 1998, EVOLUTION, V52, P935, DOI [10.2307/2411226, 10.1111/j.1558-5646.1998.tb01823.x]; Otto SP, 1997, GENETICS, V147, P879; VANDEPOL SB, 1986, VIROLOGY, V148, P312, DOI 10.1016/0042-6822(86)90328-4	23	207	208	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1745	1747		10.1126/science.285.5434.1745	http://dx.doi.org/10.1126/science.285.5434.1745			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481012				2022-12-28	WOS:000082472600038
J	Roemer, I; Grutzner, F; Winking, H; Haaf, T; Orth, A; Skidmore, L; Antczak, D; Fundele, R				Roemer, I; Grutzner, F; Winking, H; Haaf, T; Orth, A; Skidmore, L; Antczak, D; Fundele, R			Genome evolution - Global methylation in eutherian hybrids	NATURE			English	Article									Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Lubeck, Inst Biol, D-23562 Lubeck, Germany; Univ Montpellier 2, Lab Genome & Populat, F-34095 Montpellier, France; Camel Reprod Ctr, Dubai, U Arab Emirates; Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA	Max Planck Society; University of Lubeck; Universite de Montpellier; Cornell University	Roemer, I (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.		Grutzner, Frank/AAD-5834-2020; Grutzner, Frank/ABB-2820-2021	Grutzner, Frank/0000-0002-3088-7314; Antczak, Douglas/0000-0003-3336-5818				ALLEN WR, 1993, J REPROD FERTIL, V97, P55; GRAVES JAM, 1987, TRENDS GENET, V3, P252, DOI 10.1016/0168-9525(87)90259-9; Gray AP, 1971, MAMMALIAN HYBRIDS; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Orr HA, 1997, ANNU REV ECOL SYST, V28, P195, DOI 10.1146/annurev.ecolsys.28.1.195; ROGERS JF, 1970, J REPROD FERTIL, V21, P255; SMITH MJ, 1979, AUST J ZOOL, V27, P959, DOI 10.1071/ZO9790959; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323; Zechner U, 1996, NAT GENET, V12, P398, DOI 10.1038/ng0496-398	9	19	20	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					131	132		10.1038/43607	http://dx.doi.org/10.1038/43607			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490019				2022-12-28	WOS:000082458800043
J	Chochinov, HM; Tataryn, D; Clinch, JJ; Dudgeon, D				Chochinov, HM; Tataryn, D; Clinch, JJ; Dudgeon, D			Will to live in the terminally ill	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; MINI-MENTAL-STATE; DEPRESSION; PREVALENCE; PEOPLE; DIE	Background Complex biomedical and psychosocial considerations figure prominently in the debate about euthanasia and assisted suicide. No study to date, however, has examined the extent to which a dying patient's will to live fluctuates as death approaches. Methods This study examined patients with cancer in palliative care. Will to live was measured twice daily throughout the hospital stay on a self-report 100 mm visual analogue scale. This scale was incorporated into the Edmonton symptom assessment system, a series of visual analogue scales measuring pain, nausea, shortness of breath, appetite, drowsiness, depression, sense of wellbeing, anxiety, and activity. Maximum and median fluctuations in will-to-live ratings, separated by 12 h, 24 h, 7 days, and 30 days, were calculated for each patient. Findings Of 585 patients admitted to palliative care during the study period (November, 1993, to May, 1995), 168 (29%; aged 31-89 years) met criteria of cognitive and physical fitness and agreed to take part. The pattern of median changes in will-to-live score suggested that will to live was stable (median changes <10 mm on 100 mm scale for all time intervals). By contrast, the average maximum changes in will-to-live score were substantial (12 h 33.1 mm, 24 h 35.8 mm, 7 days 48.8 mm, 30 days 68.0 mm), In a series of stepwise regression models carried out at 12 h, 24 h, and 1-4 weeks after admission, the four main predictor variables of will to live were depression, anxiety, shortness of breath, and sense of well-being, with the prominence of these variables changing over time. Interpretation Among dying patients, will to live shows substantial fluctuation, with the explanation for these changes shifting as death approaches.	Univ Manitoba, Dept Psychiat, Winnipeg, MB R3E 3N4, Canada; Univ Manitoba, Fac Nursing, Winnipeg, MB R3E 3N4, Canada; St Boniface Gen Hosp, Res Fdn, Winnipeg, MB R2H 2A6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	University of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; Queens University - Canada	Chochinov, HM (corresponding author), Univ Manitoba, Dept Psychiat, PX 246-771, Winnipeg, MB R3E 3N4, Canada.			Chochinov, Harvey/0000-0003-2656-4704				Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Bruera E, 1991, J Palliat Care, V7, P6; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; DIEKSTRA R, 1995, J AFFECT DISORDERS, V36, P11; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1991, NEW ENGL J MED, V153, P217; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; Hooper SC, 1996, MED J AUSTRALIA, V165, P416, DOI 10.5694/j.1326-5377.1996.tb138576.x; JORM AF, 1995, AGE AGEING, V24, P389, DOI 10.1093/ageing/24.5.389; MacKenzie DM, 1996, PSYCHOL MED, V26, P427, DOI 10.1017/S0033291700034826; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; SEALE C, 1994, SOC SCI MED, V39, P647, DOI 10.1016/0277-9536(94)90021-3	17	227	229	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					816	819		10.1016/S0140-6736(99)80011-7	http://dx.doi.org/10.1016/S0140-6736(99)80011-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	232ZH	10485723				2022-12-28	WOS:000082400700010
J	Eary, JF				Eary, JF			Nuclear medicine in cancer diagnosis	LANCET			English	Article							POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; F-18 FLUORODEOXYGLUCOSE; FRACTIONATED RADIOTHERAPY; TREATMENT RESPONSE; HUMAN TUMORS; NECK-CANCER; PET; LYMPHOMA; 2-<F-18>-FLUORO-2-DEOXY-D-GLUCOSE	Nuclear medicine imaging has contributed significantly to diagnosis, treatment planning, and the evaluation of response to treatment in patients with cancer since the development of modern techniques in the 1970s, Diagnostic applications such as the bone scan continue to be the most common use in oncology because of their high sensitivity but the contribution of nuclear medicine to oncology can perhaps be best understood in the context of patient management, Staging of newly presenting cancer patients and restaging for treatment planning are reviewed here. For treatment response and disease recurrence nuclear medicine provides information non-invasively. The studies can be repeated with few side-effects and with low radiation absorbed doses, Results can be directly correlated with clinical laboratory data, The goals of biologically characterising an individual patient's tumour and predicting his or her response to treatment are within reach.	Univ Washington, Med Ctr, Div Nucl Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Eary, JF (corresponding author), Univ Washington, Med Ctr, Div Nucl Med, Box 356113, Seattle, WA 98195 USA.	jeary@u.washington.edu						BARES R, 1994, RADIOLOGY, V192, P79, DOI 10.1148/radiology.192.1.8208970; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; CHAIKEN L, 1993, INT J RADIAT ONCOL, V27, P455, DOI 10.1016/0360-3016(93)90259-X; CHOI BW, 1979, NEW ENGL J MED, V300, P278; Delbeke D, 1997, J NUCL MED, V38, P1196; deWit M, 1997, ANN ONCOL, V8, P57, DOI 10.1023/A:1008253917337; DOYLE WK, 1987, J COMPUT ASSIST TOMO, V11, P563, DOI 10.1097/00004728-198707000-00001; DRUCK MN, 1984, CANCER, V53, P1167; Eary JF, 1999, CANCER RES, V59, P615; Eary JF, 1998, CLIN CANCER RES, V4, P1215; Feine U, 1996, J NUCL MED, V37, P1468; GUPTA NC, 1992, RADIOLOGY, V184, P441, DOI 10.1148/radiology.184.2.1620844; HABERKORN U, 1993, J NUCL MED, V34, P12; Hendler A, 1998, POSTGRAD MED, V104, P54, DOI 10.3810/pgm.1998.11.401; HOEKSTRA OS, 1993, J NUCL MED, V34, P1706; Hoh CK, 1997, J NUCL MED, V38, P343; Hu SZ, 1996, CANCER RES, V56, P3055; Ichiya Y, 1996, Ann Nucl Med, V10, P193; KARLAN BY, 1993, GYNECOL ONCOL, V51, P175, DOI 10.1006/gyno.1993.1268; KOH WJ, 1995, INT J RADIAT ONCOL, V33, P391, DOI 10.1016/0360-3016(95)00170-4; KOH WJ, 1992, INT J RADIAT ONCOL, V22, P199, DOI 10.1016/0360-3016(92)91001-4; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Mankoff DA, 1997, NUCL MED BIOL, V24, P341, DOI 10.1016/S0969-8051(97)00002-4; MINN H, 1988, J NUCL MED, V29, P1521; MINTUN MA, 1988, RADIOLOGY, V169, P45, DOI 10.1148/radiology.169.1.3262228; NEWMAN JS, 1994, RADIOLOGY, V190, P111, DOI 10.1148/radiology.190.1.8259386; POLLEN JJ, 1984, AJR, V142, P772; Price P, 1995, EUR J CANCER, V31A, P1924, DOI 10.1016/0959-8049(95)00421-1; Rasey JS, 1996, INT J RADIAT ONCOL, V36, P417, DOI 10.1016/S0360-3016(96)00325-2; Reinhardt MJ, 1997, J NUCL MED, V38, P280; REISSER C, 1993, J OTOLARYNGOL, V22, P231; Schiepers C, 1995, Eur J Surg Oncol, V21, P517, DOI 10.1016/S0748-7983(95)97046-0; Shields AF, 1998, J NUCL MED, V39, P1757; Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337; SOM P, 1980, J NUCL MED, V21, P670; Tavitian B, 1998, NAT MED, V4, P467, DOI 10.1038/nm0498-467; WAHL RL, 1998, PPO UPDATE, V1; Warburg O., 1931, METABOLISM TUMORS; Weder W, 1998, ANN THORAC SURG, V66, P886, DOI 10.1016/S0003-4975(98)00675-4; WILSON DC, IN PRESS CLIN CANC R; YONEKURA Y, 1982, J NUCL MED, V23, P1133; Zuckier LS, 1997, SEMIN NUCL MED, V27, P10, DOI 10.1016/S0001-2998(97)80033-5	43	34	35	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1999	354	9181					853	857						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485742				2022-12-28	WOS:000082400700041
J	Richards, AM; Nicholls, MG				Richards, AM; Nicholls, MG			Aldosterone antagonism in heart failure	LANCET			English	Editorial Material							SECONDARY		Christchurch Sch Med, Cardioendocrine Res Grp, Christchurch, New Zealand	University of Otago	Richards, AM (corresponding author), Christchurch Sch Med, Cardioendocrine Res Grp, POB 4345, Christchurch, New Zealand.							BARR CS, 1995, AM J CARDIOL, V76, P1259, DOI 10.1016/S0002-9149(99)80353-1; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; Hjalmarson A, 1999, LANCET, V353, P2001; Lechat P, 1999, LANCET, V353, P9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pitt B, 1996, AM J CARDIOL, V78, P902; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Struthers A D, 1996, J Card Fail, V2, P47, DOI 10.1016/S1071-9164(96)80009-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Volpe M, 1997, HYPERTENSION, V30, P168, DOI 10.1161/01.HYP.30.2.168	11	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					789	790						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485716				2022-12-28	WOS:000082400700003
J	Jomaa, H; Wiesner, J; Sanderbrand, S; Altincicek, B; Weidemeyer, C; Hintz, M; Turbachova, I; Eberl, M; Zeidler, J; Lichtenthaler, HK; Soldati, D; Beck, E				Jomaa, H; Wiesner, J; Sanderbrand, S; Altincicek, B; Weidemeyer, C; Hintz, M; Turbachova, I; Eberl, M; Zeidler, J; Lichtenthaler, HK; Soldati, D; Beck, E			Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs	SCIENCE			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; MEVALONATE-INDEPENDENT PATHWAY; PARASITE TOXOPLASMA-GONDII; TERPENOID BIOSYNTHESIS; HIGHER-PLANTS; ISOPENTENYL DIPHOSPHATE; APICOMPLEXAN PARASITES; PLASMODIUM-FALCIPARUM; ERYTHROCYTES; FOSMIDOMYCIN	A mevalonate-independent pathway of isoprenoid biosynthesis present in Plasmodium falciparum was shown to represent an effective target for chemotherapy of malaria. This pathway includes 1-deoxy-D-xylulose 5-phosphate (DOXP) as a key metabolite. The presence of two genes encoding the enzymes DOXP synthase and DOXP reductoisomerase suggests that isoprenoid biosynthesis in P. falciparum depends on the DOXP pathway. This pathway is probably Located in the apicoplast. The recombinant P, falciparum DOXP reductoisomerase was inhibited by fosmidomycin and its derivative, FR-900098. Both drugs suppressed the in vitro growth of multidrug-resistant P. falciparum strains. After therapy with these drugs, mice infected with the rodent malaria parasite P. vinckei were cured.	Univ Giessen, Acad Hosp Ctr, Inst Biochem, D-35392 Giessen, Germany; Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Karlsruhe, Inst Bot 1, D-76128 Karlsruhe, Germany	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology	Jomaa, H (corresponding author), Univ Giessen, Acad Hosp Ctr, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	hassan.jomaa@biochemie.med.uni-giessen.de	Altincicek, Boran/C-1191-2009; Eberl, Matthias/A-5970-2009; Soldati-Favre, Dominique/A-2999-2009	Altincicek, Boran/0000-0003-2019-452X; Eberl, Matthias/0000-0002-9390-5348; 				Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; Disch A, 1998, BIOCHEM J, V333, P381, DOI 10.1042/bj3330381; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; GRELLIER P, 1994, ANTIMICROB AGENTS CH, V38, P1144, DOI 10.1128/AAC.38.5.1144; KAMIYA T, 1980, Patent No. 4206156; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KUEMMERLE HP, 1987, CHEMIOTERAPIA, V6, P113; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lichtenthaler HK, 1997, PHYSIOL PLANTARUM, V101, P643, DOI 10.1111/j.1399-3054.1997.tb01049.x; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Lichtenthaler HK, 1997, FEBS LETT, V400, P271, DOI 10.1016/S0014-5793(96)01404-4; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MURAKAWA T, 1982, ANTIMICROB AGENTS CH, V21, P224, DOI 10.1128/AAC.21.2.224; OHLER E, 1995, SYNTHESIS-STUTTGART, P539; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; PETERS W, 1980, MALARIA, V1, P160; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Schwender J, 1997, FEBS LETT, V414, P129, DOI 10.1016/S0014-5793(97)01002-8; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VACEROAKBANI A, IN PRESS METHODS EN; VIAL HJ, 1984, MOL BIOCHEM PARASIT, V13, P53, DOI 10.1016/0166-6851(84)90101-4; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	33	940	983	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1573	1576		10.1126/science.285.5433.1573	http://dx.doi.org/10.1126/science.285.5433.1573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477522				2022-12-28	WOS:000082359500067
J	Smith, O				Smith, O			Nota bene: Neuroscience - For time is the longest distance between two places	SCIENCE			English	Editorial Material																		Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Teng E, 1999, NATURE, V400, P675, DOI 10.1038/23276	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1504	1504		10.1126/science.285.5433.1504	http://dx.doi.org/10.1126/science.285.5433.1504			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10498536				2022-12-28	WOS:000082359500039
J	Suh, YA; Arnold, RS; Lassegue, B; Shi, J; Xu, XX; Sorescu, D; Chung, AB; Griendling, KK; Lambeth, JD				Suh, YA; Arnold, RS; Lassegue, B; Shi, J; Xu, XX; Sorescu, D; Chung, AB; Griendling, KK; Lambeth, JD			Cell transformation by the superoxide-generating oxidase Mox1	NATURE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; MAMMALIAN-CELLS; ANION; CYTOCHROME-B558; HYPERTROPHY; FIBROBLASTS; EXPRESSION	Reactive oxygen species (ROS) generated in some non-phagocytic cells are implicated in mitogenic signalling and cancer(1-6). Many cancer cells show increased production of ROS7, and normal cells exposed to hydrogen peroxide or superoxide show increased proliferations and express growth-related genes(9-11). ROS are generated in response to growth factors, and may affect cell growth(2,3,12,13), for example in vascular smooth-muscle cells(6,13-15) Increased ROS in Ras-transformed fibroblasts correlates with increased mitogenic rate(16). Here we describe the cloning of mox1, which encodes a homologue of the catalytic subunit of the superoxide-generating NADPH oxidase of phagocytes(17,18), gp91phox. mox1 messenger RNA is expressed in colon, prostate, uterus and vascular smooth muscle, but not in peripheral blood leukocytes. In smooth-muscle cells, platelet-derived growth factor induces mox1 mRNA production, while antisense mox1 mRNA decreases superoxide generation and serum-stimulated growth. Overexpression of mox1 in NIH3T3 cells increases superoxide generation and cell growth, Cells expressing mox1 have a transformed appearance, show,anchorage-independent growth and produce tumours in athymic mice. These data link ROS production by Mox1 to growth control in non-phagocytic cells.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.			Lassegue, Bernard/0000-0003-4924-6506; Griendling, Kathy/0000-0002-9456-8582				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERK BC, 1990, J BIOL CHEM, V265, P19632; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CRAWFORD D, 1988, ONCOGENE, V3, P27; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; FLINT DH, 1994, ARCH BIOCHEM BIOPHYS, V311, P509, DOI 10.1006/abbi.1994.1269; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WOLIN MS, 1991, KLIN WOCHENSCHR, V69, P1046, DOI 10.1007/BF01645156; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	29	1226	1289	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					79	82		10.1038/43459	http://dx.doi.org/10.1038/43459			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485709				2022-12-28	WOS:000082374400045
J	Kelley, RL; Meller, VH; Gordadze, PR; Roman, G; Davis, RL; Kuroda, MI				Kelley, RL; Meller, VH; Gordadze, PR; Roman, G; Davis, RL; Kuroda, MI			Epigenetic spreading of the Drosophila dosage compensation complex from roX RNA genes into flanking chromatin	CELL			English	Article							X-CHROMOSOME INACTIVATION; DEHYDROGENASE GENE; PROTEIN; MELANOGASTER; EXPRESSION; EVOLUTION; REPEATS; SEQUENCES; ELEMENTS; BINDING	The multisubunit MSL dosage compensation complex binds to hundreds of sites along the Drosophila single male X chromosome, mediating its hypertranscription, The male X chromosome is also coated with noncoding roX RNAs. When either msl3, mle, or mof is mutant, a partial MSL complex is bound at only similar to 35 unusual sites distributed along the X, We show that two of these sites are the roX1 and roX2 genes and postulate that one of their functions is to provide entry sites for the MSL complex to recognize the X chromosome. The roX1 gene provides a nucleation site for extensive spreading of the MSL complex into flanking chromatin even when moved to an autosome. The spreading can occur in cis or in trans between paired homologs. We present a model for how the dosage compensation complex recognizes X chromatin.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Kuroda, MI (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Davis, Ronald/J-4998-2013; Roman, Gregg/W-1586-2019	Davis, Ronald/0000-0002-5986-7608; Roman, Gregg/0000-0003-1519-4699	NIMH NIH HHS [MH55230] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055230] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; Bhadra U, 1999, GENETICS, V152, P249; Bone JR, 1996, GENETICS, V144, P705; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BONE JR, 1996, THESIS BAYLOR COLL M; BOYLE AL, 1990, P NATL ACAD SCI USA, V87, P7757, DOI 10.1073/pnas.87.19.7757; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COOPER MK, 1994, GENETICS, V138, P721; DIBARTOLOMEIS SM, 1992, NUCLEIC ACIDS RES, V20, P1113, DOI 10.1093/nar/20.5.1113; Duthie SM, 1999, HUM MOL GENET, V8, P195, DOI 10.1093/hmg/8.2.195; GERGEN JP, 1987, GENETICS, V117, P477; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; GUTIERREZ AG, 1989, DEV GENET, V10, P155, DOI 10.1002/dvg.1020100305; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LOWENHAUPT KY, 1989, MOL CELL BIOL, V9, P1173, DOI 10.1128/MCB.9.3.1173; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; Lyman LM, 1997, GENETICS, V147, P1743; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; Marin I, 1996, NATURE, V383, P160, DOI 10.1038/383160a0; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Miller AP, 1998, P NATL ACAD SCI USA, V95, P8709, DOI 10.1073/pnas.95.15.8709; OTA T, 1981, GENETICS, V81, P429; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; PARDUE ML, 1987, EMBO J, V6, P1781, DOI 10.1002/j.1460-2075.1987.tb02431.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QIAN S, 1995, GENETICS, V139, P733; RITOSSA FM, 1966, GENETICS, V54, P819; ROBERTS DB, 1979, NATURE, V280, P691, DOI 10.1038/280691a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Roman G, 1999, BIOTECHNIQUES, V27, P54, DOI 10.2144/99271bm09; Roman G, 1998, AM J PHYSIOL-CELL PH, V275, pC857, DOI 10.1152/ajpcell.1998.275.3.C857; ROSEMAN RR, 1995, DEVELOPMENT, V121, P3573; SCHOLNICK SB, 1983, CELL, V34, P37, DOI 10.1016/0092-8674(83)90134-4; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Steinemann M, 1996, CHROMOSOME RES, V4, P185, DOI 10.1007/BF02254957; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WARING GL, 1987, P NATL ACAD SCI USA, V84, P2843, DOI 10.1073/pnas.84.9.2843; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	52	244	249	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					513	522		10.1016/S0092-8674(00)81979-0	http://dx.doi.org/10.1016/S0092-8674(00)81979-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481915	Bronze			2022-12-28	WOS:000082174900011
J	Albert, T				Albert, T			Personal view - Peer review: thinking the unthinkable	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					861	861		10.1136/bmj.319.7213.861	http://dx.doi.org/10.1136/bmj.319.7213.861			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496858	Green Published			2022-12-28	WOS:000082865200071
J	Hensher, M; Edwards, N; Stokes, R				Hensher, M; Edwards, N; Stokes, R			The hospital of the future - International trends in the provision and utilisation of hospital care	BRITISH MEDICAL JOURNAL			English	Article									NHS Federat, London SE1P 4ND, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Consumers Assoc, London NW1 4DF, England	University of London; London School of Hygiene & Tropical Medicine	Edwards, N (corresponding author), NHS Federat, London SE1P 4ND, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827				AlexanderWilliams J, 1996, PRACTITIONER, V240, P152; Barnum H., 1993, PUBLIC HOSP DEV COUN; *GOV STAT SERV, 1992, STAT B HOSP ACT STAT, P1997; *MIN SANT PUBL REP, 1998, RAPP ANN SIT SAN 199; *ORG EC COOP DEV, 1997, OECD HLTH 1997 SOFTW; *ORG EC COOP DEV, 1993, OECD HLTH SYST FACTS; SALUNAN RB, 1997, WHO REGIONAL PUBLICA, V72; *WHO, 1997, HLTH IND DAT 1997; *WORLD BANK, 1996, SOC IND DEV 1996	9	35	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					845	848		10.1136/bmj.319.7213.845	http://dx.doi.org/10.1136/bmj.319.7213.845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496836	Green Published			2022-12-28	WOS:000082865200034
J	Boden, D; Hurley, A; Zhang, LQ; Cao, YZ; Guo, Y; Jones, E; Tsay, J; Ip, J; Farthing, C; Limoli, K; Parkin, N; Markowitz, M				Boden, D; Hurley, A; Zhang, LQ; Cao, YZ; Guo, Y; Jones, E; Tsay, J; Ip, J; Farthing, C; Limoli, K; Parkin, N; Markowitz, M			HIV-1 drug resistance in newly infected individuals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; ZIDOVUDINE-RESISTANCE; PROTEASE INHIBITORS; TYPE-1; TRANSMISSION; MUTATIONS; CELL; INDINAVIR	Context There is concern that the widespread use of antiretroviral drugs to treat human immunodeficiency virus 1 (HIV-1) infection may result in the increased transmission of drug-resistant virus. Objective To determine the prevalence of drug resistance-conferring mutations and phenotypic resistance to antiretroviral agents in a cohort of individuals newly infected with HIV-1. Design Case series with genetic analyses of the HIV-1 plasma-derived pol gene using reverse transcriptase polymerase chain reaction followed by direct sequencing of polymerase chain reaction products. Phenotypic analysis was performed with a recombinant virus assay. Setting and Patients Eighty individuals referred, on average, 1.7 months after infection with HIV-1 to the Aaron Diamond AIDS Research Center between July 1995 and April 1999, Subjects were from large urban areas (65 from New York, NY; 11 from Los Angeles, Calif); 60 (75%) were white, and 75 (93.8%) were homosexual men. Main Outcome Measures Prevalence of known resistance-conferring genotypes and reduced susceptibility to individual antiviral agents by phenotype. Results Thirteen individuals (16.3%) had genotypes associated with drug resistance to any antiretroviral agent. Virus with known resistance-conferring mutations to any nucleoside reverse transcriptase inhibitors was found in 10 individuals, to any nonnucleoside reverse transcriptase inhibitors in 6 subjects, and to any protease inhibitors in 2 cases. Multidrug-resistant Virus was identified in 3 individuals (3.8%), Extensive polymorphism in the protease gene was identified. Interpretation of genotypes and phenotypes was concordant in 57 (85%) of the 67 cases in which both studies were performed. Conclusion The prevalence of HIV-1 variants with known resistance-conferring genotypes to any antiretroviral agent in this cohort of 80 newly infected individuals is 16.3%., These data support expanded use of resistance testing in the setting of primary HIV-1 infection. Clinical trials should be initiated to establish whether therapy guided by resistance testing, compared with the use of empirical tri pie combination antiretroviral therapy, provides additional virological and immunological benefit when treating primary HIV-1 infection. Further efforts to expand the study of transmission of drug-resistant HIV-1 variants, particularly in cohorts with different epidemiological profiles, are indicated.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; AIDS Healthcare Fdn, Los Angeles, CA USA; ViroLog Inc, San Francisco, CA USA	Rockefeller University	Markowitz, M (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA.	mmarkowitz@adarc.org	Parkin, Neil/P-2724-2019; Ip, James E./I-1235-2019; Guo, Yong/ABF-9338-2020	Ip, James E./0000-0002-3461-505X; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, U01AI041534] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NIAID NIH HHS [AI-41534, P30AI42848] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGARANO G, 1994, AIDS, V8, P1013, DOI 10.1097/00002030-199407000-00023; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; DUNCOMBE C, 1998, 5 C RETR OPP INF FEB; Eastman PS, 1998, J VIROL, V72, P5154, DOI 10.1128/JVI.72.6.5154-5164.1998; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jena PK, 1996, J IMMUNOL METHODS, V190, P199, DOI 10.1016/0022-1759(95)00277-4; Kleim JP, 1996, P NATL ACAD SCI USA, V93, P34, DOI 10.1073/pnas.93.1.34; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARKIN N, 1997, 37 INT C ANT AG CHEM; Patick AK, 1998, ANTIMICROB AGENTS CH, V42, P2637, DOI 10.1128/AAC.42.10.2637; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Quigg M, 1997, AIDS, V11, P835; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; Shi CF, 1997, ANTIMICROB AGENTS CH, V41, P2781, DOI 10.1128/AAC.41.12.2781; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SONNERBORG A, 1993, AIDS, V7, P1684, DOI 10.1097/00002030-199312000-00027; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977	37	368	381	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1135	1141		10.1001/jama.282.12.1135	http://dx.doi.org/10.1001/jama.282.12.1135			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501116	Bronze			2022-12-28	WOS:000082596200028
J	Lahdensuo, A				Lahdensuo, A			Guided self management of asthma - how to do it	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GENERAL-PRACTICE		Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland	Tampere University; Tampere University Hospital	Lahdensuo, A (corresponding author), Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland.	aarne.lahdensuo@tays.fi						*AM LUNG ASS WORK, 1998, STAND COMPR ASTHM ED; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BLAINEY AD, 1991, HLTH TRENDS, V22, P151; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; GIBSON PG, 1995, CHEST, V107, P1003, DOI 10.1378/chest.107.4.1003; GIBSON PG, 1999, COCHRANE LIB; Holgate ST, 1996, CLIN EXP ALLERGY, V26, P1; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; KLEIGER JH, 1979, J ASTHMA RES, V16, P93, DOI 10.3109/02770907909106618; Lahdensuo A, 1996, BRIT MED J, V312, P748; Liljas B, 1997, PATIENT EDUC COUNS, V32, pS97, DOI 10.1016/S0738-3991(97)00101-8; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; Partridge MR, 1997, PATIENT EDUC COUNS, V32, pS1, DOI 10.1016/S0738-3991(97)00103-1; PARTRIDGE MR, 1993, RES CLIN FORUMS, V15, P65	15	36	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					759	760		10.1136/bmj.319.7212.759	http://dx.doi.org/10.1136/bmj.319.7212.759			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488007	Green Published			2022-12-28	WOS:000082701500024
J	Winchester, B				Winchester, B			Outlook for screening for sphingolipidoses	LANCET			English	Editorial Material							LYSOSOMAL STORAGE		Inst Child Hlth, Biochem Endocrinol & Metab Unit, London WC1N 1EH, England	University of London; University College London	Winchester, B (corresponding author), Inst Child Hlth, Biochem Endocrinol & Metab Unit, 30 Guilford St, London WC1N 1EH, England.							KOLLER T, 1998, BRAIN PATHOL, V8, P79; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Meikle PJ, 1997, CLIN CHEM, V43, P1325; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					879	880		10.1016/S0140-6736(99)00169-5	http://dx.doi.org/10.1016/S0140-6736(99)00169-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489940				2022-12-28	WOS:000082511800003
J	Ko, AI; Reis, MG; Dourado, CMR; Johnson, WD; Riley, LW				Ko, AI; Reis, MG; Dourado, CMR; Johnson, WD; Riley, LW		Salvador Leptospirosis Study Grp	Urban epidemic of severe leptospirosis in Brazil	LANCET			English	Article							INNER-CITY; ANTIBODIES; ASSAY	Background Leptospirosis has, traditionally, been considered a sporadic rural disease. We describe a large urban outbreak of leptospirosis. Methods Active surveillance for leptospirosis was established in an infectious-disease referral hospital in Salvador, Brazil, between March 10 and Nov 2, 1996. Patients meeting case criteria for severe manifestations of leptospirosis were recruited into the study. The diagnosis was confirmed in the laboratory with the microagglutination test and identification of leptospires in blood or urine. Risk factors for death were examined by multivariate analyses. Findings Surveillance identified 326 cases of which 193 (59%) were laboratory-confirmed (133) or probable (60) cases. Leptospira interrogans serovar copenhageni was isolated from 87% of the cases with positive blood cultures. Most of the cases were adult (mean age 35.9 years [SD 15.9]), and 80% were male. Complications included jaundice (91%), oliguria (35%), and severe anaemia (26%). 50 cases died (case-fatality rate 15%) despite aggressive supportive care including dialysis (in 23%). Altered mental status was the strongest independent predictor of death (odds ratio 9.12 [95% CI 4.28-20.3]), age over 37 years, renal insufficiency, and respiratory insufficiency were also significant predictors of death. Before admission to hospital, 42% were misdiagnosed as having dengue fever in the outpatient clinic; an outbreak of dengue fever was taking place concurrently. Interpretation An epidemic of leptospirosis has become a major urban health problem, associated with high mortality. Diagnostic confusion with dengue fever, another emerging infectious disease with a similar geographic distribution, prevents timely intervention that could minimise mortality.	Brazilian Minist Hlth, Ctr Pesquisas Goncalo Moniz, Fdn Oswaldo Cruz MS, BR-40295001 Salvador, BA, Brazil; Hosp Couto Maia, Secretary Hlth State Bahia, Salvador, BA, Brazil; Cornell Univ Med Coll, Div Int Med & Infect Dis, New York, NY USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Fundacao Oswaldo Cruz; Cornell University; University of California System; University of California Berkeley	Ko, AI (corresponding author), Brazilian Minist Hlth, Ctr Pesquisas Goncalo Moniz, Fdn Oswaldo Cruz MS, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.		Ko, Albert/P-2343-2015	Ko, Albert/0000-0001-9023-2339; Pedreira, Clarissa/0000-0003-1267-3344	FIC NIH HHS [D43 TW00919, D43 TW00905, D43 TW00018] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000018, D43TW000919, D43TW000905] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		CACCIAPUOTI B, 1994, EUR J EPIDEMIOL, V10, P173, DOI 10.1007/BF01730367; CASTRO JSM, 1997, B EPIDEMIOL SESAB, V5, P2; CHEN Y, 1990, CHUNG HUA SHEN CHING, V23, P226; CHILDS JE, 1992, AM J PUBLIC HEALTH, V82, P597, DOI 10.2105/AJPH.82.4.597; DEMERS RY, 1983, J FAM PRACTICE, V17, P1007; Dupont H, 1997, CLIN INFECT DIS, V25, P720, DOI 10.1086/513767; EDWARDS FA, 1964, MEDICINE, V36, P117; Faine S., 1982, GUIDELINES CONTROL L; Faine S., 1993, LEPTOSPIRA LEPTOSPIR; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; FORWELL MA, 1984, BRIT MED J, V289, P1583, DOI 10.1136/bmj.289.6458.1583; Goncalves A J, 1992, Rev Soc Bras Med Trop, V25, P261; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; Gussenhoven GC, 1997, J CLIN MICROBIOL, V35, P92, DOI 10.1128/JCM.35.1.92-97.1997; KORVER H, 1988, Israel Journal of Veterinary Medicine, V44, P15; LESSA I, 1981, LANCET, V2, P1113, DOI 10.1016/S0140-6736(81)91315-5; MERIEN F, 1992, J CLIN MICROBIOL, V30, P2219; NOGUCHI H, 1924, MONOGRAPHS ROCKEFELL, V20, P1; PARK SK, 1989, AM J TROP MED HYG, V41, P345, DOI 10.4269/ajtmh.1989.41.345; SAKATA EE, 1992, REV I MED TROP, V34, P217, DOI 10.1590/S0036-46651992000300006; Vinetz JM, 1996, ANN INTERN MED, V125, P794, DOI 10.7326/0003-4819-125-10-199611150-00002; Winslow WE, 1997, J CLIN MICROBIOL, V35, P1938, DOI 10.1128/JCM.35.8.1938-1942.1997; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; 1991, ANUARIO ESTATISTICO; 1997, MMWR MORB MORTAL WKL, V46, P577; 1998, RELATORIO GESTAO; 1998, MMWR MORB MORTAL WKL, V47, P585	27	529	559	1	115	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					820	825		10.1016/S0140-6736(99)80012-9	http://dx.doi.org/10.1016/S0140-6736(99)80012-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485724				2022-12-28	WOS:000082400700011
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1970: Bernard Katz (b 1911), Ulf Svante von Euler (1905-1983), and Julius Axelrod (b 1912)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	1	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					873	873		10.1016/S0140-6736(05)75941-9	http://dx.doi.org/10.1016/S0140-6736(05)75941-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485764				2022-12-28	WOS:000082400700066
J	Marine, JC; Topham, DJ; McKay, C; Wang, DM; Parganas, E; Stravopodis, D; Yoshimura, A; Ihle, JN				Marine, JC; Topham, DJ; McKay, C; Wang, DM; Parganas, E; Stravopodis, D; Yoshimura, A; Ihle, JN			SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality	CELL			English	Article							CHRONIC ACTIVE HEPATITIS; MICE LACKING JAK3; INTERFERON-GAMMA; INDUCIBLE GENE; CELL-DEATH; EXPRESSION; LIVER; THYMOCYTES; INHIBITOR; RECEPTORS	SOCS1. is an SH2-containing protein that is primarily expressed in thymocytes in a cytokine- and T cell receptor-independent manner. SOCS1 deletion causes perinatal lethality with death by 2-3 weeks. During this period thymic changes include a loss of cellularity and a switch from predominantly CD4(+)CD8(+) to single positive cells. Peripheral T cells express activation antigens and proliferate to IL-2 in the absence of anti-CD3. In addition, IFN gamma is present in the serum. Reconstitution of the lymphoid lineage of JAK3-deficient mice with SOCS1-deficient stem cells recapitulates the lethality and T cell alterations. Introducing a RAG2 or IFN gamma deficiency eliminates lethality. The results demonstrate that lymphocytes are critical to SOCS1-associated perinatal lethality and implicate SOCS1 in lymphocyte differentiation or regulation.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Kurume University	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wang, Demin/AAX-4449-2020; Marine, Jean-Christophe/K-3292-2016; Marine, Jean Christophe/J-2237-2015; Yoshimura, Akihiko/K-5515-2013	Wang, Demin/0000-0001-5549-3795; Marine, Jean-Christophe/0000-0003-2433-9837; Stravopodis, Dimitrios/0000-0002-9535-2134	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GRESSER I, 1981, AM J PATHOL, V102, P396; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Lerner A, 1996, EMBO J, V15, P5876, DOI 10.1002/j.1460-2075.1996.tb00974.x; MATTSSON R, 1992, BIOL REPROD, V46, P1176, DOI 10.1095/biolreprod46.6.1176; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Okamoto T, 1996, BIOCHEM BIOPH RES CO, V226, P762, DOI 10.1006/bbrc.1996.1426; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SHI YF, 1991, J IMMUNOL, V146, P3340; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SUDA T, 1990, J IMMUNOL, V144, P3039; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Young HA, 1997, BLOOD, V89, P583, DOI 10.1182/blood.V89.2.583	26	432	446	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					609	616		10.1016/S0092-8674(00)80048-3	http://dx.doi.org/10.1016/S0092-8674(00)80048-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490100	Bronze			2022-12-28	WOS:000082433500008
J	London, RF; Anderson, PM; Gill, PS; Greenfield, SH				London, RF; Anderson, PM; Gill, PS; Greenfield, SH			Educating medical students for work in culturally diverse societies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HEALTH; PROGRAM	Context Recent attention has focused on whether government health service institutions, particularly in the United Kingdom, reflect cultural sensitivity and competence and whether medical students receive proper guidance in this area. Objective To systematically identify educational programs for medical students on cultural diversity, in particular, racial and ethnic diversity. Data Sources The following databases were searched: MEDLINE (1963-August 1998); Bath international Data Service (BIDS) Institute for Scientific Information science and social science citation indexes (1981-August 1998); BIDS International Bibliography for the Social Sciences (1981-August 1998); and the Educational Resources Information Centre (1987-August 1998), In addition, the following online data sets were searched: Kings Fund; Centre for Ethnic Relations, University of Warwick; Health Education Authority; European Research Centre on Migration and Ethnic Relations, University of Utrecht; International Centre for Intercultural Studies, University of London; the Refugee Studies Programme, University of Oxford. Medical education and academic medicine journals (1994-1998) were searched manually and experts in medical education were contacted. Study Selection Studies included in the analysis were articles published in English before August 1998 that described specific programs for medical students on racial and ethnic diversity. Of 1456 studies identified by the literature search, 17 met the criteria. Two of the authors performed the study selection independently. Data Extraction The following data were extracted: publication year, program setting, student year, whether a program was required or optional, the teaching staff and involvement of minority racial and ethnic communities, program length, content and teaching methods, student assessment, and nature of program evaluation. Data Synthesis Of the 17 selected programs, 13 were conducted in North America. Eleven programs were exclusively for students in years 1 or 2. Fewer than half (n = 7) the programs were part of core teaching. Only 1 required program reported that the students were assessed on the session in cultural diversity. Conclusions Our study suggests that there is limited information available on an increasingly important subject in medical education. Further research is needed to identify effective components of educational programs on cultural diversity and valid methods of student assessment and program evaluation.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Gill, PS (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	p.s.gill@bham.ac.uk						*AM MED ASS, 1999, CULT COMP COMP; Association of American Medical Colleges, 1998, CONT ISSUES MED ED, V1, P1; CHUGH U, 1993, MED TEACH, V15, P83, DOI 10.3109/01421599309029015; *COMM RAC EQ, 1996, ROOTS FUT ETHN DIV M; COPEMAN RC, 1989, MED J AUSTRALIA, V150, P84, DOI 10.5694/j.1326-5377.1989.tb136369.x; *COUNC MED ED, 1998, 5A98 CME; Farnill D, 1997, MED EDUC, V31, P87, DOI 10.1111/j.1365-2923.1997.tb02464.x; Gill PS, 1996, MED TEACH, V18, P61, DOI 10.3109/01421599609040265; Gill PS, 1996, BRIT J GEN PRACT, V46, P704; GONZALEZLEE T, 1987, WESTERN J MED, V146, P502; Gupta A R, 1997, Acad Med, V72, P428, DOI 10.1097/00001888-199705000-00056; HENDERSON G, 1981, TRANSCULTURAL HLTH C; JOHNSTON MAC, 1992, ACAD MED, V67, P236, DOI 10.1097/00001888-199204000-00004; KAI J, 1999, VALUING DIVERSITY RE; Kaufert J M, 1984, Med Anthropol, V8, P36; LACEY EP, 1988, INT MIGR REV, V22, P301, DOI 10.2307/2546652; MACPHERSON W, 1999, REPORT S LAWRENCE IN; MAO C, 1988, J MED EDUC, V63, P624; Mulrow CD, 1994, COCHRANE LIB; NORA LM, 1994, WESTERN J MED, V161, P144; NURGE E, 1975, HUM ORGAN, V34, P345, DOI 10.17730/humo.34.4.1632p455632153r6; *OPCS GRO S, 1993, ETH GROUP COUNTR BIR; OWEN D, 1996, ETHNICITY 1991 CENSU, V1, P80; PATERSONKIMBALL C, 1970, J MED EDUC, V45, P1032; POULTON J, 1986, MED EDUC, V20, P492, DOI 10.1111/j.1365-2923.1986.tb01388.x; ROBINS S, 1995, MULTICULTURAL HLTH C; ROGERS KD, 1984, J MED EDUC, V59, P937; RUBENSTEIN HL, 1992, ACAD MED, V67, P566, DOI 10.1097/00001888-199209000-00003; Shah CP, 1996, CAN J PUBLIC HEALTH, V87, P272; SINCLAIR S, 1997, MAKING DOCTORS, P196; STRAW J, 1999, HOUSE COMMONS HANSAR; SULLIVAN PL, 1954, J ABNORM SOC PSYCH, V49, P246, DOI 10.1037/h0060175; *U OXF, 1998, REF STUD PROGR; WELLS KB, 1985, J MED EDUC, V60, P493; WOLF TM, 1989, MED EDUC, V23, P19, DOI 10.1111/j.1365-2923.1989.tb00807.x	35	77	79	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					875	880		10.1001/jama.282.9.875	http://dx.doi.org/10.1001/jama.282.9.875			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478695				2022-12-28	WOS:000082272200014
J	Mahanty, SK; Wang, YM; Farley, FW; Elion, EA				Mahanty, SK; Wang, YM; Farley, FW; Elion, EA			Nuclear shuttling of yeast scaffold Ste5 is required for its recruitment to the plasma membrane and activation of the mating MAPK cascade	CELL			English	Article							PHEROMONE RESPONSE PATHWAY; BETA-GAMMA COMPLEX; SACCHAROMYCES-CEREVISIAE; KINASE CASCADE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TRANSCRIPTION FACTOR; CELL-CYCLE; FUS3; TRANSPORT	Localization of Ste5 to G beta at the plasma membrane is essential for transmission of the pheromone signal to associated MAP kinase cascade enzymes. Here, we show that this crucial localization requires prior shuttling of Ste5 through the nucleus. Ste5 shuttles through the nucleus constitutively during vegetative growth. Pheromone enhances nuclear export of Ste5, and this pool translocates vectorial ly to the cell periphery. Remarkably, Ste5 that cannot transit the nucleus is unable to localize at the periphery and activate the pathway, while Ste5 with enhanced transit through the nucleus has enhanced ability to localize to the periphery and activate the pathway. This novel regulatory scheme may ensure that cytoplasmic Ste5 does not activate downstream kinases in the absence of pheromone and could be applicable to other membrane-recruited signaling proteins.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	elion@bcmp.med.harvard.edu			NIGMS NIH HHS [GM46962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; [Anonymous], 1991, Methods Enzymol, V194, P1; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; Choi KY, 1999, MOL BIOL CELL, V10, P1553, DOI 10.1091/mbc.10.5.1553; CHOI KY, 1994, CELL, V78, P499; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Farley FW, 1999, GENETICS, V151, P1425; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KAISER CA, 1997, MOL CELLULAR BIOL YE, V3, P91; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	57	127	130	1	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					501	512		10.1016/S0092-8674(00)81978-9	http://dx.doi.org/10.1016/S0092-8674(00)81978-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481914	Bronze			2022-12-28	WOS:000082174900010
J	Elwyn, G; Edwards, A; Gwyn, R; Grol, R				Elwyn, G; Edwards, A; Gwyn, R; Grol, R			Towards a feasible model for shared decision making: focus group study with general practice registrars	BRITISH MEDICAL JOURNAL			English	Article							PATIENT; COMMUNICATION; ENCOUNTER	Objectives To explore the views of general practice registrars about involving patients in decisions and to assess the feasibility of using the shared decision making model by means of simulated general practice consultations. Design Qualitative study based on focus group interviews. Setting General practice vocational training schemes in south Wales. Participants 39 general practice registrars and eight course organisers (acting as observers) attended four sessions; three simulated patients attended each time. Method After an introduction to the principles and suggested stages of shared decision making the registrars conducted and observed a series of consultations about choices of treatment with simulated patients using verbal, numerical, and graphical data formats. Reactions were elicited by using focus group interviews after each consultation and content analysis undertaken. Results Registrars in general practice report not being trained in the skills required to involve patients in clinical decisions. They had a wide range of opinions about "involving patients in decisions," ranging from protective paternalism ("doctor knows best"), through enlightened self interest (lightening the load), to the potential rewards of a more egalitarian relationship with patients. The work points to three contextual precursors for the process: the availability of reliable information, appropriate timing of the decision making process, and the readiness of patients to accept an active role in their own management Conclusions Sharing decisions entails sharing the uncertainties about the outcomes of medical processes and involves exposing the fact that data are often unavailable or not known; this can cause anxiety to both patient and clinician. Movement towards further patient involvement will depend on both the skills and the attitudes of professionals, and this work shows the steps that need to be taken if further progress is to be made in this direction.	Univ Wales, Coll Med, Dept Postgrad Educ Gen Practice, Cardiff CF4 4XN, S Glam, Wales; Univ Wales, Coll Med, Dept Gen Practice, Cardiff CF4 4XN, S Glam, Wales; Univ Wales, Coll Med, Dept Gen Practice, Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales; Cardiff Univ, Hlth Commun Res Ctr, Sch Engn Commun & Philosophy, Cardiff CF1 3XB, S Glam, Wales; Univ Nijmegen, Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands	Cardiff University; Cardiff University; Cardiff University; Cardiff University; Radboud University Nijmegen	Elwyn, G (corresponding author), Univ Wales, Coll Med, Dept Postgrad Educ Gen Practice, Cardiff CF4 4XN, S Glam, Wales.		Elwyn, G./L-4292-2015; Grol, Richard/C-8523-2013; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; DOWIE J, 1998, GUIDELINES HLTH CARE; Edwards A, 1998, FAM PRACT, V15, P296, DOI 10.1093/fampra/15.4.296; Edwards A, 1999, BRIT MED J, V319, P749, DOI 10.1136/bmj.319.7212.749; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; ELWYN G, 1999, SHARED DECISION MAKI; Elwyn Glyn, 1999, Health Expect, V2, P105, DOI 10.1046/j.1369-6513.1999.00045.x; FISHER S, 1986, DISCOURSE I ACTIVITY; Frankland J, 1997, USE FOCUS GROUPS HLT, P144; Gafni A, 1998, SOC SCI MED, V47, P347, DOI 10.1016/S0277-9536(98)00091-4; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Gwyn R, 1999, SOC SCI MED, V49, P437, DOI 10.1016/S0277-9536(99)00067-2; KINNERSLEY P, 1993, BRIT J GEN PRACT, V43, P297; Kreuger R, 1988, FOCUS GROUPS PRACTIC; MORGAN DL, 1988, FOCUS GROUPS QUALITA; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Richards T, 1998, BMJ-BRIT MED J, V316, P85; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917; TOWLE A, 1997, PHYSICIAN PATIENT CO	19	187	190	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					753	756		10.1136/bmj.319.7212.753	http://dx.doi.org/10.1136/bmj.319.7212.753			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	238GA	10488002	Green Published, Bronze			2022-12-28	WOS:000082701500021
J	Palmer, CA				Palmer, CA			Rapid appraisal of needs in reproductive health care in southern Sudan: qualitative Study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AID	Objectives To identify the need for reproductive health care among a community affected by conflict, and to ascertain the priority given by the community to reproductive health issues. Design Rapid appraisal. This comprised interviews with key informants, in-depth interviews, and group discussions, Secondary data were collated. Freelisting, ranking, and scenarios were used to obtain information. Setting Communities affected by conflict in southern Sudan. Participants Interviews and group discussions were chosen purposively. Twenty interviews with key informants were undertaken, in-depth interviews were held with 14 women, and 23 group discussions were held. Main outcome measures Need for reproductive health care. Perceived priority afforded to reproductive health issues in comparison with other health problems. esults Reproductive health in general and sexually transmitted diseases in particular were important issues for these communities. Problems in reproductive health were ranked differently depending on the age and sex of the respondents, Perceptions about reproductive health issues in communities varied between service providers, and community leaders. Settled and displaced communities had different priorities and differing experiences of reproductive health problems and their treatment Conclusion Rapid appraisal could be used as the first step to involving communities in assessing needs and planning service provision.	London Sch Hyg & Trop Med, Conflict & Hlth Grp, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Palmer, CA (corresponding author), London Sch Hyg & Trop Med, Conflict & Hlth Grp, Hlth Policy Unit, London WC1E 7HT, England.	celia@gn.apc.org						ANNETT H, 1990, GUIDELINES RAPID APP; Berglund S, 1997, SOC SCI MED, V44, P1, DOI 10.1016/S0277-9536(96)00084-6; BORTON J, 1996, JOINT EVALUATION EME; CHANDLER JM, 1981, HDB PEST MANAGEMENT, V1, P95; GLASS RI, 1980, LANCET, V1, P868; GUHA-SAPIR D, 1991, World Health Statistics Quarterly, V44, P171; Hancock G., 1991, LORDS POVERTY; Harrell-Bond B.E., 1986, IMPOSING AID EMERGEN; Hendrie B, 1997, DISASTERS, V21, P57, DOI 10.1111/1467-7717.00044; *INT FED RED CROSS, 1994, WORLD DIS REP; Kulig J C, 1988, J Community Health Nurs, V5, P235, DOI 10.1207/s15327655jchn0504_4; KULIG JC, 1991, ROLE STATUS FAMILY P, P222; MELVILLE B, 1993, TROP DOCT, V23, P55, DOI 10.1177/004947559302300205; Murray SA, 1999, BRIT MED J, V318, P440, DOI 10.1136/bmj.318.7181.440; ONWERE S, 1995, ASSESSMENT STDS MARI; PALMER C, 1998, 24 OV DEV I REL REH; Palmer CA, 1999, SOC SCI MED, V49, P1689, DOI 10.1016/S0277-9536(99)00253-1; Palmer CA, 1998, DISASTERS, V22, P236, DOI 10.1111/1467-7717.00089; PELTO PJ, 1998, DATA GATHERING REPRO; Pottier J, 1996, DISASTERS, V20, P324, DOI 10.1111/j.1467-7717.1996.tb01047.x; Scrimshaw S.C., 1987, RAPID ASSESSMENT PRO; Shears P, 1985, BMJ-BRIT MED J, V295, P314; TOOLE MJ, 1995, LANCET, V345, P339, DOI 10.1016/S0140-6736(95)90338-0; *UN, 1995, STESASERA149 UN DEP; WELBOURN A, 1992, RAPID RURAL APPRAISA; Weller S.C, 1988, SYSTEMATIC DATA COLL; Zwi A., 1994, WAR HUNGER RETHINKIN, P6	27	14	14	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					743	748		10.1136/bmj.319.7212.743	http://dx.doi.org/10.1136/bmj.319.7212.743			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488000	Bronze, Green Published			2022-12-28	WOS:000082701500019
J	Wigle, JT; Oliver, G				Wigle, JT; Oliver, G			Prox1 function is required for the development of the murine lymphatic system	CELL			English	Article							ANGIOGENESIS; GENE; IDENTIFICATION; CAPILLARIES; EXPRESSION; RECEPTOR; PROSPERO	The lack of specific markers has raised problems in documenting the precise manner by which the lymphatic system develops. Here we report that the homeobox gene Prox1 is expressed in a subpopulation of endothelial cells that by budding and sprouting give rise to the lymphatic system. The initial localization of these cells in the veins and their subsequent budding are both polarized, suggesting that unidentified guidance signals regulate this process. In Prox1 null mice, budding and sprouting is arrested, although vasculogenesis and angiogenesis of the vascular system is unaffected. These findings suggest that Prox1 is a specific and required regulator of the development of the lymphatic system and that the vascular and lymphatic systems develop independently.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; BOBER E, 1994, DEVELOPMENT, V120, P603; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; EZAKI T, 1990, ARCH HISTOL CYTOL, V53, P77, DOI 10.1679/aohc.53.Suppl_77; FRALEY EE, 1961, AM J ANAT, V109, P85, DOI 10.1002/aja.1001090107; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GRAY H, 1985, ANATOMY HUMAN BODY, P866; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huntington GS, 1910, AM J ANAT, V10, P177, DOI 10.1002/aja.1000100108; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEAK LV, 1968, J CELL BIOL, V36, P129, DOI 10.1083/jcb.36.1.129; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; NERLICH AG, 1991, HISTOCHEMISTRY, V96, P449, DOI 10.1007/BF00316003; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Sabin FR, 1904, AM J ANAT, V3, P183, DOI 10.1002/aja.1000030205; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844	27	1132	1183	2	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					769	778		10.1016/S0092-8674(00)81511-1	http://dx.doi.org/10.1016/S0092-8674(00)81511-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499794	Bronze			2022-12-28	WOS:000082679200004
J	Sugita, Y				Sugita, Y			Grouping of image fragments in primary visual cortex	NATURE			English	Article							ILLUSORY CONTOURS; PERCEPTION; MECHANISMS; MONKEY; INHIBITION; RESPONSES	In the visual world, objects are partially occluded by nearer objects, separating them into image fragments. However, the image fragments of the object can easily be grouped and organized together by the visual system(1-4). Psychophysical data(1-4) and theoretical analysis(5) indicate that such perceptual grouping might be mediated in the early stages of visual processing. Here I show that some orientation-selective cells in the primary visual cortex (V1) have response properties that can mediate the grouping of image fragments. These cells stopped responding to a stimulus bar when it was partly occluded by a small patch. The cells also did not respond when the patch had uncrossed disparity so that it appeared to be behind the bar. However, the cells began responding again when the patch had crossed disparity so that it appeared to be in front of the bar. These results indicate that cells as early as V1 have the computational power to make inferences about the nature of partially invisible forms seen behind occluding structures.	Natl Inst Biosci & Human Technol, Lab Neural Informat Proc, Tsukuba, Ibaraki 3058566, Japan; Japan Sci & Technol Corp, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Sugita, Y (corresponding author), Natl Inst Biosci & Human Technol, Lab Neural Informat Proc, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.							ANDERSON BL, 1995, PSYCHOL REV, V102, P705, DOI 10.1037/0033-295X.102.4.705; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; Grossberg S, 1997, TRENDS NEUROSCI, V20, P106, DOI 10.1016/S0166-2236(96)01002-8; Kanizsa G., 1955, RIV PSICOL, V49, P7; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LAMME VAF, 1995, J NEUROSCI, V15, P1605; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; Nakayama K, 1996, P NATL ACAD SCI USA, V93, P634, DOI 10.1073/pnas.93.2.634; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; NAKAYAMA K, 1989, PERCEPTION, V18, P55, DOI 10.1068/p180055; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; PETERHANS E, 1989, J NEUROSCI, V9, P1749; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SHIMOJO S, 1990, PERCEPTION, V19, P285, DOI 10.1068/p190285; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; Zipser K, 1996, J NEUROSCI, V16, P7376	21	179	181	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					269	272		10.1038/45785	http://dx.doi.org/10.1038/45785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499583				2022-12-28	WOS:000082678400051
J	Finkel, TH				Finkel, TH			Potential use of a caspase against HIV - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Jewish Med & Res Ctr, Div Basic Sci, Denver, CO USA	National Jewish Health	Finkel, TH (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Rheumatol, Philadelphia, PA 19104 USA.							Casella C R, 1997, Curr Opin Hematol, V4, P24; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FINKEL TH, 1998, CELL DEATH SIGNIFICA, P289; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Schulz TF, 1996, LANCET, V348, P587, DOI 10.1016/S0140-6736(95)11033-X; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1021	1022		10.1001/jama.282.11.1021	http://dx.doi.org/10.1001/jama.282.11.1021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493188				2022-12-28	WOS:000082512300002
J	Leitzmann, MF; Rimm, EB; Willett, WC; Spiegelman, D; Grodstein, F; Stampfer, MJ; Colditz, GA; Giovannucci, E				Leitzmann, MF; Rimm, EB; Willett, WC; Spiegelman, D; Grodstein, F; Stampfer, MJ; Colditz, GA; Giovannucci, E			Recreational physical activity and the risk of cholecystectomy in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOGISTIC-REGRESSION; GLUCOSE-TOLERANCE; GALLSTONE DISEASE; REPRODUCIBILITY; CHOLESTEROL; VALIDITY; CHOLELITHIASIS; QUESTIONNAIRE; OBESITY; PIGMENT	Background Physical activity may be an important determinant of the risk of gallstone disease in women, both independently and as a result of its role in maintaining body weight. Methods We prospectively studied recreational physical activity (such as jogging, running, and bicycling) and sedentary behavior (such as spending hours watching television) in relation to the risk of cholecystectomy, a surrogate for symptomatic cholelithiasis, in a cohort of 60,290 women who were 40 to 65 years of age in 1986 and had no history of gallstone disease. As part of the Nurses' Health Study, the women reported on questionnaires mailed to them every two years both their activity level and whether they had undergone cholecystectomy. During a 10-year follow-up period (1986 to 1996), 3257 cases of cholecystectomy were documented. Results Recreational physical activity was inversely related to the risk of cholecystectomy. The multivariate relative risk for women in the highest as compared with the lowest quintile of physical activity was 0.69 (95 percent confidence interval, 0.61 to 0.78). In contrast, sedentary behavior was independently related to an increased risk of cholecystectomy. As compared with women who spent less than 6 hours per week sitting while at work or driving, women who spent 41 to 60 hours per week sitting had a multivariate relative risk of 1.42 (95 percent confidence interval, 1.06 to 1.89), and women who spent more than 60 hours per week sitting while at work or driving had a multivariate relative risk of 2.32 (95 percent confidence interval, 1.26 to 4.26). These associations persisted after we controlled for body weight and weight change. Conclusions In women, recreational physical activity is associated with a decreased risk of cholecystectomy. The association is independent of other risk factors for gallstone disease, such as obesity and recent weight loss. (N Engl J Med 1999;341:777-84.) (C)1999, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; PHS HHS [T45 09856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ANGELICO M, 1988, HEPATOLOGY, V8, P907; Apstein MD, 1996, EUR J CLIN INVEST, V26, P343, DOI 10.1046/j.1365-2362.1996.148287.x; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; DiPietro L, 1998, J AM GERIATR SOC, V46, P875, DOI 10.1111/j.1532-5415.1998.tb02722.x; ELLISON PT, 1986, AM J OBSTET GYNECOL, V154, P100; HOFMANN AF, 1993, AM J SURG, V165, P541, DOI 10.1016/S0002-9610(05)80958-4; KALSER SC, 1993, AM J SURG, V165, P390; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; Leitzmann MF, 1998, ANN INTERN MED, V128, P417, DOI 10.7326/0003-4819-128-6-199803150-00001; Linos A D, 1989, HPB Surg, V1, P221, DOI 10.1155/1989/56539; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; Misciagna G, 1999, AM J CLIN NUTR, V69, P120; OETTLE GJ, 1991, GUT, V32, P941, DOI 10.1136/gut.32.8.941; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; PHILLIPP E, 1992, PEPTIDES, V13, P125, DOI 10.1016/0196-9781(92)90150-2; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman K., 1998, MODERN EPIDEMIOLOGY; SARIN SK, 1986, DIGEST DIS SCI, V31, P1041, DOI 10.1007/BF01300256; SEALS DR, 1984, JAMA-J AM MED ASSOC, V252, P645, DOI 10.1001/jama.252.5.645; SOUTHGATE DA, 1969, J SCI FOOD AGR, V20, P331, DOI 10.1002/jsfa.2740200603; TROTMAN BW, 1975, AM J DIG DIS, V20, P735, DOI 10.1007/BF01070831; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS CN, 1980, CAN MED ASSOC J, V122, P664; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390	31	141	147	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					777	784		10.1056/NEJM199909093411101	http://dx.doi.org/10.1056/NEJM199909093411101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477775				2022-12-28	WOS:000082534000001
J	Takala, J; Ruokonen, E; Webster, NR; Nielsen, MS; Zandstra, DF; Vundelinckx, G; Hinds, CJ; Loponen, E; Rauhala, V; Hovilehto, S; Karlsson, S; Kairi, P; Bellamy, MC; Sepers, JM; Reynaert, M; Dive, AM; Dugernier, T; Rydvall, A; Vernersson, E; Gibson, F; Botfield, C				Takala, J; Ruokonen, E; Webster, NR; Nielsen, MS; Zandstra, DF; Vundelinckx, G; Hinds, CJ; Loponen, E; Rauhala, V; Hovilehto, S; Karlsson, S; Kairi, P; Bellamy, MC; Sepers, JM; Reynaert, M; Dive, AM; Dugernier, T; Rydvall, A; Vernersson, E; Gibson, F; Botfield, C			Increased mortality associated with growth hormone treatment in critically ill adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIPLE ORGAN FAILURE; NECROSIS-FACTOR-ALPHA; PARENTERAL-NUTRITION; PROTEIN-SYNTHESIS; WHOLE-BODY; FACTOR-I; CATABOLIC RESPONSE; SURGICAL PATIENTS; NITROGEN-BALANCE; CRITICAL ILLNESS	Background The administration of growth hormone can attenuate the catabolic response to injury, surgery, and sepsis. However, the effect of high doses of growth hormone on the length of stay in intensive care and in the hospital, the duration of mechanical ventilation, and the outcome in critically ill adults who are hospitalized for long periods is not known. Methods We carried out two prospective, multicenter, double-blind, randomized, placebo-controlled trials in parallel involving 247 Finnish patients and 285 patients in other European countries who had been in an intensive care unit for 5 to 7 days and who were expected to require intensive care for at least 10 days. The patients had had cardiac surgery, abdominal surgery, multiple trauma, or acute respiratory failure. The patients received either growth hormone (mean [+/-SD] daily dose, 0.10+/-0.02 mg per kilogram of body weight) or placebo until discharge from intensive care or for a maximum of 21 days. Results The in-hospital mortality rate was higher in the patients who received growth hormone than in those who did not (P<0.001 for both studies). In the Finnish study, the mortality rate was 39 percent in the growth hormone group, as compared with 20 percent in the placebo group. The respective rates in the multinational study were 44 percent and 18 percent. The relative risk of death for patients receiving growth hormone was 1.9 (95 percent confidence interval, 1.3 to 2.9) in the Finnish study and 2.4 (95 percent confidence interval, 1.6 to 3.5) in the multinational study. Among the survivors, the length of stay in intensive care and in the hospital and the duration of mechanical ventilation were prolonged in the growth hormone group. Conclusions In patients with prolonged critical illness, high doses of growth hormone are associated with increased morbidity and mortality (N Engl J Med 1999;341:785-92.) (C)1999, Massachusetts Medical Society.	Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, Crit Care Res Program, FIN-70210 Kuopio, Finland; Aberdeen Royal Infirm, Intens Care Unit, Aberdeen, Scotland; Southampton Gen Hosp, Intens Care Unit, Southampton SO9 4XY, Hants, England; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; St Jans Hosp, Genk, Belgium; St Bartholomews Hosp, London, England	Kuopio University Hospital; University of Aberdeen; University of Southampton; University of London; Queen Mary University London	Takala, J (corresponding author), Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, Crit Care Res Program, FIN-70210 Kuopio, Finland.							ARNOLD J, 1993, CLIN SCI, V84, P655, DOI 10.1042/cs0840655; ARNOLD J, 1993, CLIN SCI COLCH, V85, pRAIK; Biolo G, 1997, CLIN NUTR, V16, P89, DOI 10.1016/S0261-5614(97)80029-5; CHRISTENSEN T, 1982, BRIT J SURG, V69, P417, DOI 10.1002/bjs.1800690721; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; EDWARDS CK, 1991, ENDOCRINOLOGY, V128, P989, DOI 10.1210/endo-128-2-989; ELSASSER TH, 1994, ENDOCRINOLOGY, V134, P1082, DOI 10.1210/en.134.3.1082; GATZEN C, 1992, SURGERY, V112, P181; Gelding SV, 1998, CLIN ENDOCRINOL, V48, P153, DOI 10.1046/j.1365-2265.1998.3641180.x; GORE DC, 1991, ARCH SURG-CHICAGO, V126, P38; GOTTARDIS M, 1991, J TRAUMA, V31, P81, DOI 10.1097/00005373-199101000-00015; HAMMARQVIST F, 1992, ANN SURG, V216, P184, DOI 10.1097/00000658-199208000-00009; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; INOUE L, 1995, ARCH SURG-CHICAGO, V130, P1115; JEEVANANDAM M, 1995, JPEN-PARENTER ENTER, V19, P137, DOI 10.1177/0148607195019002137; JEEVANANDAM M, 1994, AM J PHYSIOL-ENDOC M, V267, pE560, DOI 10.1152/ajpendo.1994.267.4.E560; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; KAPPEL M, 1994, HORM METAB RES, V26, P612, DOI 10.1055/s-2007-1001771; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNOX J, 1995, J TRAUMA, V39, P526; Knox JB, 1996, AM J SURG, V171, P576, DOI 10.1016/S0002-9610(96)00033-5; Koea JB, 1996, BRIT J SURG, V83, P196, DOI 10.1002/bjs.1800830214; Liao W, 1996, EUR J CLIN INVEST, V26, P254, DOI 10.1046/j.1365-2362.1996.140268.x; MALSTAM J, 1992, ACTA ANAESTH SCAND, V36, P758; MANSON JM, 1988, ANN SURG, V208, P136, DOI 10.1097/00000658-198808000-00002; PAPE GS, 1991, CHEST, V99, P1495, DOI 10.1378/chest.99.6.1495; Pichard C, 1996, CRIT CARE MED, V24, P403, DOI 10.1097/00003246-199603000-00008; PONTING GA, 1988, LANCET, V1, P438, DOI 10.1016/S0140-6736(88)91232-9; RENNIE MJ, 1985, BRIT MED BULL, V41, P257, DOI 10.1093/oxfordjournals.bmb.a072060; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; RUOKONEN E, 1991, CRIT CARE MED, V19, P1146, DOI 10.1097/00003246-199109000-00009; SUCHNER U, 1990, ARCH INTERN MED, V150, P1225, DOI 10.1001/archinte.150.6.1225; TACKE J, 1994, INFUSIONSTHERAPIE, V21, P24; Timmins AC, 1996, CRIT CARE MED, V24, P1460, DOI 10.1097/00003246-199609000-00006; VandenBerghe G, 1997, J CLIN ENDOCR METAB, V82, P590, DOI 10.1210/jc.82.2.590; VARATHORBECK R, 1993, WORLD J SURG, V17, P530, DOI 10.1007/BF01655116; VOERMAN BJ, 1995, CRIT CARE MED, V23, P665, DOI 10.1097/00003246-199504000-00014; VOERMAN BJ, 1994, J CRIT CARE, V9, P143, DOI 10.1016/0883-9441(94)90010-8; VOERMAN HJ, 1992, ANN SURG, V216, P648, DOI 10.1097/00000658-199212000-00006; WARWICKDAVIES J, 1995, J IMMUNOL, V154, P1909; ZIEGLER TR, 1992, J CLIN ENDOCR METAB, V74, P865, DOI 10.1210/jc.74.4.865	41	718	768	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					785	792		10.1056/NEJM199909093411102	http://dx.doi.org/10.1056/NEJM199909093411102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477776				2022-12-28	WOS:000082534000002
J	Alexander, WS; Starr, R; Fenner, JE; Scott, GL; Handman, E; Sprigg, NS; Corbin, JE; Cornish, AL; Darwiche, R; Owczarek, CM; Kay, TWH; Nicola, NA; Hertzog, PJ; Metcalf, D; Hilton, DJ				Alexander, WS; Starr, R; Fenner, JE; Scott, GL; Handman, E; Sprigg, NS; Corbin, JE; Cornish, AL; Darwiche, R; Owczarek, CM; Kay, TWH; Nicola, NA; Hertzog, PJ; Metcalf, D; Hilton, DJ			SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine	CELL			English	Article							JAK-STAT PATHWAY; MUTANT-CELL LINE; IFN-GAMMA; TARGETED DISRUPTION; TYROSINE PHOSPHORYLATION; SUCKLING MICE; RECEPTOR; PROTEIN; GENE; ACTIVATION	Mice lacking suppressor of cytokine signaling-1 (SOCS1) develop a complex fatal neonatal disease. In this study, SOCS1(-/-) mice were shown to exhibit excessive responses typical of those induced by interferon gamma (IFN gamma), were hyperresponsive to viral infection, and yielded macrophages with an enhanced IFN gamma-dependent capacity to kill L. major parasites. The complex disease in SOCS1(-/-) mice was prevented by administration of anti-IFN gamma antibodies and did not occur in SOCS1(-/-) mice also lacking the IFN gamma gene. Although IFN gamma is essential for resistance to a variety of infections, the potential toxic action of IFN gamma, particularly in neonatal mice, appears to require regulation. Our data indicate that SOCS1 is a key modulator of IFN gamma action, allowing the protective effects of this cytokine to occur without the risk of associated pathological responses.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Monash Med Ctr, Inst Reprod & Dev, Ctr Funct Gen & Human Dis, Clayton, Vic 3165, Australia	Walter & Eliza Hall Institute; Monash University	Hilton, DJ (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.	hilton@wehi.edu.au	Nicola, Nicos/D-2989-2011; Hertzog, Paul J/G-6734-2013; Hilton, Douglas J/C-7250-2013; Hertzog, Paul J/I-7053-2013	Nicola, Nicos/0000-0003-1054-7889; Hertzog, Paul J/0000-0002-1373-8472; Hilton, Douglas J/0000-0002-7698-2392; Hertzog, Paul J/0000-0002-1373-8472	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DAMELL JE, 1994, SCIENCE, V264, P1415; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Maeyer Edward, 1998, P491; De Sepulveda P, 1999, EMBO J, V18, P904; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRESSER I, 1981, AM J PATHOL, V102, P396; Gresser I, 1982, Interferon, V4, P95; GRESSER I, 1987, AM J PATHOL, V128, P13; HANDMAN E, 1983, PARASITE IMMUNOL, V5, P109, DOI 10.1111/j.1365-3024.1983.tb00728.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HERTZOG PJ, 1991, CLIN IMMUNOL IMMUNOP, V58, P18, DOI 10.1016/0090-1229(91)90145-Z; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ITO S, 1999, BLOOD, V93, P1; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIU ZQ, 1995, INFECT IMMUN, V63, P2790, DOI 10.1128/IAI.63.7.2790-2792.1995; Lu BF, 1998, P NATL ACAD SCI USA, V95, P8233, DOI 10.1073/pnas.95.14.8233; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Massa PT, 1996, J IMMUNOL, V157, P5139; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MATTHYS P, 1995, INFECT IMMUN, V63, P1158, DOI 10.1128/IAI.63.4.1158-1164.1995; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PAUL WE, 1991, BLOOD, V77, P1859; PROUDFOOT L, 1995, BIOCHEM J, V15, P45; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TATAKE RJ, 1993, P SOC EXP BIOL MED, V203, P405; Thomas HE, 1998, J CLIN INVEST, V102, P1249, DOI 10.1172/JCI2899; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	66	624	649	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					597	608		10.1016/S0092-8674(00)80047-1	http://dx.doi.org/10.1016/S0092-8674(00)80047-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490099	Bronze			2022-12-28	WOS:000082433500007
J	Marine, JC; McKay, C; Wang, DM; Topham, DJ; Parganas, E; Nakajima, H; Pendeville, H; Yasukawa, H; Sasaki, A; Yoshimura, A; Ihle, JN				Marine, JC; McKay, C; Wang, DM; Topham, DJ; Parganas, E; Nakajima, H; Pendeville, H; Yasukawa, H; Sasaki, A; Yoshimura, A; Ihle, JN			SOCS3 is essential in the regulation of fetal liver erythropoiesis	CELL			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; DEFICIENT MICE; RECEPTORS; JAK2; HEMATOPOIESIS; EXPRESSION; PROTEIN; BCL-2; DEATH	SOCS3 (CIS3/JAB2) is an SH2-containing protein that binds to the activation loop of Janus kinases, inhibiting kinase activity, and thereby suppressing cytokine signaling. During embryonic development, SOCS3 is highly expressed in erythroid lineage cells and is Epo independent. Transgene-mediated expression blocks fetal erythropoiesis, resulting in embryonic lethality. SOCS3 deletion results in an embryonic lethality at 12-16 days associated with marked erythrocytosis. Moreover, the in vitro proliferative capacity of progenitors is greatly increased. SOCS3-deficient fetal liver stem cells can reconstitute hematopoiesis in lethally irradiated adults, indicating that its absence does not disturb bone marrow erythropoiesis. Reconstitution of lymphoid lineages in JAK3-deficient mice also occurs normally. The results demonstrate that SOCS3 is critical in negatively regulating fetal liver hematopoiesis.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Memphis, TN USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Kurume University	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.	jamesihle@stjude.org	Marine, Jean-Christophe/K-3292-2016; Wang, Demin/AAX-4449-2020; Marine, Jean Christophe/J-2237-2015; Yoshimura, Akihiko/K-5515-2013	Marine, Jean-Christophe/0000-0003-2433-9837; Wang, Demin/0000-0001-5549-3795; Sasaki, Atsuo/0000-0003-2963-4501	NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Andrews N C, 1994, Curr Opin Hematol, V1, P119; ANGERER LM, 1991, METHOD CELL BIOL, V35, P37; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Auernhammer CJ, 1999, ENDOCRINOLOGY, V140, P1559, DOI 10.1210/en.140.4.1559; Bentley DJ, 1996, NAT GENET, V13, P489, DOI 10.1038/ng0896-489; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; SASAKI A, 1999, IN PRESS GENES CELLS; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	41	299	306	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					617	627		10.1016/S0092-8674(00)80049-5	http://dx.doi.org/10.1016/S0092-8674(00)80049-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490101	Bronze			2022-12-28	WOS:000082433500009
J	Issenberg, SB; McGaghie, WC; Hart, IR; Mayer, JW; Felner, JM; Petrusa, ER; Waugh, RA; Brown, DD; Safford, RR; Gessner, IH; Gordon, DL; Ewy, GA				Issenberg, SB; McGaghie, WC; Hart, IR; Mayer, JW; Felner, JM; Petrusa, ER; Waugh, RA; Brown, DD; Safford, RR; Gessner, IH; Gordon, DL; Ewy, GA			Simulation technology for health care professional skills training and assessment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOLOGY PATIENT SIMULATOR; COMPREHENSIVE ANESTHESIA SIMULATION; CRITICAL INCIDENTS; LAPAROSCOPIC SKILLS; INTERNAL-MEDICINE; PERFORMANCE; ACQUISITION; MANAGEMENT; HARVEY; COMPETENCE	Changes in medical practice that limit instruction time and patient availability, the expanding options for diagnosis and management, and advances in technology are contributing to greater use of simulation technology in medical education, Four areas of high-technology simulations currently being used are laparoscopic techniques, which provide surgeons with an opportunity to enhance their motor skills without risk to patients; a cardiovascular disease simulator, which can be used to simulate cardiac conditions; multimedia computer systems, which includes patient-centered, case-based programs that constitute a generalist curriculum in cardiology; and anesthesia simulators, which have controlled responses that vary according to numerous possible scenarios, Some benefits of simulation technology include improvements in certain surgical technical skills, in cardiovascular examination skills, and in acquisition and retention of knowledge compared with traditional lectures. These systems help to address the problem of poor skills training and proficiency and may provide a method for physicians to become self-directed lifelong learners.	Univ Miami, Sch Med, Ctr Res Med Educ, Miami, FL 33101 USA; Northwestern Univ, Sch Med, Off Med Educ, Chicago, IL USA; Univ Ottawa, Ottawa, ON, Canada; Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA; Duke Univ, Med Ctr, Durham, NC USA; Univ Iowa Hosp & Clin, Dept Med, Div Cardiovasc Dis, Iowa City, IA 52242 USA; Univ Florida, Coll Med, Div Pediat Cardiol, Gainesville, FL USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Arizona Hlth Sci Ctr, Cardiol Sect, Tucson, AZ 85724 USA	University of Miami; Northwestern University; University of Ottawa; Emory University; Duke University; University of Iowa; State University System of Florida; University of Florida; University of Mississippi; University of Mississippi Medical Center; University of Arizona Health Sciences	Issenberg, SB (corresponding author), Univ Miami, Sch Med, Ctr Res Med Educ, POB 016960,D41, Miami, FL 33101 USA.			Issenberg, Saul/0000-0002-2524-4736; Brown, Donald/0000-0002-2740-2654; McGaghie, William/0000-0003-1672-0398				ABRAHAMSON S, 1969, J MED EDUC, V44, P515; Anderson MB, 1999, ACAD MED, V74, P13; CHOPRA V, 1994, BRIT J ANAESTH, V73, P287, DOI 10.1093/bja/73.3.287; DANFORD DA, 1993, PEDIATRICS, V91, P365; DEANDA A, 1990, ANESTH ANALG, V71, P77; DEANDA A, 1991, ANESTH ANALG, V72, P308; Derossis AM, 1998, AM J SURG, V175, P482, DOI 10.1016/S0002-9610(98)00080-4; Derossis AM, 1998, SURG ENDOSC-ULTRAS, V12, P1117, DOI 10.1007/s004649900796; Dusterberry JC, 1975, SOC PHOTOOPTICAL ENG, V59, P141; ERICSSON KA, 1993, PSYCHOL REV, V100, P363, DOI 10.1037/0033-295X.100.3.363; Ericsson KA, 1996, ROAD TO EXCELLENCE, P1; EWY GA, 1987, J MED EDUC, V62, P738; Forrest F, 1998, HOSP MED, V59, P653; GABA DM, 1988, ANESTHESIOLOGY, V69, P387, DOI 10.1097/00000542-198809000-00017; Gaba DM, 1998, ANESTHESIOLOGY, V89, P8, DOI 10.1097/00000542-199807000-00005; GABA DM, 1989, ANESTH ANALG, V68, P444; GABA DM, 1992, ANESTHESIOLOGY, V76, P491; Garrison P., 1985, FLYING WINGS, p[1, 102]; GOODMAN W, 1978, FLIGHT INT MAGAZINE, V18, P435; GORDON MS, 1981, J FAM PRACTICE, V13, P353; GORDON MS, 1980, MED CLIN N AM, V64, P305, DOI 10.1016/S0025-7125(16)31620-0; Gregoratos G, 1999, J AM COLL CARDIOL, V33, P1120; HOWARD SK, 1992, AVIAT SPACE ENVIR MD, V63, P763; Howell JD, 1999, ACAD MED, V74, P244, DOI 10.1097/00001888-199903000-00013; ISSENBERG SB, 1998, P 8 INT OTT C MED ED; ISSENBERG SB, IN PRESS ACAD MED; Jones JS, 1997, ACAD EMERG MED, V4, P980, DOI 10.1111/j.1553-2712.1997.tb03664.x; Kapur PA, 1998, ANESTH ANALG, V86, P1157, DOI 10.1097/00000539-199806000-00003; KEYS B, 1990, J MANAGE, V16, P307, DOI 10.1177/014920639001600205; Lampotang S, 1997, J CLIN MONITOR, V13, P399, DOI 10.1023/A:1007447510839; MANGIONE S, 1993, ANN INTERN MED, V119, P47, DOI 10.7326/0003-4819-119-1-199307010-00009; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; Mangione S, 1998, ACAD MED, V73, pS10, DOI 10.1097/00001888-199810000-00030; Maudsley RF, 1999, ACAD MED, V74, P143, DOI 10.1097/00001888-199902000-00013; Melvin WS, 1996, AM J SURG, V172, P377; NORCINI J, 1999, PERSPECTIVES     SUM, P3; ODDONE EZ, 1993, AM J MED, V95, P389, DOI 10.1016/0002-9343(93)90308-C; *OFF NAV RES, 1973, VIS EL FLIGHT SIM; Petrusa ER, 1999, ACAD MED, V74, P123, DOI 10.1097/00001888-199902000-00011; Ressler EK, 1999, INNOVATIVE SIMULATIO, P157; Roldan CA, 1996, AM J CARDIOL, V77, P1327, DOI 10.1016/S0002-9149(96)00200-7; ROLFE JM, 1986, FLIGHT SIMULATION, P232; Rosser JC, 1997, ARCH SURG-CHICAGO, V132, P200; SCHWID HA, 1990, ANESTHESIOLOGY, V72, P191, DOI 10.1097/00000542-199001000-00028; SCHWID HA, 1987, COMPUT BIOMED RES, V20, P64, DOI 10.1016/0010-4809(87)90019-X; SCHWID HA, 1992, ANESTHESIOLOGY, V76, P495, DOI 10.1097/00000542-199204000-00002; Smith J, 1991, GEN THEORY EXPERTISE, P126; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; STREUFERT S, 1988, PERS PSYCHOL, V41, P537, DOI 10.1111/j.1744-6570.1988.tb00643.x; Takashina T, 1997, CARDIOLOGY, V88, P408, DOI 10.1159/000177369; WACHTEL J, 1985, SIMULATION NUCL REAC, P339; WAUGH RA, 1995, ARCH INTERN MED, V155, P197, DOI 10.1001/archinte.155.2.197; Windsor J A, 1993, J R Coll Surg Edinb, V38, P48; WOOLLISCROFT JO, 1987, MED TEACH, V9, P53, DOI 10.3109/01421598709028980	54	582	592	0	63	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					861	866		10.1001/jama.282.9.861	http://dx.doi.org/10.1001/jama.282.9.861			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478693				2022-12-28	WOS:000082272200012
J	Sharp, D				Sharp, D			An Ideal Husband in the wild(e)?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), The Lancet, London WC1B 3SL, England.							CONNOR S, 1999, INDEPENDENT     0819, P5; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475	2	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					700	700		10.1016/S0140-6736(99)00287-1	http://dx.doi.org/10.1016/S0140-6736(99)00287-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475179				2022-12-28	WOS:000082233000007
J	Wainapel, SF				Wainapel, SF			A clash of cultures: reflections of a physician with a disability	LANCET			English	Article									Montefiore Med Ctr, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Wainapel, SF (corresponding author), Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.							LEWIS SB, 1983, PHYSICIAN PROFESSION, P318; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; STETTEN D, 1981, NEW ENGL J MED, V305, P458, DOI 10.1056/NEJM198108203050811; WAINAPEL SF, 1987, JAMA-J AM MED ASSOC, V257, P2935, DOI 10.1001/jama.257.21.2935	4	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					763	764		10.1016/S0140-6736(99)06003-1	http://dx.doi.org/10.1016/S0140-6736(99)06003-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475208				2022-12-28	WOS:000082233000046
J	Huang, CC; Liu, CC; Chang, YC; Chen, CY; Wang, ST; Yeh, TF				Huang, CC; Liu, CC; Chang, YC; Chen, CY; Wang, ST; Yeh, TF			Neurologic complications in children with enterovirus 71 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAIN-STEM ENCEPHALITIS; CENTRAL NERVOUS-SYSTEM; MOUTH-DISEASE; POLIOMYELITIS; MRI; PARALYSIS; OUTBREAK; HAND; FOOT	Background Enterovirus 71 infection causes hand-foot-and-mouth disease in young children, which is characterized by several days of fever and vomiting, ulcerative lesions in the oral mucosa, and vesicles on the backs of the hands and feet. The initial illness resolves bur is sometimes followed by aseptic meningitis, encephalomyelitis, or even acute flaccid paralysis similar to paralytic poliomyelitis. Methods We describe the neurologic complications associated with the enterovirus 71 epidemic that occurred in Taiwan in 1998. At three major hospitals we identified 41 children with culture-confirmed entero; virus 71 infection and acute neurologic manifestations. Magnetic resonance imaging (MRI) was performed in 4 patients with acute flaccid paralysis and 24 with rhombencephalitis. Results The mean age of the patients was 2.5 years (range, 3 months to 8.2 years). Twenty-eight patients had hand-foot-and-mouth disease (68 percent), and six had herpangina (15 percent). The other seven patients had no skin or mucosal lesions. Three neurologic syndromes were identified: aseptic meningitis tin 3 patients); brain-stem encephalitis, or rhombencephalitis (in 37); and acute flaccid paralysis (in 4), which followed rhombencephalitis in 3 patients. In 20 patients with rhombencephalitis, the syndrome was characterized by myoclonic jerks and tremor, ataxia, or both (grade I disease). Ten patients had myoclonus and cranial-nerve involvement (grade II disease). In seven patients the brain-stem infection produced transient myoclonus followed by the rapid onset of respiratory distress, cyanosis, poor peripheral perfusion, shock, coma, loss of the doll's eye reflex, and apnea (grade III disease); five of these patients died within 12 hours after admission. In 17 of the 24 patients with rhombencephalitis who underwent MRI, T-2-weighted scans showed high-intensity lesions in the brain stem, most commonly in the pontine tegmentum. At follow-up, two of the patients with acute flaccid paralysis had residual limb weakness, and five of the patients with rhombencephalitis had persistent neurologic deficits, including myoclonus tin one child), cranial-nerve deficits (in two), and ventilator-dependent apnea (in two). Conclusions In the 1998 enterovirus 71 epidemic in Taiwan, the chief neurologic complication was rhombencephalitis, which had a fatality rare of 14 percent. The most common initial symptoms were myoclonic jerks, and MRI usually showed evidence of brainstem involvement. (N Engl J Med 1999;341:936-42.) (C) 1999, Massachusetts Medical Society.	Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 704, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Kaohsiung, Taiwan; Triserv Gen Hosp & Natl Def Med Ctr, Dept Radiol, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; Chang Gung Memorial Hospital; National Defense Medical Center	Huang, CC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pediat, 138 Sheng Li Rd, Tainan 704, Taiwan.			Chen, Cheng-Yu/0000-0003-0428-4373; Huang, Chao-Ching/0000-0003-2799-7181				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; ARMSTRONG RW, 1993, CLIN INFECT DIS, V16, P689, DOI 10.1093/clind/16.5.689; BICKERSTAFF ER, 1951, BMJ-BRIT MED J, V2, P77, DOI 10.1136/bmj.2.4723.77; BLOMBERG J, 1974, LANCET, V2, P112; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; CHONMAITREE T, 1981, PEDIATRICS, V67, P489; GELLER TJ, 1987, ANN NEUROL, V21, P602, DOI 10.1002/ana.410210614; GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007; Hall W A, 1993, Neurosurg Clin N Am, V4, P543; HATTORI T, 1988, J NEUROL NEUROSUR PS, V51, P1572, DOI 10.1136/jnnp.51.12.1572; Hauw J J, 1986, Adv Neurol, V43, P201; HAYWARD JC, 1989, PEDIATR INFECT DIS J, V8, P611, DOI 10.1097/00006454-198909000-00009; HSIUNG GD, 1994, HSIUNGS DIAGNOSTIC V, P119; HURST DL, 1988, PEDIATR NEUROL, V4, P122, DOI 10.1016/0887-8994(88)90054-9; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; James D., 1998, TXB PEDIAT INFECT DI, P1787; Kornreich L, 1996, NEURORADIOLOGY, V38, P371; Lai YY, 1997, BRAIN RES, V745, P257, DOI 10.1016/S0006-8993(96)01177-8; Lam SK, 1998, EMERG INFECT DIS, V4, P145, DOI 10.3201/eid0402.980201; Landry ML, 1995, PEDIATR INFECT DIS J, V14, P1095, DOI 10.1097/00006454-199512000-00013; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MALZBERG MS, 1993, AM J ROENTGENOL, V161, P863, DOI 10.2214/ajr.161.4.8372775; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; PROTHEROE SM, 1991, ARCH DIS CHILD, V66, P702, DOI 10.1136/adc.66.6.702; Sakakibara R, 1998, J NEUROL NEUROSUR PS, V64, P269, DOI 10.1136/jnnp.64.2.269; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHIAN WJ, 1994, PEDIATR RADIOL, V24, P596, DOI 10.1007/BF02012744; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; SVED AF, 1999, FUNDAMENTAL NEUROSCI, P1051; Takimoto S, 1998, T ROY SOC TROP MED H, V92, P25, DOI 10.1016/S0035-9203(98)90939-7; Tartaglino LM, 1996, RADIOLOGY, V201, P661, DOI 10.1148/radiology.201.3.8939212; WAKAMOTO H, 1992, PEDIATR RADIOL, V22, P533, DOI 10.1007/BF02013004; 1998, MMWR MORB MORTAL WKL, V47, P718	34	512	609	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					936	942		10.1056/NEJM199909233411302	http://dx.doi.org/10.1056/NEJM199909233411302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498488	Bronze			2022-12-28	WOS:000082658100002
J	Johnston, LA; Prober, DA; Edgar, BA; Eisenman, RN; Gallant, P				Johnston, LA; Prober, DA; Edgar, BA; Eisenman, RN; Gallant, P			Drosophila myc regulates cellular growth during development	CELL			English	Article							C-MYC; N-MYC; CYCLE PROGRESSION; DISC DEVELOPMENT; IN-VIVO; GENE; PROTEIN; TRANSCRIPTION; TARGET; CELLS	Transcription factors of the Myc proto-oncogene family promote cell division, but how they do this is poorly understood. Here we address the functions of Drosophila Myc (dMyc) during development. Using mosaic analysis in the fly wing, we show that loss of dMyc retards cellular growth (accumulation of cell mass) and reduces cell size, whereas dMyc overproduction increases growth rates and cell size, dMyc-induced growth promotes G1/S progression but fails to accelerate cell division because G2/M progression is independently controlled by Cdc25/String. We also show that the secreted signal Wingless patterns growth in the wing primordium by modulating dMyc expression. Our results indicate that dMyc links patterning signals to cell division by regulating primary targets involved in cellular growth and metabolism.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373, R01GM051186] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017373, F32 GM017373-03, R01 GM051186, F32 GM017373-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Ashburner M., 1989, DROSOPHILA LAB HDB; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Lehman DA, 1999, DEVELOPMENT, V126, P1793; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McCabe J, 1997, GENET RES, V69, P61, DOI 10.1017/S0016672397002620; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Milan M, 1996, P NATL ACAD SCI USA, V93, P11687, DOI 10.1073/pnas.93.21.11687; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; Stern DL, 1999, DEVELOPMENT, V126, P1091; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; XU T, 1993, DEVELOPMENT, V117, P1223; Zaffran S, 1998, DEVELOPMENT, V125, P3571; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	57	508	517	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					779	790		10.1016/S0092-8674(00)81512-3	http://dx.doi.org/10.1016/S0092-8674(00)81512-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499795	Green Accepted, Bronze			2022-12-28	WOS:000082679200005
J	Dunne, MW; Bozzette, S; McCutchan, JA; Dube, MP; Sattler, FR; Forthal, D; Kemper, CA; Havlir, D				Dunne, MW; Bozzette, S; McCutchan, JA; Dube, MP; Sattler, FR; Forthal, D; Kemper, CA; Havlir, D		California Collaborative Treatment Grp	Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial	LANCET			English	Article							MYCOBACTERIUM-AVIUM COMPLEX; AEROSOLIZED PENTAMIDINE; DAPSONE-PYRIMETHAMINE; PRIMARY PROPHYLAXIS; HIV-INFECTION; AIDS; SULFAMETHOXAZOLE; CLARITHROMYCIN; TOXOPLASMOSIS; TRIMETHOPRIM	Background Azithromycin in combination with sulphonamides is active against Pneumocystis carinii pneumonia (PCP) in animals. We assessed the clinical efficacy of azithromycin for PCP prophylaxis in human beings. Methods We identified HIV-1-infected patients with PCP during a prospective randomised trial comparing azithromycin, rifabutin, and the two drugs in combination for prevention of disseminated Mycobacterim avium infection. Patients had CD4-cell counts less than 100/mu L at entry and received PCP prophylaxis according to the standard practice of their clinician. Analysis was by intention to treat. Findings Patients receiving azithromycin, either alone (n=233) or in combination with rifabutin (n=224), had a 45% lower risk of developing PCP than those receiving rifabutin alone (n=236; p=0.008). Compared with rifabutin alone, hazard ratio for azithromycin was 0.54 (95% CI 0.32-0.94), for azithromycin plus rifabutin was 0.55 (0.32-0.94), and for regimens containing azithromycin was 0.55 (0.35-0.86). The most common side-effects involved the gastrointestinal tract with dose-limiting toxicities, and were mainly seen in patients receiving combination therapy. Interpretation Azithromycin as prophylaxis for M avium complex disease provides additional protection against P carinii over and above that of standard PCP prophylaxis, Use of azithromycin is beneficial only as primary prophylaxis.	Pfizer Inc, Cent Res, Groton, CT 06340 USA; Vet Adm Med Ctr, La Jolla, CA 90034 USA; Rand Corp, Hlth Sci Program, Santa Monica, CA USA; Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA; Univ Calif Irvine, Irvine, CA 92717 USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA	Pfizer; US Department of Veterans Affairs; Veterans Health Administration (VHA); RAND Corporation; University of Southern California; University of California System; University of California Irvine; Santa Clara Valley Medical Center	Dunne, MW (corresponding author), Pfizer Inc, Cent Res, Eastern Point Rd, Groton, CT 06340 USA.	dunnem@pfizer.com	Dunne, Michael W/AAD-7418-2020	Dunne, Michael W/0000-0001-6186-5196				ALDER J, 1994, J ANTIMICROB CHEMOTH, V33, P253, DOI 10.1093/jac/33.2.253; ANTINORI A, 1995, AIDS, V9, P1343, DOI 10.1097/00002030-199512000-00007; Apseloff G, 1998, J CLIN PHARMACOL, V38, P830; ARAUJO FG, 1992, EUR J CLIN MICROBIOL, V11, P71, DOI 10.1007/BF01971278; BACELLAR H, 1994, J INFECT DIS, V170, P1284, DOI 10.1093/infdis/170.5.1284; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; *CDCP, 1995, HIV AIDS SURVEILLANC, V7, P1; CHAVE JP, 1992, ANTIMICROB AGENTS CH, V36, P1013, DOI 10.1128/AAC.36.5.1013; CYNAMON MH, 1992, ANTIMICROB AGENTS CH, V36, P1611, DOI 10.1128/AAC.36.8.1611; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FLAHERTY J, 1996, 3 INT C MACR AZ STRE; FOULDS G, 1996, 3 INT C MACR AZ STRE; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; HARRIS S, 1995, CLIN PHARMACOL THER, V58, P310, DOI 10.1016/0009-9236(95)90247-3; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; HONIG PK, 1994, DRUG INVEST, V7, P148, DOI 10.1007/BF03258467; HUGHES WT, 1991, J PROTOZOOL, V38, pS160; HUGHES WT, 1991, J ACQ IMMUN DEF SYND, V4, P532; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; KAPLAN JE, 1995, CLIN INFECT DIS, V21, pS12, DOI 10.1093/clinids/21.Supplement_1.S12; Masur H, 1996, ANN INTERN MED, V124, P451, DOI 10.7326/0003-4819-124-4-199602150-00011; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; NIELSEN TL, 1995, SCAND J INFECT DIS, V27, P217, DOI 10.3109/00365549509019012; Oldfield EC, 1998, CLIN INFECT DIS, V26, P611, DOI 10.1086/514566; PODZAMCZER D, 1995, ANN INTERN MED, V122, P755, DOI 10.7326/0003-4819-122-10-199505150-00004; SAAH AJ, 1995, JAMA-J AM MED ASSOC, V273, P1197, DOI 10.1001/jama.273.15.1197; SMITH JW, 1990, 6 INT S INF IMM HOST; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W	31	23	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					891	895		10.1016/S0140-6736(98)10328-8	http://dx.doi.org/10.1016/S0140-6736(98)10328-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489947				2022-12-28	WOS:000082511800010
J	Fuchs, E; Yang, YM				Fuchs, E; Yang, YM			Crossroads can cytoskeletal highways	CELL			English	Review							INTERMEDIATE FILAMENTS; PROTEIN; DROSOPHILA; PLECTIN; KAKAPO; STABILIZATION; MICROTUBULES; BINDING; NEURONS; CELLS		Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	lain@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016					Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; Heil-Chapdelaine RA, 1999, J CELL BIOL, V144, P809, DOI 10.1083/jcb.144.5.809; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Strumpf D, 1998, J CELL BIOL, V143, P1259, DOI 10.1083/jcb.143.5.1259; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Vaughan KT, 1999, J CELL SCI, V112, P1437; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	20	100	104	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					547	550		10.1016/S0092-8674(00)80041-0	http://dx.doi.org/10.1016/S0092-8674(00)80041-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490093	Bronze			2022-12-28	WOS:000082433500001
J	Krafft, A; Breymann, C; Huttner, C; Huch, R; Huch, A				Krafft, A; Breymann, C; Huttner, C; Huch, R; Huch, A			Erythropoietic quality of maternal milk	LANCET			English	Letter									Univ Zurich, Dept Obstet & Gynaecol, Clin Obstet, CH-8091 Zurich, Switzerland; Univ Zurich, Div Perinatal Physiol, CH-8091 Zurich, Switzerland	University of Zurich; University of Zurich	Krafft, A (corresponding author), Univ Zurich, Dept Obstet & Gynaecol, Clin Obstet, CH-8091 Zurich, Switzerland.							Ballin A, 1999, LANCET, V353, P1849, DOI 10.1016/S0140-6736(99)01222-2; Breymann C, 1996, EUR J CLIN INVEST, V26, P123, DOI 10.1046/j.1365-2362.1996.109261.x; CARMICHAEL RD, 1992, ENDOCR REGUL, V26, P863; Kling PJ, 1998, PEDIATR RES, V43, P216, DOI 10.1203/00006450-199802000-00010	4	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					778	778		10.1016/S0140-6736(05)76022-0	http://dx.doi.org/10.1016/S0140-6736(05)76022-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475225	Bronze			2022-12-28	WOS:000082233000065
J	Clayton, RN				Clayton, RN			Perspectives: Planetary science - Primordial water	SCIENCE			English	Editorial Material							CHONDRITES		Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA	University of Chicago	Clayton, RN (corresponding author), Univ Chicago, Enrico Fermi Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.							Brearley AJ, 1999, SCIENCE, V285, P1380, DOI 10.1126/science.285.5432.1380; CLAYTON RN, 1984, EARTH PLANET SC LETT, V67, P151, DOI 10.1016/0012-821X(84)90110-9; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; OLSEN EJ, 1981, EARTH PLANET SC LETT, V56, P82, DOI 10.1016/0012-821X(81)90118-7; Wiens RC, 1999, METEORIT PLANET SCI, V34, P99, DOI 10.1111/j.1945-5100.1999.tb01735.x; Zolensky ME, 1999, SCIENCE, V285, P1377, DOI 10.1126/science.285.5432.1377	6	2	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1364	1365		10.1126/science.285.5432.1364	http://dx.doi.org/10.1126/science.285.5432.1364			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10490412				2022-12-28	WOS:000082233500029
J	Woodman, GF; Luck, SJ				Woodman, GF; Luck, SJ			Electrophysiological measurement of rapid shifts of attention during visual search	NATURE			English	Article								The perception of natural visual scenes that contain many objects poses computational problems that are absent when objects are perceived in isolation(1). Vision researchers have captured this attribute of real-world perception in the laboratory by using visual search tasks, in which subjects search for a target object in arrays containing varying numbers of non-target distracter objects. Under many conditions, the amount of time required to detect a visual search target increases as the number of objects in the stimulus array increases, and some investigators have proposed that this reflects the serial application of attention to the individual objects in the array(2,3). However, other investigators have argued that this pattern of results may instead be due to limitations in the processing capacity of a parallel processing system that identifies multiple objects concurrently(4,5), Here we attempt to address this longstanding controversy by using an electrophysiological marker of the moment-by-moment direction of attention-the N2pc component of the event-related potential waveform-to show that attention shifts rapidly among objects during visual search.	Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA	University of Iowa	Luck, SJ (corresponding author), Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA.							BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523; CARRASCO M, 1995, PERCEPT PSYCHOPHYS, V57, P1241, DOI 10.3758/BF03208380; DUNCAN J, 1994, NATURE, V369, P313, DOI 10.1038/369313a0; Luck SJ, 1997, COGNITIVE PSYCHOL, V33, P64, DOI 10.1006/cogp.1997.0660; LUCK SJ, 1994, J EXP PSYCHOL HUMAN, V20, P1000, DOI 10.1037/0096-1523.20.5.1000; LUCK SJ, 1994, PSYCHOPHYSIOLOGY, V31, P291, DOI 10.1111/j.1469-8986.1994.tb02218.x; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; Mozer M., 1991, PERCEPTION MULTIPLE; TOWNSEND JT, 1990, PSYCHOL SCI, V1, P46, DOI 10.1111/j.1467-9280.1990.tb00067.x; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774; Wolfe JM, 1998, PERCEPT PSYCHOPHYS, V60, P140, DOI 10.3758/BF03211924; Wolfe JM, 1998, PSYCHOL SCI, V9, P33, DOI 10.1111/1467-9280.00006	13	424	430	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					867	869		10.1038/23698	http://dx.doi.org/10.1038/23698			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	230CA	10476964	Green Published			2022-12-28	WOS:000082233200044
J	Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL			Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED ADULTS; ALZHEIMERS-DISEASE; MENTAL-HEALTH; BURDEN; CANCER; NEEDS	Background In addition to medical care, dying patients often need many types of assistance, including help with transportation, nursing care, homemaking services, and personal care. We interviewed terminally ill adults and their care givers in six randomly selected areas of the United States (five metropolitan areas and one rural county) to determine how their needs for assistance were met and the frequency with which they received such assistance from family members and paid and volunteer care givers. Methods The patients, whose physicians estimated them to have less than six months to live and who had clinically significant illness other than human immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the study by their physicians. Of the 1131 eligible patients, 988 (87.4 percent) consented to a detailed in-person interview conducted in English, as did 893 of the 915 eligible primary care givers (97.6 percent). Results Of the 988 terminally ill patients, 59.4 percent: were over the age of 65 years, and 51.5 percent were women; The most frequent terminal illness was cancer (in 51.8 percent of the patients), followed by heart disease (18.0 percent) and chronic obstructive pulmonary disease (10.9 percent). Four percent of the patients were in an institution, such as a nursing home, residential hospice, or hospital; the rest were living in a private residence. A need for assistance was reported by 86.8 percent of the patients; they required help with transportation (reported by 62.0 percent), homemaking services (55.2 percent), nursing care (28.7 percent), and personal care (26.0 percent). Of the care givers, 72.1 percent were women. Primary care givers were family members in 96.0 percent of cases; only 4.0 percent were unrelated. Most patients relied completely on family members and friends for assistance. A total of 15.5 percent of patients relied only on paid assistance for more than half of the types of care that they needed. Volunteers (that is, unpaid helpers who were not family members or friends) provided less than 3 percent of all care. Conclusions In our survey of terminally ill patients, family members, usually women, provided the majority of assistance with nonmedical care. Although many people received assistance from paid care givers, very few had assistance from volunteers; (N Engl J Med 1999;341:956-63.) (C) 1999, Massachusetts Medical Society.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Ctr, Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Vital Sci & Hlth, Newtonville, MA USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA.							BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ., 1997, APPROACHING DEATH IM, P50; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HEINRICH RL, 1984, J CLIN PSYCHOL, V40, P972, DOI 10.1002/1097-4679(198407)40:4<972::AID-JCLP2270400417>3.0.CO;2-W; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; JOHNSON CL, 1983, GERONTOLOGIST, V23, P612, DOI 10.1093/geront/23.6.612; KISSANE DW, 1994, PSYCHO-ONCOLOGY, V3, P47, DOI DOI 10.1002/P0N.2960030109; Kleinbaum D, 1988, APPL REGRESSION ANAL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MAX W, 1995, J AGING HEALTH, V7, P179, DOI 10.1177/089826439500700202; Meyer H, 1997, HOSP HEALTH NETWORK, V71, P26; MOR V, 1987, Journal of Psychosocial Oncology, V5, P1, DOI 10.1300/J077v05n01_01; PRUCHNO RA, 1989, J AM GERIATR SOC, V37, P697, DOI 10.1111/j.1532-5415.1989.tb02230.x; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; US Bureau of the Census, 1998, STAT ABSTR US 1998; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Ware JE, 1993, SF36 HLTH SURVEY MAN; Zubrod C.G., 1960, J CHRON DIS, V11, P7; 1998, WASHINGTON POST 0304, pA13; [No title captured]	30	240	246	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					956	963		10.1056/NEJM199909233411306	http://dx.doi.org/10.1056/NEJM199909233411306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498492				2022-12-28	WOS:000082658100006
J	Ho, MT; Chen, ER; Hsu, KH; Twu, SJ; Chen, KT; Tsai, SF; Wang, JR; Shih, SR				Ho, MT; Chen, ER; Hsu, KH; Twu, SJ; Chen, KT; Tsai, SF; Wang, JR; Shih, SR		Taiwan Enterovirus Epidemic Working Grp	An epidemic of enterovirus 71 infection in Taiwan	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROGENIC PULMONARY-EDEMA; CENTRAL NERVOUS-SYSTEM; MOUTH-DISEASE; ENCEPHALOMYELITIS; HAND; FOOT	Background Enteroviruses can cause outbreaks of hand-foot-and-mouth disease (characterized by vesicular lesions on the hands, feet, and oral mucosa) or herpangina, usually without life-threatening manifestations. In 1998 an epidemic of enterovirus 71 infection caused hand-foot-and-mouth disease and herpangina in thousands of people in Taiwan, some of whom died. Methods We assessed the epidemiologic aspects of this outbreak. Cases of hand-foot-and-mouth disease or herpangina in ambulatory patients were reported to the Taiwan Department of Health by a mean of 818 sentinel physicians. Severe cases in hospitalized patients were reported by 40 medical centers and regional hospitals. Viruses were isolated by 10 hospital laboratories and the department of health. Results The sentinel physicians reported 129,106 cases of hand-foot-and-mouth disease or herpangina in two waves of the epidemic, which probably represents less than 10 percent of the estimated total number of cases. There were 405 patients with severe disease, most of whom were five years old or younger; severe disease was seen in all regions of the island. Complications included encephalitis, aseptic meningitis, pulmonary edema or hemorrhage, acute flaccid paralysis, and myocarditis. Seventy-eight patients died, 71 of whom (91 percent) were five years of age or younger. Of the patients who died, 65 (83 percent) had pulmonary edema or pulmonary hemorrhage. Among patients from whom a virus was isolated, enterovirus 71 was present in 48.7 percent of outpatients with uncomplicated hand-foot-and-mouth disease or herpangina, 75 percent of hospitalized patients who survived, and 92 percent of patients who died. Conclusions Although several enteroviruses were circulating in Taiwan during the 1998 epidemic, enterovirus 71 infection was associated with most of the serious clinical manifestations and with nearly all the deaths. Most of those who died were young, and the majority died of pulmonary edema and pulmonary hemorrhage. (N Engl J Med 1999;341:929-35.) (C) 1999. Massachusetts Medical Society.	Natl Hlth Res Inst, Div Clin Res, Taipei 115, Taiwan; Natl Dept Hlth, Taipei, Taiwan; Natl Cheng Kung Univ, Med Ctr, Virus Lab, Tainan 70101, Taiwan; Chang Gung Med Ctr, Virus Lab, Lin Ko, Taiwan	National Health Research Institutes - Taiwan; National Cheng Kung University; Chang Gung Memorial Hospital	Ho, MT (corresponding author), Natl Hlth Res Inst, Div Clin Res, 128 Yen Chiu Yuan Rd,Sect 2, Taipei 115, Taiwan.		Wang, Jen-Ren/F-5254-2011; Shih, Shin-Ru/M-9711-2016	Chen, Kow-Tong/0000-0001-9129-7054; Shih, Shin-Ru/0000-0003-4874-401X; Wang, Jen-Ren/0000-0002-4127-4046				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; BAKER AB, 1957, NEUROLOGY, V7, P743, DOI 10.1212/WNL.7.11.743; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; *DEP ENV, 1995, POL GUID COAST, P65; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; Landry ML, 1995, PEDIATR INFECT DIS J, V14, P1095, DOI 10.1097/00006454-199512000-00013; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; MODLIN JF, 1995, PRINCIPLES PRACTICE, P1621; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321; 1998, MMWR MORB MORTAL WKL, V47, P718	17	941	1106	2	123	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					929	935		10.1056/NEJM199909233411301	http://dx.doi.org/10.1056/NEJM199909233411301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498487				2022-12-28	WOS:000082658100001
J	deShazo, RD; Williams, DF; Moak, ES				deShazo, RD; Williams, DF; Moak, ES			Fire ant attacks on residents in health care facilities: A report of two cases	ANNALS OF INTERNAL MEDICINE			English	Article							SOLENOPSIS-INVICTA; STINGS; HYPERSENSITIVITY; VENOM; HYMENOPTERA; INDOORS	Background: Imported fire ants now infest more than 310 million acres in the United States and Puerto Rico. Colonies have been found in Arizona, California, New Mexico, and Virginia. Available reports suggest that each year, fire ants sting more than 50% of persons in endemic areas, resulting in a variety of medical consequences. Objective: To describe fire ant attacks among patients in health care facilities. Design: Case series and literature review. Setting: Two nursing homes in Mississippi. Patients: Two nursing home residents. Measurements: Clinical records to describe clinical sequelae of multiple stings. Results: With the 2 incidents reported here, the total number of reported indoor fire ant attacks on humans since 1989 is 10. Six of the persons attacked, including the 2 nursing home residents described here (who died after the stings), had preexisting neurologic impairment. Eight of the 10 attacks have been reported in the past 4 years. Conclusions: The presence of fire ants in occupied dwellings indicates the presence of active fire ant colonies in the immediate proximity. Efforts to eradicate these insects should be undertaken immediately, especially if immobile persons are present. These persons should be considered at risk for fire ant attacks as long as the ants are present.	Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA; USDA ARS, Ctr Med Agr & Vet Entomol, Gainesville, FL 32604 USA	University of Mississippi; University of Mississippi Medical Center; United States Department of Agriculture (USDA)	deShazo, RD (corresponding author), Univ Mississippi, Med Ctr, Dept Med, CSB6,2500 N State St, Jackson, MS 39216 USA.							Adams C.T., 1986, P48; Amador M, 1998, J PEDIAT OPHTH STRAB, V35, P55; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; DESHAZO RD, 1994, J ALLERGY CLIN IMMUN, V93, P847, DOI 10.1016/0091-6749(94)90376-X; DESHAZO RD, 1995, SOUTHERN MED J, V88, P712, DOI 10.1097/00007611-199507000-00003; DESHAZO RD, 1995, SOUTHERN MED J, V88, P1181, DOI 10.1097/00007611-199511000-00025; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; DIAZ JD, 1989, SOUTH MED J, V82, P775, DOI 10.1097/00007611-198906000-00026; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; HARDWICK WE, 1992, PEDIATRICS, V90, P622; HOFFMAN DR, 1995, ALLERGY, V50, P535, DOI 10.1111/j.1398-9995.1995.tb01196.x; King TP, 1996, TOXICON, V34, P1455, DOI 10.1016/S0041-0101(96)00088-8; MACKAY WP, 1992, J KANSAS ENTOMOL SOC, V65, P39; PARINO J, 1981, SOUTH MED J, V74, P1361; PORTER SD, 1992, J ECON ENTOMOL, V85, P1155; PORTER SD, 1993, J ECON ENTOMOL, V86, P1344, DOI 10.1093/jee/86.5.1344; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; SMITH JD, 1971, ARCH DERMATOL, V103, P438, DOI 10.1001/archderm.103.4.438; SORENSEN AA, 1985, BEHAV ECOL SOCIOBIOL, V17, P191, DOI 10.1007/BF00300136; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; Tschinkel W.R., 1986, P72; Vinson S. Bradleigh, 1997, American Entomologist, V43, P23; WILLIAMS DF, 1994, WESTV STUD, P282; WILLIAMS DF, 1983, FLA ENTOMOL, V66, P162, DOI 10.2307/3494561; [No title captured]	27	51	55	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					424	429		10.7326/0003-4819-131-6-199909210-00005	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498558				2022-12-28	WOS:000082641100004
J	Edwards, A; Elwyn, G; Gwyn, R				Edwards, A; Elwyn, G; Gwyn, R			General practice registrar responses to the use of different risk communication tools in simulated consultations: a focus group study	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE PROFESSIONALS; DECISIONS; INFORMATION; THERAPY; DISEASE	Objectives To pilot the use of a range of complementary risk communication tools in simulated general practice consultations; to gauge the responses of general practitioners in training to these new consultation aids. Design Qualitative study based on focus group discussions. Setting General practice vocational training schemes in South Wales. Participants 39 general practice registrars and eight course organisers attended four sessions; three simulated patients attended each time. Method Registrars consulting with simulated patients used verbal or "qualitative" descriptions of risks, then numerical data, and finally graphical presentations of the same data. Responses of doctors and patients were explored by semistructured discussions that had been audiotaped for transcription and analysis. Results The process of using risk communication tools in simulated consultations was acceptable to general practitioner registrars. Providing doctors with information about risks and benefits of treatment options was generally well received. Both doctors and patients found it helped communication. There were concerns about the lack of available, unbiased, and applicable evidence and a shortage of time in the consultation to discuss treatment options adequately Graphical presentation of information was often favoured-an approach that also has the potential to save consultation time. Conclusions A range of risk communication "tools" with which to discuss treatment options is likely to be more applicable than a single ne rv strategy. These tools should include both absolute and relative risk information formats, presented in an unbiased way. Using risk communication tools in simulated consultations provides a model for training in risk communication for professional groups.	Univ Wales, Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales; Univ Wales, Coll Med, Dept Postgrad Educ Gen Practice, Cardiff CF4 4XN, S Glam, Wales; Univ Wales, Coll Med, Dept Gen Practice, Cardiff CF4 4XN, S Glam, Wales; Cardiff Univ, Hlth Commun Res Ctr, Sch English Commun & Philosophy, Cardiff CF1 3XB, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University; Cardiff University	Edwards, A (corresponding author), Univ Wales, Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales.		Elwyn, Glyn/B-4798-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; 				ASBURY JE, 1995, QUAL HEALTH RES, V5, P414, DOI 10.1177/104973239500500402; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; Edwards A, 1998, FAM PRACT, V15, P296, DOI 10.1093/fampra/15.4.296; Edwards A, 1998, FAM PRACT, V15, P301, DOI 10.1093/fampra/15.4.301; EDWARDS AGK, 1998, SYSTEMATIC REV RISK; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; Elwyn G, 1999, BRIT MED J, V319, P753, DOI 10.1136/bmj.319.7212.753; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; Frankland J, 1997, USE FOCUS GROUPS HLT, P144; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN CJ, 1995, ANTICOAGULATION STRO; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; INGLIS S, 1993, ANAESTH INTENS CARE, V21, P799, DOI 10.1177/0310057X9302100609; KINNERSLEY P, 1993, BRIT J GEN PRACT, V43, P297; Kuhberger A, 1998, ORGAN BEHAV HUM DEC, V75, P23, DOI 10.1006/obhd.1998.2781; Liao L, 1996, J GEN INTERN MED, V11, P373, DOI 10.1007/BF02600051; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; MAZUR DJ, 1997, J GEN INTERN MED, V12, P112; Rothman AJ, 1997, PSYCHOL BULL, V121, P3, DOI 10.1037/0033-2909.121.1.3; WILSON D K, 1988, Health Education Research, V3, P161, DOI 10.1093/her/3.2.161; 1995, EFFECTIVE HLTH CARE, P1	23	50	51	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					749	752		10.1136/bmj.319.7212.749	http://dx.doi.org/10.1136/bmj.319.7212.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488001	Bronze, Green Published			2022-12-28	WOS:000082701500020
J	Macaulay, AC; Commanda, LE; Freeman, WL; Gibson, N; McCabe, ML; Robbins, CM; Twohig, PL				Macaulay, AC; Commanda, LE; Freeman, WL; Gibson, N; McCabe, ML; Robbins, CM; Twohig, PL		N Amer Primary Care Res Grp	Participatory research maximises community and lay involvement	BRITISH MEDICAL JOURNAL			English	Article							PREVENTION PROGRAM; NATIVE COMMUNITY; PUBLIC-HEALTH; EMPOWERMENT; PROJECT		McGill Univ, SMBD Jewish Gen Hosp, Herzl Family Practice Ctr, Dept Family Med, Montreal, PQ H3T 1E2, Canada; Serpent River First Nat, Cutler, ON P0P 1BO, Canada; Publ Hlth Serv, Indian Hlth Serv, Res Program, Albuquerque, NM 87110 USA; Univ Alberta, Dept Human Ecol, Edmonton, AB T6G 2N1, Canada; Univ New Mexico, Dept Family & Community Med, Albuquerque, NM 87131 USA; Dalhousie Univ, Dept Family Med, Halifax, NS B3H 2E2, Canada	McGill University; United States Public Health Service; University of Alberta; University of New Mexico; Dalhousie University	Macaulay, AC (corresponding author), McGill Univ, SMBD Jewish Gen Hosp, Herzl Family Practice Ctr, Dept Family Med, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.							[Anonymous], 1993, VOICES CHANGE PARTIC; *ASS CAN U NO STUD, 1997, ETH PRINC COND RES N; Bray GA, 1999, DIABETES CARE, V22, P623; BROWN LD, 1983, J APPL BEHAV SCI, V19, P277, DOI 10.1177/002188638301900306; Centers for Disease Control and Prevention Agency for Toxic Substances and Disease Registry Committee on Community Engagement, 1997, PRINC COMM ENG; Daniel M, 1999, SOC SCI MED, V48, P815, DOI 10.1016/S0277-9536(98)00403-1; Entwistle VA, 1998, BRIT MED J, V316, P463, DOI 10.1136/bmj.316.7129.463; Fisher B, 1999, BRIT MED J, V318, P749, DOI 10.1136/bmj.318.7186.749; FREEMAN WL, 1998, STORED TISSUE SAMPLE; Green L, 1994, STUDY PARTICIPATORY; Herbert CP, 1996, CAN J PUBLIC HEALTH, V87, P109; ISRAEL B, 1992, J APPL BEHAV SCI, V28, P78; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; LABONTE R, 1994, HEALTH EDUC QUART, V21, P253, DOI 10.1177/109019819402100209; Lindqvist K, 1996, PUBLIC HEALTH, V110, P339, DOI 10.1016/S0033-3506(96)80005-9; Macaulay AC, 1998, CAN J PUBLIC HEALTH, V89, P105, DOI 10.1007/BF03404399; Macaulay AC, 1997, PREV MED, V26, P779, DOI 10.1006/pmed.1997.0241; Matsunaga Doris Segal, 1996, Cancer, V78, P1582, DOI 10.1002/(SICI)1097-0142(19961001)78:7+<1582::AID-CNCR11>3.3.CO;2-U; *NAT HLTH MRC AUST, 1991, GUID ETH MATT AB TOR; PLOUGH A, 1994, HEALTH EDUC QUART, V21, P221, DOI 10.1177/109019819402100207; QUIGLEY V, IN PRESS J HLTH COMM; Rispel L, 1996, HEALTH POLICY PLANN, V11, P385, DOI 10.1093/heapol/11.4.385; Smith SE, 1997, NURTURED KNOWLEDGE L; Travers KD, 1997, HEALTH EDUC BEHAV, V24, P344, DOI 10.1177/109019819702400307; Wax Murray L, 1991, Am Indian Q, V15, P431, DOI 10.2307/1185363; Willms D, 1996, CAN J PUBLIC HEALTH, V87, pS15	26	349	351	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					774	778		10.1136/bmj.319.7212.774	http://dx.doi.org/10.1136/bmj.319.7212.774			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	238GA	10488012	Green Published			2022-12-28	WOS:000082701500031
J	Towle, A; Godolphin, W				Towle, A; Godolphin, W			Framework for teaching and learning informed shared decision making	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-PATIENT COMMUNICATION; HEALTH-CARE; INFORMATION; DOCTOR; OUTCOMES; IMPACT; CHOICE; SKILLS; TRIAL; RISK		Univ British Columbia, Fac Med, Vancouver, BC V5Z 4E3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Towle, A (corresponding author), Univ British Columbia, Fac Med, Vancouver, BC V5Z 4E3, Canada.		Greenhalgh, Trisha/B-1825-2015; Godolphin, William/AAE-2699-2022	Greenhalgh, Trisha/0000-0003-2369-8088; 				ANDERSON LA, 1991, PATIENT EDUC COUNS, V17, P99, DOI 10.1016/0738-3991(91)90014-V; Bottorff JL, 1998, PATIENT EDUC COUNS, V33, P67, DOI 10.1016/S0738-3991(97)00047-5; BRODY DS, 1980, ANN INTERN MED, V93, P718, DOI 10.7326/0003-4819-93-5-718; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; COULTER A, 1998, INFORMING PATIENTS A; Deber R B, 1993, TREATMENT INFERTILIT, P341; *DEP HLTH, 1998, REP IND REV GROUP SI; Doyal L., 1996, ESSENTIAL PRACTICE P, P198; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Entwistle VA, 1998, INT J TECHNOL ASSESS, V14, P212, DOI 10.1017/S0266462300012204; Etchells E, 1996, CAN MED ASSOC J, V155, P387; FENWICK P, 1996, MED LAW, V16, P215; Fisher R., 2011, GETTING YES NEGOTIAT; Gore J, 1998, BRIT J GEN PRACT, V48, P1391; Greenhalgh T, 1996, BRIT MED J, V313, P957; Hibbard JH, 1997, MILBANK Q, V75, P395, DOI 10.1111/1468-0009.00061; Hope T., 1996, EVIDENCE BASED PATIE; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; MAKOUL G, 1995, SOC SCI MED, V41, P1241, DOI 10.1016/0277-9536(95)00061-B; McAshan H. H., 1979, COMPETENCY BASED ED; Milne R, 1996, INT J QUAL HEALTH C, V8, P439, DOI 10.1093/intqhc/8.5.439; OCONNOR A, 1989, NURSING DIAGNOSIS IN; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Sackett D. L., 1997, EVIDENCE BASED MED P; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SLOAN MR, 1982, READINGS COMMUNITY H, P197; STEWART M, 1989, CAN FAM PHYSICIAN, V35, P159; Stewart M, 1999, Cancer Prev Control, V3, P25; Stewart M, 1995, PATIENT CTR MED TRAN; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; STREET RL, 1991, SOC SCI MED, V32, P541, DOI 10.1016/0277-9536(91)90288-N; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; Tuckett D., 1985, M EXPERTS APPROACH S; Vertinsky I B, 1974, Health Serv Res, V9, P121	40	435	442	3	37	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					766	769		10.1136/bmj.319.7212.766	http://dx.doi.org/10.1136/bmj.319.7212.766			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488010	Green Published			2022-12-28	WOS:000082701500027
J	Poglitsch, CL; Meredith, GD; Gnatt, AL; Jensen, GJ; Chang, WH; Fu, JH; Kornberg, RD				Poglitsch, CL; Meredith, GD; Gnatt, AL; Jensen, GJ; Chang, WH; Fu, JH; Kornberg, RD			Electron crystal structure of an RNA polymerase II transcription elongation complex	CELL			English	Article							3-DIMENSIONAL STRUCTURE; 2-DIMENSIONAL CRYSTALS; ESCHERICHIA-COLI; DNA; CRYSTALLOGRAPHY; MICROSCOPY; CRYSTALLIZATION; BINDING; SITE; CONFORMATIONS	The structure of an actively transcribing complex, containing yeast RNA polymerase II with associated template DNA and product RNA, was determined by electron crystallography. Nucleic acid, in all likelihood the "transcription bubble" at the active center of the enzyme, occupies a previously noted 25 Angstrom channel in the protein structure. Details are indicative of a roughly 90 degrees bend of the DNA between upstream and downstream regions. The DNA apparently lies entirely on one face of the polymerase, rather than passing through a hole to the opposite side, as previously suggested.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.		Chang, Wei-Hau/F-1965-2015	Chang, Wei-Hau/0000-0002-2612-850X	NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM07365, 2T32GM082494] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Asturias FJ, 1998, ULTRAMICROSCOPY, V70, P133, DOI 10.1016/S0304-3991(97)00108-3; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; ASTURIAS FJ, 1995, J STRUCT BIOL, V114, P60, DOI 10.1006/jsbi.1995.1005; Asturias FJ, 1999, J BIOL CHEM, V274, P6813, DOI 10.1074/jbc.274.11.6813; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)80223-H; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fu JH, 1998, J MOL BIOL, V280, P317, DOI 10.1006/jmbi.1998.1557; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hessler D, 1992, Neuroimage, V1, P55, DOI 10.1016/1053-8119(92)90007-A; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	42	56	56	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					791	798		10.1016/S0092-8674(00)81513-5	http://dx.doi.org/10.1016/S0092-8674(00)81513-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499796	Bronze			2022-12-28	WOS:000082679200006
J	Zengler, K; Richnow, HH; Rossello-Mora, R; Michaelis, W; Widdel, F				Zengler, K; Richnow, HH; Rossello-Mora, R; Michaelis, W; Widdel, F			Methane formation from long-chain alkanes by anaerobic microorganisms	NATURE			English	Article							MICROBIAL PROCESSES; HYDROCARBONS; DEGRADATION; ENRICHMENT; SEDIMENTS	Biological formation of methane is the terminal process of biomass degradation in aquatic habitats where oxygen, nitrate, ferric iron and sulphate have been depleted as electron accepters. The pathway leading from dead biomass to methane through the metabolism of anaerobic bacteria and archaea is well understood for easily degradable biomolecules such as carbohydrates, proteins and lipids(1,2). However, little is known about the organic compounds that lead to methane in old anoxic sediments where easily degradable biomolecules are no longer available. One class of naturally formed long-lived compounds in such sediments is the saturated hydrocarbons (alkanes)(3-5). Alkanes are usually considered to be inert in the absence of oxygen, nitrate or sulphate(6), and the analysis of alkane patterns is often used for biogeochemical characterization of sediments(7,8), However, alkanes might be consumed in anoxic sediments below the zone of sulphate reduction(9,10), but the underlying process has not been elucidated. Here we used enrichment cultures to show that the biological conversion of long-chain alkanes to the simplest hydrocarbon, methane, is possible under strictly anoxic conditions.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Univ Hamburg, Inst Biogeochem & Marine Chem, D-20146 Hamburg, Germany	Max Planck Society; University of Hamburg	Widdel, F (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	fwiddel@mpi-bremen.de	Rossello-Mora, Ramon/L-4650-2014; Richnow, Hans H./H-8523-2017; Richnow, Hans/AAD-9016-2022	Rossello-Mora, Ramon/0000-0001-8253-3107; Richnow, Hans H./0000-0002-6144-4129; Richnow, Hans/0000-0002-6144-4129; Zengler, Karsten/0000-0002-8062-3296				Albert DB, 1997, MAR CHEM, V56, P27, DOI 10.1016/S0304-4203(96)00083-7; BEIER JA, 1991, NATURE, V351, P642, DOI 10.1038/351642a0; Birch L., 1988, BIOTECHNOLOGY B, V6b, P71; BLUMER M, 1971, MAR BIOL, V8, P183, DOI 10.1007/BF00355214; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; Dojka MA, 1998, APPL ENVIRON MICROB, V64, P3869; EGLINTON G, 1968, ADV ORG GEOCHEM, V31, P1; GIGER W, 1980, GEOCHIM COSMOCHIM AC, V44, P119, DOI 10.1016/0016-7037(80)90182-9; HARDER J, IN PRESS GEOMICROBIO; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Heider J, 1998, FEMS MICROBIOL REV, V22, P459, DOI 10.1111/j.1574-6976.1998.tb00381.x; LIDE DR, 1998, HDB CHEM PHYSICS; LOVLEY DR, 1995, REV GEOPHYS, V33, P365, DOI 10.1029/95RG01305; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Martini AM, 1996, NATURE, V383, P155, DOI 10.1038/383155a0; MULLER FM, 1957, ANTON LEEUW INT J G, V23, P269; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Rowe D, 1999, NATURE, V398, P61, DOI 10.1038/18007; Rozanova EP, 1997, MICROBIOLOGY+, V66, P718; Schink B, 1997, MICROBIOL MOL BIOL R, V61, P262, DOI 10.1128/.61.2.262-280.1997; SCHINK B, 1985, FEMS MICROBIOL ECOL, V31, P69, DOI 10.1111/j.1574-6968.1985.tb01133.x; SCOTT AR, 1994, AAPG BULL, V78, P1186; Seiler W., 1980, ATMOS TECHNOL, V12, P40; SIMONEIT BRT, 1986, MAR GEOL, V70, P9, DOI 10.1016/0025-3227(86)90087-3; Tissot B.P., 1984, PETROLEUM FORMATION, DOI 10.1007/978-3-642-96446-6; WERSIN P, 1991, CHEM GEOL, V90, P233, DOI 10.1016/0009-2541(91)90102-W; Widdel F., 1992, PROKARYOTES, DOI 10.1007/978-1-4757-2191-1_2	28	454	490	2	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					266	269		10.1038/45777	http://dx.doi.org/10.1038/45777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499582				2022-12-28	WOS:000082678400050
J	Farrell, AM				Farrell, AM			Staphylococcal scalded-skin syndrome	LANCET			English	Editorial Material							EXFOLIATIVE TOXIN; EPIDERMOLYTIC TOXIN; SERINE-PROTEASE; AUREUS		John Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England	University of Oxford	Farrell, AM (corresponding author), John Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England.							Acland KM, 1999, BRIT J DERMATOL, V140, P518; CRIBIER B, 1994, J AM ACAD DERMATOL, V30, P319, DOI 10.1016/S0190-9622(94)70032-X; DANCER SJ, 1990, FEBS LETT, V268, P129, DOI 10.1016/0014-5793(90)80990-Z; ELSNER P, 1988, ZBL BAKT-INT J MED M, V268, P534; Farrell AM, 1996, BRIT J DERMATOL, V134, P962, DOI 10.1111/j.1365-2133.1996.tb06337.x; Kawabata A, 1997, J CLIN MICROBIOL, V35, P1984, DOI 10.1128/JCM.35.8.1984-1987.1997; Lina G, 1997, CLIN INFECT DIS, V25, P1369, DOI 10.1086/516129; Melish M.E., 1981, ZBL BAKT S, V10, P287; MELISH ME, 1972, J INFECT DIS, V125, P129, DOI 10.1093/infdis/125.2.129; Qasim W, 1998, ARCH DIS CHILD, V79, P290, DOI 10.1136/adc.79.3.290a; REDPATH MB, 1991, FEMS MICROBIOL LETT, V81, P151; SMITH TP, 1987, HISTOCHEM J, V19, P137, DOI 10.1007/BF01695138; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; WILEY BB, 1974, INFECT IMMUN, V9, P636, DOI 10.1128/IAI.9.4.636-640.1974	14	24	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					880	881		10.1016/S0140-6736(99)90120-4	http://dx.doi.org/10.1016/S0140-6736(99)90120-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489941				2022-12-28	WOS:000082511800004
J	Wessely, S; Nimnuan, C; Sharpe, M				Wessely, S; Nimnuan, C; Sharpe, M			Functional somatic syndromes: one or many?	LANCET			English	Review							UNEXPLAINED PHYSICAL SYMPTOMS; IRRITABLE-BOWEL-SYNDROME; CHRONIC FATIGUE SYNDROME; PSYCHIATRIC-DISORDERS; PRIMARY-CARE; SOMATIZATION; DISEASE; ILLNESS; WOMEN	We review the concept and importance of functional somatic symptoms and syndromes such as irritable bowel syndrome and chronic fatigue syndrome. On the basis of a literature review, we conclude that a substantial overlap exists between the individual syndromes and that the similarities between them outweigh the differences. Similarities are apparent in case definition, reported symptoms, and in non-symptom association such as patients' sex, outlook, and response to treatment. We conclude that the existing definitions of these syndromes in terms of specific symptoms is of limited value; instead we believe a dimensional classification is likely to be more productive.	Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland; Guys Kings & St Thomas Sch Med, Dept Psychol Med, London, England	Royal Infirmary of Edinburgh; University of Edinburgh; University of London; King's College London	Sharpe, M (corresponding author), Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Kennedy Tower, Edinburgh EH10 5HF, Midlothian, Scotland.	michael.sharpe@ed.ac.uk	Wessely, Simon C/A-8713-2008	sharpe, michael/0000-0002-6474-9980; Wessely, Simon Charles/0000-0002-6743-9929				Cleare AJ, 1999, LANCET, V353, P455, DOI 10.1016/S0140-6736(98)04074-4; CLONINGER CR, 1986, AM J PSYCHIAT, V143, P873; Deary IJ, 1999, J PSYCHOSOM RES, V47, P51; FINK P, 1992, PSYCHOL MED, V22, P173, DOI 10.1017/S0033291700032827; Halliday JL, 1943, LANCET, V2, P692; HALLIDAY JL, 1945, PSYCHOSOM MED, V7, P240, DOI 10.1097/00006842-194507000-00007; Hamilton J, 1996, J ROY COLL PHYS LOND, V30, P18; KISSEN DM, 1963, J NERV MENT DIS, V136, P34, DOI 10.1097/00005053-196301000-00004; Komaroff AL, 1996, AM J MED, V101, P281, DOI 10.1016/S0002-9343(96)00174-X; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; Kroenke K, 1994, Arch Fam Med, V3, P774; Martin L, 1996, J RHEUMATOL, V23, P1050; Mayou R, 1995, TREATMENT FUNCTIONAL; MELVILLE DI, 1987, J PSYCHOSOM RES, V31, P359, DOI 10.1016/0022-3999(87)90056-0; Peveler R, 1997, J PSYCHOSOM RES, V42, P245, DOI 10.1016/S0022-3999(96)00292-9; POTTS SG, 1995, PSYCHOL MED, V25, P339, DOI 10.1017/S0033291700036242; Robbins JM, 1997, J NERV MENT DIS, V185, P606, DOI 10.1097/00005053-199710000-00003; RUSSO J, 1994, PSYCHOSOMATICS, V35, P546, DOI 10.1016/S0033-3182(94)71723-0; Ryle JA, 1939, LANCET, V2, P297; Ryle JA, 1939, LANCET, V2, P407; Ryle JA, 1939, LANCET, V2, P353; SCORDO KA, 1991, AM J CARDIOL, V67, P863, DOI 10.1016/0002-9149(91)90620-Z; Sharpe M, 1995, TREATMENT OF FUNCTIONAL SOMATIC SYMPTOMS, P3; SHARPE M, 1992, International Review of Psychiatry, V4, P81, DOI 10.3109/09540269209066305; SHARPE M, 1994, Q J MED, V87, P187; SIMON GE, 1991, AM J PSYCHIAT, V148, P1494; VANHEMERT AM, 1993, PSYCHOL MED, V23, P167, DOI 10.1017/S0033291700038952; VANOUTRYVE M, 1995, J CLIN PHARM THER, V20, P277; WALKER EA, 1990, AM J PSYCHIAT, V147, P1656; Wessely S, 1996, AM J PSYCHIAT, V153, P1050; White PD, 1997, J PSYCHOSOM RES, V42, P329, DOI 10.1016/S0022-3999(96)00296-6	31	799	829	0	46	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					936	939		10.1016/S0140-6736(98)08320-2	http://dx.doi.org/10.1016/S0140-6736(98)08320-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489969				2022-12-28	WOS:000082511800042
J	Yeung, K; Seitz, T; Li, SF; Janosch, P; McFerran, B; Kaiser, C; Fee, F; Katsanakis, KD; Rose, DW; Mischak, H; Sedivy, JM; Kolch, W				Yeung, K; Seitz, T; Li, SF; Janosch, P; McFerran, B; Kaiser, C; Fee, F; Katsanakis, KD; Rose, DW; Mischak, H; Sedivy, JM; Kolch, W			Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP	NATURE			English	Article							CELL-CYCLE ARREST; DNA-SYNTHESIS; C-FOS; ACTIVATION; INHIBITION; BINDING; TRANSFORMATION; EXPRESSION; CASCADE; PURIFICATION	Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK), This kinase cascade controls the proliferation and differentiation of different cell types(1,2). Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein). In vitro, RKIP binds to Raf-1, MEK and ERK, but not to pas, RKIP co-immunoprecipitates with Raf-1 and MEK from cell lysates and colocalizes with Raf-1 when examined by confocal microscopy, RKIP is not a substrate for Raf-1 or MEK, but competitively disrupts the interaction between these kinases, RKIP overexpression interferes with the activation of MEK and ERK, induction of AP-1-dependent reporter genes and transformation elicited by an oncogenically activated Raf-1 kinase, Downregulation of endogenous RKIP by expression of antisense RNA or antibody microinjection induces the activation of MEK-, ERK- and AP-1-dependent transcription. RKIP represents a new class of protein-kinase-inhibitor protein that regulates the activity of the Raf/MEK/ERK module.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Richmond, RI 02912 USA; GSF Munich, Res Ctr Hlth & Environm, Inst Clin Mol Biol, D-81377 Munich, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Whittier Diabet Program, La Jolla, CA 92093 USA; Franz Volhard Klinikum, Max Delbruck Ctr, D-13122 Berlin, Germany	Beatson Institute; Brown University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of California System; University of California San Diego; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kolch, W (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	john_sedivy@brown.edu; wkolch@beatson.gla.ac.uk	Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Mischak, Harald/E-8685-2011	Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306				BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Kolch W, 1996, ONCOGENE, V13, P1305; KOLCH W, 1993, ONCOGENE, V8, P361; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RAPP UR, 1994, ONCOGENE, V9, P3493; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Tombes RM, 1998, BIOCHEM J, V330, P1451; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	26	678	743	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					173	177		10.1038/43686	http://dx.doi.org/10.1038/43686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490027	Green Accepted			2022-12-28	WOS:000082458800056
J	Paradise, JL; Bluestone, CD; Colborn, DK; Bernard, BS; Smith, CG; Rockette, HE; Kurs-Lasky, M				Paradise, JL; Bluestone, CD; Colborn, DK; Bernard, BS; Smith, CG; Rockette, HE; Kurs-Lasky, M			Adenoidectomy and adenotonsillectomy for recurrent acute otitis media - Parallel randomized clinical trials in children not previously treated with tympanostomy tubes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUE EAR; EFFICACY; TONSILLECTOMY; EFFUSION	Context Adenoidectomy and adenotonsillectomy are commonly performed in US children to reduce the occurrence of persistent or recurrent otitis media, but evidence supporting the efficacy of the operations is limited. Objectives To test the efficacy of adenoidectomy and adenotonsillectomy in children with persistent or recurrent otitis media who had not previously undergone tube placement and to compare the relative efficacy of adenoidectomy alone vs adenotonsillectomy in such children. Design Two parallel randomized clinical trials. Setting and Participants A total of 461 children aged 3 to 15 years were enrolled at Children's Hospital of Pittsburgh, Pa, between April 1980 and April 1994. Four hundred ten children were observed for up to 3 years. Interventions Children without recurrent throat infection or tonsillar hypertrophy (304 enrolled; 266 followed up) were randomized to either an adenoidectomy, adenotonsillectomy, or control group; children who had such conditions (157 enrolled; 144 followed up) were randomized to an adenotonsillectomy or control group. Main Outcome Measures Occurrence rate of episodes of acute otitis media by treatment group and estimated proportion of time with otitis media. Results In both trials, most subjects were eligible because of recurrent acute otitis media, with or without persistent otitis media with effusion. A total of 47 children assigned to surgical treatment groups had no surgery. The efficacy of surgery in both trials was modest and limited mainly to the first follow-up year. The largest differences in that year were found in the 3-way trial between the adenotonsilledomy group and the control group: mean annual rate of episodes of acute otitis media, 1.4 vs 2.1 (P<.001); and mean estimated percentage of time with otitis media, 18.6% vs 29.9% (difference, 11.3%; 95% confidence interval, 4.4%-18.2%; P = .002). Perioperative and postoperative complications or other adverse events occurred not infrequently, especially among subjects undergoing adenotonsillectomy (14.6%). Conclusions Our study showed limited and short-term efficacy of both adenoidectomy and adenotonsillectomy; given the risks, morbidity, and costs of these procedures, these data suggest that neither operation should ordinarily be considered as a first surgical intervention in children whose only indication is recurrent acute otitis media.	Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Audiol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Paradise, JL (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	jpar@pitt.edu			NIDCD NIH HHS [DC 00158] Funding Source: Medline; NINDS NIH HHS [NS 16337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016337] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*AM AC OT HEAD NEC, 1995, 1995 CLIN IND COMP G; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Arnold JE, 1996, NELSON TXB PEDIAT, P1804; BAKER RJ, 1985, GEN LINEAR INTERACTI, P1; Breslow N E, 1987, IARC Sci Publ, P1; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; Crowe SJ, 1917, B JOHNS HOPKINS HOSP, V28, P1; Fleiss J, 1973, STAT METHODS RATES P; Hall M J, 1997, Stat Bull Metrop Insur Co, V78, P18; HARVEY W, 1850, EXCISION ENLARGED TO, P21; HOEKELMAN RA, 1992, PRIMARY PEDIAT CARE, P1533; Kaiser AD, 1930, J AMER MED ASSOC, V95, P837, DOI 10.1001/jama.1930.02720120005003; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MAW AR, 1986, LANCET, V1, P1399; MAW AR, 1983, BRIT MED J, V287, P1586, DOI 10.1136/bmj.287.6405.1586; MCKEE WJE, 1963, BRIT J PREV SOC MED, V17, P133; Meyer W, 1870, Med Chir Trans, V53, P191; Paradise J L, 1976, Hosp Pract, V11, P79; PARADISE J L, 1992, Pediatric Research, V31, p126A; PARADISE J L, 1992, Pediatric Research, V31, p99A; Paradise JL, 1998, PEDIATRICS, V101, P979, DOI 10.1542/peds.101.6.979; PARADISE JL, 1987, J PEDIATR-US, V111, P948, DOI 10.1016/S0022-3476(87)80226-3; PARADISE JL, 1976, PEDIATRICS, V58, P198; PARADISE JL, 1972, PEDIATRICS, V49, P648; PARADISE JL, 1995, PEDIATRICS, V96, P712; PARADISE JL, 1984, NEW ENGL J MED, V310, P674, DOI 10.1056/NEJM198403153101102; PARADISE JL, 1975, ANN OTO RHINOL LARYN, V84, P15; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; PARADISE JL, 1976, SOUTHERN MED J, V69, P1049, DOI 10.1097/00007611-197608000-00030; Paradise JL, 1996, PEDIAT OTOLARYNGOLOG, V2, P1054; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RYNNELDAGOO B, 1978, ANN OTO RHINOL LARYN, V87, P272, DOI 10.1177/000348947808700223; SMITH CG, 1982, PEDIATRICS, V69, P351; Wiatrak BJ., 1998, OTOLARYNGOLOGY HEAD, V3, P188	34	98	110	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					945	953		10.1001/jama.282.10.945	http://dx.doi.org/10.1001/jama.282.10.945			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485679				2022-12-28	WOS:000082335900032
J	Shearer, PM; Flanagan, MP				Shearer, PM; Flanagan, MP			Seismic velocity and density jumps across the 410- and 660-kilometer discontinuities	SCIENCE			English	Article							ENDOTHERMIC PHASE-CHANGE; UPPER-MANTLE; LAYERED CONVECTION; EARTHS MANTLE; SPINEL; MODEL; FORM; FORSTERITE; TRANSITION; OLIVINE	The average seismic velocity and density jumps across the 410- and 660-kilometer discontinuities in the upper mantle were determined by modeling the observed range dependence in Long-period seismic wave arrivals that reflect off of these interfaces. The preliminary reference Earth model (PREM) is within the computed 95 percent confidence ellipse for the 410-km discontinuity but outside the allowed jumps across the 660-kilometer discontinuity. Current pyrolite mantle models appear consistent with the constraints for the 410-kilometer discontinuity but overpredict amplitudes for the 660-kilometer reflections. The density jump across the 660-kilometer discontinuity is between 4 and 6 percent, below the PREM value of 9.3 percent commonly used in mantle convection calculations.	Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA; Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Shearer, PM (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA.		Flanagan, Megan/AAW-1613-2020; Shearer, Peter M/K-5247-2012	Flanagan, Megan/0000-0002-5389-3872; 				CHRISTENSEN UR, 1985, J GEOPHYS RES-SOLID, V90, P291, DOI 10.1029/JB090iB12p10291; DUFFY TS, 1989, J GEOPHYS RES-SOLID, V94, P1895, DOI 10.1029/JB094iB02p01895; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; Estabrook CH, 1996, SCIENCE, V274, P1179, DOI 10.1126/science.274.5290.1179; Flanagan MP, 1998, J GEOPHYS RES-SOL EA, V103, P2673, DOI 10.1029/97JB03212; Flanagan MP, 1999, GEOPHYS RES LETT, V26, P549, DOI 10.1029/1999GL900036; Fujisawa H, 1998, J GEOPHYS RES-SOL EA, V103, P9591, DOI 10.1029/98JB00024; Gaherty JB, 1999, GEOPHYS RES LETT, V26, P1641, DOI 10.1029/1999GL900312; GAHERTY JB, COMMUNICATION; Gu Y, 1998, EARTH PLANET SC LETT, V157, P57, DOI 10.1016/S0012-821X(98)00027-2; Helffrich GR, 1996, GEOPHYS J INT, V126, pF7, DOI 10.1111/j.1365-246X.1996.tb05292.x; HONDA S, 1993, SCIENCE, V259, P1308, DOI 10.1126/science.259.5099.1308; ITA J, 1994, J GEOPHYS RES-SOL EA, V99, P15919, DOI 10.1029/94JB00852; ITA J, 1992, J GEOPHYS RES-SOL EA, V97, P6849, DOI 10.1029/92JB00068; ITO E, 1990, SCIENCE, V249, P1275, DOI 10.1126/science.249.4974.1275; JACKSON I, 1983, EARTH PLANET SC LETT, V62, P91, DOI 10.1016/0012-821X(83)90073-0; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; LIU LG, 1976, NATURE, V262, P770, DOI 10.1038/262770a0; MACHETEL P, 1991, NATURE, V350, P55, DOI 10.1038/350055a0; NOLET G, 1994, J GEOPHYS RES-SOL EA, V99, P23753, DOI 10.1029/94JB01892; NOLET G, 1989, ENCY GEOPHYSICS, P775; REVENAUGH J, 1991, J GEOPHYS RES-SOL EA, V96, P19763, DOI 10.1029/91JB01486; RIDGEN SM, 1991, NATURE, V354, P143; Ringwood A.E, 1975, COMPOSITION PETROLOG; SHEARER PM, 1990, NATURE, V344, P121, DOI 10.1038/344121a0; SHEARER PM, 1991, J GEOPHYS RES-SOL EA, V96, P18147, DOI 10.1029/91JB01592; Shearer PM, 1996, J GEOPHYS RES-SOL EA, V101, P3053, DOI 10.1029/95JB02812; SOLHEIM LP, 1994, J GEOPHYS RES-SOL EA, V99, P15861, DOI 10.1029/94JB00730; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P14835, DOI 10.1029/97JB00550; TACKLEY PJ, 1994, J GEOPHYS RES-SOL EA, V99, P15877, DOI 10.1029/94JB00853; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; THORAVAL C, 1995, NATURE, V375, P777, DOI 10.1038/375777a0; Weidner DJ, 1998, J GEOPHYS RES-SOL EA, V103, P7431, DOI 10.1029/97JB03511	34	114	126	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1545	1548		10.1126/science.285.5433.1545	http://dx.doi.org/10.1126/science.285.5433.1545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477514				2022-12-28	WOS:000082359500059
J	Wilson, J				Wilson, J			Acknowledging the expertise of patients and their organisations	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Long Term Med Condit Alliance, London EC1N 7RJ, England		Wilson, J (corresponding author), Long Term Med Condit Alliance, London EC1N 7RJ, England.	alliance@lmca.demon.co.uk						Barlow JH, 1998, BRIT J RHEUMATOL, V37, P1315; COULTER A, 1998, INFORMING PATIENTS A; Davis RM, 1999, BRIT MED J, V318, P1090, DOI 10.1136/bmj.318.7191.1090; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; *DEP HLTH, 1999, SAV LIV HLTH NAT; DeRidder D, 1997, SOC SCI MED, V44, P553, DOI 10.1016/S0277-9536(96)00085-8; Ham C, 1999, BRIT MED J, V318, P1092, DOI 10.1136/bmj.318.7191.1092; *LONG TERM MED CON, 1998, WHAT WE NEED; *LONG TERM MED CON, 1997, PAT INFL PURCH; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; *NHS EX, 1996, PAT PARTN STRAT; *OFF NAT STAT, 1998, LIV BRIT 1996 GEN HO; Rhodes Penny, 1998, Health Expect, V1, P73; RIGGE M, 1999, GUARDIAN        0120, P7; Thorne S., 1993, NEGOTIATING HLTH CAR; *US CDCP NAT CTR C, 1999, CHRON DIS DEF OV BUR; WILSON J, 1998, WORKING PHARM IND GU	17	53	53	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					771	774		10.1136/bmj.319.7212.771	http://dx.doi.org/10.1136/bmj.319.7212.771			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488011	Green Published			2022-12-28	WOS:000082701500030
J	Mandernack, KW; Bazylinski, DA; Shanks, WC; Bullen, TD				Mandernack, KW; Bazylinski, DA; Shanks, WC; Bullen, TD			Oxygen and iron isotope studies of magnetite produced by magnetotactic bacteria	SCIENCE			English	Article							AQUASPIRILLUM-MAGNETOTACTICUM; BIOGENIC MAGNETITE; OXIDES; FRACTIONATION; GROWTH; BIOMINERALIZATION; MAGNETOFOSSILS; MAGNETOSOMES; SEDIMENTS; MARINE	A series of carefully controlled laboratory studies was carried out to investigate oxygen and iron isotope fractionation during the intracellular production of magnetite (Fe3O4) by two different species of magnetotactic bacteria at temperatures between 4 degrees and 35 degrees C under microaerobic and anaerobic conditions. No detectable fractionation of iron isotopes in the bacterial magnetites was observed. However, oxygen isotope measurements indicated a temperature-dependent fractionation for Fe3O4 and water that is consistent with that observed for Fe3O4 produced extracellularly by thermophilic Fe3+-reducing bacteria. These results contrast with established fractionation curves estimated from either high-temperature experiments or theoretical calculations. With the fractionation curve established in this report, oxygen-18 isotope Values of bacterial Fe3O4 may be useful in paleoenvironmental studies for determining the oxygen-18 isotope values of formation waters and for inferring paleotemperatures.	Colorado Sch Mines, Dept Chem & Geochem, Golden, CO 80401 USA; Iowa State Univ, Dept Microbiol, Ames, IA 50011 USA; US Geol Survey, Denver Fed Ctr 973, Denver, CO 80225 USA; US Geol Survey, Div Water Resources, Menlo Pk, CA 94025 USA	Colorado School of Mines; Iowa State University; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Mandernack, KW (corresponding author), Colorado Sch Mines, Dept Chem & Geochem, Golden, CO 80401 USA.	krnandern@mines.edu						Bazylinski DA, 1997, REV MINERAL, V35, P181; BAZYLINSKI DA, 1988, NATURE, V334, P518, DOI 10.1038/334518a0; BAZYLINSKI DA, 1994, MICROSC RES TECHNIQ, V27, P389, DOI 10.1002/jemt.1070270505; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; BECKER RH, 1976, GEOCHIM COSMOCHIM AC, V40, P1153, DOI 10.1016/0016-7037(76)90151-4; BLAKEMORE RP, 1979, J BACTERIOL, V140, P720, DOI 10.1128/JB.140.2.720-729.1979; BLAKEMORE RP, 1985, GEOMICROBIOL J, V4, P53, DOI 10.1080/01490458509385920; BLATTNER P, 1983, ISOT GEOSCI, V1, P195; Bullen T. D., 1997, EOS, V78, pS173; CHANG SBR, 1989, PRECAMBRIAN RES, V43, P305, DOI 10.1016/0301-9268(89)90062-4; CHANG SBR, 1989, ANNU REV EARTH PL SC, V17, P169, DOI 10.1146/annurev.earth.17.1.169; CLAYTON RN, 1963, GEOCHIM COSMOCHIM AC, V27, P43, DOI 10.1016/0016-7037(63)90071-1; Devouard B, 1998, AM MINERAL, V83, P1387, DOI 10.2138/am-1998-11-1228; Frankel RB, 1997, BIOPHYS J, V73, P994, DOI 10.1016/S0006-3495(97)78132-3; GUERIN WF, 1992, APPL ENVIRON MICROB, V58, P1102, DOI 10.1128/AEM.58.4.1102-1109.1992; JOHNSON TM, IN PRESS GEOCHIM COS; Kerr RA, 1998, SCIENCE, V280, P1007, DOI 10.1126/science.280.5366.1007; KIRSCHVINK JL, 1982, EARTH PLANET SC LETT, V59, P388, DOI 10.1016/0012-821X(82)90140-6; KIRSCHVINK JL, 1984, GEOLOGY, V12, P559, DOI 10.1130/0091-7613(1984)12<559:UMIDSP>2.0.CO;2; KNAUTH LP, 1976, GEOCHIM COSMOCHIM AC, V40, P1095, DOI 10.1016/0016-7037(76)90051-X; Kolodny Y, 1991, GEOCHEM SOC SPEC PUB, V3, P105; LOVLEY DR, 1987, NATURE, V330, P252, DOI 10.1038/330252a0; MANDERNACK KW, 1995, GEOCHIM COSMOCHIM AC, V59, P4409, DOI 10.1016/0016-7037(95)00299-F; Mann S., 1990, IRON BIOMINERALS, P21; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; ONEIL JR, 1964, ISOTOPIC COSMIC CHEM, P157; PAOLETTI LC, 1988, CURR MICROBIOL, V17, P339, DOI 10.1007/BF01570874; Polyakov VB, 1997, GEOCHIM COSMOCHIM AC, V61, P4213, DOI 10.1016/S0016-7037(97)00204-4; ROWE MW, 1994, GEOCHIM COSMOCHIM AC, V58, P5341, DOI 10.1016/0016-7037(94)90317-4; Schuler D, 1996, ARCH MICROBIOL, V166, P301, DOI 10.1007/s002030050387; SHACKLETON NJ, 1988, PAST 3 MILLION YEARS, P269; SHARP ZD, 1990, GEOCHIM COSMOCHIM AC, V54, P1353, DOI 10.1016/0016-7037(90)90160-M; SHORT KA, 1986, J BACTERIOL, V167, P729, DOI 10.1128/jb.167.2.729-731.1986; STOLZ JF, 1993, J GEN MICROBIOL, V139, P1663, DOI 10.1099/00221287-139-8-1663; STOLZ JF, 1989, PRECAMBRIAN RES, V43, P295, DOI 10.1016/0301-9268(89)90061-2; WEFER G, 1991, MAR GEOL, V100, P207, DOI 10.1016/0025-3227(91)90234-U; Yapp C.J., 1993, CLIMATE CHANGE CONTI, V78, P285; YAPP CJ, 1990, CHEM GEOL, V85, P329, DOI 10.1016/0009-2541(90)90010-5; Zhang CL, 1997, GEOCHIM COSMOCHIM AC, V61, P4621, DOI 10.1016/S0016-7037(97)00257-3; ZHENG YF, 1991, GEOCHIM COSMOCHIM AC, V55, P2299; ZHENG YF, 1995, CHEM GEOL, V121, P309, DOI 10.1016/0009-2541(94)00149-3	41	107	120	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1892	1896		10.1126/science.285.5435.1892	http://dx.doi.org/10.1126/science.285.5435.1892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489363				2022-12-28	WOS:000082638300043
J	Abroug, F; ElAtrous, S; Nouira, S; Haguiga, H; Touzi, N; Bouchoucha, S				Abroug, F; ElAtrous, S; Nouira, S; Haguiga, H; Touzi, N; Bouchoucha, S			Serotherapy in scorpion envenomation: a randomised controlled trial	LANCET			English	Article							AUSTRALIS-GARZONII AAG; ENVENOMING-SYNDROME; ANTIVENOM THERAPY; VENOM; PHARMACOKINETICS; MANAGEMENT; CHILDREN; TUNISIA; RAT	Background Evidence for the benefit of scorpion antivenom, the only specific treatment for scorpion envenomation, is scarce, despite its common use. We did a prospective, randomised, controlled trial to assess the efficacy of routine administration of scorpion antivenom to scorpion-stung patients, irrespective of clinical severity. Methods We included 825 consecutive patients older than 10 years, who presented to the accident and emergency department of the hospital in Tozeur, Tunisia. We graded severity by absence (grade I) or presence (grade II) of systemic manifestations of scorpion envenomation. Patients were randomly assigned placebo (n=413) or 20 mt bivalent intraveneous scorpion antivenom (n=412). All patients were observed for 4 h. Patients who developed life-threatening symptoms were admitted to the intensive-care unit. At the end of 4 h observation we reassessed grade and discharged grade I patients and admitted grade II patients. We assessed the preventive and curative effects of scorpion antivenom by prevention of worsening grade or by improvement from grade II to grade I. Findings Distribution of severity grades was similar in the two groups at baseline, as were the cure rates (55% scorpion antivenom, 66% placebo, absolute difference, 11% [95% CI -4.8 to 26.8]; p=0.234). Preventive effects were seen in 94% and 96% of patients in the scorpion antivenom and placebo groups, respectively, who were initially grade I and who remained symptom-free (absolute difference, 2% [-1.27 to 5.27]; p=0.377). Time from scorpion sting to administration of scorpion antivenom did not affect curative and preventive effects. Interpretation We found no benefit in routine administration of scorpion antivenom after scorpion sting, irrespective of clinical severity. Future studies should focus on patients with the most severe symptoms and signs.	CHU F Bourgulba, Intens Care Unit, Monastir 5000, Tunisia; Hop Reg Tozeur, Intens Care Unit, Tozeur, Tunisia; Hop Reg Tozeur, Emergency Dept, Tozeur, Tunisia	Universite de Monastir; Hopital Fattouma Bourguiba	Abroug, F (corresponding author), CHU F Bourgulba, Intens Care Unit, Monastir 5000, Tunisia.		Abroug, Fekri/ADJ-0934-2022; Abroug, Fekri/ABI-6564-2022	Abroug, Fekri/0000-0002-5626-5329; Nouira, Semir/0000-0002-0137-5491				ABROUG F, 1997, ANN EMERG MED, V30, P245; BAWASKAR HS, 1991, J TROP MED HYG, V94, P156; Belghith M, 1999, J TOXICOL-CLIN TOXIC, V37, P51, DOI 10.1081/CLT-100102408; BOND GR, 1992, ANN EMERG MED, V21, P788, DOI 10.1016/S0196-0644(05)81022-4; DEHESADAVILA M, 1994, TOXICON, V32, P1015, DOI 10.1016/0041-0101(94)90383-2; DEREZENDE NA, 1995, AM J TROP MED HYG, V52, P277, DOI 10.4269/ajtmh.1995.52.277; ELAMIN EO, 1994, ANN TROP PAEDIATR, V14, P21, DOI 10.1080/02724936.1994.11747687; FREIREMAIA L, 1994, TOXICON, V32, P1009, DOI 10.1016/0041-0101(94)90382-4; FREIREMAIA L, 1993, TOXICON, V31, P1207, DOI 10.1016/0041-0101(93)90137-8; GATEAU T, 1994, J TOXICOL-CLIN TOXIC, V32, P165, DOI 10.3109/15563659409000446; GOYFFON M, 1982, TOXICON, V20, P337, DOI 10.1016/0041-0101(82)90240-9; GUERON M, 1993, TOXICON, V31, P1071, DOI 10.1016/0041-0101(93)90122-Y; GUERON M, 1992, J TOXICOL-CLIN TOXIC, V30, P245, DOI 10.3109/15563659209038636; GWEE MCE, 1995, TOXICON, V33, P1141, DOI 10.1016/0041-0101(95)00064-S; ISMAIL M, 1994, TOXICON, V32, P1019, DOI 10.1016/0041-0101(94)90384-0; ISMAIL M, 1995, TOXICON, V33, P825, DOI 10.1016/0041-0101(95)00005-7; ISMAIL M, 1992, TOXICON, V30, P1257, DOI 10.1016/0041-0101(92)90442-8; ISMAIL M, 1983, TOXICON, V21, P47, DOI 10.1016/0041-0101(83)90048-X; Ismail M, 1998, TOXICON, V36, P1523, DOI 10.1016/S0041-0101(98)00144-5; ISMAIL M, 1980, TOXICON, V18, P301, DOI 10.1016/0041-0101(80)90009-4; ISMAIL M, 1993, TOXICON, V31, P1077, DOI 10.1016/0041-0101(93)90123-Z; Krifi MN, 1996, TOXICON, V34, P257, DOI 10.1016/0041-0101(95)00130-1; Krifi MN, 1998, TOXICON, V36, P887, DOI 10.1016/S0041-0101(97)00136-0; MULLER GJ, 1993, S AFR MED J, V83, P405; Revelo MP, 1996, TOXICON, V34, P1119, DOI 10.1016/0041-0101(96)00074-8; Rezende NA, 1998, TOXICON, V36, P1507, DOI 10.1016/S0041-0101(98)00141-X; SOFER S, 1994, J PEDIATR-US, V124, P973, DOI 10.1016/S0022-3476(05)83196-8; Sofer S, 1996, TOXICON, V34, P389, DOI 10.1016/0041-0101(95)00136-0; Tarasiuk A, 1998, TOXICON, V36, P963, DOI 10.1016/S0041-0101(98)00011-7	29	124	130	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					906	909		10.1016/S0140-6736(98)12083-4	http://dx.doi.org/10.1016/S0140-6736(98)12083-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489950				2022-12-28	WOS:000082511800013
J	Chen, CS; Patterson, MC; Wheatley, CL; O'Brien, JF; Pagano, RE				Chen, CS; Patterson, MC; Wheatley, CL; O'Brien, JF; Pagano, RE			Broad screening test for sphingolipid-storage diseases	LANCET			English	Article							PLASMA-MEMBRANE; GOLGI-APPARATUS; SPECTRAL PROPERTIES; SKIN FIBROBLASTS; ACCUMULATION; TRANSPORT; ANALOG; CELLS; MUCOLIPIDOSIS; DISORDERS	Background Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods We used a fluorescent analogue of lactosylceramide, called N-{5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl}-D-lactosylsphingosine (BODIPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM(1) gangliosidosis, GM(2) gangliosidosis (Tay-Sachs and Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2% (95% CI 80.4-99.9) and the specificity 90.0% (68.3-98.8). Interpretation This method may be useful as an initial general screen for lipid-storage diseases, and, with modification, could be used for large-scale automated screening of drugs to abrogate lysosomal storage in various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Div Child & Adolescent Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Lab Genet, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Guggenheim 621-C,200 1st St SW, Rochester, MN 55905 USA.		Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Patterson, Marc/0000-0002-1116-126X	NIGMS NIH HHS [GM-22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022942, R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGMON V, 1993, CLIN CHIM ACTA, V218, P139; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BACH G, 1977, AM J HUM GENET, V29, P610; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burkhardt JK, 1997, EUR J CELL BIOL, V73, P10; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; GALJAARD H, 1980, GENETIC METABOLIC DI; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; Hua CT, 1998, CLIN CHEM, V44, P2094; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kopitz J, 1996, AM J MED GENET, V63, P198; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Meikle PJ, 1997, CLIN CHEM, V43, P1325; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, IN PRESS METHODS ENZ; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625	22	108	108	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					901	905		10.1016/S0140-6736(98)10034-X	http://dx.doi.org/10.1016/S0140-6736(98)10034-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489949				2022-12-28	WOS:000082511800012
J	Ghebreyesus, TA; Haile, M; Witten, KH; Getachew, A; Yohannes, AM; Yohannes, M; Teklehaimanot, HD; Lindsay, SW; Byass, P				Ghebreyesus, TA; Haile, M; Witten, KH; Getachew, A; Yohannes, AM; Yohannes, M; Teklehaimanot, HD; Lindsay, SW; Byass, P			Incidence of malaria among children living near dams in northern Ethiopia: community based incidence survey	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY	Objective To assess the impact of construction of microdams on the incidence of malaria in nearby communities in terms of possibly increasing peak incidence and prolonging transmission. Design Four quarterly cycles of malaria incidence surveys, each taking 30 days, undertaken in eight at risk communities close to dams paired with eight control villages at similar altitudes but beyond flight range of mosquitoes. Setting Tigray region in northern Ethiopia at altitudes of 1800 to 2225 m. Subjects About 7000 children under 10 years living in villages within 3 km of microdams and in control villages 8-10 km distant. Main outcome measures Incidence of malaria in both communities. Results Overall incidence of malaria for the villages close to dams was 14.0 episodes/1000 child months at risk compared with 1.9 in the control villages-a sevenfold ratio. Incidence was significantly higher in both communities at altitudes below 1900 m. Conclusions There is a need for attention to be given to health issues in the implementation of ecological and environmental development programmes, specifically for appropriate malaria control measures to counteract the increased risks near these dams.	Tigray Reg Hlth Bur, Dept Malaria Control, Mekelle, Ethiopia; Mekelle Univ Coll, Mekelle, Ethiopia; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Univ Nottingham, Sch Community Hlth Sci, Nottingham NG13 8FD, England	Mekelle University; Durham University; University of Nottingham	Ghebreyesus, TA (corresponding author), Tigray Reg Hlth Bur, Dept Malaria Control, Mekelle, Ethiopia.			Byass, Peter/0000-0001-5474-4361				Alemayehu T., 1998, Parassitologia (Rome), V40, P259; [Anonymous], 1993, PARASITIC DIS WATER; BOUMA MJ, 1994, LANCET, V343, P302, DOI 10.1016/S0140-6736(94)91152-5; BRADLEY DJ, 1998, VECTOR BORNE DIS CON, P29; COOSEMANS M, 1984, ANN SOC BELG MED TR, V64, P135; DEMEILLON B, 1947, PUBLICATIONS S AFRIC, V10, P190; ELGADDAL AA, 1985, J TROP MED HYG, V88, P153; Ghebreyesus TA, 1996, ACTA TROP, V61, P145, DOI 10.1016/0001-706X(95)00107-P; Ghebreyesus TA, 1998, J PUBLIC HEALTH MED, V20, P238, DOI 10.1093/oxfordjournals.pubmed.a024754; Gillies M. T., 1988, Malaria: principles and practice of malariology. Volume 1., P453; Gratz N. G., 1988, Vector-borne disease control in humans through rice agroecosystem management. Proceedings of the Workshop on Research and Training Needs in the Field of Integrated Vector-borne Disease Control in Riceland Agroecosystems of Developing Countries, 9-14 March 1987., P7; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; RAMASAMY R, 1992, AM J TROP MED HYG, V47, P547, DOI 10.4269/ajtmh.1992.47.547; STEPHENS J, 1989, METHOD INFORM MED, V28, P155; TEKLEHAIMANOT A, 1986, LANCET, V2, P127	15	143	147	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					663	666		10.1136/bmj.319.7211.663	http://dx.doi.org/10.1136/bmj.319.7211.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480820	Green Published, Bronze			2022-12-28	WOS:000082636800019
J	Roizen, R; Kerr, WC; Fillmore, KM				Roizen, R; Kerr, WC; Fillmore, KM			Cirrhosis mortality and per capita consumption of distilled spirits, United States, 1949-94: trend analysis	BRITISH MEDICAL JOURNAL			English	Article							ALCOHOL; WINE; CONSEQUENCES; IMPACT; RISK; BEER	Objective To describe, evaluate, and suggest interpretations for an observed aggregate level relation between trends in mortality from cirrhosis and per capita consumption of distilled spirits in the United States. Design Trend analysis using data on US cirrhosis mortality and per capita alcohol consumption. Results There is a consistent long term trend relation between mortality from cirrhosis and per capita consumption of distilled spirits in the United States from 1949 to 1994. Two instances of comparatively sharp drops in the consumption of spirits earlier in the 1940s generated mixed results in predicting changes in cirrhosis mortality. Conclusions An aggregate level relation between trends in long term cirrhosis mortality and the consumption of spirits falls considerably short of establishing a direct causal link between the two for individuals. Moreover, two sharp drops in the consumption of spirits generated only mixed results with respect to the short term trend in cirrhosis. Nevertheless, the observed relation between the consumption of spirits and cirrhosis mortality merits further investigation.	Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Roizen, R (corresponding author), Univ Calif San Francisco, Dept Social & Behav Sci, Box 0612, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007034, R01AA009623] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09623, KO1 AA00073, R01 AA07034] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOX EP, 1976, TIME SERIES ANAL FOR; Derr RF, 1996, BIOCHEM ARCH, V12, P277; Edwards G., 1994, ALCOHOL POLICY PUBLI; GODFREY LG, 1988, SPECIFICATION TESTS; GOTTMAN J. M., 1981, TIME SERIES ANAL COM; GRANT BF, 1985, US ALCOHOL EPIDEMIOL; GRUENEWALD PJ, 1995, J STUD ALCOHOL, V56, P635, DOI 10.15288/jsa.1995.56.635; HARFORD TC, 1979, INT J ADDICT, V14, P197, DOI 10.3109/10826087909060365; HERD D, 1992, ADDICTION, V87, P1113; HILTON ME, 1991, ALCOHOL AM DRINKING, P121; Holder HD, 1997, ADDICTION, V92, P5, DOI 10.1111/j.1360-0443.1997.tb03632.x; HYMAN MM, 1981, J STUD ALCOHOL, V42, P336, DOI 10.15288/jsa.1981.42.336; KLATSKY AL, 1990, BRIT J ADDICT, V85, P1279; Kling W, 1991, J Stud Alcohol, V52, P503; KLING W, 1989, J STUD ALCOHOL, V50, P456, DOI 10.15288/jsa.1989.50.456; LELBACH WK, 1975, MED CONSEQUENCES ALC, V252; LINGEMAN RR, 1970, DONT YOU KNOW THERES, P247; LJUNG GM, 1979, BIOMETRIKA, V66, P265, DOI 10.1093/biomet/66.2.265; LONGNECKER MP, 1981, J STUD ALCOHOL, V42, P791, DOI 10.15288/jsa.1981.42.791; NORSTROM T, 1987, BRIT J ADDICT, V82, P67; PHILLIPS PCB, 1988, BIOMETRIKA, V75, P335, DOI 10.2307/2336182; Pindyck R.S., 1998, ECONOMETRIC MODELS E, V4th edition; *QUANT MICR SOFTW, 1994, E VIEWS US GUID; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; SAADATMAND R, 1997, 45 US DEP HLTH HUM S; SCHMIDT DN, 1991, INT J PANCREATOL, V8, P45; SELZER MI, 1977, J STUD ALCOHOL, V38, P1204; SKOG OJ, 1980, BRIT J ADDICT, V75, P227; SKOG OJ, 1988, ALCOHOL ALCOHOLISM, V22, P193; Smart RG, 1996, J STUD ALCOHOL, V57, P77, DOI 10.15288/jsa.1996.57.77; SMART RG, 1993, ADDICTION, V88, P193, DOI 10.1111/j.1360-0443.1993.tb00802.x; TERRIS M, 1967, AM J PUBLIC HEALTH N, V57, P2076, DOI 10.2105/AJPH.57.12.2076; TURRELL V, 1946, ALCOHOL POLICIES WAR; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; WILLIAMS GD, 1996, APPARENT CAPITA ALCO	36	55	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					666	670A		10.1136/bmj.319.7211.666	http://dx.doi.org/10.1136/bmj.319.7211.666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	237CH	10480821	Green Published, Bronze			2022-12-28	WOS:000082636800020
J	Cubas, P; Vincent, C; Coen, E				Cubas, P; Vincent, C; Coen, E			An epigenetic mutation responsible for natural variation in floral symmetry	NATURE			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; METHYLATION; MERISTEM	Although there have been many molecular studies of morphological mutants generated in the laboratory, it is unclear how these are related to mutants in natural populations, where the constraints of natural selection and breeding structure are quite different. sere we characterize a naturally occurring mutant of Linaria vulgaris, originally described more than 250 years ago by Linnaeus(1-3), in which the fundamental symmetry of the newer is changed from bilateral to radial. We show that the mutant carries a defect in Lcyc, a homologue of the cycloidea gene which controls dorsoventral asymmetry in Antirrhinum(4). The Lcyc gene is extensively methylated and transcriptionally silent in the mutant. This modification is heritable and co-segregates with the mutant phenotype. Occasionally the mutant reverts phenotypically during, somatic development, correlating with demethylation of Lcyc and restoration of gene expression. It is surprising that the first natural morphological mutant to be characterized should trace to methylation, given the rarity of this mutational mechanism in the laboratory. This indicates that epigenetic mutations may play a more significant role in evolution than has hitherto been suspected.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Cubas, Pilar/ABE-8670-2020; Cubas, Pilar/M-2268-2015	Cubas, Pilar/0000-0003-4679-2173; Cubas, Pilar/0000-0003-4679-2173				Almeida J, 1997, DEVELOPMENT, V124, P1387; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRIEGER F. G., 1935, GENETICA, V17, P385, DOI 10.1007/BF01508186; CAMBARERI EB, 1989, SCIENCE, V244, P1571, DOI 10.1126/science.2544994; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; DAS OP, 1994, GENETICS, V136, P1121; DEVRIES H, 1904, SPECIES VARIETIES TH, P459; DOCHERTY Z, 1982, HEREDITY, V49, P349, DOI 10.1038/hdy.1982.108; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; GUSTAFSSON A, 1979, THEOR APPL GENET, V54, P241, DOI 10.1007/BF00281206; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; Jablonka E, 1998, J EVOLUTION BIOL, V11, P159, DOI 10.1007/s000360050073; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; LINNAEUS C, 1749, THESIS UPPSALA; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; SHERMAN M, 1939, Z INDUKT ABSTAMMUNGS, V77, P1; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	24	849	914	7	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					157	161		10.1038/43657	http://dx.doi.org/10.1038/43657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490023				2022-12-28	WOS:000082458800052
J	Press, JM; Lawler, MH; Smith, JC				Press, JM; Lawler, MH; Smith, JC			Physical medicine and rehabilitation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Rehabil Inst Chicago, Ctr Spine Sports & Occupat Rehabil, Chicago, IL 60610 USA	Shirley Ryan AbilityLab	Press, JM (corresponding author), Rehabil Inst Chicago, Ctr Spine Sports & Occupat Rehabil, 1030 N Clark St,5th Floor, Chicago, IL 60610 USA.							BREWER V, 1983, MED SCI SPORT EXER, V15, P445; DALEN N, 1974, ACTA ORTHOP SCAND, V45, P170, DOI 10.3109/17453677408989136; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; VONKORFF M, 1994, SPINE S, V9, P2041; Wahlgren DR, 1997, PAIN, V73, P213, DOI 10.1016/S0304-3959(97)00106-1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					925	926		10.1001/jama.282.10.925	http://dx.doi.org/10.1001/jama.282.10.925			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485662				2022-12-28	WOS:000082335900002
J	Mullan, F				Mullan, F			Centennial physician: Richard Ferry, MD, struggles with the future	ANNALS OF INTERNAL MEDICINE			English	Biographical-Item									Hlth Affairs Project Hope, Bethesda, MD 20814 USA		Mullan, F (corresponding author), Hlth Affairs Project Hope, Suite 600,7500 Georgetown Rd, Bethesda, MD 20814 USA.	fmullan@projhope.org							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					395	398		10.7326/0003-4819-131-5-199909070-00021	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475899				2022-12-28	WOS:000082458500019
J	Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF				Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF			In vivo protein transduction: Delivery of a biologically active protein into the mouse	SCIENCE			English	Article							CELLS; DRUGS; BRAIN	Delivery of therapeutic proteins into tissues and across the blood-brain barrier is severely limited by the size and biochemical properties of the proteins. Here it is shown that intraperitoneal injection of the 120-kilodalton beta-galactosidase protein, fused to the protein transduction domain from the human immunodeficiency virus TAT protein, results in-delivery of the biologically active fusion protein to all tissues in mice, including the brain. These results open new possibilities for direct delivery of proteins into patients in the context of protein therapy, as well as for epigenetic experimentation with model organisms.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.							Anderson WF, 1998, NATURE, V392, P25; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Elefanty AG, 1998, P NATL ACAD SCI USA, V95, P11897, DOI 10.1073/pnas.95.20.11897; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Gius DR, 1999, CANCER RES, V59, P2577; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HO AF, UNPUB, P42707; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KRALL WJ, 1992, NEW BIOL, V4, P581; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; RAPOPORT SI, 1972, SCIENCE, V170, P1243; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHELD WM, 1989, REV INFECT DIS S, V7, P1669; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHWARZE S, UNPUB; van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710	22	2084	2474	2	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1569	1572		10.1126/science.285.5433.1569	http://dx.doi.org/10.1126/science.285.5433.1569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477521				2022-12-28	WOS:000082359500066
J	Epstein, RM				Epstein, RM			Mindful practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHYSICIANS RISK ATTITUDES; PATIENT-RELATIONSHIP; CLINICAL JUDGMENT; MEDICAL-EDUCATION; DECISION-ANALYSIS; STUDENTS; CURRICULUM; SKILLS; CARE; COMMUNICATION	Mindful practitioners attend in a nonjudgmental way to their own physical and mental processes during ordinary, everyday tasks. This critical selfreflection enables physicians to listen attentively to patients' distress, recognize their own errors, refine their technical skills, make evidence-based decisions, and clarify their values so that they can act with compassion, technical competence, presence, and insight. Mindfulness informs all types of professionally relevant knowledge, including propositional facts, personal experiences, processes, and know-how, each of which may be tacit or explicit. Explicit knowledge is readily taught, accessible to awareness, quantifiable and easily translated into evidence-based guidelines. Tacit knowledge is usually learned during observation and practice, includes prior experiences, theories-in-action, and deeply held values, and is usually applied more inductively. Mindful practitioners use a variety of means to enhance their ability to engage in moment-to-moment self-monitoring, bring to consciousness their tacit personal knowledge and deeply held values, use peripheral vision and subsidiary awareness to become aware of new information and perspectives, and adopt curiosity in both ordinary and novel situations. In contrast, mindlessness may account for some deviations from professionalism and errors in judgment and technique. Although mindfulness cannot be taught explicitly, it can be modeled by mentors and cultivated in learners. As a link between relationship-centered care and evidence-based medicine, mindfulness should be considered a characteristic of good clinical practice.	Univ Rochester, Sch Med & Dent, Dept Family Med, Rochester, NY 14620 USA; Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14620 USA	University of Rochester; University of Rochester	Epstein, RM (corresponding author), Univ Rochester, Sch Med & Dent, Dept Family Med, 885 S Ave, Rochester, NY 14620 USA.							Argyris C., 1974, THEORY PRACTICE INCR; Aronowitz S., 1998, P FREIRE PEDAGOGY FR, P1; Asch E, 1998, Acad Med, V73, P575, DOI 10.1097/00001888-199805000-00034; *ASS AM MED COLL, 1998, 1 ASS AM MED COLL; Austin JamesH, 1998, ZEN BRAIN UNDERSTAND; Balint M., 1964, DOCTOR HIS PATIENT I; BARON RJ, 1985, ANN INTERN MED, V103, P606, DOI 10.7326/0003-4819-103-4-606; BARSKY AJ, 1979, ANN INTERN MED, V91, P63, DOI 10.7326/0003-4819-91-1-63; Belenky M. F., 1997, WOMENS WAYS KNOWING; Benner P., 1984, NOVICE EXPERT; BERNSTEIN S, 1981, YOUR OWN 2 HANDS, P215; Bertakis K D, 1992, Fam Med, V24, P307; Brock C D, 1990, Fam Med, V22, P33; CHRISTAKIS DA, 1993, ACAD MED, V68, P249, DOI 10.1097/00001888-199304000-00003; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; Coles, 1996, J CONTIN EDUC HEALTH, V16, P152, DOI DOI 10.1002/chp.4750160305; Crawshaw R, 1996, BRIT MED J, V313, P1596, DOI 10.1136/bmj.313.7072.1596a; Crouch M, 1986, Fam Med, V18, P93; Damasio A.R., 2005, DESCARTES ERROR EMOT; DETSKY AS, 1987, J CHRON DIS, V40, P831, DOI 10.1016/0021-9681(87)90181-0; DIMSDALE JE, 1984, PERSPECT BIOL MED, V27, P213; EPSTEIN R, 1997, INT MED NEWS     APR, P13; Epstein RM, 1998, ARCH FAM MED, V7, P149, DOI 10.1001/archfami.7.2.149; Epstein RM, 1998, ANN INTERN MED, V128, P435, DOI 10.7326/0003-4819-128-6-199803150-00003; EPSTEIN RM, 1999, 3 INT C COMM MED JUL; EPSTEIN RM, 1996, 29 ANN M SOC TEACH F; Epstein RM, 1991, MED ENCOUNTER, V8, P9; ERAUT M, 1994, DEV PROFESSIONAL KNO, P100; ERAUT M, 1994, DEV PROFESSIONAL KNO, P1; Eraut Michael, 1994, DEV PROFESSIONAL KNO; FEINSTEIN AR, 1994, ANN INTERN MED, V120, P799, DOI 10.7326/0003-4819-120-9-199405010-00012; FEUDTNER C, 1994, ACAD MED, V69, P670, DOI 10.1097/00001888-199408000-00017; Fitzgerald FT, 1999, ANN INTERN MED, V130, P70, DOI 10.7326/0003-4819-130-1-199901050-00015; FLEETWOOD J, 1997, MEDETHEX STANDARDIZE; FRANKEL RM, 1997, BEHAV MED PRIMARY CA, P30; FRANKS P, 1982, J FAM PRACTICE, V14, P745; Friere P., 1998, PEDAGOGY FREEDOM; Gardner H., 1993, MULTIPLE INTELLIGENC; GOLDBERG P, 1983, INTUITIVE EDGE UNDER; GOLDMAN GM, 1990, YALE J BIOL MED, V63, P47; Goleman D, 2020, EMOTIONAL INTELLIGEN, V25th; GREENBERG DB, 1984, AFFECTIVE ASPECTS CL, P55; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; HAHN SR, 1994, J CLIN EPIDEMIOL, V47, P647, DOI 10.1016/0895-4356(94)90212-7; Heisenberg W., 1958, PHYS PHILOS, P58; Hensel WA, 1998, ACAD MED, V73, P865, DOI 10.1097/00001888-199808000-00011; HEWSON MGAB, 1991, MED TEACH, V13, P227, DOI 10.3109/01421599109098987; HOLTGRAVE DR, 1991, MED DECIS MAKING, V11, P125, DOI 10.1177/0272989X9101100210; Hundert EM, 1996, ACAD MED, V71, P624, DOI 10.1097/00001888-199606000-00014; James William, 1975, PRAGMATISM; Kabat-Zinn J., 1994, WHEREVER YOU GO THER; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; Kaufmann Walter, 1970, I THOU; LACOMBE MA, 1996, AM J MED, V5, P654; Langer Ellen, 1989, MINDFULNESS; LEDOUX JE, 1994, SCI AM, V270, P50, DOI 10.1038/scientificamerican0694-50; Makoul G, 1998, ACAD MED, V73, P48, DOI 10.1097/00001888-199801000-00011; MALTERUD K, 1995, THEOR MED, V16, P183, DOI 10.1007/BF00998544; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MCDANIEL SH, 1991, FAM PROCESS, V30, P459, DOI 10.1111/j.1545-5300.1991.00459.x; McPhee S. J., 1981, ALPH OM ALPH HON SOC; McWhinney IR, 1996, BRIT J GEN PRACT, V46, P433; McWhinney IR, 1999, BRIT J GEN PRACT, V49, P418; Mengel MB, 1987, FAM SYST MED, V5, P176; NHAT H, 1992, PEACE IS EVERY STEP; NIGHTINGALE SD, 1987, J GEN INTERN MED, V2, P25, DOI 10.1007/BF02596246; Nin A., 1969, DIARY ANAIS NIN 1939; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Novack DH, 1999, ACAD MED, V74, P516, DOI 10.1097/00001888-199905000-00017; NOVACK DH, 1992, ARCH INTERN MED, V152, P1814, DOI 10.1001/archinte.152.9.1814; NOVACK DH, 1993, JAMA-J AM MED ASSOC, V269, P2101, DOI 10.1001/jama.269.16.2101; NOVACK DH, 1997, MED ENCOUNTER, V13, P2; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; PEARSON SD, 1995, J GEN INTERN MED, V10, P557, DOI 10.1007/BF02640365; Peters R M, 1995, Arch Fam Med, V4, P939, DOI 10.1001/archfami.4.11.939; Polanyi M, 1974, PERSONAL KNOWLEDGE P, V2; QUILL TE, 1993, HUM MED, V9, P109; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; Ryle G., 1949, CONCEPT MIND, DOI 10.4324/9780203875858; Sackett D. L., 1997, EVIDENCE BASED MED P; Schon D.A., 1987, ED REFLECTIVE PRACTI; Schon D.A, 2017, REFLECTIVE PRACTITIO; Searle J.R., 1992, REDISCOVERY MIND; Stern DT, 1998, AM J MED, V104, P569, DOI 10.1016/S0002-9343(98)00109-0; STETTEN D, 1981, NEW ENGL J MED, V305, P458, DOI 10.1056/NEJM198108203050811; Streng F., 1967, EMPTINESS STUDY RELI; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; Suzuki Shunryu, 1980, ZEN MIND BEGINNERS M; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; Tresolini C. P., 1994, HLTH PROFESSIONS ED; VARELA FJ, 1991, EMBODIES MIND COGNIT; WARTOFSKY MW, 1986, J MED PHILOS, V11, P81, DOI 10.1093/jmp/11.1.81; Wear D, 1997, ACAD MED, V72, P1056, DOI 10.1097/00001888-199712000-00015; Westberg J, 1994, Fam Med, V26, P278; Westberg J., 1993, COLLABORATIVE CLIN E; WESTBERG J, 1994, TEACHING CREATIVELY; Wu AW, 1997, J GEN INTERN MED, V12, P770, DOI 10.1046/j.1525-1497.1997.07163.x	103	789	798	8	192	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					833	839		10.1001/jama.282.9.833	http://dx.doi.org/10.1001/jama.282.9.833			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478689				2022-12-28	WOS:000082272200008
J	Scott, J				Scott, J			Heart disease - Good cholesterol news	NATURE			English	Editorial Material							ABC		Univ London Imperial Coll Sci Technol & Med, Sch Med, London W12 0NN, England; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England	Imperial College London; Imperial College London	Scott, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Du Cane Rd, London W12 0NN, England.							Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MARCIL M, IN PRESS LANCET; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408	11	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					816	+		10.1038/23584	http://dx.doi.org/10.1038/23584			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476954				2022-12-28	WOS:000082233200019
J	Siegel, JM				Siegel, JM			Narcolepsy: A key role for hypocretins (orexins)	CELL			English	Review							NEURONS		Vet Adm Med Ctr, N Hills, CA 91343 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Siegel, JM (corresponding author), Vet Adm Med Ctr, N Hills, CA 91343 USA.				NINDS NIH HHS [R01 NS014610] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basun H, 1997, ARCH NEUROL-CHICAGO, V54, P539, DOI 10.1001/archneur.1997.00550170021010; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Horvath TL, 1999, J NEUROSCI, V19, P1072; Ichinose M, 1998, FEBS LETT, V440, P51, DOI 10.1016/S0014-5793(98)01432-X; Ida T, 1999, BRAIN RES, V821, P526, DOI 10.1016/S0006-8993(99)01131-2; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; Peyron C, 1998, J NEUROSCI, V18, P9996; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Siegel J. M., 1994, PRINCIPLES PRACTICE, P125; SIEGEL JM, 1991, SCIENCE, V252, P1315, DOI 10.1126/science.1925546; Siegel JM, 1999, J NEUROSCI, V19, P248, DOI 10.1523/JNEUROSCI.19-01-00248.1999; Sweet DC, 1999, BRAIN RES, V821, P535, DOI 10.1016/S0006-8993(99)01136-1; Tafti M, 1996, J NEUROSCI, V16, P4588; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; van den Pol AN, 1998, J NEUROSCI, V18, P7962; Wu MF, 1999, NEUROSCIENCE, V91, P1389, DOI 10.1016/S0306-4522(98)00600-9	20	175	183	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					409	412		10.1016/S0092-8674(00)81969-8	http://dx.doi.org/10.1016/S0092-8674(00)81969-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481905	Green Accepted, Bronze			2022-12-28	WOS:000082174900001
J	Caffee, MW; Hudson, GU; Velsko, C; Huss, GR; Alexander, EC; Chivas, AR				Caffee, MW; Hudson, GU; Velsko, C; Huss, GR; Alexander, EC; Chivas, AR			Primordial noble cases from Earth's mantle: Identification of a primitive volatile component	SCIENCE			English	Article							STATE UPPER-MANTLE; CO2 WELL GAS; MASS FRACTIONATION; EXCESS XE-129; EARLY HISTORY; XENON; NEON; EVOLUTION; ORIGIN; CONSTRAINTS	Carbon dioxide well gases in Colorado, New Mexico, and South Australia show excesses of Xe124-128 correlated with I-129-derived Xe-129 and Ne-20/Ne-22 ratios that are higher than the atmospheric Ne-20/Ne-22 ratio. The xenon isotopic data indicate the presence of a solarlike component deep within Earth. The presence of this component in crustal and upper mantle reservoirs may be explained by a steady-state transport of noble gases from the Lower mantle, which still retains much of its juvenile volatile inventory. These measurements also indicate that the mantle source of these noble gases in the carbon dioxide well gases cannot be the source of Earth's present atmosphere. The variations observed in Xe-129/Xe-130 between solar wind xenon, Earth's atmosphere, and mantle samples may be generated by variations of iodine/xenon in terrestrial reservoirs, as opposed to rapid early degassing.	Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Univ Wollongong, Sch Geosci, Wollongong, NSW 2522, Australia	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Arizona State University; Arizona State University-Tempe; University of Minnesota System; University of Minnesota Twin Cities; University of Wollongong	Caffee, MW (corresponding author), Univ Calif Lawrence Livermore Natl Lab, POB 808, Livermore, CA 94550 USA.		Chivas, Allan/B-4242-2013	Velsko, Carol/0000-0002-0955-4021; Chivas, Allan/0000-0002-1459-6330; Huss, Gary/0000-0003-4281-7839				Allegre CJ, 1995, EARTH PLANET SC LETT, V136, P629, DOI 10.1016/0012-821X(95)00184-E; ALLEGRE CJ, 1983, NATURE, V303, P765; ANDERS E, 1977, SCIENCE, V198, P453, DOI 10.1126/science.198.4316.453; AZBEL IYA, 1993, METEORITICS, V28, P609, DOI 10.1111/j.1945-5100.1993.tb00631.x; BASFORD JR, 1973, P LUNAR PLANET SCI C, V4, P1915; BERNATOWICZ TJ, 1978, NUCL COMPONENTS ATMO; BOULOS MS, 1971, SCIENCE, V174, P1334, DOI 10.1126/science.174.4016.1334; Brown H., 1952, ATMOSPHERES EARTH PL, P258; BUTLER WA, 1963, J GEOPHYS RES, V68, P3283, DOI 10.1029/JZ068i010p03283; CHIVAS AR, 1987, NATURE, V326, P587, DOI 10.1038/326587a0; CLAYTON RN, 1984, J GEOPHYS RES, V89, P245; CRABB J, 1981, GEOCHIM COSMOCHIM AC, V45, P2443, DOI 10.1016/0016-7037(81)90097-1; CRAIG H, 1976, EARTH PLANET SC LETT, V31, P369, DOI 10.1016/0012-821X(76)90118-7; CRAIG H, 1975, EARTH PLANET SC LETT, V26, P125, DOI 10.1016/0012-821X(75)90079-5; DROZD RJ, 1977, ASTROPHYS J, V212, P567, DOI 10.1086/155076; FARLEY KA, 1993, EARTH PLANET SC LETT, V114, P325, DOI 10.1016/0012-821X(93)90034-7; HENNECKE EW, 1975, EARTH PLANET SC LETT, V27, P346, DOI 10.1016/0012-821X(75)90047-3; HIYAGON H, 1992, GEOCHIM COSMOCHIM AC, V56, P1301, DOI 10.1016/0016-7037(92)90063-O; HOHENBERG CM, 1967, SCIENCE, V156, P233, DOI 10.1126/science.156.3772.233; HONDA M, 1991, NATURE, V349, P149, DOI 10.1038/349149a0; HONDA M, 1993, GEOCHIM COSMOCHIM AC, V57, P859, DOI 10.1016/0016-7037(93)90174-U; HUDSON GB, 1989, P LUN PLAN SCI C 19, P547; HUNTEN DM, 1987, ICARUS, V69, P532, DOI 10.1016/0019-1035(87)90022-4; HUNTEN DM, 1988, METEORITES EARLY SOL, P565; KANEOKA I, 1978, EARTH PLANET SC LETT, V39, P382, DOI 10.1016/0012-821X(78)90026-2; KENNEDY BM, 1988, GEOCHIM COSMOCHIM AC, V52, P101, DOI 10.1016/0016-7037(88)90059-2; Kunz J, 1998, SCIENCE, V280, P877, DOI 10.1126/science.280.5365.877; MARTY B, 1989, EARTH PLANET SC LETT, V94, P45, DOI 10.1016/0012-821X(89)90082-4; NIER AO, 1950, PHYS REV, V77, P789, DOI 10.1103/PhysRev.77.789; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; OZIMA M, 1991, EARTH PLANET SC LETT, V105, P13, DOI 10.1016/0012-821X(91)90117-Z; OZIMA M, 1994, REV GEOPHYS, V32, P405, DOI 10.1029/94RG01875; OZIMA M, 1985, NATURE, V315, P471, DOI 10.1038/315471a0; OZIMA M, 1983, EARTH PLANET SC LETT, V62, P24, DOI 10.1016/0012-821X(83)90068-7; OZIMA M, 1988, GEOCHIM COSMOCHIM AC, V52, P19, DOI 10.1016/0016-7037(88)90052-X; OZIMA M, 1989, ORIGIN EVOLUTION PLA, P306; Pepin RO, 1997, ICARUS, V126, P148, DOI 10.1006/icar.1996.5639; PEPIN RO, 1991, ICARUS, V92, P2, DOI 10.1016/0019-1035(91)90036-S; PEPIN RO, 1992, ANNU REV EARTH PL SC, V20, P389, DOI 10.1146/annurev.ea.20.050192.002133; PHINNEY D, 1978, J GEOPHYS RES, V83, P2313, DOI 10.1029/JB083iB05p02313; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P1991, DOI 10.1016/0016-7037(95)00122-0; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; REYNOLDS JH, 1964, J GEOPHYS RES, V69, P3263, DOI 10.1029/JZ069i015p03263; SARDA P, 1988, EARTH PLANET SC LETT, V91, P73, DOI 10.1016/0012-821X(88)90152-5; SARDA P, 1991, NATURE, V352, P388, DOI 10.1038/352388a0; SHILLIBEER HA, 1955, GEOCHIM COSMOCHIM AC, V8, P16, DOI 10.1016/0016-7037(55)90014-4; SMITH SP, 1981, EARTH PLANET SC LETT, V54, P236, DOI 10.1016/0012-821X(81)90006-6; STAUDACHER T, 1982, EARTH PLANET SC LETT, V60, P605; TURCOTTE DL, 1986, REV GEOPHYS, V24, P311, DOI 10.1029/RG024i002p00311; TUREKIAN KK, 1959, GEOCHIM COSMOCHIM AC, V17, P37, DOI 10.1016/0016-7037(59)90077-8; TUREKIAN KK, 1969, EARTH PLANET SC LETT, V6, P346, DOI 10.1016/0012-821X(69)90183-6; WEIDENSCHILLING SJ, 1980, ICARUS, V44, P172, DOI 10.1016/0019-1035(80)90064-0; WETHERILL GW, 1954, PHYS REV, V96, P679, DOI 10.1103/PhysRev.96.679; WIELER R, 1994, METEORITICS, V29, P570, DOI 10.1111/j.1945-5100.1994.tb00770.x; WOOLUM DS, 1999, LUNAR PLANET SCI, V30; ZAHNLE K, 1990, ICARUS, V84, P502, DOI 10.1016/0019-1035(90)90050-J; ZAHNLE K, 1990, GEOCHIM COSMOCHIM AC, V54, P2577, DOI 10.1016/0016-7037(90)90243-E; ZAHNLE KJ, 1982, REV GEOPHYS, V20, P280, DOI 10.1029/RG020i002p00280	59	85	85	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2115	2118		10.1126/science.285.5436.2115	http://dx.doi.org/10.1126/science.285.5436.2115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497127				2022-12-28	WOS:000082734300039
J	Montagne, J; Stewart, MJ; Stocker, H; Hafen, E; Kozma, SC; Thomas, G				Montagne, J; Stewart, MJ; Stocker, H; Hafen, E; Kozma, SC; Thomas, G			Drosophila S6 kinase: A regulator of cell size	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; WING DEVELOPMENT; GROWTH; MELANOGASTER; COORDINATION; ACTIVATION; DIVISION; PROTEIN; CYCLE; DISKS	Cell proliferation requires cell growth; that is. cells only divide after they reach a critical size. However, the mechanisms by which cells grow and maintain their appropriate size have remained elusive. Drosophila deficient in the S6 kinase gene (dS6K) exhibited an extreme delay in development and a severe reduction in body size. These flies had smaller cells rather than fewer cells. The effect was cell-autonomous, displayed throughout Larval development, and distinct from that of ribosomal protein mutants (Minutes). Thus, the dS6K gene product regulates cell size in a cell-autonomous manner without impinging on cell number.	Friedrich Miescher Inst, CH-4056 Basel, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Zurich	Thomas, G (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4056 Basel, Switzerland.		Thomas, George/K-9235-2014; Stoecker, Horst/F-8382-2012	Thomas, George/0000-0003-3518-8149; Stoecker, Horst/0000-0002-3282-3664	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015926] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM15926] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BRAND AH, 1993, DEVELOPMENT, V118, P401; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CONSORTIUM TF, 1994, NUCLEIC ACIDS RES, V22, P3456; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; FRISTROM D, 1993, DEVELOPMENT, V117, P509; GARCIABELLIDO A, 1994, P NATL ACAD SCI USA, V91, P10222, DOI 10.1073/pnas.91.21.10222; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GLOOR GB, 1993, GENETICS, V135, P81; Gorfinkiel N, 1997, GENE DEV, V11, P2259, DOI 10.1101/gad.11.17.2259; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KARPEN GH, 1992, GENETICS, V132, P737; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MITCHISON JM, 1971, BIOL CELL CYCLE; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nurse P., 1985, P185; PIRROTTA V, 1986, DROSOPHILA PRACTICAL, P82; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUBIGER M, 1987, DEV BIOL, V123, P145, DOI 10.1016/0012-1606(87)90436-2; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; STEWART MJ, 1993, MOL CELL BIOL, V13, P2524, DOI 10.1128/MCB.13.4.2524; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; XU T, 1993, DEVELOPMENT, V117, P1223	41	599	617	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2126	2129		10.1126/science.285.5436.2126	http://dx.doi.org/10.1126/science.285.5436.2126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497130				2022-12-28	WOS:000082734300042
J	Farooqi, IS; Jebb, SA; Langmack, G; Lawrence, E; Cheetham, CH; Prentice, AM; Hughes, IA; McCamish, MA; O'Rahilly, S				Farooqi, IS; Jebb, SA; Langmack, G; Lawrence, E; Cheetham, CH; Prentice, AM; Hughes, IA; McCamish, MA; O'Rahilly, S			Effects of recombinant leptin therapy in a child with congenital leptin deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBESE GENE; ENERGY-EXPENDITURE; FEMALE MICE; WEIGHT; PROTEIN; SIGNAL; ONSET; MUTATION; PUBERTY; HUMANS		Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England; MRC, Dunn Clin Nutr Unit, Cambridge, England; Amgen Inc, Thousand Oaks, CA 91320 USA; Wycombe Hosp, Dept Paediat, High Wycombe, Bucks, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Amgen	O'Rahilly, S (corresponding author), Addenbrookes Hosp, Dept Med, Box 157, Cambridge CB2 2QQ, England.		O'Rahilly, Stephen/ABF-6509-2020; Farooqi, Ismaa Sadaf/AAZ-3046-2020; Prentice, Andrew/AAG-1961-2019	O'Rahilly, Stephen/0000-0003-2199-4449; Langmack, Gill/0000-0002-6198-1274; Farooqi, Sadaf/0000-0001-7609-3504; Jebb, Susan/0000-0001-9190-2920	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; APTER D, 1993, J CLIN ENDOCR METAB, V76, P940, DOI 10.1210/jc.76.4.940; Barash IA, 1996, ENDOCRINOLOGY, V137, P3144, DOI 10.1210/en.137.7.3144; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; Butler MG, 1998, AM J MED GENET, V75, P7, DOI 10.1002/(SICI)1096-8628(19980106)75:1<7::AID-AJMG3>3.3.CO;2-B; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DESIMONE M, 1995, INT J OBESITY, V19, P851; DUBUC PU, 1976, METABOLISM, V25, P1567, DOI 10.1016/0026-0495(76)90109-8; EDWARDSON JA, 1975, J ENDOCRINOL, V65, P99, DOI 10.1677/joe.0.0650099; Ellis KJ, 1997, PEDIATR RES, V42, P484, DOI 10.1203/00006450-199710000-00010; FOMON SJ, 1982, AM J CLIN NUTR, V35, P1169, DOI 10.1093/ajcn/35.5.1169; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jebb SA, 1997, BRIT J NUTR, V77, P151, DOI 10.1079/BJN19970021; LIVINGSTONE MBE, 1992, AM J CLIN NUTR, V56, P343, DOI 10.1093/ajcn/56.2.343; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MURGATROYD PR, 1993, INT J OBESITY, V17, P549; Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy, 1991, 41 PAN DIET REF VAL; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PRENTICE AM, 1990, NAHRES, V4; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; TANNER JM, 1975, ARCH DIS CHILD, V50, P14, DOI 10.1136/adc.50.1.14; Tanner JM, 1975, ASSESSMENT SKELETAL; TRAYHURN P, 1977, NATURE, V266, P60, DOI 10.1038/266060a0; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1291	1337	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					879	884		10.1056/NEJM199909163411204	http://dx.doi.org/10.1056/NEJM199909163411204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10486419				2022-12-28	WOS:000082569100004
J	Asta, LM				Asta, LM			Mikey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1019	1020		10.1001/jama.282.11.1019	http://dx.doi.org/10.1001/jama.282.11.1019			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493187				2022-12-28	WOS:000082512300001
J	Kerse, NM; Flicker, L; Jolley, D; Arroll, B; Young, D				Kerse, NM; Flicker, L; Jolley, D; Arroll, B; Young, D			Improving the health behaviours of elderly people: randomised controlled trial of a general practice education programme	BRITISH MEDICAL JOURNAL			English	Article							CUSTOMARY PHYSICAL-ACTIVITY; SOCIAL SUPPORT; COMMUNITY; PROMOTION; POPULATION; PREVENTION; MORTALITY; SURVIVAL; FITNESS; ADULTS	Objectives To establish the effect of art educational intervention for general practitioners on the health behaviours and wellbeing of elderly patients. Design Randomised controlled trial with 1 year follow up. Setting Metropolitan general practices in Melbourne, Australia. Subjects 42 general practitioners and 267 of their patients aged over 65 years. Intervention Educational and clinical practice audit programme for general practitioners on health promotion for elderly people. Main outcome measures Patients' physical activity, functional status, self rated health, immunisation status, social contacts, psychological wellbeing, drug usage, and rate of influenza vaccination. Primary efficacy variables were changes in outcome measures over 1 year period. Results Patients in the intervention group had increased (a) walking by an average of 88 minutes per fortnight, (b) frequency of pleasurable activities, and (c) self rated health compared with the control group. No change was seen in drug usage, rate of influenza vaccination, functional status. or psychological wellbeing as a result of the intervention. Extrapolations of the known effect of these changes in behaviour suggest mortality could be reduced by 22% if activity was sustained for 5 years. Conclusions Education of the general practitioners had a positive effect on health outcomes of their elderly patients. General practitioners may have considerable public health impact in promotion of health for elderly patients.	Univ Melbourne, Dept Gen Practice & Publ Hlth, Parkville, Vic 3052, Australia; Natl Aging Res Inst, Parkville, Vic, Australia	University of Melbourne	Kerse, NM (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Gen Practice & Primary Hlth Care, Private Bag 92019, Auckland, New Zealand.		Flicker, Leon/AAE-1530-2022; Kerse, Ngaire/AFF-8119-2022	Flicker, Leon/0000-0002-3650-0475; 				ANDERSON P, 1993, BRIT J GEN PRACT, V43, P386; ATKIN PA, 1995, ADVERSE DRUG REACT T, V14, P175; *AUSTR BUR STAT, 1989, NAT HLTH SURV; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLAZER DG, 1982, AM J EPIDEMIOL, V115, P684, DOI 10.1093/oxfordjournals.aje.a113351; BOWLING A, 1991, FAM PRACT, V8, P68, DOI 10.1093/fampra/8.1.68; Bridges-Webb Charles, 1992, Medical Journal of Australia, V157, pS1; COULTER A, 1995, BRIT MED J, V310, P1099; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; DALLOSSO HM, 1988, J EPIDEMIOL COMMUN H, V42, P121, DOI 10.1136/jech.42.2.121; FIX AJ, 1988, HUMAN ACTIVITIES PRO, P25; GOLDSTEIN H, 1986, BIOMETRIKA, V73, P43; HAMDORF PA, 1993, ARCH PHYS MED REHAB, V74, P473, DOI 10.1016/0003-9993(93)90108-M; HILLSDON M, 1995, J EPIDEMIOL COMMUN H, V49, P448, DOI 10.1136/jech.49.5.448; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MACINTYRE CR, 1993, MED J AUSTRALIA, V159, P257; Morgan K, 1997, J EPIDEMIOL COMMUN H, V51, P490, DOI 10.1136/jech.51.5.490; National Heart Foundation and Australian Institute of Health and Welfare, 1990, RISK FACT PREV STUD; SCHMIDT RM, 1993, METHOD INFORM MED, V32, P245; Shenfield GM, 1996, HEALTH PROMOT J AUST, V6, P14; VETTER NJ, 1990, AGE AGEING, V19, P164, DOI 10.1093/ageing/19.3.164; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Williams P, 1997, AUST NZ J PUBL HEAL, V21, P45, DOI 10.1111/j.1467-842X.1997.tb01653.x; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	28	88	89	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					683	687		10.1136/bmj.319.7211.683	http://dx.doi.org/10.1136/bmj.319.7211.683			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480825	Green Published, Bronze			2022-12-28	WOS:000082636800025
J	Parsons, H				Parsons, H			More doctors would aid communication	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					717	717		10.1136/bmj.319.7211.717	http://dx.doi.org/10.1136/bmj.319.7211.717			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480853	Green Published			2022-12-28	WOS:000082636800070
J	Singer, ST; Vichinsky, EP				Singer, ST; Vichinsky, EP			Bone disease in beta-thalassaemia	LANCET			English	Editorial Material							THALASSEMIA MAJOR; OSTEOPOROSIS; OSTEOPENIA; DENSITY; GROWTH		Childrens Hosp Oakland, Div Hematol Oncol, Oakland, CA 94609 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Singer, ST (corresponding author), Childrens Hosp Oakland, Div Hematol Oncol, Oakland, CA 94609 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				DeSanctis V, 1996, EUR J PEDIATR, V155, P368, DOI 10.1007/BF01955263; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Filosa A, 1996, J PEDIATR ENDOCR MET, V9, P401; Filosa A, 1997, ACTA PAEDIATR, V86, P342, DOI 10.1111/j.1651-2227.1997.tb09019.x; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; Jensen CE, 1998, BRIT J HAEMATOL, V103, P911; Pafumi C, 1998, J PEDIATR ENDOCR MET, V11, P989; POOTRAKUL P, 1981, NEW ENGL J MED, V304, P1470, DOI 10.1056/NEJM198106113042406; Roth C, 1997, EUR J PEDIATR, V156, P777, DOI 10.1007/s004310050711; Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502; Wonke B, 1998, J PEDIATR ENDOCR MET, V11, P795	11	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					881	882		10.1016/S0140-6736(99)00013-6	http://dx.doi.org/10.1016/S0140-6736(99)00013-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489942				2022-12-28	WOS:000082511800005
J	Loxterkamp, D				Loxterkamp, D			Facing our morality - The virtue of a common life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BERGER J, 1997, FORTUNATE MAN, P105; COLES R, 1989, CALL STORIES, P117; DICKENS C, 1920, CHRISTMAS CAROL, P33; PELLEGRINO ED, 1990, B NEW YORK ACAD MED, V66, P221; SMITH H, 1986, PROFESSIONAL ETHICS, P50	5	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					923	924		10.1001/jama.282.10.923	http://dx.doi.org/10.1001/jama.282.10.923			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485661				2022-12-28	WOS:000082335900001
J	Eikelboom, JW; Lonn, E; Genest, J; Hankey, G; Yusuf, S				Eikelboom, JW; Lonn, E; Genest, J; Hankey, G; Yusuf, S			Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; ENDOTHELIAL-CELL INJURY; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; PLASMA TOTAL HOMOCYSTEINE; PROTEIN-C ACTIVATION; RISK FACTOR; VASCULAR-DISEASE; MYOCARDIAL-INFARCTION; ARTERY DISEASE; ATHEROSCLEROTIC DISEASE	Purpose: To review epidemiologic studies on the association between homocyst(e)ine level and risk for cardiovascular disease and the potential benefits of homocysteine-decreasing therapies. Data Sources: Computerized and manual searches of the literature on total homocysteine levels and cardiovascular disease. Study Selection: Prospective studies and major retrospective epidemiologic studies evaluating the association between homocyst(e)ine levels and cardiovascular disease and the association between blood levels or dietary intake of folate, vitamin B-6, and vitamin B-12 and cardiovascular disease. Data Extraction: Relevant data on patient population, plasma homocyst(e)ine levels, duration of follow-up, and main results were extracted from studies that met the inclusion criteria. Data Synthesis: The designs and results of studies included in this review are summarized. A formal metaanalysis was not performed because the studies were heterogeneous in method and design. Conclusions: Results of epidemiologic studies suggest that moderately elevated plasma or serum homocyst(e)ine levels are prevalent in the general population and are associated with an increased risk for cardiovascular disease, independent of classic cardiovascular risk factors. Simple, inexpensive, nontoxic therapy with folic acid, vitamin B-6, and vitamin B-12 reduces plasma homocyst(e)ine levels. Although the association between homocyst(e)ine levels and cardiovascular disease is generally strong and biologically plausible, the data from the prospective studies are less consistent. In addition, epidemiologic observations of an association between hyperhomocyst(e)inemia and cardiovascular risk do not prove the existence of a causal relation. Therefore, the effectiveness of folate, vitamin B-6, and vitamin B-12 in reducing cardiovascular morbidity and mortality requires rigorous testing in randomized clinical trials. Several such trials are under way; their results may greatly affect cardiovascular morbidity and mortality, given the simplicity and low cost of vitamin therapy.	McMaster Univ, HGH, McMaster Clin, Prevent Cardiol & Therapeut Program, Hamilton, ON L8L 2X2, Canada; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia	McMaster University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Royal Perth Hospital; University of Western Australia	Lonn, E (corresponding author), McMaster Univ, HGH, McMaster Clin, Prevent Cardiol & Therapeut Program, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.		Hankey, Graeme J/H-4968-2014; Eikelboom, John/AAG-6117-2019	Hankey, Graeme J/0000-0002-6044-7328; Eikelboom, John/0000-0003-4126-1285; Yusuf, Salim/0000-0003-4776-5601				Alfthan G, 1997, LANCET, V349, P397, DOI 10.1016/S0140-6736(97)80014-1; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Aronow WS, 1997, AM J CARDIOL, V79, P1432, DOI 10.1016/S0002-9149(97)00161-6; Arruda VR, 1997, THROMB HAEMOSTASIS, V77, P818; BLOM HJ, 1992, J INHERIT METAB DIS, V15, P419, DOI 10.1007/BF02435993; Blundell G, 1996, ATHEROSCLEROSIS, V122, P163, DOI 10.1016/0021-9150(95)05730-7; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; Bots ML, 1999, ARCH INTERN MED, V159, P38, DOI 10.1001/archinte.159.1.38; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; CELERMAJER DS, 1993, J AM COLL CARDIOL, V22, P854, DOI 10.1016/0735-1097(93)90203-D; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; Clarke R, 1998, J Cardiovasc Risk, V5, P249, DOI 10.1097/00043798-199808000-00007; CLARKE R, 1992, IRISH J MED SCI, V161, P61, DOI 10.1007/BF02983714; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; deBree A, 1997, EUR J CLIN NUTR, V51, P643, DOI 10.1038/sj.ejcn.1600467; den Heijer M, 1998, ARTERIOSCL THROM VAS, V18, P356, DOI 10.1161/01.ATV.18.3.356; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Frantzen F, 1998, CLIN CHEM, V44, P311; FRAUSCHER G, 1995, LIFE SCI, V57, P813, DOI 10.1016/0024-3205(95)02009-8; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GILES WH, 1995, STROKE, V26, P1166, DOI 10.1161/01.STR.26.7.1166; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GORDON T, 1974, J CHRON DIS, V27, P329, DOI 10.1016/0021-9681(74)90013-7; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; Halvorsen B, 1996, J LIPID RES, V37, P1591; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HAYASHI T, 1992, BLOOD, V79, P2930; HOPKINS PN, 1995, ARTERIOSCL THROM VAS, V15, P1314, DOI 10.1161/01.ATV.15.9.1314; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; Konecky N, 1997, AM HEART J, V133, P534, DOI 10.1016/S0002-8703(97)70148-0; Krans JP, 1998, EUR J PEDIATR, V157, pS50, DOI 10.1007/PL00014304; *LAB CTR DIS CONTR, 1999, HEART DIS STROK CAN, V2; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; LONN E, HEART OUTCOMES PREVE; Malinow MR, 1996, ATHEROSCLEROSIS, V126, P27, DOI 10.1016/0021-9150(96)05890-X; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Markus HS, 1997, STROKE, V28, P1739, DOI 10.1161/01.STR.28.9.1739; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Montalescot G, 1997, INT J CARDIOL, V60, P295, DOI 10.1016/S0167-5273(97)00099-5; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MUDD SH, 1985, AM J HUM GENET, V37, P1; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; Robinson K, 1998, CIRCULATION, V97, P437; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P31; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Stehouwer CDA, 1998, ARTERIOSCL THROM VAS, V18, P1895, DOI 10.1161/01.ATV.18.12.1895; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tawakol A, 1997, CIRCULATION, V95, P1119; Tonstad S, 1996, ARTERIOSCL THROM VAS, V16, P984, DOI 10.1161/01.ATV.16.8.984; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UBBINK JB, 1992, CLIN CHIM ACTA, V207, P119, DOI 10.1016/0009-8981(92)90155-J; UELAND PM, 1995, CLIN CHEM, V41, P340; vandenBerg M, 1996, ARTERIOSCL THROM VAS, V16, P165, DOI 10.1161/01.ATV.16.1.165; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1997, ARTERIOSCL THROM VAS, V17, P989, DOI 10.1161/01.ATV.17.5.989; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; *VITATOPS STUD GRO, VIT PREV STROK VITAT; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WILSON JW, 1999, DATA TABLES COMBINED; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	95	699	736	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					363	375		10.7326/0003-4819-131-5-199909070-00008	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00008			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475890				2022-12-28	WOS:000082458500007
J	Schafer, WR				Schafer, WR			How do antidepressants work? Prospects for genetic analysis of drug mechanisms	CELL			English	Review							CAENORHABDITIS-ELEGANS		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Schafer, WR (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Schafer, William/0000-0002-6676-8034				BALDESSARINI RJ, 1996, PHARM BASIS THERAPEU; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Choy RKM, 1999, MOL CELL, V4, P143, DOI 10.1016/S1097-2765(00)80362-7; CULOTTI JG, 1994, CURR OPIN GENET DEV, V4, P587, DOI 10.1016/0959-437X(94)90077-G; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; JOHNSON CD, 1985, J NEUROSCI, V5, P1984; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LEONARD BE, 1994, PSYCHOPHARMACOLOGY D, P19; MCALLISTERWILLI.RH, 1998, NEW MODELS DEPRESSIO; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Rand J.B., 1997, C ELEGANS, VII; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; van Swinderen B, 1999, P NATL ACAD SCI USA, V96, P2479, DOI 10.1073/pnas.96.5.2479; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734	16	46	49	2	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					551	554		10.1016/S0092-8674(00)80042-2	http://dx.doi.org/10.1016/S0092-8674(00)80042-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490094	Bronze			2022-12-28	WOS:000082433500002
J	Davis, D; O'Brien, MAT; Freemantle, N; Wolf, FM; Mazmanian, P; Taylor-Vaisey, A				Davis, D; O'Brien, MAT; Freemantle, N; Wolf, FM; Mazmanian, P; Taylor-Vaisey, A			Impact of formal continuing medical education - Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIALS; GENERAL-PRACTITIONERS; MYOCARDIAL-INFARCTION; PROFESSIONAL PRACTICE; CME; INTERVENTIONS; METAANALYSIS; GUIDELINES; PROGRAM; IMPROVE	Context Although physicians report spending a considerable amount of time in continuing medical education (CME) activities, studies have shown a sizable difference between real and ideal performance, suggesting a lack of effect of formal CME. Objective To review, collate, and interpret the effect of formal CME interventions on physician performance and health care outcomes. Data Sources Sources included searches of the complete Research and Development Resource Base in Continuing Medical Education and the Specialised Register of the Cochrane Effective Practice and Organisation of Care Group, supplemented by searches of MEDLINE from 1993 to January 1999. Study Selection Studies were included in the analyses if they were randomized controlled trials of formal didactic and/or interactive CME interventions (conferences, courses, rounds, meetings, symposia, lectures, and other formats) in which at least 50% of the participants were practicing physicians. Fourteen of 64 studies identified met these criteria and were included in the analyses. Articles were reviewed independently by 3 of the authors. Data Extraction Determinations were made about the nature of the CME intervention (didactic, interactive, or mixed), its occurrence as a 1-time or sequenced event, and other information about its educational content and format. Two of 3 reviewers independently applied all inclusion/exclusion criteria. Data were then subjected to metaanalytic techniques. Data Synthesis The 14 studies generated 17 interventions fitting our criteria. Nine generated positive changes in professional practice, and 3 of 4 interventions altered health care outcomes in 1 or more measures. In 7 studies, sufficient data were available for effect sizes to be calculated; overall, no significant effect of these educational methods was detected (standardized effect size, 0.34; 95% confidence interval [CI], -0.22 to 0.97). However, interactive and mixed educational sessions were associated with a significant effect on practice (standardized effect size, 0.67; 95% CI, 0.01-1.45). Conclusions Our data show some evidence that interactive CME sessions that enhance participant activity and provide the opportunity to practice skills can effect change in professional practice and, on occasion, health care outcomes. Based on a small number of well-conducted trials, didactic sessions do not appear to be effective in changing physician performance.	Univ Toronto, Fac Med, Toronto, ON M5S 1A8, Canada; McMaster Univ, Sch Rehabil Sci, Hamilton, ON L8S 4L8, Canada; Social & Publ Hlth Serv, Hamilton, ON, Canada; Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO1 5DD, N Yorkshire, England; Univ Washington, Dept Med Educ, Seattle, WA 98195 USA; Virginia Commonwealth Univ, Med Coll Virginia Campus, Richmond, VA 23298 USA	University of Toronto; McMaster University; University of York - UK; University of Washington; University of Washington Seattle; Virginia Commonwealth University	Davis, D (corresponding author), Univ Toronto, Fac Med, 150 Coll St, Toronto, ON M5S 1A8, Canada.			Taylor-Vaisey, Anne/0000-0002-9650-0418; Freemantle, Nick/0000-0001-5807-5740	FIC NIH HHS [1 F06 TW 02123] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002123] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		*ACCR COUNC CONT M, 1997, ACCME REP; *AM MED ASS, 1998, PHYS REC AW INF BOOK; BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; Berlo David K., 1960, PROCESS COMMUNICATIO; BERO L, 1999, COCHRANE EFFECTIVE P; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Boissel JP, 1995, REV EPIDEMIOL SANTE, V43, P541; Brookfield S., 1986, UNDERSTANDING FACILI; BROWNER WS, 1994, WESTERN J MED, V161, P572; Campbell C.M, 1999, J CONTIN EDUC HEALTH, V19, P16; Candy PC., 1991, SELF DIRECTION LIFEL; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Cross KP, 1981, ADULTS LEARNERS INCR; CURRY L, 1986, J MED EDUC, V61, P579; CURRY L, 1981, CAN MED ASSOC J, V124, P563; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; DIFFORD F, 1992, BRIT J GEN PRACT, V42, P290; Festinger L., 1957, THEORY COGNITIVE DIS, V2; FOX RD, 1989, CHANGING LEARNING LI; Freemantle N, 1998, J EPIDEMIOL COMMUN H, V52, P75, DOI 10.1136/jech.52.2.75; Goulet F, 1998, CAN FAM PHYSICIAN, V44, P541; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; Grimshaw JM, 1998, J ROY SOC MED, V91, P20, DOI 10.1177/014107689809135S06; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HEALE J, 1988, P ANN C RES MED ED, V27, P72; JENNETT PA, 1988, MED EDUC, V22, P139, DOI 10.1111/j.1365-2923.1988.tb00424.x; Kanouse D E, 1988, Int J Technol Assess Health Care, V4, P27; Knowles MS, 1970, MODERN PRACTICE ADUL; KOTTKE TE, 1989, JAMA-J AM MED ASSOC, V261, P2101, DOI 10.1001/jama.261.14.2101; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; Lewin K., 1975, FIELD THEORY SOCIAL; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; MALMAN LA, 1988, AJDC, V142, P773; Mason J, 1999, J Health Serv Res Policy, V4, P106; Mazmanian PE, 1998, ACAD MED, V73, P882, DOI 10.1097/00001888-199808000-00013; MAZMANIAN PE, 1990, J CONTIN EDUC HEALTH, V10, P23; Moher D, 1998, JAMA-J AM MED ASSOC, V279, P1489, DOI 10.1001/jama.279.18.1489; MOORE DE, 1994, J CONTIN ED HLTH PRO, V14, P4, DOI DOI 10.1002/CHP.4750140102; Ockene IS, 1996, AM J PREV MED, V12, P252, DOI 10.1016/S0749-3797(18)30321-0; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PARBOOSINGH IJT, 1993, CAN J SURG, V36, P29; PERERA DR, 1983, J FAM PRACTICE, V16, P785; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Schon D.A., 1990, ED REFLECTIVE PRACTI; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; TAYLORVAISEY AL, 1995, J CONTIN ED HLTH PRO, V15, P117; THOMSON MA, 1999, ED M WORKSH PREC IMP; WHITE CW, 1985, ANN INTERN MED, V102, P686, DOI 10.7326/0003-4819-102-5-686; WILSON DMC, 1992, CAN FAM PHYSICIAN, V38, P2003; Wood J, 1999, J Health Serv Res Policy, V4, P44	56	1623	1646	1	112	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					867	874		10.1001/jama.282.9.867	http://dx.doi.org/10.1001/jama.282.9.867			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478694				2022-12-28	WOS:000082272200013
J	Yerly, S; Kaiser, L; Race, E; Bru, JP; Clavel, F; Perrin, L				Yerly, S; Kaiser, L; Race, E; Bru, JP; Clavel, F; Perrin, L			Transmission of antiretroviral-drug-resistant HIV-1 variants	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITORS; IN-VIVO; ZIDOVUDINE; NEVIRAPINE; THERAPY; SWITZERLAND; PREVALENCE; LAMIVUDINE; INFECTION	Background Resistance of HIV-1 to antiretroviral drugs is the main cause of antiretroviral-treatment failure. We assessed the transmission of drug-resistant variants among individuals with primary HIV-1 infection. Methods Population-based sequencing of the viral reverse transcriptase and protease genes derived from plasma viral RNA was done in 82 consecutive individuals with documented primary HIV-1 infection from January, 1996, to July, 1998. Phenotypic resistance to protease inhibitors was assessed by recombinant virus assay in individuals with two or more mutations associated with resistance to protease inhibitors. Findings Zidovudine-resistance mutations were detected in seven (9%) of 82 individuals. Mutations associated with resistance to other reverse-transcriptase inhibitors (RTls) were detected in two individuals. Primary-resistance mutations associated with protease inhibitors (V82A, L90M) were detected in three (4%) of 70 individuals; two of these had also RTI-resistance mutations. Decreased sensitivity to three or four protease inhibitors was seen in three individuals, one of whom was infected with HIV-1 variants that harboured 12 mutations associated with resistance to multiple RTI and protease inhibitors. Interpretation To introduce the best antiretroviral treatment, resistance testing should be done in recently HIV-1-infected individuals.	Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Infect Dis, AIDS Unit, Geneva, Switzerland; Hop Xavier Bichat, INSERM, Antiviral Res Lab, Paris, France; Annecy Hosp Ctr, Div Infect Dis, Annecy, France	University of Geneva; University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Annecy Genevois	Perrin, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland.	luc.perrin@hcuge.ch		Kaiser, Laurent/0000-0002-0857-2252				Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Eron J, 1998, AIDS, V12, pS13; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; GRANT RM, 1998, ANTIVIR THER S, V3, P108; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; PERRIN L, 1998, 12 WORLD AIDS C GEN; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Schinazi R. F., 1997, International Antiviral News, V5, P129; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998	26	332	342	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					729	733		10.1016/S0140-6736(98)12262-6	http://dx.doi.org/10.1016/S0140-6736(98)12262-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475184				2022-12-28	WOS:000082233000012
J	Jewell, D				Jewell, D			Commentary: Use of personal experience should be legitimised	BRITISH MEDICAL JOURNAL			English	Editorial Material									Dept Epidemiol, Bristol BS8 2PR, Avon, England		Jewell, D (corresponding author), Dept Epidemiol, Canynge hall, Bristol BS8 2PR, Avon, England.							*GEN MED COUNC, 1993, TOM DOCT REC UND MED; PLATT R, 1965, BRIT MED J, V2, P551, DOI 10.1136/bmj.2.5461.551	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					296	296						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10495220				2022-12-28	WOS:000081909100026
J	Kageyama, K; Tamazawa, J; Aida, T				Kageyama, K; Tamazawa, J; Aida, T			Extrusion polymerization: Catalyzed synthesis of crystalline linear polyethylene nanofibers within a mesoporous silica	SCIENCE			English	Article							LONGITUDINAL GROWTH; FLOWING SOLUTIONS; PROPENE; DENDRIMERS; TEMPLATES; CHANNELS; ZEOLITE; MCM-41	Crystalline nanofibers of Linear polyethylene with an ultrahigh molecular weight (6,200,000) and a diameter of 30 to 50 nanometers were formed by the polymerization of ethylene with mesoporous silica fiber-supported titanocene, with methylalumoxane as a cocatalyst. Small-angle x-ray scattering analysis indicated that the polyethylene fibers consist predominantly of extended-chain crystals. This observation indicates a potential utility of the honeycomb-like porous framework as an extruder for nanofabrication of polymeric materials.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Aida, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	aida@macro.t.u-tokyo.ac.jp	Aida, Takuzo/I-9117-2012; Tajima, Keisuke/D-1530-2009	Tajima, Keisuke/0000-0003-1590-2640				Akagi K, 1998, SCIENCE, V282, P1683, DOI 10.1126/science.282.5394.1683; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n; Evans E, 1996, SCIENCE, V273, P933, DOI 10.1126/science.273.5277.933; Fischer M, 1999, ANGEW CHEM INT EDIT, V38, P885, DOI 10.1002/(SICI)1521-3773(19990401)38:7<884::AID-ANIE884>3.0.CO;2-K; Galland GB, 1999, MACROMOLECULES, V32, P1620, DOI 10.1021/ma981669h; Jiang DL, 1997, NATURE, V388, P454, DOI 10.1038/41290; Kageyama K, 1998, MACROMOLECULES, V31, P4069, DOI 10.1021/ma980270q; Ko YS, 1996, MACROMOL RAPID COMM, V17, P749, DOI 10.1002/marc.1996.030171101; Kobayashi S., 1997, CATALYSIS PRECISION; KRIMM S, 1951, J POLYM SCI, V7, P57, DOI 10.1002/pol.1951.120070105; LEE JH, 1994, P NATL ACAD SCI USA, V91, P7425, DOI 10.1073/pnas.91.16.7425; MANDELKERN L, 1961, J APPL PHYS, V32, P1509, DOI 10.1063/1.1728386; MASCHMEYER T, 1995, NATURE, V378, P159, DOI 10.1038/378159a0; NEVELL TP, 1985, CELLULOSE CHEM ITS A, pCH2; Ng SM, 1997, MACROMOL RAPID COMM, V18, P991, DOI 10.1002/marc.1997.030181201; NIEGISCH WD, 1960, J APPL PHYS, V31, P1906, DOI 10.1063/1.1735472; OKAMOTO Y, 1994, CHEM REV, V94, P349, DOI 10.1021/cr00026a004; PENNINGS A, 1972, J POLYMER SCI      C, V38, P167; PENNINGS AJ, 1979, J POLYM SCI POL PHYS, V17, P1011, DOI 10.1002/pol.1979.180170610; RANBY BG, 1960, J POLYM SCI, V44, P349, DOI 10.1002/pol.1960.1204414407; Roscoe SB, 1998, SCIENCE, V280, P270, DOI 10.1126/science.280.5361.270; SMITH P, 1980, J MATER SCI, V15, P505, DOI 10.1007/BF02396802; STUCKY GD, 1997, ADV MATER, V9, P974; TOMALIA DA, 1994, ADV MATER, V6, P529, DOI 10.1002/adma.19940060703; TORFS JCM, 1981, J APPL POLYM SCI, V26, P303, DOI 10.1002/app.1981.070260128; Tudor J, 1997, CHEM COMMUN, P603, DOI 10.1039/a607886i; Van Looveren LK, 1998, ANGEW CHEM INT EDIT, V37, P517, DOI 10.1002/(SICI)1521-3773(19980302)37:4<517::AID-ANIE517>3.0.CO;2-I; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887; WU CG, 1994, SCIENCE, V266, P1013, DOI 10.1126/science.266.5187.1013	30	435	465	8	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2113	2115		10.1126/science.285.5436.2113	http://dx.doi.org/10.1126/science.285.5436.2113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497126				2022-12-28	WOS:000082734300038
J	Pisetsky, DS				Pisetsky, DS			What we are made of	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1112	1112		10.1001/jama.282.12.1112-c	http://dx.doi.org/10.1001/jama.282.12.1112-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501098				2022-12-28	WOS:000082596200001
J	Levashina, EA; Langley, E; Green, C; Gubb, D; Ashburner, M; Hoffmann, JA; Reichhart, JM				Levashina, EA; Langley, E; Green, C; Gubb, D; Ashburner, M; Hoffmann, JA; Reichhart, JM			Constitutive activation of toll-mediated antifungal defense in serpin-deficient Drosophila	SCIENCE			English	Article							DORSAL-VENTRAL PATTERN; SIGNALING PATHWAY; GENE; PROTEIN; PEPTIDE; METCHNIKOWIN; EXPRESSION; POLARITY; EMBRYO	The antifungal defense of Drosophila is controlled by the spaetzle/Toll/cactus gene cassette, Here, a Loss-of-function mutation in the gene encoding a blood serine protease inhibitor, Spn43Ac, was shown to Lead to constitutive expression of the antifungal peptide drosomycin, and this effect was mediated by the spaetzle and Toll gene products. Spaetzle was cleaved by proteolytic enzymes to its active Ligand form shortly after immune challenge, and cleaved Spaetzle was constitutively present in Spn4Ac-deficient flies. Hence, Spn43Ac negatively regulates the Toll signaling pathway, and Toll does not function as a pattern recognition receptor in the Drosophila host defense.	Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Cambridge	Reichhart, JM (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	reichhart@ibmc.u-strasbg.fr	Gubb, David/F-9793-2011	Levashina, Elena/0000-0003-4605-906X				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boswell D. R., 1986, REC ADV CLIN IMMUNOL, V4, P1; BRAND AH, 1993, DEVELOPMENT, V118, P401; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Gerard C, 1998, NATURE, V395, P217, DOI 10.1038/26104; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giebel B, 1997, MECH DEVELOP, V63, P75, DOI 10.1016/S0925-4773(97)00029-4; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEITZLER P, 1993, GENETICS, V135, P105; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Iwanaga S, 1998, J BIOCHEM, V123, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	23	358	374	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1917	1919		10.1126/science.285.5435.1917	http://dx.doi.org/10.1126/science.285.5435.1917			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489372				2022-12-28	WOS:000082638300052
J	Komarov, PG; Komarova, EA; Kondratov, RV; Christov-Tselkov, K; Coon, JS; Chernov, MV; Gudkov, AV				Komarov, PG; Komarova, EA; Kondratov, RV; Christov-Tselkov, K; Coon, JS; Chernov, MV; Gudkov, AV			A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy	SCIENCE			English	Article							HEMATOPOIETIC GROWTH-FACTORS; TUMOR-SUPPRESSOR GENE; IN-VIVO; P53-DEFICIENT MICE; APOPTOSIS; RADIATION; TUMORIGENESIS; IRRADIATION; ACTIVATION; RESISTANCE	Chemotherapy and radiation therapy for cancer often have severe side effects that limit their efficacy. Because these effects are in part determined by p53-mediated apoptosis, temporary suppression of p53 has been suggested as a therapeutic strategy to prevent damage of normal tissues during treatment of p53-deficient tumors. To test this possibility, a small molecule was isolated for its ability to reversibly block p53-dependent transcriptional activation and apoptosis. This compound, pifithrin-alpha, protected mice from the Lethal genotoxic stress associated with anticancer treatment without promoting the formation of tumors. Thus, inhibitors of p53 may be useful dregs for reducing the side effects of cancer therapy and other types of stress associated with p53 induction.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Cleveland Clin Fdn, Res Inst, Cleveland, OH 44195 USA; Quark Biotech, Pleasanton, CA 94566 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Komarov, PG (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.			Kondratov, Roman/0000-0003-3449-745X; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179, CA60730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRONCHUD M, 1993, ANTI-CANCER DRUG, V4, P127, DOI 10.1097/00001813-199304000-00002; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Deichman GI, 1998, INT J CANCER, V75, P277, DOI 10.1002/(SICI)1097-0215(19980119)75:2<277::AID-IJC17>3.3.CO;2-H; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Johnston EM, 1998, SEMIN ONCOL, V25, P552; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KOMAROVA EA, UNPUB; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Steele RJC, 1998, BRIT J SURG, V85, P1460; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Westphal CH, 1998, CANCER RES, V58, P5637; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	31	1075	1136	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1733	1737		10.1126/science.285.5434.1733	http://dx.doi.org/10.1126/science.285.5434.1733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481009				2022-12-28	WOS:000082472600035
J	De Stefano, V; Martinelli, I; Mannucci, PM; Paciaroni, K; Chiusolo, P; Casorelli, I; Rossi, E; Leone, G				De Stefano, V; Martinelli, I; Mannucci, PM; Paciaroni, K; Chiusolo, P; Casorelli, I; Rossi, E; Leone, G			The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; INHERITED THROMBOPHILIA; 20210A ALLELE; GLN MUTATION; GENE; THROMBOEMBOLISM; RESISTANCE; PREVALENCE; ARG-506; VARIANT	Background Point mutations in the factor V gene (factor V Leiden) and the prothrombin gene (the substitution of A for G at position 20210) are the most common causes of inherited thrombophilia. Whether or not factor V Leiden increases the risk of recurrent deep venous thrombosis is controversial, and there is no information on the risk of recurrence among carriers of both mutations. Methods We studied a retrospective cohort of 624 patients who were referred for a first episode of deep venous thrombosis. After excluding 212 patients with other inherited or acquired causes of thrombophilia, we compared 112 patients who were heterozygous carriers of factor V Leiden with 17 patients who were heterozygous for both factor V Leiden and the prothrombin mutation and 283 patients who had neither mutation. The relative risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards model. Results Patients who were heterozygous for factor V Leiden alone had a risk of recurrent deep venous thrombosis that was similar to that among patients who had neither mutation (relative risk, 1.1; 95 percent confidence interval, 0.7 to 1.6; P = 0.76). In contrast, patients who were heterozygous for both factor V Leiden and the prothrombin mutation had a higher risk of recurrent thrombosis than did carriers of factor V Leiden alone (relative risk, 2.6; 95 percent confidence interval, 1.3 to 5.1; P = 0.002). When the analysis was restricted to patients with spontaneous recurrences (i.e., ones that occurred in the absence of transient risk factors for venous thrombosis), the risk among carriers of both mutations, as compared with carriers of factor V Leiden alone, remained high (relative risk, 3.7; 95 percent confidence interval, 1.7 to 7.7; P<0.001), particularly if the first event had also been spontaneous (relative risk, 5.4; 95 percent confidence interval, 2.0 to 14.1; P<0.001). In contrast, the risk of recurrence in the presence of transient risk factors was similar among carriers of both mutations and carriers of factor V Leiden alone. Conclusions The risk of recurrent deep venous thrombosis is similar among carriers of factor V Leiden and patients without this mutation. Carriers of both factor V Leiden and the G20210A prothrombin mutation have an increased risk of recurrent deep venous thrombosis after a first episode and are candidates for lifelong anticoagulation. (N Engl J Med 1999;341:801-6.) (C)1999, Massachusetts Medical Society.	Univ Cattolica, Ist Semeiot Med, Dept Hematol, I-00168 Rome, Italy; Univ Milan, Osped Maggiore, Ist Ricovero & Cura Carattere Sci, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	De Stefano, V (corresponding author), Univ Cattolica, Ist Semeiot Med, Dept Hematol, Largo Gemelli 8, I-00168 Rome, Italy.		De Stefano, Valerio/J-3650-2018; Giuseppe Leone, Full Professor/I-9166-2019; Martinelli, ida/J-2287-2015; CHIUSOLO, PATRIZIA/J-3003-2018	De Stefano, Valerio/0000-0002-5178-5827; Giuseppe Leone, Full Professor/0000-0002-7812-5300; Martinelli, ida/0000-0001-9218-3622; CHIUSOLO, PATRIZIA/0000-0002-1355-1587				[Anonymous], 1998, BR J HAEMATOL, V101, P374; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; De Stefano V, 1998, SEMIN THROMB HEMOST, V24, P367, DOI 10.1055/s-2007-996025; De Stefano V, 1998, THROMB HAEMOSTASIS, V80, P342; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Ehrenforth S, 1998, BLOOD, V91, P2209, DOI 10.1182/blood.V91.6.2209; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Eichinger S, 1999, THROMB HAEMOSTASIS, V81, P14; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P1047; Leroyer C, 1998, THROMB HAEMOSTASIS, V80, P49; Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684; Makris M, 1997, THROMB HAEMOSTASIS, V78, P1426; Margaglione M, 1998, ANN INTERN MED, V129, P89, DOI 10.7326/0003-4819-129-2-199807150-00003; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, CIRCULATION, V95, P1777; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; Zoller B, 1998, BLOOD, V91, P2210, DOI 10.1182/blood.V91.6.2210	28	327	341	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					801	806		10.1056/NEJM199909093411104	http://dx.doi.org/10.1056/NEJM199909093411104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477778				2022-12-28	WOS:000082534000004
J	Finnin, MS; Donigian, JR; Cohen, A; Richon, VM; Rifkind, RA; Marks, PA; Breslow, R; Pavletich, NP				Finnin, MS; Donigian, JR; Cohen, A; Richon, VM; Rifkind, RA; Marks, PA; Breslow, R; Pavletich, NP			Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors	NATURE			English	Article							TRANSFORMED-CELL DIFFERENTIATION; TRANSCRIPTIONAL REPRESSION; PROTEINS; INDUCERS	Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression(1). HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers(2,3). HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell. growth(4-6), induce terminal differentiation(4,5) and prevent the formation of tumours in mice models(7,8), and they are effective in the treatment of promyelocytic leukemia(3). Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolieus, that shares 35.2% identity with human HDACl over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.	nikola@xray2.mskcc.org		Finnin, Michael/0000-0003-2794-2703				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cohen L. A., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P108; Davie JR, 1998, J CELL BIOCHEM, P203; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DESAI D, 1999, P AM ASSOC CANC RES, V40, P2396; Fenrick R, 1998, J CELL BIOCHEM, P194; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; SHUTE RE, 1987, J MED CHEM, V30, P71, DOI 10.1021/jm00384a013; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; YOSHIDA T, 1993, CHEM EXPRESS, V8, P17	30	1420	1580	5	217	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					188	193		10.1038/43710	http://dx.doi.org/10.1038/43710			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490031				2022-12-28	WOS:000082458800060
J	Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR				Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR			Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-STREAM INFECTIONS; INSERTED CENTRAL CATHETERS; NOSOCOMIAL INFECTIONS; ACCESS DEVICES; VENOUS ACCESS; RECIPIENTS; POPULATION; PREVENTION; SYSTEM; CANCER	Background: Intravenous therapy in the outpatient and home settings is commonplace for many diseases and nutritional disorders. Few data are available on the rate of and risk factors for bloodstream infection among patients receiving such therapy. Objective: To determine rates of and risk factors for bloodstream infection among patients receiving home infusion therapy. Design: Prospective, observational cohort study. Setting: Cleveland, Ohio, and Toronto, Ontario, Canada. Patients: Patients receiving home infusion therapy through a central or midline catheter. Measurements: Primary laboratory-confirmed bloodstream infection. Results: Among 827 patients (988 catheters), the most common diagnoses were infections other than HIV (67%), cancer (24%), nutritional and digestive disease (17%), heart disease (14%), receipt of bone marrow or solid organ transplants (11%), and HIV infection (7%). Sixty-nine bloodstream infections occurred during 69 532 catheter-days (0.99 infections per 1000 days). In a Cox regression model with time-dependent covariates, independent risk factors for bloodstream infection were recent receipt of a bone marrow transplant (hazard ratio, 5.8 [95% CI, 3.0 to 11.3]), receipt of total parenteral nutrition (hazard ratio, 4.1 [CI, 2.3 to 7.2]), receipt of therapy outside the home (for example, in an outpatient clinic or physician's office) (hazard ratio, 3.6 [CI, 2.2 to 5.9]), use of a multilumen catheter (hazard ratio, 2.8 [CI, 1.7 to 4.7]), and previous bloodstream infection (hazard ratio, 2.5 [CI, 1.5 to 4.2]). Rates of bloodstream infection per 1000 catheter-days varied from 0.16 for patients with none of these 5 risk factors to 6.77 for patients with 3 or more risk factors. Centrally inserted venous catheters were associated with a higher risk than implanted ports were, but the difference was not statistically significant. Conclusion: Bloodstream infections seem to be infrequent among outpatients receiving infusions through central and midline catheters. However, the rate of infection increases with bone marrow transplantation, parenteral nutrition, infusion therapy in a hospital clinic or physician's office, and use of multilumen catheters. Compared with implanted ports or peripherally inserted catheters, centrally inserted venous catheters may confer greater risk for bloodstream infection.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Centers for Disease Control & Prevention - USA; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cleveland Clinic Foundation	Tokars, JI (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA.		mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				CAMPION E, 1998, NEW ENGL J MED, V333, P1213; Cookson ST, 1998, INFECT CONT HOSP EP, V19, P23; DANZIG LE, 1995, JAMA-J AM MED ASSOC, V273, P1862, DOI 10.1001/jama.273.23.1862; Do AN, 1999, J INFECT DIS, V179, P442, DOI 10.1086/314592; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Engelhard D, 1996, TRANSPLANTATION, V61, P430, DOI 10.1097/00007890-199602150-00020; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; HOWELL PB, 1995, CANCER, V75, P1367, DOI 10.1002/1097-0142(19950315)75:6<1367::AID-CNCR2820750620>3.0.CO;2-Z; Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477; Kellerman S, 1996, J PEDIATR-US, V129, P711, DOI 10.1016/S0022-3476(96)70154-3; LAM S, 1994, ARCH INTERN MED, V154, P1833, DOI 10.1001/archinte.154.16.1833; McDonald LC, 1998, INFECT CONT HOSP EP, V19, P772; Ng PK, 1997, MAYO CLIN PROC, V72, P225, DOI 10.4065/72.3.225; PARKER JW, 1995, J BONE JOINT SURG AM, V77A, P572, DOI 10.2106/00004623-199504000-00010; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pittet D, 1997, CLIN INFECT DIS, V24, P1068, DOI 10.1086/513640; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; RAVIGLIONE MC, 1989, AM J MED, V86, P780, DOI 10.1016/0002-9343(89)90473-7; *SAS I INC, 1992, P229 SAS I INC STAT, P434; Serody JS, 1997, INFECT DIS CLIN N AM, V11, P459, DOI 10.1016/S0891-5520(05)70365-2; Stroud L, 1997, INFECT CONT HOSP EP, V18, P479; VLADECK BC, 1994, JAMA-J AM MED ASSOC, V271, P1566	24	107	110	3	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					340	+		10.7326/0003-4819-131-5-199909070-00004	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475886				2022-12-28	WOS:000082458500003
J	Guay, LA; Musoke, P; Fleming, T; Bagenda, D; Allen, M; Nakabiito, C; Sherman, J; Bakaki, P; Ducar, C; Deseyve, M; Emel, L; Mirochnick, M; Fowler, MG; Mofenson, L; Miotti, P; Dransfield, K; Bray, D; Mmiro, F; Jackson, JB				Guay, LA; Musoke, P; Fleming, T; Bagenda, D; Allen, M; Nakabiito, C; Sherman, J; Bakaki, P; Ducar, C; Deseyve, M; Emel, L; Mirochnick, M; Fowler, MG; Mofenson, L; Miotti, P; Dransfield, K; Bray, D; Mmiro, F; Jackson, JB			Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1	Background The AIDS Clinical Trials Group protocol 076 zidovudine prophylaxis regimen for HIV-1-infected pregnant women and their babies has been associated with a significant decrease in vertical HIV-1 transmission in non-breastfeeding women in developed countries. We compared the safety and efficacy of short-course nevirapine or zidovudine during labour and the first week of life. Methods From November, 1997, to April, 1999, we enrolled 626 HIV-1-infected pregnant women at Mulago Hospital in Kampala, Uganda. We randomly assigned mothers nevirapine 200 mg orally at onset of labour and 2 mg/kg to babies within 72 h of birth, or zidovudine 600 mg orally to the mother at onset of labour and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily to babies for 7 days after birth. We tested babies for HIV-1 infection at birth, 6-8 weeks, and 14-16 weeks by HIV-1 RNA PCR. We assessed HIV-1 transmission and HIV-1-free survival with Kaplan-Meier analysis. Findings Nearly all babies (98.8%) were breastfed, and 95.6% were still breastfeeding at age 14-16 weeks. The estimated risks of HIV-1 transmission in the zidovudine and nevirapine groups were: 10.4% and 8.2% at birth (p=0.354); 21.3% and 11.9% by age 6-8 weeks (p=0.0027); and 25.1% and 13.1% by age 14-16 weeks (p=0.0006). The efficacy of nevirapine compared with zidovudine was 47% (95% CI 20-64) up to age 14-16 weeks. The two regimens were well tolerated and adverse events were similar in the two groups. Interpretation Nevirapine lowered the risk of HIV-1 transmission during the first 14-16 weeks of life by nearly 50% in a breastfeeding population. This simple and inexpensive regimen could decrease mother-to-child HIV-1 transmission in less-developed countries.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Makerere Univ, Dept Paediat, Kampala, Uganda; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, HIVNET Stat Ctr, Seattle, WA 98104 USA; Makerere Univ, Dept Obstet & Gynaecol, Kampala, Uganda; Family Hlth Int, Durham, NC USA; NIAID, Div AIDS, NIH, Boston, MA USA; NICHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD USA; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; Glaxo Wellcome, London, England	Johns Hopkins University; Makerere University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Makerere University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Boehringer Ingelheim; GlaxoSmithKline	Jackson, JB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Carnegie Bldg,Room 420,600 N Wolfe St, Baltimore, MD 21205 USA.	BJACKSO@jhmi.edu	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; jackson, brooks/0000-0001-9458-135X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Dunn DT, 1998, AIDS, V12, P2211, DOI 10.1097/00002030-199816000-00017; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mirochnick M, 1998, J INFECT DIS, V178, P368, DOI 10.1086/515641; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SABA J, 1999, 6 C RETR OPP INF CHI, V6; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Triques K, 1999, J CLIN MICROBIOL, V37, P110, DOI 10.1128/JCM.37.1.110-116.1999; *WHO, 1998, WKLY EPIDEMIOL REC, V73, P313; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Zhang H, 1996, J VIROL, V70, P628, DOI 10.1128/JVI.70.1.628-634.1996	20	1256	1279	0	54	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1999	354	9181					795	802		10.1016/S0140-6736(99)80008-7	http://dx.doi.org/10.1016/S0140-6736(99)80008-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485720	hybrid			2022-12-28	WOS:000082400700007
J	Freedman, RR; Girgis, R; Mayes, MD				Freedman, RR; Girgis, R; Mayes, MD			Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma	LANCET			English	Article								Intra-arterial infusions of L-arginine and sodium nitroprusside significantly decreased the occurrence of laboratory-induced Raynaud's phenomenon in scleroderma patients. Raising the concentration of nitric oxide may he of therapeutic value in this population.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Obstet & Gynaecol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Freedman, RR (corresponding author), CS Mott Ctr, 275 E Hancock Ave, Detroit, MI 48201 USA.	aa2613@wayne.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR052217] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30604] Funding Source: Medline; NIAMS NIH HHS [AR5-2217] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		FREEDMAN RR, 1995, CIRCULATION, V92, P1448, DOI 10.1161/01.CIR.92.6.1448; FREEDMAN RR, IN PRESS J RHEUMATOL; Herrick AL, 1998, LANCET, V352, P1874, DOI 10.1016/S0140-6736(05)60391-1; KAHN R, 1994, CIRCULATION, V89, P1183; VALLANCE P, 1989, LANCET, V2, P997	5	31	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					739	739		10.1016/S0140-6736(99)03557-6	http://dx.doi.org/10.1016/S0140-6736(99)03557-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475187				2022-12-28	WOS:000082233000015
J	Perucchini, D; Fischer, U; Spinas, GA; Huch, R; Huch, A; Lehmann, R				Perucchini, D; Fischer, U; Spinas, GA; Huch, R; Huch, A; Lehmann, R			Using fasting plasma glucose concentrations to screen for gestational diabetes mellitus: prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; TOLERANCE; TESTS; CRITERIA; INSULIN; DISEASE; BIRTH; WOMEN	Objective To evaluate whether measuring fasting Plasma glucose concentration is an easier screening procedure for gestational diabetes mellitus than the 1 hour 50 g glucose challenge test. Design Prospective population based study. Setting Outpatient clinic in a university hospital. Participants 520 pregnant women (328 (63%) white, 99 (19%) Asian, 31 (6%) African, 62 (12%) others) with mean age 28.4 (SD 0.2; range 17-45) years. All underwent a glucose challenge test between the 24th and 28th gestational week, followed by a diagnostic 3 hour 100 g or al glucose tolerance test within one week. This was done irrespective of the result of the challenge lest. Main outcome measure Receiver operating curves were used to determine the best cut off values for screening with fasting plasma glucose concentrations, Results Fasting plasma glucose concentration at a threshold value of 4.5 mmol/l and the glucose challenge test with a threshold value of 7.8 mmol/l. yielded sensitivities of 81%, and 59% respectively and specificities of 76%, and 91% respectively Measuring fasting plasma glucose concentration as a screening procedure required a diagnostic test in 30%, compared with 14% when the challenge test was used. Conclusions Measuring fasting plasma glucose concentrations using a cut off value of greater than or equal to 4.8 mmol/l is an easier screening procedure for gestational diabetes than the 50 g glucose challenge test and allows 70% of women to avoid the challenge test.	Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland; Univ Zurich Hosp, Dept Obstet, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Gynaecol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Lehmann, R (corresponding author), Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland.	Roger.Lehmann@dim.usz.ch	Lehmann, Roger/B-9120-2015	Lehmann, Roger/0000-0002-3681-4431				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P958; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13; BORTHEIRY AL, 1994, DIABETES CARE, V17, P1269, DOI 10.2337/diacare.17.11.1269; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; COUSTAN DR, 1993, DIABETES CARE, V16, P8, DOI 10.2337/diacare.16.3.8; DOOLEY SL, 1991, DIABETES, V40, P25, DOI 10.2337/diab.40.2.S25; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Eriksson UJ, 1996, DIABETOLOGIA, V39, P1123; Gavin JR, 1997, DIABETES CARE, V20, P1183; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LEWIS GF, 1993, DIABETES CARE, V16, P1551, DOI 10.2337/diacare.16.12.1551; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MESTMAN JH, 1972, OBSTET GYNECOL, V39, P421; Metzger BE, 1998, DIABETES CARE, V21, pB161; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; MORTENSEN HB, 1985, DIABETES METAB, V11, P249; Purdy LP, 1996, DIABETOLOGIA, V39, P1126; Reichelt AJ, 1998, DIABETES CARE, V21, P1246, DOI 10.2337/diacare.21.8.1246; SACKS DA, 1992, J REPROD MED, V37, P907; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; Weiss PAM, 1998, GYNAKOLOGE, V31, P12, DOI 10.1007/s001290050219; *WHO EXP COMM DIAB, 1985, DIAB MELL REP WHO ST	26	75	78	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					812	815		10.1136/bmj.319.7213.812	http://dx.doi.org/10.1136/bmj.319.7213.812			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496823	Bronze, Green Published			2022-12-28	WOS:000082865200021
J	Cnattingius, S; Granath, F; Petersson, G; Harlow, BL				Cnattingius, S; Granath, F; Petersson, G; Harlow, BL			The influence of gestational age and smoking habits on the risk of subsequent preterm deliveries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLATELET-ACTIVATING-FACTOR; BIRTH-WEIGHT; BACTERIAL VAGINOSIS; MATERNAL SMOKING; PREVENTION; PREGNANCY; METRONIDAZOLE; WOMEN; LABOR	Background Previous preterm delivery and maternal smoking are associated with increased risks of preterm delivery. It is not known whether gestational age at the time of a preterm delivery is correlated with gestational age in successive preterm deliveries and whether changes in smoking habits influence the subsequent risk of preterm delivery. Methods We studied the associations among smoking habits, previous very preterm or moderately preterm delivery (before 32 weeks and at 32 to 36 weeks, respectively), and the risk of a subsequent very preterm or moderately preterm delivery in a population-based cohort of 243,858 women in Sweden between 1983 and 1993. The results were adjusted for covariates known to be associated with preterm delivery. Results The odds ratios for very or moderately preterm delivery in a subsequent pregnancy among women with a previous very preterm delivery, as compared with women who had a previous term delivery, were 12.4 (95 percent confidence interval, 9.1 to 17.0) and 7.1 (95 percent confidence interval, 6.0 to 8.4), respectively. Among women with a previous moderately preterm delivery, the corresponding odds ratios were 2.3 (95 percent confidence interval, 1.9 to 3.0) and 5.9 (95 percent confidence interval, 5.5 to 6.3), respectively. The odds ratios for a very preterm second delivery among the women who smoked 1 to 9 cigarettes per day and those who smoked 10 or more cigarettes per day, as compared with nonsmokers, were 1.4 (95 percent confidence interval, 1.1 to 1.7) and 1.6 (95 percent confidence interval, 1.3 to 2.0), respectively. The corresponding odds ratios for moderate preterm delivery were 1.3 (95 percent confidence interval, 1.2 to 1.4) and 1.5 (95 percent confidence interval, 1.4 to 1.6). The women who quit smoking between pregnancies were not at increased risk for very or moderately preterm delivery, whereas the women who started to smoke in the second pregnancy had the same risk as those who continued to smoke. Conclusions The risk of a very preterm delivery in successive pregnancies is increased primarily among women with a previous very preterm delivery. Changes in smoking habits influence the risk of preterm delivery as well. (N Engl J Med 1999;341: 943-8.) (C) 1999, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden; Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA	Karolinska Institutet; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, SE-17177 Stockholm, Sweden.			Harlow, Bernard/0000-0002-6735-8862				BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; Basso O, 1998, AM J OBSTET GYNECOL, V178, P259, DOI 10.1016/S0002-9378(98)80010-0; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; Berkowitz GS, 1998, EPIDEMIOLOGY, V9, P279, DOI 10.1097/00001648-199805000-00011; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; *CIV, 1969, SWED VERS INT CLASS; Clausson B, 1998, BRIT J OBSTET GYNAEC, V105, P1011, DOI 10.1111/j.1471-0528.1998.tb10266.x; CNATTINGIUS S, 1992, J EPIDEMIOL COMMUN H, V46, P218, DOI 10.1136/jech.46.3.218; CNATTINGIUS S, 1993, OBSTET GYNECOL, V81, P512; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; FARUQUE MO, 1995, BRIT J NUTR, V73, P625, DOI 10.1079/BJN19950064; Gibbs RS, 1997, AM J OBSTET GYNECOL, V177, P375, DOI 10.1016/S0002-9378(97)70201-1; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; GOLDENBERG RL, 1993, OBSTET GYNECOL, V81, P444; Goldenberg RL, 1996, AM J PUBLIC HEALTH, V86, P781, DOI 10.2105/AJPH.86.6.781; HADLEY CB, 1990, AM J PERINAT, V7, P374, DOI 10.1055/s-2007-999527; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HOFFMAN DR, 1990, AM J OBSTET GYNECOL, V162, P525, DOI 10.1016/0002-9378(90)90423-5; Hogberg U, 1997, ACTA OBSTET GYN SCAN, V76, P907, DOI 10.3109/00016349709034900; Iams J, 1998, NEW ENGL J MED, V338, P54, DOI 10.1056/NEJM199801013380110; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JUN Z, 1992, EPIDEMIOLOGY, V3, P428, DOI 10.1097/00001648-199209000-00008; Kyrklund-Blomberg NB, 1998, AM J OBSTET GYNECOL, V179, P1051, DOI 10.1016/S0002-9378(98)70214-5; LUNDE AS, 1980, VITAL HLTH STAT, V2, P5; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; NAEYE RL, 1978, BRIT J OBSTET GYNAEC, V85, P732, DOI 10.1111/j.1471-0528.1978.tb15593.x; NARAHARA H, 1993, AM J OBSTET GYNECOL, V169, P1321, DOI 10.1016/0002-9378(93)90300-8; Olsen J, 1997, EPIDEMIOLOGY, V8, P6, DOI 10.1097/00001648-199701000-00001; PAPIERNIK E, 1993, BAILLIERE CLIN OB GY, V7, P499, DOI 10.1016/S0950-3552(05)80446-8; PICKERING RM, 1991, INT J EPIDEMIOL, V20, P456, DOI 10.1093/ije/20.2.456; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; 1986, SWED VERS INT CLASS; 1998, INT J GYNAECOL OBSTE, V60, P71	36	119	125	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					943	948		10.1056/NEJM199909233411303	http://dx.doi.org/10.1056/NEJM199909233411303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498489				2022-12-28	WOS:000082658100003
J	Herrington, DM				Herrington, DM			The HERS trial results: Paradigms lost?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; RISK; ESTROGEN; DISEASE; USERS; PREVENTION; PROGESTIN	The Heart and Estrogen/progestin Replacement Study (HERS) found no overall effect of 4.1 years of therapy with estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. However, within the overall null effect, a 50% increase in cardiovascular events was seen in the first year, followed by fewer events after 2 years of treatment in the hormone therapy group than in the placebo group. Understanding the cause of th is pattern of early increase and late reduction in risk is key to interpreting the HERS results and reconciling them with the large number of observational and other studies of the cardiovascular effects of estrogen. There are two possibilities. One is that the HERS regimen of estrogen plus progestin has no effect on risk for heart disease, and the pattern of changing risk over time is simply the result of chance or confounding. The other is that the pattern of early increase and late reduction in risk is due to real but opposing effects of this regimen. Several lines of evidence support each possibility. Attrition of a susceptible cohort of women uniquely at risk for a cardiovascular complication from hormone therapy coupled with a gradually progressive beneficial effect due to lipid lowering and other factors is a promising potential explanation. The HERS results remind us of the need for clinical trials to evaluate both the benefits and risks of new therapies. They also illustrate how much more we need to know about the cardiovascular effects of hormone replacement therapy.	Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27157 USA	Wake Forest University	Herrington, DM (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dherring@wfubmc.edu						Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grundy SM, 1997, CIRCULATION, V95, P2329, DOI 10.1161/01.CIR.95.9.2329; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1329; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SMITH SC, 1995, CIRCULATION, V92, P2; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8	16	84	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					463	466		10.7326/0003-4819-131-6-199909210-00012	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498564				2022-12-28	WOS:000082641100010
J	Tasker, SA; Treanor, JJ; Paxton, WB; Wallace, MR				Tasker, SA; Treanor, JJ; Paxton, WB; Wallace, MR			Efficacy of influenza vaccination in HIV-infected persons - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIBODY-RESPONSES; HIV-1-INFECTED PATIENTS; IMMUNIZATION; INDIVIDUALS; LYMPHOCYTES; REPLICATION; VACCINES; ADULTS; LOAD; MEN	Background: Although influenza vaccination is recommended in persons infected with HIV-1, its efficacy is unknown. Objective: To assess the immunogenicity, efficacy, and risks associated with influenza vaccination in persons infected with HIV-1. Design: Randomized, double-blind, placebo-controlled trial. Setting: Outpatient military clinic. Patients: 102 patients with HIV-1 infection. Intervention: Influenza vaccine (n = 55) or saline pla cebo (n = 47). Measurements: Influenza antibody titers, CD4(+) cell counts, and plasma HIV-1 RNA levels at baseline, 1 month after immunization, and 3 months after immunization; viral cultures from persons presenting with respiratory illness; and respiratory symptom interview. Results: Twenty-three placebo recipients (49%) and 16 vaccine recipients (29%) reported respiratory symptoms (P = 0.04). Ten placebo recipients but no vaccine recipients had laboratory-confirmed symptomatic influenza (P < 0.001) (protective efficacy, 100% [95% CI, 73% to 100%]). No effect on plasma HIV-1 RNA levels or CD4+ cell counts was noted. Conclusion: Influenza vaccination is highly effective in HIV-l-infected persons and does not seem to be associated with substantial changes in viral load or CD4 cell count.	USN, Med Ctr, Dept Clin Res, Infect Dis Div, San Diego, CA 92134 USA; Univ Rochester, Rochester, NY 14642 USA; Nichols Inst, Quest Diagnost, San Juan Capistrano, CA USA	United States Department of Defense; United States Navy; University of Rochester; Nichols Institute	Tasker, SA (corresponding author), USN, Med Ctr, Dept Clin Res, Infect Dis Div, 34800 Bob Wilson Dr,Suite 5, San Diego, CA 92134 USA.							[Anonymous], DIAGNOSTIC PROCEDURE; Fowke KR, 1997, AIDS, V11, P1013, DOI 10.1097/00002030-199708000-00010; Glesby MJ, 1996, J INFECT DIS, V174, P1332, DOI 10.1093/infdis/174.6.1332; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; HUANG KL, 1987, JAMA-J AM MED ASSOC, V257, P2047, DOI 10.1001/jama.257.15.2047; HUENGSBERG M, 1995, GENITOURIN MED, V71, P355; Iorio AM, 1997, VACCINE, V15, P97, DOI 10.1016/S0264-410X(96)00057-6; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; MIOTTI PG, 1989, JAMA-J AM MED ASSOC, V262, P779, DOI 10.1001/jama.262.6.779; NELSON KE, 1988, ANN INTERN MED, V109, P383, DOI 10.7326/0003-4819-109-5-383; Neuzil KM, 1999, JAMA-J AM MED ASSOC, V281, P901, DOI 10.1001/jama.281.10.901; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; OBRIEN WA, 1995, BLOOD, V86, P1082; Paxton WB, 1997, J INFECT DIS, V175, P247, DOI 10.1093/infdis/175.2.247; RAGNI MV, 1987, J LAB CLIN MED, V109, P545; ROSE DN, 1993, AM J MED, V94, P160, DOI 10.1016/0002-9343(93)90178-R; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; Tasker SA, 1998, VACCINE, V16, P1039, DOI 10.1016/S0264-410X(97)00275-2; YERLY S, 1994, AIDS, V8, P1503, DOI 10.1097/00002030-199410000-00022; 1999, MMWR MORB MORTAL WKL, V48, P1	20	129	132	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					430	433		10.7326/0003-4819-131-6-199909210-00006	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498559				2022-12-28	WOS:000082641100005
J	Wattchow, DA; Rieger, N				Wattchow, DA; Rieger, N			Faecal incontinence after vaginal delivery	LANCET			English	Editorial Material									Flinders Med Ctr, Dept Surg, Bedford Pk, SA 5042, Australia; Queen Elizabeth Hosp, Dept Surg, Woodville, SA 5011, Australia	Flinders Medical Centre	Wattchow, DA (corresponding author), Flinders Med Ctr, Dept Surg, Bedford Pk, SA 5042, Australia.							DEEN KI, 1993, GUT, V34, P685, DOI 10.1136/gut.34.5.685; Rieger N, 1998, SCAND J GASTROENTERO, V33, P950; Rieger N, 1997, ACTA OBSTET GYN SCAN, V76, P769, DOI 10.3109/00016349709024345; Rieger N, 1999, AUST NZ J SURG, V69, P172, DOI 10.1046/j.1440-1622.1999.01517.x; Rieger NA, 1997, INT J COLORECTAL DIS, V12, P303, DOI 10.1007/s003840050111; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601	6	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					965	966		10.1016/S0140-6736(99)90203-9	http://dx.doi.org/10.1016/S0140-6736(99)90203-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501352				2022-12-28	WOS:000082596000003
J	Malenka, RC; Nicoll, RA				Malenka, RC; Nicoll, RA			Neuroscience - Long-term potentiation - A decade of progress?	SCIENCE			English	Review							PAIRED-PULSE FACILITATION; HIPPOCAMPAL CA1 REGION; PROTEIN-KINASE-C; EXCITATORY POSTSYNAPTIC CURRENTS; RABBIT FOLLOWING STIMULATION; RECEPTOR GLUR1 SUBUNIT; SYNAPTIC TRANSMISSION; NMDA-RECEPTOR; PYRAMIDAL CELLS; REGULATORY PHOSPHORYLATION		Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Friend Pritzker Lab, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Malenka, RC (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Friend Pritzker Lab, Palo Alto, CA 94304 USA.	malenka@stanford.edu; nicoll@phys.ucsf.edu	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ANIKSZTEJN L, 1989, NEUROSCIENCE, V28, P387, DOI 10.1016/0306-4522(89)90185-1; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; Asztely F, 1996, NEUROREPORT, V7, P1609, DOI 10.1097/00001756-199607080-00016; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BENARI Y, 1995, SEMIN NEUROSCI, V7, P127, DOI 10.1006/smns.1995.0014; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Carroll RC, 1998, J NEUROPHYSIOL, V80, P2797, DOI 10.1152/jn.1998.80.5.2797; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CLARK KA, 1995, J PHYSIOL-LONDON, V482, P39, DOI 10.1113/jphysiol.1995.sp020498; Cline HT, 1998, CURR BIOL, V8, pR836, DOI 10.1016/S0960-9822(07)00525-8; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P19, DOI 10.1113/jphysiol.1983.sp014477; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Craig AM, 1998, NEURON, V21, P459, DOI 10.1016/S0896-6273(00)80555-3; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Diamond JS, 1998, NEURON, V21, P425, DOI 10.1016/S0896-6273(00)80551-6; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Eichenbaum H, 1996, LEARN MEMORY, V3, P61, DOI 10.1101/lm.3.2-3.61; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FIELDS RD, 1992, INT REV NEUROBIOL, V34, P133, DOI 10.1016/S0074-7742(08)60098-7; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; GLESE KP, 1998, SCIENCE, V279, P870; Gomperts SN, 1998, NEURON, V21, P1443, DOI 10.1016/S0896-6273(00)80662-5; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; Hjelmstad GO, 1997, NEURON, V19, P1309, DOI 10.1016/S0896-6273(00)80421-3; Hrabetova S, 1996, J NEUROSCI, V16, P5324; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; Isaac JTR, 1996, P NATL ACAD SCI USA, V93, P8710, DOI 10.1073/pnas.93.16.8710; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Jay TM, 1999, J NEUROPHYSIOL, V81, P1741, DOI 10.1152/jn.1999.81.4.1741; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; Kandler K, 1998, NAT NEUROSCI, V1, P119, DOI 10.1038/368; Kato K, 1996, J LIPID MEDIAT CELL, V14, P341, DOI 10.1016/0929-7855(96)00543-3; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KENNEDY MB, 1990, COLD SH Q B, V55, P101; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KUHNT U, 1994, NEUROSCIENCE, V62, P391, DOI 10.1016/0306-4522(94)90374-3; Kullmann DM, 1996, NEURON, V17, P461, DOI 10.1016/S0896-6273(00)80178-6; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Luscher C, 1998, NEURON, V21, P435, DOI 10.1016/S0896-6273(00)80552-8; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; Makhinson M, 1999, J NEUROSCI, V19, P2500; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Malinow R, 1996, SCIENCE, V271, P1604, DOI 10.1126/science.271.5255.1604; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Oliet SHR, 1996, SCIENCE, V271, P1294, DOI 10.1126/science.271.5253.1294; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Pananceau M, 1998, J PHYSIOL-LONDON, V508, P503, DOI 10.1111/j.1469-7793.1998.503bq.x; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Ryan TA, 1996, NEURON, V17, P125, DOI 10.1016/S0896-6273(00)80286-X; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; Selig DK, 1999, J NEUROSCI, V19, P1236; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Shors TJ, 1997, BEHAV BRAIN SCI, V20, P597, DOI 10.1017/S0140525X97001593; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Stevens CF, 1996, CELL, V87, P1147, DOI 10.1016/S0092-8674(00)81808-5; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Svoboda K, 1999, NEURON, V22, P427, DOI 10.1016/S0896-6273(00)80698-4; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TEYLER TJ, 1994, HIPPOCAMPUS, V4, P623, DOI 10.1002/hipo.450040602; WILEY DJA, 1994, NEURON, V12, P127; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	130	2095	2213	4	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1870	1874		10.1126/science.285.5435.1870	http://dx.doi.org/10.1126/science.285.5435.1870			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489359				2022-12-28	WOS:000082638300039
J	Rollmann, SM; Houck, LD; Feldhoff, RC				Rollmann, SM; Houck, LD; Feldhoff, RC			Proteinaceous pheromone affecting female receptivity in a terrestrial salamander	SCIENCE			English	Article								A 22-kilodalton protein was isolated from the submandibular (mental) gland of the male terrestrial salamander, Plethodon jordani (family: Plethodontidae). This proteinaceous pheromone, termed plethodontid receptivity factor (PRF), was experimentally delivered to the female during courtship and shown to increase female receptivity, In most plethodontid salamanders, ovulation occurs weeks or months after insemination, so the pheromone-induced change in receptivity is the only known function of PRF, The messenger RNAs corresponding to isoforms of PRF were transcribed into complementary DNA, cloned, sequenced, and shown to have homology with cytokines of the interleukin-6 family. Pheromone activity would represent a previously unrecognized function for cytokines.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Univ Louisville, Sch Med, Dept Biochem, Louisville, KY 40292 USA	University of Chicago; Oregon State University; University of Louisville	Rollmann, SM (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57 St, Chicago, IL 60637 USA.	smrollma@midway.uchicago.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNOLD SJ, 1976, Z TIERPSYCHOL, V42, P247; Arnold SJ., 1982, BIOCH ASP EVOL BIOL, P173; ARNOLD SJ, 1972, THESIS U MICHIGAN AN; DUELLMAN WE, 1986, BIOL AMPHIBIANS, pCH2; DULKA JG, 1987, NATURE, V325, P251, DOI 10.1038/325251a0; Feldhoff Richard C., 1999, P117; Houck LD, 1998, COPEIA, P214; HOUCK LD, 1990, ANIM BEHAV, V39, P729, DOI 10.1016/S0003-3472(05)80384-7; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; Meager T., 1998, MOL BIOL CYTOKINES; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; NICOLA NN, 1994, GUIDEBOOK CYTOKINES, P57; SIGNORET JP, 1961, 4 INT C AN REPR ART, P171; SINGER AG, 1986, J BIOL CHEM, V261, P3323	16	157	159	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1907	1909		10.1126/science.285.5435.1907	http://dx.doi.org/10.1126/science.285.5435.1907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489368				2022-12-28	WOS:000082638300048
J	Antson, AA; Dodson, EJ; Dodson, G; Greaves, RB; Chen, XP; Gollnick, P				Antson, AA; Dodson, EJ; Dodson, G; Greaves, RB; Chen, XP; Gollnick, P			Structure of the trp RNA-binding attenuation protein, TRAP, bound to RNA	NATURE			English	Article							BACILLUS-SUBTILIS BINDS; CRYSTAL-STRUCTURE; LEADER RNA; TRANSCRIPTION ATTENUATION; OPERON; COMPLEX; SYNTHETASE; EXPRESSION; REPEATS; DOMAIN	The frp RNA-binding attenuation protein (TRAP) regulates expression of the tryptophan biosynthetic genes of several bacilli by binding single-stranded RNA. The binding sequence is composed of eleven triplet repeats, predominantly GAG, separated by two or three non-conserved nucleotides, Here we present the crystal structure of a complex of TRAP and a 53-base single-stranded RNA containing eleven GAG triplets, revealing that each triplet is accommodated in a binding pocket formed by beta-strands. In the complex, the RNA has an extended structure without any base-pairing and binds to the protein mostly by specific protein-base interactions. Eleven binding pockets on the circular TRAP Il-mer form a belt with a diameter of about 80 Angstrom. This simple but elegant mechanism of arresting the RNA segment by encircling it around a protein disk is applicable to both transcription, when TRAP binds the nascent RNA, and to translation, when TRAP binds the same sequence within a non-coding leader region of the messenger RNA.	Univ York, Dept Chem, York Struct Biol Lab, York Y010 5DD, N Yorkshire, England; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	University of York - UK; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Antson, AA (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York Y010 5DD, N Yorkshire, England.	fred@yorvic.york.ac.uk	Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816				Allemand JF, 1998, P NATL ACAD SCI USA, V95, P14152, DOI 10.1073/pnas.95.24.14152; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRZOZOWSKI AM, 1993, ACTA CRYSTALLOGR D, V49, P352, DOI 10.1107/S0907444993000952; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; ELLIOTT MB, IN PRESS RNA; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OLDFIELD TJ, 1994, P CCP4 STUD WEEK; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Schneider B, 1997, BIOPOLYMERS, V42, P113, DOI 10.1002/(SICI)1097-0282(199707)42:1<113::AID-BIP10>3.0.CO;2-O; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; Tomchick DR, 1998, STRUCTURE, V6, P337, DOI 10.1016/S0969-2126(98)00036-7; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	50	203	209	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					235	242		10.1038/45730	http://dx.doi.org/10.1038/45730			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499579				2022-12-28	WOS:000082678400043
J	Kudenchuk, PJ; Cobb, LA; Copass, MK; Cummins, RO; Doherty, AM; Fahrenbruch, CE; Hallstrom, AP; Murray, WA; Olsufka, M; Walsh, T				Kudenchuk, PJ; Cobb, LA; Copass, MK; Cummins, RO; Doherty, AM; Fahrenbruch, CE; Hallstrom, AP; Murray, WA; Olsufka, M; Walsh, T			Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-ARRHYTHMIC DRUGS; LIFE-SUPPORT DRUGS; INTRAVENOUS AMIODARONE; DEFIBRILLATION THRESHOLD; ENERGY-REQUIREMENTS; BRETYLIUM TOSYLATE; CIRCULATION TIMES; LIDOCAINE; SURVIVAL; TRIAL	Background Whether antiarrhythmic drugs improve the rate of successful resuscitation after out-of-hospital I cardiac arrest has not been determined in randomized clinical trials. Methods We conducted a randomized, double-blind, placebo-controlled study of intravenous amiodarone in patients with out-of-hospital cardiac arrest. Patients who had cardiac arrest with ventricular fibrillation (or pulseless ventricular tachycardia) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to receive 300 mg of intravenous amiodarone (246 patients) or placebo (258 patients). Results The treatment groups had similar clinical profiles. There was no significant difference between the amiodarone and placebo groups in the mean (+/-SD) duration of the resuscitation attempt (42+/-16 and 43+/-16 minutes, respectively), the number of shocks delivered (4+/-3 and 6+/-5), or the proportion of patients who required additional antiarrhythmic drugs after the administration of the study drug (66 percent and 73 percent). More patients in the amiodarone group than in the placebo group had hypotension (59 percent vs. 48 percent, P=0.04) or bradycardia (41 percent vs. 25 percent, P=0.004)after receiving the study drug. Recipients of amiodarone were more likely to survive to be admitted to the hospital (44 percent, vs. 34 percent of the placebo group; P=0.03). The benefit of amiodarone was consistent among all subgroups and at all times of drug administration. The adjusted odds ratio for survival to admission to the hospital in the amiodarone group as compared with the placebo group was 1.6 (95 percent confidence interval, 1.1 to 2.4; P=0.02). The trial did not have sufficient statistical power to detect differences in survival to hospital discharge, which differed only slightly between the two groups. Conclusions In patients with out-of-hospital cardiac arrest due to refractory ventricular arrhythmias, treatment with amiodarone resulted in a higher rate of survival to hospital admission. Whether this benefit extends to survival to discharge from the hospital merits further investigation. (N Engl J Med 1999; 341:871-8.) (C) 1999, Massachusetts Medical Society.	Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Seattle Fire Dept, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kudenchuk, PJ (corresponding author), Univ Washington, Div Cardiol, Dept Med, Box 356422, Seattle, WA 98195 USA.							BABBS CF, 1979, AM HEART J, V98, P345, DOI 10.1016/0002-8703(79)90047-4; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1992, CIRCULATION, V85, P98; COX SV, 1993, RESUSCITATION, V26, P53, DOI 10.1016/0300-9572(93)90163-K; CUMMINS RO, 1997, ADV CARDIAC LIFE SUP, P1; Department of Agriculture Department of Energy National Aeronautics and Space Administration Department of Commerce Consumer Product Safety Commission International Development Cooperation Agency Agency for International Development Department of Housing and Urban Development Department of Justice Department of Defense Department of Education Department of Veterans Affairs Environmental Protection Agency Department of Health and Human Services National Science Foundation and Department of Transportation, 1991, FED REGISTER, V56, P28003; DORIAN P, 1986, J AM COLL CARDIOL, V8, P327, DOI 10.1016/S0735-1097(86)80047-X; ECHT DS, 1989, CIRCULATION, V79, P1106, DOI 10.1161/01.CIR.79.5.1106; EMERMAN CL, 1990, AM J EMERG MED, V8, P190, DOI 10.1016/0735-6757(90)90319-U; EMERMAN CL, 1988, CRIT CARE MED, V16, P1138, DOI 10.1097/00003246-198811000-00011; Fatovich DM, 1997, RESUSCITATION, V35, P237, DOI 10.1016/S0300-9572(97)00062-2; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GOUGH WB, 1982, J CARDIOVASC PHARM, V4, P375, DOI 10.1097/00005344-198205000-00006; HARRISON EE, 1981, ANN EMERG MED, V10, P420, DOI 10.1016/S0196-0644(81)80309-5; HAYNES RE, 1981, AM J CARDIOL, V48, P353, DOI 10.1016/0002-9149(81)90619-6; Herlitz J, 1997, RESUSCITATION, V33, P199, DOI 10.1016/S0300-9572(96)01018-0; JAFFE AS, 1993, ANN EMERG MED, V22, P307, DOI 10.1016/S0196-0644(05)80461-5; KERBER RE, 1986, J AM COLL CARDIOL, V7, P397, DOI 10.1016/S0735-1097(86)80512-5; KOWEY PR, 1995, CIRCULATION, V92, P3255, DOI 10.1161/01.CIR.92.11.3255; KUHN GJ, 1981, ANN EMERG MED, V10, P417, DOI 10.1016/S0196-0644(81)80308-3; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MARTIN TG, 1988, AM J EMERG MED, V6, P113, DOI 10.1016/0735-6757(88)90046-0; MUNOZ A, 1988, EUR HEART J, V9, P142, DOI 10.1093/oxfordjournals.eurheartj.a062467; *NAT CTR HLTH STAT, 1997, MON VITAL STAT RE S2, V45; NOWAK RM, 1981, ANN EMERG MED, V10, P404, DOI 10.1016/S0196-0644(81)80306-X; OLSON DW, 1984, ANN EMERG MED, V13, P807, DOI 10.1016/S0196-0644(84)80444-8; PLATOU ES, 1986, ACTA PHARMACOL TOX, V58, P163; SCHEINMAN MM, 1995, CIRCULATION, V92, P3264, DOI 10.1161/01.CIR.92.11.3264; SICART M, 1977, ARCH MAL COEUR VAISS, V70, P219; SINGH BN, 1989, PROG CARDIOVASC DIS, V31, P249, DOI 10.1016/0033-0620(89)90033-9; STIELL IG, 1995, ACAD EMERG MED, V2, P264, DOI 10.1111/j.1553-2712.1995.tb03220.x; TACKER WA, 1980, CRIT CARE MED, V8, P177, DOI 10.1097/00003246-198003000-00018; Thel MC, 1997, LANCET, V350, P1272, DOI 10.1016/S0140-6736(97)05048-4; van Walraven C, 1998, ANN EMERG MED, V32, P544, DOI 10.1016/S0196-0644(98)70031-9; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; WEAVER WD, 1991, NEW ENGL J MED, V325, P1437, DOI 10.1056/NEJM199111143252008; WEAVER WD, 1990, CIRCULATION, V82, P2027, DOI 10.1161/01.CIR.82.6.2027; Weston CFM, 1997, RESUSCITATION, V34, P27, DOI 10.1016/S0300-9572(96)01031-3; YOON MS, 1974, AM J CARDIOL, V33, P238, DOI 10.1016/0002-9149(74)90281-1	42	600	628	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					871	878		10.1056/NEJM199909163411203	http://dx.doi.org/10.1056/NEJM199909163411203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10486418				2022-12-28	WOS:000082569100003
J	Lu, MF; Pressman, C; Dyer, R; Johnson, RL; Martin, JF				Lu, MF; Pressman, C; Dyer, R; Johnson, RL; Martin, JF			Function of Rieger syndrome gene in left-right asymmetry and craniofacial development	NATURE			English	Article							SIGNALING PATHWAY; PITX2; REGULATOR; SEQUENCE; TISSUES; FAMILY	Rieger syndrome, an autosomal dominant disorder, includes ocular, craniofacial and umbilical abnormalities, The pitx2 homeobox gene, which is mutated in Rieger syndrome(1,2), has been proposed to be the effector molecule interpreting left-right axial information from the early embryonic trunk to each organ(3-7). Here we have used gene targeting in mice to generate a loss-of-function allele that would be predicted to result in organ randomization or isomerization. Although pitx2(-/-) embryos had abnormal cardiac morphogenesis, mutant hearts looped in the normal direction. Pitx2(-/-) embryos had correctly oriented, but arrested, embryonic rotation and right pulmonary isomerism. They also had defective development of the mandibular and maxillary facial prominences, regression of the stomodeum and arrested tooth development. Fgf8 expression was absent, and Bmp4 expression was expanded in the branchial-arch ectoderm. These data reveal a critical role for pitx2 in left-right asymmetry but indicate that pitx2 may function at an intermediate step in cardiac morphogenesis and embryonic rotation.	Texas A&M Univ Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Martin, JF (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Alkek Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.							Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Campione M, 1999, DEVELOPMENT, V126, P1225; Flomen RH, 1998, GENOMICS, V47, P409, DOI 10.1006/geno.1997.5127; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7; Kaufman M.H., 1992, ATLAS MOUSE DEV; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lu MF, 1999, DEVELOPMENT, V126, P495; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; MIKKILA SP, 1994, AM J MED GENET, V49, P435, DOI 10.1002/ajmg.1320490417; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6	20	404	406	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					276	278		10.1038/45797	http://dx.doi.org/10.1038/45797			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499585				2022-12-28	WOS:000082678400053
J	Hollis, S; Campbell, F				Hollis, S; Campbell, F			What is meant by intention to treat analysis? Survey of published randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; SURGERY; NONCOMPLIANCE; ANGIOPLASTY	Objectives To assess the methodological quality of intention to treat analysis as reported in randomised controlled trials in four large medical journals. Design Survey of all reports of randomised controlled trials published in 1997 in the BMJ, Lancet, JAMA, and New England Journal of Medicine. Main outcome measures Methods of dealing with deviations from random allocation and missing data. Results 119 (48%) of the reports mentioned intention to treat analysis. Of these, 12 excluded any patients who did not start the allocated intervention and three did not analyse all randomised subjects as allocated. Five reports explicitly stated that there were no deviations from random allocation, The remaining 99 reports: seemed to analyse according to random allocation, but only 34 of these explicitly stated this. 89 (75%) trials had some missing data on the primary outcome variable. The methods used to deal with this were generally inadequate, potentially leading to a biased treatment effect 29 (24%) trials had more than 10% of responses missing for the primary outcome, the methods of handling the missing responses were similar in this subset. Conclusions The intention to neat approach is often inadequately described and inadequately applied. Authors should explicitly describe the handling of deviations from randomised allocation and missing responses and discuss the potential effect of any missing response. Readers should critically assess the validity of reported intention to treat analyses.	Univ Lancaster, Fylde Coll, Med Stat Unit, Lancaster LA1 4YF, England; AstraZeneca, Macclesfield SK10 4TG, Cheshire, England	Lancaster University; AstraZeneca	Hollis, S (corresponding author), Univ Lancaster, Fylde Coll, Med Stat Unit, Lancaster LA1 4YF, England.			Hollis, Sally/0000-0003-0156-9189				Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bollini P, 1999, BRIT J PSYCHIAT, V174, P297, DOI 10.1192/bjp.174.4.297; Campeau L, 1997, NEW ENGL J MED, V336, P153; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; Choi SC, 1995, STAT MED, V14, P2675, DOI 10.1002/sim.4780142407; *COCHR COLL, 1997, COCHR LIBR; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; Cuzick J, 1997, STAT MED, V16, P1017, DOI 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V; DALY S, 1997, LANCET, V350, P1662; Daoud EG, 1997, NEW ENGL J MED, V337, P1785, DOI 10.1056/NEJM199712183372501; EFRON B, 1991, J AM STAT ASSOC, V86, P9, DOI 10.2307/2289707; ENGLUND JA, 1997, NEW ENGL J MED, V336, P174; *EUR COR SURG STUD, 1979, LANCET, V1, P889; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Fisher L.D., 1990, STAT ISSUES DRUG RES, P331, DOI DOI 10.1201/9780203738610; Goetghebeur EJT, 1996, STAT MED, V15, P2813; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; Kaplan LD, 1997, NEW ENGL J MED, V336, P1641, DOI 10.1056/NEJM199706053362304; LAGAKOS SW, 1990, STAT MED, V9, P1417, DOI 10.1002/sim.4780091204; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; Liem MSL, 1997, NEW ENGL J MED, V336, P1541, DOI 10.1056/NEJM199705293362201; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Little R. J. A., 1987, STAT ANAL MISSING DA; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; OCONNOR H, 1997, LANCET, V349, P879; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Rutgeerts P, 1997, LANCET, V350, P692, DOI 10.1016/S0140-6736(97)03233-9; SACKETT DL, 1997, EVIDENCE BASED MED; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schulz KF, 1996, BRIT MED J, V312, P742; Senn S., 2021, THE BLIND DAT; SOMMER A, 1991, STAT MED, V10, P45, DOI 10.1002/sim.4780100110; Spruance SL, 1997, JAMA-J AM MED ASSOC, V277, P1374, DOI 10.1001/jama.277.17.1374; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; 1996, BANDOLIER, V3, P6	39	1431	1455	2	64	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					670	+		10.1136/bmj.319.7211.670	http://dx.doi.org/10.1136/bmj.319.7211.670			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480822	Green Published, Bronze			2022-12-28	WOS:000082636800021
J	Keller, MW; Eichenberger, AL; Martinis, JM; Zimmerman, NM				Keller, MW; Eichenberger, AL; Martinis, JM; Zimmerman, NM			A capacitance standard based on counting electrons	SCIENCE			English	Article							PUMP	A capacitance standard based directly on the definition of capacitance was built. Single-electron tunneling devices were used to place N electrons of charge e onto a cryogenic capacitor C, and the resulting voltage change Delta V was measured. Repeated measurements of C = Ne/Delta V with this method have a relative standard deviation of 0.3 X 10(-6). This standard offers a natural basis for capacitance analogous to the Josephson effect for voltage and the quantum Hall effect for resistance.	Natl Inst Stand & Technol, Boulder, CO 80303 USA; Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA	Keller, MW (corresponding author), Natl Inst Stand & Technol, 325 Broadway, Boulder, CO 80303 USA.		Keller, Mark William/AAD-2883-2019; Eichenberger, Ali/J-3073-2012	Keller, Mark William/0000-0001-8573-2953; 				CLOTHIER WK, 1965, METROLOGIA, V1, P36, DOI DOI 10.1088/0026-1394/1/2/002; COHEN ER, 1987, REV MOD PHYS, V59, P1121, DOI 10.1103/RevModPhys.59.1121; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Keller MW, 1997, IEEE T INSTRUM MEAS, V46, P307, DOI 10.1109/19.571841; Keller MW, 1996, APPL PHYS LETT, V69, P1804, DOI 10.1063/1.117492; POTHIER H, 1992, EUROPHYS LETT, V17, P249, DOI 10.1209/0295-5075/17/3/011; TAYLOR BN, 1989, METROLOGIA, V26, P47, DOI 10.1088/0026-1394/26/1/004; TAYLOR BN, 1991, NIST SPEC PUBL, V330; WILLIAMS ER, 1992, J RES NATL INST STAN, V97, P299, DOI 10.6028/jres.097.010; Zimmerman NM, 1997, IEEE T INSTRUM MEAS, V46, P294, DOI 10.1109/19.571835; Zimmerman NM, 1996, IEEE T INSTRUM MEAS, V45, P841, DOI 10.1109/19.536699; Zimmerman NM, 1998, AM J PHYS, V66, P324, DOI 10.1119/1.18859	12	184	186	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1706	1709		10.1126/science.285.5434.1706	http://dx.doi.org/10.1126/science.285.5434.1706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481001				2022-12-28	WOS:000082472600027
J	Marseille, E; Kahn, JG; Mmiro, F; Guay, L; Musoke, P; Fowler, MG; Jackson, JB				Marseille, E; Kahn, JG; Mmiro, F; Guay, L; Musoke, P; Fowler, MG; Jackson, JB			Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; SEXUAL-BEHAVIOR; CONDOM USE; TYPE-1; INFECTION; SEROCONVERSION; ZIDOVUDINE; COUPLES; ZAIRE	Background Identification of economical interventions to decrease HIV-1 transmission to children is an urgent public-health priority in sub-Saharan Africa. We assessed the cost effectiveness of the HIVNET 012 nevirapine regimen. Methods We assessed cost effectiveness in a hypothetical cohort of 20 000 pregnant women in sub-Saharan Africa. Our main outcome measures were programme cost, paediatric HIV-1 cases averted, cost per case averted, and cost per disability-adjusted life-year (DALY). We compared HIVNET 012 with other short-course antiretroviral regimens. We also compared two implementation strategies: counselling and HIV-1 testing before treatment (targeted treatment), or nevirapine for all pregnant women (universal treatment, no counselling and testing). We did univariate and multivariate sensitivity analyses. Findings For universal treatment with 30% HIV-1 seroprevalence, the HIVNET 012 regimen would avert 603 cases of HIV-1 in babies, cost US$83 333, and generate 15 862 DALYs. The associated cost-effectiveness ratios were $138 per case averted or $5.25 per DALY. At 15% seroprevalence, the universal treatment option would cost $83 333 and avert 302 cases at $276 per case averted or $10.51 per DALY. For targeted treatment at 30% seroprevalence, HIVNET 012 would cost $141 922 and avert 476 cases at $298 per case averted or $11.29 per DALY. With seroprevalence higher than 3.0% for universal and 4.5% for targeted treatment, the HIVNET 012 regimen was likely to be as cost effective as other public-health interventions. The cost effectiveness of HIVNET 012 was robust under a wide range of parameters in the sensitivity analysis. Interpretation The HIVNET 012 regimen can be highly cost-effective in high seroprevalence settings. In lower seroprevalence areas, when multidose regimens are not cost effective, nevirapine therapy could have a major public-health impact at a reasonable cost.	Hlth Strategies Int, Orinda, CA 94563 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, AIDS Res Inst, San Francisco, CA 94143 USA; Makerere Univ, Dept Obstet & Gynaecol, Kampala, Uganda; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Makerere Univ, Dept Paediat, Kampala, Uganda; Ctr Dis Control & Prevent, HIV AIDS Branch, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Makerere University; Johns Hopkins University; Makerere University; Centers for Disease Control & Prevention - USA	Marseille, E (corresponding author), Hlth Strategies Int, 2 Madrone Pl, Orinda, CA 94563 USA.			jackson, brooks/0000-0001-9458-135X	PHS HHS [T32 M.H18261, N01/A1-35173] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; ALWANOEDYEGU MG, 1999, KNOWLEDGE POWER VOLU; [Anonymous], 1997, CONFR AIDS PUBL PRIO; Becquart P, 1998, J INFECT DIS, V177, P1770, DOI 10.1086/515321; Bentley ME, 1998, AIDS, V12, P1869, DOI 10.1097/00002030-199814000-00019; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; CHIN J, 1989, DIS MORTALITY SUBSAH; Chin J, 1991, EPIDEMIOLOGY PROJECT; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; HAUB C, 1998, WORLD POPULATION DAT; JAMISON DT, 1993, DIS CONTROL PRIORITI, P455; KAHN J, 1999, FEEDING STRATEGIES H; KAHN J, 1998, PREVENTION HIV TRANS; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KINGHORN A, 1998, PROJECTIONS COSTS AN; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; LUTTER C, 1998, MOTHER CHILD TRANSMI; *MACR INT CENTR OF, 1997, ZAMB DEM HLTH SURV 1; *MACR INT US DEP H, 1996, UG DAM HLTH SURV 199; Mansergh G, 1996, JAMA-J AM MED ASSOC, V276, P139, DOI 10.1001/jama.276.2.139; Marseille E, 1998, AIDS, V12, P939, DOI 10.1097/00002030-199808000-00017; NICOLL A, 1998, JAMA-J AM MED ASSOC, V276, P1562; SABA J, 1999, UNAIDS 6 C RETR OPP; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Soderlund N, 1999, BRIT MED J, V318, P1650, DOI 10.1136/bmj.318.7199.1650; SWEAT M, 1998, INT C AIDS, V12, P648; UNAIDS, 1998, MOTH CHILD TRANSM HI; *UNAIDS WHO, 1998, ZIMB EP FACT SHEET H, P12; United Nations Children's Fund (UNICEF), 1997, STAT WORLDS CHILDR 1; WHO, 1996, CHILDH DIS AFR; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016; WILKINSON D, 1999, NATL PROGRAMME REDUC; *WORLD BANK, 1993, WORLD DEV REP 1993 I; 1998, NY TIMES        0306, P87	38	198	200	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					803	809						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485721				2022-12-28	WOS:000082400700008
J	Gong, JP; Xu, J; Bezanilla, M; van Huizen, R; Derin, R; Li, M				Gong, JP; Xu, J; Bezanilla, M; van Huizen, R; Derin, R; Li, M			Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2	SCIENCE			English	Article							ION CHANNELS; TYROSINE KINASE; PROTEIN-KINASES; K+ CHANNELS; MODULATION; SUBUNIT; BINDING; DOMAIN; ALPHA; LOCALIZATION	Targeting of protein modification enzymes is a key biochemical step to achieve specific and effective posttranslational modifications, Two alternatively spliced ZIP1 and ZIP2 proteins are described, which bind to both Kv beta 2 subunits of potassium channel and protein kinase C (PKC) zeta, thereby acting as a physical link in the assembly of PKC zeta-ZIP-potassium channel complexes. ZIP1 and ZIP2 differentially stimulate phosphorylation of Kv beta 2 by PKC zeta. They also interact to form heteromultimers, which allows for a hybrid stimulatory activity to PKC zeta. Finally, ZIP1 and ZIP2 coexist in the same cell type and are elevated differentially by neurotrophic factors. These results provide a mechanism for specificity and regulation of PKC zeta-targeted phosphorylation.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Li, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	minli@jhmi.edu			NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS033324, R01NS033324] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIELEFELDT K, 1994, BIOPHYS J, V66, P1904, DOI 10.1016/S0006-3495(94)80984-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONG JP, UNPUB; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hille B., 1991, IONIC CHANNELS EXCIT; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; REINHART PH, 1995, J NEUROSCI, V15, P4572; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Xu J, 1998, TRENDS CARDIOVAS MED, V8, P229, DOI 10.1016/S1050-1738(98)00011-5; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Xu J, 1998, METHOD ENZYMOL, V293, P3; Xu J, 1998, P NATL ACAD SCI USA, V95, P1846, DOI 10.1073/pnas.95.4.1846; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	35	111	116	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1565	1569		10.1126/science.285.5433.1565	http://dx.doi.org/10.1126/science.285.5433.1565			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477520				2022-12-28	WOS:000082359500065
J	Kaplan, LC				Kaplan, LC			Community-based disability services in the USA: a paediatric perspective	LANCET			English	Article							HEALTH		Yale Univ, Sch Med, Yale Ctr Children Special Hlth Care Needs, Dept Pediat, New Haven, CT 06520 USA	Yale University	Kaplan, LC (corresponding author), Yale Univ, Sch Med, Yale Ctr Children Special Hlth Care Needs, Dept Pediat, 333 Cedar St, New Haven, CT 06520 USA.							Butler C, 1999, DEV MED CHILD NEUROL, V41, P55, DOI 10.1017/S0012162299000110; *DIV SERV CHILDR S, 1996, CHILDR SPEC HLTH CAR; IREYS HT, 1992, PEDIATRICS, V90, P321; MULIK JA, 1983, PARENT PROFESSIONAL; PERRIN EC, 1993, PEDIATRICS, V91, P787; WELLS N, 1993, FAMILIES PROGRAM POL	6	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					761	762		10.1016/S0140-6736(99)06141-3	http://dx.doi.org/10.1016/S0140-6736(99)06141-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475206	hybrid			2022-12-28	WOS:000082233000044
J	Frogley, MR; Tzedakis, PC; Heaton, THE				Frogley, MR; Tzedakis, PC; Heaton, THE			Climate variability in northwest Greece during the last interglacial	SCIENCE			English	Article							ISOTOPE RECORDS; EEMIAN CLIMATE; CENTRAL-EUROPE; POLLEN; ATLANTIC; CIRCULATION; HOLOCENE; CORE; LONG; RECONSTRUCTION	Isotopic and palynological data over the period 115,000 to 135,000 years ago from a Lacustrine sequence in northwest Greece show distinct oscillations during the intervals Leading into and out of the full interglacial, whereas in between, changes were Less pronounced but included a brief fluctuation. After peak interglacial conditions, temperatures decreased and precipitation increased in a series of steps. These data suggest that Eemian climate variability was similar to that of the Holocene both in terms of amplitude and, possibly, of pacing.	Univ Cambridge, Dept Zool, Godwin Inst Quaternary Res, Cambridge CB2 3EJ, England; Univ Cambridge, Dept Geog, Godwin Inst Quaternary Res, Cambridge CB2 3EN, England; Kingsley Dunham Ctr, NERC, Isotope Geosci Lab, Nottingham NG12 5GG, England	University of Cambridge; University of Cambridge; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Geological Survey	Frogley, MR (corresponding author), Univ Cambridge, Dept Zool, Godwin Inst Quaternary Res, Downing St, Cambridge CB2 3EJ, England.		Heaton, Timothy/E-7626-2010; Tzedakis, Polychronis/J-1894-2012; Frogley, Michael R/H-2956-2016	Frogley, Michael R/0000-0003-4273-0901; Tzedakis, Polychronis/0000-0001-6072-1166				Adkins JF, 1997, NATURE, V390, P154, DOI 10.1038/36540; Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Cheddadi R, 1998, CLIM DYNAM, V14, P883, DOI 10.1007/s003820050262; Cheddadi R, 1998, PALAEOGEOGR PALAEOCL, V143, P73, DOI 10.1016/S0031-0182(98)00067-4; CHEDDADI R, 1995, PALEOCEANOGRAPHY, V10, P291, DOI 10.1029/94PA02672; CORTIJO E, 1994, NATURE, V372, P446, DOI 10.1038/372446a0; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; de Beaulieu J.L., 1992, VEG HIST ARCHAEOBOT, V1, P233, DOI DOI 10.1007/BF00189500; FIELD MH, 1994, NATURE, V371, P779, DOI 10.1038/371779a0; Frogley MR, 1997, THESIS U CAMBRIDGE; Fronval T, 1996, NATURE, V383, P806, DOI 10.1038/383806a0; GLEN JM, 1997, GEOL SOC AM SPEC PAP, V317, P67; Kukla G, 1997, QUATERNARY SCI REV, V16, P605, DOI 10.1016/S0277-3791(96)00114-X; Langereis CG, 1997, GEOPHYS J INT, V129, P75, DOI 10.1111/j.1365-246X.1997.tb00938.x; Li HC, 1997, PALAEOGEOGR PALAEOCL, V133, P69, DOI 10.1016/S0031-0182(96)00153-8; Litt T, 1996, VEG HIST ARCHAEOBOT, V5, P247, DOI 10.1007/BF00217502; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Maslin M, 1998, GEOL SOC SPEC PUBL, V131, P91, DOI 10.1144/GSL.SP.1998.131.01.07; MCMANUS JF, 1994, NATURE, V371, P326, DOI 10.1038/371326a0; Muller H., 1974, GEOL JB, V21, P149; Oppo DW, 1997, PALEOCEANOGRAPHY, V12, P51, DOI 10.1029/96PA03133; ROZANSKI K, 1985, CHEM GEOL, V52, P349, DOI 10.1016/0168-9622(85)90045-4; Sarnthein M, 1990, PALEOCEANOGRAPHY, V5, P1041, DOI 10.1029/PA005i006p01041; Stager JC, 1997, SCIENCE, V276, P1834, DOI 10.1126/science.276.5320.1834; THOUVENY N, 1994, NATURE, V371, P503, DOI 10.1038/371503a0; TZEDAKIS PC, 1994, PHILOS T R SOC B, V345, P403, DOI 10.1098/rstb.1994.0118; Tzedakis PC, 1995, QUATERNARY SCI REV, V14, P967, DOI 10.1016/0277-3791(95)00042-9; Tzedakis PC, 1997, EARTH PLANET SC LETT, V150, P171, DOI 10.1016/S0012-821X(97)00078-2; TZEDAKIS PC, 1993, NATURE, V364, P437, DOI 10.1038/364437a0; TZEDAKIS PC, 1998, J GEOL SOC, V156, P255; van Geel B, 1999, QUATERNARY SCI REV, V18, P331, DOI 10.1016/S0277-3791(98)00088-2; von Grafenstein U, 1999, SCIENCE, V284, P1654, DOI 10.1126/science.284.5420.1654; von Grafenstein U, 1998, CLIM DYNAM, V14, P73, DOI 10.1007/s003820050210; Zagwijn WH, 1996, QUATERNARY SCI REV, V15, P451, DOI 10.1016/0277-3791(96)00011-X	35	79	92	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1886	1889		10.1126/science.285.5435.1886	http://dx.doi.org/10.1126/science.285.5435.1886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489361				2022-12-28	WOS:000082638300041
J	Wylie, JJ; Voight, B; Whitehead, JA				Wylie, JJ; Voight, B; Whitehead, JA			Instability of magma flow from volatile-dependent viscosity	SCIENCE			English	Article							SOUFRIERE HILLS VOLCANO; WEST-INDIES; LAVA DOME; ERUPTIONS; MONTSERRAT; MODEL; FLUID	Volatiles dissolved in silicic magma at depth exsolve as the magma nears the surface and cause an increase in viscosity of the magma. A model of a volcanic conduit within an elastic medium and a viscosity dependent on the volatile content of the magma produces oscillatory magma flow for a critical range of steady input flow rates. Oscillatory flow is recognized as a fundamental mode of behavior at silicic volcanoes, and understanding it allows improved shortterm forecasting of timing and eruption style.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; US Geol Survey, Volcano Hazards Program, Cascades Volcano Observ, Vancouver, WA 98661 USA	Woods Hole Oceanographic Institution; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; United States Department of the Interior; United States Geological Survey	Wylie, JJ (corresponding author), Woods Hole Oceanog Inst, 360 Woods Hole Rd, Woods Hole, MA 02543 USA.			WYLIE, Jonathan James/0000-0001-8314-9764				CASHMAN KV, 1994, REV MINERAL, V30, P447; Denlinger RP, 1999, GEOLOGY, V27, P459, DOI 10.1130/0091-7613(1999)027<0459:CEBOSV>2.3.CO;2; Dingwell DB, 1998, GEOL SOC SPEC PUBL, V145, P9, DOI 10.1144/GSL.SP.1996.145.01.02; Hess KU, 1996, AM MINERAL, V81, P1297; Hoblitt RP, 1996, FIRE AND MUD, P457; Ida Y, 1996, GEOPHYS RES LETT, V23, P1457, DOI 10.1029/96GL01325; JAUPART C, 1991, EARTH PLANET SC LETT, V102, P413, DOI 10.1016/0012-821X(91)90032-D; JAUPART C, 1988, NATURE, V331, P58, DOI 10.1038/331058a0; Manga M, 1998, J VOLCANOL GEOTH RES, V87, P15, DOI 10.1016/S0377-0273(98)00091-2; Murphy MD, 1998, GEOPHYS RES LETT, V25, P3433, DOI 10.1029/98GL00713; Navon O, 1998, GEOL SOC SPEC PUBL, V145, P27, DOI 10.1144/GSL.SP.1996.145.01.03; Papale P, 1997, CONTRIB MINERAL PETR, V126, P237, DOI 10.1007/s004100050247; Popov E. P., 1952, MECH MAT; Sparks RSJ, 1998, GEOPHYS RES LETT, V25, P3421, DOI 10.1029/98GL00639; Sparks RSJ, 1997, EARTH PLANET SC LETT, V150, P177, DOI 10.1016/S0012-821X(97)00109-X; Turcotte D. L., 1982, GEODYNAMICS APPL CON, DOI 10.1017/CBO9780511843877; Voight B, 1998, GEOPHYS RES LETT, V25, P3405, DOI 10.1029/98GL01160; Voight B, 1999, SCIENCE, V283, P1138, DOI 10.1126/science.283.5405.1138; WHITEHEAD JA, 1991, J GEOPHYS RES-SOLID, V96, P4145, DOI 10.1029/90JB02342; WOODS AW, 1994, NATURE, V370, P641, DOI 10.1038/370641a0; YAMASHINA K, 1995, JPN EARTH PLAN SCI J, P45	21	82	83	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1883	1885		10.1126/science.285.5435.1883	http://dx.doi.org/10.1126/science.285.5435.1883			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489360				2022-12-28	WOS:000082638300040
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - How to randomise	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of Oxford; St Georges University London	Altman, DG (corresponding author), Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England.							Altman DG, 1999, BRIT MED J, V318, P1209; Altman DG, 1990, PRACTICAL STAT MED R, P540; Treasure T, 1998, BRIT MED J, V317, P362	3	304	312	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					703	704		10.1136/bmj.319.7211.703	http://dx.doi.org/10.1136/bmj.319.7211.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480833	Green Published, Bronze			2022-12-28	WOS:000082636800033
J	de Medina, EOR; Algra, A				de Medina, EOR; Algra, A			Digoxin in the treatment of paroxysmal atrial fibrillation	LANCET			English	Editorial Material							SINUS RHYTHM; PLACEBO		Univ Utrecht, Med Ctr, Heart Lung Inst, Dept Cardiol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Neurol, Utrecht, Netherlands; Univ Med Ctr, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	de Medina, EOR (corresponding author), Univ Utrecht, Med Ctr, Heart Lung Inst, Dept Cardiol, NL-3508 GA Utrecht, Netherlands.							ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; BEASLEY R, 1985, BRIT MED J, V290, P9, DOI 10.1136/bmj.290.6461.9; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Jordaens L, 1997, EUR HEART J, V18, P643; Karki K, 1997, EUR HEART J, V18, P649; Levy S, 1998, EUR HEART J, V19, P1294, DOI 10.1053/euhj.1998.1050; Murgatroyd FD, 1999, CIRCULATION, V99, P2765, DOI 10.1161/01.CIR.99.21.2765; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622	10	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					882	883						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489943				2022-12-28	WOS:000082511800006
J	Liebl, U; Lipowski, G; Negrerie, M; Lambry, JC; Martin, JL; Vos, MH				Liebl, U; Lipowski, G; Negrerie, M; Lambry, JC; Martin, JL; Vos, MH			Coherent reaction dynamics in a bacterial cytochrome c oxidase	NATURE			English	Article							PARACOCCUS-DENITRIFICANS; REACTION CENTERS; VIBRATIONAL COHERENCE; ELECTRON-TRANSFER; HEME-PROTEINS; PRIMARY EVENT; SPECTROSCOPY; ACTIVATION; ABSORPTION; PROGRAM	Biological reactions in protein complexes involve structural dynamics spanning many orders of magnitude in time. In standard descriptions of catalysis by enzymes, the transition state between reactant and product is reached by thermal, stochastic motion. In the ultrashort time domain, however, the protein moiety and cofactor motions leading to altered conformations can be coherent rather than stochastic in nature(1-4). Such coherent motions may play a key role in controlling the accessibility of the transition state and explain the high efficiency of the reaction. Here we present evidence for coherent population transfer to the product state during an ultrafast reaction catalysed by a key enzyme in aerobic organisms. Using the enzyme cytochrome c oxidase aa(3) from the bacterium Paracoccus denitrificans, we have studied haem dynamics during the photo-initiated ultrafast transfer of carbon monoxide from haem a(3) to CuB by femtosecond spectroscopy. The ground state of the unliganded a(3) species is populated in a stepwise manner in time, indicating that the reaction is mainly governed by coherent vibrations (47 cm(-1)). The reaction coordinate involves conformational relaxation of the haem group and we suggest that ligand transfer also contributes.	Ecole Polytech, ENSTA, Lab Opt Appl, INSERM,U451, F-91761 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	Vos, MH (corresponding author), Ecole Polytech, ENSTA, Lab Opt Appl, INSERM,U451, F-91761 Palaiseau, France.		Negrerie, Michel/L-2283-2018	Negrerie, Michel/0000-0001-9918-031X; Lambry, Jean-Christophe/0000-0001-8264-0391; Vos, Marten/0000-0003-0493-4831				Asher S, 1981, Methods Enzymol, V76, P371; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAGCHI B, 1990, J PHYS CHEM-US, V94, P9, DOI 10.1021/j100364a004; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHAMPION PM, 1998, P 16 INT C RAM SPECT, P73; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; FRANZEN S, 1994, NAT STRUCT BIOL, V1, P230, DOI 10.1038/nsb0494-230; GEORGIADIS KE, 1994, BIOCHEMISTRY-US, V33, P9245, DOI 10.1021/bi00197a028; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMON DD, 1993, BIOCHEMISTRY-US, V32, P11953, DOI 10.1021/bi00096a002; LI XY, 1992, CHEM PHYS LETT, V188, P16, DOI 10.1016/0009-2614(92)85081-K; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; Martin J. L., 1984, ULTRAFAST PHENOMENA, VIV, P447; MARTIN JL, 1994, METHOD ENZYMOL, V232, P416; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rischel C, 1998, P NATL ACAD SCI USA, V95, P12306, DOI 10.1073/pnas.95.21.12306; Schelvis JPM, 1997, J AM CHEM SOC, V119, P8409, DOI 10.1021/ja964133p; STOUTLAND PO, 1991, J PHYS CHEM-US, V95, P6406, DOI 10.1021/j100170a004; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; VOS MH, 1991, P NATL ACAD SCI USA, V88, P8885, DOI 10.1073/pnas.88.20.8885; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; Vos MH, 1998, CHEM PHYS, V233, P179, DOI 10.1016/S0301-0104(97)00355-8; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; ZHU LY, 1994, SCIENCE, V266, P629, DOI 10.1126/science.7939716	30	92	93	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					181	184		10.1038/43699	http://dx.doi.org/10.1038/43699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490029				2022-12-28	WOS:000082458800058
J	Ingstad, B				Ingstad, B			The myth of disability in developing nations	LANCET			English	Article									Univ Oslo, Dept Gen Practice & Community Med, Sect Med Anthropol, N-0316 Oslo, Norway	University of Oslo	Ingstad, B (corresponding author), Univ Oslo, Dept Gen Practice & Community Med, Sect Med Anthropol, N-0316 Oslo, Norway.							HELANDER E, 1984, REHABILITATION ALL G, V1; Ingstad B, 1992, J Cross Cult Gerontol, V7, P379, DOI 10.1007/BF01848700; Ingstad B, 1995, DISABILITY CULTURE; Ingstad B., 1997, COMMUNITY BASED REHA; JENKINS R, 1997, QUESTIONS COMPETENCE; WHYTE SR, 1998, QUESTIONS COMPETENCE; Whyte Susan Reynolds, 1998, QUESTIONING MISFORTU	7	29	29	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					757	758		10.1016/S0140-6736(99)06049-3	http://dx.doi.org/10.1016/S0140-6736(99)06049-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475204				2022-12-28	WOS:000082233000042
J	Van de Werf, F; Adgey, J; Ardissino, D; Armstrong, PW; Aylward, P; Barbash, G; Betriu, A; Binbrek, AS; Califf, R; Diaz, R; Fanebust, R; Fox, K; Granger, C; Heikkila, J; Husted, S; Jansky, P; Langer, A; Lupi, E; Maseri, A; Meyer, J; Mlczoch, J; Mocceti, D; Myburgh, D; Oto, A; Paolasso, E; Pehrsson, K; Seabra-Gomes, R; Soares-Piegas, L; Sugrue, D; Tendera, M; Topol, E; Toutouzas, P; Vahanian, A; Verheugt, F; Wallentin, L; White, H; Berioli, S; Bluhmki, E; Brower, R; Danays, T; Fox, NL; Girault, C; Goetz, G; Houbracken, K; Jakob, H; Kaye, J; Sarelin, H; Clow, FW; Hacke, W; von Kummer, L; Lesaffre, E; Bluhmki, E; Bogaerts, K; Munster, K; Scheys, I; Truyen, M; Clow, FW; Fox, KAA; Brower, R; Hallstrom, A; Jones, D; Maggioni, A; Weaver, D				Van de Werf, F; Adgey, J; Ardissino, D; Armstrong, PW; Aylward, P; Barbash, G; Betriu, A; Binbrek, AS; Califf, R; Diaz, R; Fanebust, R; Fox, K; Granger, C; Heikkila, J; Husted, S; Jansky, P; Langer, A; Lupi, E; Maseri, A; Meyer, J; Mlczoch, J; Mocceti, D; Myburgh, D; Oto, A; Paolasso, E; Pehrsson, K; Seabra-Gomes, R; Soares-Piegas, L; Sugrue, D; Tendera, M; Topol, E; Toutouzas, P; Vahanian, A; Verheugt, F; Wallentin, L; White, H; Berioli, S; Bluhmki, E; Brower, R; Danays, T; Fox, NL; Girault, C; Goetz, G; Houbracken, K; Jakob, H; Kaye, J; Sarelin, H; Clow, FW; Hacke, W; von Kummer, L; Lesaffre, E; Bluhmki, E; Bogaerts, K; Munster, K; Scheys, I; Truyen, M; Clow, FW; Fox, KAA; Brower, R; Hallstrom, A; Jones, D; Maggioni, A; Weaver, D		ASSENT-2 Investigators	Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial	LANCET			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; EQUIVALENCE TRIALS; THROMBOLYSIS	Background Bolus fibrinolytic therapy facilitates early efficient institution of reperfusion therapy. Tenecteplase is a genetically engineered variant of alteplase with slower plasma clearance, better fibrin specificity, and high resistance to plasminogen-activator inhibitor-1. We did a double-blind, randomised, controlled trial to assess the efficacy and safety of tenecteplase compared with alteplase. Methods In 1021 hospitals, we randomly assigned 16 949 patients with acute myocardial infarction of less than 6 h duration rapid infusion of alteplase (less than or equal to 100 mg) or single-bolus injection of tenecteplase (30-50 mg according to bodyweight). All patients received aspirin and heparin (target activated partial thromboplastin time 50-75 s). The primary outcome was equivalence in all-cause mortality at 30 days. Findings Covariate-adjusted 30-day mortality rates were almost identical for the two groups-6.18% for tenecteplase and 6.15% for alteplase. The 95% one-sided upper boundaries of the absolute and relative differences in 30-day mortality were 0.61% and 10.00%, respectively, which met the prespecified criteria of equivalence (1% absolute or 14% relative difference in 30-day mortality, whichever difference proved smaller). Rates of intracranial haemorrhage were similar (0.93% for tenecteplase and 0.94% for alteplase), but fewer non-cerebral bleeding complications (26.43 vs 28.95%, p=0.0003) and less need for blood transfusion (4.25 vs 5.49%, p=0.0002) were seen with tenecteplase. The rate of death or non-fatal stroke at 30 days was 7.11% with tenecteplase and 7.04% with alteplase (relative risk 1.01 [95% CI 0.91-1.13]). Interpretation Tenecteplase and alteplase were equivalent for 30-day mortality. The ease of administration of tenecteplase may facilitate more rapid treatment in and out of hospital.	Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	Van de Werf, F (corresponding author), Univ Hosp Gasthuisberg, Dept Cardiol, Herestr 49, B-3000 Louvain, Belgium.	frans.vandewerf@uz.kuleuven.ac.be	Hacke, Werner/ABE-8661-2020; Manolis, Antonis/F-5003-2014; Tendera, Michal/AAA-1875-2022; Fox, keith A A/I-3742-2013; Ardissino, Diego/AAC-4041-2022	Manolis, Antonis/0000-0002-0336-4745; Piegas, Leopoldo/0000-0003-1021-817X; solinas, emilia/0000-0003-3532-1317; Aylward, Philip/0000-0002-5358-8552; Topol, Eric/0000-0002-1478-4729; Armstrong, Paul/0000-0002-0460-3445; Bogaerts, Kris/0000-0003-0188-8665				Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; Cannon CP, 1997, CIRCULATION, V95, P351; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; Koch GG, 1998, STAT MED, V17, P1863, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1863::AID-SIM989>3.0.CO;2-M; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; VANDEWERF F, 1990, LANCET, V336, P71; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632; White HD, 1998, J AM COLL CARDIOL, V31, P494	14	576	605	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					716	722		10.1016/S0140-6736(99)07403-6	http://dx.doi.org/10.1016/S0140-6736(99)07403-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475182				2022-12-28	WOS:000082233000010
J	Shellens, T				Shellens, T			The legal position	BRITISH MEDICAL JOURNAL			English	Article									Bevam Ashford Solicitors, Cardiff CF240BA, S Glam, Wales		Shellens, T (corresponding author), Bevam Ashford Solicitors, Waterloo House,Fitzalan Court, Cardiff CF240BA, S Glam, Wales.							Caldicott Committee Department of Health, 1997, REP REV PAT ID INF; *DEP HLTH WELSH OF, 1996, GUID PROT US PAT INF	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					374	374						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490323				2022-12-28	WOS:000082001700031
J	Culver, GM; Cate, JH; Yusupova, GZ; Yusupov, MM; Noller, HF				Culver, GM; Cate, JH; Yusupova, GZ; Yusupov, MM; Noller, HF			Identification of an RNA-protein bridge spanning the ribosomal subunit interface	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOME; CHEMICAL MODIFICATION; ASSOCIATION; 16S; FE(II); SITES; NEIGHBORHOOD; PROTECTION; 30-S; ACID	The 7.8 angstrom crystal structure of the 70S ribosome reveals a discrete double-helical bridge (B4) that projects from the 50S subunit, making contact with the 30S subunit. Preliminary modeling studies Localized its contact site, near the bottom of the platform, to the binding site for ribosomal protein S15. Directed hydroxyl radical probing from iron(II) tethered to S15 specifically cleaved nucleotides in the 715 Loop of domain II of 23S ribosomal RNA, one of the known sites in 23S ribosomal RNA that are footprinted by the 30S subunit. Reconstitution studies show that protection of the 715 Loop, but none of the other 30S-dependent protections, is correlated with the presence of S15 in the 30S subunit. The 715 loop is specifically protected by binding free S15 to 50S subunits. Moreover, the previously determined structure of a homologous stem-loop from U2 small nuclear RNA fits closely to the electron density of the bridge.	Univ Calif Santa Cruz, Ctr Mol Biol RNA, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Noller, HF (corresponding author), Univ Calif Santa Cruz, Ctr Mol Biol RNA, Sinsheimer Labs, Santa Cruz, CA 95064 USA.		Yusupova, Gulnara/E-1877-2014; Yusupov, Marat/I-6126-2013	Yusupov, Marat/0000-0001-5544-0597	NIGMS NIH HHS [GM-59140, GM-17129, 1F32GM18065-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129, F32GM018065, R01GM059140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDURASHIDOVA GG, 1985, FEBS LETT, V185, P291, DOI 10.1016/0014-5793(85)80925-X; Berglund H, 1997, NAT STRUCT BIOL, V4, P20, DOI 10.1038/nsb0197-20; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHAMPNEY WS, 1980, BIOCHIM BIOPHYS ACTA, V609, P464, DOI 10.1016/0005-2787(80)90120-3; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; CHIAM CL, 1983, BIOCHEMISTRY-US, V22, P1193, DOI 10.1021/bi00274a032; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; Culver GM, 1999, RNA, V5, P832, DOI 10.1017/S1355838299990714; Culver GM, 1999, J MOL BIOL, V286, P355, DOI 10.1006/jmbi.1998.2483; Culver GM, 1998, RNA, V4, P1471, DOI 10.1017/S1355838298981201; CULVER GM, IN PRESS METHODS ENZ; CULVER GM, UNPUB; DERIEMER LH, 1981, J LABELLED COMPD RAD, V18, P1517, DOI 10.1002/jlcr.2580181017; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; Heilek GM, 1996, RNA, V2, P597; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; Holmberg L, 1999, J MOL BIOL, V289, P223, DOI 10.1006/jmbi.1999.2706; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; Lieberman KR, 1998, J MOL BIOL, V284, P1367, DOI 10.1006/jmbi.1998.2236; MEIER N, 1985, EUR J BIOCHEM, V146, P83, DOI 10.1111/j.1432-1033.1985.tb08622.x; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; Merryman C, 1999, J MOL BIOL, V285, P107, DOI 10.1006/jmbi.1998.2243; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MORAN JK, 1995, BIOCONJUGATE CHEM, V6, P296, DOI 10.1021/bc00033a010; MORRISON CA, 1973, MOL GEN GENET, V127, P359, DOI 10.1007/BF00267106; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; SANTER M, 1977, J BACTERIOL, V130, P900, DOI 10.1128/JB.130.2.900-910.1977; SCHEIBE U, 1986, BIOCHIM BIOPHYS ACTA, V869, P1, DOI 10.1016/0167-4838(86)90302-X; Stallings SC, 1997, STRUCTURE, V5, P1173, DOI 10.1016/S0969-2126(97)00268-2; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; SUN TT, 1974, J MOL BIOL, V87, P509, DOI 10.1016/0022-2836(74)90101-6; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5	37	68	74	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2133	2135		10.1126/science.285.5436.2133	http://dx.doi.org/10.1126/science.285.5436.2133			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497132				2022-12-28	WOS:000082734300044
J	Horz, F; Cintala, MJ; Rochelle, WC; Kirk, B				Horz, F; Cintala, MJ; Rochelle, WC; Kirk, B			Collisionally processed rocks on Mars	SCIENCE			English	Article							PATHFINDER	The Pathfinder Landing site on Mars has boulders that may be cratered (Stimpy), split (Chimp), fragmented (Book End and Flat Top), or otherwise partly destroyed (Yogi and Frog) by collisional processes. Atmospheric-entry calculations show that centimeter-sized projectiles survive passage through the martian atmosphere and encounter the surface of Mars at velocities of a few kilometers per second. Craters Less than 1 meter in diameter may contribute to the evolution of the martian surface and its soils.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Lockheed Martin, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Lockheed Martin	Horz, F (corresponding author), NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA.							ARVIDSON RE, 1989, REV GEOPHYS, V27, P39, DOI 10.1029/RG027i001p00039; Basilevsky AT, 1999, J GEOPHYS RES-PLANET, V104, P8617, DOI 10.1029/1998JE900039; BINZEL RP, 1989, ASTEROIDS, V2; BLAND PA, 1999, LUNAR PLANET SCI, V30; Bridges NT, 1999, J GEOPHYS RES-PLANET, V104, P8595, DOI 10.1029/98JE02550; DYCUS RD, 1969, PUBL ASTRON SOC PAC, V81, P399, DOI 10.1086/128793; Fujiwara A., 1989, ASTEROIDS, VII, P240; Gault D. E., 1973, Moon, V6, P32, DOI 10.1007/BF02630651; GAULT DE, 1970, EOS T AM GEOPHYS UN, V51, P343; Golombek MP, 1999, J GEOPHYS RES-PLANET, V104, P8523, DOI 10.1029/98JE02554; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; Greeley R, 1999, J GEOPHYS RES-PLANET, V104, P8573, DOI 10.1029/98JE02553; Hartmann WK, 1999, METEORIT PLANET SCI, V34, P167, DOI 10.1111/j.1945-5100.1999.tb01743.x; HEIKEN H, 1991, LUNAR SOURCEBOOK; HORZ F, 1971, J GEOPHYS RES, V76, P5770, DOI 10.1029/JB076i023p05770; Horz F, 1997, METEORIT PLANET SCI, V32, P179; MUTCH TA, 1978, NASA SP, V425; RICE JW, 1999, LUNAR PLANET, V30; ROCHELLE WC, 1999, LUNAR PLANET SCI, V30; ROCHELLE WC, 1997, 8 ANN THERM FLUIDS A; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; STEFANIS MS, 1999, LUNAR PLANET SCI, V30; VASAVADA AR, 1993, J GEOPHYS RES-PLANET, V98, P3469, DOI 10.1029/92JE02942	23	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2105	2107		10.1126/science.285.5436.2105	http://dx.doi.org/10.1126/science.285.5436.2105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497123				2022-12-28	WOS:000082734300035
J	Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH				Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH			Safety of early discharge for Medicaid newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL READMISSION; STAY	Context Neonates are being discharged from the hospital more rapidly, but the risks associated with this practice, especially for low-income populations, are unclear. Objective To determine the impact of decreasing postnatal length of stay on rehospitalization rates in the immediate postdischarge period for Medicaid neonates. Design and Setting Retrospective, population-based cohort study using Ohio Medicaid claims data linked to vital statistics files from July 1, 1991, to June 15, 1995. Participants A total of 102 678 full-term neonates born to mothers receiving Medicaid for at least 30 days after birth. Main Outcome Measures Rehospitalization rates within 7 and 14 days of discharge, postdischarge health care use, and regional variations in length of stay and rehospitalization. Results The proportion of neonates who were discharged following a short stay (less than 1 day after vaginal delivery, less than 2 days after cesarean birth) increased 185%, from 21 % to 59.8% (P<.001) and the mean (SD) length of stay decreased 27%, from 2.2 (1.0) to 1.6 (0.9) days (P<.001), over the course of the study, The proportion of neonates who received a primary care visit within 14 days of birth increased 117% (P = .001). Rehospitalization rates within 7 and 14 days of discharge decreased by 23 %, from 1.3 % to 1.0% (P = .01), and by 19%, from 2.1% to 1.7% (P = .03), respectively. Short stay across the 6 regions of the state varied significantly over time (P<.001), Factors significantly associated with increased likelihood of rehospitalization within both 7 and 14 days of discharge were white race, shorter gestation, primiparity, earlier year of birth, lower 5-minute Apgar score, vaginal delivery, married mother, and region of the state. Conclusion Our data suggest that reductions in length of stay for full-term Medicaid newborns in Ohio have not resulted in an increase in rehospitalization rates in the immediate postnatal period.	Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Neonatol, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH USA; Ohio Dept Human Serv, Bur Medicaid Policy, Columbus, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Kotagal, UR (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							ADEBONOJO FO, 1973, CLIN PEDIATR, V12, P644, DOI 10.1177/000992287301201107; Bragg EJ, 1997, OBSTET GYNECOL, V89, P930, DOI 10.1016/S0029-7844(97)85764-X; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; CATZ C, 1995, PEDIATRICS, V96, P743; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; COOPER WO, 1995, PEDIATRICS, V96, P957; COTTRELL DG, 1983, J AM OSTEOPATH ASSOC, V83, P216; Czarnecki M T, 1996, J Nurs Care Qual, V10, P1; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; Fox M H, 1995, Am J Med Qual, V10, P206, DOI 10.1177/0885713X9501000407; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; Kotagal UR, 1996, J PEDIATR GASTR NUTR, V22, P402, DOI 10.1097/00005176-199605000-00012; KRAMER MS, 1991, PEDIATRICS, V87, P399; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P293, DOI 10.1001/jama.278.4.293; Maisels MJ, 1998, PEDIATRICS, V101, P995, DOI 10.1542/peds.101.6.995; *NAT CTR HLTH STAT, 1995, HLTH PEOPL 2000 REV; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; *OH DEP HLTH, 1977, STAT PER GUID; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; Pruett S H, 1996, Am J Med Qual, V11, pS39; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; RYAN AS, 1991, PEDIATRICS, V88, P719; Smith R D, 1988, Pediatr Emerg Care, V4, P107, DOI 10.1097/00006565-198806000-00005; SPONG FW, 1997, INPATIENT CARE MOTHE	27	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1150	1156		10.1001/jama.282.12.1150	http://dx.doi.org/10.1001/jama.282.12.1150			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501118				2022-12-28	WOS:000082596200030
J	Hook, EW; Stephens, J; Ennis, DM				Hook, EW; Stephens, J; Ennis, DM			Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis	ANNALS OF INTERNAL MEDICINE			English	Article							CEFTRIAXONE; ELIMINATION; URETHRITIS; GONORRHEA; THERAPY; TRIAL	Background: Preventive therapy is an important element of syphilis control efforts. No currently recommended, single-dose alternatives to penicillin G benzathine are available for treatment of incubating syphilis. Objective: To evaluate the use of a single 1.0-g dose of azithromycin for treatment of persons recently exposed to sexual partners with infectious syphilis. Design: Single-center, open-label, randomized pilot study to compare azithromycin with penicillin G benzathine therapy. Participants were evaluated serologically for 3 months. Setting: Sexually transmitted disease clinic in Birmingham, Alabama. Participants: 96 participants who in the preceding 30 days had been exposed to partners with infectious syphilis through sexual intercourse. Measurements: Syphilis prevention, as indicated by nonreactive serologic tests (rapid plasma reagin and fluorescent treponemal antibody-absorbed), throughout the 3-month follow-up. Results: Among 96 participants enrolled, none of 40 evaluable persons in the azithromycin group and none of 23 evaluable persons in the penicillin group developed evidence of syphilis. Significantly more penicillin-treated participants (21 of 44 [48%]) than azithromycin-treated participants (12 of 52 [23%]) became nonevaluable during follow-up (P = 0.01). Conclusion: A single 1.0-g dose of azithromycin seems to be efficacious for prevention of syphilis in persons exposed to infected sexual partners.	Univ Alabama Birmingham, Dept Med, Div Infect Dis, Sch Med, Birmingham, AL 35294 USA; Jefferson Cty Dept Hlth, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Hook, EW (corresponding author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Sch Med, 229 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.				NIAID NIH HHS [U19-AI38514] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038514] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; HANDSFIELD HH, 1994, SEX TRANSM DIS, V21, P107, DOI 10.1097/00007435-199403000-00010; Hook EW, 1998, LANCET, V351, P19; HOOK EW, 1992, NEW ENGL J MED, V326, P1060, DOI 10.1056/NEJM199204163261606; LUKEHART SA, 1990, J ANTIMICROB CHEMOTH, V25, P91, DOI 10.1093/jac/25.suppl_A.91; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MARTIN DH, 1995, CLIN INFECT DIS, V21, P409, DOI 10.1093/clinids/21.2.409; MOORE MB, 1963, PUBLIC HEALTH REP, V78, P966, DOI 10.2307/4591989; SCHOBER PC, 1983, BRIT J VENER DIS, V59, P217; SCHROETER AL, 1971, J AMER MED ASSOC, V218, P711, DOI 10.1001/jama.218.5.711; St Louis ME, 1998, SCIENCE, V281, P353, DOI 10.1126/science.281.5375.353; STAMM WE, 1995, JAMA-J AM MED ASSOC, V274, P545, DOI 10.1001/jama.274.7.545; VERDON MS, 1994, CLIN INFECT DIS, V19, P486, DOI 10.1093/clinids/19.3.486	13	57	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					434	437		10.7326/0003-4819-131-6-199909210-00007	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498560				2022-12-28	WOS:000082641100006
J	Lindsay, M				Lindsay, M			Entering the minds of the elderly - A dilemma	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					737	737		10.1136/bmj.319.7212.737	http://dx.doi.org/10.1136/bmj.319.7212.737			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487998	Green Published			2022-12-28	WOS:000082701500017
J	Dal Santo, P; Logan, MA; Chisholm, AD; Jorgensen, EM				Dal Santo, P; Logan, MA; Chisholm, AD; Jorgensen, EM			The inositol trisphosphate receptor regulates a 50-second behavioral rhythm in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; PHORBOL-ESTER; 1,4,5-TRISPHOSPHATE RECEPTOR; PATTERN GENERATION; MOLECULAR-CLONING; GENETIC-ANALYSIS; MOSAIC ANALYSIS; PROTEIN-KINASE; CALCIUM; OSCILLATIONS	The C. elegans defecation cycle is characterized by the contraction of three distinct sets of muscles every 50 s. Our data indicate that this cycle is regulated by periodic calcium release mediated by the inositol trisphosphate receptor (IP3 receptor). Mutations in the IF, receptor slow down or eliminate the cycle, while overexpression speeds up the cycle. The IP3 receptor controls these periodic muscle contractions nonautonomously from the intestine. In the intestinal cells, calcium levels oscillate with the same period as the defecation cycle and peak calcium levels immediately precede the first muscle contraction. Mutations in the IF, receptor slow or eliminate these calcium oscillations. Thus, the IP3 receptor is an essential component of the timekeeper for this cycle and represents a novel mechanism for the control of behavioral rhythms.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Program Neurosci, Salt Lake City, UT 84112 USA; Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Santa Cruz	Jorgensen, EM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.			Chisholm, Andrew/0000-0001-5091-0537	NINDS NIH HHS [NS 34307] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034307, R01NS034307] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arshavsky YI, 1997, CURR OPIN NEUROBIOL, V7, P781, DOI 10.1016/S0959-4388(97)80136-5; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRENNER S, 1974, GENETICS, V77, P71; Calabrese RL, 1995, CURR OPIN NEUROBIOL, V5, P816, DOI 10.1016/0959-4388(95)80111-1; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; CLARK SG, 1994, GENETICS, V137, P987; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Edmunds LN, 1988, CELLULAR MOL BASES B; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Fleming JT, 1996, PARASITOLOGY, V113, pS175, DOI 10.1017/S0031182000077969; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; GILES W, 1986, CARDIAC MUSCLE REGUL, P1; HEDGECOCK EM, 1995, GENETICS, V141, P989; Iwasaki K, 1997, TRENDS GENET, V13, P111, DOI 10.1016/S0168-9525(97)01059-7; IWASAKI K, 1995, P NATL ACAD SCI USA, V92, P10317, DOI 10.1073/pnas.92.22.10317; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; LIU DWC, 1994, J NEUROSCI, V14, P1953; MACVICAR BA, 1987, NATURE, V329, P242, DOI 10.1038/329242a0; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mikoshiba Katsuhiko, 1994, Seminars in Cell Biology, V5, P273, DOI 10.1006/scel.1994.1033; Miller LM, 1996, GENETICS, V143, P1181; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; PAYNE R, 1991, J GEN PHYSIOL, V97, P1165, DOI 10.1085/jgp.97.6.1165; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Take-uchi M, 1998, P NATL ACAD SCI USA, V95, P11775, DOI 10.1073/pnas.95.20.11775; THOMAS JH, 1990, GENETICS, V124, P855; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; Wang SSH, 1995, BIOPHYS J, V69, P1683, DOI 10.1016/S0006-3495(95)80086-X; Wood WB, 1988, NEMATODE CAENORHABDI; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; Yochem J, 1998, GENETICS, V149, P1323; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	44	164	169	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					757	767		10.1016/S0092-8674(00)81510-X	http://dx.doi.org/10.1016/S0092-8674(00)81510-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499793	Bronze			2022-12-28	WOS:000082679200003
J	Valverde, MA; Rojas, P; Amigo, J; Cosmelli, D; Orio, P; Bahamonde, MI; Mann, GE; Vergara, C; Latorre, R				Valverde, MA; Rojas, P; Amigo, J; Cosmelli, D; Orio, P; Bahamonde, MI; Mann, GE; Vergara, C; Latorre, R			Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit	SCIENCE			English	Article							VASCULAR SMOOTH-MUSCLE; POTASSIUM CHANNELS; CA2+ CURRENTS; CELL-LINE; ESTROGEN; MEMBRANE; 17-BETA-ESTRADIOL; RECEPTOR; INHIBITION; RELAXATION	Maxi-K channels consist of a pore-forming alpha subunit and a regulatory beta subunit, which confers the channel with a higher Ca2+ sensitivity. Estradiol bound to the beta subunit and activated the Maxi-K channel (hSlo) only when both a and beta subunits were present. This activation was independent of the generation of intracellular signals and could be triggered by estradiol conjugated to a membrane-impenetrable carrier protein. This study documents the direct interaction of a hormone with a voltage-gated channel subunit and provides the molecular mechanism for the modulation of vascular smooth muscle Maxi-K channels by estrogens.	Univ Pompeu Fabra, Dept Ciencias Expt & Salut, Barcelona 08003, Spain; Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Ctr Estudios Cient, Valdivia 9, Chile; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Kings Coll London, Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 9RT, England	Pompeu Fabra University; Universidad de Chile; University of California System; University of California Los Angeles; University of London; King's College London	Valverde, MA (corresponding author), Univ Pompeu Fabra, Dept Ciencias Expt & Salut, C-Doctor Aiguader 80, Barcelona 08003, Spain.	miguel.valverde@cexs.upf.es	Vergara, Cecilia/H-6964-2014; Orio, Patricio/F-6207-2010	Vergara, Cecilia/0000-0002-4015-7438; Orio, Patricio/0000-0003-0332-8098; Valverde, Miguel A./0000-0002-6961-3361; ROZALI, ZALNIATI FONNA/0000-0003-2242-5125	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Clark AG, 1999, J PHYSIOL-LONDON, V516, P45, DOI 10.1111/j.1469-7793.1999.045aa.x; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; JIANG C, 1994, BRIT J PHARMACOL, V104, P1033; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Moats RK, 1998, BIOL REPROD, V58, P531, DOI 10.1095/biolreprod58.2.531; MOCZYDLOWSKI EG, 1983, BIOCHIM BIOPHYS ACTA, V732, P412, DOI 10.1016/0005-2736(83)90058-5; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nakajima T, 1995, EUR J PHARMACOL, V294, P625, DOI 10.1016/0014-2999(95)00602-8; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Ogata R, 1996, BRIT J PHARMACOL, V117, P351, DOI 10.1111/j.1476-5381.1996.tb15198.x; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Russell KS, 1997, CIRCULATION, V96, P256; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TAGLIALATELA M, 1993, P NATL ACAD SCI USA, V90, P4758, DOI 10.1073/pnas.90.10.4758; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wetzel CHR, 1998, MOL ENDOCRINOL, V12, P1441, DOI 10.1210/me.12.9.1441; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	38	429	447	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1929	1931		10.1126/science.285.5435.1929	http://dx.doi.org/10.1126/science.285.5435.1929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489376				2022-12-28	WOS:000082638300056
J	Pillay, T; Jeena, PM				Pillay, T; Jeena, PM			A neonate with haemorrhagic ascites	LANCET			English	Article							TUBERCULOSIS		Univ Natal, Sch Med, Dept Paediat & Child Hlth, ZA-4013 Durban, South Africa	University of Kwazulu Natal	Pillay, T (corresponding author), Univ Natal, Sch Med, Dept Paediat & Child Hlth, ZA-4013 Durban, South Africa.			Pillay, Thillagavathie/0000-0002-4159-3282				Adhikari M, 1997, PEDIATR INFECT DIS J, V16, P1108, DOI 10.1097/00006454-199712000-00003; CANTWELL MF, 1994, NEW ENGL J MED, V330, P1051, DOI 10.1056/NEJM199404143301505; *CDC, 1994, MMWR MORB MORTAL WKL, V43; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; WANG JH, 1990, CHIN MED J, V45, P266	5	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					914	914		10.1016/S0140-6736(99)04321-4	http://dx.doi.org/10.1016/S0140-6736(99)04321-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489952				2022-12-28	WOS:000082511800015
J	van der Meulen, MFG; Rinkel, GJE; Witkamp, TD; van Gijn, J				van der Meulen, MFG; Rinkel, GJE; Witkamp, TD; van Gijn, J			A man with progressive weakness in his legs	LANCET			English	Article							DURAL ARTERIOVENOUS-FISTULA; SPINAL-CORD; MYELOPATHY		Univ Utrecht, Med Ctr, Dept Neurol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Radiol, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	van der Meulen, MFG (corresponding author), Univ Utrecht, Med Ctr, Dept Neurol, NL-3584 CX Utrecht, Netherlands.		van Gijn, Jan/A-9444-2008					DEEN HG, 1994, MAYO CLIN PROC, V69, P83, DOI 10.1016/S0025-6196(12)61617-6; Foix C, 1926, REV NEUROL-FRANCE, V46, P1; HURST RW, 1995, NEUROLOGY, V45, P1309, DOI 10.1212/WNL.45.7.1309; OLDFIELD EH, 1983, J NEUROSURG, V59, P1019, DOI 10.3171/jns.1983.59.6.1019; TOMLINSON FH, 1993, J NEUROSURG, V79, P16, DOI 10.3171/jns.1993.79.1.0016	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					830	830						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485726				2022-12-28	WOS:000082400700013
J	Fath, M; Freisem, S; Menovsky, AA; Tomioka, Y; Aarts, J; Mydosh, JA				Fath, M; Freisem, S; Menovsky, AA; Tomioka, Y; Aarts, J; Mydosh, JA			Spatially inhomogeneous metal-insulator transition in doped manganites	SCIENCE			English	Article							MANGANESE PEROVSKITES; FERROMAGNETIC TRANSITION; THIN-FILMS; LA0.67CA0.33MNO3; LA1-XCAXMNO3; CROSSOVER; POLARONS; OXIDES; RAMAN; PHASE	Scanning tunneling spectroscopy was used to investigate single crystals and thin films of La1-xCaxMnO3 (with x of about 0.3), which exhibit colossal magnetoresistance, The different spectroscopic signatures of the insulating (paramagnetic) and metallic (ferromagnetic) phases enable their spatial extent to be imaged down to a Lateral scale of the order of 10 nanometers. Above the bulk transition temperature T-c, the images show mostly insulating behavior. Below T-c, a phase separation is observed where inhomogeneous structures of metallic and more insulating areas coexist and are strongly field dependent in their size and structure. Insulating areas are found to persist far below T-c. These results suggest that the transition and the associated magnetoresistance behavior should be viewed as a percolation of metallic ferromagnetic domains.	Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands; Univ Amsterdam, Van der Waals Zeeman Lab, NL-1081 XE Amsterdam, Netherlands; Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan	Leiden University; Leiden University - Excl LUMC; University of Amsterdam; National Institute of Advanced Industrial Science & Technology (AIST)	Aarts, J (corresponding author), Leiden Univ, Kamerlingh Onnes Lab, POB 9506, NL-2300 RA Leiden, Netherlands.		Aarts, Jan/D-5959-2018	Aarts, Jan/0000-0002-4113-0835				Aarts J, 1998, APPL PHYS LETT, V72, P2975, DOI 10.1063/1.121512; Booth CH, 1998, PHYS REV B, V57, P10440, DOI 10.1103/PhysRevB.57.10440; COEY JMD, 1995, PHYS REV LETT, V75, P3910, DOI 10.1103/PhysRevLett.75.3910; DeTeresa JM, 1997, NATURE, V386, P256, DOI 10.1038/386256a0; Freisem S, 1997, J MAGN MAGN MATER, V165, P380, DOI 10.1016/S0304-8853(96)00563-X; Heffner RH, 1996, PHYS REV LETT, V77, P1869, DOI 10.1103/PhysRevLett.77.1869; Lanzara A, 1998, PHYS REV LETT, V81, P878, DOI 10.1103/PhysRevLett.81.878; Liu HL, 1998, PHYS REV B, V58, P10115, DOI 10.1103/PhysRevB.58.R10115; Lynn JW, 1996, PHYS REV LETT, V76, P4046, DOI 10.1103/PhysRevLett.76.4046; Maezono R, 1998, PHYS REV B, V58, P11583, DOI 10.1103/PhysRevB.58.11583; Millis AJ, 1998, NATURE, V392, P147, DOI 10.1038/32348; Moreo A, 1999, SCIENCE, V283, P2034, DOI 10.1126/science.283.5410.2034; Mori S, 1998, PHYS REV LETT, V81, P3972, DOI 10.1103/PhysRevLett.81.3972; Park JH, 1996, PHYS REV LETT, V76, P4215, DOI 10.1103/PhysRevLett.76.4215; Wei JYT, 1997, PHYS REV LETT, V79, P5150, DOI 10.1103/PhysRevLett.79.5150; Yoon S, 1998, PHYS REV B, V58, P2795, DOI 10.1103/PhysRevB.58.2795; ZANDBERGEN HW, UNPUB; ZENER C, 1951, PHYS REV, V82, P403, DOI 10.1103/PhysRev.82.403	18	779	798	6	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1540	1542		10.1126/science.285.5433.1540	http://dx.doi.org/10.1126/science.285.5433.1540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477512				2022-12-28	WOS:000082359500057
J	Larkin, M				Larkin, M			US online pharmacies strive for respectability	LANCET			English	Editorial Material																		1999, LANCET, V354, P138	1	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					782	782		10.1016/S0140-6736(05)76034-7	http://dx.doi.org/10.1016/S0140-6736(05)76034-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475233				2022-12-28	WOS:000082233000077
J	Thorburn, MJ				Thorburn, MJ			The role of the family: disability and rehabilitation in rural Jamaica	LANCET			English	Article									Univ W Indies, Fac Med Sci, Mona, Jamaica	University West Indies Mona Jamaica	Thorburn, MJ (corresponding author), Univ W Indies, Fac Med Sci, Mona, Jamaica.							Bischoff R, 1996, CHILD CARE HLTH DEV, V22, P397; LEAVITT RL, 1992, DISABILITY REHABILIT, P173; OpHeij J, 1997, W INDIAN MED J, V46, P83; PAUL TJ, 1992, W INDIAN MED J, V41, P8; THORBURN MJ, 1998, W INDIAN MED J S, V47, P36; THORBURN MJ, 1998, ASIA PAC DISAB REHAB, V9, P20; THORBURN MJ, 1997, ADV APPL DEV PSYCHOL, V14, P177; VANDERPUTTEN AAJ, 1996, W INDIAN MED J, V45, P13	8	5	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					762	763		10.1016/S0140-6736(99)06072-9	http://dx.doi.org/10.1016/S0140-6736(99)06072-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475207				2022-12-28	WOS:000082233000045
J	Wetzel, DL; LeVine, SM				Wetzel, DL; LeVine, SM			Microspectroscopy - Imaging molecular chemistry with infrared microscopy	SCIENCE			English	Article							PLANE ARRAY DETECTOR; CHEMICAL-ANALYSIS; IN-SITU; TISSUE; BRAIN		Kansas State Univ, Microbeam Mol Spect Lab, Manhattan, KS 66506 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	Kansas State University; University of Kansas; University of Kansas Medical Center	Wetzel, DL (corresponding author), Kansas State Univ, Microbeam Mol Spect Lab, Shellenberger Hall, Manhattan, KS 66506 USA.	dwetzel@ksu.edu; slevine@kumc.edu						Cho LL, 1998, AIP CONF PROC, P539, DOI 10.1063/1.55723; Cho LL, 1999, J FORENSIC SCI, V44, P283; Cho LL, 1999, J FORENSIC SCI, V44, P275; Guilhaumou N, 1998, APPL SPECTROSC, V52, P1029, DOI 10.1366/0003702981944797; Jamin N, 1998, P NATL ACAD SCI USA, V95, P4837, DOI 10.1073/pnas.95.9.4837; Kalasinsky KS, 1998, CELL MOL BIOL, V44, P81; Kalasinsky VF, 1998, CELL MOL BIOL, V44, P141; LeVine SM, 1998, FREE RADICAL BIO MED, V25, P33, DOI 10.1016/S0891-5849(98)00019-7; LEVINE SM, 1994, AM J PATHOL, V145, P1041; LEWIS EN, 1995, ANAL CHEM, V67, P3377, DOI 10.1021/ac00115a003; Marcott C, 1998, CELL MOL BIOL, V44, P109; Miller LM, 1998, CELL MOL BIOL, V44, P117; REFFNER JA, 1995, REV SCI INSTRUM, V66, P1298, DOI 10.1063/1.1145958; REFFNER JA, 1999, Patent No. 5864137; Wetzel DL, 1998, AIP CONF PROC, P567, DOI 10.1063/1.55825; Wetzel DL, 1998, CELL MOL BIOL, V44, P15; Wetzel DL, 1997, MIKROCHIM ACTA, P349; WETZEL DL, 1993, CEREAL FOOD WORLD, V38, P9; Wetzel DL, 1998, CELL MOL BIOL, V44, P145; WETZEL DL, 1993, SPECTROSCOPY, V8, P40; WETZEL DL, IN PRESS INFRARED RA; 1998, CELL MOL BIOL, V44	22	133	138	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1999	285	5431					1224	1225		10.1126/science.285.5431.1224	http://dx.doi.org/10.1126/science.285.5431.1224			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10484732				2022-12-28	WOS:000082130200028
J	Harland, J; White, M; Drinkwater, C; Chinn, D; Farr, L; Howel, D				Harland, J; White, M; Drinkwater, C; Chinn, D; Farr, L; Howel, D			The Newcastle exercise project: a randomised controlled trial of methods, to promote physical activity in primary care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH PROMOTION; DISEASE	Objective To evaluate the effectiveness of combinations of three methods to promote physical activity. Design Randomised controlled trial. Baseline assessment with post-intervention follow up at 12 weeks and 1 year, Setting One urban general practice, 1995-7. Participants 523 adults aged 40 to 64 years, randomised to four intervention groups and a control group. Interventions Brief (one interview) or intensive (six interviews over 12 weeks) motivational interviewing based on the stages of change model of behaviour change, with or without financial incentive (30 vouchers entitling free access to leisure facilities). Main outcome measures Physical activity score; sessions of moderate and vigorous activity in die preceding four weeks. Results Response rate was 81% at 12 weeks and 85% at one year. More participants in the intervention group reported increased physical activity scores at 12 weeks than controls (38% v 16%, difference 22%, 95% confidence interval for difference 13% to 32%), with a 55% increase observed in those offered six interviews plus vouchers. Vigorous activity increased in 29% of intervention participants and 11% of controls (difference 18%, 10% to 26%), but differences between the intervention groups were not significant. short term increases in activity were not sustained, regardless of intensity of intervention. Conclusions The most effective intervention for promoting adoption of exercise was the most intensive. Even this did not promote long term adherence to exercise. Brief interventions promoting physical activity that are used by many schemes in the United Kingdom are questionable effectiveness.	Univ Newcastle Upon Tyne, Sch Hlth Sci, Hlth Promot Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Harland, J (corresponding author), Univ Newcastle Upon Tyne, Sch Hlth Sci, Hlth Promot Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		White, Martin J. R./G-2410-2010					Breeze E, 1994, HLTH SURVEY ENGLAND; Buxton K., 1996, HLTH ED J, V55, P239; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; Chinn DJ, 1999, J EPIDEMIOL COMMUN H, V53, P191, DOI 10.1136/jech.53.3.191; FENTEM P, 1994, BRIT MED J, V308, P1291, DOI 10.1136/bmj.308.6939.1291; Fentem P, 1994, ALLIED DUNBAR NATL F; Fox K, 1997, BRIT J GEN PRACT, V47, P367; GARDENER M, 1991, CONFIDENCE INTERVAL; HARLAND J, 1997, J EPIDEMIOL COMMUNIT, V51, P587; HARRINGTON B, 1994, INDICATORS HLTH PROM; HARVEY J, 1995, HLTH PROFILES LOCALI; HILLSDON M, 1995, J EPIDEMIOL COMMUN H, V49, P448, DOI 10.1136/jech.49.5.448; Hillsdon M, 1996, BRIT J SPORT MED, V30, P84, DOI 10.1136/bjsm.30.2.84; *HLTH ED AUTH, 1997, HLTH ENGL 1996 PEOPL; *HLTH ED BOARD SCO, 1995, PROM PHYS ACT SCOTL; KING AC, 1988, ADHERENCE EXERCISE R, P335; MARCUS BH, 1993, J SPORT MED PHYS FIT, V33, P83; McArdle W., 2014, EXERCISE PHYSL ENERG, P253; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; MORRIS JN, 1994, MED SCI SPORT EXER, V26, P807; Nutbeam D, 1996, HEALTH EDUC RES, V11, P317, DOI 10.1093/her/11.3.317; Nutbeam D, 1998, HEALTH PROMOT INT, V13, P27, DOI 10.1093/heapro/13.1.27; Prochaska J. O., 1994, ADV EXERCISE ADHEREN, P161; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; RIDDOCH CJ, 1998, EFFECTIVENESS PHYSIC; Sallis J F, 1990, Exerc Sport Sci Rev, V18, P307; *SECR STAT HLTH, 1998, OUR HLTH NAT CONTR H; Smith F, 1997, BRIT J GEN PRACT, V47, P272; *SPORTS COUNC HLTH, 1992, ALL DUNB NAT FITN SU; *SPSS, 1996, STAT PACK SOC SCI SP; Stevens W, 1998, BRIT J SPORT MED, V32, P236, DOI 10.1136/bjsm.32.3.236; Taylor AH, 1996, EVALUATING GP EXERCI; TAYLOR E, 1996, 6 CSRC U BRIGHT CHEL; Ziebland S, 1998, SOC SCI MED, V46, P461, DOI 10.1016/S0277-9536(97)00190-1; [No title captured]	36	237	240	1	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					828	832B		10.1136/bmj.319.7213.828	http://dx.doi.org/10.1136/bmj.319.7213.828			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241CR	10496829	Green Published, Bronze			2022-12-28	WOS:000082865200028
J	Quinn, C				Quinn, C			The pirates	ANNALS OF INTERNAL MEDICINE			English	Article											Quinn, C (corresponding author), 49 Thomas Rd, Rockville Ctr, NY 11570 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					472	473		10.7326/0003-4819-131-6-199909210-00015	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498567				2022-12-28	WOS:000082641100013
J	Christie, B				Christie, B			Patients asked to judge quality of care they receive in hospital	BRITISH MEDICAL JOURNAL			English	News Item																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					729	729		10.1136/bmj.319.7212.729	http://dx.doi.org/10.1136/bmj.319.7212.729			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487992	Green Published			2022-12-28	WOS:000082701500011
J	O'Connor, AM; Rostom, A; Fiset, V; Tetroe, J; Entwhistle, V; Llewellyn-Thomas, H; Holmes-Rovner, M; Barry, M; Jones, J				O'Connor, AM; Rostom, A; Fiset, V; Tetroe, J; Entwhistle, V; Llewellyn-Thomas, H; Holmes-Rovner, M; Barry, M; Jones, J			Decision aids for patients facing health treatment or screening decisions: systematic review	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; PROSTATE-CANCER; HORMONE-THERAPY; INFORMATION; WOMEN; CIRCUMCISION; EDUCATION; FRAMEWORK; SUPPORT	Objective To conduct a systematic review of randornised trials of patient decision aids in improving decision making and outcomes. Design We included randomised trials of interventions providing structured, detailed, and specific information on treatment or screening options and outcomes to aid decision making. Two reviewers independently screened and extracted data on several evaluation criteria. Results were pooled by using weighted mean differences and relative risks. Results 17 studies met the inclusion criteria. Compared with the controls, decision aids produced higher knowledge scores (weighted mean difference = 19/100, 95% confidence interval 14 to 25); lower decisional conflict scores (weighted mean difference = -0.3/5, -0.4 to -0.1); more active patient participation in decision making (relative risk = 2.27, 95% confidence interval 1.3 to 4); and no differences in anxiety, satisfaction with decisions (weighted mean difference = 0.6/100, -3 to 4), or satisfaction with the decision malting process (2/100, -3 to 7). Decision aids had a variable effect on decisions. When complex decision aids were compared with simpler versions, they were better at reducing decisional conflict, improved knowledge marginally, but did not affect satisfaction. Conclusions Decision aids improve knowledge, reduce decisional conflict, and stimulate patients to be more active in decision making without increasing their anxiety. Decision aids have little effect on satisfaction and a variable effect on decisions. The effects on outcomes of decisions (persistence with choice, quality of life) remain uncertain.	Univ Ottawa, Sch Nursing, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Fac Med, Loeb Hlth Res Inst, Clin Epidemiol Unit,Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; Sisters Charity Ottawa Hlth Serv, Ottawa, ON, Canada; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland; Univ Toronto, INst Clin Evaluat Sci, N York, ON, Canada; Michigan State Univ, Dept Med, E Lansing, MI 48824 USA; Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Aberdeen; University of Toronto; Michigan State University; Harvard University; Massachusetts General Hospital	O'Connor, AM (corresponding author), Univ Ottawa, Sch Nursing, Ottawa, ON K1Y 4E9, Canada.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				[Anonymous], 1992, MANUAL ASSESSING HLT; Barry M.J., 1997, DIS MANAG CLIN OUTCO, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; Bernstein Steven J., 1998, Health Expect, V1, P50, DOI 10.1046/j.1369-6513.1998.00007.x; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; CLANCY CM, 1988, AM J MED, V84, P283, DOI 10.1016/0002-9343(88)90426-3; Davison BJ, 1997, CANCER NURS, V20, P187, DOI 10.1097/00002820-199706000-00004; Davison BJ, 1999, PATIENT EDUC COUNS, V37, P255, DOI 10.1016/S0738-3991(98)00123-2; Entwistle V A, 1998, J Health Serv Res Policy, V3, P100; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; GRADY D, 1992, ANN INTERN MED, V117, P1038; GRUPPEN LD, 1994, ACAD MED S, V10, pS57; HERRERA AJ, 1983, PEDIATRICS, V71, P233; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; Lerman C, 1997, JNCI-J NATL CANCER I, V89, P148, DOI 10.1093/jnci/89.2.148; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P101, DOI 10.1177/0272989X9501500201; MAISELS MJ, 1983, PEDIATRICS, V71, P453; Michie S, 1997, BRIT J HEALTH PSYCH, V2, P317, DOI 10.1111/j.2044-8287.1997.tb00545.x; MORGAN MW, 1997, THESIS U TORONTO TOR; MULLEY A, 1995, OUTCOMES CLIN PRACTI, P13; MULROW CD, 1997, CONDUCT COCHRANE SYS; O'Connor A M, 1997, Can J Nurs Res, V29, P113; O'Connor AM, 1998, PATIENT EDUC COUNS, V33, P267, DOI 10.1016/S0738-3991(98)00026-3; O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307; OCONNOR AM, 1999, COCHRANE LIB; OCONNOR AM, IN PRESS MONOGR NATL; PHILLIPS C, 1995, ANGLE ORTHOD, V65, P263; *RES TRIANGL I, 1997, AHCPR PUBL; Rothert ML, 1997, RES NURS HEALTH, V20, P377, DOI 10.1002/(SICI)1098-240X(199710)20:5<377::AID-NUR2>3.0.CO;2-L; STREET RL, 1995, CANCER, V76, P2275, DOI 10.1002/1097-0142(19951201)76:11<2275::AID-CNCR2820761115>3.0.CO;2-S; THORNTON JG, 1995, BMJ-BRIT MED J, V311, P1127, DOI 10.1136/bmj.311.7013.1127; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333; [No title captured]	32	587	591	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					731	734		10.1136/bmj.319.7212.731	http://dx.doi.org/10.1136/bmj.319.7212.731			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487995	Green Published, Bronze			2022-12-28	WOS:000082701500014
J	Aubrey, R				Aubrey, R			Patrick Forsyth Aitken Crawshaw - Obituaries	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					713	713		10.1136/bmj.319.7211.713	http://dx.doi.org/10.1136/bmj.319.7211.713			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480848	Green Published			2022-12-28	WOS:000082636800059
J	Chien, KR				Chien, KR			Stress pathways and heart failure	CELL			English	Review							DILATED CARDIOMYOPATHY; MICE; INHIBITOR		Univ Calif San Diego, Sch Med, Salk Program Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Chien, KR (corresponding author), Univ Calif San Diego, Sch Med, Salk Program Mol Med, La Jolla, CA 92093 USA.							Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chen J, 1999, J CLIN INVEST, V103, P1483, DOI 10.1172/JCI7297; CHIEN KR, 1999, MOL BASIS CARDIOVASC, P211; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Hemler ME, 1999, CELL, V97, P543, DOI 10.1016/S0092-8674(00)80764-3; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Kadambi V J, 1998, J Card Fail, V4, P349, DOI 10.1016/S1071-9164(98)90241-X; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; SELDMAN CE, 1999, MOL BASIS CARDIVOASC, P251; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9	20	366	372	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					555	558		10.1016/S0092-8674(00)80043-4	http://dx.doi.org/10.1016/S0092-8674(00)80043-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490095	Bronze			2022-12-28	WOS:000082433500003
J	Lee, SB; Huang, K; Palmer, R; Truong, VB; Herzlinger, D; Kolquist, KA; Wong, J; Paulding, C; Yoon, SK; Gerald, W; Oliner, JD; Haber, DA				Lee, SB; Huang, K; Palmer, R; Truong, VB; Herzlinger, D; Kolquist, KA; Wong, J; Paulding, C; Yoon, SK; Gerald, W; Oliner, JD; Haber, DA			The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; MICE LACKING GDNF; GENE-PRODUCT; KIDNEY DEVELOPMENT; DNA-BINDING; EXPRESSION; PROTEIN; PROLIFERATION; RECEPTOR; SEQUENCE	WT1 encodes a zinc finger transcription factor implicated in kidney differentiation and tumorigenesis. In reporter assays, WT1 represses transcription from GC- and To-rich promoters, but its physiological targets remain uncertain. We used hybridization to high-density oligonucleotide arrays to search for native genes whose expression is altered following inducible expression of WT1. The major target of WT1 was amphiregulin, a member of the epidermal growth factor family. The WT1(-KTS) isoform binds directly to the amphiregulin promoter, resulting in potent transcriptional activation. The in vivo expression profile of amphiregulin during fetal kidney development mirrors the highly specific pattern of WT1 itself, and recombinant Amphiregulin stimulates epithelial branching in organ cultures of embryonic mouse kidney. These observations suggest a model for WT1 as a transcriptional regulator during kidney differentiation.	Massachusetts Gen Hosp, Ctr Canc, Genet Mol Lab, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA; Cornell Univ, Dept Physiol & Biophys, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Affymetrix; Cornell University; Memorial Sloan Kettering Cancer Center	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Genet Mol Lab, Charlestown, MA 02129 USA.			Wong, Jenise C./0000-0003-0573-6650; Lee, Sean/0000-0001-6211-3498	NATIONAL CANCER INSTITUTE [R37CA058596, F32CA071167, R01CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA71167, CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; COLES HSR, 1993, DEVELOPMENT, V118, P777; Davies JA, 1996, ACTA ANAT, V156, P187; Donovan MJ, 1999, DEV GENET, V24, P252, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<252::AID-DVG8>3.0.CO;2-K; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.physiol.51.1.67; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim J, 1999, MOL CELL BIOL, V19, P2289; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Qiao JZ, 1999, DEVELOPMENT, V126, P547; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Vainio S, 1997, CELL, V90, P975, DOI 10.1016/S0092-8674(00)80363-3; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	42	238	242	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					663	673		10.1016/S0092-8674(00)80053-7	http://dx.doi.org/10.1016/S0092-8674(00)80053-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490105	Bronze			2022-12-28	WOS:000082433500013
J	Green, A; Williams, G; Neale, R; Hart, V; Leslie, D; Parsons, P; Marks, GC; Gaffney, P; Battistutta, D; Frost, C; Lang, C; Russell, A				Green, A; Williams, G; Neale, R; Hart, V; Leslie, D; Parsons, P; Marks, GC; Gaffney, P; Battistutta, D; Frost, C; Lang, C; Russell, A			Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial	LANCET			English	Article							BETA-CAROTENE; CANCER; POPULATION; AUSTRALIA; DISEASE	Background The use of sunscreens on the skin can prevent sunburn but whether long-term use can prevent skin cancer is not known. Also, there is evidence that oral betacarotene supplementation lowers skin-cancer rates in animals, but there is limited evidence of its effect in human beings. Methods In a community-based randomised trial with a 2 by 2 factorial design, individuals were assigned to four treatment groups: daily application of a sun protection factor 15-plus sunscreen to the head, neck, arms, and hands, and betacarotene supplementation (30 mg per day); sunscreen plus placebo tablets; betacarotene only; or placebo only. Participants were 1621 residents of Nambour in southeast Queensland, Australia. The endpoints after 4.5 years of follow-up were the incidence of basal-cell and squamous-cell carcinomas both in terms of people treated for newly diagnosed disease and in terms of the numbers of tumours that occurred. Analysis of the effect of sunscreen was based only on skin cancers that developed on sites of daily application. All analyses were by intention to treat. Findings 1383 participants underwent full shin examination by a dermatologist in the follow-up period. 250 of them developed 758 new skin cancers during the follow-up period. There were no significant differences in the incidence of first new shin cancers between groups randomly assigned daily sunscreen and no daily sunscreen (basal-cell carcinoma 2588 vs 2509 per 100 000; rate ratio 1.03 [95% CI 0.73-1.46]; squamous-cell carcinoma 876 vs 996 per 100 000; rate ratio 0.88 [0.50-1.56]). Similarly, there was no significant difference between the betacarotene and placebo groups in incidence of either cancer (basal-cell carcinoma 3954 vs 3806 per 100 000; 1.04 [0.73-1.27]; squamous-cell carcinoma 1508 vs 1146 per 100 000; 1.35 [0.84-2.19]). In terms of the number of tumours, there was no effect on incidence of basal-cell carcinoma by sunscreen use or by betacarotene but the incidence of squamous-cell carcinoma was significantly lower in the sunscreen group than in the no daily sunscreen group (1115 vs 1832 per 100 000; 0.61 [0.46-0.81]). Interpretation There was no harmful effect of daily use of sunscreen in this medium-term study. Cutaneous squamous-cell carcinoma, but not basal-cell carcinoma seems to be amenable to prevention through the routine use of sunscreen by adults for 4.5 years. There was no beneficial or harmful effect on the rates of either type of skin cancer, as a result of betacarotene supplementation.	Queensland Inst Med Res, Epidemiol & Populat Hlth Unit, Brisbane, Qld 4029, Australia; Queensland Inst Med Res, Canc Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld, Australia; Griffith Univ, Sch Hlth Sci, Gold Coast, Australia	QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; University of Queensland; Griffith University	Green, A (corresponding author), Queensland Inst Med Res, Epidemiol & Populat Hlth Unit, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Parsons, Peter G/H-8163-2015; Green, Adele C/P-2736-2014; Green, Adele C/B-5324-2011; Marks, Geoffrey C/E-7368-2010; Neale, Rachel/I-4427-2018	Parsons, Peter G/0000-0002-0473-3346; Green, Adele C/0000-0002-2753-4841; Marks, Geoffrey C/0000-0002-9497-680X; Neale, Rachel/0000-0001-7162-0854; Williams, Gail/0000-0002-4822-5263				Bastiaens MT, 1998, J INVEST DERMATOL, V110, P880, DOI 10.1046/j.1523-1747.1998.00217.x; Bavinck JNB, 1996, TRANSPLANTATION, V61, P715, DOI 10.1097/00007890-199603150-00008; BERTRAM JS, 1995, AM J CLIN NUTR, V62, P1327; deGruijl FR, 1996, PHOTOCHEM PHOTOBIOL, V63, P372; FRIELING UM, IN PRESS ARCH DERMAT; GAFFNEY PT, 1988, P 7 ANN C DIET ASS A, P72; Gasparro FP, 1998, PHOTOCHEM PHOTOBIOL, V68, P243, DOI 10.1111/j.1751-1097.1998.tb09677.x; GREEN A, 1988, J AM ACAD DERMATOL, V19, P1045, DOI 10.1016/S0190-9622(88)70270-4; GREEN A, 1994, CONTROL CLIN TRIALS, V15, P512, DOI 10.1016/0197-2456(94)90008-6; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; Hall HI, 1997, PREV MED, V26, P401, DOI 10.1006/pmed.1997.0168; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; *INT AG RES CANC, 1992, IARC MON EV CARC HUM, V55; KRICKER A, 1995, INT J CANCER, V60, P489, DOI 10.1002/ijc.2910600411; LAMBERT LA, 1994, NUTR CANCER, V21, P1, DOI 10.1080/01635589409514299; MATHEWSROTH MM, 1987, PHOTOCHEM PHOTOBIOL, V46, P507, DOI 10.1111/j.1751-1097.1987.tb04803.x; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Moon TE, 1997, CANCER EPIDEM BIOMAR, V6, P949; NAYLOR MF, 1995, ARCH DERMOL, V131, P1701; Neale R, 1997, PHOTOCHEM PHOTOBIOL, V66, P260, DOI 10.1111/j.1751-1097.1997.tb08652.x; ROBERTS LK, 1995, J INVEST DERMATOL, V105, P339, DOI 10.1111/1523-1747.ep12320339; Rosso S, 1996, BRIT J CANCER, V73, P1447, DOI 10.1038/bjc.1996.275; *STAND ASS AUSTR, 1986, 26041986 STAND ASS A; Staples M, 1998, INT J CANCER, V78, P144, DOI 10.1002/(SICI)1097-0215(19981005)78:2<144::AID-IJC3>3.0.CO;2-Z; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; VANPOPPEL G, 1993, EUR J CANCER, V29A, P1335, DOI 10.1016/0959-8049(93)90087-V; ZELEN M, 1988, J NATL CANCER I, V80, P1442, DOI 10.1093/jnci/80.18.1442	28	641	657	1	81	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					723	729		10.1016/S0140-6736(98)12168-2	http://dx.doi.org/10.1016/S0140-6736(98)12168-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475183				2022-12-28	WOS:000082233000011
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1969, Max Delbruck (1906-81); Salvador Luria (1912-91); and Alfred Hershey (1908-97)	LANCET			English	Article									Univ Illinois, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60607 USA.							WATSON, 1999, LANCET, V354, P171	1	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					784	784		10.1016/S0140-6736(05)76036-0	http://dx.doi.org/10.1016/S0140-6736(05)76036-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475234				2022-12-28	WOS:000082233000078
J	Friedberg, EC; Gerlach, VL				Friedberg, EC; Gerlach, VL			Novel DNA polymerases offer clues to the molecular basis of mutagenesis	CELL			English	Review							SOS-INDUCED MUTAGENESIS; ESCHERICHIA-COLI DINB; SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; GENE; UMUC; HOMOLOG; BYPASS		Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERLACH VL, 1999, IN PRESS P NATL ACAD; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; OHMORI H, 1995, MUTAT RES LETT, V347, P1, DOI 10.1016/0165-7992(95)90024-1; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Roush AA, 1998, MOL GEN GENET, V257, P686; TANG M, 1999, P NATL ACAD SCI USA, V96, P9218; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Walker GC, 1998, P NATL ACAD SCI USA, V95, P10348, DOI 10.1073/pnas.95.18.10348	19	118	119	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					413	416		10.1016/S0092-8674(00)81970-4	http://dx.doi.org/10.1016/S0092-8674(00)81970-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481906	Bronze			2022-12-28	WOS:000082174900002
J	Romelsjo, A; Leifman, A				Romelsjo, A; Leifman, A			Association between alcohol consumption and mortality, myocardial infarction, and stroke in 25 year follow up of 49 618 young Swedish men	BRITISH MEDICAL JOURNAL			English	Article									Karolinska Inst, Novum, Dept Publ Hlth Sci, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Ctr Alcohol & Drug Prevent, S-14157 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Romelsjo, A (corresponding author), Karolinska Inst, Novum, Dept Publ Hlth Sci, S-14157 Huddinge, Sweden.							ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Edwards G., 1994, ALCOHOL POLICY PUBLI; REHM J, 1998, ALCOHOLISM CLIN EX S, V22, P15; ROTHMAN K, 1998, MODERN EPIDEMIOLOGY, P430	5	47	47	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					821	822		10.1136/bmj.319.7213.821	http://dx.doi.org/10.1136/bmj.319.7213.821			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496826	Bronze, Green Published			2022-12-28	WOS:000082865200024
J	Wylie, IU; Griffiths, S; Hunter, DJ				Wylie, IU; Griffiths, S; Hunter, DJ			Everywhere and nowhere - a Socratic dialogue on the new public health	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, Corp Affairs, London W1M 0AN, England; Oxfordshire Hlth Author, Dept Hlth Policy & Public Hlth, Oxford OX3 7LG, England; Univ Leeds, Naffield Inst Hlth, Dept Hlth Policy & Management, Leeds LS2 9PL, W Yorkshire, England	University of Leeds	Wylie, IU (corresponding author), Kings Fund, Corp Affairs, London W1M 0AN, England.							Berkeley George, 1998, 3 DIALOGUES HYLAS PH; *CHIEF MED OFF, 1998, ANN REP CHIEF MED OF, P10; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; GRIFFITHS S, 1999, PERSPECTIVES PUBLIC, P1; HUNTER DJ, 1999, MANAGING HLTH IMPLEM	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					839	840		10.1136/bmj.319.7213.839	http://dx.doi.org/10.1136/bmj.319.7213.839			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496833	Green Published			2022-12-28	WOS:000082865200031
J	Kakei, S; Hoffman, DS; Strick, PL				Kakei, S; Hoffman, DS; Strick, PL			Muscle and movement representations in the primary motor cortex	SCIENCE			English	Article							STEP-TRACKING MOVEMENTS; FREE ARM MOVEMENTS; 3-DIMENSIONAL SPACE; CORTICOMOTONEURONAL CELLS; NEURAL REPRESENTATIONS; VISUAL TARGETS; REACHING TASK; DIRECTION; FORCE; DISCHARGE	What aspects of movement are represented in the primary motor cortex (M1): relatively low-level parameters like muscle force, or more abstract parameters like handpath? To examine this issue, the activity of neurons in M1 was recorded in a monkey trained to perform a task that dissociates three major variables of wrist movement: muscle activity, direction of movement at the wrist joint, and direction of movement in space. A substantial group of neurons in M1 (28 out of 88) displayed changes in activity that were muscle-like. Unexpectedly an even larger group of neurons in M1 (44 out of 88) displayed changes in activity that were related to the direction of wrist movement in space independent of the pattern of muscle activity that generated the movement. Thus, both "muscles" and "movements" appear to be strongly represented in M1.	Vet Affairs Med Ctr, Res Serv 151S, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurosurg, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Strick, PL (corresponding author), Vet Affairs Med Ctr, Res Serv 151S, 800 Irving Ave, Syracuse, NY 13210 USA.			Kakei, Shinji/0000-0001-5111-5789				ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; Crammond DJ, 1996, EXP BRAIN RES, V108, P45; Evarts E. V., 1967, NEUROPHYSIOLOGICAL B, P215; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1983, EXP BRAIN RES S, V7; HOFFMAN DS, 1986, J NEUROSCI, V6, P3309; HOFFMAN DS, 1995, J NEUROPHYSIOL, V73, P891, DOI 10.1152/jn.1995.73.2.891; Hoffman DS, 1999, J NEUROPHYSIOL, V81, P319, DOI 10.1152/jn.1999.81.1.319; HOLLERBACH JM, 1982, TRENDS NEUROSCI, V5, P189, DOI 10.1016/0166-2236(82)90111-4; Kakei S., 1998, Society for Neuroscience Abstracts, V24, P2108; Kakei S., 1997, Society for Neuroscience Abstracts, V23, P2096; KALASKA JF, 1989, J NEUROSCI, V9, P2080; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SCHWARTZ AB, 1993, J NEUROPHYSIOL, V70, P28, DOI 10.1152/jn.1993.70.1.28; Scott SH, 1997, J NEUROPHYSIOL, V77, P826, DOI 10.1152/jn.1997.77.2.826; Sergio LE, 1998, J NEUROPHYSIOL, V80, P1577, DOI 10.1152/jn.1998.80.3.1577; Shen LM, 1997, J NEUROPHYSIOL, V77, P1171, DOI 10.1152/jn.1997.77.3.1171; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654	29	515	520	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2136	2139		10.1126/science.285.5436.2136	http://dx.doi.org/10.1126/science.285.5436.2136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497133	Green Submitted			2022-12-28	WOS:000082734300045
J	Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M				Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M			Use of complementary therapies for arthritis among patients of rheumatologists	ANNALS OF INTERNAL MEDICINE			English	Article							ALTERNATIVE MEDICINE USE; UNCONVENTIONAL MEDICINE; RHEUMATOID-ARTHRITIS; UNITED-STATES; HEALTH-CARE; PREVALENCE; REMEDIES; OSTEOARTHRITIS; COMMUNITY; PRACTITIONERS	Background: Use of complementary and alternative medicine (CAM) is common among persons with chronic conditions. Objective: To identify correlates of and describe patients' perspective on use of CAM for rheumatologic conditions. Design: Telephone survey. Setting: Three university practices and three private rheumatology practices. Patients: 232 of 428 eligible consecutive patients (54%) with scheduled appointments. Measurements: Patients answered questions on CAM use, functional status, pain, provider satisfaction, and health services utilization. Chart reviews provided demographic information and rheumatologic diagnoses. Bivariate analyses identified correlates of four CAM outcomes (history, magnitude, and frequency of CAM use and communication about CAM use with a physician), and multiple logistic regression identified independent correlates of regular CAM use. Results: Approximately two thirds of the respondents (n = 146) had used CAM. Of these 146 respondents, 82 (56%) currently used CAM and 132 (90%) regularly used CAM or had done so in the past. Fifty-five respondents (24%) had used three or more types of CAM. In multivariate analyses, persons who used CAM regularly were more likely to have osteoarthritis (odds ratio, 5.6 [95% CI, 1.9 to 16.8]), severe pain (odds ratio, 2.5 [CI, 1.4 to 4.8]), and a college degree (odds ratio, 2.6 [CI, 1.3 to 5.4]) than patients who had never used CAM. Nearly half of the respondents discussed CAM use with their physicians. The most common reasons for not disclosing CAM use were that the physician had not asked about it and that the patient forgot to tell the physician; fear of disapproval was rarely cited. Discussions about CAM use between patient and physician occurred more frequently among patients with fibromyalgia and persons who regularly used CAM or used several types of CAM. Conclusions: Patients with rheumatologic conditions frequently use CAM. Severe pain and osteoarthritis predict regular use of CAM but do not predict a greater likelihood of discussing CAM use with physicians. Routine inquiry by physicians will probably detect CAM use.	Indiana Univ, Richard L Roudebush Vet Affairs Med Ctr, Sch Med, Indianapolis, IN 46202 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Rao, JK (corresponding author), Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, MHS, 508 Fulton St, Durham, NC 27705 USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Arcury TA, 1996, ARTHRIT CARE RES, V9, P384, DOI 10.1002/1529-0131(199610)9:5<384::AID-ANR1790090507>3.0.CO;2-Y; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BOISSET M, 1994, J RHEUMATOL, V21, P148; CAMPION EW, 1993, NEW ENGL J MED, V328, P282, DOI 10.1056/NEJM199301283280413; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; CORNELISSEN PGJ, 1988, ANN RHEUM DIS, V47, P150, DOI 10.1136/ard.47.2.150; Cronan T A, 1993, Arthritis Care Res, V6, P149, DOI 10.1002/art.1790060307; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Dalen JE, 1998, ARCH INTERN MED, V158, P2179, DOI 10.1001/archinte.158.20.2179; Davidoff F, 1998, ANN INTERN MED, V129, P1068, DOI 10.7326/0003-4819-129-12-199812150-00014; DEVELLIS RF, 1993, J RHEUMATOL, V20, P866; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fairfield KM, 1998, ARCH INTERN MED, V158, P2257, DOI 10.1001/archinte.158.20.2257; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P2111, DOI 10.1001/jama.1997.03550230087045; GRAY D, 1985, SOC SCI MED, V21, P507, DOI 10.1016/0277-9536(85)90034-6; GRAY D, 1983, MED ANTHROPOL, V7, P29; HIGHAM C, 1983, PRACTITIONER, V227, P1201; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KESTIN M, 1985, MED J AUSTRALIA, V143, P516, DOI 10.5694/j.1326-5377.1985.tb119916.x; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MILLER IW, 1979, PSYCHOL BULL, V86, P93, DOI 10.1037/0033-2909.86.1.93; Nicassio PM, 1997, J RHEUMATOL, V24, P2008; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Rao JK, 1998, ARTHRIT CARE RES, V11, P253, DOI 10.1002/art.1790110406; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; STRUTHERS GR, 1983, RHEUMATOL INT, V3, P151, DOI 10.1007/BF00541593; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; VECCHIO PC, 1994, J RHEUMATOL, V21, P145; VISSER GJ, 1992, BRIT J RHEUMATOL, V31, P485; WASNER CK, 1991, RHEUM DIS CLIN N AM, V17, P197; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; WIENER CL, 1975, SOC SCI MED, V9, P97, DOI 10.1016/0037-7856(75)90101-8; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1124	46	283	287	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					409	416		10.7326/0003-4819-131-6-199909210-00003	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498556				2022-12-28	WOS:000082641100002
J	Fu, YX; Galan, JE				Fu, YX; Galan, JE			A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion	NATURE			English	Article							RHO-GTPASES; PSEUDOMONAS-AERUGINOSA; NUCLEAR RESPONSES; EXOENZYME-S; TYPHIMURIUM; IDENTIFICATION; DISRUPTION; YERSINIA; GENE	An essential feature of the bacterial pathogen Salmonella spp. is its ability to enter cells that are normally non-phagocytic, such as those of the intestinal epithelium(1). The bacterium achieves entry by delivering effector proteins into the host-cell cytosol by means of a specialized protein-secretion system (termed type III), which causes reorganization of the cell's actin cytoskeleton and ruffling of its membrane(2-4). One of the bacterial effecters that stimulates these cellular responses is SopE, which acts as a guanyl-nucleotide-exchange factor on Rho GTPase proteins such as Cdc42 and Rac (ref. 5). As the actin-cytoskeleton reorganization induced by Salmonella is reversible and short-lived, infected cells regain their normal architecture after bacterial internalization(6,7). We show here that the S. Typhimurium effector protein SptP, which is delivered to the host-cell cytosol by the type-III secretion system, is directly responsible for the reversal of the actin cytoskeletal changes induced by the bacterium. SptP exerts this function by acting as a GTPase-activating protein (GAP) for Rac-1 and Cdc42.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.	jorge.galan@yale.edu						Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; FORSBERG A, 1990, J BACTERIOL, V172, P1547, DOI 10.1128/jb.172.3.1547-1555.1990; FrithzLindsten E, 1997, MOL MICROBIOL, V25, P1125, DOI 10.1046/j.1365-2958.1997.5411905.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hobbie S, 1997, J IMMUNOL, V159, P5550; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KULICH SM, 1994, J BIOL CHEM, V269, P10431; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Vallis AJ, 1999, INFECT IMMUN, V67, P2040; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	21	430	445	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					293	297		10.1038/45829	http://dx.doi.org/10.1038/45829			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499590				2022-12-28	WOS:000082678400058
J	Smilack, JD				Smilack, JD			Pulmonary and disseminated nocardiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Smilack, JD (corresponding author), Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA.								0	5	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					885	885		10.1056/NEJM199909163411205	http://dx.doi.org/10.1056/NEJM199909163411205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10486420				2022-12-28	WOS:000082569100005
J	Naidoo, N; Song, W; Hunter-Ensor, M; Sehgal, A				Naidoo, N; Song, W; Hunter-Ensor, M; Sehgal, A			A role for the proteasome in the light response of the timeless clock protein	SCIENCE			English	Article							DROSOPHILA CLOCK; CIRCADIAN CLOCK; IN-VIVO; DEGRADATION; KINASE; PERIOD; PROTEOLYSIS; INHIBITORS; MECHANISM; GENE	The cyclic expression of the period (PER) and timeless (TIM) proteins is critical for the molecular circadian feedback Loop in Drosophila. The entrainment by Light of the circadian clock is mediated by a reduction in TIM Levels. To elucidate the mechanism of this process, the sensitivity of TIM regulation by Light was tested in an in vitro assay with inhibitors of candidate proteolytic pathways. The data suggested that TIM is degraded through a ubiquitin-proteasome mechanism. In addition, in cultures from third-instar Larvae, TIM degradation was blocked specifically by inhibitors of proteasome activity. Degradation appeared to be preceded by tyrosine phosphorylation. Finally, TIM was ubiquitinated in response to Light in cultured cells.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Sehgal, A (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA.			Naidoo, Navindhra/0000-0001-9142-3751; Song, Wei/0000-0001-6531-8317; Naidoo, Nirinjini/0000-0002-7463-2559				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHEN Y, 1998, CELL, V13, P364; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; HARDIN PE, 1999, HDB BEHAV STATE CONT, P61; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaneko M, 1997, J NEUROSCI, V17, P6745; KOBAYASHI E, 1989, J ANTIBIOT, V42, P1470, DOI 10.7164/antibiotics.42.1470; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; MYERS MP, 1996, SCIENCE, V271, P1740; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yang XM, 1998, J IRON STEEL RES INT, V5, P21; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	35	220	223	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1737	1741		10.1126/science.285.5434.1737	http://dx.doi.org/10.1126/science.285.5434.1737			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481010				2022-12-28	WOS:000082472600036
J	Ottemann, KM; Xiao, WZ; Shin, YK; Koshland, DE				Ottemann, KM; Xiao, WZ; Shin, YK; Koshland, DE			A piston model for transmembrane signaling of the aspartate receptor	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; SINGLE CYTOPLASMIC DOMAIN; DISULFIDE CROSS-LINKING; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SENSORY RECEPTOR; SPIN LABELS; TRANSDUCTION; CHEMORECEPTOR; ADAPTATION	To characterize the mechanism by which receptors propagate conformational changes across membranes, nitroxide spin labels were attached at strategic positions in the bacterial aspartate receptor. By collecting the electron paramagnetic resonance spectra of these labeled receptors in the presence and absence of the Ligand aspartate, ligand binding was shown to generate an similar to 1 angstrom intrasubunit piston-type movement of one transmembrane helix downward relative to the other transmembrane helix. The receptor-associated phosphorylation cascade proteins CheA and CheW did not alter the ligand-induced movement. Because the piston movement is very small, the ability of receptors to produce Large outcomes in response to stimuli is caused by the ability of the receptor-coupled enzymes to detect small changes in the conformation of the receptor.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Shin, YK (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.			Ottemann, Karen/0000-0001-6265-7401; xiao, wenzhong/0000-0003-4944-6380	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051290, R29GM051290] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [GM51290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; CHEN X, 1997, BIOCHEM, V39, P11858; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; OGAWA S, 1967, P NATL ACAD SCI USA, V58, P719; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; REIDEL H, 1986, NATURE, V324, P68; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	46	228	229	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1751	1754		10.1126/science.285.5434.1751	http://dx.doi.org/10.1126/science.285.5434.1751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481014				2022-12-28	WOS:000082472600040
J	Thurman, D; Guerrero, J				Thurman, D; Guerrero, J			Trends in hospitalization associated with traumatic brain injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE-PAYMENT SYSTEM; HEAD-INJURY; ACCURACY	Context Traumatic brain injury (TBI) is associated with more than 50 000 deaths in the United States each year, and recent observations suggest a substantial decline in TBI-related hospitalizations and deaths. Objective To analyze long-term trends in TBI-related hospitalization in the United States. Design, Setting, and Participants Analysis of existing data from 1980 through 1995 from the National Hospital Discharge Survey, an annual survey representing the US general population. The number of participating hospitals ranged from 400 to 494. Main Outcome Measures Annual rates of TBI-related hospitalization, stratified by age, sex, severity of injury, and outcome. Results The annual number of TBI cases identified from the sample during the study : period ranged from 1611 to 3129. Overall rates of hospitalization for TBI declined an estimated 51 %, from 199 to 98 per 100 000 per year. When analyzed by severity of injury, mild TBIs declined most during this period, from 130 to 51 hospitalizations per 100 000 per year (61 % decline; P<.001 compared with intermediate and severe TBI); The decline was greatest among those aged 5-14 years (-66%) and least among those. aged 65 years or older (-9%). The ratio of male to female rates showed little variation during the study period (ratio, 1.8; 95% confidence interval [CI], 1.6-2.0), as did the in-hospital mortality rate (mean, 5.3 per 100 000; 95% CI, 3.6-7.1). Conclusions Changes in hospital practices may be a major factor in the declining rates of TBI-related hospital admissions. These practices increasingly appear to exclude persons with less severe TBI from hospital admission and shift: their care to outpatient settings.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Thurman, D (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Mailstop F-41,4770 Buford Hwy NE, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062				ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Burt C W, 1998, Vital Health Stat 13, P1; *CDCP, 1997, DAT FIL DOC NAT HOSP; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; *CTR INJ RES POL J, 1997, ICDMAP90 SOTW; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; Graves E J, 1997, Vital Health Stat 13, P1; Gronwall D., 1989, MILD HEAD INJURY, P153; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; KISH L, 1965, SURVEY SAMPLING, P206; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; *NAT CTR HLTH STAT, 1997, DAT FIL DOC NAT HOSP; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Ruff R. M., 1989, MILD HEAD INJURY, P176; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THURMAN DJ, IN PRESS J HEAD TRAU; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DHHS, 1989, FED INT HEAD INJ TAS; *US DHHS, 1996, INT CLASS DIS	24	370	379	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					954	957		10.1001/jama.282.10.954	http://dx.doi.org/10.1001/jama.282.10.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485680				2022-12-28	WOS:000082335900033
J	Swick, HM; Szenas, P; Danoff, D; Whitcomb, ME				Swick, HM; Szenas, P; Danoff, D; Whitcomb, ME			Teaching professionalism in undergraduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context There is a growing consensus among medical educators that to promote the professional development of medical students, schools of medicine should provide explicit learning experiences in professionalism. Objective To determine whether and how schools of medicine were teaching professionalism in the 1998-1999 academic year. Design, Setting, and Participants A 2-stage survey was sent to 125 US medical schools in the fall of 1998. A total of 116 (92.3%) responded to the first stage of the survey. The second survey led to a qualitative analysis of curriculum materials submitted by 41 schools. Main Outcome Measures Presence or absence of learning experiences (didactic or experiential) in undergraduate medical curriculum explicitly intended to promote professionalism in medical students, with curriculum evaluation based on 4 attributes commonly recognized as essential to professionalism: subordination of one's self-interests, adherence to high ethical and moral standards, response to societal needs, and demonstration of evincible core humanistic values. Results Of the 116 responding medical schools, 104 (89.7%) reported that they offer some formal instruction related to professionalism. Fewer schools have explicit methods for assessing professional behaviors (n = 64 [55.2%]) or conduct targeted faculty development programs (n = 39 [33.6%]). Schools use diverse strategies to promote professionalism, ranging from an isolated white-coat ceremony or other orientation experience (n = 71 [78.9%]) to an integrated sequence of courses over multiple years of the curriculum (n = 25 [27.8%]), Of the 41 schools that provided curriculum materials, 27 (65.9%) addressed subordinating self-interests; 31 (75.6%), adhering to high ethical and moral standards; 17 (41.5%), responding to societal needs; and 22 (53.7%), evincing core humanistic values. Conclusions Our results suggest that the teaching of professionalism in undergraduate medical education varies widely. Although most medical schools in the United States now address this important topic in some manner, the strategies used to teach professionalism may not always be adequate.	Assoc Amer Med Coll, Div Med Educ, Washington, DC 20037 USA; Univ Kansas, Dept Neurol, Kansas City, KS USA	Association of American Medical Colleges; University of Kansas	Whitcomb, ME (corresponding author), Assoc Amer Med Coll, Div Med Educ, 2450 N St NW, Washington, DC 20037 USA.							American Board of Internal Medicine, 1995, PROJ PROF; Brint S.G., 1994, AGE EXPERTS CHANGING; Cruess RL, 1997, ACAD MED, V72, P941, DOI 10.1097/00001888-199711000-00009; Hensel WA, 1998, ACAD MED, V73, P865, DOI 10.1097/00001888-199808000-00011; Relman AS, 1998, ACAD MED, V73, P1229, DOI 10.1097/00001888-199812000-00010; REYNOLDS PP, 1994, ANN INTERN MED, V120, P609, DOI 10.7326/0003-4819-120-7-199404010-00013; Sullivan W., 1995, WORK INTEGRITY CRISI; Sullivan WM, 1999, HASTINGS CENT REP, V29, P7, DOI 10.2307/3528344; Swick HM, 1998, ACAD MED, V73, P751, DOI 10.1097/00001888-199807000-00010; Wear D, 1998, ANN INTERN MED, V129, P734, DOI 10.7326/0003-4819-129-9-199811010-00010	10	216	227	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					830	832		10.1001/jama.282.9.830	http://dx.doi.org/10.1001/jama.282.9.830			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478688	Bronze			2022-12-28	WOS:000082272200007
J	Wallentin, L; Swahn, E; Kontny, F; Husted, S; Lagerqvist, B; Stahle, E; Nielsen, JD; Dellborg, M; Geiran, O; Grande, P; Hulting, J; Kyst-Madsen, J; Nordrehaug, JE; Naslund, U; Pilegaard, H; Rollag, A; Nielsen, TT; Saetre, H; Siegbahn, A; Ohlin, H; Arbeus, M; Bylund, H; Ekstrom, SL; Eriksson, GP; Geiran, O; Holmgren, A; Kellerth, T; Kyst-Madsen, J; Lindblom, D; Lindvall, B; Nordrehaug, J; Pilegaard, H; Radegran, K; Sjogren, I; Stenport, G; Stahl, E; Svane, B; Svedjeholm, R; Toftegaard-Nielsen, T; Hassan, SY; Naslund, U; Persson, S; Jacobsson, KA; Thygesen, K; von der Lippe, G; Julian, D; Bertrand, M; Wedel, H; Andren, B; Diderholm, E; Frostfeldt, G; Jernberg, T; Dellborg, M; Abrahamsson, P; Lindahl, B; Jernberg, T; Siegbahn, A; Venge, P; Swahn, E; Janzon, M; Logander, E; Svensson, E; Lindstrom, G; Alsjo, G; Gulin, M; Setterberg, G; Wikstrom, L; Andersen, IM; Seim, T				Wallentin, L; Swahn, E; Kontny, F; Husted, S; Lagerqvist, B; Stahle, E; Nielsen, JD; Dellborg, M; Geiran, O; Grande, P; Hulting, J; Kyst-Madsen, J; Nordrehaug, JE; Naslund, U; Pilegaard, H; Rollag, A; Nielsen, TT; Saetre, H; Siegbahn, A; Ohlin, H; Arbeus, M; Bylund, H; Ekstrom, SL; Eriksson, GP; Geiran, O; Holmgren, A; Kellerth, T; Kyst-Madsen, J; Lindblom, D; Lindvall, B; Nordrehaug, J; Pilegaard, H; Radegran, K; Sjogren, I; Stenport, G; Stahl, E; Svane, B; Svedjeholm, R; Toftegaard-Nielsen, T; Hassan, SY; Naslund, U; Persson, S; Jacobsson, KA; Thygesen, K; von der Lippe, G; Julian, D; Bertrand, M; Wedel, H; Andren, B; Diderholm, E; Frostfeldt, G; Jernberg, T; Dellborg, M; Abrahamsson, P; Lindahl, B; Jernberg, T; Siegbahn, A; Venge, P; Swahn, E; Janzon, M; Logander, E; Svensson, E; Lindstrom, G; Alsjo, G; Gulin, M; Setterberg, G; Wikstrom, L; Andersen, IM; Seim, T		FRISC II Investigators	Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study	LANCET			English	Article							WAVE MYOCARDIAL-INFARCTION; WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; ANGINA; STRATEGIES; MANAGEMENT	Background Short-term treatment with subcutaneous low-molecular-mass heparin in addition to aspirin is effective in unstable coronary-artery disease. We assessed the efficacy of long-term treatment with dalteparin in patients managed with a non-invasive treatment strategy. Methods 2267 patients from three Scandinavian countries (median age 67 years, 68% men) with unstable coronary-artery disease were randomly assigned to continue double blind subcutaneous dalteparin twice daily or placebo for 3 months, after at least 5 days' treatment with open-label dalteparin. The composite primacy endpoint was death or myocardial infarction. Analysis was by intention to treat. Findings During the 3 months of double-blind treatment, there was a non-significant decrease in the composite endpoint of death or myocardial infarction of 6.7% and 8.0% in the dalteparin and placebo groups, respectively (risk ratio 0.8% [95% CI 0.60-1.10], p=0.17). At 30 days, this decrease was significant (3.1 vs 5.9%, 0.53 [0.35-0.80]; p=0.002). In the total cohort there was at 3 months a decrease in death, myocardial infarction, or revascularisation (29.1 vs 33.4%, 0.87 [0.77-0.99]; p=0.031). The initial benefits were not sustained at 6-month follow-up. Interpretation Long-term dalteparin lowers the risk of death, myocardial infarction, and revascularisation in unstable coronary-artery disease at least during the first month of therapy. These early protective effects could be used to lower the risk of events in patients waiting for invasive procedures.	Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Wallentin, L (corresponding author), Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, S-75185 Uppsala, Sweden.	Lars.Wallentin@card.uas.lul.se		Jernberg, Tomas/0000-0003-1695-379X				Anand SS, 1998, CIRCULATION, V98, P1064, DOI 10.1161/01.CIR.98.11.1064; Antman EM, 1998, CIRCULATION, V98, P504; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Campbell RWF, 1998, CLIN CARDIOL, V21, P314, DOI 10.1002/clc.4960210504; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Ernofsson M, 1998, THROMB HAEMOSTASIS, V79, P491; Grip L, 1997, EUR HEART J, V18, P1416; GRIP L, 1991, EUR HEART J, V12, P1225, DOI 10.1093/eurheartj/12.11.1225; Klein W, 1997, CIRCULATION, V96, P61; LEIZOROVICZ A, 1998, PRELIMINARY RESULTS; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; NYMAN I, 1993, INT J CARDIOL, V39, P131, DOI 10.1016/0167-5273(93)90024-B; *PRISM STUD INV, 1998, NEW ENGL J MED, V228, P1498; ROOS J, 1980, LANCET, V2, P989; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Toss H, 1999, AM HEART J, V137, P72, DOI 10.1016/S0002-8703(99)70461-8; Van Belle E, 1998, CIRCULATION, V97, P26, DOI 10.1161/01.CIR.97.1.26; Wallentin L, 1996, LANCET, V347, P561	22	330	338	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					701	707						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475180				2022-12-28	WOS:000082233000008
J	Steel, KP				Steel, KP			Perspectives: Biomedicine - The benefits of recycling	SCIENCE			English	Editorial Material							DEFECTS		MRC, Inst Hearing Res, Nottingham NG7 2RD, England		Steel, KP (corresponding author), MRC, Inst Hearing Res, Univ Pk, Nottingham NG7 2RD, England.							Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Dixon MJ, 1999, HUM MOL GENET, V8, P1579, DOI 10.1093/hmg/8.8.1579; Everett LA, 1999, P NATL ACAD SCI USA, V96, P9727, DOI 10.1073/pnas.96.17.9727; Fransen E, 1999, HUM MOL GENET, V8, P1425, DOI 10.1093/hmg/8.8.1425; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Minowa O, 1999, SCIENCE, V285, P1408, DOI 10.1126/science.285.5432.1408; Phippard D, 1999, J NEUROSCI, V19, P5980, DOI 10.1523/JNEUROSCI.19-14-05980.1999; Steel KP, 1999, TRENDS GENET, V15, P207, DOI 10.1016/S0168-9525(99)01753-9; Steel KP, 1995, ANNU REV GENET, V29, P675; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X	12	55	62	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1363	1364		10.1126/science.285.5432.1363	http://dx.doi.org/10.1126/science.285.5432.1363			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10490411				2022-12-28	WOS:000082233500028
J	Sugase, Y; Yamane, S; Ueno, S; Kawano, K				Sugase, Y; Yamane, S; Ueno, S; Kawano, K			Global and fine information coded by single neurons in the temporal visual cortex	NATURE			English	Article							INFEROTEMPORAL CORTEX; POLYSENSORY AREA; MACAQUE MONKEY; RHESUS-MONKEY; RESPONSES; SULCUS; FACE; CONNECTIONS; IDENTITY	When we see a person's face, we can easily recognize their species, individual identity and emotional state. How does the brain represent such complex information? A substantial number of neurons in the macaque temporal cortex respond to faces(1-12) However, the neuronal mechanisms underlying the processing of complex information are not yet clear. Here we recorded the activity of single neurons in the temporal cortex of macaque monkeys while presenting visual stimuli consisting of geometric shapes, and monkey and human faces with various expressions. Information theory was used to investigate how well the neuronal responses could categorize the stimuli. We found that single neurons conveyed two different scales of facial information in their firing patterns, starting at different latencies. Global information, categorizing stimuli as monkey faces, human faces or shapes, was conveyed in the earliest part of the responses. Fine information about identity or expression was conveyed later, beginning on average 51 ms after global information. We speculate that global information could be used as a 'header' to prepare destination areas for receiving more detailed information.	Electrotech Lab, Tsukuba, Ibaraki 3058568, Japan; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Sugase, Y (corresponding author), Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan.		sugase-miyamoto, yasuko/N-2769-2016	sugase-miyamoto, yasuko/0000-0003-3097-3789				AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; AMARI SI, 1977, BIOL CYBERN, V26, P175, DOI 10.1007/BF00365229; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; Ellis HD, 1986, NEUROPSYCHOLOGY FACE, P1; Golomb D, 1997, NEURAL COMPUT, V9, P649, DOI 10.1162/neco.1997.9.3.649; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; HECAEN H, 1962, INTERHEMISPHER RELAT, P215; HELLER J, 1995, J COMPUT NEUROSCI, V2, P175, DOI 10.1007/BF00961433; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; Lavenex P., 1998, Society for Neuroscience Abstracts, V24, P1905; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MIKAMI A, 1994, BEHAV BRAIN RES, V60, P1, DOI 10.1016/0166-4328(94)90057-4; NAKAMURA K, 1994, J NEUROPHYSIOL, V71, P1206, DOI 10.1152/jn.1994.71.3.1206; NAKAMURA K, 1992, J NEUROPHYSIOL, V67, P1447, DOI 10.1152/jn.1992.67.6.1447; ORAM MW, 1992, J NEUROPHYSIOL, V68, P70, DOI 10.1152/jn.1992.68.1.70; Oram MW, 1996, J NEUROPHYSIOL, V76, P109, DOI 10.1152/jn.1996.76.1.109; Panzeri S, 1996, NETWORK-COMP NEURAL, V7, P87, DOI [10.1088/0954-898X/7/1/006, 10.1080/0954898X.1996.11978656]; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Sugase Y., 1998, Society for Neuroscience Abstracts, V24, P899; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	28	553	563	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					869	873		10.1038/23703	http://dx.doi.org/10.1038/23703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476965				2022-12-28	WOS:000082233200045
J	Yin, XM; Wang, K; Gross, A; Zhao, YG; Zinkel, S; Klocke, B; Roth, KA; Korsmeyer, SJ				Yin, XM; Wang, K; Gross, A; Zhao, YG; Zinkel, S; Klocke, B; Roth, KA; Korsmeyer, SJ			Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis	NATURE			English	Article							CYTOCHROME-C; CELL-DEATH; PROTEASE; PATHWAYS; ANTIBODY; FAMILY; REQUIREMENT; ACTIVATION; CASPASE-9; INDUCTION	The protein Bid is a participant in the pathway that leads to cell death (apoptosis), mediating the release of cytochrome c from mitochondria in response to signals from 'death' receptors known as TNFR1/Fas on the cell surface(1-7). It is a member of the pro-apoptotic Bcl-2 familys and is activated as a result of its cleavage by caspase 8, one of a family of proteolytic cell-death proteins. To investigate the role of Bid in vivo, we have generated mice deficient for Bid. We find that when these mice are injected with an antibody directed against Fas, they nearly all survive, whereas wild-type mice die from hepatocellular apoptosis and haemorrhagic necrosis. About half of the Bid-deficient animals had no apparent liver injury and showed no evidence of activation of the effector caspases 3 and 7, although the initiator caspase 8 had been activated. Other Bid-deficient mice survived with only moderate damage: all three caspases (8 and 37) were activated but their cell nuclei were intact and no mitochondrial cytochrome c was released. We also investigated the effects of Bid deficiency in cultured cells treated with anti-pas antibody (hepatocytes and thymocytes) or with TNF-alpha. (fibroblasts). In these Bid(-/-) cells, mitochondrial dysfunction was delayed, cytochrome c was not released, effector caspase activity was reduced and the cleavage of apoptosis substrates was altered. This loss-of-function model indicates that Bid is a critical substrate in vivo for signalling by death-receptor agonists, which mediates a mitochondrial amplification loop that is essential for the apoptosis of selected cells.	Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Korsmeyer, SJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA.			Roth, Kevin/0000-0002-0643-995X; zinkel, sandra/0000-0002-2818-9795				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, GENOMICS, V53, P235, DOI 10.1006/geno.1998.5489; XUESONG L, 1997, CELL, V89, P175; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	30	831	858	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					886	891		10.1038/23730	http://dx.doi.org/10.1038/23730			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476969				2022-12-28	WOS:000082233200049
J	Frommer, WB; Ludewig, U; Rentsch, D				Frommer, WB; Ludewig, U; Rentsch, D			Plant biology - Taking transgenic plants with a pinch of salt	SCIENCE			English	Editorial Material									Zentrum Mol Biol Pflanzen, Dept Plant Pathol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Frommer, WB (corresponding author), Zentrum Mol Biol Pflanzen, Dept Plant Pathol, Morganstelle 1, D-72076 Tubingen, Germany.	frommer@uni-tuebingen.de	Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Rentsch, Doris/0000-0003-4313-7683				Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; delaFuente JM, 1997, SCIENCE, V276, P1566, DOI 10.1126/science.276.5318.1566; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Li Y, 1999, MOL CELL BIOL, V19, P3588; Nanjo T, 1999, PLANT J, V18, P185, DOI 10.1046/j.1365-313X.1999.00438.x; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; STAAL M, 1991, PHYSIOL PLANTARUM, V82, P179, DOI 10.1111/j.1399-3054.1991.tb00078.x; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508	9	51	55	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1999	285	5431					1222	1223		10.1126/science.285.5431.1222	http://dx.doi.org/10.1126/science.285.5431.1222			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10484731				2022-12-28	WOS:000082130200027
J	Schneider, EC; Riehl, V; Courte-Wienecke, S; Eddy, DM; Sennett, C				Schneider, EC; Riehl, V; Courte-Wienecke, S; Eddy, DM; Sennett, C			Enhancing performance measurement - NCQA's road map for a health information framework	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DECISION-SUPPORT SYSTEMS; CARE QUALITY; MANAGED-CARE; OUTCOMES; PHYSICIANS; CHALLENGES; STANDARDS; PRIVACY; NEED	Measuring the quality of health care delivery is one of the most critical challenges facing US health care. Performance measurement can be used to track the quality of care that health plans and medical groups deliver, but effective performance measurement requires timely access to detailed and accurate data. In 1996, the National Committee for Quality Assurance (NCQA) commissioned a report to learn what actions would improve health plans' capacity to electronically report performance data for the Health Plan Employer Data and Information Set (HEDIS). Tracking clinical performance will require not just clinical data stored in information systems, but an integrated health information framework. Seven features are essential to this framework: (1) it specifies data elements; (2) it establishes linkage capability among data elements and records; (3) it standardizes the element definitions; (4) it is automated to the greatest possible extent; (5) it specifies procedures for continually assessing data quality; (6) it maintains strict controls for protecting security and confidentiality of the data; and (7) it specifies protocols for sharing data across institutions under appropriate and well-defined circumstances. Health plans should anticipate the use of computerized patient records and prepare their data management for an information framework by (1) expanding and improving the capture and use of currently available data; (2) creating an environment that rewards the automation of data; (3) improving the quality of currently automated data; (4) implementing national standards; (5) improving clinical data management practices; (6) establishing a clear commitment to protecting the confidentiality of enrollee information; and (7) careful capital planning, Health care purchasers can provide the impetus for implementing the information framework if they demand detailed, accurate data on the quality of care.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; Natl Comm Qual Assurance, Washington, DC USA; GSF, Inst Med Informat & Hlth Serv Res, Neuherberg, Germany	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Schneider, EC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	eschneid@hsph.harvard.edu		Schneider, Eric/0000-0002-1132-5084				Aronow D B, 1993, Jt Comm J Qual Improv, V19, P465; Barrows RC, 1996, J AM MED INFORM ASSN, V3, P139, DOI 10.1136/jamia.1996.96236282; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Blumenthal D, 1996, NEW ENGL J MED, V335, P1146, DOI 10.1056/NEJM199610103351511; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; BURING JE, 1990, STAT MED, V9, P29, DOI 10.1002/sim.4780090109; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Classen DC, 1998, JAMA-J AM MED ASSOC, V280, P1360, DOI 10.1001/jama.280.15.1360; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; *CPRI WORK GROUP C, 1995, GUID EST INF SEC POL; *DAT INT STAND ASS, 1997, ASC X12N 834 BEN ENR; Dick RS, 1997, COMPUTER BASED PATIE; DONALDSON MS, 1994, HLTH DATA INFORMATIO; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; *GEN ACC OFF, 1991, GAOIMTEC9115; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2482; Higgins M W, 1984, Prog Clin Biol Res, V147, P51; *HLTH LEV M, 1997, APPL PROT EL DAT EXC; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; JOHNSTON ME, 1993, ANN INTERN MED, V119, P844; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; McDonald CJ, 1998, HEALTH AFFAIR, V17, P44, DOI 10.1377/hlthaff.17.6.44; MCDONALD CJ, 1995, M D COMPUT, V12, P180; McGlynn EA, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.3.7; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; *NAT ASTHM ED PREV, 1997, US DEP HLTH HUMAN SE; *NAT COMM QUAL ASS, 1996, HEDIS 3 0 HLTH PLAN; *NAT COMM QUAL ASS, 1996, HEDIS 3 0, V4, P19; *NAT COMM VIT HLTH, 1998, 1 NAT COMM VIT HLTH; *NAT RES COUNC COM, 1997, REC PROT EL HLTH INF; *OFF TECHN ASS, 1993, OTATCT576; Shaller DV, 1998, JAMA-J AM MED ASSOC, V279, P1254, DOI 10.1001/jama.279.16.1254; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	42	90	90	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1184	1190		10.1001/jama.282.12.1184	http://dx.doi.org/10.1001/jama.282.12.1184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501126				2022-12-28	WOS:000082596200038
J	Sandham, JD				Sandham, JD			Complications of acute anaemia: caused by low packed-cell volume or by transfusion?	LANCET			English	Editorial Material							POSTOPERATIVE DELIRIUM		Univ Calgary, Reg Div Crit Care, Calgary, AB T2N 2T9, Canada	University of Calgary	Sandham, JD (corresponding author), Univ Calgary, Reg Div Crit Care, Foothills Hosp Site, Calgary, AB T2N 2T9, Canada.							Ely EW, 1999, NEW ENGL J MED, V340, P467, DOI 10.1056/NEJM199902113400610; FREDERICK AM, 1997, ARCH SURG-CHICAGO, V132, P620; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7	6	1	1	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					883	884		10.1016/S0140-6736(99)90268-4	http://dx.doi.org/10.1016/S0140-6736(99)90268-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489944				2022-12-28	WOS:000082511800007
J	Yamey, G				Yamey, G			Anti-flu drug may not reduce death rate	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					659	659		10.1136/bmj.319.7211.659	http://dx.doi.org/10.1136/bmj.319.7211.659			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480811	Green Published			2022-12-28	WOS:000082636800010
J	Klinke, R; Kral, A; Heid, S; Tillein, J; Hartmann, R				Klinke, R; Kral, A; Heid, S; Tillein, J; Hartmann, R			Recruitment of the auditory cortex in congenitally deaf cats by long-term cochlear electrostimulation	SCIENCE			English	Article							INTRACOCHLEAR ELECTRICAL-STIMULATION; NEURONAL RESPONSES; WHITE CAT; EVOKED-POTENTIALS; CEREBRAL-CORTEX; REPETITION RATE; BRAIN-STEM; PLASTICITY; IMPLANT; NUCLEUS	In congenitally deaf cats, the central auditory system is deprived of acoustic input because of degeneration of the organ of Corti before the onset of hearing. Primary auditory afferents survive and can be stimulated electrically. By means of an intracochlear implant and an accompanying sound processor, congenitally deaf kittens were exposed to sounds and conditioned to respond to tones. After months of exposure to meaningful stimuli, the cortical activity in chronically implanted cats produced field potentials of higher amplitudes, expanded in area, developed Long Latency responses indicative of intracortical information processing, and showed more synaptic efficacy than in naive, unstimulated deaf cats. The activity established by auditory experience resembles activity in hearing animals.	Physiol Inst 3, D-60590 Frankfurt, Germany		Klinke, R (corresponding author), Physiol Inst 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	klinke@em.uni-frankuft.de		Kral, Andrej/0000-0002-7762-4642				AITKIN L, 1990, AUDITORY CORTEX; BAKIN JS, 1990, BRAIN RES, V536, P271, DOI 10.1016/0006-8993(90)90035-A; BLAKEMORE C, 1978, HDB SENSORY PHYSL, V8, P392; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; BUSBY PA, 1993, J ACOUST SOC AM, V93, P1058, DOI 10.1121/1.405554; CHOUARD CH, 1983, ANN NY ACAD SCI, V405, P387, DOI 10.1111/j.1749-6632.1983.tb31653.x; FOX K, 1994, J NEUROSCI, V14, P7665; FREGNAC Y, 1984, PHYSIOL REV, V64, P325, DOI 10.1152/physrev.1984.64.1.325; Hardie NA, 1999, HEARING RES, V128, P147, DOI 10.1016/S0378-5955(98)00209-3; HARTMANN R, 1984, HEARING RES, V13, P47, DOI 10.1016/0378-5955(84)90094-7; Hartmann R, 1997, HEARING RES, V112, P115, DOI 10.1016/S0378-5955(97)00114-7; Heid S, 1997, HEARING RES, V110, P191, DOI 10.1016/S0378-5955(97)00074-9; Heid S, 1998, HEARING RES, V115, P101, DOI 10.1016/S0378-5955(97)00182-2; HOCHMAIR ES, 1979, INT J ARTIF ORGANS, V2, P255; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kral A, 1999, NEUROREPORT, V10, P781, DOI 10.1097/00001756-199903170-00022; Kral A, 1998, HEARING RES, V121, P11, DOI 10.1016/S0378-5955(98)00061-6; KRAUS N, 1993, HEARING RES, V65, P118, DOI 10.1016/0378-5955(93)90206-G; LARSEN SA, 1992, EXP NEUROL, V115, P151, DOI 10.1016/0014-4886(92)90240-Q; LEAKE PA, 1988, HEARING RES, V33, P11, DOI 10.1016/0378-5955(88)90018-4; Mair I W, 1973, Acta Otolaryngol Suppl, V314, P1; MITANI A, 1985, J COMP NEUROL, V235, P430, DOI 10.1002/cne.902350403; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Popelar J, 1995, HEARING RES, V92, P63, DOI 10.1016/0378-5955(95)00199-9; PRIETO JJ, 1994, J COMP NEUROL, V344, P349, DOI 10.1002/cne.903440304; RAGGIO MW, 1994, J NEUROPHYSIOL, V72, P2334, DOI 10.1152/jn.1994.72.5.2334; Rajan R, 1998, AUDIOL NEURO-OTOL, V3, P123, DOI 10.1159/000013786; Rauschecker JP, 1999, TRENDS NEUROSCI, V22, P74, DOI 10.1016/S0166-2236(98)01303-4; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; REBILLARD G, 1980, BRAIN RES, V188, P252, DOI 10.1016/0006-8993(80)90572-7; ROMAND R, 1992, DEV AUDITORY VESTIBU, V2; Ryugo DK, 1998, J COMP NEUROL, V397, P532, DOI 10.1002/(SICI)1096-9861(19980810)397:4<532::AID-CNE6>3.0.CO;2-2; Schreiner CE, 1996, J NEUROPHYSIOL, V75, P1283, DOI 10.1152/jn.1996.75.3.1283; SCHWARTZ IR, 1982, ACTA OTO-LARYNGOL, V93, P9, DOI 10.3109/00016488209130847; Shepherd RK, 1997, ACTA OTO-LARYNGOL, P28; SKUSE SDH, 1993, LANGUAGE DEV EXCEPTI, P29; SNYDER RL, 1991, HEARING RES, V56, P246, DOI 10.1016/0378-5955(91)90175-9; SNYDER RL, 1990, HEARING RES, V50, P7, DOI 10.1016/0378-5955(90)90030-S; VANDENHONERT C, 1984, HEARING RES, V14, P225, DOI 10.1016/0378-5955(84)90052-2; Weinberger NM, 1998, TRENDS COGN SCI, V2, P271, DOI 10.1016/S1364-6613(98)01200-5; WURTH N, 1999, GOTTINGEN NEUROBIO R, V27, P318	41	148	154	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1729	1733		10.1126/science.285.5434.1729	http://dx.doi.org/10.1126/science.285.5434.1729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481008				2022-12-28	WOS:000082472600034
J	Millett, S; Campbell, K; Epstein, DJ; Losos, K; Harris, E; Joyner, AL				Millett, S; Campbell, K; Epstein, DJ; Losos, K; Harris, E; Joyner, AL			A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer	NATURE			English	Article							EXPRESSION; GENE; SPECIFICATION; FOREBRAIN; BRAIN; NEUROECTODERM; INFORMATION; CEREBELLUM; INDUCTION; HINDBRAIN	The mid/hindbrain (MHB) junction can act as an organizer to direct the development of the midbrain and anterior hindbrain(1,2) In mice, Otx2 is expressed in the forebrain and midbrain and Gbx2 is expressed in the anterior hindbrain, with a shared border at the level of the MHB organizer. Here we show that, in Gbx2(-/-) mutants, the earliest phenotype is a posterior expansion of the Otx2 domain during early somite stages. Furthermore, organizer genes are expressed at the shifted Otx2 border, but not in a normal spatial relationship. To test whether Gbx2 is sufficient to position the MHB organizer, we transiently expressed Gbx2 in the caudal Otx2 domain and found that the Otx2 caudal border was indeed shifted rostrally and a normal appearing organizer formed at this new Otx2 border. Transgenic embryos then showed an expanded hindbrain and a reduced midbrain at embryonic day 9.5-10. We propose that formation of a normal MHB organizer depends on a sharp Otx2 caudal border and that Gbx2 is required to position and sharpen this border.	NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol & Physiol & Neurosci, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University; New York University	Joyner, AL (corresponding author), NYU, Sch Med, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.		Campbell, Kenneth/ABC-3570-2021					ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Acampora D, 1997, DEVELOPMENT, V124, P3639; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; ALVARADOMALLART RM, 1993, J NEUROBIOL, V24, P1341, DOI 10.1002/neu.480241007; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Hogan B, 1994, MANIPULATING MOUSE E; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Millen KJ, 1995, DEVELOPMENT, V121, P3935; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; Rhinn M, 1998, DEVELOPMENT, V125, P845; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Toresson H, 1999, DEVELOPMENT, V126, P1317; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wassef M, 1997, PERSPECT DEV NEUROBI, V5, P3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	19	237	237	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					161	164		10.1038/43664	http://dx.doi.org/10.1038/43664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490024				2022-12-28	WOS:000082458800053
J	Seto, AG; Zaug, AJ; Sobel, SG; Wolin, SL; Cech, TR				Seto, AG; Zaug, AJ; Sobel, SG; Wolin, SL; Cech, TR			Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle	NATURE			English	Article							REVERSE-TRANSCRIPTASE; YEAST; PROTEIN; RNA; BINDING; CELLS; IDENTIFICATION; COMPONENTS; SNRNA	Activation of the chromosome end-replicating enzyme telomerase can greatly extend the lifespan of normal human cells' and is associated with most human cancers(2). In all eukaryotes examined, telomerase has an RNA subunit(3), a conserved reverse transcriptase subunit(4) and additional proteins(5,6) but little is known about the assembly of these components. Here we show that the Saccharomyces cerevisiae telomerase RNA(7) has a 5'-2,2,7-trimethyl-guanosine (TMG) cap and a binding site for the Sm proteins, both hallmarks of small nuclear ribonucleoprotein particles (snRNPs) that are involved in nuclear messenger RNA splicing(8,9). Immunoprecipitation of telomerase from yeast extracts shows that Sm proteins are assembled on the RNA and that most or all of the telomerase activity is associated with the Sm-containing complex These data support a model in which telomerase RNA is transcribed by RNA polymerase II (ref. 10) and 7-methylguanosine-capped, binds the seven Sm proteins, becomes TMG-capped and picks up the other protein subunits, We conclude that the functions of snRNPs assembled by this pathway are not restricted to RNA processing, but also include chromosome telomere replication.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Yale University; Howard Hughes Medical Institute; Yale University	Cech, TR (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399	NIGMS NIH HHS [R01 GM048410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048410] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Chapon C, 1997, RNA, V3, P1337; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; ROY J, 1995, MOL CELL BIOL, V15, P445, DOI 10.1128/MCB.15.1.445; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Yu YT, 1999, RNA WORLD, P487; [No title captured]	27	230	237	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					177	180		10.1038/43694	http://dx.doi.org/10.1038/43694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490028				2022-12-28	WOS:000082458800057
J	Xu, QA; Buckley, D; Guan, CD; Guo, HC				Xu, QA; Buckley, D; Guan, CD; Guo, HC			Structural insights into the mechanism of intramolecular proteolysis	CELL			English	Article							N-TERMINAL NUCLEOPHILE; CRYSTAL-STRUCTURE; 20S PROTEASOME; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; FLAVOBACTERIUM-MENINGOSEPTICUM; HISTIDINE-DECARBOXYLASE; BETA-SUBUNITS; GLYCOSYLASPARAGINASE; RESOLUTION; HEDGEHOG	A variety of proteins, including glycosylasparaginase, have recently been found to activate functions by self-catalyzed peptide bond rearrangements from single-chain precursors. Here we present the 1.9 Angstrom crystal structures of glycosylasparaginase precursors that are able to autoproteolyze via an N --> O acyl shift. Several conserved residues are aligned around the scissile peptide bond that is in a highly strained trans peptide bond configuration. The structure illustrates how a nucleophilic side chain may attack the scissile peptide bond at the immediate upstream backbone carbonyl and provides an understanding of the structural basis for peptide bond cleavage via an N --> O or N --> S acyl shift that is used by various groups of intramolecular autoprocessing proteins.	Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Boston University	Guo, HC (corresponding author), Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA.	hcguo@bu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALASUBR.R, 1972, INT J PEPT PROT RES, V4, P91; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; CUI T, 1999, IN PRESS ACTA CRYS D; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fisher AJ, 1996, J BIOL CHEM, V271, P21956, DOI 10.1074/jbc.271.36.21956; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; Khan AR, 1998, PROTEIN SCI, V7, P815; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xuan JC, 1998, PROTEIN SCI, V7, P774, DOI 10.1002/pro.5560070327; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	62	115	116	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					651	661		10.1016/S0092-8674(00)80052-5	http://dx.doi.org/10.1016/S0092-8674(00)80052-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490104	hybrid			2022-12-28	WOS:000082433500012
J	Ban, N; Nissen, P; Hansen, J; Capel, M; Moore, PB; Steitz, TA				Ban, N; Nissen, P; Hansen, J; Capel, M; Moore, PB; Steitz, TA			Placement of protein and RNA structures into a 5 angstrom-resolution map of the 50S ribosomal subunit	NATURE			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI RIBOSOME; CRYSTAL-STRUCTURE; CROSS-LINKING; 23S RNA; EF-TU; DOMAIN; LOOP; VISUALIZATION; ARRANGEMENT	We have calculated at 5.0 Angstrom resolution an electron-density map of the large 50S ribosomal subunit from the bacterium Haloarcula marismortui by using phases derived from four heavy-atom derivatives, intercrystal density averaging and density-modification procedures. More than 300 base pairs of A-form RNA duplex have been fitted into this map, as have regions of non-A-form duplex, single-stranded segments and tetraloops. The long rods of RNA crisscrossing the subunit arise from the stacking of short, separate double helices, not all of which are A-form, and in many places proteins crosslink two or more of these rods. The polypeptide exit channel was marked by tungsten cluster compounds bound in one heavy-atom-derivatized crystal. We have determined the structure of the translation-factor-binding centre by fitting the crystal structures of the ribosomal proteins L6, L11 and L14, the sarcin-ricin loop RNA, and the RNA sequence that binds L11 into the electron density. We can position either elongation factor a or elongation factor Tu complexed with an aminoacylated transfer RNA and GTP onto the factor-binding centre in a manner that is consistent with results from biochemical and electron microscopy studies.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; United States Department of Energy (DOE); Brookhaven National Laboratory	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009; Nissen, Poul/D-5774-2014	Nissen, Poul/0000-0003-0948-6628				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dallas A, 1997, STRUCTURE, V5, P1639, DOI 10.1016/S0969-2126(97)00311-0; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; LEFFERS H, 1988, J MOL BIOL, V204, P507, DOI 10.1016/0022-2836(88)90351-8; LEFFERS H, 1987, J MOL BIOL, V195, P43, DOI 10.1016/0022-2836(87)90326-3; LILJAS A, 1990, RIBOSOME, P309; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MILLER KD, 1993, J AM HIST, V80, P319, DOI 10.2307/2079816; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Nakagawa A, 1999, EMBO J, V18, P1459, DOI 10.1093/emboj/18.6.1459; NEVSKAYA N, IN PRESS J MOL BIOL; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P52; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SKOLD SE, 1982, EUR J BIOCHEM, V127, P225, DOI 10.1111/j.1432-1033.1982.tb06859.x; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STOEFFLER G, 1986, STRUCTURE FUNCTION G, P28; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	50	341	368	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					841	847		10.1038/23641	http://dx.doi.org/10.1038/23641			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476961				2022-12-28	WOS:000082233200036
J	Goodman, NW				Goodman, NW			A memorable teacher - Reasons to be thankful	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					844	844		10.1136/bmj.319.7213.844	http://dx.doi.org/10.1136/bmj.319.7213.844			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496835	Green Published			2022-12-28	WOS:000082865200033
J	Dobson, R				Dobson, R			Patients satisfied with nurse run practices	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					728	728		10.1136/bmj.319.7212.728	http://dx.doi.org/10.1136/bmj.319.7212.728			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487989	Green Published			2022-12-28	WOS:000082701500009
J	Fu, JH; Gnatt, AL; Bushnell, DA; Jensen, GJ; Thompson, NE; Burgess, RR; David, PR; Kornberg, RD				Fu, JH; Gnatt, AL; Bushnell, DA; Jensen, GJ; Thompson, NE; Burgess, RR; David, PR; Kornberg, RD			Yeast RNA polymerase II at 5 angstrom resolution	CELL			English	Article							2 DISSOCIABLE SUBUNITS; NASCENT RNA; TERNARY COMPLEXES; 3-DIMENSIONAL STRUCTURE; ELONGATION COMPLEX; DNA-REPLICATION; TRANSCRIPTION; CRYSTALLOGRAPHY; INITIATION; PROMOTER	Appropriate treatment of X-ray diffraction from an unoriented 18-heavy atom cluster derivative of a yeast RNA polymerase II crystal gave significant phase information to 5 Angstrom resolution. The validity of the phases was shown by close similarity of a 6 Angstrom electron density map to a 16 Angstrom molecular envelope of the polymerase from electron crystallography. Comparison of the 6 Angstrom X-ray map with results of electron crystallography of a paused transcription elongation complex suggests functional roles for two mobile protein domains: the tip of a flexible arm forms a downstream DNA clamp; and a hinged domain may serve as an RNA clamp, enclosing the transcript from about 8-18 residues upstream of the 3'-end in a tunnel.	Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Sci Ctr, Stanford, CA 94305 USA; Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	Stanford University; University of Wisconsin System; University of Wisconsin Madison	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Sci Ctr, Stanford, CA 94305 USA.	kornberg@stanford.edu		Burgess, Richard/0000-0001-9545-3165	NIGMS NIH HHS [GM49985] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BLUNDELL TL, 1976, PROGEIN CRYSTALLOGRA, P180; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; CRICK FHC, 1956, ACTA CRYSTALLOGR, V9, P901, DOI 10.1107/S0365110X56002552; DAMOUR H, 1976, ACTA CRYSTALLOGR B, V32, P729, DOI 10.1107/S0567740876003890; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1994, NAT STRUCT BIOL, V1, P195, DOI 10.1038/nsb0394-195; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; Keene RG, 1999, J BIOL CHEM, V274, P11526, DOI 10.1074/jbc.274.17.11526; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Knablein J, 1997, J MOL BIOL, V270, P1, DOI 10.1006/jmbi.1997.1074; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; Mcree D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; ROSSMANN MG, 1960, ACTA CRYSTALLOGR, V13, P221, DOI 10.1107/S0365110X60000510; ROSSMANN MG, 1961, ACTA CRYSTALLOGR, V14, P383, DOI 10.1107/S0365110X61001297; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; Thygesen J, 1996, STRUCTURE, V4, P513, DOI 10.1016/S0969-2126(96)00057-3; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Woolfson M. M., 1970, INTRO XRAY CRYSTALLO; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; 1974, INT TABLES CRAY CRYS, V4, P71	61	107	107	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					799	810		10.1016/S0092-8674(00)81514-7	http://dx.doi.org/10.1016/S0092-8674(00)81514-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499797	Bronze			2022-12-28	WOS:000082679200007
J	Zhang, GY; Campbell, EA; Minakhin, L; Richter, C; Severinov, K; Darst, SA				Zhang, GY; Campbell, EA; Minakhin, L; Richter, C; Severinov, K; Darst, SA			Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 angstrom resolution	CELL			English	Article							TRANSCRIPTION ELONGATION COMPLEX; COLI RPOB GENE; ESCHERICHIA-COLI; ACTIVE-CENTER; BETA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; ALPHA-SUBUNIT; BINDING; DETERMINANTS; ORGANIZATION	The X-ray crystal structure of Thermus aquaticus core RNA polymerase reveals a "crab claw"-shaped molecule with a 27 Angstrom wide internal channel. Located on the back wall of the channel is a Mg2+ ion required for catalytic activity, which is chelated by an absolutely conserved motif from all bacterial and eukaryotic cellular RNA polymerases. The structure places key functional sites, defined by mutational and cross-linking analysis, on the inner walls of the channel in close proximity to the active center Mg2+. Further out from the catalytic center, structural features are found that may be involved in maintaining the melted transcription bubble, clamping onto the RNA product and/or DNA template to assure processivity, and delivering nucleotide substrates to the active center.	Rockefeller Univ, New York, NY 10021 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rockefeller University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Severinov, Konstantin/C-8545-2016	Campbell, Elizabeth/0000-0002-1332-128X	NIGMS NIH HHS [GM19441-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; CHAMBERLIN M, 1962, P NATL ACAD SCI USA, V48, P81, DOI 10.1073/pnas.48.1.81; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Darst SA, 1998, COLD SPRING HARB SYM, V63, P269, DOI 10.1101/sqb.1998.63.269; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; de La Fortelle E., 1997, CRYSTALLOGRAPHIC COM, P1; DEGRYSE E, 1978, ARCH MICROBIOL, V117, P189, DOI 10.1007/BF00402307; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GENTRY DR, 1993, BIOCHEMISTRY-US, V32, P11224, DOI 10.1021/bi00092a036; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gross CA, 1996, PHILOS T R SOC B, V351, P475, DOI 10.1098/rstb.1996.0045; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HUANG RC, 1960, BIOCHEM BIOPH RES CO, V3, P689, DOI 10.1016/0006-291X(60)90088-7; HURWITZ J, 1960, BIOCHEM BIOPH RES CO, V3, P15, DOI 10.1016/0006-291X(60)90094-2; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARKOV D, 1999, IN PRESS GENES DEV; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Mukherjee K, 1997, EUR J BIOCHEM, V247, P884, DOI 10.1111/j.1432-1033.1997.00884.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Sentenac A., 1992, YEAST RNA POLYM SUBU, P27; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; STEVENS A, 1960, BIOCHEM BIOPH RES CO, V3, P92, DOI 10.1016/0006-291X(60)90110-8; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WEISS SB, 1959, J AM CHEM SOC, V81, P4118, DOI 10.1021/ja01524a087; Zakharova N, 1999, J BACTERIOL, V181, P3857, DOI 10.1128/JB.181.12.3857-3859.1999; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262	61	636	666	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					811	824		10.1016/S0092-8674(00)81515-9	http://dx.doi.org/10.1016/S0092-8674(00)81515-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499798	Bronze			2022-12-28	WOS:000082679200008
J	Brahams, D				Brahams, D			Court order for HIV-1 test for baby	LANCET			English	Editorial Material									Old Sq Chambers, London WC1R 5LQ, England		Brahams, D (corresponding author), Old Sq Chambers, Grays Inn, London WC1R 5LQ, England.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					884	884		10.1016/S0140-6736(99)90306-9	http://dx.doi.org/10.1016/S0140-6736(99)90306-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489945				2022-12-28	WOS:000082511800008
J	Cote, RJ; Peterson, HF; Chaiwun, B; Gelber, RD; Goldhirsch, A; Castiglione-Gertsch, M; Gusterson, B; Neville, AM				Cote, RJ; Peterson, HF; Chaiwun, B; Gelber, RD; Goldhirsch, A; Castiglione-Gertsch, M; Gusterson, B; Neville, AM		Int Breast Canc Study Grp	Role of immunohistochemical detection of lymph-node metastases in management of breast cancer	LANCET			English	Article							TUMOR-CELLS; PROGNOSTIC-SIGNIFICANCE; BONE-MARROW; STAGE-I; MICROMETASTASES; CARCINOMA; FUTURE	Background This study was designed to ascertain whether immunohistochemical methods could improve the detection of metastases in primary breast-cancer patients whose axillary lymph nodes were classified, by conventional methods, as disease free. Methods Ipsilateral lymph nodes (negative for metastases by routine histology) from 736 patients (participants in Trial V of the International [Ludwig] Breast Cancer Study) were examined by serial sectioning and staining with haematoxylin and eosin (two sections from each of six levels) and by immunohistochemistry of a single section (with two anticytokeratins AE-1 and CAM 5.2). After median follow-up of 12 years, disease-free and overall survival were estimated by Kaplan-Meier methods. Findings Occult nodal metastases were detected by serial sectioning and haematoxylin and eosin in 52 (7%) of 736 patients and by immunohistochemistry in 148 (20%). Only two (3%) of 64 invasive lobular or mixed invasive lobular and ductal cancers had node micrometastases, detected by haematoxylin and eosin, compared with 25 (39%) by immunohistochemistry. Occult metastases, detected by either method, were associated with significantly poor disease-free and overall survival in postmenopausal but not in premenopausal patients. Immunohistochemically detected occult lymph-node metastases remained an independent and highly significant predictor of recurrence even after control for tumour grade, tumour size, oestrogen-receptor status, vascular invasion, and treatment assignment (hazard ratio 1.79 [95% CI 1.17-2.74], p=0.007). Interpretation The immunohistochemical examination of ipsilateral axillary lymph nodes is a reliable, prognostically valuable, and simple method for the detection of occult nodal metastases. Immunohistochemistry is recommended as a standard method of node examination in postmenopausal patients.	Ludwig Inst Canc Res, London SW1E 5AG, England; USC Sch Med, Norris Canc Ctr, Dept Pathol, Los Angeles, CA USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Int Breast Canc Study Grp Stat Ctr, Boston, MA USA; European Inst Oncol, Milan, Italy; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Int Breast Canc Study Grp Coordinating Ctr, Bern, Switzerland	Ludwig Institute for Cancer Research; University of Southern California; Harvard University; Dana-Farber Cancer Institute; IRCCS European Institute of Oncology (IEO); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; International Breast Cancer Study Group	Neville, AM (corresponding author), Ludwig Inst Canc Res, 6th Floor,Glen House,Stag Pl, London SW1E 5AG, England.		gusterson, barry a/D-3752-2009		NCI NIH HHS [CA-75362] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COCHRAN AJ, 1988, AM J SURG PATHOL, V12, P612, DOI 10.1097/00000478-198808000-00002; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; DEARNALEY DP, 1991, EUR J CANCER, V27, P236, DOI 10.1016/0277-5379(91)90504-7; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; GOLDHIRSCH A, 1994, CANCER, V74, P1139, DOI 10.1002/1097-0142(19940801)74:3+<1139::AID-CNCR2820741524>3.0.CO;2-K; GOLDHIRSCH A, 1990, LANCET, V335, P1565; HAINSWORTH PJ, 1993, BRIT J SURG, V80, P459, DOI 10.1002/bjs.1800800417; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; REDDING WH, 1983, LANCET, V2, P1271; SAEZ RA, 1989, SEMIN SURG ONCOL, V5, P102, DOI 10.1002/ssu.2980050206; SAPHIR O, 1948, CANCER, V1, P238, DOI 10.1002/1097-0142(194807)1:2<238::AID-CNCR2820010208>3.0.CO;2-U; SEDMAK DD, 1989, MODERN PATHOL, V2, P516; Shi SR, 1997, J HISTOCHEM CYTOCHEM, V45, P327, DOI 10.1177/002215549704500301; STOTO MA, 1989, NEW ENGL J MED, V320, P461, DOI 10.1056/NEJM198902163200711; TROJANI M, 1987, BRIT J CANCER, V55, P303, DOI 10.1038/bjc.1987.59; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0	21	398	412	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					896	900		10.1016/S0140-6736(98)11104-2	http://dx.doi.org/10.1016/S0140-6736(98)11104-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489948				2022-12-28	WOS:000082511800011
J	Davies, EK; Peters, AD; Keightley, PD				Davies, EK; Peters, AD; Keightley, PD			High frequency of cryptic deleterious mutations in Caenorhabditis elegans	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; AMBER SUPPRESSORS; SELECTION; RATES; RISK	Deleterious mutations with very small phenotypic effects could be important for several evolutionary phenomena, but the extent of their contribution has been unknown. Fitness effects of induced mutations in Lines of Caenorhabditis elegans were measured using a system for which the number of deleterious point mutations in the DNA can be estimated. In fitness assays, only about 4 percent of the deleterious mutations fixed in each Line were detectable. The remaining 96 percent, though cryptic, are significant for mutation Load and, potentially, for the evolution of sex.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Keightley, PD (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	p.keightley@ed.ac.uk						ANDERSON P, 1995, CAENORHABDITIS ELEGA, P31; BARNES TM, 1995, GENETICS, V141, P159; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; BEJSOVEC A, 1988, GENE DEV, V2, P1307, DOI 10.1101/gad.2.10.1307; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; EIDE D, 1985, GENETICS, V109, P67; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Fry JD, 1999, P NATL ACAD SCI USA, V96, P574, DOI 10.1073/pnas.96.2.574; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; HODGKIN J, 1985, GENETICS, V111, P287; Keightley PD, 1997, P NATL ACAD SCI USA, V94, P3823, DOI 10.1073/pnas.94.8.3823; Keightley PD, 1998, CURR BIOL, V8, pR235, DOI 10.1016/S0960-9822(98)70148-4; Keightley PD, 1996, GENETICS, V144, P1993; Keightley PD, 1998, GENETICS, V148, P753; KONDO K, 1990, J MOL BIOL, V215, P7, DOI 10.1016/S0022-2836(05)80090-7; KONDRASHOV AS, 1995, J THEOR BIOL, V175, P583, DOI 10.1006/jtbi.1995.0167; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1994, P ROY SOC B-BIOL SCI, V258, P221, DOI 10.1098/rspb.1994.0166; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; Nakamura Y, 1999, NUCLEIC ACIDS RES, V27, P292, DOI 10.1093/nar/27.1.292; ROSENBLUTH RE, 1983, MUTAT RES, V110, P39, DOI 10.1016/0027-5107(83)90016-7; Shabalina SA, 1997, P NATL ACAD SCI USA, V94, P13034, DOI 10.1073/pnas.94.24.13034; SHABALINA SA, IN PRESS GENET RES; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Vassilieva LL, 1999, GENETICS, V151, P119; WATERSTON RH, 1981, GENETICS, V97, P307	30	110	112	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1748	1751		10.1126/science.285.5434.1748	http://dx.doi.org/10.1126/science.285.5434.1748			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481013				2022-12-28	WOS:000082472600039
J	Bodo, I; Peters, M; Radich, JP; Hess, J; Blinder, M; Watson, MS; Van Rheeden, R; Natarajan, S; Lowell, JA; Brown, R; DiPersio, J; Adkins, D				Bodo, I; Peters, M; Radich, JP; Hess, J; Blinder, M; Watson, MS; Van Rheeden, R; Natarajan, S; Lowell, JA; Brown, R; DiPersio, J; Adkins, D			Donor-derived acute promyelocytic leukemia in a liver-transplant recipient	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE CHAIN-REACTION; RETINOIC ACID SYNDROME; CELL LEUKEMIA; PCR AMPLIFICATION; APLASTIC-ANEMIA; RECURRENCE		Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Fred Hutchinson Cancer Center	Bodo, I (corresponding author), Euro Med Net, 6-7 Gyori Ut, H-1123 Budapest, Hungary.							Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BORROW J, 1992, BRIT J HAEMATOL, V82, P529, DOI 10.1111/j.1365-2141.1992.tb06463.x; BOYD CN, 1982, LEUKEMIA RES, V6, P833, DOI 10.1016/0145-2126(82)90067-4; BROWN SA, 1995, EUR J HAEMATOL, V54, P198; BROWNE PV, 1991, NEW ENGL J MED, V325, P710, DOI 10.1056/NEJM199109053251007; BUGAWAN TL, 1994, TISSUE ANTIGENS, V44, P137, DOI 10.1111/j.1399-0039.1994.tb02371.x; COLLINS RH, 1993, NEW ENGL J MED, V328, P762, DOI 10.1056/NEJM199303183281104; CRANSAC M, 1993, TRANSPLANTATION, V56, P120, DOI 10.1097/00007890-199307000-00022; ELFENBEIN GJ, 1978, BLOOD, V52, P627; ERLICH H, 1991, EUR J IMMUNOGENET, V18, P33, DOI 10.1111/j.1744-313X.1991.tb00005.x; FEIG SA, 1988, BONE MARROW TRANSPL, V3, P331; FIALKOW PJ, 1971, LANCET, V1, P251; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; FUKUTANI H, 1995, LEUKEMIA, V9, P1478; GALLAGHER RE, 1995, BLOOD, V86, P1540, DOI 10.1182/blood.V86.4.1540.bloodjournal8641540; Gallagher RE, 1997, BLOOD, V90, P1656; GOH KO, 1977, AM J HEMATOL, V2, P283, DOI 10.1002/ajh.2830020310; Hohaus S, 1998, BLOOD, V92, p132A; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; KATZ F, 1993, BRIT J HAEMATOL, V85, P326, DOI 10.1111/j.1365-2141.1993.tb03174.x; Lowsky R, 1996, BRIT J HAEMATOL, V93, P163, DOI 10.1046/j.1365-2141.1996.454991.x; MARMONT A, 1984, NEW ENGL J MED, V310, P903, DOI 10.1056/NEJM198404053101408; MCCANN SR, 1992, BLOOD, V79, P2803; MOURATIDOU M, 1993, BONE MARROW TRANSPL, V12, P77; NEWBURGER PE, 1981, NEW ENGL J MED, V304, P712, DOI 10.1056/NEJM198103193041206; NIEDERWIESER DW, 1990, NEW ENGL J MED, V322, P1794, DOI 10.1056/NEJM199006213222507; PALKA G, 1991, CANCER GENET CYTOGEN, V51, P223, DOI 10.1016/0165-4608(91)90135-H; RADICH JP, 1990, BLOOD, V76, P801; Rao AS, 1996, CLIN IMMUNOL IMMUNOP, V80, pS46, DOI 10.1006/clin.1996.0141; SARKAR FH, 1993, BIOTECHNIQUES, V15, P36; SCHMITZ N, 1987, BLOOD, V70, P1099; SMITH AG, 1998, ASHI Q, V22, P3; SMITH JL, 1985, BRIT J HAEMATOL, V60, P415, DOI 10.1111/j.1365-2141.1985.tb07438.x; THOMAS ED, 1972, LANCET, V1, P1310; TOBAL K, 1995, BRIT J HAEMATOL, V90, P615, DOI 10.1111/j.1365-2141.1995.tb05592.x; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1985, BLOOD, V65, P1172; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628	40	47	51	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					807	813		10.1056/NEJM199909093411105	http://dx.doi.org/10.1056/NEJM199909093411105			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477779	Bronze			2022-12-28	WOS:000082534000005
J	Broccoli, V; Boncinelli, E; Wurst, W				Broccoli, V; Boncinelli, E; Wurst, W			The caudal limit of Otx2 expression positions the isthmic organizer	NATURE			English	Article							MIDBRAIN-HINDBRAIN BOUNDARY; NERVOUS-SYSTEM; ROSTRAL BRAIN; MOUSE; GENES; PHENOTYPE; FGF8; ENGRAILED-1; RHOMBOMERES; INDUCTION	The homeobox gene Otx2 is expressed in the anterior neural tube with a sharp limit at the midbrain/hindbrain junction (the isthmic organizer)(1). Otx2 inactivation experiments have shown that this gene is essential for the development of its expression domain(2). Here we investigate whether the caudal limit of Otx2 expression is instrumental in positioning the isthmic organizer and in specifying midbrain versus hindbrain fate, by ectopically expressing Otx2 in the presumptive anterior hindbrain using a knock-in strategy into the En1 locus. Transgenic offspring display a cerebellar ataxia. Morphological and histological studies of adult transgenic brains reveal that most of the anterior cerebellar vermis is missing whereas the inferior colliculus is complementarily enlarged. During early neural pattern formation expression of the midbrain markers Wnt1 and Ephrin-A5, the isthmic organizer markers Pax2 and Fgf-8 and the hindbrain marker Gbx2 are shifted caudally in the presumptive hindbrain territory. These findings show that the caudal limit of Otx2 expression is sufficient for positioning the isthmic organizer and encoding caudal midbrain fate within the mid/hindbrain domain.	GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Neuherberg, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Hosp San Raffaele, DIBIT, I-20132 Milan, Italy	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Wurst, W (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Broccoli, Vania/K-3464-2016	Broccoli, Vania/0000-0003-4050-0926; Wurst, Wolfgang/0000-0003-4422-7410				Acampora D, 1999, TRENDS NEUROSCI, V22, P116, DOI 10.1016/S0166-2236(98)01387-3; Acampora D, 1997, DEVELOPMENT, V124, P3639; ANG SL, 1994, DEVELOPMENT, V120, P2979; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lun K, 1998, DEVELOPMENT, V125, P3049; Mallamaci A, 1996, MECH DEVELOP, V58, P165, DOI 10.1016/S0925-4773(96)00571-0; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; Martinez S, 1999, DEVELOPMENT, V126, P1189; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Millet S, 1996, DEVELOPMENT, V122, P3785; Reifers F, 1998, DEVELOPMENT, V125, P2381; Schwarz M, 1997, P NATL ACAD SCI USA, V94, P14518, DOI 10.1073/pnas.94.26.14518; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wassilew S, 1997, ANTIVIR CHEM CHEMOTH, V8, P3, DOI 10.1177/09563202970080S602; WURST W, 1994, DEVELOPMENT, V120, P2065	30	246	246	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					164	168		10.1038/43670	http://dx.doi.org/10.1038/43670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490025				2022-12-28	WOS:000082458800054
J	Franco, G				Franco, G			Ramazzini and workers' health	LANCET			English	Article									Univ Modena & Reggio Emilia, Sch Med, Dept Internal Med, Postgrad Sch Occupat Med, I-44100 Modena, Italy	Universita di Modena e Reggio Emilia	Franco, G (corresponding author), Univ Modena & Reggio Emilia, Sch Med, Dept Internal Med, Postgrad Sch Occupat Med, Largo Pozzo 71, I-44100 Modena, Italy.			Franco, Giuliano/0000-0002-6580-7994				AMBROSI L, 1996, TRATTAO MED LAVORO; CARNEVALE F, 1982, MALATTIE DEI LAVORAT, P9; DIPIETRO P, 1983, B RAMAZZINI CCCL ANN; DIPIETRO P, 1981, HIST PHIL LIFE SCI, V3, P95; HANSENNE M, 1998, ENCY OCCUPATIONAL HL, V5; HERINGTON TN, 1995, OCCUPATIONAL INJURIE, P333; HOFFMAN H, 1994, PRACTICAL APPROACH O, P48; *IS MED US, 1995, ENV MED INT MISS EL, P14; MASTROMATTEO E, 1975, J OCCUP ENVIRON MED, V17, P289; MURRAY R, 1987, HUNTERS DIS OCCUPATI, P1; Parmeggiani L, 1983, Med Lav, V74, P426; RAMAZZINI B, 1700, MORBIS ARTIFICUM; RAMAZZINI B, 1983, CLASSICS MED LIB DIV; REINECKE MA, 1994, EARLY DEV PARENTING, V3, P181; ROBERTS MA, 1996, OCCUPATIONAL ENV MED, P38; ROM WN, 1983, ENV OCCUPATIONAL MED, P3; TICHAUER ER, 1991, PATTYS IND HYGIENE B, V1, P743; VOLINI IF, 1995, CLASSICS MED LIB DIV; WALDRON HA, 1990, LECT NOTES OCCUPATIO; WELTER ES, 1988, OCCUPATIONAL MED, P62; WHO Geneva, 1998, WORLD HLTH REP 1998	21	41	42	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					858	861						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485743				2022-12-28	WOS:000082400700042
J	Yokouchi, Y; Vogan, KJ; Pearse, RV; Tabin, CJ				Yokouchi, Y; Vogan, KJ; Pearse, RV; Tabin, CJ			Antagonistic signaling by Caronte, a novel Cerberus-related gene, establishes left-right asymmetric gene expression	CELL			English	Article							SONIC-HEDGEHOG; NEURALIZING ACTIVITY; CHICK EMBRYOGENESIS; SECRETED FACTOR; PATHWAY; LIMB; CONSERVATION; INDUCTION; ENDODERM; HOMOLOG	Left-right asymmetry is initiated during chick embryogenesis in small domains near Hensen's node. Subsequently, broad asymmetric gene expression domains are established in the lateral plate mesoderm, ultimately determining the directionality of morphogenetic events. The transfer of asymmetric information from the node to the lateral plate is mediated by Caronte (Car), a navel member of the Cerberus/Dan gene family, which induces targets by antagonizing symmetrically expressed BMP signals. In addition, BMP antagonism by Car induces asymmetric expression of Lefty in the midline, preventing spread of left-sided signals to the contralateral side.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Nagoya Univ, Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan	Harvard University; Harvard Medical School; Nagoya University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			Vogan, Kyle/0000-0001-9565-9665; Pearse, Richard/0000-0003-3972-1457				Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LEVIN M, 1996, MOL BASIS LEFT RIGHT; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Marigo V, 1996, DEVELOPMENT, V122, P1225; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; RAMSDELL AF, 1999, IN PRESS DEVELOPMENT; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RODRIGUEZESTEBA.C, 1999, IN PRESS NATURE; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; THOMSEN HS, 1997, TRENDS GENET, V13, P209; Vogan KJ, 1999, NATURE, V397, P295, DOI 10.1038/16796; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; ZHU L, 1999, IN PRESS CURR BIOL	36	143	150	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					573	583		10.1016/S0092-8674(00)80045-8	http://dx.doi.org/10.1016/S0092-8674(00)80045-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490097	Bronze			2022-12-28	WOS:000082433500005
J	Wallentin, L; Swahn, E; Kontny, F; Husted, S; Lagerqvist, B; Stahle, E; Nielsen, JD; Dellborg, M; Geiran, O; Grande, P; Hulting, J; Kyst-Madsen, J; Nordrehaug, JE; Naslund, U; Pilegaard, H; Rollag, A; Nielsen, TT; Saetre, H; Siegbahn, A; Ohlin, H; Lagerqvist, B; Arbeus, M; Bylund, H; Ekstrom, L; Eriksson, P; Geiran, O; Holmgren, A; Kellerth, T; Kyst-Madsen, J; Lindblom, D; Lindvall, B; Nordrehaug, J; Pilegaard, H; Radegran, K; Sjogren, I; Stenport, G; Stahl, E; Svane, B; Svedjeholm, R; Toftegaard-Nielsen, T; Hassan, SY; Naslund, U; Persson, S; Jacobsson, KA; Thygesen, K; von der Lippe, G; Julian, D; Bertrand, M; Wedel, H; Andren, B; Diderholm, E; Frostfeldt, G; Jernberg, T; Dellborg, M; Abrahamsson, P; Lindahl, B; Jernberg, T; Siegbahn, A; Venge, P; Swahn, E; Janzon, M; Logander, E; Svensson, E; Lindstrom, G; Alsjo, G; Gulin, M; Setterberg, G; Wikstrom, L; M-Andersen, I; Seim, T				Wallentin, L; Swahn, E; Kontny, F; Husted, S; Lagerqvist, B; Stahle, E; Nielsen, JD; Dellborg, M; Geiran, O; Grande, P; Hulting, J; Kyst-Madsen, J; Nordrehaug, JE; Naslund, U; Pilegaard, H; Rollag, A; Nielsen, TT; Saetre, H; Siegbahn, A; Ohlin, H; Lagerqvist, B; Arbeus, M; Bylund, H; Ekstrom, L; Eriksson, P; Geiran, O; Holmgren, A; Kellerth, T; Kyst-Madsen, J; Lindblom, D; Lindvall, B; Nordrehaug, J; Pilegaard, H; Radegran, K; Sjogren, I; Stenport, G; Stahl, E; Svane, B; Svedjeholm, R; Toftegaard-Nielsen, T; Hassan, SY; Naslund, U; Persson, S; Jacobsson, KA; Thygesen, K; von der Lippe, G; Julian, D; Bertrand, M; Wedel, H; Andren, B; Diderholm, E; Frostfeldt, G; Jernberg, T; Dellborg, M; Abrahamsson, P; Lindahl, B; Jernberg, T; Siegbahn, A; Venge, P; Swahn, E; Janzon, M; Logander, E; Svensson, E; Lindstrom, G; Alsjo, G; Gulin, M; Setterberg, G; Wikstrom, L; M-Andersen, I; Seim, T		FRISC II Investigators	Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study	LANCET			English	Article							WAVE MYOCARDIAL-INFARCTION; ANGINA-PECTORIS; FOLLOW-UP; SURGERY; THROMBOLYSIS; ANGIOPLASTY; STRATEGIES; SURVIVAL; OUTCOMES; TRIAL	Background In unstable coronary-artery disease early invasive procedures are common, despite lack of evidence for the superiority of this approach. We compared an early invasive with a non-invasive treatment strategy in unstable coronary-artery disease. Methods In a prospective randomised multicentre study, we randomly assigned 2457 patients in 58 Scandinavian hospitals (median age 66 years, 70% men) an early invasive or non-invasive treatment strategy with placebo-controlled long-term low-molecular-mass heparin (dalteparin) for 3 months. Coronary angiography was done within the first 7 days in 96% and 10%, and revascularisation within the first 10 days in 71% and 9% of patients in the invasive and noninvasive groups, respectively. We followed up patients for 6 months. Analysis was by intention to treat. Findings After 6 months there was a decrease in the composite endpoint of death or myocardial infarction of 9.4% in the invasive group, compared with 12.1% in the noninvasive group (risk ratio 0.78 [95% CI 0.62-0.98], p=0.031). There was a significant decrease in myocardial infarction alone (7.8 vs 10.1%. 0.77 [0.60-0.99]; p=0.045) and non-significantly lower mortality (1.9 vs 2.9%, 0.65 [0.39-1.09]; p=0.10). Symptoms of angina and re-admission were halved by the invasive strategy. Results were independent of the randomised dalteparin treatment. The greatest advantages were seen in high-risk patients. Interpretation The early invasive approach should be the preferred strategy in most patients with unstable coronary-artery disease who have signs of ischaemia on electrocardiography or raised biochemical markers of myocardial damage.	Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Wallentin, L (corresponding author), Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, S-75185 Uppsala, Sweden.			Jernberg, Tomas/0000-0003-1695-379X				Abdelmeguid AE, 1996, CIRCULATION, V94, P3369, DOI 10.1161/01.CIR.94.12.3369; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; [Anonymous], 1994, AHCPR PUBL, V94-0592; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Brorsson B, 1997, EUR J CARDIO-THORAC, V12, P746, DOI 10.1016/S1010-7940(97)00089-4; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Campbell RWF, 1998, CLIN CARDIOL, V21, P314, DOI 10.1002/clc.4960210504; Chamberlain DA, 1997, LANCET, V350, P461; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; DEFEYTER PJ, 1985, NEW ENGL J MED, V313, P342, DOI 10.1056/NEJM198508083130602; Favaloro RG, 1998, CIRCULATION, V98, P466, DOI 10.1161/01.CIR.98.5.466; *FRISC 2 INV, 1999, LANCET, V354; LUCHI RJ, 1987, NEW ENGL J MED, V316, P977, DOI 10.1056/NEJM198704163161603; Madsen JK, 1997, CIRCULATION, V96, P748; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; NYMAN I, 1993, J INTERN MED, V234, P293, DOI 10.1111/j.1365-2796.1993.tb00746.x; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Simoons ML, 1997, LANCET, V349, P1429; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; Wallentin L, 1996, LANCET, V347, P561; Wood D, 1998, EUR HEART J, V19, P1434	24	951	986	0	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					708	715						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475181				2022-12-28	WOS:000082233000009
J	Donelly, PD				Donelly, PD			Potential problems for tenants	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales		Donelly, PD (corresponding author), Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					373	373						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490322				2022-12-28	WOS:000082001700029
J	Macklin, R				Macklin, R			The ethical problems with sham surgery in clinical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEVELOPING-COUNTRIES; PLACEBO ORTHODOXY; TRIALS; MYTHS		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Macklin, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							Advisory Committee on Human Radiation Experiments, 1996, FIN REP ADV COMM HUM; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Cohen Peter J, 1998, IRB, V20, P6, DOI 10.2307/3563555; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; KING NMP, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562155; Levit K R, 1985, Health Care Financ Rev, V7, P1; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Martin Douglas K, 1995, IRB, V17, P8, DOI 10.2307/3563530; Meslin Eric M, 1990, IRB, V12, P7, DOI 10.2307/3563683; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978, BELM REP ETH PRINC G; Orr RD, 1996, PSYCHIATR SERV, V47, P1262; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Stolberg Sheryl Gay, 1999, N Y Times Web, pF2; Stolberg Sheryl Gay, 1999, N Y Times Web, P3; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Williams Peter C, 1984, IRB, V6, P1, DOI 10.2307/3563870	25	197	200	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					992	996		10.1056/NEJM199909233411312	http://dx.doi.org/10.1056/NEJM199909233411312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498498				2022-12-28	WOS:000082658100012
J	Plsek, P				Plsek, P			Innovative thinking for the improvement of medical systems	ANNALS OF INTERNAL MEDICINE			English	Article								If health care systems are not delivering the desired results, those systems must be changed in some way. Innovative thinking is sometimes needed to generate ideas for improvement. Many persons erroneously believe that innovative thinking is a special gift or that it requires an air of lightheartedness that seems inappropriate in a health ca re setting. Current research in the cognitive sciences has yielded methods to help individual persons and groups generate innovative ideas. These methods do not require any special gift and can be practiced in a serious way. Through a case example from a health maintenance organization, this paper shows that, given some direction, groups of health care professionals can produce useful and innovative ideas. The tools of idea generation are based on three principles: mental attention, escape, and movement. Activities that help persons pay attention to their current situations in a different way, escape their current mental patterns about the situation, and maintain movement in their thoughts support efforts to generate innovative, testable ideas for health system improvements. This paper illustrates several methods of stimulating innovative thinking and shows the ways in which they can be applied in health care.	Paul E Plsek & Associates Inc, Roswell, GA 30075 USA		Plsek, P (corresponding author), Paul E Plsek & Associates Inc, 1005 Allenbrook Lane, Roswell, GA 30075 USA.							Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; Black R, 1995, BROKEN CRAYONS BREAK; Clemmer TP, 1998, ANN INTERN MED, V128, P1004, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00008; de Bono E., 1992, SERIOUS CREATIVITY; de Groot AD, 1965, THOUGHT CHOICE CHESS; Higgins J.M., 1994, 101 CREATIVE PROBLEM; Kauffman S., 1995, HOME UNIVERSE SEARCH; KOBERG D, 1972, ALL NEW UNIVERSAL TR; Kolb D. A, 2014, EXPERIENTIAL LEARNIN; MCGARTLAND G, 1994, THUNDERBOLT THINKING; Michalko M., 1991, THINKERTOYS HDB BUSI; Nolan TW, 1998, ANN INTERN MED, V128, P293, DOI 10.7326/0003-4819-128-4-199802150-00009; Plsek P E, 1994, Qual Manag Health Care, V2, P62; Plsek P. E., 1997, CREATIVITY INNOVATIO; PLSEK PE, 1998, REENGINEERING HLTH C; Polya G., 1957, SOLVE IT NEW ASPECT; POTTER MC, 1990, INVITATION COGNITIVE, V3; RUNCO MA, 1997, CREATIVITY RES HDB P; Senge PM, 2006, 5 DISCIPLINE ART PRA; Stacey R., 1996, COMPLEXITY CREATIVIT; STACEY RD, 1996, STRATEGIC MANAGEMENT; Sternberg R., 1988, NATURE CREATIVITY; TAYLOR CW, 1998, NATURE CREATIVITY; Van Oech Roger, 1986, KICK SEAT PANTS; VANGUNDY AB, 1992, IDEA POWER; VANOECH R, 1983, WHACK SIDE HEAD; Weisberg R. W., 1993, CREATIVITY MYTH GENI; Zimmerman B. J., 1998, EDGEWARE COMPLEXITY; [No title captured]	29	18	18	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					438	444		10.7326/0003-4819-131-6-199909210-00009	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498561				2022-12-28	WOS:000082641100007
J	Harrison, A				Harrison, A			All change?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					793	793		10.1136/bmj.319.7212.793	http://dx.doi.org/10.1136/bmj.319.7212.793			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488041	Green Published			2022-12-28	WOS:000082701500056
J	Leggatt, V; Mackay, J; Yates, JRW				Leggatt, V; Mackay, J; Yates, JRW			Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER		E Barnwell Hlth Ctr, Cambridge CB5 8SP, England; Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Leggatt, V (corresponding author), E Barnwell Hlth Ctr, Cambridge CB5 8SP, England.							Dunlop MG, 1997, BMJ-BRIT MED J, V314, P1882, DOI 10.1136/bmj.314.7098.1882; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Lalloo F, 1998, EUR J CANCER, V34, P937, DOI 10.1016/S0959-8049(98)00005-7; Mackay James, 1997, Cancer Treatment Reviews, V23, pS13, DOI 10.1016/S0305-7372(97)90003-7; Pharoah PDP, 1998, BRIT MED BULL, V54, P823	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					757	758		10.1136/bmj.319.7212.757	http://dx.doi.org/10.1136/bmj.319.7212.757			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488003	Green Published, Bronze			2022-12-28	WOS:000082701500022
J	Shepperd, S; Charnock, D; Gann, B				Shepperd, S; Charnock, D; Gann, B			Helping patients access high quality health information	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, Div Primary Care & Populat Hlth Sci, London W2 1PG, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England; Ctr Hlth Informat Qual, Winchester SO22 5DH, Hants, England	Imperial College London; University of Oxford	Shepperd, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, Div Primary Care & Populat Hlth Sci, London W2 1PG, England.	S.Shepperd@ic.ac.uk		Shepperd, Sasha/0000-0001-6384-8322				Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105; Charnock D, 1998, DISCERN HDB QUALITY; Coulter A, 1998, BMJ-BRIT MED J, V317, P225, DOI 10.1136/bmj.317.7153.225; COULTER A, 1998, INFORMING PATIENTS A; COULTER A, 1996, MANAGEMENT GEN PRACT, V20, P40; Dunning M, 1999, TURNING EVIDENCE EVE; Entwistle V A, 1998, J Health Serv Res Policy, V3, P100; Entwistle VA, 1996, INT J QUAL HEALTH C, V8, P425; EWLES L, 1995, PROMOTING HLTH PRACT; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Kim P, 1999, BMJ-BRIT MED J, V318, P647, DOI 10.1136/bmj.318.7184.647; MEADE CD, 1991, PATIENT EDUC COUNS, V17, P153, DOI 10.1016/0738-3991(91)90017-Y; *NHS EX, 1996, PAT PARTN BUILD COLL; NHS Executive, 1998, INF HLTH INF STRAT M; Rees AM, 1991, MANAGING CONSUMER HL; Secker J, 1995, WRITING LEAFLETS PAT; Sless D., 1997, WRITING MED PEOPLE U; SMITH T, 1992, BRIT MED J, V305, P1242, DOI 10.1136/bmj.305.6864.1242; WRIGHT P, 1998, WRITING TEXTS PROCES; 1999, MITRETEK SYSTEMS INN	21	114	121	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					764	766		10.1136/bmj.319.7212.764	http://dx.doi.org/10.1136/bmj.319.7212.764			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488009	Green Published			2022-12-28	WOS:000082701500026
J	Harbour, JW; Luo, RX; Santi, AD; Postigo, AA; Dean, DC				Harbour, JW; Luo, RX; Santi, AD; Postigo, AA; Dean, DC			Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1	CELL			English	Article							TRANSCRIPTIONAL REPRESSOR MOTIF; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; PRB PHOSPHORYLATION; PHASE-TRANSITION; E2F; FAMILY; BINDING; POCKET	We present evidence that phosphorylation of the C-terminal region of Rb by Cdk4/6 initiates successive intramolecular interactions between the C-terminal region and the central pocket. The initial interaction displaces histone deacetylase from the pocket, blocking active transcriptional repression by Rb. This facilitates a second interaction that leads to phosphorylation of the pocket by Cdk2 and disruption of pocket structure. These intramolecular interactions provide a molecular basis for sequential phosphorylation of Rb by Cdk4/6 and Cdk2. Cdk4/6 is activated early in G1, blocking active repression by Rb. However, it is not until near the end of G1, when cyclin E is expressed and Cdk2 is activated, that Rb is prevented from binding and inactivating E2F.	Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.	ddean@im.wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Adams PD, 1999, MOL CELL BIOL, V19, P1068; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 1996, ONCOGENE, V12, P1173; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; KATO J, 1993, GENE DEV, V7, P331; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, SCIENCE, V258, P424; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	49	791	820	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					859	869		10.1016/S0092-8674(00)81519-6	http://dx.doi.org/10.1016/S0092-8674(00)81519-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499802	Bronze			2022-12-28	WOS:000082679200012
J	O'Reilly, MS; Pirie-Shepherd, S; Lane, WS; Folkman, J				O'Reilly, MS; Pirie-Shepherd, S; Lane, WS; Folkman, J			Antiangiogenic activity of the cleaved conformation of the serpin antithrombin	SCIENCE			English	Article							SMALL CELL-CARCINOMA; ANGIOGENESIS; INHIBITOR; TUMORS; LUNG; ANGIOSTATIN; PEPTIDES; HEPARIN; CANCER; GROWTH	Antithrombin, a member of the serpin family, functions as an inhibitor of thrombin and other enzymes. Cleavage of the carboxyl-terminal Loop of antithrombin induces a conformational change in the molecule. Here it is shown that the cleaved conformation of antithrombin has potent antiangiogenic and antitumor activity in mouse models. The latent form of intact antithrombin, which is similar in conformation to the cleaved molecule, also inhibited angiogenesis and tumor growth. These data provide further evidence that the clotting and fibrinolytic pathways are directly involved in the regulation of angiogenesis.	Childrens Hosp, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Dept Surg, Microchem Facil, Cambridge, MA 02138 USA; Harvard Univ, Dept Cellular Biol, Microchem Facil, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Harvard Medical School	O'Reilly, MS (corresponding author), Childrens Hosp, Dept Surg, 16 Divin Ave, Cambridge, MA 02138 USA.	oreilly@hub.tch.harvard.edu			NCI NIH HHS [P01-CA45548, R01-CA64481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548, R01CA064481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1993, THROMB RES, V72, P193, DOI 10.1016/0049-3848(93)90186-R; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Colman RW, 1998, BLOOD, V92, p174A; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1988, AM J PATHOL, V133, P95; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; Folkman J, 1985, Important Adv Oncol, P42; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; ZACHARSKI LR, 1987, ONKOLOGIE, V10, P264, DOI 10.1159/000216419; ZACHARSKI LR, 1987, CANCER, V60, P2675, DOI 10.1002/1097-0142(19871201)60:11<2675::AID-CNCR2820601117>3.0.CO;2-C	25	387	423	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1926	1928		10.1126/science.285.5435.1926	http://dx.doi.org/10.1126/science.285.5435.1926			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489375				2022-12-28	WOS:000082638300055
J	Ames, RS; Sarau, HM; Chambers, JK; Willette, RN; Alyar, NV; Romanic, AM; Louden, CS; Foley, JJ; Sauermelch, CF; Coatney, RW; Ao, ZH; Disa, J; Holmes, SD; Stadel, JM; Martin, JD; Liu, WS; Glover, GI; Wilson, S; McNulty, DE; Ellis, CE; Elshourbagy, NA; Shabon, U; Trill, JJ; Hay, DWP; Ohlstein, EH; Bergsma, DJ; Douglas, SA				Ames, RS; Sarau, HM; Chambers, JK; Willette, RN; Alyar, NV; Romanic, AM; Louden, CS; Foley, JJ; Sauermelch, CF; Coatney, RW; Ao, ZH; Disa, J; Holmes, SD; Stadel, JM; Martin, JD; Liu, WS; Glover, GI; Wilson, S; McNulty, DE; Ellis, CE; Elshourbagy, NA; Shabon, U; Trill, JJ; Hay, DWP; Ohlstein, EH; Bergsma, DJ; Douglas, SA			Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14	NATURE			English	Article							CLONING; PEPTIDE; GENES; RATS	Urotensin-II (U-II) is a vasoactive 'somatostatin-like' cyclic peptide which was originally isolated from fish spinal cords(1,2), and which has recently been cloned from man(3). Here we describe the identification of an orphan human G-protein-coupled receptor homologous to rat GPR14 (refs 4, 5) and expressed predominantly in cardiovascular tissue, which functions as a U-II receptor. Goby and human U-II bind to recombinant human GPR14 with high affinity, and the binding is functionally coupled to calcium mobilization. Human U-II is found within both vascular and cardiac tissue (including coronary atheroma) and effectively constricts isolated arteries from non-human primates. The potency of vasoconstriction of U-II is an order of magnitude greater than that of endothelin-1, making human U-II the most potent mammalian vasoconstrictor identified so far. In vivo, human U-II markedly increases total peripheral resistance in anaesthetized non-human primates, a response associated with profound cardiac contractile dysfunction. Furthermore, as U-II immunoreactivity is also found within central nervous system and endocrine tissues, it may have additional activities.	SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm & Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Funct Gene Anal, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pathol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Lab Anim Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; USA & So Way, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Ames, RS (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Biol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Conlon JM, 1996, J EXP ZOOL, V275, P226, DOI 10.1002/(SICI)1097-010X(19960601/15)275:2/3<226::AID-JEZ14>3.3.CO;2-Y; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; DOUGLAS SA, 1991, BRIT J PHARMACOL, V104, P311, DOI 10.1111/j.1476-5381.1991.tb12428.x; Elshourbagy NA, 1998, ENDOCRINOLOGY, V139, P1678, DOI 10.1210/en.139.4.1678; GIBSON A, 1986, GEN COMP ENDOCR, V64, P435, DOI 10.1016/0016-6480(86)90080-8; HASEGAWA K, 1992, NEUROENDOCRINOL LETT, V14, P357; ITOH H, 1988, EUR J PHARMACOL, V149, P61, DOI 10.1016/0014-2999(88)90042-8; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Libert F, 1991, CURR OPIN CELL BIOL, V3, P218, DOI 10.1016/0955-0674(91)90142-L; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; OHSAKO S, 1986, J NEUROSCI, V6, P2730; PEARSON D, 1980, P NATL ACAD SCI-BIOL, V77, P5021, DOI 10.1073/pnas.77.8.5021; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TAL M, 1995, BIOCHEM BIOPH RES CO, V209, P752, DOI 10.1006/bbrc.1995.1563; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	19	713	865	3	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					282	286		10.1038/45809	http://dx.doi.org/10.1038/45809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499587				2022-12-28	WOS:000082678400055
J	Pizzo, PA				Pizzo, PA			Fever in immunocompromised patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTROPENIC PATIENTS; RANDOMIZED TRIAL; CANCER-PATIENTS; CHANGING EPIDEMIOLOGY; TRANSPLANT RECIPIENTS; EMPIRIC TREATMENT; UNKNOWN ORIGIN; INFECTION; CEFTAZIDIME		Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Pizzo, PA (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.							AQUINO VM, 1995, PEDIATR INFECT DIS J, V14, P140; Avery RK, 1998, CLEV CLIN J MED, V65, P305, DOI 10.3949/ccjm.65.6.305; BISSUEL F, 1994, J INTERN MED, V236, P529, DOI 10.1111/j.1365-2796.1994.tb00840.x; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; DEPAUW BE, 1994, ANN INTERN MED, V120, P834, DOI 10.7326/0003-4819-120-10-199405150-00004; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; Freifeld A, 1999, NEW ENGL J MED, V341, P305, DOI 10.1056/NEJM199907293410501; FREIFELD AG, 1995, J CLIN ONCOL, V13, P165, DOI 10.1200/JCO.1995.13.1.165; Freifeld Alison G., 1997, P2659; Gerard C, 1998, NATURE, V395, P217, DOI 10.1038/26104; Green M, 1992, Adv Pediatr Infect Dis, V7, P181; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; Kieff E, 1998, J Natl Cancer Inst Monogr, P7; KOLL BS, 1993, CLIN INFECT DIS   S2, V17, P322; Lehrnbecher T, 1997, J PEDIAT HEMATOL ONC, V19, P399, DOI 10.1097/00043426-199709000-00001; LEWIS LL, 1992, J PEDIATR-US, V121, P677, DOI 10.1016/S0022-3476(05)81892-X; Mackall CL, 1997, IMMUNOL REV, V160, P91, DOI 10.1111/j.1600-065X.1997.tb01030.x; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackowiak PA, 1997, CLIN INFECT DIS, V25, P119, DOI 10.1086/514520; MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2; Mayo J, 1997, SCAND J INFECT DIS, V29, P327, DOI 10.3109/00365549709011826; MIRALLES P, 1995, CLIN INFECT DIS, V20, P872, DOI 10.1093/clinids/20.4.872; PFALLER M, 1992, EUR J CLIN MICROBIOL, V11, P287, DOI 10.1007/BF01962067; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; PIZZO PA, IN PRESS CECIL TXB M; ROILIDES E, 1992, PEDIATR INFECT DIS J, V11, P547, DOI 10.1097/00006454-199207000-00008; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; RUBENSTEIN EB, 1993, CANCER-AM CANCER SOC, V71, P3640, DOI 10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H; SANDERS JW, 1991, J INFECT DIS, V164, P907, DOI 10.1093/infdis/164.5.907; WEINBERGER M, 1992, MEDICINE, V71, P24, DOI 10.1097/00005792-199201000-00003; WILFERT CM, 1998, PREDIAT AIDS CHALLEN, P117	32	159	173	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					893	900		10.1056/NEJM199909163411207	http://dx.doi.org/10.1056/NEJM199909163411207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10486422				2022-12-28	WOS:000082569100007
J	Vogt, M; Lang, T; Frosner, G; Klingler, C; Sendl, AF; Zeller, A; Wiebecke, B; Langer, B; Meisner, H; Hess, J				Vogt, M; Lang, T; Frosner, G; Klingler, C; Sendl, AF; Zeller, A; Wiebecke, B; Langer, B; Meisner, H; Hess, J			Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 49th	NOV 06-10, 1998	CHICAGO, ILLINOIS	Amer Assoc Study Liver Dis			NON-B-HEPATITIS; CHRONIC NON-A; VIRUS-INFECTION; LIVER-DISEASE; INTERFERON-ALFA; FOLLOW-UP; TRANSMISSION; ANTIBODIES; RIBAVIRIN; LEUKEMIA	Background and Methods There are few data on the prevalence and clinical outcome of hepatitis C infection in children. We studied 458 children who underwent cardiac surgery in Munich, Germany, before 1991, when blood-donor screening for hepatitis C was introduced in Germany. Their mean age at first operation was 2.8 years; none of the children had received blood transfusions before or after cardiac surgery, and none of their mothers had antibodies to hepatitis C virus (anti-HCV). We compared these patients with 458 control subjects matched for age and sex. Results Sixty-seven (14.6 percent) of the 458 patients who had undergone cardiac surgery had anti-HCV, as compared with 3 (0.7 percent) of the control subjects (P<0.001). At a mean interval of 19.8 years after the first operation, 37 (55 percent) of the 67 patients who were positive for anti-HCV had detectable HCV RNA in their blood. The infection had cleared in the other 30 patients, as evidenced by negative results on three polymerase-chain-reaction analyses performed at six-month intervals. Only 1 of the 37 patients who were positive for HCV RNA had elevated levels of liver enzymes; that patient had severe right-sided congestive heart failure. Of the 17 patients who underwent liver biopsies, only 3 had histologic signs of progressive liver damage. These three patients had additional risk factors: two had congestive heart failure, and the third had also been infected with hepatitis B virus. Conclusions Children who had undergone cardiac surgery in Germany before the implementation of blood-donor screening for hepatitis C had a substantial risk of acquiring the infection. However, after about 20 years, the virus had spontaneously cleared in many patients. The clinical course in those still infected seems more benign than would be expected in people infected as adults. (N Engl J Med 1999;341:866-70.) (C) 1999, Massachusetts Medical Society.	Childrens Univ Hosp, D-80337 Munich, Germany; Tech Univ Munich, Dept Pediat Cardiol, Munich, Germany; Tech Univ Munich, Dept Cardiac Surg, German Heart Ctr, Munich, Germany; Univ Munich, Inst Pathol, Munich, Germany; Max Von Pettenkofer Inst, D-8000 Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Technical University of Munich; German Heart Centre Munich; Technical University of Munich; University of Munich; University of Munich	Lang, T (corresponding author), Childrens Univ Hosp, Lindwurmstr 4, D-80337 Munich, Germany.							ARICO M, 1994, BLOOD, V84, P2919; Badizadegan K, 1998, HEPATOLOGY, V28, P1416, DOI 10.1002/hep.510280534; Bortolotti F, 1997, J PEDIATR-US, V130, P990, DOI 10.1016/S0022-3476(97)70289-0; Cesaro S, 1997, BLOOD, V90, P1315, DOI 10.1182/blood.V90.3.1315.1315_1315_1320; Chung JL, 1997, EUR J PEDIATR, V156, P546, DOI 10.1007/s004310050659; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DI BA, 1989, NEW ENGL J MED, V321, P1506; Fujisawa T, 1997, EUR J PEDIATR, V156, P773, DOI 10.1007/s004310050710; Gish RG, 1996, J PEDIATR GASTR NUTR, V22, P118, DOI 10.1097/00005176-199601000-00026; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Jonas MM, 1996, PEDIATRICS, V98, P211; Kage M, 1997, HEPATOLOGY, V26, P771, DOI 10.1002/hep.510260333; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Locasciulli A, 1997, BLOOD, V90, P4628; Mathurin P, 1998, HEPATOLOGY, V27, P868, DOI 10.1002/hep.510270333; Matsuoka S, 1997, EUR J PEDIATR, V156, P704, DOI 10.1007/s004310050694; MATSUOKA S, 1994, J PAEDIATR CHILD H, V30, P544, DOI 10.1111/j.1440-1754.1994.tb00731.x; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Misra S, 1996, J GASTROEN HEPATOL, V11, pS4, DOI 10.1111/j.1440-1746.1996.tb00282.x; Nelson SP, 1996, J PEDIATR SURG, V31, P644, DOI 10.1016/S0022-3468(96)90665-X; Pocock SJ., 2013, CLIN TRIALS PRACTICA; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; RESTI M, 1992, EUR J PEDIATR, V151, P573, DOI 10.1007/BF01957724; Sasaki N, 1997, PEDIATR RES, V42, P263, DOI 10.1203/00006450-199709000-00003; SCHLEBUSCH H, 1974, DEUT MED WOCHENSCHR, V99, P765, DOI 10.1055/s-0028-1107840; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Serfaty L, 1996, GASTROENTEROLOGY, V110, P291, DOI 10.1053/gast.1996.v110.pm8536870; Tada H, 1997, TRANSFUSION, V37, P641, DOI 10.1046/j.1537-2995.1997.37697335160.x; TAKAHASHI M, 1991, GASTROENTEROL JPN, V26, P483; Tobler LH, 1997, CLIN CHEM, V43, P1487; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5	36	364	370	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					866	870		10.1056/NEJM199909163411202	http://dx.doi.org/10.1056/NEJM199909163411202			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10498458				2022-12-28	WOS:000082569100002
J	Boers, M				Boers, M			Combination therapy in rheumatoid arthritis	LANCET			English	Letter									Free Univ Amsterdam Hosp, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Boers, M (corresponding author), Free Univ Amsterdam Hosp, Dept Clin Epidemiol & Biostat, POB 7057, NL-1007 MB Amsterdam, Netherlands.							Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4	3	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					952	952		10.1016/S0140-6736(05)75700-7	http://dx.doi.org/10.1016/S0140-6736(05)75700-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489981				2022-12-28	WOS:000082511800058
J	Selhub, J; Jacques, PF; Rosenberg, IH; Rogers, G; Bowman, BA; Gunter, EW; Wright, JD; Johnson, CL				Selhub, J; Jacques, PF; Rosenberg, IH; Rogers, G; Bowman, BA; Gunter, EW; Wright, JD; Johnson, CL			Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations	ANNALS OF INTERNAL MEDICINE			English	Article							PLASMA TOTAL HOMOCYSTEINE; FOLIC-ACID; COBALAMIN DEFICIENCY; REFERENCE INTERVALS; METHYLMALONIC ACID; ELDERLY POPULATION; VASCULAR-DISEASE; BRITISH MEN; RISK; HYPERHOMOCYSTEINEMIA	Background: The concentration of circulating total homocysteine is a sensitive marker of inadequate folate and vitamin B-12 status. Elevated homocysteine concentrations are associated with an increased risk for vascular disease. Objective: To identify reference ranges for serum total homocysteine concentration in U.S. residents and quantify the contribution of circulating vitamin concentrations to high homocysteine concentrations. Design: Cross-sectional prevalence study. Setting: United States. Patients: A nationally representative sample of 3563 male participants and 4523 female participants 12 years of age or older who participated in the third National Health and Nutrition Examination Survey. Measurements: Reference ranges (5th and 95th percentiles) for the total homocysteine concentration were defined among participants who were folate- and vitamin B-12-replete and had normal creatinine concentrations. A high total homocysteine concentration was defined as one that exceeded the sex-specific 95th percentile for the reference sample (participants 20 to 39 years of age). The population attributable risk percentage was calculated to determine the contribution of low folate (<11 nmol/L) and vitamin B-12 (<185 pmol/L) concentrations to a high homocysteine concentration. Results: Reference ranges for serum total homocysteine concentration increased with age; these ranges were 4.3 to 9.9 mu mol/L for male participants and 3.3 to 7.2 mu mol/L for female participants 12 to 19 years of age and from 5.9 to 15.3 mu mol/L for men and 4.9 to 11.6 mu mol/L for women 60 years of age or older. A high homocysteine concentration was defined as at least 11.4 mu mol/L for male participants and at least 10.4 mu mol/L for female participants. Approximately two thirds of the cases of high homocysteine concentrations were associated with low vitamin concentrations. Conclusions: Upper reference limits for the serum total homocysteine concentration increased with age and were higher for male participants than for female participants at all ages. In most cases, high homocysteine concentrations were associated with low serum vitamin concentrations.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Ctr Dis Control & Prevent, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Environm Hlth Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Tufts University; United States Department of Agriculture (USDA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Selhub, J (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.				NHLBI NIH HHS [R01 HL52630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Bates CJ, 1997, EUR J CLIN NUTR, V51, P691, DOI 10.1038/sj.ejcn.1600468; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; Chambers J. M., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Gunter EW, 1996, LAB PROCEDURES USED; Guttormsen AB, 1997, KIDNEY INT, V52, P495, DOI 10.1038/ki.1997.359; Herbert V, 1999, MODERN NUTR HLTH DIS, P433; Jacques PF, 1999, AM J CLIN NUTR, V69, P482; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Joosten E, 1996, EUR J HAEMATOL, V57, P222; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Mijatovic V, 1998, OBSTET GYNECOL, V91, P432, DOI 10.1016/S0029-7844(97)00704-7; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Rasmussen K, 1996, CLIN CHEM, V42, P630; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; ROSENBERG IH, 1992, AM J CLIN NUTR, V55, P1237; *SAS I INC, 1996, SAS SYST WIND VERS 6; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Selhub J., 1996, PRESENT KNOWLEDGE NU, P206; Shah BV, 1996, SUDAAN USERS MANUAL; *SPSS INC, 1997, SYSTAT 7 0 WIND; *THREE NAT HLTH NU, 1996, REF MAN REP WEIGHT E; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; UBBINK JB, 1995, CLIN CHEM, V41, P1033; *US DEP HHS, 1994, DHHS PUBL PHS; Weir D. G., 1999, MODERN NUTR HLTH DIS, P447; WILCKEN DEL, 1988, METABOLISM, V37, P697, DOI 10.1016/0026-0495(88)90093-5; Wright J.D., 1998, VITAL HLTH STAT, V11, P1; 1997, MMWR MORB MORTAL WKL, V46, P721	41	302	320	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					331	+		10.7326/0003-4819-131-5-199909070-00003	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475885				2022-12-28	WOS:000082458500002
J	Ferry, LH; Grissino, LM; Runfola, PS				Ferry, LH; Grissino, LM; Runfola, PS			Tobacco dependence curricula in US undergraduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING-CESSATION; UNITED-STATES; STUDENTS; PHYSICIANS; QUIT	Context Tobacco use is the leading preventable cause of death in the United States. And yet only 21% of practicing physicians claim they received adequate training to help their patients stop smoking. Objective To assess the content and extent of tobacco education and intervention skills in US medical schools' curricula. Design A survey with 13 multiple-response items on tobacco education, Survey questions were based on the recommendations of the Agency for Health Care Policy and Research and the National Cancer Institute Expert Panel, The Liaison Committee on Medical Education included 4 of these items in a modified form on the 1997 annual questionnaire. Setting One hundred twenty-six US medical schools. Participants Surveys were obtained from 122 associate deans for medical education (98.6%), Main Outcome Measures Curriculum content in basic science and clinical science, elective or required clinical experience, hours of instruction, and resource materials, Results Inclusion of all 6 tobacco curricula content areas recommended by the National Cancer Institute and the Agency for Health Care Policy and Research was higher in basic science (63/115 [54.8%]) than in clinical science (5/115 [4.4%]). Most medical schools (83/120 [69.2%]) did not require clinical training in smoking cessation techniques, while 23.5% (27/115) offered additional experience as an elective course, Thirty-one percent (32/102) of schools averaged less than 1 hour of instruction per year in smoking cessation techniques during the 4 years of medical school. A minority of schools reported 3 or more hours of clinical smoking cessation instruction in the third (14.7%) and fourth (4.9%) years. Conclusions A majority of US medical school graduates are not adequately trained to treat nicotine dependence. The major deficit is the lack of smoking cessation instruction and evaluation in the clinical years. A model core tobacco curricula that meets national recommendations should be developed and implemented in all US medical schools.	Loma Linda Univ, Sch Med, Dept Prevent Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Publ Hlth, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Ferry, LH (corresponding author), Loma Linda Univ, Sch Med, Dept Prevent Med, Nichol Hall,Room 1516, Loma Linda, CA 92350 USA.							ALLEN SS, 1990, AM J PREV MED, V6, P28, DOI 10.1016/S0749-3797(18)31041-9; *AM AC FAM PHYS, 1987, STOP SMOK KIT; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P854; COULTAS DB, 1994, ACAD MED, V69, pS48, DOI 10.1097/00001888-199410000-00039; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P624, DOI 10.1001/jama.271.8.624; GLYNN TJ, 1993, NIH PUBLICATION; GOLDSTEIN MG, 1989, PROJECT ADEPT CURRIC; HORTON J, 1986, CANCER DETECT PREV, V9, P417; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Richmond R, 1997, ED MED STUDENTS TOBA, P281; Richmond RL, 1998, TOB CONTROL, V7, P247, DOI 10.1136/tc.7.3.247; U. S. Department of Health and Human Services, 1998, HLTH PEOPL 2010 OBJ; [U.S. Department of Health and Human Services Public Health Service Agency], 1996, AHCPR PUBL; U. S. Department of Health and Human Services Public Health Service Office of Disease Prevention and Health Promotion., 1994, CLIN HDB PREV SERV P; *US DEP HHS, 1995, HLTH PEOPL 2000 MIDC; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VARNER KF, 1996, DIRECTORY AM MED ED	19	154	157	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					825	829		10.1001/jama.282.9.825	http://dx.doi.org/10.1001/jama.282.9.825			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478687	Bronze			2022-12-28	WOS:000082272200006
J	Yao, Y; Ferrer-Montiel, AV; Montal, M; Tsien, RY				Yao, Y; Ferrer-Montiel, AV; Montal, M; Tsien, RY			Activation of store-operated Ca2+ current in Xenopus oocytes requires SNAP-25 but not a diffusible messenger	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; 3T3-L1 ADIPOCYTES; SNARE-COMPLEX; INOSITOL TRISPHOSPHATE; LAEVIS OOCYTES; RHO-GTPASES; G-PROTEIN; INFLUX; MEMBRANE; CELLS	Depletion of Ca2+ stores in Xenopos oocytes activated entry of Ca2+ across the plasma membrane, which was measured as a current I-soc in subsequently formed cell-attached patches. I-soc survived excision into inside-out configuration. If cell-attached patches were formed before store depletion, I-soc was activated outside but not inside the patches. I-soc was potentiated by microinjection of Clostridium C3 transferase, which inhibits Rho GTPase, whereas I-soc was inhibited by expression of wild-type or constitutively active Rho. Activation of I-soc was also inhibited by botulinum neurotoxin A and dominant-negative mutants of SNAP-25 but was unaffected by brefeldin A. These results suggest that oocyte I-soc is dependent not on aqueous diffusible messengers but on SNAP-25, probably via exocytosis of membrane channels or regulatory molecules.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607	NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; Calakos N, 1996, PHYSIOL REV, V76, P1; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; Ferrer-Montiel AV, 1998, FEBS LETT, V435, P84, DOI 10.1016/S0014-5793(98)01012-6; FerrerMontiel AV, 1996, J BIOL CHEM, V271, P18322, DOI 10.1074/jbc.271.31.18322; Fomina AF, 1999, J NEUROSCI, V19, P3711; Gregory RB, 1996, BIOCHEM J, V319, P755, DOI 10.1042/bj3190755; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hilgemann Donald W., 1995, P307; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Holda JR, 1998, NEWS PHYSIOL SCI, V13, P157; Huang XH, 1998, MOL ENDOCRINOL, V12, P1060, DOI 10.1210/me.12.7.1060; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Putney JW, 1999, BIOESSAYS, V21, P38; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SOKABE M, 1990, J CELL BIOL, V111, P599, DOI 10.1083/jcb.111.2.599; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandenBerghe N, 1996, BIOCHEM BIOPH RES CO, V229, P430, DOI 10.1006/bbrc.1996.1821; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	57	225	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					475	485		10.1016/S0092-8674(00)81976-5	http://dx.doi.org/10.1016/S0092-8674(00)81976-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481912	Bronze			2022-12-28	WOS:000082174900008
J	Eisenberg, D				Eisenberg, D			Structural biology - How chaperones protect virgin proteins	SCIENCE			English	Editorial Material									Univ Calif Los Angeles, DOE Lab Stuct Biol & Mol Med, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, DOE Lab Stuct Biol & Mol Med, Los Angeles, CA 90095 USA.							BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ellis RJ, 1999, CURR BIOL, V9, pR137; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FERSHT A, 1999, STRUCTURE MECHANISM, P603; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Wang JD, 1999, NAT STRUCT BIOL, V6, P597	10	12	14	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1021	1022		10.1126/science.285.5430.1021	http://dx.doi.org/10.1126/science.285.5430.1021			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10475844				2022-12-28	WOS:000082033100030
J	Delaney, BC; Hyde, CJ; McManus, RJ; Wilson, S; Fitzmaurice, DA; Jowett, S; Tobias, R; Thorpe, GH; Hobbs, FDR				Delaney, BC; Hyde, CJ; McManus, RJ; Wilson, S; Fitzmaurice, DA; Jowett, S; Tobias, R; Thorpe, GH; Hobbs, FDR			Systematic review of near patient test evaluations in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTIONS; DESK-TOP ANALYZERS; GENERAL-PRACTICE; HELICOBACTER-PYLORI; DIAGNOSTIC-TEST; STREPTOCOCCAL PHARYNGITIS; MEDICAL LITERATURE; PROTHROMBIN TIME; DIPSTICK TEST; USERS GUIDES	Objective To identify and qualitatively synthesise the findings from all studies that have examined the performance and effect of near patient tests in the primary care setting. Design systematic review of published and unpublished research 1986-99. Main outcome measures Test performance characteristics, measures of effect on clinical practice or patient outcome. Results 101 relevant publications were identified. The general quality of these papers was low,and consequently only 32 papers were assessed in detail. Although these papers gave some indication of the value of near patient testing in areas such as anticoagulation monitoring and group A beta haemolytic streptococcus testing, the research raised many more questions than it answered. Almost no reports were found of unbiased assessment of the effect of near patient tests in primary care on patient outcomes, organisational outcomes, or cost. Conclusions Available research provides little evidence to guide the expansion of use of near patient testing in primary care. Further research is needed in areas of clinical practice where near patient tests might be most beneficial.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Wolfson Appl Technol Lab, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Hobbs, FDR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	f.d.r.hobbs@bham.ac.uk	Jowett, Sue/AAO-4198-2021; Delaney, Brendan C/C-5578-2008	Jowett, Sue/0000-0001-8936-3745; hobbs, richard/0000-0001-7976-7172; Christopher, Hyde/0000-0002-7349-0616; Delaney, Brendan/0000-0002-3518-0131				ANDERSEN J S, 1992, Scandinavian Journal of Primary Health Care, V10, P223, DOI 10.3109/02813439209014065; ANDERSON DR, 1993, ARCH INTERN MED, V153, P1441, DOI 10.1001/archinte.153.12.1441; *ASS CLIN BIOCH, 1993, GUID IMPL NEAR PAT T; Banchongaksorn Trairat, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P243; BLOCH MJ, 1988, JAMA-J AM MED ASSOC, V260, P230, DOI 10.1001/jama.260.2.230; Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9; DAVIAUD J, 1993, CLIN CHEM, V39, P53; DEGRAUW WJC, 1995, DIABETIC MED, V12, P657; DELANEY BC, 1995, FAM PRACT, V12, P263; DENEEF P, 1986, J FAM PRACTICE, V22, P215; DINANT G J, 1989, Scandinavian Journal of Primary Health Care, V7, P231, DOI 10.3109/02813438909088670; DITCHBURN RK, 1990, BRIT J GEN PRACT, V40, P406; ERICKSON KA, 1993, CLIN CHEM, V39, P283; FISCHER PM, 1991, J FAM PRACTICE, V33, P453; Fitzmaurice DA, 1998, FAM PRACT, V15, P144, DOI 10.1093/fampra/15.2.144; Hackelsberger A, 1998, HELICOBACTER, V3, P179, DOI 10.1046/j.1523-5378.1998.08002.x; HILTON S, 1990, BRIT J GEN PRACT, V40, P32; Hjortdahl P, 1990, Scand J Prim Health Care, V8, P188, DOI 10.3109/02813439008994956; HJORTDAHL P, 1991, Scandinavian Journal of Primary Health Care, V9, P3, DOI 10.3109/02813439109026574; HOBBS FD, 1997, HLTH TECHNOL ASSESS, V1; HOBBS FDR, 1992, BRIT J GEN PRACT, V42, P317; Hobbs R, 1996, BRIT MED J, V312, P263; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Jones R, 1997, ALIMENT PHARM THERAP, V11, P101, DOI 10.1046/j.1365-2036.1997.125296000.x; Kendall J, 1998, BRIT MED J, V316, P1052; KOCH TR, 1987, CLIN CHEM, V33, P2262; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; Lilford RJ, 1998, BMJ-BRIT MED J, V317, P405; MCCURDY SA, 1992, ARCH INTERN MED, V152, P589, DOI 10.1001/archinte.152.3.589; McManus RJ, 1998, BMJ-BRIT MED J, V317, P1562, DOI 10.1136/bmj.317.7172.1562; MESSING EM, 1989, CANCER, V64, P2361, DOI 10.1002/1097-0142(19891201)64:11<2361::AID-CNCR2820641128>3.0.CO;2-4; NANJI AA, 1988, CAN MED ASSOC J, V138, P517; NEVILLE RG, 1987, BRIT MED J, V294, P1263, DOI 10.1136/bmj.294.6582.1263; PHILLIPS S, 1988, MED J AUSTRALIA, V149, P122, DOI 10.5694/j.1326-5377.1988.tb120533.x; POPE RM, 1993, DIABETIC MED, V10, P260, DOI 10.1111/j.1464-5491.1993.tb00054.x; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; RINK E, 1993, BRIT MED J, V307, P775, DOI 10.1136/bmj.307.6907.775; ROSE VL, 1993, ARCH PATHOL LAB MED, V117, P611; SANDS VM, 1995, ACAD EMERG MED, V2, P172, DOI 10.1111/j.1553-2712.1995.tb03190.x; Seamark DA, 1997, J ROY SOC MED, V90, P657, DOI 10.1177/014107689709001206; SONDENAA K, 1992, SCAND J CLIN LAB INV, V52, P585, DOI 10.3109/00365519209115500; Stahl M, 1997, CLIN CHEM, V43, P1926; Talley NJ, 1998, ALIMENT PHARM THERAP, V12, P641; TRUE BL, 1986, J FAM PRACTICE, V23, P215; TSAI W, 1994, CLIN THER, V16, P198; VALENSTEIN PN, 1990, AM J CLIN PATHOL, V93, P252, DOI 10.1093/ajcp/93.2.252; WEGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695, DOI 10.1001/jama.267.5.695; *WHO REG OFF EUR, 1989, ROL LAB MED PRIM HLT; WINKENS RAG, 1995, FAM PRACT, V12, P290, DOI 10.1093/fampra/12.3.290; WRIGHT A, 1987, J FAM PRACTICE, V25, P505	51	51	48	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					824	827		10.1136/bmj.319.7213.824	http://dx.doi.org/10.1136/bmj.319.7213.824			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496828	Bronze, Green Published			2022-12-28	WOS:000082865200027
J	Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH				Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH			Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; RISK		Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark; Aarhus Univ Hosp, Dept Med 5, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danish Cancer Society; Aarhus University; Aarhus University	Mellemkjaer, L (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Olsen, Jorgen Helge/0000-0001-9633-5662				JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; POULTER NR, 1995, LANCET, V346, P1575; Spitzer WO, 1996, BRIT MED J, V312, P83; Thomas SHL, 1996, LANCET, V348, P402, DOI 10.1016/S0140-6736(05)65016-7; Vandenbroucke JP, 1996, LANCET, V348, P401, DOI 10.1016/S0140-6736(96)24032-2	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					820	821		10.1136/bmj.319.7213.820	http://dx.doi.org/10.1136/bmj.319.7213.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496825	Bronze, Green Published			2022-12-28	WOS:000082865200023
J	Price, VH				Price, VH			Treatment of hair loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BENIGN PROSTATIC HYPERPLASIA; 2-PERCENT TOPICAL MINOXIDIL; MALE PATTERN BALDNESS; ALLERGIC CONTACT-DERMATITIS; SEVERE ALOPECIA-AREATA; LONG-TERM EFFICACY; ANDROGENETIC ALOPECIA; 5-ALPHA-REDUCTASE INHIBITOR; MALE PSEUDOHERMAPHRODITISM; TESTOSTERONE-METABOLISM		Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Price, VH (corresponding author), 350 Parnassus Ave,Ste 404, San Francisco, CA 94117 USA.							ABELL E, 1994, DISORDERS HAIR GROWT, P1; Andriole GL, 1998, UROLOGY, V52, P195, DOI 10.1016/S0090-4295(98)00184-8; BERGFELD WF, 1995, AM J MED, V98, pS95, DOI 10.1016/S0002-9343(99)80065-5; BUCHNER U, 1979, ARCH DERMATOL RES, V264, P123; BUHL AE, 1989, J INVEST DERMATOL, V92, P315, DOI 10.1111/1523-1747.ep12277095; BUHL AE, 1991, J INVEST DERMATOL, V96, pS73, DOI 10.1111/1523-1747.ep12471911; CASH TF, 1993, J AM ACAD DERMATOL, V29, P568, DOI 10.1016/0190-9622(93)70223-G; CASH TF, 1992, J AM ACAD DERMATOL, V26, P926, DOI 10.1016/0190-9622(92)70134-2; COLOMBE BW, 1995, J AM ACAD DERMATOL, V33, P757; COLOMBE BW, IN PRESS J INVEST DE; COSKEY R, 1992, J AM ACAD DERMATOL, V26, P247; DALLOB AL, 1994, J CLIN ENDOCR METAB, V79, P703, DOI 10.1210/jc.79.3.703; DEVILLEZ RL, 1994, ARCH DERMATOL, V130, P303, DOI 10.1001/archderm.130.3.303; DIANI AR, 1992, J CLIN ENDOCR METAB, V74, P345, DOI 10.1210/jc.74.2.345; EBNER H, 1995, CONTACT DERMATITIS, V32, P316, DOI 10.1111/j.1600-0536.1995.tb00798.x; Fiedler VC, 1996, DERMATOL CLIN, V14, P733, DOI 10.1016/S0733-8635(05)70399-5; FIEDLER VC, 1992, ARCH DERMATOL, V128, P1519, DOI 10.1001/archderm.128.11.1519; FIEDLERWEISS VC, 1987, J AM ACAD DERMATOL, V16, P745, DOI 10.1016/S0190-9622(87)80003-8; FIELDERWEISS VC, 1987, ARCH DERMATOL, V123, P1491; FIELDLERWEISS VC, 1986, ARCH DERMATOL, V122, P180; FRIEDEN IJ, 1986, PATHOGENESIS SKIN DI, P41; Gilhar A, 1998, J CLIN INVEST, V101, P62, DOI 10.1172/JCI551; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GRIFFIN JE, 1989, METABOLIC BASIS INHE, V2, P1919; HAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708, DOI 10.1111/j.1749-6632.1951.tb31971.x; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HAPPLE R, 1983, ACTA DERM-VENEREOL, V63, P49; HAPPLE R, 1991, J INVEST DERMATOL, V96, pS71, DOI 10.1111/1523-1747.ep12471884; HEADINGTON JT, 1984, CURR THER RES CLIN E, V36, P1098; HEADINGTON JT, 1993, ARCH DERMATOL, V129, P356, DOI 10.1001/archderm.129.3.356; Hoffmann R, 1996, DERMATOL CLIN, V14, P739, DOI 10.1016/S0733-8635(05)70400-9; HULL SM, 1991, BRIT J DERMATOL, V125, P164, DOI 10.1111/j.1365-2133.1991.tb06064.x; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; IMPERATOMCGINLEY J, 1991, CLIN ENDOCRINOL, V34, P293, DOI 10.1111/j.1365-2265.1991.tb03769.x; JACOBS JP, 1993, INT J DERMATOL, V32, P758, DOI 10.1111/j.1365-4362.1993.tb02755.x; KATZ HI, 1987, J AM ACAD DERMATOL, V16, P711; Kaufman KD, 1996, DERMATOL CLIN, V14, P697, DOI 10.1016/S0733-8635(05)70396-X; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; Keetch DW, 1997, UROLOGY, V50, P901, DOI 10.1016/S0090-4295(97)00453-6; KHOURY EL, 1992, J INVEST DERMATOL, V99, P40, DOI 10.1111/1523-1747.ep12611409; KREINDLER TG, 1987, J AM ACAD DERMATOL, V16, P718, DOI 10.1016/S0190-9622(87)70093-0; KUBILUS J, 1987, J AM ACAD DERMATOL, V16, P648, DOI 10.1016/S0190-9622(87)70082-6; KUSTER W, 1984, J AM ACAD DERMATOL, V11, P921, DOI 10.1016/S0190-9622(84)80498-3; Leyden J, 1999, J AM ACAD DERMATOL, V40, P930, DOI 10.1016/S0190-9622(99)70081-2; LIANG T, 1984, J BIOL CHEM, V259, P734; LOBO RA, 1985, FERTIL STERIL, V43, P200; LUDWIG E, 1977, BRIT J DERMATOL, V97, P247, DOI 10.1111/j.1365-2133.1977.tb15179.x; Matzkin H, 1996, BRIT J UROL, V78, P405, DOI 10.1046/j.1464-410X.1996.00143.x; *MERCK, 1997, PHYS CIRC PROP; MESSENGER AG, 1997, DIS HAIR SCALP, P1; MONTAGNA W, 1974, STRUCTURE FUNCTION S, P186; MORHENN VB, 1983, J INVEST DERMATOL, V81, P23, DOI 10.1111/1523-1747.ep12537586; Olsen E.A., 1994, DISORDERS HAIR GROWT, P257; OLSEN EA, 1990, J AM ACAD DERMATOL, V22, P643, DOI 10.1016/0190-9622(90)70089-Z; OLSEN EA, 1992, ARCH DERMATOL, V128, P1467, DOI 10.1001/archderm.128.11.1467; ORECCHIA G, 1994, PEDIATR DERMATOL, V11, P65, DOI 10.1111/j.1525-1470.1994.tb00078.x; *PHARM UPJ, 1997, ROG EXTR STRENGTH ME; Philpott MP, 1996, DERMATOL CLIN, V14, P595, DOI 10.1016/S0733-8635(05)70387-9; PRICE V H, 1987, Dermatologica (Basel), V175, P36; PRICE VH, 1990, J INVEST DERMATOL, V95, P683, DOI 10.1111/1523-1747.ep12514348; PRICE VH, 1975, ARCH DERMATOL, V111, P1496, DOI 10.1001/archderm.111.11.1496; PRICE VH, 1987, J AM ACAD DERMATOL, V16, P737, DOI 10.1016/S0190-9622(87)70096-6; PRICE VH, 1996, J AM ACAD DERMATOL, V35, P465; PRICE VH, IN PRESS J AM ACAD D; RANDALL VA, 1991, ANN NY ACAD SCI, V642, P355; RIETSCHEL RL, 1987, J AM ACAD DERMATOL, V16, P677, DOI 10.1016/S0190-9622(87)70087-5; RITTMASTER RS, 1994, NEW ENGL J MED, V330, P120; ROBERTS J, 1998, HAIR WORKSH BRUSS BE, P16; SAFAVI KH, 1995, MAYO CLIN PROC, V70, P628, DOI 10.4065/70.7.628; Sawaya M E, 1995, J Invest Dermatol, V104, p30S; Sawaya ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.ep12335779; SCHWEIKERT HU, 1974, J CLIN ENDOCR METAB, V38, P811, DOI 10.1210/jcem-38-5-811; SHAPIRO J, 1993, DERMATOL CLIN, V11, P611, DOI 10.1016/S0733-8635(18)30254-7; Shapiro J, 1998, DERMATOL CLIN, V16, P341, DOI 10.1016/S0733-8635(05)70017-6; SHAPIRO J, 1993, DERMATOL CLIN, V11, P35, DOI 10.1016/S0733-8635(18)30280-8; STONER E, 1990, J STEROID BIOCHEM, V37, P375, DOI 10.1016/0960-0760(90)90487-6; SWANSON NA, 1981, ARCH DERMATOL, V117, P384, DOI 10.1001/archderm.117.7.384; TODESTAYLOR N, 1984, J AM ACAD DERMATOL, V11, P216, DOI 10.1016/S0190-9622(84)70152-6; Tosti A, 1996, J AM ACAD DERMATOL, V35, P199, DOI 10.1016/S0190-9622(96)90323-0; TOSTI A, 1985, CONTACT DERMATITIS, V13, P275; TRANCIK R, IN PRESS J INVEST DE; UNO H, 1986, SEMIN REPROD ENDOCR, V4, P131, DOI 10.1055/s-2007-1022494; UNO H, 1985, AM J DERMATOPATH, V7, P283, DOI 10.1097/00000372-198506000-00012; VANDERSTEEN P, 1992, ARCH DERMATOL, V128, P518, DOI 10.1001/archderm.128.4.518; VANDERSTEEN PHM, 1991, J AM ACAD DERMATOL, V24, P253, DOI 10.1016/0190-9622(91)70037-3; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806; WELSH EA, 1994, J INVEST DERMATOL, V103, P758, DOI 10.1111/1523-1747.ep12412584; Whiting DA, 1996, DERMATOL CLIN, V14, P723, DOI 10.1016/S0733-8635(05)70398-3; WHITING DA, 1993, J AM ACAD DERMATOL, V29, P554; WHITING DA, 1993, J AM ACAD DERMATOL, V28, P755, DOI 10.1016/0190-9622(93)70106-4; WILSON C, 1991, J AM ACAD DERMATOL, V24, P661, DOI 10.1016/S0190-9622(08)80171-5	91	239	254	4	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					964	973		10.1056/NEJM199909233411307	http://dx.doi.org/10.1056/NEJM199909233411307			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498493				2022-12-28	WOS:000082658100007
J	Fischer, D; Stewart, AL; Bloch, DA; Lorig, K; Laurent, D; Holman, H				Fischer, D; Stewart, AL; Bloch, DA; Lorig, K; Laurent, D; Holman, H			Capturing the patient's view of change as a clinical outcome measure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; HEALTH ASSESSMENT QUESTIONNAIRE; MINIMAL IMPORTANT DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID-ARTHRITIS; SENSITIVITY; CARE; SATISFACTION; ENCOUNTERS; MANAGEMENT	Context Measurement of change in patients' health status is central to both clinical trials and clinical practice. Trials commonly use serial measurements by the patients at 2 points in time while clinicians use the patient's retrospective assessment of change made at 1 point in time. How well these measures correlate is not known. Objective To compare the 2 methods in measurement of changes in pain and disability. Design Longitudinal survey of patients starting new therapy for chronic arthritis in 1994 and 1995, Surveys were completed at baseline (before intervention) and at 6 weeks and 4 months. Setting Community health education program and university medical and orthopedic services. Subjects A total of 202 patients undertaking self-management education (n = 140), therapy with prednisone or methotrexate; (n = 34), or arthroplasty of the knee or hip (n = 28). Main Outcome Measures Concordance between serial (visual analog scale for pain and Health Assessment Questionnaire for disability) and retrospective (7-point Likert scale) measures, sensitivities of these measures, and their correlation with patients' satisfaction with the change (7-point Likert scale). Results When change was small (education group), serial measures correlated poorly with retrospective assessments (eg, r = 0.13-0.21 at 6 weeks). With greater change, correlations improved (eg, r = 0.45-0.71 at 6 weeks). Average agreement between all pairs of assessments was 29%. Significant lack of concordance was confirmed in all 12 comparisons by McNemar tests (P = .02 to < .001) and by 5 tests (P = .03 to < .001). Retrospective measures were more sensitive to change than serial measures and correlated more strongly with patients' satisfaction with change. Conclusion The 2 methods for measuring health status change did not give concordant results. Including patient retrospective assessments in clinical trials might increase the comprehensiveness of information gained and its accord with clinical practice.	Palo Alto Med Clin, Palo Alto, CA USA; Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	Palo Alto Medical Foundation Research Institute; University of California System; University of California San Francisco; Stanford University	Holman, H (corresponding author), Stanford Univ, Sch Med, 1000 Welch Rd,Suite 203, Palo Alto, CA 94304 USA.	Holman@leland.stanford.edu			NIAMS NIH HHS [AR20610] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020610] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON JJ, 1993, J RHEUMATOL, V20, P535; ASELTINE RH, 1995, MED CARE, V33, pAS67; BAYLEY KB, 1995, MED CARE, V33, pAS226; BECKER MH, 1985, MED CARE, V23, P539, DOI 10.1097/00005650-198505000-00014; BUCHBINDER R, 1995, ARTHRITIS RHEUM, V38, P1568, DOI 10.1002/art.1780381108; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; DEYO RA, 1984, HEALTH SERV RES, V19, P275; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FORTIN PR, 1995, ARTHRITIS RHEUM, V38, P1027, DOI 10.1002/art.1780380802; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GOTZSCHE PC, 1990, J CLIN EPIDEMIOL, V43, P1313; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HERRMANN D, 1995, MED CARE, V33, pAS89; JAESCHKE R, 1994, CONTROL TRIALS, V10, P407; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; MANCUSO CA, 1995, MED CARE, V33, pAS77; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; Stucki G, 1996, J CLIN EPIDEMIOL, V49, P711, DOI 10.1016/0895-4356(96)00016-9; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; TUGWELL P, 1987, J RHEUMATOL, V14, P446; Wagner E H, 1996, Manag Care Q, V4, P12; WARD MM, 1994, J RHEUMATOL, V21, P17; WARE JE, 1985, MED CARE, V23, P705, DOI 10.1097/00005650-198505000-00029; WELLS GA, 1993, J RHEUMATOL, V20, P557; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; Wright JG, 1996, J CLIN EPIDEMIOL, V49, P1221, DOI 10.1016/S0895-4356(96)00207-7; WRIGHT JG, 1994, J BONE JOINT SURG BR, V76B, P229, DOI 10.1302/0301-620X.76B2.8113282; ZIEBLAND S, 1992, ANN RHEUM DIS, V51, P1202, DOI 10.1136/ard.51.11.1202	38	361	364	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1157	1162		10.1001/jama.282.12.1157	http://dx.doi.org/10.1001/jama.282.12.1157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501119	Bronze			2022-12-28	WOS:000082596200031
J	Mooney, RA; Landick, R				Mooney, RA; Landick, R			RNA polymerase unveiled	CELL			English	Review							TRYPSIN CLEAVAGE; OPEN COMPLEX; SUBUNIT; SITES; ELONGATION; HAIRPIN		Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mooney, RA (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.							Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; Chamberlin Michael J., 1996, P7; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Daube SS, 1999, P NATL ACAD SCI USA, V96, P8390, DOI 10.1073/pnas.96.15.8390; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FISHER R, 1980, J BIOL CHEM, V255, P1056; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	20	54	57	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					687	690		10.1016/S0092-8674(00)81483-X	http://dx.doi.org/10.1016/S0092-8674(00)81483-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499791	Bronze			2022-12-28	WOS:000082679200001
J	Orth, K; Palmer, LE; Bao, ZQ; Stewart, S; Rudolph, AE; Bliska, JB; Dixon, JE				Orth, K; Palmer, LE; Bao, ZQ; Stewart, S; Rudolph, AE; Bliska, JB; Dixon, JE			Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector	SCIENCE			English	Article							NF-KAPPA-B; ALPHA PRODUCTION; CELL-DEATH; BETA; MACROPHAGES; APOPTOSIS; YOPJ; PHOSPHORYLATION; SUPPRESSION; RESISTANCE	The bacterial pathogen Yersinia uses a type III secretion system to inject several virulence factors into target cells. One of the Yersinia virulence factors, YopJ, was shown to bind directly to the superfamily of MAPK (mitogen-activated protein kinase) kinases (MKKs) blocking both phosphorylation and subsequent activation of the MKKs. These results explain the diverse activities of YopJ in inhibiting the extracellular signal-regulated kinase, c-Jun amino-terminal kinase, p38, and nuclear factor kappa B signaling pathways, preventing cytokine synthesis and promoting apoptosis. YopJ-related proteins that are found in a number of bacterial pathogens of animals and plants may function to block MKKs so that host signaling responses can be modulated upon infection.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Ctr Infect Dis, Stony Brook, NY 11794 USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035175] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35175] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Brubaker R R, 1972, Curr Top Microbiol Immunol, V57, P111; Ciesiolka LD, 1999, MOL PLANT MICROBE IN, V12, P35, DOI 10.1094/MPMI.1999.12.1.35; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; ORTH K, UNPUB; Palmer L. C., UNPUB; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Stewart S, 1999, MOL CELL BIOL, V19, P5523; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1993, MOL PLANT MICROBE IN, V6, P616, DOI 10.1094/MPMI-6-616; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	43	327	338	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1920	1923		10.1126/science.285.5435.1920	http://dx.doi.org/10.1126/science.285.5435.1920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489373				2022-12-28	WOS:000082638300053
J	Lin, CR; Kioussi, C; O'Connell, S; Briata, P; Szeto, D; Liu, F; Izpisua-Belmonte, JC; Rosenfeld, MG				Lin, CR; Kioussi, C; O'Connell, S; Briata, P; Szeto, D; Liu, F; Izpisua-Belmonte, JC; Rosenfeld, MG			Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis	NATURE			English	Article							SIGNALING PATHWAY; NODAL EXPRESSION; HOMEOBOX GENE; ORGANOGENESIS; FAMILY; EHAND; MOUSE	Pitx1 (refs 1-3) and Pitx2 (refs 4, 5) are highly homologous, bicoid-related transcription factors. Pitx2 was initially identified as the gene responsible for the human Rieger syndrome(4), an autosomal dominant condition that causes developmental abnormalities. Pitx2 is asymmetrically expressed in the left lateral-plate mesoderm(5-11), and mutant mice with laterality defects show altered patterns of Pitx2 expression that correlate with changes in the visceral symmetry (situs). Ectopic expression of Pitx2 in the right lateral-plate mesoderm alters looping of the heart and gut and reverses body rotation in chick and Xenopus embryose(6-11). Here we describe the phenotype of Pitx2 gene-deleted mice, characterized by defective body-wall closure, right pulmonary isomerism, altered cardiac position, arrest in turning and, subsequently a block in the determination and proliferation events of anterior pituitary gland and tooth organogenesis. Thus, Pitx2 is a transcription factor that encodes 'leftness' of the lung.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Salk Institute	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu	Briata, Paola/AAC-6039-2020	Briata, Paola/0000-0003-3470-0454				Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Campione M, 1999, DEVELOPMENT, V126, P1225; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Ericson J, 1998, DEVELOPMENT, V125, P1005; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Martinez S, 1999, DEVELOPMENT, V126, P1189; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	26	452	464	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					279	282		10.1038/45803	http://dx.doi.org/10.1038/45803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499586				2022-12-28	WOS:000082678400054
J	Bailey, JE; Van Brunt, DL; Mirvis, DM; McDaniel, S; Spears, CR; Chang, CF; Schaberg, DR				Bailey, JE; Van Brunt, DL; Mirvis, DM; McDaniel, S; Spears, CR; Chang, CF; Schaberg, DR			Academic managed care organizations and adverse selection under Medicaid managed care in Tennessee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-ADJUSTMENT; RAPID CHANGES; CENTERS; TENNCARE; SYSTEM; PAYMENTS	Context Health plans competing in a managed care system may face serious financial consequences if they are disproportionately selected by enrollees with expensive health conditions. Academic medical centers (AMCs) have traditionally provided medical care for the sickest patients and may be at particularly high risk for adverse selection, but whether this occurs is not known. Objective To determine whether managed care organizations (MCOs) representing AMCs are adversely selected by Medicaid managed care (MMC) enrollees with expensive chronic health conditions. Design and Setting Observational study using state Medicaid claims data from all of 1994 and January to August 1995 for Tennessee's statewide MMC program (TennCare). Participants All 12 capitated MCOs in Tennessee, which collectively provided services for 1.2 million Medicaid enrollees from January 1994 through August 1995 following the initiation of TennCare. Main Outcome Measures Prevalence of 6 state-specified high-cost chronic conditions-acquired immunodeficiency syndrome (AIDS), coagulation defects, cystic fibrosis, pregnancy, prematurity, and organ transplantation-and 27 additional high-cost conditions compared by academic, statewide, and regional MCOs, Results The prevalence of state-specified high-cost chronic conditions was generally higher for academic MCOs compared with other MCOs, Specifically, prevalence of AIDS was 14.1 times higher in academic MCOs than in statewide MCOs; coagulation defects, 6.4 times higher; transplantations, 4.4; pregnancy, 3.3; cystic fibrosis, 2.4; and prevalence of prematurity was equivalent. Prevalence was higher for academic than for statewide MCOs for 22 of the additional 27 high-cost conditions considered and similar for the remaining 5 conditions, Conclusions Our results suggest that academic MCOs in an MMC system are selected by a large percentage of the sickest patients. Adverse selection may present serious financial risks for AMCs participating in managed care.	Univ Tennessee, Dept Med, Div Gen Internal Med, Memphis, TN 38103 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN 38103 USA; Univ Memphis, Memphis Managed Care Corp, Memphis, TN 38103 USA; Univ Memphis, Dept Econ, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis	Bailey, JE (corresponding author), Univ Tennessee, Dept Med, Div Gen Internal Med, 842 Jefferson Ave,Room A607, Memphis, TN 38103 USA.	jebailey@utmem.edu						CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Culbertson RA, 1997, J HEALTH POLIT POLIC, V22, P1359; DIEHR P, 1993, MED CARE, V31, P1093, DOI 10.1097/00005650-199312000-00003; Eggers P, 1980, Health Care Financ Rev, V1, P91; Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; Fowles JB, 1996, JAMA-J AM MED ASSOC, V276, P1316, DOI 10.1001/jama.276.16.1316; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; GOLDMAN L, 1995, JAMA-J AM MED ASSOC, V273, P1549, DOI 10.1001/jama.273.19.1549; Hellinger F J, 1987, Health Care Financ Rev, V9, P55; HILLMAN AL, 1991, ACAD MED, V66, P134, DOI 10.1097/00001888-199103000-00003; Holahan J, 1999, HEALTH AFFAIR, V18, P217, DOI 10.1377/hlthaff.18.3.217; HUGHES R, 1995, PUBLICATION GAO HEHS; HUNT S, 1999, ACTUARIAL REV CAPITA; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; Kilbreth EH, 1998, INQUIRY-J HEALTH CAR, V35, P250; KRONICK R, 1997, CHALLENGE RISK ADJUS, P1; Ku LT, 1998, INQUIRY-J HEALTH CAR, V35, P332; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; NEWHOUSE JP, 1997, HLTH AFF MILLWOOD, V15, P27; REUTER JA, 1999, PATTERNS SPECIALITY; ROBINSON JC, 1995, MED CARE, V33, P1161, DOI 10.1097/00005650-199512000-00001; Rogal DL, 1998, INQUIRY-J HEALTH CAR, V35, P115; Smith N S, 1994, Manag Care Q, V2, P21; Summitt RL, 1998, JAMA-J AM MED ASSOC, V279, P767, DOI 10.1001/jama.279.10.767; Wilensky G R, 1986, Health Aff (Millwood), V5, P66, DOI 10.1377/hlthaff.5.1.66	29	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1067	1072		10.1001/jama.282.11.1067	http://dx.doi.org/10.1001/jama.282.11.1067			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493206				2022-12-28	WOS:000082512300031
J	De Paepe, A				De Paepe, A			Dural ectasia and the diagnosis of Marfan's syndrome	LANCET			English	Editorial Material							LIFE EXPECTANCY; GENE		State Univ Ghent Hosp OK5, Dept Med Genet, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	De Paepe, A (corresponding author), State Univ Ghent Hosp OK5, Dept Med Genet, B-9000 Ghent, Belgium.							BEIGHTON P, 1986, AM J MED GENET, V29, P581; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; NELSON JD, 1958, BRIT J RADIOL, V31, P561, DOI 10.1259/0007-1285-31-370-561; PYERITZ RE, 1988, AM J HUM GENET, V43, P726; Pyeritz RE, 1996, EMERY RIMOINS PRINCI, P1027; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; VILLEIRS GM, IN PRESS NEURORADIOL	11	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					878	879		10.1016/S0140-6736(99)00168-3	http://dx.doi.org/10.1016/S0140-6736(99)00168-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489939				2022-12-28	WOS:000082511800002
J	Collins, MW; Grindel, SH; Lovell, MR; Dede, DE; Moser, DJ; Phalin, BR; Nogle, S; Wasik, M; Cordry, D; Daugherty, MK; Sears, SF; Nicolette, G; Indelicato, P; McKeag, DB				Collins, MW; Grindel, SH; Lovell, MR; Dede, DE; Moser, DJ; Phalin, BR; Nogle, S; Wasik, M; Cordry, D; Daugherty, MK; Sears, SF; Nicolette, G; Indelicato, P; McKeag, DB			Relationship between concussion and neuropsychological performance in college football players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINOR HEAD-INJURY	Context Despite the high prevalence and potentially serious outcomes associated with concussion in athletes, there is little systematic research examining risk factors and short- and long-term outcomes. Objectives To assess the relationship between concussion history and learning disability (LD) and the association of these variables with neuropsychological performance and to evaluate postconcussion recovery in a sample of college football players. Design, Setting, and Participants A total of 393 athletes from 4 university football programs across the United States received preseason baseline evaluations between May 1997 and February 1999. Subjects who had subsequent football-related acute concussions (n = 16) underwent neuropsychological comparison with matched control athletes from within the sample (n = 10). Main Outcome Measures Clinical interview, 8 neuropsychological measures, and concussion symptom scale ratings at baseline and after concussion. Results Of the 393 players, 129 (34%) had experienced 1 previous concussion and 79 (20%) had experienced 2 or more concussions. Multivariate analysis of variance yielded significant main effects for both LD (P<.001) and concussion history (P = .009), resulting in lowered baseline neuropsychological performance. A significant interaction was found between LD and history of multiple concussions and LD on 2 neurol psychological measures (Trail-Making Test, Form B [P = .007] and Symbol Digit Modalities Test [P = .009]), indicating poorer performance for the group with LD and multiple concussions compared with other groups. A discriminant function analysis using neuropsychological testing of athletes 24 hours after acute in-season concussion compared with controls resulted in an overall 89.5% correct classification rate. Conclusions Our study suggests that neuropsychological assessment is a useful indicator of cognitive functioning in athletes and that bath history of multiple concussions and LD are associated with reduced cognitive performance. These variables may be detrimentally synergistic and should receive further study.	Henry Ford Hlth Syst, Div Neuropsychol, Dept Behav Hlth, Detroit, MI 48202 USA; Univ Pittsburgh, Dept Family Practice, Pittsburgh, PA USA; Univ Pittsburgh, Dept Family Med Sports Med, Pittsburgh, PA USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Florida, Coll Med, Dept Orthoped & Rehabil, Gainesville, FL USA; Univ Florida, Dept Community & Family Hlth, Gainesville, FL USA; Univ Florida, Dept Sports Hlth, Gainesville, FL USA; Michigan State Univ, Dept Athlet Training, E Lansing, MI 48824 USA; Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; St Vincents Med Ctr, Dept Sports Med, Erie, PA USA	Henry Ford Health System; Henry Ford Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Michigan State University; Michigan State University	Collins, MW (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, Dept Behav Hlth, 1 Ford Pl 1E, Detroit, MI 48202 USA.			Moser, David/0000-0003-4102-5266; sears, samuel/0000-0002-7863-3591				Barth J.T., 1989, MILD HEAD INJURY, P257; BEARS SR, 1995, J LEARN DISABIL, V27, P315; Bream H., 1996, ATHLETIC THERAPY TOD, V1, P7; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Donders J, 1997, Pediatr Rehabil, V1, P179; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HENDERSON C, 1994, COLL FRESHMEN DISABI; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HURBERT RT, 1994, COMPREHENDING BEHAV; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1994, MILD BRAIN INJURY SP; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 1999, SPORTS RELATED CONCU; Nicolson RI, 1999, LANCET, V353, P1662, DOI 10.1016/S0140-6736(98)09165-X; Powell JW, 1999, SPORTS-RELATED CONCUSSION, P75; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Spreen O, 1998, COMPENDIUM NEUROPSYC; Spreen O, 1995, DEV NEUROPSYCHOLOGY; *STATS, 1995, STAT WIND COMP PROGR; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Torg JS, 1982, ATHLETIC INJURIES HE; [No title captured]	29	585	598	3	82	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					964	970		10.1001/jama.282.10.964	http://dx.doi.org/10.1001/jama.282.10.964			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485682				2022-12-28	WOS:000082335900035
J	Bostom, AG; Rosenberg, IH; Silbershatz, H; Jacques, PF; Selhub, J; D'Agostino, RB; Wilson, PWF; Wolf, PA				Bostom, AG; Rosenberg, IH; Silbershatz, H; Jacques, PF; Selhub, J; D'Agostino, RB; Wilson, PWF; Wolf, PA			Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study	ANNALS OF INTERNAL MEDICINE			English	Article							VASCULAR-DISEASE; NATURAL-HISTORY; RISK FACTOR; HYPERHOMOCYSTEINEMIA; SERUM; HOMOCYSTINURIA; ADULTS	Background: Total homocysteine levels are associated with arteriosclerotic outcomes. Objective: To determine whether total homocysteine levels predict incident stroke in elderly persons. Design: Prospective population-based cohort study with 9.9 years of follow-up. Setting: Framingham, Massachusetts. Patients: 1947 Framingham Study participants (1158 women and 789 men; mean age +/- SD, 70 +/- 7 years). Measurements: Baseline total homocysteine levels and 9.9-year stroke incidence. Results: The quartiles of nonfasting total homocysteine levels were as follows: quartile 1, 4.13 to 9.25 mu mol/L; quartile 2, 9.26 to 11.43 mu mol/L; quartite 3, 11.44 to 14.23 mu mol/L; quartile 4, 14.24 to 219.84 mu mol/L. During follow-up, 165 incident strokes occurred. In proportional hazards models adjusted for age, sex, systolic blood pressure, diabetes, smoking, and history of atrial fibrillation and coronary heart disease, relative risk (RR) estimates comparing quartile 1 with the other three quartiles were as follows: quartile 2 compared with quartile 1-RR, 1.32 (95% CI, 0.81 to 2.14); quartile 3 compared with quartile 1-RR, 1.44 (CI, 0.89 to 2.34); quartile 4 compared with quartile 1-RR, 1.82 (CI, 1.14 to 2.91). The linear trend across the quartiles was significant (P < 0.001). Conclusion: Nonfasting total homocysteine levels are an independent risk factor for incident stroke in elderly persons.	Tufts Univ, New England Med Ctr, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Brown Univ, Mem Hosp Rhode Isl, Providence, RI 02912 USA; NHLBI, Framingham Study, Framingham, MA 01701 USA	Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA); Boston University; Brown University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rosenberg, IH (corresponding author), Tufts Univ, New England Med Ctr, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	rosenberg@hnrc.tufts.edu	Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [R01-HL-40423-05, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-17] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Bellamy MF, 1998, CIRCULATION, V98, P1848, DOI 10.1161/01.CIR.98.18.1848; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; KANNEL WB, 1987, FRAMINGHAM STUDY EPI, P1; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479; MUDD SH, 1985, AM J HUM GENET, V37, P1; Omenn GS, 1998, CIRCULATION, V97, P421; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Robins M., 1981, STROKE, V12, pI45; ROLLAND PH, 1995, CIRCULATION, V91, P1161, DOI 10.1161/01.CIR.91.4.1161; UELAND PM, 1993, CLIN CHEM, V39, P1764; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	20	327	341	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					352	355		10.7326/0003-4819-131-5-199909070-00006	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475888				2022-12-28	WOS:000082458500005
J	Kark, JD; Selhub, J; Adler, B; Gofin, J; Abramson, JH; Friedman, G; Rosenberg, IH				Kark, JD; Selhub, J; Adler, B; Gofin, J; Abramson, JH; Friedman, G; Rosenberg, IH			Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM TOTAL HOMOCYSTEINE; REDUCTASE GENE MUTATION; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; RISK FACTOR; HEALTH; HYPERHOMOCYSTEINEMIA; PHYSICIANS; VITAMINS	Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 mu mol/L in 28% of men and 20% of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend), The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths "attributable" to elevated plasma homocysteine level(greater than or equal to 14 mu mol/L) were 12.5% (95% CI, 6.7% to 18.8%)for all deaths, 16.0% (CI, 7.2% to 25.6%) for deaths during the first 5 years of follow-up, and 8.3% (CI, 1.5% to 16.1%) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.	Hadassah Univ Hosp, Dept Social Med, IL-91120 Ein Kerem, Israel; Hebrew Univ Jerusalem, Hadassah Sch Publ Hlth & Community Med, Ein Kerem, Israel; Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Hadassah Univ Hosp, Geriatr Unit, IL-91120 Ein Kerem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tufts University; United States Department of Agriculture (USDA); Hebrew University of Jerusalem	Kark, JD (corresponding author), Hadassah Univ Hosp, Dept Social Med, POB 12000, IL-91120 Ein Kerem, Israel.	jeremyl@vms.huji.ac.il						ABRAMSON JH, 1992, J CLIN EPIDEMIOL, V45, P651, DOI 10.1016/0895-4356(92)90137-C; ABRAMSON JH, 1994, INT J EPIDEMIOL, V23, P98, DOI 10.1093/ije/23.1.98; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Arnadottir M, 1996, SCAND J CLIN LAB INV, V56, P41, DOI 10.3109/00365519609088586; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; Bostom AG, 1997, KIDNEY INT, V52, P10, DOI 10.1038/ki.1997.298; Bostom AG, 1999, ARCH INTERN MED, V159, P1077, DOI 10.1001/archinte.159.10.1077; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, ATHEROSCLEROSIS, V141, P315, DOI 10.1016/S0021-9150(98)00154-3; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DAngelo A, 1997, BLOOD, V90, P1; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Gofin J, 1996, INT J OBESITY, V20, P260; Gofin J, 1995, EUR HEART J, V16, P1988, DOI 10.1093/oxfordjournals.eurheartj.a060858; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Guttormsen AB, 1997, KIDNEY INT, V52, P495, DOI 10.1038/ki.1997.359; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; KAPLAN G, 1988, J GERONTOL, V43, pS114, DOI 10.1093/geronj/43.4.S114; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; Kuller LH, 1998, CIRCULATION, V98, P196, DOI 10.1161/01.CIR.98.3.196; LARUE A, 1979, J GERONTOL, V34, P687, DOI 10.1093/geronj/34.5.687; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; MCCULLY KS, 1969, AM J PATHOL, V56, P111; NEWMAN DJ, 1995, KIDNEY INT, V47, P312, DOI 10.1038/ki.1995.40; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Rose G, 1982, CARDIOVASCULAR SURVE; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; *WHO REG OFF EUR, 1996, HIGHL HLTH ISR, P21; Wollesen F, 1999, KIDNEY INT, V55, P1028, DOI 10.1046/j.1523-1755.1999.0550031028.x	43	113	116	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					321	+		10.7326/0003-4819-131-5-199909070-00002	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475884				2022-12-28	WOS:000082458500001
J	Krauchi, K; Cajochen, C; Werth, E; Wirz-Justice, A				Krauchi, K; Cajochen, C; Werth, E; Wirz-Justice, A			Physiology - Warm feet promote the rapid onset of sleep	NATURE			English	Article							TEMPERATURE		Univ Basel, Psychiat Clin, Chronobiol & Sleep Lab, CH-4025 Basel, Switzerland	University of Basel	Krauchi, K (corresponding author), Univ Basel, Psychiat Clin, Chronobiol & Sleep Lab, Wilhelm Klein Str 27, CH-4025 Basel, Switzerland.		Werth, E/AAN-7955-2021; Cajochen, Christian/N-6748-2014	Werth, Esther/0000-0002-5099-3122				Aschoff J, 1958, Wien Med Wochenschr, V108, P404; Cajochen C, 1998, J SLEEP RES, V7, P145, DOI 10.1046/j.1365-2869.1998.00106.x; CAMPBELL SS, 1994, CHRONOBIOL INT, V11, P126, DOI 10.3109/07420529409055899; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; Gilbert SS, 1999, J PHYSIOL-LONDON, V514, P905, DOI 10.1111/j.1469-7793.1999.905ad.x; Krauchi K, 1997, AM J PHYSIOL-REG I, V272, pR1178, DOI 10.1152/ajpregu.1997.272.4.R1178; Krauchi K., 1998, CIRCADIAN CLOCKS ENT, V7, P131; RUBINSTEIN EH, 1990, ANESTHESIOLOGY, V73, P541, DOI 10.1097/00000542-199009000-00027; Weber Jakob M., 1998, Journal of Sleep Research, V7, P302; Wirz-Justice A., 1998, Journal of Sleep Research, V7, P308	10	254	269	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					36	37		10.1038/43366	http://dx.doi.org/10.1038/43366			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485703				2022-12-28	WOS:000082374400030
J	Reirden, DH				Reirden, DH			Lessons outside the lecture hall	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA; Connecticut Childrens Med Ctr, Farmington, CT USA	University of Connecticut; Connecticut Children's Medical Center	Reirden, DH (corresponding author), Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					820	821		10.1001/jama.282.9.820	http://dx.doi.org/10.1001/jama.282.9.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478685	hybrid			2022-12-28	WOS:000082272200004
J	Apelqvist, A; Li, H; Sommer, L; Beatus, P; Anderson, DJ; Honjo, T; de Angelis, MH; Lendahl, U; Edlund, H				Apelqvist, A; Li, H; Sommer, L; Beatus, P; Anderson, DJ; Honjo, T; de Angelis, MH; Lendahl, U; Edlund, H			Notch signalling controls pancreatic cell differentiation	NATURE			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTION FACTOR; INSULIN GENE; EXPRESSION; PROGENITOR; NEURONS; NEUROGENESIS; ORIGIN; MICE	The pancreas contains both exocrine and endocrine cells, but the molecular mechanisms controlling the differentiation of these cell types are largely unknown. Despite their endodermal origin, pancreatic endocrine cells share several molecular characteristics with neurons(1-5), and, like neurons in the central nervous system(6,7) differentiating endocrine cells in the pancreas appear in a scattered fashion within a field of progenitor coils(8,9). This indicates that they may be generated by lateral specification through Notch signalling(6,7). Here, to test this idea, we analysed pancreas development in mice genetically altered at several steps in the Notch signalling pathway, Mice deficient for Delta-like gene 1 (Dll1)(10) or the intracellular mediator RBP-JK(11) showed accelerated differentiation of pancreatic endocrine cells. A similar phenotype was observed in mice over-expressing neurogenin 3 (ngn 3)(12) or the intracellular form of Notch3 (ref. 13) (a repressor of Notch signalling). These data provide evidence that ngn3 acts as pro-endocrine gene and that Notch signalling is critical for the decision between the endocrine and progenitor/exocrine fates in the developing pancreas.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; ETH Honggerberg, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; GSF, Inst Mammalian Genet, D-85764 Neuherberg, Germany; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Umea University; Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Kyoto University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet	Edlund, H (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.		de Angelis, Martin Hrabe/F-5531-2012; Honjo, Tasuku/N-4470-2016	de Angelis, Martin Hrabe/0000-0002-7898-2353; Edlund, Helena/0000-0002-3553-7348; Lendahl, Urban/0000-0001-9543-8141; Sommer, Lukas/0000-0002-1143-7908				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Beatus P, 1999, DEVELOPMENT, V126, P3925; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; FONTAINE J, 1977, J EMBRYOL EXP MORPH, V41, P209; Hogan B, 1994, MANIPULATING MOUSE E; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lewis J, 1996, CURR OPIN NEUROBIOL, V6, P3, DOI 10.1016/S0959-4388(96)80002-X; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MISHIBASHI M, 1995, GENE DEV, V15, P3136; Mitsiadis TA, 1998, DEV BIOL, V204, P420, DOI 10.1006/dbio.1998.9092; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OKA C, 1995, DEVELOPMENT, V121, P3291; Pictet R., 1972, HDB PHYSL, P25; PICTET RL, 1976, SCIENCE, V191, P191, DOI 10.1126/science.1108195; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245	30	912	949	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					877	881		10.1038/23716	http://dx.doi.org/10.1038/23716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476967				2022-12-28	WOS:000082233200047
J	O'Neill, P				O'Neill, P			Clinical evidence - Acute otitis media	BRITISH MEDICAL JOURNAL			English	Review							INITIAL TREATMENT; CHILDREN; ANTIBIOTICS; METAANALYSIS; EFFICACY		Norton Med Ctr, Stockton On Tees TS20 1AN, England		O'Neill, P (corresponding author), Norton Med Ctr, Stockton On Tees TS20 1AN, England.							Bertin L, 1996, FUNDAM CLIN PHARM, V10, P387, DOI 10.1111/j.1472-8206.1996.tb00590.x; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; Johansen HK, 1997, BRIT MED J, V315, P879, DOI 10.1136/bmj.315.7112.879; Kozyrskyj AL, 1998, JAMA-J AM MED ASSOC, V279, P1736, DOI 10.1001/jama.279.21.1736; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; WILLIAMS RL, 1994, JAMA-J AM MED ASSOC, V271, P430	9	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					833	835		10.1136/bmj.319.7213.833	http://dx.doi.org/10.1136/bmj.319.7213.833			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496831	Green Published			2022-12-28	WOS:000082865200029
J	Aramburu, J; Yaffe, MB; Lopez-Rodriguez, C; Cantley, LC; Hogan, PG; Rao, A				Aramburu, J; Yaffe, MB; Lopez-Rodriguez, C; Cantley, LC; Hogan, PG; Rao, A			Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A	SCIENCE			English	Article							TRANSCRIPTION FACTOR NFAT1; T-CELLS; CALCINEURIN; ACTIVATION; FAMILY; DOMAIN; COMPONENTS; MECHANISM; PATHWAY; KINASES	The flow of information from calcium-mobilizing receptors to nuclear factor of activated T cells (NFAT)-dependent genes is critically dependent on interaction between the phosphatase calcineurin and the transcription factor NFAT. A high-affinity calcineurin-binding peptide was selected from combinatorial peptide Libraries based on the calcineurin docking motif of NFAT, This peptide potently inhibited NFAT activation and NFAT-dependent expression of endogenous cytokine genes in T cells, without affecting the expression of other cytokines that require calcineurin but not NFAT. Substitution of the optimized peptide sequence into the natural calcineurin docking site increased the calcineurin responsiveness of NFAT. Compounds that interfere selectively with the calcineurin-NFAT interaction without affecting calcineurin phosphatase activity may be useful as therapeutic agents that are Less toxic than current drugs.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA; Harvard Univ, Sch Med, Harvard Inst Med, Dept Cell Biol, Boston, MA 02215 USA; CBR Labs, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hogan, PG (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Cantley, Lewis C/D-1800-2014; Lopez-Rodriguez, C/G-4482-2014; Aramburu, J/G-8991-2014	Cantley, Lewis C/0000-0002-1298-7653; Lopez-Rodriguez, C/0000-0002-2311-2406; Aramburu, J/0000-0001-9279-9523	NHLBI NIH HHS [R01 HL 03601] Funding Source: Medline; NIAID NIH HHS [R43 AI 43726, R01 AI 40127] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040127, R43AI043726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Cecka M, 1998, SURG CLIN N AM, V78, P133, DOI 10.1016/S0039-6109(05)70639-3; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Izumo S, 1998, NAT MED, V4, P661, DOI 10.1038/nm0698-661; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; LOPEZRODRIGUEZ C, IN PRESS COLD SPRING; Luo C, 1996, MOL CELL BIOL, V16, P3955; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mihatsch MJ, 1998, CLIN NEPHROL, V49, P356; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOLKENTIN JD, 1998, SCIENCE, V282, P1007; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nabel GJ, 1999, NATURE, V397, P471, DOI 10.1038/17207; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Pascual M, 1998, IMMUNOL TODAY, V19, P514, DOI 10.1016/S0167-5699(98)01324-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	39	498	529	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2129	2133		10.1126/science.285.5436.2129	http://dx.doi.org/10.1126/science.285.5436.2129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497131				2022-12-28	WOS:000082734300043
J	Luke, SGM; Gallagher, A; Lloyd, BW				Luke, SGM; Gallagher, A; Lloyd, BW			Staff and family attitudes to keeping joint medical and nursing notes at the foot of the bed: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							RECORDS	Some years ago we introduced joint medical and nursing notes in our children's department.(1) In 1995, to promote openness and teamwork with families, we started placing these notes at the foot of the bed and encouraged parents to read them. We evaluated this innovation.	N Middlesex Hosp, Childrens Dept, London N18 1QX, England		Lloyd, BW (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.							BALDRY M, 1986, BRIT MED J, V292, P596, DOI 10.1136/bmj.292.6520.596; ELBOURNE D, 1987, BRIT J OBSTET GYNAEC, V94, P612, DOI 10.1111/j.1471-0528.1987.tb03165.x; OFLAHERTY S, 1987, ARCH DIS CHILD, V62, P1152, DOI 10.1136/adc.62.11.1152; Robins A, 1997, QUAL HEALTH CARE, V6, P192, DOI 10.1136/qshc.6.4.192; SHENKIN BN, 1973, NEW ENGL J MED, V289, P688, DOI 10.1056/NEJM197309272891311	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					735	735		10.1136/bmj.319.7212.735	http://dx.doi.org/10.1136/bmj.319.7212.735			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487996	Green Published, Bronze			2022-12-28	WOS:000082701500015
J	Metayer, P				Metayer, P			A meeting which changed me - There is another way	BRITISH MEDICAL JOURNAL			English	Article									Gastroenterol & Med Dept, Dieppe, France		Metayer, P (corresponding author), Gastroenterol & Med Dept, Dieppe, France.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					758	758		10.1136/bmj.319.7212.758	http://dx.doi.org/10.1136/bmj.319.7212.758			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488006	Green Published			2022-12-28	WOS:000082701500023
J	Yamey, G				Yamey, G			Struck off, but why?	BRITISH MEDICAL JOURNAL			English	Review																		1999, J ROYAL SOC MED, V92, P443	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					791	791		10.1136/bmj.319.7212.791	http://dx.doi.org/10.1136/bmj.319.7212.791			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488038	Green Published			2022-12-28	WOS:000082701500054
J	Tanaka, TU; Cosma, MP; Wirth, K; Nasmyth, K				Tanaka, TU; Cosma, MP; Wirth, K; Nasmyth, K			Identification of cohesin association sites at centromeres and along chromosome arms	CELL			English	Article							SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; DNA-REPLICATION; BUDDING YEAST; MCM PROTEIN; MEIOSIS; COMPLEX; NONDISJUNCTION; RECOMBINATION	A multisubunit cohesin complex holds sister chromatids together after DNA replication. Using chromatin immunoprecipitation, we detected cohesin association with centromeres and with discrete sites along chromosome arms from S phase until metaphase in S. cerevisiae, Short DNA sequences (130-280 bp) are sufficient to confer cohesin association. Cohesin association with a centromere depends on Mif2p, the centromere binding factor CBF3, and a centromere-specific histone variant, Cse4p. Because only active centromeres confer cohesin association with centromeric DNA, we suggest that cohesin is recruited by the same chromatin structure that confers the attachment of microtubules. Propagation of this structure might be partly epigenetic. Finally, cohesion associated with "minimal" centromeres is insufficient to resist the splitting force exerted by microtubules and appears to be reinforced by cohesion provided by their flanking DNA sequences.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Tanaka, Tomoyuki U/A-4775-2008; Cosma, Maria Pia/E-8731-2015	Cosma, Maria Pia/0000-0003-4207-5097; Tanaka, Tomoyuki/0000-0002-9886-5947; Nasmyth, Kim/0000-0001-7030-4403				Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; Choo KHA., 1997, CENTROMERE; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hartwell LW, 1982, RECENT ADV YEAST MOL, V1, P28; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HILL A, 1989, MOL CELL BIOL, V9, P1368, DOI 10.1128/MCB.9.3.1368; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, SCIENCE, V285, P254, DOI 10.1126/science.285.5425.254; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; SEARS DD, 1995, GENETICS, V139, P1159; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460	36	249	253	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					847	858		10.1016/S0092-8674(00)81518-4	http://dx.doi.org/10.1016/S0092-8674(00)81518-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499801	Bronze			2022-12-28	WOS:000082679200011
J	Kelz, MB; Chen, JS; Carlezon, WA; Whisler, K; Gilden, L; Beckmann, AM; Steffen, C; Zhang, YJ; Marotti, L; Self, DW; Tkatch, T; Baranauskas, G; Surmeier, DJ; Neve, RL; Duman, RS; Picciotto, MR; Nestler, EJ				Kelz, MB; Chen, JS; Carlezon, WA; Whisler, K; Gilden, L; Beckmann, AM; Steffen, C; Zhang, YJ; Marotti, L; Self, DW; Tkatch, T; Baranauskas, G; Surmeier, DJ; Neve, RL; Duman, RS; Picciotto, MR; Nestler, EJ			Expression of the transcription factor Delta FosB in the brain controls sensitivity to cocaine	NATURE			English	Article							NUCLEUS-ACCUMBENS NEURONS; DOPAMINE-RECEPTORS; GENE-EXPRESSION; SENSITIZATION; INDUCTION; ADDICTION; PROTEINS; MICE; RAT; PSYCHOMOTOR	Acute exposure to cocaine transiently induces several Fos family transcription factors in the nucleus accumbens(1), a region of the brain that is important for addiction(2,3). In contrast, chronic exposure to cocaine does not induce these proteins, but instead causes the persistent expression of highly stable isoforms of Delta FosB(4-6). Delta FoSB is also induced in the nucleus accumbens by repeated exposure to other drugs of abuse, including amphetamine, morphine, nicotine and phencyclidine(7-10). The sustained accumulation of Delta FosB in the nucleus accumbens indicates that this transcription factor may mediate some of the persistent neural and behavioural plasticity that accompanies chronic drug exposure(1). Using transgenic mice in which Delta FosB can be induced in adults in the subset of nucleus accumbens neurons in which cocaine induces the protein,we show that Delta FosB expression increases the responsiveness of an animal to the rewarding and locomotor-activating effects of cocaine. These effects of Delta FosB appear to be mediated partly by induction of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole) glutamate receptor subunit GluR2 in the nucleus accumbens. These results support a model in which Delta FosB, by altering gene expression, enhances sensitivity to cocaine and may thereby contribute to cocaine addiction.	Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA; Yale Univ, Sch Med, Yale Ctr Genes & Behav, New Haven, CT 06508 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA 02178 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Genet, Belmont, MA 02178 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA	Yale University; Yale University; Harvard University; McLean Hospital; Harvard University; McLean Hospital; Northwestern University	Nestler, EJ (corresponding author), Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA.		Kelz, Max/E-4054-2010; Picciotto, Marina R./F-8747-2012	Kelz, Max/0000-0002-2803-6078; Picciotto, Marina R./0000-0002-4404-1280; /0000-0002-4162-3947; Tkatch, Tatiana/0000-0001-6626-7435				Atkins JB, 1999, SYNAPSE, V33, P118, DOI 10.1002/(SICI)1098-2396(199908)33:2<118::AID-SYN2>3.0.CO;2-L; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; Brene S., 1997, Society for Neuroscience Abstracts, V23, P923; Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen JS, 1997, J NEUROSCI, V17, P4933; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GERFEN CR, 1991, J NEUROSCI, V11, P1016; Hiroi N, 1998, J NEUROSCI, V18, P6952; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Moratalla R, 1996, NEUROREPORT, V8, P1, DOI 10.1097/00001756-199612200-00001; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671; Nye HE, 1996, MOL PHARMACOL, V49, P636; PENNARTZ CMA, 1994, PROG NEUROBIOL, V42, P719, DOI 10.1016/0301-0082(94)90025-6; Peoples LL, 1998, NEUROSCIENCE, V86, P13, DOI 10.1016/S0306-4522(98)00116-X; Pich EM, 1997, SCIENCE, V275, P83; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; White F J, 1998, Adv Pharmacol, V42, P1006; Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7	30	490	508	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					272	276		10.1038/45790	http://dx.doi.org/10.1038/45790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499584				2022-12-28	WOS:000082678400052
J	Cupples, ME; McKnight, A				Cupples, ME; McKnight, A			Five year follow up of patients at high cardiovascular risk who took part in randomised controlled trial of health promotion	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Queens Univ, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland; No Ireland Council Postgrad Med & Dent Educ, Belfast BT7 3JH, Antrim, North Ireland	Queens University Belfast	Cupples, ME (corresponding author), Queens Univ, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland.	m.cupples@qub.ac.uk		Cupples, Margaret/0000-0002-4248-9700				Campbell H, 1998, BMJ-BRIT MED J, V316, P133; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Cupples ME, 1996, HLTH ED J, V55, P75; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; *NHS CTR REV DISS, 1998, EFFECTIVE HLTH CARE, V4, P7	5	57	59	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	1999	319	7211					687	688		10.1136/bmj.319.7211.687	http://dx.doi.org/10.1136/bmj.319.7211.687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480826	Bronze, Green Published			2022-12-28	WOS:000082636800026
J	Clay, K; Holah, J				Clay, K; Holah, J			Fungal endophyte symbiosis and plant diversity in successional fields	SCIENCE			English	Article							TALL-FESCUE ENDOPHYTE; SPECIES RICHNESS; GRASSES; COMMUNITIES; INFECTION; INVASION; DISEASES; FORESTS; GROWTH; TERM	Increasing evidence suggests that microbial interactions are important determinants of plant biodiversity. The hypothesis that fungal endophyte symbiosis reduces diversity in successional fields was tested by manipulating infection of tall fescue, the most abundant perennial grass in the eastern United States. Over a 4-year period. species richness declined and tall fescue dominance increased in infected plots relative to uninfected plots without differences in total productivity. A host-specific endophyte, with negligible biomass, altered plant community structure in this Long-term field experiment and may be reducing plant diversity throughout its expanding range.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Clay, K (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	clay@indiana.edu	Clay, Keith/C-8730-2012					ARACHEVALETA M, 1989, AGRON J, V81, P83, DOI 10.2134/agronj1989.00021962008100010015x; BACON C W, 1988, Journal of Production Agriculture, V1, P45; Bacon C.W., 1994, BIOTECHNOLOGY ENDOPH; BACON CW, 1977, APPL ENVIRON MICROB, V34, P576, DOI 10.1128/AEM.34.5.576-581.1977; BALL DM, 1993, AM SCI, V81, P370; BEVER JD, 1994, ECOLOGY, V75, P1965, DOI 10.2307/1941601; Bor NL., 1960, GRASSES BURMA CEYLON; BROTHERS TS, 1992, CONSERV BIOL, V6, P91, DOI 10.1046/j.1523-1739.1992.610091.x; CHUCHOU M, 1992, SOIL BIOL BIOCHEM, V24, P633, DOI 10.1016/0038-0717(92)90041-U; CLAY K, 1993, ECOLOGY, V74, P1767, DOI 10.2307/1939935; CLAY K, 1988, ECOLOGY, V69, P10, DOI 10.2307/1943155; Clay K., 1991, MICROBIAL ECOLOGY LE, P331, DOI [10.1007/978-1-4612-3168-4_17, DOI 10.1007/978-1-4612-3168-4_17]; Clay K., 1994, BIOTECHNOLOGY ENDOPH, P73; COLEY AB, 1995, J ENVIRON QUAL, V24, P472, DOI 10.2134/jeq1995.00472425002400030012x; CONNELL JH, 1989, AM NAT, V134, P88, DOI 10.1086/284967; Foster BL, 1998, ECOLOGY, V79, P2593, DOI 10.1890/0012-9658(1998)079[2593:SRIASG]2.0.CO;2; Giuliano William M., 1994, Prairie Naturalist, V26, P53; GOUGH L, 1994, OIKOS, V70, P271, DOI 10.2307/3545638; GRIME JP, 1987, NATURE, V328, P420, DOI 10.1038/328420a0; GUREVITCH J, 1986, ECOLOGY, V67, P251, DOI 10.2307/1938525; Harper J. L., 1990, Pests, pathogens and plant communities., P3; Hartnett DC, 1999, ECOLOGY, V80, P1187, DOI 10.1890/0012-9658(1999)080[1187:MIPCSA]2.0.CO;2; HARTNETT DC, 1993, J ECOL, V81, P787, DOI 10.2307/2261676; Hiatt EE, 1997, J CHEM ECOL, V23, P2721, DOI 10.1023/A:1022558909690; HIEBERT R D, 1990, Natural Areas Journal, V10, P181; Hill NS, 1996, CROP SCI, V36, P665, DOI 10.2135/cropsci1996.0011183X003600030025x; HINTON DM, 1985, CAN J BOT, V63, P36, DOI 10.1139/b85-006; JOHNSON NC, 1992, ECOLOGY, V73, P2034, DOI 10.2307/1941453; Joost R.E., 1990, P INT S ACR GRASS IN, P58; KRANZ J, 1990, NEW PHYTOL, V116, P383, DOI 10.1111/j.1469-8137.1990.tb00525.x; Leuchtmann A.BaconCW, 2014, MYCOTA, V106, P202, DOI 10.3852/13-251; LYONS PC, 1986, SCIENCE, V232, P487, DOI 10.1126/science.3008328; Maron JL, 1996, OECOLOGIA, V105, P302, DOI 10.1007/BF00328732; Miles CO, 1996, J AGR FOOD CHEM, V44, P1285, DOI 10.1021/jf950410k; Newsham KK, 1995, J ECOL, V83, P991, DOI 10.2307/2261180; PALMER MW, 1990, ECOLOGY, V71, P1195, DOI 10.2307/1937387; RICE JS, 1990, CROP SCI, V30, P1303, DOI 10.2135/cropsci1990.0011183X003000060029x; ROTHROCK PE, 1997, NATURAL HERITAGE IND, P135; Saikkonen K, 1998, ANNU REV ECOL SYST, V29, P319, DOI 10.1146/annurev.ecolsys.29.1.319; Schardl C.L., 1997, MYCOTA, P221; SHAW J, 1873, BOT J LINN SOC, V14, P202; SHELBY RA, 1993, GRASS FORAGE SCI, V48, P356, DOI 10.1111/j.1365-2494.1993.tb01869.x; Simard SW, 1997, NATURE, V388, P579, DOI 10.1038/41557; THOMPSON RW, 1989, AGRON J, V81, P966, DOI 10.2134/agronj1989.00021962008100060024x; Tilman D., 1982, Monographs in Population Biology, pi; Tilman David, 1993, P13; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; VANDERPUTTEN WH, 1993, NATURE, V362, P53; VITOUSEK PM, 1989, ECOL MONOGR, V59, P247, DOI 10.2307/1942601; WEST CP, 1993, AGRON J, V85, P264, DOI 10.2134/agronj1993.00021962008500020019x; Westover KM, 1997, J ECOL, V85, P863, DOI 10.2307/2960607	51	435	515	12	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1742	1744		10.1126/science.285.5434.1742	http://dx.doi.org/10.1126/science.285.5434.1742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481011				2022-12-28	WOS:000082472600037
J	DeMarco, B; Jin, DS				DeMarco, B; Jin, DS			Onset of Fermi degeneracy in a trapped atomic gas	SCIENCE			English	Article							BOSE-EINSTEIN CONDENSATION; HARMONIC TRAP; MAGNETIC TRAP; SUPERFLUIDITY; TEMPERATURE; SCATTERING	An evaporative cooling strategy that uses a two-component Fermi gas was employed to cool a magnetically trapped gas of 7 X 10(5) K-40 atoms to 0.5 of the Fermi temperature T-F. In this temperature regime, where the state occupation at the Lowest energies has increased from essentially zero at high temperatures to nearly 60 percent, quantum degeneracy was observed as a barrier to evaporative cooling and as a modification of the thermodynamics. Measurements of the momentum distribution and the total energy of the confined Fermi gas directly revealed the quantum statistics.	Univ Colorado, Natl Inst Stand & Technol, Quantum Phys Div, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA	National Institute of Standards & Technology (NIST) - USA; University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA; University of Colorado System; University of Colorado Boulder	Jin, DS (corresponding author), Univ Colorado, Natl Inst Stand & Technol, Quantum Phys Div, Boulder, CO 80309 USA.	jin@jilau1.colorado.edu		DeMarco, Brian/0000-0002-2791-0413				Baranov MA, 1998, PHYS REV A, V58, pR801, DOI 10.1103/PhysRevA.58.R801; BASHKIN EP, 1980, J PHYS C FRANCE, V41, P61; Busch T, 1998, EUROPHYS LETT, V44, P1, DOI 10.1209/epl/i1998-00426-2; Butts DA, 1997, PHYS REV A, V55, P4346, DOI 10.1103/PhysRevA.55.4346; Courteille P, 1998, PHYS REV LETT, V81, P69, DOI 10.1103/PhysRevLett.81.69; DeMarco B, 1999, REV SCI INSTRUM, V70, P1967, DOI 10.1063/1.1149695; DeMarco B, 1999, PHYS REV LETT, V82, P4208, DOI 10.1103/PhysRevLett.82.4208; DeMarco B, 1998, PHYS REV A, V58, pR4267, DOI 10.1103/PhysRevA.58.R4267; Ensher JR, 1996, PHYS REV LETT, V77, P4984, DOI 10.1103/PhysRevLett.77.4984; Ferrari G, 1999, PHYS REV A, V59, pR4125, DOI 10.1103/PhysRevA.59.R4125; Geist W, 1999, PHYS REV A, V59, P1500, DOI 10.1103/PhysRevA.59.1500; GOTT YV, 1962, NUCL FUSION, P1045; GOTT YV, 1962, NUCL FUSION S, P1284; Greiner W., 1995, THERMODYNAMICS STAT, P359; HELMERSON K, 1990, INT QUANT EL C 1990; HESS HF, 1987, PHYS REV LETT, V59, P672, DOI 10.1103/PhysRevLett.59.672; HOLLAND M, 1976, PHYS REV LETT, V78, P3801; Houbiers M, 1999, PHYS REV A, V59, P1556, DOI 10.1103/PhysRevA.59.1556; Inouye S, 1998, NATURE, V392, P151, DOI 10.1038/32354; KOELMAN JMVA, 1987, PHYS REV LETT, V59, P676, DOI 10.1103/PhysRevLett.59.676; Mewes MO, 1996, PHYS REV LETT, V77, P416, DOI 10.1103/PhysRevLett.77.416; Myatt CJ, 1996, OPT LETT, V21, P290, DOI 10.1364/OL.21.000290; Myatt CJ, 1997, PHYS REV LETT, V78, P586, DOI 10.1103/PhysRevLett.78.586; OLIVA J, 1989, PHYS REV B, V39, P4204, DOI 10.1103/PhysRevB.39.4204; PRITCHARD DE, 1983, PHYS REV LETT, V51, P1336, DOI 10.1103/PhysRevLett.51.1336; Roberts JL, 1998, PHYS REV LETT, V81, P5109, DOI 10.1103/PhysRevLett.81.5109; Ruostekoski J, 1999, PHYS REV LETT, V82, P4741, DOI 10.1103/PhysRevLett.82.4741; SILVERA IF, 1981, J APPL PHYS, V52, P2304, DOI 10.1063/1.328914; Stoof HTC, 1996, PHYS REV LETT, V76, P10, DOI 10.1103/PhysRevLett.76.10; Timmermans E, 1998, PHYS REV LETT, V80, P3419, DOI 10.1103/PhysRevLett.80.3419; Vuletic V, 1999, PHYS REV LETT, V82, P1406, DOI 10.1103/PhysRevLett.82.1406; Yip SK, 1999, PHYS REV A, V59, P4653, DOI 10.1103/PhysRevA.59.4653	34	958	972	6	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1703	1706		10.1126/science.285.5434.1703	http://dx.doi.org/10.1126/science.285.5434.1703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481000				2022-12-28	WOS:000082472600026
J	Yoshizawa, S; Fourmy, D; Puglisi, JD				Yoshizawa, S; Fourmy, D; Puglisi, JD			Recognition of the codon-anticodon helix by ribosomal RNA	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOMES; DEACYLATED TRANSFER-RNA; A-SITE; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; CATALYTIC CORE; MESSENGER-RNA; BINDING-SITES; TRANSLATION; COMPLEX	Translational fidelity is established by ribosomal recognition of the codon-anticodon interaction within the aminoacyl-transfer RNA (tRNA) site (A site) of the ribosome. Experiments are presented that reveal possible contacts between 16S ribosomal RNA and the codon-anticodon complex. Nf methylation of adenine at position 1492 (A1492) and A1493 interfered with A-site tRNA binding. Mutation of A1492 and A1493 to guanine or cytosine also impaired A-site tRNA binding. The deleterious effects of A1492G or A1493G (or both) mutations were compensated by 2' fluorine substitutions in the mRNA codon. The results suggest that the ribosome recognizes the codon-anticodon complex by adenine contacts to the messenger RNA backbone and provide a mechanism for molecular discrimination of correct versus incorrect codon-anticodon pairs.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Puglisi, JD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	puglisi@stanford.edu	fourmy, dominique/J-4766-2014; Yoshizawa, Satoko/T-8302-2018	fourmy, dominique/0000-0002-2170-3536; Yoshizawa, Satoko/0000-0002-9333-8961	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURUP H, 1994, NUCLEIC ACIDS RES, V22, P4963, DOI 10.1093/nar/22.23.4963; Blanchard SC, 1998, BIOCHEMISTRY-US, V37, P7716, DOI 10.1021/bi973125y; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7600, DOI 10.1021/bi00485a009; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; DAVIES J, 1964, P NATL ACAD SCI USA, V51, P883, DOI 10.1073/pnas.51.5.883; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; KARIMI R, 1994, EUR J BIOCHEM, V226, P355, DOI 10.1111/j.1432-1033.1994.tb20059.x; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUTLAND CG, 1992, ANNU REV GENET, V26, P29; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; MCCARTHY BJ, 1965, P NATL ACAD SCI USA, V54, P880, DOI 10.1073/pnas.54.3.880; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Narlikar GJ, 1998, BIOCHEMISTRY-US, V37, P9902, DOI 10.1021/bi980495t; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; POTAPOV AP, 1995, J BIOL CHEM, V270, P17680, DOI 10.1074/jbc.270.30.17680; POWERS T, 1994, TRENDS GENET, V10, P27, DOI 10.1016/0168-9525(94)90016-7; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Recht MI, 1999, J MOL BIOL, V286, P33, DOI 10.1006/jmbi.1998.2446; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Szewczak AA, 1998, NAT STRUCT BIOL, V5, P1037, DOI 10.1038/4146; TAKAHASHI LH, 1989, J AM CHEM SOC, V111, P3368, DOI 10.1021/ja00191a039; VanLoock MS, 1999, J MOL BIOL, V285, P2069, DOI 10.1006/jmbi.1998.2442; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437; YOSHIZAWA S, UNPUB	39	196	206	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1722	1725		10.1126/science.285.5434.1722	http://dx.doi.org/10.1126/science.285.5434.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481006				2022-12-28	WOS:000082472600032
J	Matser, EJT; Kessels, AG; Lezak, MD; Jordan, BD; Troost, J				Matser, EJT; Kessels, AG; Lezak, MD; Jordan, BD; Troost, J			Neuropsychological impairment in amateur soccer players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN INJURY	Context Soccer players incur concussions during matches and training sessions, as well as numerous subconcussive blows to the head from impacts with the soccer ball (headers). The combination of soccer-related concussions and the number of headers may be a risk for chronic traumatic brain injury (CTBI). Objective To determine whether amateur soccer players have evidence of CTBI. Design, Setting, and Participants Cross-sectional study of 33 amateur soccer players and 27 amateur athletes involved in swimming and track (controls) in the Netherlands who underwent interviews and neuropsychological testing. Main Outcome Measures Performance of soccer players vs controls on 16 neuropsychological tests having 27 outcomes. Results Compared with control athletes, amateur soccer players exhibited impaired performance on tests of planning (39% vs 13%; P = .001) and memory (27% vs 7%; P = .004). Among soccer players, 9 (27%) had incurred 1 soccer-related concussion and 7 (23%) had had 2 to 5 concussions during their career. The number of concussions incurred in soccer was inversely related to the neuropsychological performance on 6 of the neuropsychological tests. Conclusions Our results indicate that participation in amateur soccer in general and concussion specifically is associated with impaired performance in memory and planning functions. Due to the worldwide popularity of soccer, these observations may have important public health implications.	St Anna Hosp, Det Neuropsychol & Sports Neurol, NL-5560 AB Geldrop, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Anat, NL-3000 DR Rotterdam, Netherlands; Univ Hosp Maastricht, Res Unit Patient Care, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Burke Rehabil Hosp, Traumat Brain Injury Program, White Plains, NY USA	Erasmus University Rotterdam; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Oregon Health & Science University	Matser, EJT (corresponding author), St Anna Hosp, Det Neuropsychol & Sports Neurol, POB 90, NL-5560 AB Geldrop, Netherlands.							[Anonymous], 1981, WAIS R MANUAL; Army Individual Test Battery, 1944, ARM COMB FITN TEST; Benton A.L., 1994, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; CORSELLIS JA, 1976, LANCET, V1, P401; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Deelman B.G., 1980, NEUROPSYCHOLOGIE NED; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lauter J, 1996, BIOMETRICS, V52, P964, DOI 10.2307/2533057; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luteyn, 1966, DUTCH J PSYCHOL, V2, P675; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATSER JT, 1996, GENEESKUNDE SPORT, V29, P66; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Osterrieth P., 1944, ARCH PSYCHOL-GENEVE, V30, P206; Raven J.C., 1960, GUIDE STANDARD PROGR; ROBBERTS AH, 1969, BRAIN DAMAGE BOXERS; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Van De Loo L., 1956, TIJIKSCHRIFT PSYCHOL, V2, P33; VANDERVLUGT H, 1979, LATERALISATIES HERSE; Wechsler D, 1974, WECHSLER MEMORY SCAL; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	28	272	275	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					971	973		10.1001/jama.282.10.971	http://dx.doi.org/10.1001/jama.282.10.971			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485683	Bronze			2022-12-28	WOS:000082335900036
J	Ozes, ON; Mayo, LD; Gustin, JA; Pfeffer, SR; Pfeffer, LM; Donner, DB				Ozes, ON; Mayo, LD; Gustin, JA; Pfeffer, SR; Pfeffer, LM; Donner, DB			NF-kappa B activation by tumour necrosis factor requires the Akt serine-threonine kinase	NATURE			English	Article							SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; IKK-ALPHA; TNF; COMPLEX; PHOSPHORYLATION; 3-KINASE; BETA	Activation of the nuclear transcription factor NF-kappa B by inflammatory cytokines requires the successive action of NF-kappa B-inducing kinase (NIK) and an I kappa B-kinase (IKK) complex composed of IKK alpha and IKK beta(1-5). Here we show that the Akt serine-threonine kinase(6) is involved in the activation of NF-kappa B by tumour necrosis factor (TNF). TNF activates phosphatidylinositol-3-OH kinase (PI(3)K) and its downstream target Akt (protein kinase B). Wortmannin (a PI(3)K inhibitor), dominant-negative PI(3)K or kinase-dead Akt inhibits TNF-mediated NF-kappa B activation. Constitutively active Akt induces NF-kappa B activity and this effect is blocked by dominant-negative NIK. Conversely, NIK activates NF-KB and this is blocked by kinase-dead Akt. Thus, both Akt and NIK are necessary for TNF activation of NF-kappa B. Akt mediates IKKa phosphorylation at threonine 23. Mutation of this amino acid blocks phosphorylation by Akt or TNF and activation of NF-kappa B. These findings indicate that Akt is part of a signalling pathway that is necessary for inducing key immune and inflammatory responses.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Oncol Ctr, Indianapolis, IN 46202 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center	Donner, DB (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.			Pfeffer, Lawrence/0000-0003-2809-1234				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bauerle PA, 1996, CELL, V87, P13; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	20	1830	1885	1	107	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					82	85						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485710				2022-12-28	WOS:000082374400046
J	Corstens, FHM; van der Meer, JWM				Corstens, FHM; van der Meer, JWM			Nuclear medicine's role in infection and inflammation	LANCET			English	Article							HUMAN-IMMUNOGLOBULIN-G; MONOCLONAL-ANTIBODY; UNKNOWN ORIGIN; CHRONIC OSTEOMYELITIS; LABELED LEUKOCYTE; G SCINTIGRAPHY; GA-67; DIAGNOSIS; ARTHRITIS; FRAGMENT	Nuclear medicine imaging techniques can help In patient evaluation where infectious and non-infectious inflammatory disorders are suspected. When selected and tailored to the clinical situation, most techniques already in use or available soon provide information with high sensitivity. However, almost ail currently available techniques lack the specificity to discriminate between infectious and non infectious inflammation. In undiagnosed fever, this nonspecificity may be an advantage since fever of unknown origin is caused by infection in only about 25% of cases, but in the postoperative patient the reliable differentiation between infection and sterile inflammation is highly relevant to clinical management. The range of radiopharmceuticals to investigate infectious and non-microbial inflammatory disorders is expanding and developments in protein/peptide chemistry and in labelling technology should lead to agents with very high specific activities. Nuclear medicine has to add specificity to Its already high sensitivity if it Is to distinguish both categories of inflammatory disorder.	Univ Nijmegen Hosp, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen Hosp, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Corstens, FHM (corresponding author), Univ Nijmegen Hosp, Dept Nucl Med, POB 9109, NL-6500 HB Nijmegen, Netherlands.		van der Meer, Jos W.M./C-8521-2013	van der Meer, Jos W.M./0000-0001-5120-3690				ALAZRAKI N, 1985, AM J ROENTGENOL, V145, P767, DOI 10.2214/ajr.145.4.767; Barron B, 1999, SURGERY, V125, P288, DOI 10.1067/msy.1999.95210; BECKER W, 1994, J NUCL MED, V35, P1436; BECKERMAN C, 1988, SEMIN NUCL MED, V18, P273; CORSTENS FHM, 1991, J NUCL MED, V32, P491; Dams ETM, 1999, EUR J NUCL MED, V26, P311, DOI 10.1007/s002590050391; Dams ETM, 1998, J NUCL MED, V39, P119; DAVIES SG, 1990, BRIT J RADIOL, V63, P850, DOI 10.1259/0007-1285-63-755-850; DEBOIS MHW, 1995, EUR J NUCL MED, V22, P1339, DOI 10.1007/BF00801624; deKleijn EMHA, 1997, J NUCL MED, V38, P484; Guhlmann A, 1998, J NUCL MED, V39, P2145; Hakki S, 1997, CLIN ORTHOP RELAT R, P275; ISRAEL HL, 1991, AM REV RESPIR DIS, V144, P1182, DOI 10.1164/ajrccm/144.5.1182; JAMAR F, 1995, RADIOLOGY, V194, P843, DOI 10.1148/radiology.194.3.7532314; KEELAN ETM, 1994, AM J PHYSIOL, V266, pH279, DOI 10.1152/ajpheart.1994.266.1.H279; KING AD, 1990, EUR J NUCL MED, V17, P148, DOI 10.1007/BF00811443; KNOCKAERT DC, 1994, CLIN INFECT DIS, V18, P601, DOI 10.1093/clinids/18.4.601; Lazzeri E, 1999, EUR J NUCL MED, V26, P606, DOI 10.1007/s002590050428; MORTELMANS J, 1990, J NUCL MED S5, V40, pP201; Nijhof MW, 1997, ACTA ORTHOP SCAND, V68, P332, DOI 10.3109/17453679708996172; OYEN WJG, 1992, RADIOLOGY, V182, P195, DOI 10.1148/radiology.182.1.1727281; OYEN WJG, 1992, J NUCL MED, V33, P1330; OYEN WJG, 1992, J CLIN ONCOL, V10, P61, DOI 10.1200/JCO.1992.10.1.61; OYEN WJG, 1991, J NUCL MED, V32, P1854; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; Procaccini E, 1999, Q J NUCL MED, V43, P100; REULAND P, 1991, J NUCL MED, V32, P526; RUBIN RH, 1989, NEW ENGL J MED, V321, P935, DOI 10.1056/NEJM198910053211404; SIEMSEN JK, 1978, SEMIN NUCL MED, V8, P235, DOI 10.1016/S0001-2998(78)80031-2; STAAB EV, 1978, SEMIN NUCL MED, V8, P219, DOI 10.1016/S0001-2998(78)80030-0; Sugawara Y, 1998, EUR J NUCL MED, V25, P1238, DOI 10.1007/s002590050290; Thakur ML, 1996, J NUCL MED, V37, P1789; van der Laken CJ, 1998, EUR J NUCL MED, V25, P535, DOI 10.1007/s002590050255; vanderLaken CJ, 1996, EUR J NUCL MED, V23, P1531, DOI 10.1007/BF01254480; Vinjamuri S, 1996, LANCET, V347, P233, DOI 10.1016/S0140-6736(96)90407-9; WELDON MJ, 1995, GUT, V37, P557, DOI 10.1136/gut.37.4.557	36	80	101	2	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					765	770		10.1016/S0140-6736(99)06070-5	http://dx.doi.org/10.1016/S0140-6736(99)06070-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475209				2022-12-28	WOS:000082233000047
J	Groce, NE				Groce, NE			Disability in cross-cultural perspective: rethinking disability	LANCET			English	Article									Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University	Groce, NE (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208234, New Haven, CT 06520 USA.		Chesters, Heather/C-6089-2009	Groce, Nora/0000-0002-7885-7042				GROCE NE, 1993, PEDIATRICS, V91, P1048; Helander E, 1993, PREJUDICE DIGNITY; INGSTAD B, 1988, INT J REHABIL RES, V11, P351, DOI 10.1097/00004356-198812000-00004; Ingstad B, 1995, DISABILITY CULTURE; *INT LAB ORG, 1989, DISP SHAD NEGL SURV; MADIROS M, 1989, MED ANTHROPOL, V12, P55; SOLECKI R., 1971, SHANIDAR 1 FLOWER PE; United Nations, 1983, WORLD PROGR ACT DIS	8	62	63	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					756	757		10.1016/S0140-6736(99)06140-1	http://dx.doi.org/10.1016/S0140-6736(99)06140-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475203				2022-12-28	WOS:000082233000041
J	Bahcall, DO; Kowler, E				Bahcall, DO; Kowler, E			Illusory shifts in visual direction accompany adaptation of saccadic eye movements	NATURE			English	Article							DISPLACEMENT; TARGETS; REPRESENTATION; LOCALIZATION; PERCEPTION	A central problem in human vision is to explain how the visual world remains stable despite the continual displacements of the retinal image produced by rapid saccadic movements of the eyes. Perceived stability has been attributed to 'efferent-copy' signals, representing the saccadic motor commands, that cancel the effects of saccade-related retinal displacements(1-6). Here we show by means of a perceptual illusion, that traditional cancellation theories cannot explain stability. The perceptual illusion was produced by first inducing adaptive changes in saccadic gain (ratio of saccade size to target eccentricity). Following adaptation, subjects experienced an illusory mislocalization in which widely separated targets flashed before and after saccades appeared to be in the same place. The illusion shows that the perceptual system did not take the adaptive changes into account, Perceptual localization is based on signals representing the size of the initially-intended saccade, not the size of the saccade that is ultimately executed, Signals representing intended saccades initiate a visual comparison process used to maintain perceptual stability across saccades and to generate the oculomotor error signals that ensure saccadic accuracy.	Rutgers State Univ, Dept Psychol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kowler, E (corresponding author), Rutgers State Univ, Dept Psychol, Piscataway, NJ 08854 USA.	kowler@rci.rutgers.edu						ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; CARPENTER RHS, 1992, MOVEMENTS EYES; CORNSWEET TN, 1962, AM J PSYCHOL, V75, P485, DOI 10.2307/1419876; CRANE HD, 1978, APPL OPTICS, V17, P691, DOI 10.1364/AO.17.000691; DASSONVILLE P, 1992, VISUAL NEUROSCI, V9, P261, DOI 10.1017/S0952523800010671; Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; DEUBEL H, 1995, VISION RES, V35, P3529, DOI 10.1016/0042-6989(95)00058-M; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; ERKELENS CJ, 1993, EXP BRAIN RES, V93, P157; Frens MA, 1997, BRAIN RES BULL, V43, P473, DOI 10.1016/S0361-9230(97)80001-9; GOLDBERG ME, 1993, INT CONGR SER, V1024, P203; GOODALE MA, 1986, NATURE, V320, P748, DOI 10.1038/320748a0; KOWLER E, 1995, VISION RES, V35, P1741, DOI 10.1016/0042-6989(94)00255-K; LEIGH RJ, 1991, NEUROBIOLOGY EYE MOV, P82; LENNIE P, 1978, NATURE, V275, P766, DOI 10.1038/275766a0; LUDVIGH E, 1952, AMA ARCH OPHTHALMOL, V48, P442; MACKAY DM, 1973, HDB SENSORY PHYSIOLO, V7, P307; MATIN L, 1965, SCIENCE, V148, P1485, DOI 10.1126/science.148.3676.1485; MATIN L, 1972, HDB SENSORY PHYSIOLO, V7, P331; McGowan JW, 1998, VISION RES, V38, P895, DOI 10.1016/S0042-6989(97)00232-0; MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071; MILLER JM, 1981, J EXP PSYCHOL HUMAN, V7, P356, DOI 10.1037/0096-1523.7.2.356; OPTICAN LM, 1985, ADAPTIVE MECH GAZE C, P71; POLA J, 1976, EYE MOVEMENTS PSYCHO, P245; Skavenski A. A., 1990, EYE MOVEMENTS THEIR, P263; SKAVENSKI AA, 1972, PERCEPT PSYCHOPHYS, V11, P287, DOI 10.3758/BF03210380; Sperling G., 1990, EYE MOVEMENTS THEIR, P307; VONHELMHOLTZ H, 1963, TREATISE PHYSL OPTIC, V3; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503	30	81	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					864	866		10.1038/23693	http://dx.doi.org/10.1038/23693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476963				2022-12-28	WOS:000082233200043
J	Coral-Vazquez, R; Cohn, RD; Moore, SA; Hill, JA; Weiss, RM; Davisson, RL; Straub, V; Barresi, R; Bansal, D; Hrstka, RF; Williamson, R; Campbell, KP				Coral-Vazquez, R; Cohn, RD; Moore, SA; Hill, JA; Weiss, RM; Davisson, RL; Straub, V; Barresi, R; Bansal, D; Hrstka, RF; Williamson, R; Campbell, KP			Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy	CELL			English	Article							GLYCOPROTEIN COMPLEX; DILATED CARDIOMYOPATHY; GAMMA-SARCOGLYCAN; DEFICIENT MICE; HEART-FAILURE; MUTATIONS; GENE; NICORANDIL; LGMD2F; ACTIN	To investigate mechanisms in the pathogenesis of cardiomyopathy associated with mutations of the dystrophin-glycoprotein complex, we analyzed genetically engineered mice deficient for either alpha-sarcoglycan (Sgca) or delta-sarcoglycan (Sgcd). We found that only Sgcd null mice developed cardiomyopathy with focal areas of necrosis as the histological hallmark in cardiac and skeletal muscle. Absence of the sarcoglycan-sarcospan (SG-SSPN) complex in skeletal and cardiac membranes was observed in both animal models. Loss of vascular smooth muscle SG-SSPN complex was only detected in Sgcd null mice and associated with irregularities of the coronary vasculature. Administration of a vascular smooth muscle relaxant prevented onset of myocardial necrosis. Our data indicate that disruption of the SG-SSPN complex in vascular smooth muscle perturbs vascular function, which initiates cardiomyopathy and exacerbates muscular dystrophy.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Dept Vet Affairs, Iowa City, IA 52242 USA; Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Cohn, Ronald/AAC-5835-2021; Barresi, Rita/AAB-9569-2022; Pillay, Nischalan/F-9536-2012	Barresi, Rita/0000-0001-7351-959X; Campbell, Kevin/0000-0003-2066-5889; Coral, Ramon/0000-0001-6126-2002; Moore, Steven/0000-0002-6353-7900; Straub, Volker/0000-0001-9046-3540	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline; Telethon [305/B] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; KASKI JC, 1995, CARDIOVASC DRUG THER, V9, P221, DOI 10.1007/BF00878469; KUKOVETZ WR, 1992, J CARDIOVASC PHARM, V20, pS1, DOI 10.1097/00005344-199206203-00002; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; Melacini P, 1999, MUSCLE NERVE, V22, P473, DOI 10.1002/(SICI)1097-4598(199904)22:4<473::AID-MUS8>3.0.CO;2-5; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Moreira ES, 1998, J MED GENET, V35, P951, DOI 10.1136/jmg.35.11.951; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Sakamoto A, 1999, FEBS LETT, V447, P124, DOI 10.1016/S0014-5793(99)00267-7; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; STRAUB V, 1999, IN PRESS J BIOL CHEM; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3	25	300	310	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					465	474		10.1016/S0092-8674(00)81975-3	http://dx.doi.org/10.1016/S0092-8674(00)81975-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481911	Bronze			2022-12-28	WOS:000082174900007
J	Evans, D				Evans, D			Ethical viewpoint	BRITISH MEDICAL JOURNAL			English	Article									Univ Otago, Dunedin Sch Med, Ctr Bioeth, Dunedin, New Zealand	University of Otago	Evans, D (corresponding author), Univ Otago, Dunedin Sch Med, Ctr Bioeth, POB 913, Dunedin, New Zealand.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					374	375						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490324				2022-12-28	WOS:000082001700030
J	Clark, WF; Rock, GA; Buskard, N; Shumak, KH; LeBlond, P; Anderson, D; Sutton, DM				Clark, WF; Rock, GA; Buskard, N; Shumak, KH; LeBlond, P; Anderson, D; Sutton, DM		Canadian Apheresis Grp	Therapeutic plasma exchange: An update from the Canadian Apheresis Group	ANNALS OF INTERNAL MEDICINE			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; SYSTEMIC LUPUS-ERYTHEMATOSUS; PROGRESSIVE MULTIPLE-SCLEROSIS; INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; GUILLAIN-BARRE-SYNDROME; MYASTHENIA-GRAVIS; RANDOMIZED TRIAL; DOUBLE-BLIND	In 1997, the Canadian Apheresis Group reviewed data on 103 416 plasma exchange procedures that had been collected since 1980, Although the number of plasma exchanges gradually increased (from 3189 to 8208 per year), the pattern changed. In 1981, the five most frequent indications for plasma exchange resulted in 55% of all such procedures; by 1997, the five most frequent indications for plasma exchange resulted in 81.1% of all such procedures. During this period, three conditions that were originally among the most frequent indications for plasma exchange became among the least frequent. This paper reviews the published evidence that supports or refutes the use of plasma exchange in the category of the five most frequent indications from 1981 to 1997: thrombotic thrombocytopenic purpura, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Waldenstrom macroglobulinemia, the Guillain-Barre syndrome, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. For most disorders, use of plasma exchange procedures is correlated with published evidence, and the changing patterns of plasma exchange use by members of the Canadian Apheresis Group reflect published evidence. Annual center-by-center reviews of use of plasma exchange may also have influenced practice patterns.	London Hlth Sci Ctr, Div Nephrol, London, ON N6A 4G5, Canada; Ottawa Hosp, Ottawa, ON, Canada; Canadian Apheresis Grp, Ottawa, ON, Canada; Vancouver Hosp & Hlth Ctr, Vancouver, BC, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada; Hop St Sacrement, Quebec City, PQ, Canada; Victoria Gen Hosp, Halifax, NS B3H 2Y9, Canada	London Health Sciences Centre; University of Ottawa; Ottawa Hospital Research Institute; University of British Columbia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Laval University; Dalhousie University; University of Victoria	Clark, WF (corresponding author), London Hlth Sci Ctr, Div Nephrol, Victoria Campus,375 South St, London, ON N6A 4G5, Canada.		Clark, Bill/G-3287-2011					Annane D, 1997, ANN NEUROL, V41, P298; [Anonymous], 1991, Lancet, V337, P441; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; BUKOWSKI RM, 1977, BLOOD, V50, P413; BUSKARD NA, 1977, CAN MED ASSOC J, V117, P135; BYRNES JJ, 1977, NEW ENGL J MED, V297, P1386, DOI 10.1056/NEJM197712222972507; BYRNES JJ, 1990, AM J HEMATOL, V34, P169, DOI 10.1002/ajh.2830340303; Clark W F, 1991, J Clin Apher, V6, P40, DOI 10.1002/jca.2920060109; CLARK WF, 1984, PLASMA THER TRANSFUS, V5, P353; COLE E, 1992, AM J KIDNEY DIS, V20, P261, DOI 10.1016/S0272-6386(12)80699-8; DAU PC, 1977, NEW ENGL J MED, V297, P1134, DOI 10.1056/NEJM197711242972102; DWOSH IL, 1983, NEW ENGL J MED, V308, P1124, DOI 10.1056/NEJM198305123081903; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; DYCK PJ, 1986, NEW ENGL J MED, V314, P461, DOI 10.1056/NEJM198602203140801; EULER HH, 1994, ARTHRITIS RHEUM, V37, P1784, DOI 10.1002/art.1780371212; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; Hahn AF, 1996, BRAIN, V119, P1055, DOI 10.1093/brain/119.4.1055; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HENON PR, 1986, PLASMA THER TRANSFUS, V7, P101; JONES JV, 1976, LANCET, V1, P709; KHATRI BO, 1985, NEUROLOGY, V35, P312, DOI 10.1212/WNL.35.3.312; LEVY RL, 1979, LANCET, V2, P259; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; MCKHANN, 1985, NEUROLOGY, V35, P1096; Moschcowitz E, 1925, ARCH INTERN MED, V36, P89, DOI 10.1001/archinte.1925.00120130092009; NEWSOMDAVIS J, 1978, NEUROLOGY, V28, P266, DOI 10.1212/WNL.28.3.266; *NIH CONS DEV C, 1988, TRANSFUS MED REV, V2, P48; PINCHING AJ, 1976, LANCET, V2, P1373; *PLASM EXCH SAND G, 1997, LANCET, V347, P225; Rock G, 1996, BRIT J HAEMATOL, V94, P383, DOI 10.1046/j.1365-2141.1996.d01-1800.x; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; RUBINSTEIN MA, 1959, ANN INTERN MED, V51, P1409, DOI 10.7326/0003-4819-51-6-1409; SCHWAB PJ, 1960, NEW ENGL J MED, V263, P574, DOI 10.1056/NEJM196009222631202; Skoog W., 1959, CLIN RES, V7, P96; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Vamvakas EC, 1995, J CLIN APHERESIS, V10, P163, DOI 10.1002/jca.2920100402; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; WEI N, 1983, LANCET, V1, P17	39	122	125	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					453	462		10.7326/0003-4819-131-6-199909210-00011	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498563				2022-12-28	WOS:000082641100009
J	Lee, AYY; Julian, JA; Levine, MN; Weitz, JI; Kearon, C; Wells, PS; Ginsberg, JS				Lee, AYY; Julian, JA; Levine, MN; Weitz, JI; Kearon, C; Wells, PS; Ginsberg, JS			Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							FIBRIN DEGRADATION PRODUCTS; VEIN THROMBOSIS; PULMONARY-EMBOLISM; DIAGNOSIS; THROMBOEMBOLISM; ULTRASONOGRAPHY; OUTPATIENTS; IMMUNOASSAY; HOME	Background: Although D-dimer assays have high negative predictive values for the diagnosis of deep venous thrombosis, their accuracy in patients with cancer is uncertain. Objective: To compare the clinical utility of a whole-blood D-dimer assay for the diagnosis of deep venous thrombosis in patients with and those without cancer. Design: Retrospective analysis of three prospective studies. Setting: Two tertiary care hospitals. Patients: 1068 consecutive outpatients with suspected deep venous thrombosis. Measurements: All patients underwent D-dimer testing and assessment with a priori diagnostic strategies that incorporated impedance plethysmography, compression ultrasonography, or contrast venography. Patients in whom deep venous thrombosis was not diagnosed initially were followed for 3 months for the development of thrombosis. Results of D-dimer testing were assessed according to the final diagnosis based on objective testing and clinical follow-up. Cancer status was identified at presentation. Results: The prevalence of deep venous thrombosis was 48.8% in 121 patients with cancer and 14.6% in 947 pa patients without cancer. Although the sensitivity of the D-dimer assay was similar in patients with and those without cancer (86.4% [95% CI, 75.0% to 94.0%] and 82.6% [CI, 75.2% to 88.5%], respectively), the specificity was significantly lower in patients with cancer (48.4% [CI, 35.5% to 61.4%] and 82.2% [CI, 79.4% to 84.8%]), as was the negative predictive value (78.9% [CI, 62.7% to 90.4%] and 96.5% [CI, 94.9% to 97.8%]). In contrast, the likelihood ratios of a negative test result (0.28 [CI, 0.14 to 0.56] and 0.21 [CI, 0.15 to 0.31]) did not differ significantly. Conclusions: A negative D-dimer test result in patients with cancer does not reliably exclude deep venous thrombosis because the negative predictive value of the test is significantly lower in these patients than in patients without cancer.	McMaster Univ, Hamilton, ON, Canada; Univ Ottawa, Ottawa, ON K1N 6N5, Canada	McMaster University; University of Ottawa	Lee, AYY (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	alee@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; 				AMBRUS JL, 1975, J MED, V6, P61; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRENNER B, 1995, BLOOD COAGUL FIBRIN, V6, P219, DOI 10.1097/00001721-199505000-00004; CHAPMAN CS, 1990, CLIN LAB HAEMATOL, V12, P37; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; Falanga A, 1999, SEMIN THROMB HEMOST, V25, P173, DOI 10.1055/s-2007-994919; FALANGA A, 1993, THROMB HAEMOSTASIS, V70, P540; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GABAZZA EC, 1991, EUR J CANCER, V30, P1271; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kearon C, 1997, THROMB HAEMOSTASIS, V78, P553; KEEFE DL, 1994, ANGIOLOGY, V45, P771, DOI 10.1177/000331979404500904; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE M, 1990, SEMIN ONCOL, V17, P160; LUZZATTO G, 1990, SEMIN ONCOL, V17, P147; Mayer W, 1997, VASA-J VASCULAR DIS, V26, P97; NANNINGA PB, 1990, THROMB HAEMOSTASIS, V64, P361; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; PINI M, 1993, FIBRINOLYSIS, V7, P391, DOI 10.1016/0268-9499(93)90064-3; RAIMONDI P, 1993, THROMB RES, V69, P125, DOI 10.1016/0049-3848(93)90009-D; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCATES SM, 1992, SEMIN THROMB HEMOST, V18, P373, DOI 10.1055/s-2007-1002576; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Turkstra F, 1996, THROMB HAEMOSTASIS, V76, P9; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921; WILDE JT, 1989, BRIT J HAEMATOL, V71, P65, DOI 10.1111/j.1365-2141.1989.tb06276.x; ZUFFA M, 1982, NEOPLASMA, V29, P241	35	98	103	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					417	423		10.7326/0003-4819-131-6-199909210-00004	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498557				2022-12-28	WOS:000082641100003
J	Chin, J; Lee, SS; Lee, KJ; Park, S; Kim, DH				Chin, J; Lee, SS; Lee, KJ; Park, S; Kim, DH			A metal complex that binds alpha-amino acids with high and predictable stereospecificity	NATURE			English	Article							COBALT(III) COMPLEXES; RECOGNITION; RECEPTORS; LIGANDS; ESTERS; RNA	Molecular recognition is the key step in a wide range of controlled separation and chemical transformation processes, with enzymes performing this task with an unsurpassed degree of selectivity. Enzymes contain only 20 simple amino acids, yet it remains difficult to rationalize or even predict these stereospecific recognition events. Nonetheless, the rational design of receptors able to recognize amino acids stereospecifically is attracting considerable interest because therapeutic drugs, that may be developed from chiral amino acid intermediates, are increasingly required in enantiomerically pure form(1). Early work(2-4) has stimulated the development of efficient receptors based on small molecules(5-8), but binding of amino acids with high and predictable stereospecificity remains difficult to achieve. Directed molecular evolution(9), on the other hand, does select for RNA sequences or antibodies that bind amino acids with high specificity(10-12), but typically without providing insights into the molecular recognition mechanisms involved. Here we show that a rationally designed metal complex formed from a trivalent cobalt ion and a tetradentate ligand binds natural amino acids, including the simple yet challenging amino acid alanine, with high and predictable regio- and stereospecificity. We expect that our approach will allow the binding as well as separation and stereospecific catalytic formation of its target amino acids.	McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada; Pohang Univ Sci & Technol, Ctr Biofunct Mol, Pohang 790784, South Korea	McGill University; Pohang University of Science & Technology (POSTECH)	Chin, J (corresponding author), McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 2K6, Canada.							BUCKINGHAM DA, 1967, J AM CHEM SOC, V89, P5133, DOI 10.1021/ja00996a009; CHIN J, 1991, ACCOUNTS CHEM RES, V24, P145, DOI 10.1021/ar00005a004; Collins A.N., 1997, CHIRALITY IND, VII; COLLINS AN, 1992, CHIRALITY IND, V1; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; DABROWIAK JC, 1975, INORG CHEM, V14, P1305, DOI 10.1021/ic50148a020; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Evans DA, 1997, J AM CHEM SOC, V119, P7893, DOI 10.1021/ja971521y; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FENTON RR, 1995, INORG CHIM ACTA, V236, P109, DOI 10.1016/0020-1693(95)04625-J; FUJII Y, 1981, B CHEM SOC JPN, V54, P2029, DOI 10.1246/bcsj.54.2029; GREENSTEIN JP, 1996, CHEM AMINO ACIDS, V1, P594; Hofstetter O, 1998, J AM CHEM SOC, V120, P3251, DOI 10.1021/ja973680n; JOB RC, 1974, J AM CHEM SOC, V96, P809, DOI 10.1021/ja00810a028; JOYCE GE, 1992, SCI AM, V12, P92; KURODA Y, 1995, J AM CHEM SOC, V117, P10950, DOI 10.1021/ja00149a018; LEHN JM, 1978, J CHEM SOC CHEM COMM, P949, DOI 10.1039/c39780000949; Li GG, 1996, ANGEW CHEM INT EDIT, V35, P451, DOI 10.1002/anie.199604511; SCRIMIN P, 1994, J ORG CHEM, V59, P4194, DOI 10.1021/jo00094a034; Sessler JL, 1998, CHEM-EUR J, V4, P159, DOI 10.1002/(SICI)1521-3765(199801)4:1<159::AID-CHEM159>3.0.CO;2-N; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; Tokunaga M, 1997, SCIENCE, V277, P936, DOI 10.1126/science.277.5328.936; YAMAGUCHI M, 1980, INORG CHEM, V19, P2010, DOI 10.1021/ic50209a035; Zelewsky A.V., 1996, STEREOCHEMISTRY COOR; Zhang XX, 1997, CHEM REV, V97, P3313, DOI 10.1021/cr960144p	25	155	158	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					254	257		10.1038/45751	http://dx.doi.org/10.1038/45751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499581				2022-12-28	WOS:000082678400046
J	Eisenstat, SA; Bancroft, L				Eisenstat, SA; Bancroft, L			Domestic violence	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PHYSICAL ABUSE; PREGNANT-WOMEN; BATTERED WOMEN; MEDICAL-CARE; SEXUAL ABUSE; VICTIMS; VICTIMIZATION; EXPERIENCES; PREVALENCE; EMERGENCY		Massachusetts Gen Hosp, Womens Hlth Associates, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, HAVEN Program, Hosp Helping Abuse & Violence End Now, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Eisenstat, SA (corresponding author), Massachusetts Gen Hosp, Womens Hlth Associates, Dept Med, Blake 10, Boston, MA 02114 USA.							ALPERT EJ, 1996, PARTNER VIOLENCE REC; *AM COLL OBST GYN, 1995, TECHN B AM COLL OBST, V209; [Anonymous], 1998, MEN BATTER WOMEN NEW; ATWOOD JD, 1991, JAMA-J AM MED ASSOC, V265, P460, DOI 10.1001/jama.1991.03460040036019; Bays JA, 1998, PEDIATRICS, V101, P1091; BOWKER LH, 1987, WOMEN HEALTH, V12, P25, DOI 10.1300/J013v12n01_03; *BUR JUST STAT, 1997, VIOL REL INMJ TREAT; CAMPBELL JC, 1992, RES NURS HEALTH, V15, P219, DOI 10.1002/nur.4770150308; Caralis PV, 1997, SOUTH MED J, V90, P1075, DOI 10.1097/00007611-199711000-00003; CARDARELLI AP, 1997, VIOLENCE INTIMATE PA; CARMEN E, 1984, AM J PSYCHIAT, V141, P378; Chalk R, 1998, VIOLENCE FAMILIES AS; Cohen S, 1997, ACAD MED, V72, pS19; CURRIE D, 1990, WOMEN WELL BEING; Davies J., 1998, SAFETY PLANNING BATT; deLahunta EA, 1996, JAMA-J AM MED ASSOC, V275, P1903, DOI 10.1001/jama.275.24.1903; DOUGLASS A, 1994, BUREAU JUSTICE STAT; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; Eby K K, 1995, Health Care Women Int, V16, P563; Family Violence Prevention Fund, 1997, BEST PRACT INN DOM V; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Fisher ER., 1988, BATTERED WOMEN SURVI; Flitcraft A.H., 1992, DIAGNOSTIC TREATMENT; FREUND KM, 1990, CLIN RES, V38, pA738; Freund KM, 1996, J GEN INTERN MED, V11, P44, DOI 10.1007/BF02603485; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; Gazmararian JA, 1997, JAMA-J AM MED ASSOC, V277, P1125; Gazmararian JA, 1996, JAMA-J AM MED ASSOC, V275, P1915, DOI 10.1001/jama.275.24.1915; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; Gondolf E.W., 1985, MEN WHO BATTER INTEG; GONDOLF EW, 1998, ASSESSING WOMAN BATT; Gremillion DH, 1996, ANN EMERG MED, V27, P769, DOI 10.1016/S0196-0644(96)70200-7; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; Hadley S M, 1992, J Emerg Nurs, V18, P18; Hayden S R, 1997, J Emerg Med, V15, P447, DOI 10.1016/S0736-4679(97)00070-X; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HYMAN A, 1995, JAMA-J AM MED ASSOC, V273, P1781, DOI 10.1001/jama.273.22.1781; JACOBSON A, 1987, AM J PSYCHIAT, V144, P908; Jaffe P.G., 1990, CHILDREN BATTERED WO; Kleinschmidt KC, 1997, ANN EMERG MED, V30, P463, DOI 10.1016/S0196-0644(97)70006-4; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; Liebschutz JM, 1997, ARCH INTERN MED, V157, P1093, DOI 10.1001/archinte.157.10.1093; Lobel K., 1986, NAMING VIOLENCE SPEA; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MCKIBBEN L, 1989, PEDIATRICS, V84, P531; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; Muelleman RL, 1998, ACAD EMERG MED, V5, P866, DOI 10.1111/j.1553-2712.1998.tb02815.x; Muelleman RL, 1996, ANN EMERG MED, V28, P486, DOI 10.1016/S0196-0644(96)70110-5; NELSON KG, 1984, PEDIATRICS, V73, P251; NEWBERGER EH, 1992, JAMA-J AM MED ASSOC, V267, P2370, DOI 10.1001/jama.267.17.2370; Pinn VW, 1997, ACAD MED, V72, pS65; Rodriguez MA, 1996, ARCH FAM MED, V5, P153, DOI 10.1001/archfami.5.3.153; Root M. P. P., 1988, J INTERPERS VIOLENCE, V3, P161, DOI DOI 10.1177/088626088003002003; Sachs CJ, 1998, ANN EMERG MED, V31, P488, DOI 10.1016/S0196-0644(98)70259-8; SALBER PR, 1995, PHYSICIANS GUIDE DOM; Saltzman L E, 1990, Atlanta Med, V64, P45; SCHECTER S, 1987, INTERVIEWING BATTERE; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; STARK E, 1981, MONOGRAPH NATL CLEAR, V7; Stark E, 1996, WOMEN RISK DOMESTIC; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; TAYLOR RB, 1997, PREVENTING VIOLENCE; Tjaden Patricia., 1998, PREVALENCE INCIDENCE; WALLING MK, 1994, OBSTET GYNECOL, V84, P193; Warshaw C., 1995, IMPROVING HLTH CARE; WOLFE DA, 1994, PEDIATRICS, V94, P594; ZIERLER S, 1991, AM J PUBLIC HEALTH, V81, P572, DOI 10.2105/AJPH.81.5.572	69	130	136	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					886	892		10.1056/NEJM199909163411206	http://dx.doi.org/10.1056/NEJM199909163411206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10486421				2022-12-28	WOS:000082569100006
J	Gilliver, MA; Bennett, M; Begon, M; Hazel, SM; Hart, CA				Gilliver, MA; Bennett, M; Begon, M; Hazel, SM; Hart, CA			Enterobacteria - Antibiotic resistance found in wild rodents	NATURE			English	Article							BACTERIA; FITNESS		Univ Liverpool, Ctr Comp Infect Dis, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Gilliver, MA (corresponding author), Univ Liverpool, Ctr Comp Infect Dis, POB 147, Liverpool L69 3BX, Merseyside, England.		; Bennett, Malcolm/G-4004-2010	Begon, Mike/0000-0003-1715-5327; Bennett, Malcolm/0000-0003-0475-390X				Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; *BSAC, GUID SENS TEST METH, V35; Davies JE, 1997, CIBA F SYMP, V207, P15; HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; LEVIN BR, 1997, CLIN INFECT DIS   S1, V24, P9; MEDEIROS AA, 1997, CLIN INFECT DIS   S1, V24, P19; Piddock LJV, 1996, J ANTIMICROB CHEMOTH, V38, P1, DOI 10.1093/jac/38.1.1; ROLLAND RM, 1985, APPL ENVIRON MICROB, V49, P791, DOI 10.1128/AEM.49.4.791-794.1985; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Waters B, 1997, ANTIMICROB AGENTS CH, V41, P2766, DOI 10.1128/AAC.41.12.2766; Wiener P, 1998, MOL ECOL, V7, P1205, DOI 10.1046/j.1365-294x.1998.00450.x	13	192	198	4	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					233	234		10.1038/45724	http://dx.doi.org/10.1038/45724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499578				2022-12-28	WOS:000082678400041
J	Scita, G; Nordstrom, J; Carbone, R; Tenca, P; Giardina, G; Gutkind, S; Bjarnegard, M; Betsholtz, C; Di Fiore, PP				Scita, G; Nordstrom, J; Carbone, R; Tenca, P; Giardina, G; Gutkind, S; Bjarnegard, M; Betsholtz, C; Di Fiore, PP			EPS8 and E3B1 transduce signals from Ras to Rac	NATURE			English	Article							SH3 DOMAIN; BINDING-PROTEIN; RHO-GTPASES; GROWTH; KINASE; CDC42; AFFINITY; PATHWAYS	The small guanine nucleotide (GTP)-binding protein Rac regulates mitogen-induced cytoskeletal changes and c-Jun aminoterminal kinase (JNK), and its activity is required for Ras-mediated cell transformation(1). Epistatic analysis placed Rac as a key downstream target in pas signalling(2); however, the biochemical mechanism regulating the cross-talk among these small GTP-binding proteins remains to be elucidated. Eps8 (relative molecular mass 97,000) is a substrate of receptors with tyrosine kinase activity(3) which binds, through its SH3 domain, to a protein designated E3b1/Abi-1 (refs 4, 5). Here we show that Eps8 and E3b1/Abi-1 participate in the transduction of signals from pas to Rac, by regulating Rac-specific guanine nucleotide exchange factor (GEF) activities. We also show that Eps8, E3b1 and Sos-1 form a tri-complex in vivo that exhibits Rac-specific GEF activity in vitro. We propose a model in which Eps8 mediates the transfer of signals between Ras and pac, by forming a complex with E3b1 and Sos-1.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Bari, Ist Microbiol, I-70124 Bari, Italy; NIH, Mol Signaling Unit, Cellular Dev & Oncol Lab, Bethesda, MD 20892 USA	IRCCS European Institute of Oncology (IEO); University of Gothenburg; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.cilea.it	Gutkind, J. Silvio/A-1053-2009; Di Fiore, Pier Paolo/K-2130-2012; Scita, Giorgio/J-9670-2012; Gutkind, J. Silvio/J-1201-2016	Di Fiore, Pier Paolo/0000-0002-2252-0950; Gutkind, J. Silvio/0000-0002-5150-4482; Scita, Giorgio/0000-0001-7984-1889				Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1997, SCIENCE, V276, P185; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LANFRANCONE L, 1995, ONCOGENE, V11, P607; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matoskova B, 1996, ONCOGENE, V12, P2679; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; SASTRY L, 1995, ONCOGENE, V11, P1107; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	23	278	289	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					290	293		10.1038/45822	http://dx.doi.org/10.1038/45822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499589				2022-12-28	WOS:000082678400057
J	Dimigen, G; Del Priore, C; Butler, S; Evans, S; Ferguson, L; Swan, M				Dimigen, G; Del Priore, C; Butler, S; Evans, S; Ferguson, L; Swan, M			Psychiatric disorder among children at time of entering local authority care: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Psychol, Glasgow G12 8RT, Lanark, Scotland; Royal Hosp Sick Children, Yorkhill NHS Trust, Psychol Serv, Glasgow G3 8SJ, Lanark, Scotland; Yorkhill NHS Trust, Glasgow, Lanark, Scotland; Springburn Hlth Ctr, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	Dimigen, G (corresponding author), Univ Glasgow, Dept Psychol, Glasgow G12 8RT, Lanark, Scotland.							BAMFORD F, 1988, PHYSICAL MENTAL HLTH; McCann JB, 1996, BRIT MED J, V313, P1529, DOI 10.1136/bmj.313.7071.1529; NAGLIERI JA, 1993, DEVEREXU SCALES MENT; POLANY L, 1996, ARCH DIS CHILD, V75, P263; Wolkind S., 1994, CHILD ADOL PSYCH CL, P252	5	67	67	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					675	675		10.1136/bmj.319.7211.675	http://dx.doi.org/10.1136/bmj.319.7211.675			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480823	Green Published, Bronze			2022-12-28	WOS:000082636800022
J	Pontesilli, O; Aiuti, F				Pontesilli, O; Aiuti, F			Immunisation with gp160 in HIV-1 infection	LANCET			English	Letter							ANTIRETROVIRAL THERAPY; IMMUNIZATION		Erasmus Univ, Inst Virol, NL-3000 DR Rotterdam, Netherlands; Univ Roma La Sapienza, Cattedra Immunol Clin & Allergol, Rome, Italy	Erasmus University Rotterdam; Sapienza University Rome	Pontesilli, O (corresponding author), Erasmus Univ, Inst Virol, NL-3000 DR Rotterdam, Netherlands.							Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Carlesimo M, 1997, J INFECT DIS, V176, P904, DOI 10.1086/516500; Pontesilli O, 1998, AIDS, V12, P473, DOI 10.1097/00002030-199805000-00008; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Sandstrom E, 1999, LANCET, V353, P1735, DOI 10.1016/S0140-6736(98)06493-9	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					948	949		10.1016/S0140-6736(05)75694-4	http://dx.doi.org/10.1016/S0140-6736(05)75694-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489977				2022-12-28	WOS:000082511800052
J	Levinson, W; Rubenstein, A				Levinson, W; Rubenstein, A			Mission critical - Integrating clinician-educators into academic medical centers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; FACULTY TRACKS; PRIMARY-CARE; PROMOTION; SCHOOLS; TENURE; EXPERIENCE; TEACHERS; SUCCESS		Univ Chicago, Chicago, IL 60637 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA	University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Levinson, W (corresponding author), Univ Chicago, Chicago, IL 60637 USA.							BARDES CL, 1995, ACAD MED, V70, P111, DOI 10.1097/00001888-199502000-00013; BATSHAW ML, 1988, NEW ENGL J MED, V318, P741, DOI 10.1056/NEJM198803243181204; Beasley BW, 1997, JAMA-J AM MED ASSOC, V278, P723, DOI 10.1001/jama.278.9.723; BICKEL J, 1991, ACAD MED, V66, P249, DOI 10.1097/00001888-199105000-00002; Block SD, 1996, JAMA-J AM MED ASSOC, V276, P677, DOI 10.1001/jama.276.9.677; Boyer EL, 1990, SCHOLARSHIP RECONSID; CAREY RM, 1993, ACAD MED, V68, P813, DOI 10.1097/00001888-199311000-00001; Carroll R G, 1996, Am J Physiol, V271, pS10; Henderson MC, 1996, AM J MED, V101, P648, DOI 10.1016/S0002-9343(96)00334-8; Humphrey HJ, 1997, J GEN INTERN MED, V12, pS79, DOI 10.1046/j.1525-1497.12.s2.11.x; JACKSON M, 1984, J FAM PRACTICE, V18, P435; JACOBS MB, 1992, ACAD MED, V67, P623, DOI 10.1097/00001888-199210000-00001; Jones RF, 1998, ACAD MED, V73, P212, DOI 10.1097/00001888-199802000-00023; JONES RF, 1987, J MED EDUC, V62, P444; JONES RF, 1994, ACAD MED, V69, P476, DOI 10.1097/00001888-199406000-00015; KELLEY WN, 1992, ANN INTERN MED, V116, P654, DOI 10.7326/0003-4819-116-8-654; Levinson W, 1998, ANN INTERN MED, V129, P59, DOI 10.7326/0003-4819-129-1-199807010-00013; Lovejoy FH, 1995, ACAD MED, V70, P1079, DOI 10.1097/00001888-199512000-00009; Lubitz RM, 1997, J GEN INTERN MED, V12, pS71, DOI 10.1046/j.1525-1497.12.s2.10.x; MCHUGH PR, 1994, ACAD MED, V69, P877, DOI 10.1097/00001888-199411000-00003; PARRIS M, 1984, J MED EDUC, V59, P465; PETERSDORF RG, 1984, JAMA-J AM MED ASSOC, V251, P920, DOI 10.1001/jama.251.7.920; Ramsey PG, 1996, ACAD MED, V71, P364, DOI 10.1097/00001888-199604000-00014; ROTHMAN AI, 1989, ACAD MED, V64, P774, DOI 10.1097/00001888-198912000-00016; Sheffield JVL, 1998, J GEN INTERN MED, V13, P406, DOI 10.1046/j.1525-1497.1998.00120.x; Williams RL, 1998, ACAD MED, V73, P333, DOI 10.1097/00001888-199803000-00023; Wright SM, 1998, NEW ENGL J MED, V339, P1986, DOI 10.1056/NEJM199812313392706; Yonke A, 1996, ACAD MED, V71, P1277, DOI 10.1097/00001888-199612000-00003; Zyzanski S J, 1996, Fam Med, V28, P358	29	84	85	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					840	843		10.1056/NEJM199909093411111	http://dx.doi.org/10.1056/NEJM199909093411111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477784				2022-12-28	WOS:000082534000011
J	Park, DH; Somers, DE; Kim, YS; Choy, YH; Lim, HK; Soh, MS; Kim, HJ; Kay, SA; Nam, HG				Park, DH; Somers, DE; Kim, YS; Choy, YH; Lim, HK; Soh, MS; Kim, HJ; Kay, SA; Nam, HG			Control of circadian rhythms and photoperiodic flowering by the Arabidopsis GIGANTEA gene	SCIENCE			English	Article							CDNA CLONE; CLOCK; THALIANA; TRANSCRIPTION; PERIOD; DROSOPHILA; MUTANT; PLANTS; ENTRAINMENT; EXPRESSION	Photoperiodic responses in plants include flowering that is day-length-dependent. Mutations in the Arabidopsis thaliana GIGANTEA (GI) gene cause photoperiod-insensitive flowering and alteration of circadian rhythms. The GI gene encodes a protein containing six putative transmembrane domains. Circadian expression patterns of the GI gene and the clock-associated genes, LHY and CCA1, are altered in gi mutants, showing that GI is required for maintaining circadian amplitude and appropriate period length of these genes. The gi-1 mutation also affects Light signaling to the clock, which suggests that GI participates in a feedback loop of the plant circadian system.	Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92307 USA; Scripps Res Inst, Natl Sci Fdn, Ctr Biol Timing, La Jolla, CA 92307 USA	Pohang University of Science & Technology (POSTECH); Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute	Nam, HG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea.		Somers, David E/A-9209-2010; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; SOH, MOON-SOO/0000-0002-4430-516X	NIGMS NIH HHS [GM56006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Amasino RM, 1996, CURR OPIN GENET DEV, V6, P480, DOI 10.1016/S0959-437X(96)80071-2; ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Carre IA, 1996, SEMIN CELL DEV BIOL, V7, P775, DOI 10.1006/scdb.1996.0095; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Green RM, 1999, P NATL ACAD SCI USA, V96, P4176, DOI 10.1073/pnas.96.7.4176; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; Kim YS, 1998, PLANT MOL BIOL, V37, P955, DOI 10.1023/A:1006030617502; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Kwak JM, 1997, PLANTA, V201, P245, DOI 10.1007/s004250050063; Lumsden P. J., 1998, BIOL RHYTHMS PHOTOPE; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Redei G. P., 1974, STADLER S, V6, P135; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Somers DE, 1998, DEVELOPMENT, V125, P485; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Thomas B., 1997, PHOTOPERIODISM PLANT; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; WHITELAM GC, 1998, ARABIDOPSIS ANN PLAN, V1, P331; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	36	452	480	5	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1579	1582		10.1126/science.285.5433.1579	http://dx.doi.org/10.1126/science.285.5433.1579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477524				2022-12-28	WOS:000082359500069
J	Mochizuki, N; Ohba, Y; Kiyokawa, E; Kurata, T; Murakami, T; Ozaki, T; Kitabatake, A; Nagashima, K; Matsuda, M				Mochizuki, N; Ohba, Y; Kiyokawa, E; Kurata, T; Murakami, T; Ozaki, T; Kitabatake, A; Nagashima, K; Matsuda, M			Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i)	NATURE			English	Article							PROTEIN-KINASE ACTIVATION; RAS-DEPENDENT ACTIVATION; MAP KINASE; FIBROBLASTS; TRANSFORMATION; RECEPTORS; SUBUNITS; P21(RAS); GENE	Many receptors for neuropeptides and hormones are coupled with the heterotrimeric G(i) protein, which activates the p42/44 mitogen-activated protein kinase (ERK/MAPE;) cascade through both the alpha- and beta gamma-subunits of G(i) (refs 1-3). The beta gamma-subunit activates the ERK/MAPK cascade through tyrosine kinase(4-6). Constitutively active G alpha(i2) (gip2) isolated from adrenal and ovarian tumours(7,8) transforms Rat-1 fibroblasts and also activates the ERK/MAPK cascade by an unknown mechanism(9,10). The ERK/MAPK pathway is activated by Ras, and is inhibited when the low-molecular-mass GTP-binding protein Rap1 antagonizes pas function(11). Here we show that a novel isoform of Rap1 GTPase-activating protein, called rap1GAPII, binds specifically to the alpha-subunits of the G(i) family of heterotrimeric G-proteins. Stimulation of the G(i)-coupled m2-muscarinic receptor translocates rap1GAPII from the cytosol to the membrane and decreases the amount of GTP-bound Rap1. This decrease in GTP-bound Rap1 activates ERK/MAPK. Thus, the alpha-subunit of G(i) activates the Ras-ERK/MAPK mitogenic pathway by membrane recruitment of rap1GAPII and reduction of GTP-bound Rap1.	Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan; Hokkaido Univ, Sch Med, Dept Cardiovasc Med, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Hokkaido University; Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan.		Ohba, Yusuke/E-7944-2011	Matsuda, Michiyuki/0000-0002-5876-9969				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PIZON V, 1994, J CELL SCI, V107, P1661; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	25	193	197	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					891	894		10.1038/23738	http://dx.doi.org/10.1038/23738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476970				2022-12-28	WOS:000082233200050
J	Davies, H				Davies, H			A memorable patient - On the power of communication	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					782	782		10.1136/bmj.319.7212.782	http://dx.doi.org/10.1136/bmj.319.7212.782			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488015	Green Published			2022-12-28	WOS:000082701500034
J	Deo, RC; Bonanno, JB; Sonenberg, N; Burley, SK				Deo, RC; Bonanno, JB; Sonenberg, N; Burley, SK			Recognition of polyadenylate RNA by the poly(A)-binding protein	CELL			English	Article							POLY(A) BINDING-PROTEIN; TRANSLATION INITIATION; MESSENGER-RNA; CRYSTAL-STRUCTURE; CYTOPLASMIC POLY(A)-RIBONUCLEOPROTEIN; ANGSTROM RESOLUTION; REPEATING STRUCTURE; DOMAINS; YEAST; TAIL	The cocrystal structure of human poly(A)-binding protein (PABP) has been determined at 2.6 Angstrom resolution. PABP recognizes the 3' mRNA poly(A) tail and plays critical roles in eukaryotic translation initiation and mRNA stabilization/degradation. The minimal PABP used in this study consists of the N-terminal two RRM-type RNA-binding domains connected by a short linker (RRM1/2). These two RRMs form a continuous RNA-binding trough, lined by an antiparallel beta sheet backed by four alpha helices. The polyadenylate RNA adopts an extended conformation running the length of the molecular trough. Adenine recognition is primarily mediated by contacts with conserved residues found in the RNP motifs of the two RRMs. The convex dorsum of RRM1/2 displays a phylogenetically conserved hydrophobic/acidic portion, which may interact with translation initiation factors and regulatory proteins.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; McGill University; McGill University; Howard Hughes Medical Institute; Rockefeller University	Burley, SK (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Burley, Stephen K./0000-0002-2487-9713				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1993, J BIOL CHEM, V268, P2937; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	47	397	406	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					835	845		10.1016/S0092-8674(00)81517-2	http://dx.doi.org/10.1016/S0092-8674(00)81517-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499800	Bronze			2022-12-28	WOS:000082679200010
J	Kwok, JMF; Miller, TD; Christian, TF; Hodge, DO; Gibbons, RJ				Kwok, JMF; Miller, TD; Christian, TF; Hodge, DO; Gibbons, RJ			Prognostic value of a treadmill exercise score in symptomatic patients with nonspecific ST-T abnormalities on resting ECG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; LEFT-VENTRICULAR FUNCTION; ASSOCIATION TASK-FORCE; SEGMENT DEPRESSION; ELECTROCARDIOGRAPHIC FINDINGS; ARTERY-DISEASE; DIAGNOSIS; PREVALENCE; GUIDELINES; MORTALITY	Context Exercise testing of patients with ST-T abnormalities on the resting electrocardiogram (ECG) is problematic because in the presence of pre-existing ST-T abnormalities, the exercise test is less specific for the diagnosis of coronary artery disease. The prognostic capability of the Duke treadmill score in patients with ST-T abnormalities vs those with normal findings on resting ECG has, to our knowledge, not been evaluated. Objective To compare the prognostic accuracy of the Duke treadmill score in patients with nonspecific ST-T abnormalities vs those with normal results on resting ECG. Design Inception cohort study with 7 years of follow-up. Setting Nuclear cardiology laboratory of a US referral center. Patients All symptomatic patients who underwent exercise thallium testing between 1989 and 1991, 939 of whom had nonspecific ST-T abnormalities and 1466 of whom had normal findings on resting ECG. Exclusion criteria included congenital, valvular, or cardiomyopathic heart disease; prior coronary artery revascularization; resting ECC with secondary ST-T abnormalities; or missing data. Main Outcome Measures Rates of overall mortality and cardiac death for subjects classified by Duke treadmill store risk group. Results For the end point cardiac death, 7-year survival in the study population in the low-, intermediate-, and high-risk groups was 97%, 92%, and 76%, respectively (P<.001), Compared with the control group, the study group had lower 7-year survival (94% vs 98%; P<.001), fewer low-risk patients (426 [45%] vs 811 [55%]; P<.001) with worse 7-year survival (97% vs 99%; P=.008), and more high-risk patients (49 [5%] vs 34 [2%];P<.001) with a nonsignificant trend toward worse 7-year survival (76% vs 93%; P =.36). Conclusions The Duke treadmill score can effectively risk-stratify patients with ST-T abnormalities on the resting EGG. In classified risk categories, patients with ST-T abnormalities have a worse prognosis than those with normal results on resting ECG.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Princess Margaret Hosp, Dept Med, Kowloon, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic	Miller, TD (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA.	miller.todd@mayo.edu						ARAVINDAKSHAN V, 1977, AM HEART J, V93, P706, DOI 10.1016/S0002-8703(77)80065-3; ARONOW WS, 1989, AM J CARDIOL, V64, P232, DOI 10.1016/0002-9149(89)90465-7; BERMAN JL, 1978, CIRCULATION, V58, P505, DOI 10.1161/01.CIR.58.3.505; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; Christian TF, 1997, AM J CARDIOL, V79, P1295, DOI 10.1016/S0002-9149(97)00108-2; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; COHN K, 1979, CIRCULATION, V59, P286, DOI 10.1161/01.CIR.59.2.286; COHN PF, 1971, CIRCULATION, V43, P648, DOI 10.1161/01.CIR.43.5.648; CONNOLLY DC, 1984, MAYO CLIN PROC, V59, P247, DOI 10.1016/S0025-6196(12)61257-9; CULLEN K, 1982, BRIT HEART J, V47, P209; DETRANO R, 1989, J AM COLL CARDIOL, V14, P1501, DOI 10.1016/0735-1097(89)90388-4; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P474; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; GOLDSCHLAGER N, 1976, ANN INTERN MED, V85, P277, DOI 10.7326/0003-4819-85-3-277; HARRIS FJ, 1977, ADV CARDIOL, V22, P11; HOLLENBERG M, 1980, CIRCULATION, V61, P276, DOI 10.1161/01.CIR.61.2.276; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KANSAL S, 1976, CIRCULATION, V54, P636, DOI 10.1161/01.CIR.54.4.636; KREGER BE, 1987, AM HEART J, V113, P377, DOI 10.1016/0002-8703(87)90281-X; LADENHEIM ML, 1987, AM J CARDIOL, V59, P270, DOI 10.1016/0002-9149(87)90798-3; LINHART JW, 1974, CIRCULATION, V49, P667; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MEYERS DG, 1990, AM HEART J, V119, P272, DOI 10.1016/S0002-8703(05)80016-X; MIRANDA CP, 1991, AM HEART J, V122, P1617, DOI 10.1016/0002-8703(91)90279-Q; MIRVIS DM, 1990, AM J CARDIOL, V66, P699, DOI 10.1016/0002-9149(90)91133-Q; OKEEFE JH, 1989, AM J MED, V86, P658, DOI 10.1016/0002-9343(89)90439-7; OSTOR E, 1981, EUR HEART J, V2, P317; Pollock ML, 1990, EXERCISE HLTH DIS EV; REUNANEN A, 1977, ADV CARDIOL, V21, P310; ROMHILT DW, 1968, CIRCULATION, V37, P15, DOI 10.1161/01.CIR.37.1.15; ROSE G, 1978, BRIT HEART J, V40, P636; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; WEINER DA, 1983, AM HEART J, V105, P749, DOI 10.1016/0002-8703(83)90236-3	37	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1047	1053		10.1001/jama.282.11.1047	http://dx.doi.org/10.1001/jama.282.11.1047			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493203	Bronze			2022-12-28	WOS:000082512300028
J	Fattori, R; Nienaber, CA; Descovich, B; Ambrosetto, P; Reggiani, LB; Pepe, G; Kaufmann, U; Negrini, N; von Kodolitsch, Y; Gensini, GF				Fattori, R; Nienaber, CA; Descovich, B; Ambrosetto, P; Reggiani, LB; Pepe, G; Kaufmann, U; Negrini, N; von Kodolitsch, Y; Gensini, GF			Importance of dural ectasia in phenotypic assessment of Marfan's syndrome	LANCET			English	Article							FIBRILLIN-1 FBN1; MUTATIONS	Background Early identification of Marfan's syndrome is fundamental in the prevention of aortic dilatation, but the wide phenotypic expression of the disorder makes the clinical diagnosis very difficult. Dural ectasia has been classified as a major diagnostic criterion; however, its prevalence is not known. We aimed to identify the true prevalence of dural ectasia in Marfan's syndrome, and to investigate its relation to aortic pathology. Methods A magnetic-resonance-imaging (MRI) study of the thoracic aorta and of the lumbosacral spine was done in an inclusive series of 83 patients with Marfan's syndrome to assess the presence and degree of dural ectasia and aortic involvement; 12 patients were younger than 18 years. 100 individuals who underwent MRI of the lumbar spine for routine clinical indications represented the control group; none of them had any potential causes for dural ectasia. Findings Dural ectasia was identified in 76 (92%) patients and none of the control group. The severity of dural ectasia was related to age; the mean (SD) age of patients with mild dural ectasia was 26 years (14) whereas that of those with severe disease (meningocele) was 36 years (9) (p=0.038). 11 of 12 patients younger than 18 years had dural ectasia. No association was found between aortic dilatation and dural ectasia. Interpretation Dural ectasia is a highly characteristic sign of Marian's syndrome, even at an early age.	Univ Hosp S Orsola, Inst Radiol, Bologna, Italy; Univ Hosp S Orsola, Neurol Inst, Bologna, Italy; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, Div Cardiol, D-20246 Hamburg, Germany; Univ Roma Tor Vergata, Dept Internal Med, Clin Biochem Sect, I-00173 Rome, Italy; Univ Hosp Careggi, Dept Internal Med & Cardiol, Florence, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University of Hamburg; University of Rome Tor Vergata; University of Florence; Azienda Ospedaliero Universitaria Careggi	Fattori, R (corresponding author), Osped S Orsola Malpighi, Ist Radiol Radiol 3, Via Massarenti 9, I-40100 Bologna, Italy.	ross@med.unibo.it	Pepe, Guglielmina/K-8013-2016; Fattori, Rossella/L-1017-2016; Bacchi Reggiani, Maria Letizia/O-2311-2014	Pepe, Guglielmina/0000-0001-9825-6618; Bacchi Reggiani, Maria Letizia/0000-0003-3985-1542				[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DUNCAN RW, 1995, SPINE, V20, P1197, DOI 10.1097/00007632-199505150-00016; ELDADAH ZA, 1995, J CLIN INVEST, V95, P874, DOI 10.1172/JCI117737; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; Legget ME, 1996, HEART, V75, P389, DOI 10.1136/hrt.75.4.389; Milewicz DM, 1996, CIRCULATION, V94, P2708, DOI 10.1161/01.CIR.94.11.2708; MITCHELL GE, 1967, RADIOLOGY, V89, P67, DOI 10.1148/89.1.67; NELSON JD, 1958, BRIT J RADIOL, V31, P561, DOI 10.1259/0007-1285-31-370-561; PEPIN MG, 1992, AM J HUM GENET, V5, pA44; PYERITZ RE, 1988, AM J HUM GENET, V43, P726; PYERITZ RE, 1993, AM J MED GENET, V47, P127, DOI 10.1002/ajmg.1320470131; RAFTOPOULOS C, 1993, ACTA CHIR BELG, P1; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; SMITH MD, 1993, J BONE JOINT SURG AM, V75A, P1067, DOI 10.2106/00004623-199307000-00013; SONIER CB, 1993, J NEURORADIOLOGY, V20, P292; SOULEN RL, 1987, RADIOLOGY, V165, P697, DOI 10.1148/radiology.165.3.3685348; STERN WE, 1988, J NEUROSURG, V69, P221, DOI 10.3171/jns.1988.69.2.0221; ZANHKA KG, 1989, J AM COLL CARDIOL  S, V13, pA119	23	144	145	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					910	913		10.1016/S0140-6736(98)12448-0	http://dx.doi.org/10.1016/S0140-6736(98)12448-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489951				2022-12-28	WOS:000082511800014
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1971: Earl Wilbur Sutherland, Jr - (1915-74)	LANCET			English	Article									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Raju, TNK (corresponding author), Univ Chicago, Chicago, IL 60637 USA.							1999, LANCET, V354, P1108	1	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					961	961		10.1016/S0140-6736(05)75718-4	http://dx.doi.org/10.1016/S0140-6736(05)75718-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489991				2022-12-28	WOS:000082511800070
J	Richards, T				Richards, T			New EU health commissioner airs his priorities	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					662	662		10.1136/bmj.319.7211.662	http://dx.doi.org/10.1136/bmj.319.7211.662			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480817	Green Published			2022-12-28	WOS:000082636800016
J	Schmidt, A; Wolde, M; Thiele, C; Fest, W; Kratzin, H; Podtelejnikov, AV; Witke, W; Huttner, WB; Soling, HD				Schmidt, A; Wolde, M; Thiele, C; Fest, W; Kratzin, H; Podtelejnikov, AV; Witke, W; Huttner, WB; Soling, HD			Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid	NATURE			English	Article							ACYL-COENZYME-A; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; PHOSPHOLIPID-METABOLISM; TRANSPORT VESICLES; BINDING PARTNERS; PROTEIN; DYNAMIN; ENDOCYTOSIS; DOMAIN	Endophilin I is a presynaptic protein of unknown function that binds to dynamin, a GTPase that is implicated in endocytosis and recycling of synaptic vesicles. Here we show that endophilin I is essential for the formation of synaptic-like microvesicles (SLMVs) from the plasma membrane. Endophilin I exhibits lysophosphatidic acid acyl transferase (LPAAT) activity, and endophilin-I-mediated SLMV formation requires the transfer of the unsaturated fatty acid arachidonate to lysophosphatidic acid, converting it to phosphatidic acid. A deletion mutant lacking the SH3 domain through which endophilin I interacts with dynamin still exhibits LPAAT activity but no longer mediates SLMV formation. These results indicate that endophilin I may induce negative membrane curvature by converting an inverted-cone-shaped lipid to a cone-shaped lipid in the cytoplasmic leaflet of the bilayer. We propose that, through this action, endophilin I works with dynamin to mediate synaptic vesicle invagination from the plasma membrane and fission.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Heidelberg Univ, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Gottingen, Dept Clin Biochem, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg; Max Planck Society; University of Gottingen; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Huttner, WB (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 110, D-01307 Dresden, Germany.	whuttner@sun0.urz.uni-heidelberg.de; hsoelin@gwdg.de	Huttner, Wieland B./P-4080-2018; Podtelejnikov, Alexandre/B-6120-2017	Podtelejnikov, Alexandre/0000-0002-8124-6584; Schmidt, Anne/0000-0002-8326-0937				Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; DUZGUNES N, 1995, NATO ADV SCI INST SE, V91, P97; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; Kates M, 1986, LAB TECHNIQUES BIOCH, V3; Kirchhausen T, 1999, NATURE, V398, P470, DOI 10.1038/18989; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; LIPOWSKY R, 1993, BIOPHYS J, V64, P1133, DOI 10.1016/S0006-3495(93)81479-6; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MORRIS SA, 1995, CURR BIOL, V5, P113, DOI 10.1016/S0960-9822(95)00028-5; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SOLING HD, 1989, ADV ENZYME REGUL, V28, P35, DOI 10.1016/0065-2571(89)90062-9; SOLING HD, 1989, J BIOL CHEM, V264, P10643; SOLING HD, 1987, J BIOL CHEM, V262, P16786; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	49	436	457	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					133	141		10.1038/43613	http://dx.doi.org/10.1038/43613			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490020				2022-12-28	WOS:000082458800045
J	Katan, MB				Katan, MB			Functional foods	LANCET			English	Editorial Material									Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands; Agr Univ Wageningen, Div Human Nutr & Epidemiol, NL-6703 HD Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Katan, MB (corresponding author), Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands.							Bellisle F, 1998, BRIT J NUTR, V80, pS173, DOI 10.1079/BJN19980109; Diplock AT, 1999, BRIT J NUTR, V81, pS1, DOI 10.1017/S0007114599000471; Levin A, 1999, ANN INTERN MED, V131, P161, DOI 10.7326/0003-4819-131-2-199907200-00101; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559	6	14	15	6	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1999	354	9181					794	794						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485719				2022-12-28	WOS:000082400700006
J	Fernandez, G; Effern, A; Grunwald, T; Pezer, N; Lehnertz, K; Dumpelmann, M; Van Roost, D; Elger, CE				Fernandez, G; Effern, A; Grunwald, T; Pezer, N; Lehnertz, K; Dumpelmann, M; Van Roost, D; Elger, CE			Real-time tracking of memory formation in the human rhinal cortex and hippocampus	SCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; EVENT-RELATED POTENTIALS; EPISODIC MEMORY; ANTIEPILEPTIC DRUGS; SEMANTIC MEMORY; BRAIN ACTIVITY; SYSTEM; WORDS; ORGANIZATION; RECOGNITION	A fundamental question about human memory is which brain structures are involved, and when, in transforming experiences into memories. This experiment sought to identify neural correlates of memory formation with the use of intracerebral electrodes implanted in the brains of patients with temporal Lobe epilepsy. Event-related potentials (ERPs) were recorded directly from the medial temporal Lobe (MTL) as the patients studied single words. ERPs elicited by words subsequently recalled in a memory test were contrasted with ERPs elicited by unrecalled words. Memory formation was associated with distinct but interrelated ERP differences within the rhinal cortex and the hippocampus, which arose after about 300 and 500 milliseconds, respectively. These findings suggest that declarative memory formation is dissociable into subprocesses and sequentially organized within the MTL.	Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany; Univ Bonn, Dept Radiat & Nucl Phys, D-53105 Bonn, Germany; Univ Bonn, Dept Neurosurg, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Fernandez, G (corresponding author), Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany.		Fernandez, Guillen/B-3771-2009; Duempelmann, Matthias/K-2583-2012	Fernandez, Guillen/0000-0002-5522-0604; Duempelmann, Matthias/0000-0002-1476-7777; Lehnertz, Klaus/0000-0002-5529-8559				AGGLETON JP, IN PRESS BEHAV BRAIN; Akaho R, 1996, PSYCHIAT CLIN NEUROS, V50, P61, DOI 10.1111/j.1440-1819.1996.tb01665.x; Amaral DG, 1990, HUMAN NERVOUS SYSTEM, P711; Baayen R. H., 1993, CELEX LEXICAL DATABA; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Chen YJ, 1996, EPILEPSIA, V37, P81, DOI 10.1111/j.1528-1157.1996.tb00516.x; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; Dolan RJ, 1999, HIPPOCAMPUS, V9, P25, DOI 10.1002/(SICI)1098-1063(1999)9:1<25::AID-HIPO3>3.0.CO;2-4; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Elger CE, 1997, NEUROPSYCHOLOGIA, V35, P657, DOI 10.1016/S0028-3932(96)00110-8; Fernandez G, 1998, PSYCHOPHYSIOLOGY, V35, P709, DOI 10.1017/S0048577298970500; Fernandez G, 1999, HIPPOCAMPUS, V9, P35, DOI 10.1002/(SICI)1098-1063(1999)9:1<35::AID-HIPO4>3.0.CO;2-Z; Fernandez G, 1998, J NEUROSCI, V18, P1841; Gleissner U, 1997, NEUROREPORT, V8, P2893, DOI 10.1097/00001756-199709080-00018; Gregg V., 1976, RECALL RECOGNITION, P183; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; HEIT G, 1988, NATURE, V333, P773, DOI 10.1038/333773a0; Henke K, 1999, P NATL ACAD SCI USA, V96, P5884, DOI 10.1073/pnas.96.10.5884; JACKSON GD, 1996, MRI NEUROANATOMY; JONESGOTMAN M, 1991, EPILEPSY SURG, P469; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; KLEE M, 1977, J NEUROPHYSIOL, V40, P647, DOI 10.1152/jn.1977.40.3.647; KUTAS M, 1997, COGNITIVE NEUROSCIEN, P197; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; NEVILLE HJ, 1986, J MEM LANG, V25, P75, DOI 10.1016/0749-596X(86)90022-7; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; PALLER KA, 1992, ELECTROEN CLIN NEURO, V84, P269, DOI 10.1016/0168-5597(92)90008-Y; PALLER KA, 1990, J EXP PSYCHOL LEARN, V16, P1021, DOI 10.1037/0278-7393.16.6.1021; Panagopoulos GR, 1997, ACTA NEUROL SCAND, V96, P62; Picton TW., 1995, HDB NEUROPHYSIOLOGY, P3; RINGO JL, 1995, J NEUROPHYSIOL, V73, P1712, DOI 10.1152/jn.1995.73.4.1712; RUGG MD, 1995, NEUROPSYCHOLOGIA, V33, P471, DOI 10.1016/0028-3932(94)00132-9; Rugg MD, 1998, HUM BRAIN MAPP, V6, P394, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<394::AID-HBM12>3.3.CO;2-G; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; SUZUKI WA, 1994, J NEUROSCI, V14, P1856, DOI 10.1523/JNEUROSCI.14-03-01856.1994; Tulving E., 1972, ORG MEMORY, DOI DOI 10.1017/S0140525X00047257; UNDERWOO.BJ, 1969, PSYCHOL REV, V76, P559, DOI 10.1037/h0028143; Van Roost D, 1998, NEUROSURGERY, V43, P819, DOI 10.1097/00006123-199810000-00058; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	51	243	245	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1582	1585		10.1126/science.285.5433.1582	http://dx.doi.org/10.1126/science.285.5433.1582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477525				2022-12-28	WOS:000082359500070
J	Harvell, CD; Kim, K; Burkholder, JM; Colwell, RR; Epstein, PR; Grimes, DJ; Hofmann, EE; Lipp, EK; Osterhaus, ADME; Overstreet, RM; Porter, JW; Smith, GW; Vasta, GR				Harvell, CD; Kim, K; Burkholder, JM; Colwell, RR; Epstein, PR; Grimes, DJ; Hofmann, EE; Lipp, EK; Osterhaus, ADME; Overstreet, RM; Porter, JW; Smith, GW; Vasta, GR			Review: Marine ecology - Emerging marine diseases - Climate links and anthropogenic factors	SCIENCE			English	Article							STRONGYLOCENTROTUS-DROEBACHIENSIS ECHINODERMATA; SARDINOPS-SAGAX-NEOPILCHARDUS; CANINE-DISTEMPER VIRUS; HARMFUL ALGAL BLOOMS; MONK SEAL MORTALITY; INFLUENZA-A VIRUSES; POX-LIKE LESIONS; GULF-OF-MEXICO; MASS MORTALITY; PERKINSUS-MARINUS	Mass mortalities due to disease outbreaks have recently affected major taxa in the oceans. For closely monitored groups like corals and marine mammals, reports of the frequency of epidemics and the number of new diseases have increased recently. A dramatic global increase in the severity of coral bleaching in 1997-98 is coincident with high El Nino temperatures. Such climate-mediated, physiological stresses may compromise host resistance and increase frequency of opportunistic diseases. Where documented, new diseases typically have emerged through host or range shifts of known pathogens. Both climate and human activities may have also accelerated global transport of species, bringing together pathogens and previously unexposed host populations.	Cornell Univ, Ithaca, NY 14853 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA; N Carolina State Univ, Dept Bot, Raleigh, NC 27695 USA; Univ Maryland, Inst Biotechnol, Ctr Marine Biotechnol, Baltimore, MD 21202 USA; Univ Maryland, Dept Cell & Mol Biol, College Pk, MD 20742 USA; Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA 02115 USA; Univ So Mississippi, Inst Marine Sci, Ocean Springs, MS 39566 USA; Old Dominion Univ, Ctr Coastal Phys Oceanog, Norfolk, VA 23529 USA; Univ S Florida, Dept Marine Sci, St Petersburg, FL 33701 USA; Erasmus Univ, Inst Virol, NL-3000 DR Rotterdam, Netherlands; Univ So Mississippi, Gulf Coast Res Lab, Ocean Springs, MS 39566 USA; Univ Georgia, Inst Ecol, Athens, GA 30602 USA; Univ S Carolina, Aiken, SC 29801 USA	Cornell University; University System of Maryland; University of Maryland College Park; University of North Carolina; North Carolina State University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland College Park; Harvard University; Harvard Medical School; University of Southern Mississippi; Old Dominion University; State University System of Florida; University of South Florida; Erasmus University Rotterdam; University of Southern Mississippi; University System of Georgia; University of Georgia; University of South Carolina	Harvell, CD (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.			Kim, Kiho/0000-0003-2454-4013; Lipp, Erin/0000-0002-8066-0636	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009563] Funding Source: NIH RePORTER; NIEHS NIH HHS [1PO1 ES09563] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDERMAN DJ, 1979, MAR FISH REV, V41, P67; ALHAJJAR BJ, 1988, WATER RES, V22, P907, DOI 10.1016/0043-1354(88)90028-0; ANDERSON DM, 1995, REV GEOPHYS, V33, P1189, DOI 10.1029/95RG00440; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; Anderson RM, 1998, BIOMED RES REP, P23; Aronson RB, 1997, PALEOBIOLOGY, V23, P326, DOI 10.1017/S0094837300019710; AZEVEDO C, 1990, PATHOLOGY IN MARINE SCIENCE, P181; Baird AH, 1998, CORAL REEFS, V17, P376, DOI 10.1007/s003380050142; BARLOW ND, 1991, J APPL ECOL, V28, P794, DOI 10.2307/2404208; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BARRY JP, 1995, SCIENCE, V267, P672, DOI 10.1126/science.267.5198.672; BAYNE CJ, 1998, ENCY IMMUNOLOGY, V3, P1498; Belgrader P, 1999, SCIENCE, V284, P449, DOI 10.1126/science.284.5413.449; BENGTSON JL, 1991, MAR MAMMAL SCI, V7, P85, DOI 10.1111/j.1748-7692.1991.tb00553.x; BITTON G, 1983, GROUND WATER, V21, P405, DOI 10.1111/j.1745-6584.1983.tb00741.x; Blackbourn J, 1998, CAN J ZOOL, V76, P942, DOI 10.1139/cjz-76-5-942; BROWN BE, 1985, ADV MAR BIOL, V22, P1, DOI 10.1016/S0065-2881(08)60049-8; Bruckner AW, 1997, CORAL REEFS, V16, P260, DOI 10.1007/s003380050081; Burkholder JM, 1997, J EUKARYOT MICROBIOL, V44, P200, DOI 10.1111/j.1550-7408.1997.tb05700.x; BURKHOLDER JM, 1992, NATURE, V358, P407, DOI 10.1038/358407a0; Burkholder JM, 1998, ECOL APPL, V8, pS37; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; CARLTON JT, 1991, BIOL BULL, V180, P72, DOI 10.2307/1542430; CARLTON RG, 1995, FEMS MICROBIOL ECOL, V18, P155, DOI 10.1016/0168-6496(95)00052-C; Carte BK, 1996, BIOSCIENCE, V46, P271, DOI 10.2307/1312834; Cohen AN, 1998, SCIENCE, V279, P555, DOI 10.1126/science.279.5350.555; Cole RG, 1996, MAR FRESHWATER RES, V47, P907, DOI 10.1071/MF9960907; Colwell Rita R., 1992, P107; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Cook T, 1998, ESTUAR COAST SHELF S, V46, P587, DOI 10.1006/ecss.1997.0283; Craun G. F., 1984, GROUNDWATER POLLUTIO, P135; DEGUISE S, 1995, ENVIRON HEALTH PERSP, V103, P73, DOI 10.1289/ehp.95103s473; DEVRIES DJ, 1995, TRENDS PHARMACOL SCI, V16, P275, DOI 10.1016/S0165-6147(00)89045-8; DIETZ R, 1989, NATURE, V338, P627, DOI 10.1038/338627a0; DOBSON AP, 1992, J ANIM ECOL, V61, P487, DOI 10.2307/5339; DOMINGO M, 1990, NATURE, V348, P21, DOI 10.1038/348021a0; DUIGNAN PJ, 1995, VET MICROBIOL, V44, P241, DOI 10.1016/0378-1135(95)00017-5; DUNGAN ML, 1982, SCIENCE, V216, P989, DOI 10.1126/science.216.4549.989; DURAKO MJ, 1994, B MAR SCI, V54, P727; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; Enfield DB, 1988, OCEANOGRAPHY, V1, P23; Epstein P., 1998, MARINE ECOSYSTEMS EM, P85; Farley C. Austin, 1992, P139; Fenical W, 1996, OCEANOGRAPHY, V9, P23; *FL DEP ENV PROT, 1996, WAT QUAL ASS STAT FL; Fleisher JM, 1996, AM J PUBLIC HEALTH, V86, P1228, DOI 10.2105/AJPH.86.9.1228; Fleisher JM, 1996, WATER RES, V30, P2341, DOI 10.1016/0043-1354(96)00126-1; Ford SE, 1996, J SHELLFISH RES, V15, P45; Galtsoff PS, 1939, NATURE, V143, P807, DOI 10.1038/143807a0; Ganzhorn Jack, 1992, P175; Geiser DM, 1998, NATURE, V394, P137, DOI 10.1038/28079; GERACI JR, 1982, SCIENCE, V215, P1129; GERBA CP, 1984, GROUNDWATER POLLUTIO, P225; GIL A, UNPUB; GLADFELTER WB, 1982, B MAR SCI, V32, P639; Goreau TJ, 1998, REV BIOL TROP, V46, P157; Greenstein Benjamin J., 1999, American Paleontologist, V7, P2; Greenstein BJ, 1998, CORAL REEFS, V17, P249, DOI 10.1007/s003380050125; Grenfell B. T., 1995, ECOLOGY INFECT DIS N; GRIMES DJ, 1991, ESTUARIES, V14, P345, DOI 10.2307/1352260; GRIMES DJ, 1986, MICROBIOL SCI, V3, P324; HAAS CN, 1993, RISK ANAL, V13, P545, DOI 10.1111/j.1539-6924.1993.tb00013.x; HALLEGRAEFF GM, 1993, PHYCOLOGIA, V32, P79, DOI 10.2216/i0031-8884-32-2-79.1; HARVELL CD, UNPUB; HARWOOD J, 1990, MAR POLLUT BULL, V21, P284, DOI 10.1016/0025-326X(90)90591-U; HAVELAAR AH, 1993, APPL ENVIRON MICROB, V59, P2956, DOI 10.1128/AEM.59.9.2956-2962.1993; Hay ME., 1996, OCEANOGRAPHY, V9, P10, DOI [10.5670/oceanog.1996.21, DOI 10.5670/OCEANOG.1996.21]; Hernandez M, 1998, NATURE, V393, P28, DOI 10.1038/29906; HINSHAW VS, 1986, J VIROL, V58, P655, DOI 10.1128/JVI.58.2.655-656.1986; HINSHAW VS, 1984, VIROLOGY, V51, P836; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOFMANN EE, 1995, J SHELLFISH RES, V14, P121; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; HUQ A, 1990, APPL ENVIRON MICROB, V56, P2370, DOI 10.1128/AEM.56.8.2370-2373.1990; Hyatt AD, 1997, DIS AQUAT ORGAN, V28, P17, DOI 10.3354/dao028017; Ishikura H, 1998, ICOPA IX - 9TH INTERNATIONAL CONGRESS OF PARASITOLOGY, P379; JAAP WC, 1999, CORAL REEF MONITORIN; JONES B, COMMUNICATION; JONES GM, 1985, J PARASITOL, V71, P559, DOI 10.2307/3281424; Jones JB, 1997, WORLD J MICROB BIOT, V13, P383, DOI 10.1023/A:1018568031621; KARL DM, 1995, NATURE, V373, P230, DOI 10.1038/373230a0; KENNEDY S, 1988, NATURE, V335, P404, DOI 10.1038/335404a0; KIM KK, UNPUB; Kim YK, 1998, J SHELLFISH RES, V17, P265; KONIG GM, 1994, PLANTA MED, V60, P532, DOI 10.1055/s-2006-959565; Kushmaro A, 1996, NATURE, V380, P396, DOI 10.1038/380396a0; LAFFERTY KD, 1993, MAR ECOL PROG SER, V96, P239, DOI 10.3354/meps096239; LAHVIS GP, 1995, ENVIRON HEALTH PERSP, V103, P67, DOI 10.2307/3432414; LANDSBERG JH, 1995, DIS AQUAT ORGAN, V22, P83, DOI 10.3354/dao022083; LAVIGNE DM, 1990, MAR POLLUT BULL, V21, P280, DOI 10.1016/0025-326X(90)90590-5; LESSIOS HA, 1984, SCIENCE, V226, P335, DOI 10.1126/science.226.4672.335; LESSIOS HA, 1988, ANNU REV ECOL SYST, V19, P371, DOI 10.1146/annurev.es.19.110188.002103; LESSIOS HA, 1984, CORAL REEFS, V3, P173, DOI 10.1007/BF00288252; LESSIOS HA, 1995, P ROY SOC B-BIOL SCI, V259, P331, DOI 10.1098/rspb.1995.0049; LESSIOS HA, 1990, EVOLUTION, V44, P933, DOI 10.1111/j.1558-5646.1990.tb03815.x; LESTER RJG, 1990, PATHOLOGY IN MARINE SCIENCE, P189; LEVINS R, 1994, AM SCI, V82, P52; LEWITUS AJ, 1995, ESTUARIES, V18, P373, DOI 10.2307/1352319; Lightner DV, 1996, REV SCI TECH OIE, V15, P579, DOI 10.20506/rst.15.2.944; LIGHTNER DV, 1992, DISPERSAL LIVING ORG, P155; Lipp EK, 1997, REV SCI TECH OIE, V16, P620, DOI 10.20506/rst.16.2.1048; LIPP EK, 1999, MICROBIOLOGICAL WATE, P120; Littler MM, 1998, CORAL REEFS, V17, P144, DOI 10.1007/s003380050108; LITTLER MM, 1995, SCIENCE, V267, P1356, DOI 10.1126/science.267.5202.1356; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Mamaev LV, 1996, VET REC, V138, P437, DOI 10.1136/vr.138.18.437; MARSH AG, 1995, J PARASITOL, V81, P577, DOI 10.2307/3283856; McClanahan TR, 1998, ENVIRON CONSERV, V25, P122, DOI 10.1017/S0376892998000174; MCGLADDERY SE, 1991, DIS AQUAT ORGAN, V10, P127, DOI 10.3354/dao010127; McGowan JA, 1998, SCIENCE, V281, P210, DOI 10.1126/science.281.5374.210; MILLER RJ, 1983, MAR BIOL, V73, P263, DOI 10.1007/BF00392252; MOYER MA, 1993, J SHELLFISH RES, V12, P305; MUEHLSTEIN LK, 1988, MAR BIOL, V99, P465, DOI 10.1007/BF00392553; Nagelkerken I, 1997, MAR ECOL PROG SER, V160, P255, DOI 10.3354/meps160255; NAGELKERKEN I, 1996, INT CORAL REEF S, V1, P679; OLIVE PJW, 1990, MAR POLLUT BULL, V21, P542, DOI 10.1016/0025-326X(90)90303-P; OSHEA ML, 1992, CAN J MICROBIOL, V38, P267, DOI 10.1139/m92-045; Osterhaus A, 1998, VACCINE, V16, P979, DOI 10.1016/S0264-410X(98)00006-1; Osterhaus A, 1997, NATURE, V388, P838, DOI 10.1038/42163; OSTERHAUS ADM, UNPUB; OSTERHAUS ADME, 1994, VET REC, V135, P601; OSTERHAUS ADME, 1990, VET REC, V127, P91; OSTERHAUS ADME, 1995, VET MICROBIOL, V44, P219, DOI 10.1016/0378-1135(95)00015-3; OSTERHAUS ADME, 1988, NATURE, V335, P20, DOI 10.1038/335020a0; OSTERHAUS ADME, 1989, NATURE, V338, P209, DOI 10.1038/338209b0; OSTERHAUS ADME, 1993, ARCH VIROL, V133, P189, DOI 10.1007/BF01309754; Paul JH, 1997, WATER RES, V31, P1448, DOI 10.1016/S0043-1354(96)00374-0; PAUL JH, 1995, APPL ENVIRON MICROB, V61, P2230, DOI 10.1128/AEM.61.6.2230-2234.1995; PAYMENT P, 1985, APPL ENVIRON MICROB, V49, P1418, DOI 10.1128/AEM.49.6.1418-1428.1985; Polovina Jeffrey J., 1994, Fisheries Oceanography, V3, P15, DOI 10.1111/j.1365-2419.1994.tb00044.x; PORTE RJW, UNPUB; PORTER JW, 1992, AM ZOOL, V32, P625; PORTER JW, UNPUB; Powell EN, 1996, J SHELLFISH RES, V15, P141; Rahimian H, 1996, DIS AQUAT ORGAN, V27, P187, DOI 10.3354/dao027187; RASMUSSEN E, 1977, SEAGRASS ECOSYSTEMS, P00001; Reid KBM, 1998, IMMUNOL TODAY, V19, P56, DOI 10.1016/S0167-5699(97)01207-3; Richardson LL, 1998, TRENDS ECOL EVOL, V13, P438, DOI 10.1016/S0169-5347(98)01460-8; Richardson LL, 1998, NATURE, V392, P557, DOI 10.1038/33302; RINALDI MG, 1983, REV INFECT DIS, V5, P1061; ROBBLEE MB, 1991, MAR ECOL PROG SER, V71, P297, DOI 10.3354/meps071297; Robledo JAF, 1998, J PARASITOL, V84, P1237, DOI 10.2307/3284680; ROBLEDO JAF, IN PRESS J PARASITOL; Rodbell DT, 1999, SCIENCE, V283, P516, DOI 10.1126/science.283.5401.516; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; ROSE JB, 1993, J FOOD PROTECT, V56, P1043, DOI 10.4315/0362-028X-56.12.1043; Ross P, 1996, TOXICOLOGY, V112, P157, DOI 10.1016/0300-483X(96)03396-3; Ross PS, 1996, AQUAT TOXICOL, V34, P71, DOI 10.1016/0166-445X(95)00031-X; Rutzler K, 1983, PSZNI MAR ECOL, V4, P329, DOI DOI 10.1111/J.1439-0485.1983.TB00118.X; SCHEIBLING RE, 1984, MAR BIOL, V78, P153, DOI 10.1007/BF00394695; Shulman MJ, 1996, CORAL REEFS, V15, P231, DOI 10.1007/s003380050048; SINDERMANN CJ, 1993, MAR FISH REV, V54, P1; SINDERMANN CJ, 1956, MAINE DEP SEA SHORE, V25, P1; SKADSHEIM A, 1995, MAR ECOL PROG SER, V119, P199, DOI 10.3354/meps119199; Smith FGW, 1939, NATURE, V144, P785, DOI 10.1038/144785a0; Smith GW, 1996, NATURE, V383, P487, DOI 10.1038/383487a0; SMITH JMB, 1989, OPPORTUNISTIC MYCOSE; SODERHALL K, 1996, NEW DIRECTIONS INVER, P442; Soniat TM, 1996, J SHELLFISH RES, V15, P35; Steidinger KA, 1996, J PHYCOL, V32, P157, DOI 10.1111/j.0022-3646.1996.00157.x; Strong A.E., 1998, REEF ENCOUNTERS, V24, P20; SULLIVAN CSB, 1989, AM J PUBLIC HEALTH, V79, P1561, DOI 10.2105/AJPH.79.11.1561; SWART RD, 1994, AMBIO, V23, P155; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; VANBANNING P, 1991, AQUACULTURE, V93, P205, DOI 10.1016/0044-8486(91)90232-V; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; VASTA GR, 1998, AGR BIOTECHNOLOGY, P563; VASTA GR, 1998, INT C PAR, P563; VISSER IKG, 1993, J GEN VIROL, V74, P631, DOI 10.1099/0022-1317-74-4-631; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; Welch DW, 1998, CAN J FISH AQUAT SCI, V55, P937, DOI 10.1139/cjfas-55-4-937; Whittington RJ, 1997, DIS AQUAT ORGAN, V28, P1, DOI 10.3354/dao028001; Wilkinson C, 1999, AMBIO, V28, P188; Williams EH, 1990, ATOLL RES B, P330, DOI DOI 10.5479/SI.00775630.335.1; WILSON EA, 1992, HELGOLANDER MEERESUN, V46, P201, DOI 10.1007/BF02366055; 1999, REEF ENCOUNTERS, V24, P19; 1999, REEF ENCOUNTERS, V25, P24	177	1318	1378	16	585	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1505	1510		10.1126/science.285.5433.1505	http://dx.doi.org/10.1126/science.285.5433.1505			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10498537	Green Submitted			2022-12-28	WOS:000082359500040
J	Krakower, JY; Williams, DJ; Jones, RF				Krakower, JY; Williams, DJ; Jones, RF			Review of US medical school finances, 1997-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Based on data from the Annual Medical School Questionnaire of the Liaison Committee on Medical Education (LCME), to which 100% of schools responded, we found that revenue supporting programs and activities of the 125 accredited medical schools in the United States totaled $36 997 million in 1997-1998, A large proportion of revenue (79%) was derived from 3 sources: practice plans ($12 559 million; 33.9%), grants and contracts ($10 916 million; 29.5%), and hospital support ($5741 million; 15.5%), An analysis of revenue trends revealed that medical schools, in aggregate, have continued to experience growth during the last 2 years. However, the aggregate numbers mask considerable variation among schools with regard to changes in financing. Between 1995-1996 and 1996-1997, 46 schools (37%) reported constant-dollar declines in the sum of practice plan and hospital revenue, and 50 schools (40%) reported a decline from 1996-1997 to 1997-1998, The financial data reviewed in this report demonstrate the continued dependence of medical schools on faculty-generated sources of revenue and confirm the perception that a growing number of medical schools are experiencing reductions in key sources of financial support. Current and projected reductions in teaching hospital revenue due to the implementation of the Balanced Budget Amendment are expected to erode further hospital support for medical school programs and activities.	Assoc Amer Med Coll, Inst Data Syst, Sect Inst & Fac Studies, Washington, DC 20037 USA	Association of American Medical Colleges	Krakower, JY (corresponding author), Assoc Amer Med Coll, Inst Data Syst, Sect Inst & Fac Studies, 2450 N St NW, Washington, DC 20037 USA.							ABATE T, 1999, SAN FRANCISCO C 0305, pA1; ANSTETT P, 1999, DETROIT FREE PR 0324, pB1; FREYER F, 1999, PROVIDENCE J    0318, pB1; GOLDSTEIN A, 1999, WASHINGTON POST 0706, pB1; JAPSEN B, 1999, CHICAGO TRIBUNE 0309, P3; JONES B, 1999, PROVIDENCE J    0325, pA1; PHAM A, 1999, BOSTON GLOBE    0320, pC1	7	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					847	854		10.1001/jama.282.9.847	http://dx.doi.org/10.1001/jama.282.9.847			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478691				2022-12-28	WOS:000082272200010
J	Ma, WY; Korngreen, A; Uzlaner, N; Priel, Z; Silberberg, SD				Ma, WY; Korngreen, A; Uzlaner, N; Priel, Z; Silberberg, SD			Extracellular sodium regulates airway ciliary motility by inhibiting a P2X receptor	NATURE			English	Article							HYPERTONIC SALINE AEROSOL; CYSTIC-FIBROSIS; MUCOCILIARY CLEARANCE; SURFACE LIQUID; HUMAN LUNG; EPITHELIA; INHALATION; INCREASES; HEALTHY; FLUID	The mucociliary system is responsible for clearing inhaled particles and pathogens from the airways, This important task is performed by the beating of cilia and the consequent movement of mucus from the lungs to the upper airways(1,2). Because ciliary motility is enhanced by elevated intracellular calcium concentrations, inhibition of calcium influx could lead to disease by jeopardizing mucociliary clearance. Several hormones and neurotransmitters stimulate ciliary motility, one of the most potent of which is extracellular ATP (ATP(0))(1), which acts by releasing calcium ions from internal stores and by activating calcium influx(3-5). Here we show that, in airway ciliated cells, extracellular sodium ions (Na-0(+)) specifically and competitively inhibit an ATP. gated channel that is permeable to calcium ions, and thereby attenuate ATP(0)-induced ciliary motility, Our finding points to a physiological role for Na-0(+) in ciliary function, and indicates that mucociliary clearance might be improved in respiratory disorders such as chronic bronchitis and cystic fibrosis by decreasing the sodium concentration of the airway surface fluid in which the cilia are bathed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Silberberg, SD (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.		Silberberg, Shai/ABA-2778-2020	Korngreen, Alon/0000-0002-2036-6160				Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Boitano S, 1997, AM J PHYSIOL-LUNG C, V272, pL1189, DOI 10.1152/ajplung.1997.272.6.L1189; Daviskas E, 1997, EUR RESPIR J, V10, P2449, DOI 10.1183/09031936.97.10112449; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hull J, 1998, AM J RESP CRIT CARE, V157, P10, DOI 10.1164/ajrccm.157.1.9703045; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; SILBERBERG A, 1990, BIORHEOLOGY, V27, P295; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Uzlaner N, 1999, J PHYSIOL-LONDON, V516, P179, DOI 10.1111/j.1469-7793.1999.179aa.x; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	24	64	68	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					894	897		10.1038/23743	http://dx.doi.org/10.1038/23743			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476971				2022-12-28	WOS:000082233200051
J	Moreno, E; Morata, G				Moreno, E; Morata, G			Caudal is the Hox gene that specifies the most posterior Drosophile segment	NATURE			English	Article							PROXIMAL-DISTAL AXIS; BRACHYURY GENE; HOMEOBOX GENES; GENITAL DISC; PROTEIN; MELANOGASTER; HEDGEHOG; EXPRESSION; ENCODES; ORGANIZATION	The homeobox gene caudal (can) has a maternal embryonic function that establishes the antero-posterior body axis of Drosophila(1,2). It also has a conserved(2,4) late embryonic and imaginal function(1) related to the development of the posterior body region. Here we report the developmental role of can in adult Drosophila, It is required for the normal development of the analia structures, which derive from the most posterior body segment. In the absence of cad function, the analia develop like the immediately anterior segment (male genitalia), following the transformation rule of the canonical Hox genes(5), We also show that cad can induce ectopic analia development if expressed in the head or wing. We propose that cad is the Hox gene that determines the development of the fly's most posterior segment. cad acts in combination with the Hedgehog (Hh) pathway(6) to specify the different components of the analia: the activities of cad and of the Hh pathway induce Distal-less expression that, together with cad, promote external analia development. In the absence of the Hh pathway, cad induces internal analia development, probably by activating the brachyenteron and even-skipped genes.	UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Morata, G (corresponding author), UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain.		Moreno, Eduardo/D-7262-2011	Morata, Gines/0000-0003-3274-5173; moreno, eduardo/0000-0001-5040-452X				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; Casares F, 1997, DEV GENES EVOL, V207, P216, DOI 10.1007/s004270050110; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; EPPER F, 1983, ROUX ARCH DEV BIOL, V192, P270, DOI 10.1007/BF00848659; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Gorfinkiel N, 1997, GENE DEV, V11, P2259, DOI 10.1101/gad.11.17.2259; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MURAKAMI R, 1995, ROUX ARCH DEV BIOL, V205, P89, DOI 10.1007/BF00188847; NOTHIGER R, 1977, ROUX ARCH DEV BIOL, V181, P367, DOI 10.1007/BF00848062; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; Sanchez L, 1997, DEV GENES EVOL, V207, P229, DOI 10.1007/s004270050111; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SINGER JB, 1996, DEVELOPMENT, V122, P3703; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wu LH, 1998, DEVELOPMENT, V125, P2433	28	111	114	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					873	877		10.1038/23709	http://dx.doi.org/10.1038/23709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476966				2022-12-28	WOS:000082233200046
J	Wang, SL; Hawkins, CJ; Yoo, SJ; Muller, HAJ; Hay, BA				Wang, SL; Hawkins, CJ; Yoo, SJ; Muller, HAJ; Hay, BA			The Drosophila caspase inhibitor DIAP1 is essential for cell survival and is negatively regulated by HID	CELL			English	Article							REAPER-INDUCED APOPTOSIS; BACULOVIRUS INHIBITOR; NURSE CELLS; DEATH; GENE; PROTEINS; GRIM; MELANOGASTER; EXPRESSION; PROTEASES	Drosophila Reaper (RPR), Head Involution Defective (HID), and GRIM induce caspase-dependent cell death and physically interact with the cell death inhibitor DIAP1. Here we show that HID blocks DIAP1's ability to inhibit caspase activity and provide evidence suggesting that RPR and GRIM can act similarly. Based on these results, we propose that RPR, HID, and GRIM promote apoptosis by disrupting productive IAP-caspase interactions and that DIAP1 is required to block apoptosis-inducing caspase activity. Supporting this hypothesis, we show that elimination of DIAP1 function results in global early embryonic cell death and a large increase in DIAP1-inhibitable caspase activity and that DIAP1 is still required for cell survival when expression of rpr, hid, and grim is eliminated.	CALTECH, Div Biol MC156 29, Pasadena, CA 91125 USA; Univ Dusseldorf, Genet Inst, D-40225 Dusseldorf, Germany	California Institute of Technology; Heinrich Heine University Dusseldorf	Muller, HAJ (corresponding author), CALTECH, Div Biol MC156 29, Pasadena, CA 91125 USA.		Muller, Hans-Arno/Q-2864-2019; Hawkins, Christine/B-8769-2011; Müller, Hans-Arno/G-5753-2012	Muller, Hans-Arno/0000-0002-7525-6874; Hawkins, Christine/0000-0001-8120-1071; Müller, Hans-Arno/0000-0002-7525-6874	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM057422-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Cavaliere V, 1998, DEV GENES EVOL, V208, P106, DOI 10.1007/s004270050160; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	49	417	432	1	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					453	463		10.1016/S0092-8674(00)81974-1	http://dx.doi.org/10.1016/S0092-8674(00)81974-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481910	Bronze			2022-12-28	WOS:000082174900006
J	Javaheri, S				Javaheri, S			A mechanism of central sleep apnea in patients with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEYNE-STOKES RESPIRATION; VENTILATORY RESPONSE; HYPOPNEA SYNDROME; HYPERCAPNIA; RESPONSIVENESS; PATHOGENESIS; THEOPHYLLINE; INSTABILITY; HYPOCAPNIA; DISEASE	Background Breathing is controlled by a negative-feedback system in which an increase in the partial pressure of arterial carbon dioxide stimulates breathing and a decrease inhibits it. Although enhanced sensitivity to carbon dioxide helps maintain the partial pressure of arterial carbon dioxide within a narrow range during waking hours, in some persons a large hyperventilatory response during sleep may lower the value below the apneic threshold, thereby resulting in central apnea. I tested the hypothesis that enhanced sensitivity to carbon dioxide contributes to the development of central sleep apnea in some patients with heart failure. Methods This prospective study included 20 men who had treated, stable heart failure with left ventricular systolic dysfunction. Ten had central sleep apnea, and 10 did not. The patients underwent polysomnography and studies of their ventilatory response to carbon dioxide. Results Patients who met the criteria for central sleep apnea had significantly more episodes of central apnea per hour than those without central sleep apnea (mean [+/-SD], 35+/-24 vs. 0.5+/-1.0 episodes per hour). Those with sleep apnea also had a significantly larger ventilatory response to carbon dioxide than those without central sleep apnea (5.1+/-3.1 vs. 2.1=/-1.0 liters per minute per millimeter of mercury, P=0.007), and there was a significant positive correlation between ventilatory response and the number of episodes of apnea and hypopnea per hour during sleep (r=0.6, P=0.01). Conclusions Enhanced sensitivity to carbon dioxide may predispose some patients with heart failure to the development of central sleep apnea. (N Engl J Med 1999;341:949-54.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Pulm Serv, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Javaheri, S (corresponding author), VA Med Ctr, Pulm Sect 111F, 3200 Vine St, Cincinnati, OH 45220 USA.	javaheri.shahrokh@cincinnati.va.gov						Andreas S, 1998, RESP MED, V92, P426, DOI 10.1016/S0954-6111(98)90286-4; [Anonymous], 1992, SLEEP, V15, P174; Bradley T D, 1996, J Card Fail, V2, P223, DOI 10.1016/S1071-9164(96)80045-5; CARSKADON MA, 1994, PRINCIPLES PRACTICE, P16; CHAPMAN KR, 1988, J APPL PHYSIOL, V64, P1000, DOI 10.1152/jappl.1988.64.3.1000; CHERNIACK NS, 1990, PROG CLIN BIOL RES, V345, P167; CHERNIACK NS, 1973, NEW ENGL J MED, V288, P952, DOI 10.1056/NEJM197305032881810; CHERNIACK NS, 1981, NEW ENGL J MED, V305, P325; Dempsey JA, 1996, SLEEP, V19, P236; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; ESPINOZA H, 1991, AM REV RESPIR DIS, V144, P1121, DOI 10.1164/ajrccm/144.5.1121; GUYTON AC, 1956, AM J PHYSIOL, V187, P395, DOI 10.1152/ajplegacy.1956.187.2.395; Hall MJ, 1996, AM J RESP CRIT CARE, V154, P376, DOI 10.1164/ajrccm.154.2.8756809; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; Javaheri S, 1998, ANN INTERN MED, V128, P204, DOI 10.7326/0003-4819-128-3-199802010-00006; JAVAHERI S, 1995, ANN INTERN MED, V123, P77; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1990, THORAX, V45, P743, DOI 10.1136/thx.45.10.743; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; JAVAHERI S, 1992, AM REV RESPIR DIS, V145, P837, DOI 10.1164/ajrccm/145.4_Pt_1.837; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; KAWAKAMI Y, 1984, AM REV RESPIR DIS, V129, P703, DOI 10.1164/arrd.1984.129.5.703; KELLER CA, 1984, AM REV RESPIR DIS, V130, P606; KELSEN SG, 1984, CHRONIC OBSTRUCTIVE, P65; KHOO MCK, 1982, J APPL PHYSIOL, V53, P644, DOI 10.1152/jappl.1982.53.3.644; KHOO MCK, 1991, LUNG SCI FDN, V2, P1419; MOORE GC, 1976, NEW ENGL J MED, V295, P861, DOI 10.1056/NEJM197610142951604; MOUNTAIN R, 1978, NEW ENGL J MED, V298, P521, DOI 10.1056/NEJM197803092981001; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; SAUNDERS NA, 1976, AM REV RESPIR DIS, V113, P497; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; SMITH CA, 1995, J APPL PHYSIOL, V79, P689, DOI 10.1152/jappl.1995.79.3.689; Weil J, 1984, PULMONARY HYPERTENSI, P321; WHITE DP, 1983, AM REV RESPIR DIS, V128, P984; WHITE DP, 1994, PRINCIPLES PRACTICE, P630; Wilcox I, 1998, EUR RESPIR J, V11, P7, DOI 10.1183/09031936.98.11010007; XIE AL, 1995, AM J RESP CRIT CARE, V152, P1950, DOI 10.1164/ajrccm.152.6.8520761; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	43	331	366	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					949	954		10.1056/NEJM199909233411304	http://dx.doi.org/10.1056/NEJM199909233411304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498490				2022-12-28	WOS:000082658100004
J	Liebelt, EL; DeAngelis, CD				Liebelt, EL; DeAngelis, CD			Evolving trends and treatment advances in pediatric poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROL-CENTERS; EFFICACY; CHARCOAL; IPECAC; SAFETY; HOME		Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Liebelt, EL (corresponding author), Johns Hopkins Sch Med, Dept Pediat, 600 N Wolfe St,CMSC 144, Baltimore, MD 21287 USA.							*AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P711; *AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P699; American Academy of Clinical Toxicology European Association of Poison Centres and Clinical Toxicologists, 1997, CLIN TOXICOL, V35, P721; BOND GR, 1995, ANN EMERG MED, V25, P338, DOI 10.1016/S0196-0644(95)70291-1; BOND GR, 1993, ANN EMERG MED, V22, P1403, DOI 10.1016/S0196-0644(05)81986-9; BOYLE PJ, 1993, J CLIN ENDOCR METAB, V76, P752, DOI 10.1210/jc.76.3.752; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; KORNBERG AE, 1991, ANN EMERG MED, V20, P648, DOI 10.1016/S0196-0644(05)82385-6; LAMMINPAA A, 1993, HUM EXP TOXICOL, V12, P29, DOI 10.1177/096032719301200106; LITOVITZ T, 1992, PEDIATRICS, V89, P999; LOVEJOY FH, 1994, PEDIATRICS, V94, P220; Miller TR, 1997, ANN EMERG MED, V29, P239, DOI 10.1016/S0196-0644(97)70275-0; POND SM, 1995, MED J AUSTRALIA, V163, P345, DOI 10.5694/j.1326-5377.1995.tb124625.x; Rodgers GB, 1996, JAMA-J AM MED ASSOC, V275, P1661, DOI 10.1001/jama.275.21.1661; SCALZO AJ, 1990, AM J DIS CHILD, V144, P867, DOI 10.1001/archpedi.1990.02150320031020; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; Shanon M, 1998, PEDIATR EMERG CARE, V14, P293, DOI 10.1097/00006565-199808000-00015; TENENBEIN M, 1987, J PEDIATR-US, V111, P142, DOI 10.1016/S0022-3476(87)80365-7; WOOLF AD, 1992, NEW ENGL J MED, V326, P1739, DOI 10.1056/NEJM199206253262604	19	40	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1113	1115		10.1001/jama.282.12.1113	http://dx.doi.org/10.1001/jama.282.12.1113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501099				2022-12-28	WOS:000082596200002
J	Howie, JGR; Heaney, DJ; Maxwell, M; Walker, JJ; Freeman, GK; Rai, H				Howie, JGR; Heaney, DJ; Maxwell, M; Walker, JJ; Freeman, GK; Rai, H			Quality at general practice consultations: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE INDICATORS; PATIENT SATISFACTION; CLINICAL GUIDELINES; HEALTH PROMOTION; MEDICAL-CARE; BACK-PAIN; PRACTITIONERS; CONTINUITY; ATTITUDES	Objectives To measure quality of care at general practice consultations in diverse geographical areas, and to determine the principal correlates associated with enablement as an outcome measure. Design Cross sectional multipractice questionnaire based study. Setting Random sample of practices in four participating regions: Lothian, Coventry, Oxfordshire, and west London. Participants 25994 adults attending 53 practices over two weeks in March and April 1998. Main outcome measures Patient enablement, duration of consultation, how well patients know their doctor, and the size of the practice list. Results A hierarchy of needs or reasons for consultation was created. Similar overall enablement scores were achieved for most casemix presentations (mean 3.1, 95% confidence interval 3.1 to 3.1). Mean duration of consultation for all patients was 8.0 minutes (8.0 to 8.1); however, duration of consultation increased for patients with psychological problems or where psychological and social problems coexisted (mean 9.1, 9.0 to 9.2). The 2195 patients who spoke languages other than English at home were analysed separately as they had generally higher enablement scores (mean 4.5, 4.3 to 4.7) than those patients who spoke English only despite having shorter consultations (mean 7.1 (6.9 to 7.3) minutes. At individual consultations, enablement score was most closely correlated with duration of consultation and knowing the doctor well. Individual doctors had a wide range of mean enablement scores (1.1-5.3) and mean durations of consultation (3.8-14.4 minutes). Doctors' ability to enable was linked to die duration of their consultation and the percentage of their patients who knew them well and was inversely related to the size of their practice. At practice level, mean enablement scores ranged from 2.3 to 4.4, and duration of consultation ranged from 4.9 to 12.2 minutes. Correlations between ranks at practice level were not significant. Conclusions It may be time to reward doctors who have longer consultations, provide greater continuity of care, and both enable more patients and enable patients more.	Univ Edinburgh, Dept Community Hlth Sci Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland; Chelsea & Westminster Hosp, Imperial Coll, Sch Med, Dept Primary Hlth Care & Gen Practice, London SW10 9NH, England	University of Edinburgh; Imperial College London	Howie, JGR (corresponding author), Univ Edinburgh, Dept Community Hlth Sci Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland.	John.Howie@ed.ac.uk		Maxwell, Margaret/0000-0003-3318-9500				BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Buck D, 1997, HEALTH PROMOT INT, V12, P239, DOI 10.1093/heapro/12.3.239; Campbell JL, 1996, BRIT J GEN PRACT, V46, P465; Campbell SM, 1998, J PUBLIC HEALTH MED, V20, P414, DOI 10.1093/oxfordjournals.pubmed.a024796; Campbell SM, 1999, QUAL HEALTH CARE, V8, P6, DOI 10.1136/qshc.8.1.6; COCKBURN J, 1987, FAM PRACT, V4, P192, DOI 10.1093/fampra/4.3.192; Deane M, 1998, BRIT MED J, V317, P1083; Donaldson LJ, 1998, QUAL HEALTH CARE, V7, pS37; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; Gray DP, 1998, BRIT J GEN PRACT, V48, P1816; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; HJORTDAHL P, 1989, FAM PRACT, V6, P292, DOI 10.1093/fampra/6.4.292; Howie J. G., 1997, 75 ROYAL COLL GEN PR; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; HOWIE JGR, 1992, BRIT J GEN PRACT, V42, P181; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; LANGHAM S, 1995, BRIT J GEN PRACT, V45, P665; Lazarus RichardS., 1976, PATTERNS ADJUSTMENT; Little P, 1996, BMJ-BRIT MED J, V312, P485, DOI 10.1136/bmj.312.7029.485; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; *SECR STAT HLTH, 1998, NEW NHS	23	245	246	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					738	743		10.1136/bmj.319.7212.738	http://dx.doi.org/10.1136/bmj.319.7212.738			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487999	Green Published, Bronze			2022-12-28	WOS:000082701500018
J	Hendrich, B; Hardeland, U; Ng, HH; Jiricny, J; Bird, A				Hendrich, B; Hardeland, U; Ng, HH; Jiricny, J; Bird, A			The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites	NATURE			English	Article							CYTOSINE RESIDUES; DNA GLYCOSYLASES; ESCHERICHIA-COLI; ENDONUCLEASE; DINUCLEOTIDE; MUTATION; MISPAIRS; CLONING; URACIL; CANCER	In addition to its well-documented effects on gene silencing, cytosine methylation is a prominent cause of mutations. In humans, the mutation rate from 5-methylcytosine (m(5)C) to thymine (T) is 10-50-fold higher(1-4) than other transitions and the methylated sequence CpG is consequently under-represented(5). Over one-third of germline point mutations associated with human genetic disease(6) and many somatic mutations leading to cancer(7,8) involve loss of CpG. The primary cause of mutability appears to be hydrolytic deamination. Cytosine deamination produces mismatched uracil (U), which can be removed by uracil glycosylase(9,10), whereas m(5)C deamination generates a GT mispair that cannot be processed by this enzyme. Correction of m(5)CpG.TpG mismatches may instead be initiated by the thymine DNA glycosylase, TDG(11,12). Here we show that MBD4, an unrelated mammalian protein that contains a methyl-CpG binding domain(13,14), can also efficiently remove thymine or uracil from a mismatches CpG site in vitro. Furthermore, the methyl-CpG binding domain of MBD4 binds preferentially to m(5)CpG.TpG mismatches-the primary product of deamination at methyl-CpG. The combined specificities of binding and catalysis indicate that this enzyme may function to minimize mutation at methyl-CpG.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Med Radiobiol, CH-8008 Zurich, Switzerland	University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk	Ng, Huck Hui/A-1135-2009; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P444; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BULMER M, 1986, MOL BIOL EVOL, V3, P322; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horst JP, 1996, EMBO J, V15, P5459, DOI 10.1002/j.1460-2075.1996.tb00929.x; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MANIATIS T, 1982, MOL CLONING LABORATO, P196; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; Shiota S, 1997, P NATL ACAD SCI USA, V94, P593, DOI 10.1073/pnas.94.2.593; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	27	496	510	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					301	304		10.1038/45843	http://dx.doi.org/10.1038/45843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499592				2022-12-28	WOS:000082678400060
J	Loveland, ME; Carley, SD; Cranfield, N; Hillier, VF; Mackway-Jones, K				Loveland, ME; Carley, SD; Cranfield, N; Hillier, VF; Mackway-Jones, K			Assessment of the pain of blood-sugar testing: a randomised controlled trial	LANCET			English	Article							VENIPUNCTURE	Lancet puncture to the side of the thumb resulted in less pain than lancet puncture to the finger or venepuncture at the elbow. Success rates were the same.	Manchester Royal Infirm, Dept Emergency Med, Manchester M13 9WL, Lancs, England; Univ Manchester, Fac Med, Manchester M13 9DP, Lancs, England	University of Manchester; University of Manchester	Loveland, ME (corresponding author), Manchester Royal Infirm, Dept Emergency Med, Oxford Rd, Manchester M13 9WL, Lancs, England.		carley, simon/W-7944-2019	carley, simon/0000-0003-1561-5553				COWETT RM, 1992, BIOL NEONATE, V62, P32, DOI 10.1159/000243850; FRUHSTOFER H, 1996, PAIN BLOOD GLUCOSE M, P5; HUSKISSON EC, 1974, LANCET, V2, P884; Larsson BA, 1998, PEDIATRICS, V101, P882, DOI 10.1542/peds.101.5.882; Shah VS, 1997, ARCH DIS CHILD-FETAL, V77, pF143, DOI 10.1136/fn.77.2.F143	5	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					921	922		10.1016/S0140-6736(99)02902-5	http://dx.doi.org/10.1016/S0140-6736(99)02902-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489959				2022-12-28	WOS:000082511800022
J	Garcia, AG; Jimenez, RR				Garcia, AG; Jimenez, RR			Bacillus anthracis Meningitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hosp Univ Virgen Macarena, Seville 41071, Spain	Hospital Universitario Virgen Macarena	Garcia, AG (corresponding author), Hosp Univ Virgen Macarena, Seville 41071, Spain.								0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					814	814		10.1056/NEJM199909093411106	http://dx.doi.org/10.1056/NEJM199909093411106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477780				2022-12-28	WOS:000082534000006
J	Hussein, WI; Green, R; Jacobsen, DW; Faiman, C				Hussein, WI; Green, R; Jacobsen, DW; Faiman, C			Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Clinical-Endocrinology	1998	ORLANDO, FL	Amer Assoc Clin Endocrinol			VASCULAR-DISEASE; RISK FACTOR; PLASMA HOMOCYSTEINE; HYPERTENSION	Background: Hyperhomocysteinemia is an independent risk factor for coronary, peripheral, and cerebrovascular disease. Elevated plasma homocysteine levels were described in a preliminary report on primary hypothyroidism. Objective: To determine whether restoration of euthyroidism by L-thyroxine replacement therapy would reduce or normalize plasma homocysteine levels. Design: Prospective cohort study. Setting: Outpatient endocrinology department of a tertiary center. Patients: 14 patients (10 women and 4 men; 25 to 77 years of age): 4 with newly diagnosed chronic (Hashimoto) hypothyroidism and 10 who had been rendered acutely hypothyroid (thyroid-stimulating hormone level > 25 mU/L) by total thyroidectomy for thyroid carcinoma. Measurements: Total plasma homocysteine levels were measured at baseline and 3 to 9 months later, after euthyroidism had been attained by L-thyroxine replacement therapy. Results: Median baseline plasma homocysteine levels in both sexes (women, 11.65 mu mol/L [range, 7.2 to 26.5 mu mol/ L]; men, 15.1 mu mol/L [range, 14.1 to 16.3 mu mol/L]) were higher (P = 0.002) than those in healthy female (n = 35) and male (n = 36) volunteers (women, 7.52 mu mol/L [range, 4.3 to 14.0 mu mol/L]; men, 8.72 mu mol/L [range, 5.94 to 14.98 mu mol/L]). Eight patients (57%) had baseline plasma homocysteine levels that exceeded the upper limit of sex-specific reference ranges. Upon attainment of euthyroidism, all patients had a diminution in plasma homocysteine levels. The median overall change of -5.5 mu mol/L (range, -15.4 to -1.8 mu mol/L) corresponds to a difference of -44% (range, -58% to -13%) (P < 0.001). Homocysteine levels returned to normal in 7 of the 8 patients with elevated pretreatment values. Conclusions: Hypothyroidism may be a treatable cause of hyperhomocysteinemia, and elevated plasma homocysteine levels may be an independent risk factor for the accelerated atherosclerosis seen in primary hypothyroidism.	Cleveland Clin Fdn, Dept Endocrinol, Cleveland, OH 44195 USA; Univ Calif Davis, Davis, CA 95616 USA	Cleveland Clinic Foundation; University of California System; University of California Davis	Faiman, C (corresponding author), Cleveland Clin Fdn, Dept Endocrinol, 9500 Euclid Ave,Desk A30, Cleveland, OH 44195 USA.	faimancl@cesmtp.ccf.org		Hussein, Wiam/0000-0002-7416-4521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GREEN R, 1995, IRISH J MED SCI S15, V164, P27; GRYTTING G, 1957, ACTA MED SCAND, V157, P169; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; LINDENBAUM J, 1964, J CLIN PATHOL, V17, P666, DOI 10.1136/jcp.17.6.666; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; NAIR CPP, 1994, METABOLISM, V43, P1575, DOI 10.1016/0026-0495(94)90019-1; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; SAITO I, 1994, ENDOCRIN METAB CLIN, V23, P379, DOI 10.1016/S0889-8529(18)30103-8; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; STREETEN DHP, 1988, HYPERTENSION, V11, P78, DOI 10.1161/01.HYP.11.1.78; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; WILLIAMS GH, 1984, HEART DISEASE TXB CA, P1722	20	72	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					348	351		10.7326/0003-4819-131-5-199909070-00005	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	234AC	10475887				2022-12-28	WOS:000082458500004
J	Kinrade, SD; Del Nin, JW; Schach, AS; Sloan, TA; Wilson, KL; Knight, CTG				Kinrade, SD; Del Nin, JW; Schach, AS; Sloan, TA; Wilson, KL; Knight, CTG			Stable five- and six-coordinated silicate anions in aqueous solution	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SI-29 NMR; PENTACOORDINATE; SILICON(IV); ALUMINUM(III); EQUILIBRIUM; COMPLEXES; SIO2; ACID	Addition of aliphatic polyols to aqueous silicate solutions is shown to yield high concentrations of stable polyolate complexes containing five- or six-coordinated silicon. Coordinating polyols require at Least four hydroxy groups, two of which must be in three configuration, and coordinate to silicon via hydroxy oxygens at chain positions on either side of the threo pair. The remarkable ease by which these simple sugar-like molecules react to form hypervalent silicon complexes in aqueous solution supports a long-standing supposition that such species play a significant role in the biological uptake and transport of silicon and in mineral diagenesis.	Lakehead Univ, Dept Chem, Thunder Bay, ON P7B 5E1, Canada; Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA	Lakehead University; University of Illinois System; University of Illinois Urbana-Champaign	Kinrade, SD (corresponding author), Lakehead Univ, Dept Chem, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042208] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01811, 1 S10 RR 10444-01] Funding Source: Medline; NIGMS NIH HHS [GM-42208] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRCHALL JD, 1995, CHEM SOC REV, V24, P351, DOI 10.1039/cs9952400351; BLOHOWIAK KY, 1994, CHEM MATER, V6, P2177, DOI 10.1021/cm00047a045; CHUIT C, 1993, CHEM REV, V93, P1371, DOI 10.1021/cr00020a003; EVANS DF, 1992, POLYHEDRON, V11, P567, DOI 10.1016/S0277-5387(00)83306-9; GAINSFORD GJ, 1995, ACTA CRYSTALLOGR C, V51, P8, DOI 10.1107/S010827019400702X; HERREROS B, 1994, SCIENCE, V263, P1585, DOI 10.1126/science.263.5153.1585; HOPPE ML, 1993, ANGEW CHEM INT EDIT, V32, P287, DOI 10.1002/anie.199302871; Iler R. K, 1979, CHEM SILICA; KEMMITT T, 1995, AUST J CHEM, V48, P93, DOI 10.1071/CH9950093; Kinrade SD, 1998, INORG CHEM, V37, P4278, DOI 10.1021/ic971630d; Kinrade SD, 1998, INORG CHEM, V37, P4272, DOI 10.1021/ic971629e; Kinrade SD, 1996, J PHYS CHEM-US, V100, P4760, DOI 10.1021/jp952683o; KINRADE SD, IN PRESS J CHEM S DA; KNIGHT CTG, 1989, ZEOLITES, V9, P448, DOI 10.1016/0144-2449(89)90103-6; LAINE RM, 1991, NATURE, V353, P642, DOI 10.1038/353642a0; Laine RM, 1996, J MATER CHEM, V6, P1441, DOI 10.1039/jm9960601441; Liebau F., 1985, STRUCTURAL CHEM SILI; MUNOZ A, 1991, CARBOHYD RES, V225, P113; Rosenheim A, 1931, Z ANORG ALLG CHEM, V196, P160, DOI 10.1002/zaac.19311960117; SEDEH IF, 1993, J INORG BIOCHEM, V50, P119, DOI 10.1016/0162-0134(93)80019-6; SEDEH IF, 1992, ACTA CHEM SCAND, V46, P933, DOI 10.3891/acta.chem.scand.46-0933; SJOBERG S, 1985, J INORG BIOCHEM, V24, P267, DOI 10.1016/0162-0134(85)85055-8; SMALL JH, 1995, ACS SYM SER, V585, P248; STEBBINS JF, 1993, J NON-CRYST SOLIDS, V160, P116, DOI 10.1016/0022-3093(93)90292-6; STEBBINS JF, 1989, AM MINERAL, V74, P965; SVENSSON IL, 1989, J CHEM SOC FARADAY T, V31, P4558; Weiss A., 1964, ANGEW CHEM, V76, P818; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	28	156	168	3	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1542	1545		10.1126/science.285.5433.1542	http://dx.doi.org/10.1126/science.285.5433.1542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477513				2022-12-28	WOS:000082359500058
J	Nerad, M; Cerny, J				Nerad, M; Cerny, J			Postdoctoral patterns, career advancement, and problems	SCIENCE			English	Editorial Material								Postdoctoral appointments can have different functions and meanings, depending on the field and whether the postdoc is a man or a woman. The Ph.D.'s-Ten Years Later study confirmed that in biochemistry, the post dec, not the Ph.D., has become the general proving ground for excellence both in academia and industry. Because they spent a Longer time in these "mandatory" postdocs, biochemists had the Largest proportion of untenured faculty 10 to 13 years after the Ph.D. in mathematics, where substantially fewer postdoctoral positions are available, Ph.D.'s taking postdocs are more Likely to obtain faculty positions, but this is true only for men. University administrators should be accountable for monitoring the total time spent in these positions and should provide administrative assistance for skills training, career growth, and the job search. In addition, creative solutions concerning the dual-career couple phenomenon are necessary.	Univ Calif Berkeley, Grad Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Nerad, M (corresponding author), Univ Calif Berkeley, Grad Div, 424 Sproul Hall, Berkeley, CA 94720 USA.							ARMSTRONG E, PHDS 10 YEARS LATER; National Research Council (NRC), 1998, TRENDS EARL CAR LIF; National Research Council (NRC), 1981, POSTD APP DIS; National Research Council (NRC), 1969, INV U POSTD ED US; ZUMETA W, 1984, EXTENDING ED LADDER; 1982, ASSESSMENT RES DOCTO	6	86	88	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1533	1535		10.1126/science.285.5433.1533	http://dx.doi.org/10.1126/science.285.5433.1533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477510				2022-12-28	WOS:000082359500055
J	Usui, T; Shima, Y; Shimada, Y; Hirano, S; Burgess, RW; Schwarz, TL; Takeichi, M; Uemura, T				Usui, T; Shima, Y; Shimada, Y; Hirano, S; Burgess, RW; Schwarz, TL; Takeichi, M; Uemura, T			Flamingo, a seven-pass transmembrane cadherin, regulates planar cell polarity under the control of frizzled	CELL			English	Article							TISSUE POLARITY; DROSOPHILA-MELANOGASTER; MOLECULAR ANALYSIS; GENE-EXPRESSION; MORPHOGENESIS; PROTEIN; RECEPTOR; ADHESION; DOMAINS; ROLES	We identified a seven-pass transmembrane receptor of the cadherin superfamily, designated Flamingo (Fmi), localized at cell-cell boundaries in the Drosophila wing. In the absence of Fmi, planar polarity was distorted. Before morphological polarization of wing cells along the proximal-distal (P-D) axis, Fmi was redistributed predominantly to proximal and distal cell edges. This biased localization of Fmi appears to be driven by an imbalance of the activity of Frizzled (Fz) across the proximal/distal cell boundary. These results, together with phenotypes caused by ectopic expression of fz and fmi, suggest that cells acquire the P-D polarity by way of the Fz-dependent boundary localization of Fmi.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Sci & Technol Corp, PRESTO, Osaka 5650082, Japan; Stanford Univ, Dept Mol Cellular Physiol, Sch Med, Stanford, CA 94305 USA	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Stanford University	Uemura, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378; Burgess, Robert/0000-0002-9229-3407; UEMURA, Tadashi/0000-0001-7204-3606; Usui, Tadao/0000-0002-0507-1495				ADLER PN, 1994, MECH DEVELOP, V46, P101, DOI 10.1016/0925-4773(94)90079-5; ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bolt MW, 1997, ANAL BIOCHEM, V247, P185, DOI 10.1006/abio.1997.2061; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Eaton S, 1997, CURR OPIN CELL BIOL, V9, P860, DOI 10.1016/S0955-0674(97)80089-0; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Gubb D, 1998, INT J DEV BIOL, V42, P369; Hadjantonakis AK, 1998, MECH DEVELOP, V78, P91, DOI 10.1016/S0925-4773(98)00153-1; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jones KH, 1996, GENETICS, V142, P205; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; MITCHELL HK, 1983, DEV BIOL, V95, P387, DOI 10.1016/0012-1606(83)90040-4; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PARK WJ, 1994, DEV GENET, V15, P383, DOI 10.1002/dvg.1020150410; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Taylor J, 1998, GENETICS, V150, P199; Turner CM, 1998, MECH DEVELOP, V70, P181, DOI 10.1016/S0925-4773(97)00194-9; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wolff T, 1998, DEVELOPMENT, V125, P1149; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; XU T, 1993, DEVELOPMENT, V117, P1223; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719	51	561	569	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					585	595		10.1016/S0092-8674(00)80046-X	http://dx.doi.org/10.1016/S0092-8674(00)80046-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490098	Bronze			2022-12-28	WOS:000082433500006
J	Ziegler, BL; Valtieri, M; Porada, GA; De Maria, R; Muller, R; Masella, B; Gabbianelli, M; Casella, I; Pelosi, E; Bock, T; Zanjani, ED; Peschle, C				Ziegler, BL; Valtieri, M; Porada, GA; De Maria, R; Muller, R; Masella, B; Gabbianelli, M; Casella, I; Pelosi, E; Bock, T; Zanjani, ED; Peschle, C			KDR receptor: A key marker defining hematopoietic stem cells	SCIENCE			English	Article							HUMAN BONE-MARROW; LONG-TERM CULTURE; GROWTH-FACTOR; IN-VIVO; REPOPULATING ACTIVITY; ENDOTHELIAL-CELLS; COMMON PRECURSOR; EXPRESSION; DIFFERENTIATION; IDENTIFICATION	Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR). Pluripotent HSCs were restricted to the CD34(+)KDR(+) cell fraction. Conversely, Lineage-committed HPCs were in the CD34(+)KDR(-) subset. On the basis of Limiting dilution analysis, the HSC frequency in the CD34(+)KDR(+) fraction was 20 percent in bone marrow (BM) by mouse xenograft assay and 25 to 42 percent in BM, peripheral blood, and cord blood by 12-week long-term culture (LTC) assay. The latter values rose to 53 to 63 percent in LTC supplemented with VEGF and to greater than 95 percent, for the cell subfraction resistant to growth factor starvation. Thus, KDR is a positive functional marker defining stem cells and distinguishing them from progenitors.	Univ Tubingen, Dept Hematol & Oncol, D-72076 Tubingen, Germany; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ Nevada, Dept Vet Affairs, Reno, NV 89520 USA	Eberhard Karls University of Tubingen; Jefferson University; Istituto Superiore di Sanita (ISS); Nevada System of Higher Education (NSHE); University of Nevada Reno	Peschle, C (corresponding author), Univ Tubingen, Dept Hematol & Oncol, Otfried Muller Str 10, D-72076 Tubingen, Germany.	cesare.peschle@mail.tju.edu	pelosi, elvira/J-7298-2016; valtieri, mauro/H-1044-2016; Gabbianelli, Marco/O-1210-2017; De Maria, Ruggero/S-6385-2019	pelosi, elvira/0000-0002-3043-6249; valtieri, mauro/0000-0002-9139-6754; Gabbianelli, Marco/0000-0002-7824-780X; De Maria, Ruggero/0000-0003-2255-0583; Casella, Ida/0000-0002-3358-4976				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; BRANDT J, 1990, J CLIN INVEST, V86, P932, DOI 10.1172/JCI114795; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Choi K, 1998, DEVELOPMENT, V125, P725; Civin CI, 1996, BLOOD, V88, P4102, DOI 10.1182/blood.V88.11.4102.bloodjournal88114102; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Garcia-Ojeda ME, 1998, J EXP MED, V187, P1813, DOI 10.1084/jem.187.11.1813; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KATOH O, 1995, CANCER RES, V55, P5687; Kawashima I, 1996, BLOOD, V87, P4136, DOI 10.1182/blood.V87.10.4136.bloodjournal87104136; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; OGAWA M, 1993, BLOOD, V81, P2844; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Sutherland DR, 1996, EXP HEMATOL, V24, P795; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; TERMAN BI, 1991, ONCOGENE, V6, P1677; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Uchida N, 1996, BLOOD, V88, P1297, DOI 10.1182/blood.V88.4.1297.bloodjournal8841297; VANDERLOO JCM, 1995, BLOOD, V85, P2598, DOI 10.1182/blood.V85.9.2598.bloodjournal8592598; Verstegen MMA, 1998, BLOOD, V91, P1966, DOI 10.1182/blood.V91.6.1966.1966_1966_1976; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; Zanjani ED, 1998, EXP HEMATOL, V26, P353	34	368	419	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1553	1558		10.1126/science.285.5433.1553	http://dx.doi.org/10.1126/science.285.5433.1553			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477517				2022-12-28	WOS:000082359500062
J	Slifka, MK; Rodriguez, F; Whitton, JL				Slifka, MK; Rodriguez, F; Whitton, JL			Rapid on/off cycling of cytokine production by virus-specific CD8(+) T cells	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TUMOR-NECROSIS-FACTOR; VIRAL-INFECTION; MESSENGER-RNA; HOST-DEFENSE; MICE; PERFORIN; CYTOTOXICITY; ACTIVATION; CLEARANCE	CD8-positive T cells protect the body against viral pathogens by two important mechanisms: production of antiviral cytokines(1,2) and lysis of infected cells(3,4). Cytokine production can have both local and systemic consequences(5,6), whereas cytolytic activity is limited to infected cells that are in direct contact with T cells(7-9). Here we analyse activated CD8-positive T cells from mice infected with lymphocytic choriomeningitis virus and find that cytokines are not produced ex vivo in the absence of peptide stimulation, but that they are rapidly generated after T cells encounter viral peptides bound to the major histocompatibility complex. Remarkably, cytokine production ceases immediately upon dissociation of the T cells from their targets and resumes when antigenic contact is restored. In contrast to the 'on/off/on' cycling of cytokines, the pore-forming cytotoxic protein perforin is constitutively maintained. Our results indicate that there is differential expression of effector molecules according to whether the antiviral product is secreted (like cytokines) or stored inside the cell (like perforin). The ability to turn cytokines on and off while maintaining intracellular stores of perforin shows the versatility of the cellular immune response and provides a mechanism for maintaining effective immune surveillance while reducing systemic immunopathology.	Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Slifka, MK (corresponding author), Scripps Res Inst, Dept Neuropharmacol, CVN-9,10550 N torrey Pines Rd, La Jolla, CA 92037 USA.		Rodriguez, Fernando/C-3972-2011; Rodriguez, Fernando/GLN-3947-2022	Rodriguez, Fernando/0000-0001-7361-8408				AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CAMPBELL IL, 1995, INT J DEV NEUROSCI, V13, P275, DOI 10.1016/0736-5748(94)00073-C; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Guidotti LG, 1996, CURR OPIN IMMUNOL, V8, P478, DOI 10.1016/S0952-7915(96)80034-3; HAHN K, 1994, VIROLOGY, V201, P330, DOI 10.1006/viro.1994.1298; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Masuda N, 1998, BRIT J CANCER, V78, P388, DOI 10.1038/bjc.1998.504; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; TRACEY KJ, 1992, P SOC EXP BIOL MED, V200, P233; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WHITTON JL, 1990, SEMIN VIROL, V1, P257; WHITTON JL, 1996, FIELDS VIROLOGY, V3, P345; Yang Y, 1998, J EXP MED, V188, P247, DOI 10.1084/jem.188.2.247	26	216	220	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					76	79		10.1038/43454	http://dx.doi.org/10.1038/43454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485708				2022-12-28	WOS:000082374400044
J	Barzansky, B; Jonas, HS; Etzel, SI				Barzansky, B; Jonas, HS; Etzel, SI			Educational programs in US medical schools, 1998-1999	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								To describe the current status of medical education programs in the United States and to trace trends in medical education over this century, we used data from the 1998-1999 Liaison Committee on Medical Education Annual Medical School Questionnaire, which had a 100% response rate, and data from other sources. In 1998-1999, total full-time faculty members numbered 98 202, a 1.5% increase from 1997-1998. The number of applicants to medical school declined for the second consecutive year, from 43 020 in 1997 to 41 004 in 1998, but the academic qualifications of entering students remained steady. The number of applicants from underrepresented minority groups decreased 1.3% from 1997 to 1998, compared with an 11.1% decrease between 1996 and 1997, Women constituted 43.4% of applicants in 1998, slightly more than the 42.5% in 1997, The total number of required hours in the first and second years of the curriculum and the number of scheduled hours per week have declined over the past 15 years, while the average lengths of clinical clerkships remained about the same. The number of schools requiring students to pass Steps 1 and 2 of the United States Medical Licensing Examination continued to increase in 1998-1999, with 50% of schools requiring passing both examinations, compared with 46% in 1997-1998.	Amer Med Assoc, Div Undergrad Med Educ, Chicago, IL 60610 USA; Amer Med Assoc, Dept Res & Data Anal, Chicago, IL 60610 USA	American Medical Association; American Medical Association	Barzansky, B (corresponding author), Amer Med Assoc, Div Undergrad Med Educ, 515 N State St, Chicago, IL 60610 USA.							*ASS AM MED COLL, 1999, DAT BOOK; BARZANSKY B, 1992, FLEXNER MED ED 20 CE, P19; Flexner A, 1910, CARNEGIE FDN B; Liaison Committee on Medical Education, 1998, FUNCT STRUCT MED SCH; *MED ED US, 1908, JAMA-J AM MED ASSOC, V52, P607; *MED ED US, 1989, JAMA-J AM MED ASSOC, V262, P1016; *MED ED US, 1928, JAMA-J AM MED ASSOC, V93, P529; *MED ED US, 1948, JAMA-J AM MED ASSOC, V138, P32; *US MED SCH, 1901, JAMA-J AM MED ASSOC, V37, P744	9	43	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					840	846		10.1001/jama.282.9.840	http://dx.doi.org/10.1001/jama.282.9.840			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478690				2022-12-28	WOS:000082272200009
J	Patterson, RL; van Rossum, DB; Gill, DL				Patterson, RL; van Rossum, DB; Gill, DL			Store-operated Ca2+ entry: Evidence for a secretion-like coupling model	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; OKADAIC ACID; CALYCULIN-A; PROTEIN PHOSPHATASE-1; ENDOTHELIAL-CELLS; ERM PROTEINS; F-ACTIN; RELEASE; POOLS; INHIBITION	elusive coupling between endoplasmic reticulum (ER) Ca2+ stores and plasma membrane (PM) "store-operated" Ca2+ entry channels was probed through a novel combination of cytoskeletal modifications. Whereas coupling was unaffected by disassembly of the actin cytoskeleton, in situ redistribution of F-actin into a tight cortical layer subjacent to the PM displaced cortical ER and prevented coupling between ER and PM Ca2+ entry channels, while not affecting inositol 1,4,5-trisphosphate-mediated store release, Importantly, disassembly of the induced cortical actin layer allowed ER to regain access to the PM and reestablish coupling of Ca2+ entry channels to Ca2+ store depletion. Coupling is concluded to be mediated by a physical "secretion-like" mechanism involving close but reversible interactions between the ER and the PM.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.			van Rossum, Damian/0000-0003-1011-2586	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Amieva MR, 1999, J CELL SCI, V112, P111; Becker KA, 1999, J CELL SCI, V112, P97; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Carbajal ME, 1997, ENDOCRINOLOGY, V138, P5374, DOI 10.1210/en.138.12.5374; Chen J, 1997, AM J PHYSIOL-CELL PH, V273, pC710, DOI 10.1152/ajpcell.1997.273.2.C710; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; DOWNEY GP, 1993, J CELL PHYSIOL, V155, P505, DOI 10.1002/jcp.1041550309; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Favre CJ, 1998, J BIOL CHEM, V273, P30855, DOI 10.1074/jbc.273.47.30855; Fernando KC, 1997, BIOCHEM J, V328, P463; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; GILL DL, 1993, HDB EXPT PHARM GTPAS, V108, P625; Gregory RB, 1996, BIOCHEM J, V319, P755, DOI 10.1042/bj3190755; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; HOSOYA N, 1993, J CELL SCI, V105, P883; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; KREIENBUHL P, 1992, BLOOD, V80, P2911; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MATTHEWS JB, 1997, AM J PHYSIOL, V272, P254; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NEHER E, 1997, PHYSIOL REV, V77, P901; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rys-Sikora KE, 1998, J BIOL CHEM, V273, P32627, DOI 10.1074/jbc.273.49.32627; RYSSIKORA KE, 1994, J BIOL CHEM, V269, P31607; Sakai T, 1996, AM J PHYSIOL-CELL PH, V271, pC284, DOI 10.1152/ajpcell.1996.271.1.C284; SHINOKI N, 1995, J CELL BIOCHEM, V59, P368, DOI 10.1002/jcb.240590308; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; TOLVOLA DM, 1997, J CELL SCI, V110, P23; Trifaro JM, 1997, NEUROCHEM RES, V22, P831, DOI 10.1023/A:1022087910902; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	52	381	390	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					487	499		10.1016/S0092-8674(00)81977-7	http://dx.doi.org/10.1016/S0092-8674(00)81977-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481913	Bronze			2022-12-28	WOS:000082174900009
J	Weiss, RA				Weiss, RA			Biomedicine - Xenografts and retroviruses	SCIENCE			English	Editorial Material							PIG ENDOGENOUS RETROVIRUS; HUMAN-CELLS; NO EVIDENCE; INFECTION; TRANSPLANTATION; XENOTRANSPLANTATION; DISEASE; SAFETY		UCL, Windeyer Inst Med Sci, Wohl Virion Ctr, London W1P 6DB, England	University of London; University College London	Weiss, RA (corresponding author), UCL, Windeyer Inst Med Sci, Wohl Virion Ctr, London W1P 6DB, England.	r.weiss@ucl.ac.uk						ACHONG BG, 1976, BRIT J CANCER, V34, P203, DOI 10.1038/bjc.1976.144; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; Butler D, 1998, NATURE, V391, P320; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; *DEP HLTH ADV GROU, 1997, AN TISS HUM; DINSMORE JH, 1999, FOOD DRUG ADM ADV PA; ELLIAS SA, 1997, MOVEMENT DISORD, V12, P839; Fishman JA, 1998, ANN NY ACAD SCI, V862, P1; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; Hooper Edward, 1999, RIVER JOURNEY SOURCE; Hoopes CW, 1997, TRANSPLANTATION, V64, P347, DOI 10.1097/00007890-199707270-00029; Institute of Medicine, 1996, XEN SCI ETH PUBL POL; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; Martin U, 1998, LANCET, V352, P692, DOI 10.1016/S0140-6736(98)07144-X; Nuffield Council on Bioethics, 1996, AN HUM TRANSPL ETH X; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Rother RP, 1996, CELL, V86, P185, DOI 10.1016/S0092-8674(00)80090-2; St Hillaire M, 1998, NEUROLOGY, V50, pA80; Stoye J, 1998, LANCET, V352, P666, DOI 10.1016/S0140-6736(98)22035-6; Takeuchi Y, 1998, J VIROL, V72, P9986, DOI 10.1128/JVI.72.12.9986-9991.1998; Weiss RA, 1999, NATURE, V397, P385, DOI 10.1038/17008; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Weiss RA, 1998, BMJ-BRIT MED J, V317, P931; WEISS RA, 1978, NATL CANCER I MONOGR, V48, P183; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	30	69	79	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1999	285	5431					1221	1222		10.1126/science.285.5431.1221	http://dx.doi.org/10.1126/science.285.5431.1221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10484730				2022-12-28	WOS:000082130200026
J	Cate, JH; Yusupov, MM; Yusupova, GZ; Earnest, TN; Noller, HF				Cate, JH; Yusupov, MM; Yusupova, GZ; Earnest, TN; Noller, HF			X-ray crystal structures of 70S ribosome functional complexes	SCIENCE			English	Review							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA BINDING; NUCLEAR MAGNETIC-RESONANCE; P-SITE; THERMUS-THERMOPHILUS; A-SITE; BACILLUS-STEAROTHERMOPHILUS; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; PROMOTES TRANSLOCATION	Structures of 70S ribosome complexes containing messenger RNA and transfer RNA (tRNA), or tRNA analogs, have been solved by x-ray crystallography at up to 7.8 angstrom resolution. Many details of the interactions between tRNA and the ribosome, and of the packing arrangements of ribosomal RNA (rRNA) helices in and between the ribosomal subunits, can be seen. Numerous contacts are made between the 30S subunit and the P-tRNA anticodon stem-loop; in contrast, the anticodon region of A-tRNA is much more exposed. A complex network of molecular interactions suggestive of a functional relay is centered around the Long penultimate stem of 16S rRNA at the subunit interface, including interactions involving the "switch" helix and decoding site of 16S rRNA, and RNA bridges from the 50S subunit.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Lawrence Berkeley Lab, Phys Biosci Div, Macromol Crystallog Facil, Berkeley, CA 94720 USA	University of California System; University of California Santa Cruz; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Cate, JH (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.	cate@wi.mit.edu; marat@darwin.ucsc.edu; harry@nuvolari.ucsc.edu	Yusupova, Gulnara/E-1877-2014; Yusupov, Marat/I-6126-2013	Yusupov, Marat/0000-0001-5544-0597	NIGMS NIH HHS [GM-17129, GM-59140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129, R01GM059140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BOUSSERT AS, 1977, J MOL BIOL, V116, P577; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; CULVER GM, UNPUB; Dallas A, 1997, STRUCTURE, V5, P1639, DOI 10.1016/S0969-2126(97)00311-0; Easterwood TR, 1995, BIOCHEM CELL BIOL, V73, P751, DOI 10.1139/o95-083; Fink DL, 1996, RNA, V2, P851; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; GATE L, UNPUB; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; GAVRILOVA L P, 1972, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V6, P248; GERSTEIN M, 1992, ACTA CRYSTALLOGR A, V48, P271, DOI 10.1107/S0108767391012680; GOGIYA Z B, 1986, Molekulyarnaya Biologiya (Moscow), V20, P519; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; GUDKOV AT, 1982, FEBS LETT, V138, P229, DOI 10.1016/0014-5793(82)80448-1; GULVER GM, 1999, J MOL BIOL, V286, P355; HANSEN HAS, 1990, BIOCHIM BIOPHYS ACTA, V1050, P1, DOI 10.1016/0167-4781(90)90132-L; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; Hill WE., 1990, RIBOSOME STRUCTURE F; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; KASTNER B, 1981, P NATL ACAD SCI-BIOL, V78, P6652, DOI 10.1073/pnas.78.11.6652; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; KURLAND CG, 1980, RIBOSOMES STRUCTURE, P597; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Leontis NB, 1998, J MOL BIOL, V283, P571, DOI 10.1006/jmbi.1998.2106; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Mangroo D, 1995, BIOCHEM CELL BIOL, V73, P1023, DOI 10.1139/o95-109; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; Merryman C, 1999, J MOL BIOL, V285, P107, DOI 10.1006/jmbi.1998.2243; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Moore PB, 1998, ANNU REV BIOPH BIOM, V27, P35, DOI 10.1146/annurev.biophys.27.1.35; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Newcomb LF, 1999, BIOCHEMISTRY-US, V38, P945, DOI 10.1021/bi981644a; Nikonov SV, 1998, BIOL CHEM, V379, P795, DOI 10.1515/bchm.1998.379.7.795; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1990, RIBOSOME, P73; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NOLLER HF, 1986, STRUCTURE FUNCTION G, P143; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OFENGAND J, 1979, BIOCHEMISTRY-US, V18, P4322, DOI 10.1021/bi00587a010; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1995, RNA, V1, P194; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; SANTER M, 1977, J BACTERIOL, V130, P900, DOI 10.1128/JB.130.2.900-910.1977; SCHNEIDER G, 1994, ACTA CRYSTALLOGR D, V50, P186, DOI 10.1107/S0907444993009679; SCHWEDLER G, 1993, EUR J BIOCHEM, V217, P361, DOI 10.1111/j.1432-1033.1993.tb18254.x; SPIRIN AS, 1974, FEBS LETT, V40, P38; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; TRAKHANOV S, 1989, J MOL BIOL, V209, P327, DOI 10.1016/0022-2836(89)90282-9; TRAKHANOV SD, 1987, FEBS LETT, V220, P319, DOI 10.1016/0014-5793(87)80838-4; TRAUT RR, 1986, STRUCTURE FUNCTION G; VASILIEV VD, 1983, J MOL BIOL, V171, P561, DOI 10.1016/0022-2836(83)90043-8; VASSILENKO SK, 1981, J MOL BIOL, V152, P699, DOI 10.1016/0022-2836(81)90123-6; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOWER J, 1990, BIOCHIM BIOPHYS ACTA, V1050, P38, DOI 10.1016/0167-4781(90)90138-R; YONATH AE, 1980, BIOCHEM INT, V1, P428; YUSUPOV M M, 1987, Doklady Akademii Nauk SSSR, V292, P1271; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5; YUSUPOV MM, 1991, BIOCHIMIE, V73, P887, DOI 10.1016/0300-9084(91)90130-S; YUSUPOVA G, 1991, FEBS LETT, V290, P69, DOI 10.1016/0014-5793(91)81228-Z	125	500	525	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2095	2104		10.1126/science.285.5436.2095	http://dx.doi.org/10.1126/science.285.5436.2095			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497122				2022-12-28	WOS:000082734300034
J	Bayley, M; Holmstrup, M				Bayley, M; Holmstrup, M			Water vapor absorption in arthropods by accumulation of myoinositol and glucose	SCIENCE			English	Article							ONYCHIURUS-ARCTICUS TULLBERG; COLD-HARDINESS; DESICCATION; COLLEMBOLA; ANHYDROBIOSIS; ADAPTATIONS	Hydrophilic soil arthropods have been thought to respond to soil desiccation exclusively by migrating to deeper soil Layers. Numerous studies have shown that their survival below 90 percent relative humidity dry weight, is Limited to hours. However, Little attention has been paid to physiological adaptations to more realistic desiccation regimes, such as at the permanent wilting point of plants (98.9 percent relative humidity). A water vapor absorption mechanism is described that allows a common soil collembolan, Folsomia candida, to remain active down to below the permanent wilting point. A reevaluation of the water physiology of this widespread and diverse animal group is required.	Natl Environm Res Inst, Dept Terr Ecol, DK-8600 Silkeborg, Denmark	Aarhus University	Holmstrup, M (corresponding author), Natl Environm Res Inst, Dept Terr Ecol, Vejlsovej 25,POB 314, DK-8600 Silkeborg, Denmark.		Holmstrup, Martin/I-7463-2013; Bayley, Mark/J-5947-2013; Holmstrup, Martin/E-8731-2017	Holmstrup, Martin/0000-0001-8395-6582; Bayley, Mark/0000-0001-8052-2551; Holmstrup, Martin/0000-0001-8395-6582				BELGNAOUI S, 1988, Biological Structures and Morphogenesis, V1, P147; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; GARDNER W. R., 1960, SOIL SCI, V89, P63, DOI 10.1097/00010694-196002000-00001; Hadley N. F, 1994, WATER RELATIONS TERR; HARRISSON PM, 1991, J INSECT PHYSIOL, V37, P883, DOI 10.1016/0022-1910(91)90003-I; Holmstrup M, 1998, J COMP PHYSIOL B, V168, P197, DOI 10.1007/s003600050137; NOBLENESBITT J, 1963, J EXP BIOL, V40, P681; RING RA, 1994, CRYOLETTERS, V15, P181; Storey K.B., 1991, P64; VANNIER G, 1987, BIOL FERT SOILS, V3, P39, DOI 10.1007/BF00260577; WEAST RC, 1989, CRC HDB CHEM PHYSICS; WEIGMANN G, 1973, Z WISS ZOOL ABT A, V186, P295; WITTEVEEN J, 1987, J INSECT PHYSIOL, V33, P59, DOI 10.1016/0022-1910(87)90105-3; WOMERSLEY C, 1981, COMP BIOCHEM PHYS B, V70, P579, DOI 10.1016/0305-0491(81)90299-6; Worland MR, 1998, J INSECT PHYSIOL, V44, P211, DOI 10.1016/S0022-1910(97)00166-2; WRIGHT JC, 1992, BIOL REV, V67, P1, DOI 10.1111/j.1469-185X.1992.tb01657.x; ZETTEL J, 1984, REV ECOL BIOL SOL, V21, P189	18	107	109	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1909	1911		10.1126/science.285.5435.1909	http://dx.doi.org/10.1126/science.285.5435.1909			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489369				2022-12-28	WOS:000082638300049
J	Hoppa, GV; Tufts, BR; Greenberg, R; Geissler, PE				Hoppa, GV; Tufts, BR; Greenberg, R; Geissler, PE			Formation of cycloidal features on Europa	SCIENCE			English	Article							TIDAL STRESSES; FRACTURE; SEPARATION; PATTERNS	Cycloidal patterns are widely distributed on the surface of Jupiter's moon Europa. Tensile cracks may have developed such a pattern in response to diurnal variations in tidal stress in Europa's outer ice shell. When the tensile strength of the ice is reached, a crack may occur. Propagating cracks would move across an ever-changing stress field, following a curving path to a place and time where the tensile stress was insufficient to continue the propagation. A few hours Later, when the stress at the end of the crack again exceeded the strength, propagation would continue in a new direction. Thus, one arcuate segment of the cycloidal chain would be produced during each day on Europa. For this model to work, the tensile strength of Europa's ice crust must be Less than 40 kilo-pascals, and there must be a thick fluid Layer below the ice to allow sufficient tidal amplitude.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Hoppa, GV (corresponding author), Univ Arizona, Lunar & Planetary Lab, 1629 E Univ Blvd, Tucson, AZ 85721 USA.							CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; GAMMON PH, 1983, J PHYS CHEM-US, V87, P4025, DOI 10.1021/j100244a004; GOLOMBEK MP, 1990, ICARUS, V83, P441, DOI 10.1016/0019-1035(90)90078-N; Greenberg R, 1998, ICARUS, V135, P64, DOI 10.1006/icar.1998.5986; HEAD JW, IN PRESS J GEOPHYS R; HELFENSTEIN P, 1983, ICARUS, V53, P415, DOI 10.1016/0019-1035(83)90206-3; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; HOPPA GV, 1996, LUNAR PLANET SCI C, V30; KADEL SD, 1998, LUNAR PLANET SCI C, V29; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MALIN MC, 1986, SATELLITES, P689; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; NOLAN M, 1987, B AM ASTRON SOC, V19, P860; OJKANGASGW, 1989, ICARUS, V81, P242; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; Smith RA, 1976, J GLACIOL, V17, P223; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; Tufts B. R., 1998, THESIS U ARIZONA TUC; TUFTS BJ, UNPUB; TURTLE EP, 1998, EOS, V79, pS202	24	168	171	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1899	1902		10.1126/science.285.5435.1899	http://dx.doi.org/10.1126/science.285.5435.1899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489365				2022-12-28	WOS:000082638300045
J	Torp-Pedersen, C; Moller, M; Bloch-Thomsen, PE; Kober, L; Sandoe, E; Egstrup, K; Agner, E; Carlsen, J; Videbaek, J; Marchant, B; Camm, AJ				Torp-Pedersen, C; Moller, M; Bloch-Thomsen, PE; Kober, L; Sandoe, E; Egstrup, K; Agner, E; Carlsen, J; Videbaek, J; Marchant, B; Camm, AJ		Danish Investigations Arrhythmia Mortality Dofe	Dofetilide in patients with congestive heart failure and left ventricular dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE AMIODARONE; MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; RANDOMIZED TRIAL; ANTIARRHYTHMIC DRUG; SINUS RHYTHM; D-SOTALOL; MORTALITY; THERAPY; ARRHYTHMIA	Background Atrial fibrillation occurs frequently in patients with congestive heart failure and commonly results in clinical deterioration and hospitalization. Sinus rhythm may be maintained with antiarrhythmic drugs, but some of these drugs increase the risk of death. Methods We studied 1518 patients with symptomatic congestive heart failure and severe left ventricular dysfunction at 34 Danish hospitals. We randomly assigned 762 patients to receive dofetilide, a novel class III antiarrhythmic agent, and 756 to receive placebo in a double-blind study. Treatment was initiated in the hospital and included three days of cardiac monitoring and dose adjustment. The primary end point was death from any cause. Results During a median follow-up of 18 months, 311 patients in the dofetilide group (41 percent) and 317 patients in the placebo group (42 percent) died (hazard ratio, 0.95; 95 percent confidence interval, 0.81 to 1.11). Treatment with dofetilide significantly reduced the risk of hospitalization for worsening congestive heart failure (risk ratio, 0.75; 95 percent confidence interval, 0.63 to 0.89). Dofetilide was effective in converting atrial fibrillation to sinus rhythm. After one month, 22 of 190 patients with atrial fibrillation at base line (12 percent) had sinus rhythm restored with dofetilide, as compared with only 3 of 201 patients (1 percent) given placebo. Once sinus rhythm was restored, dofetilide was significantly more effective than placebo in maintaining sinus rhythm (hazard ratio for the recurrence of atrial fibrillation, 0.35; 95 percent confidence interval, 0.22 to 0.57; P < 0.001). There were 25 cases of torsade de pointes in the dofetilide group (3.3 percent) as compared with none in the placebo group. Conclusions In patients with congestive heart failure and reduced left ventricular function, dofetilide was effective in converting atrial fibrillation, preventing its recurrence, and reducing the risk of hospitalization for worsening heart failure. Dofetilide had no effect on mortality. (N Engl J Med 1999;341:857-65.) (C) 1999, Massachusetts Medical Society.	Odense Univ Hosp, Dept Cardiol B, DK-5000 Odense, Denmark; Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; Haderslev Hosp, Dept Cardiol, Haderslev, Denmark; Helsingborg Hosp, Dept Cardiol, Helsingor, Denmark; Bispebjerg Hosp, Dept Cardiol, Bispebjerg, Denmark; Pfizer Ltd, Sandwich, Kent, England; St George Hosp, Dept Cardiol, London, England	University of Southern Denmark; Odense University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; Pfizer; St Georges University London	Moller, M (corresponding author), Odense Univ Hosp, Dept Cardiol B, DK-5000 Odense, Denmark.	moller@pacemaker.dk	Torp-Pedersen, Christian/E-5931-2013	Kober, Lars/0000-0002-6635-1466				ALAM M, 1992, AM J CARDIOL, V69, P694, DOI 10.1016/0002-9149(92)90169-Y; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Camm AJ, 1997, CLIN CARDIOL, V20, P704; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Deedwania PC, 1998, CIRCULATION, V98, P2574, DOI 10.1161/01.CIR.98.23.2574; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FREEDMAN MD, 1991, J CLIN PHARMACOL, V31, P1061, DOI 10.1002/j.1552-4604.1991.tb03673.x; FRIEDRICH T, 1996, CARDIOVASCULAR DRUG, P1296; GARGUICHEVICH JJ, 1995, AM HEART J, V130, P494, DOI 10.1016/0002-8703(95)90357-7; Green MS, 1997, CIRCULATION, V96, P2536; GREENBAUM R, 1998, EUR HEART J S661, V19; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; GWILT M, 1991, J PHARMACOL EXP THER, V256, P318; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOBER L, 1995, AM J CARDIOL, V76, P1, DOI 10.1016/S0002-9149(99)80791-7; KOBER L, 1994, EUR HEART J, V15, P1616; LANG R, 1983, CHEST, V83, P491, DOI 10.1378/chest.83.3.491; MIDDLEKAUFF HR, 1991, CIRCULATION, V84, P40, DOI 10.1161/01.CIR.84.1.40; Nademanee K, 1998, PACE, V21, P1442, DOI 10.1111/j.1540-8159.1998.tb00216.x; Pardaens K, 1997, HEART, V78, P564, DOI 10.1136/hrt.78.6.564; Pratt CM, 1998, AM J CARDIOL, V81, P869, DOI 10.1016/S0002-9149(98)00006-X; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SEDGWICK ML, 1992, AM J CARDIOL, V69, P513, DOI 10.1016/0002-9149(92)90996-C; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SINGH SN, 1997, CIRCULATION S1, V96, P383; VIGNA C, 1992, AM J CARDIOL, V70, P1500, DOI 10.1016/0002-9149(92)90310-U; Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6	34	687	697	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1999	341	12					857	865		10.1056/NEJM199909163411201	http://dx.doi.org/10.1056/NEJM199909163411201			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235XL	10486417				2022-12-28	WOS:000082569100001
J	Plotnikov, AN; Schlessinger, J; Hubbard, SR; Mohammadi, M				Plotnikov, AN; Schlessinger, J; Hubbard, SR; Mohammadi, M			Structural basis for FGF receptor dimerization and activation	CELL			English	Article							FIBROBLAST-GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; 3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; POINT MUTATION; CELL-ADHESION; FACTOR FAMILY; HEPARIN; AFFINITY; PROTEIN	The crystal structure of FGF2 bound to a naturally occurring variant of FGF receptor 1 (FGFR1) consisting of immunoglobulin-like domains 2 (D2) and 3 (D3) has been determined at 2.8 Angstrom resolution. Two FGF2:FGFR1 complexes form a 2-fold symmetric dimer. Within each complex, FGF2 interacts extensively with D2 and D3 as well as with the linker between the two domains. The dimer is stabilized by interactions between FGF2 and D2 of the adjoining complex and by a direct interaction between D2 of each receptor. A positively charged canyon formed by a cluster of exposed basic residues likely represents the heparin-binding site. A general model for FGF- and heparin-induced FGFR dimerization is inferred from the crystal structure, unifying a wealth of biochemical data.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University; New York University	Mohammadi, M (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BATEMAN A, 1995, NAT STRUCT BIOL, V2, P1068, DOI 10.1038/nsb1295-1068; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; DELL KR, 1992, J BIOL CHEM, V267, P21225; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4327; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOBRIN MS, 1993, CANCER RES, V53, P4741; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Naski M C, 1998, Front Biosci, V3, pd781; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noe V, 1999, J CELL SCI, V112, P127; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAR; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; Zhu HY, 1998, PROTEIN ENG, V11, P937, DOI 10.1093/protein/11.10.937; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	57	481	527	2	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					641	650		10.1016/S0092-8674(00)80051-3	http://dx.doi.org/10.1016/S0092-8674(00)80051-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490103	hybrid			2022-12-28	WOS:000082433500011
J	Rojas, JR; Trievel, RC; Zhou, JX; Mo, Y; Li, XM; Berger, SL; Allis, CD; Marmorstein, R				Rojas, JR; Trievel, RC; Zhou, JX; Mo, Y; Li, XM; Berger, SL; Allis, CD; Marmorstein, R			Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide	NATURE			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; CRYSTAL-STRUCTURE; IN-VIVO; REFINEMENT; COMPLEXES; PROTEIN; SUPERFAMILY; ACETYLATION; DYNAMICS; ADA	Gene activation is a highly regulated process that requires the coordinated action of proteins to relieve chromatin repression and to promote transcriptional activation. Nuclear histone acetyltransferase (HAT) enzymes provide a mechanistic link between chromatin destabilization and gene activation by acetylating the E-amino group of specific lysine residues within the aminoterminal tails of core histones to facilitate access to DNA by transcriptional activators(1,2). Here we report the high-resolution crystal structure of the HAT domain of Tetrahymena GCN5 (tGCN5) bound with both its physiologically relevant ligands, coenzyme A (CoA) and a histone H3 peptide, and the structures of nascent tGCN5 and a tGCN5/acetyl-CoA complex. Our structural data reveal histone-binding specificity for a random-coil structure Containing a G-K-X-P recognition sequence, and show that CoA is essential for reorienting the enzyme for histone binding. Catalysis appears to involve water-mediated proton extraction from the substrate lysine by a glutamic acid general base and a backbone amide that stabilizes the transition-state reaction intermediate. Comparison with related N-acetyltransferases indicates a conserved structural framework for CoA binding and catalysis, and structural variability in regions associated with substrate-specific binding.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Rochester	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.		li, xinmin/C-6173-2011	Berger, Shelley/0000-0001-5398-4400				Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR MANUAL VERSION; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; FUREY W, 1995, METHOD ENZYMOL, P590; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Leslie A.G.W., 1992, CCP4 ESF EACMB NEWSL; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	29	225	230	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					93	98		10.1038/43487	http://dx.doi.org/10.1038/43487			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485713				2022-12-28	WOS:000082374400049
J	Hill, D				Hill, D			Efficacy of sunscreens in protection against skin cancer	LANCET			English	Editorial Material							PREVENTION		Anticanc Council Victoria, Canc Control Res Inst, Ctr Behav Res Canc, Carlton S, Vic 3053, Australia		Hill, D (corresponding author), Anticanc Council Victoria, Canc Control Res Inst, Ctr Behav Res Canc, Carlton S, Vic 3053, Australia.							Autier P, 1999, JNCI-J NATL CANCER I, V91, P1304, DOI 10.1093/jnci/91.15.1304; BLUM FH, 1941, JNCI, V3, P259; Carter R, 1999, HEALTH PROMOT INT, V14, P73, DOI 10.1093/heapro/14.1.73; CRIPPS S, 1974, ARCH DERMATOL, V109, P202; DROMGOOLE SH, 1990, SUNSCREENS DEV EVALU; GALLAGHER CH, 1989, T MENZIES FDN, V15, P201; Hill D, 1993, Eur J Cancer Prev, V2, P447; HILL D, 1992, PREV MED, V21, P654, DOI 10.1016/0091-7435(92)90072-P; *INT SPEC INF SYST, 1992, ISIS MAMM ABSTR, P55; KLIGMAN LH, 1980, J AM ACAD DERMATOL, V3, P30, DOI 10.1016/S0190-9622(80)80221-0; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Staples M, 1998, INT J CANCER, V78, P144, DOI 10.1002/(SICI)1097-0215(19981005)78:2<144::AID-IJC3>3.0.CO;2-Z; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; WULF HC, 1982, J AM ACAD DERMATOL, V7, P194, DOI 10.1016/S0190-9622(82)70108-2	14	12	12	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					699	700		10.1016/S0140-6736(99)00192-0	http://dx.doi.org/10.1016/S0140-6736(99)00192-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475178				2022-12-28	WOS:000082233000006
J	Lenormand, T; Bourguet, D; Guillemaud, T; Raymond, M				Lenormand, T; Bourguet, D; Guillemaud, T; Raymond, M			Tracking the evolution of insecticide resistance in the mosquito Culex pipiens	NATURE			English	Article							GENE FLOW; HYBRID ZONE; SELECTION; MODEL; CLINE	The evolution of pesticide resistance provides some of the most striking examples of darwinian evolution occurring over a human life span. Identification of resistance alleles opens an outstanding framework in which to study the evolution of adaptive mutations from the beginning of pesticide application(1-3), the evolution of interactions between alleles (dominance(4)) or between loci (epistasis(5,6)). Here we shaw that resistance alleles can also be used as markers to dissect population processes at a microevolutionary scale. We have focused on the antagonistic roles of selection and migration involved in the dynamics of local adaptation with reference to allelic frequencies at two resistance loci in the mosquito Culex pipiens, We find that their frequencies follow an annual cycle of large amplitude (25%), and we precisely unravel the seasonal variation of migration and selection underlying this cycle. Our results provide a firm basis on which to devise an insecticide treatment strategy that will better control the evolution of resistance genes and the growth of mosquito populations.	Univ Montpellier 2, Inst Sci Evolut, Lab Genet & Environm, UMR 5554, F-34095 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Lenormand, T (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.		Raymond, Michel/C-9049-2015; guillemaud, thomas/B-4899-2012; Lenormand, Thomas/A-5328-2012	guillemaud, thomas/0000-0003-0451-1644; Lenormand, Thomas/0000-0001-8930-5393; Bourguet, Denis/0000-0002-2109-5323; Raymond, Michel/0000-0002-1714-6984				ANDERSON DR, 1994, ECOLOGY, V75, P1780, DOI 10.2307/1939637; BARTON NH, 1989, NATURE, V341, P497, DOI 10.1038/341497a0; BARTON NH, 1982, EVOLUTION, V36, P863, DOI 10.1111/j.1558-5646.1982.tb05452.x; Bourguet D, 1997, GENETICS, V147, P1225; Chevillon C, 1997, GENET RES, V70, P195, DOI 10.1017/S0016672397003029; Cook LM, 1999, P ROY SOC B-BIOL SCI, V266, P293, DOI 10.1098/rspb.1999.0636; Davies AG, 1996, GENETICS, V143, P1321; Guillemaud T, 1998, EVOLUTION, V52, P443, DOI [10.2307/2411080, 10.1111/j.1558-5646.1998.tb01644.x]; HALDANE JBS, 1948, J GENET, V48, P277, DOI 10.1007/BF02986626; Harrison R.G., 1990, Oxford Surveys in Evolutionary Biology, V7, P69; JAIN SK, 1966, HEREDITY, V21, P407, DOI 10.1038/hdy.1966.42; Kettlewell H. B. D., 1961, Heredity, V16, P403, DOI 10.1038/hdy.1961.49; Lenormand T, 1998, EVOLUTION, V52, P1705, DOI [10.2307/2411343, 10.1111/j.1558-5646.1998.tb02250.x]; Lenormand T, 1998, GENETICS, V149, P1383; Lenormand T, 1998, P ROY SOC B-BIOL SCI, V265, P1985, DOI 10.1098/rspb.1998.0529; LENORMAND T, IN PRESS AM NAT; MALLET J, 1990, GENETICS, V124, P921; MALLET J, 1989, TRENDS ECOL EVOL, V4, P336, DOI 10.1016/0169-5347(89)90088-8; MANI GS, 1980, PROC R SOC SER B-BIO, V210, P299, DOI 10.1098/rspb.1980.0135; MAY RM, 1975, AM NAT, V109, P659, DOI 10.1086/283036; McKenzie J., 1996, ECOLOGICAL EVOLUTION; MUTERO A, 1994, P NATL ACAD SCI USA, V91, P5922, DOI 10.1073/pnas.91.13.5922; NAGLAKI T, 1975, GENETICS, V80, P595; Porter AH, 1997, EVOLUTION, V51, P1561, DOI [10.1111/j.1558-5646.1997.tb01479.x, 10.2307/2411208]; RAYMOND M, 1989, GENETICS, V123, P543; SITES JW, 1995, EVOLUTION, V49, P9, DOI 10.1111/j.1558-5646.1995.tb05955.x; SLATKIN M, 1975, GENETICS, V81, P787; SLATKIN M, 1973, GENETICS, V75, P733; SZYMURA JM, 1986, EVOLUTION, V40, P1141, DOI 10.1111/j.1558-5646.1986.tb05740.x	29	161	166	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					861	864		10.1038/23685	http://dx.doi.org/10.1038/23685			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476962				2022-12-28	WOS:000082233200042
J	Steele, KM; Dalla Bella, S; Peretz, I; Dunlop, T; Dawe, LA; Humphrey, GK; Shannon, RA; Kirby, JL; Olmstead, CG				Steele, KM; Dalla Bella, S; Peretz, I; Dunlop, T; Dawe, LA; Humphrey, GK; Shannon, RA; Kirby, JL; Olmstead, CG			Prelude or requiem for the 'Mozart effect'?	NATURE			English	Letter							MUSIC; PERFORMANCE		Appalachian State Univ, Dept Psychol, Boone, NC 28608 USA; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Univ Western Ontario, Dept Psychol, Social Sci Ctr, London, ON N6A 5C2, Canada	University of North Carolina; Appalachian State University; Universite de Montreal; Western University (University of Western Ontario)	Steele, KM (corresponding author), Appalachian State Univ, Dept Psychol, Boone, NC 28608 USA.			Dalla Bella, Simone/0000-0001-9813-7408				CARSTENS CB, 1995, PSYCHOL REP, V77, P111, DOI 10.2466/pr0.1995.77.1.111; KENEALY P, 1994, PSYCHOLOGIST, V7, P346; Newman J, 1995, PERCEPT MOTOR SKILL, V81, P1379, DOI 10.2466/pms.1995.81.3f.1379; Rauscher FH, 1998, PERCEPT MOTOR SKILL, V86, P835, DOI 10.2466/pms.1998.86.3.835; RAUSCHER FH, 1993, NATURE, V365, P611, DOI 10.1038/365611a0; STOUGH C, 1994, PERS INDIV DIFFER, V17, P695, DOI 10.1016/0191-8869(94)90145-7; THORNDIKE RL, 1986, STANFORDBINET INTELL	7	59	62	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					827	827		10.1038/23611	http://dx.doi.org/10.1038/23611			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476959	Green Submitted			2022-12-28	WOS:000082233200027
J	Macarthur, C; Saunders, N; Feldman, W; Ipp, M; Winders-Lee, P; Roberts, S; Best, L; Sherman, P; Pencharz, P; van Zanten, SV				Macarthur, C; Saunders, N; Feldman, W; Ipp, M; Winders-Lee, P; Roberts, S; Best, L; Sherman, P; Pencharz, P; van Zanten, SV			Helicobacter pylori and childhood recurrent abdominal pain: community based case-control study	BRITISH MEDICAL JOURNAL			English	Article							YOUNG MEN; MORTALITY; ALCOHOL		Univ Calgary, Hlth Sci Ctr, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada; Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; Victoria Gen Hosp, Dept Microbiol, Halifax, NS B3H 2Y9, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Dalhousie University; University of Victoria	Macarthur, C (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada.			Sherman, Philip/0000-0002-4733-6690				*ADD RES FDN ONT C, 1994, CAN MED ASS J S, V151; ANDERSON P, 1995, ALCOHOL PUBLIC POLIC, P82; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; ANDREASSON S, 1991, BRIT J ADDICT, V86, P877; Edwards G., 1994, ALCOHOL POLICY PUBLI; KAPLAN GA, 1993, SOCIOECONOMIC FACTOR; *NAT BOARD HLTH WE, 1996, DODS 1994; *NAT BOARD HLTH WE, 1996, PAT 1987 1994 KVAL I; Rothman K., 1998, MODERN EPIDEMIOLOGY	9	40	43	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					822	+		10.1136/bmj.319.7213.822	http://dx.doi.org/10.1136/bmj.319.7213.822			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496827	Green Published, Bronze			2022-12-28	WOS:000082865200025
J	Little, P; Gould, C; Williamson, I; Warner, G; Gantley, M; Kinmonth, AL				Little, P; Gould, C; Williamson, I; Warner, G; Gantley, M; Kinmonth, AL			Clinical and psychosocial predictors of illness duration from randomised controlled trial of prescribing strategies for sore throat	BRITISH MEDICAL JOURNAL			English	Article									Univ Southampton, Aldermoor Hlth Ctr, Fac Hlth Med & Biol Sci, Primary Med Care Grp, Southampton SO16 5ST, Hants, England; Nightingale Surg, Romsey SO51 7QH, Hants, England	University of Southampton	Little, P (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Fac Hlth Med & Biol Sci, Primary Med Care Grp, Southampton SO16 5ST, Hants, England.			Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; WILKIN D, 1992, MEASURES NEED OUTCOM	5	25	25	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					736	737		10.1136/bmj.319.7212.736	http://dx.doi.org/10.1136/bmj.319.7212.736			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10487997	Green Published, Bronze			2022-12-28	WOS:000082701500016
J	Sherff, CM; Carew, TJ				Sherff, CM; Carew, TJ			Coincident induction of long-term facilitation in Aplysia: Cooperativity between cell bodies and remote synapses	SCIENCE			English	Article							LOCAL PROTEIN-SYNTHESIS; SENSORY NEURONS; LATE-PHASE; SYNAPTIC FACILITATION; MACROMOLECULAR-SYNTHESIS; CRITICAL PERIOD; POTENTIATION; PLASTICITY; REQUIREMENT; EXPRESSION	Induction of Long-term synaptic changes at one synapse can facilitate the induction of Long-term plasticity at another synapse. Evidence is presented here that if Aplysia sensory neuron somata and their remote motor neuron synapses are simultaneously exposed to serotonin pulses insufficient to induce Long-term facilitation (LTF) at either site along, processes activated at these sites interact to induce LTF. This coincident induction of LTF requires that (i) the synaptic pulse occur within a brief temporal window of the somatic pulse, and (ii) Local protein synthesis occur immediately at the synapse, followed by delayed protein synthesis at the soma.	Yale Univ, Dept Psychol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Sherff, CM (corresponding author), Yale Univ, Dept Psychol, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH012004] Funding Source: NIH RePORTER; NIMH NIH HHS [F32-MH12004, R01MH-14-1083] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARNBRON RT, 1992, J NEUROSCI, V12, P2813; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLEARY LJ, 1993, J NEUROPHYSIOL, V70, P1767, DOI 10.1152/jn.1993.70.5.1767; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GLANZMAN DL, 1994, J NEUROBIOL, V25, P666, DOI 10.1002/neu.480250608; GUNSTREAM JD, 1995, J NEUROSCI, V15, P439; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JAFFE DB, 1994, J NEUROPHYSIOL, V72, P471, DOI 10.1152/jn.1994.72.1.471; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; Mauelshagen J, 1996, J NEUROSCI, V16, P7099; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; TRUDEAU LE, 1995, J NEUROSCI, V15, P1275; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; XU YL, 1995, J NEUROPHYSIOL, V73, P1313, DOI 10.1152/jn.1995.73.3.1313; Zhang F, 1997, SCIENCE, V275, P1318, DOI 10.1126/science.275.5304.1318	29	72	73	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1911	1914		10.1126/science.285.5435.1911	http://dx.doi.org/10.1126/science.285.5435.1911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489370				2022-12-28	WOS:000082638300050
J	Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF				Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF			Admission trends in a rural south African hospital during the early years of the HIV epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESOURCE UTILIZATION; DRUG-USERS; TUBERCULOSIS; INFECTION; RISK; IMPACT; DISTRICT; NAIROBI; COHORT; WOMEN	Context Few studies have attempted to quantify the effect of the epidemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for health care in developing countries. More data are required to improve understanding of its impact and to guide development of appropriate response strategies. Objective To assess the HIV/AIDS epidemic's impact on demand for inpatient hospital care in a rural area of South Africa. Design Retrospective analysis of data from general hospital and individual ward admission registers, a tuberculosis program database, and patient case notes. Setting and Patients Patients admitted between 1991 and 1998 to a 450-bed hospital that serves Hlabisa District, South Africa (population approximate to 200 000), where HIV seroprevalence among antenatal clinic attendees increased from 4% in 1992 to 29% in 1998, Main Outcome Measures Number of admissions to 9 hospital wards, number of clinical AIDS and general medical admissions (both excluding tuberculosis), and number of tuberculosis admissions to adult medical wards during the study period. Results Total hospital admissions increased by 81%, from 6562 in 1991 to 11 872 in 1998, Adult tuberculosis ward admissions increased by 360%, from 303 to 1393, In 1998, tuberculosis patients accounted for 47% and 30% of adult male and female medical ward admissions, respectively, and for 11% of total hospital admissions. Nontuberculosis clinical AIDS cases increased 43-fold, accounting for 4% of adult medical admissions in 1997 vs 0.2% in 1991. Tuberculosis and nontuberculosis clinical AIDS cases were the only types of admission to show a clear and consistent upward trend over the period studied. Patterns in other types of admissions varied more and changes were smaller. Conclusions The HIV/AIDS epidemic has had an important impact on demand for adult tuberculosis and general medical care in a rural South African district hospital. If this impact is shown to extend to other rural South African areas, response strategies are urgently needed.	Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England; Hlabisa Hosp, Hlabisa, South Africa; MRC, Ctr Epidemiol Res S Africa, Mtubatuba, South Africa	Liverpool School of Tropical Medicine; University of Liverpool	Floyd, K (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.	kfloyd@liverpool.ac.uk	Gilks, Charles/B-4184-2012; Wilkinson, David/A-6207-2008	Gilks, Charles/0000-0002-8953-3123; Wilkinson, David/0000-0002-7265-9846				ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1997, HUM DEV REP 1997; ARTHUR G, 1998, 12 WORLD AIDS C JUN; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BUVE AMA, 1992, 8 INT C AIDS JUL 19, V2; Coleman RL, 1997, J ACQ IMMUN DEF SYND, V16, P50, DOI 10.1097/00042560-199709010-00008; DUNN DT, 1992, LANCET, V87, P456; FOSTER SD, 1993, COST BURDEN AIDS ZAM; GILKS CF, 1992, Q J MED, V82, P25; Harries A, 1996, TB HIV CLIN MANUAL; Harries AD, 1997, ANN TROP MED PARASIT, V91, P771, DOI 10.1080/00034989760527; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KARSTAEDT AS, 1996, S AFR MED J, V86, P1490; KING R, 1994, T ROY SOC TROP MED H, V88, P295, DOI 10.1016/0035-9203(94)90083-3; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NUNN P, 1993, TUBERCLE LUNG DIS, V74, P273, DOI 10.1016/0962-8479(93)90054-2; OKELLO DO, 1994, E AFR MED J, V71, P816; *REP S AFR DEP HLT, 1996, EPIDEMIOLOGICAL COMM, V23, P4; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMITH PG, 1994, TUBERCULOSIS PATHOGE, pCH4; *STAT CORP, 1999, STAT STAT SOFTW COMP; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; *UNAIDS, UNAIDS9810; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P420, DOI 10.1016/S0035-9203(97)90263-7; Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016; Wilkinson D, 1997, S AFR MED J, V87, P447; YEUNG S, IN PRESS J TROP PAED	30	45	45	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1087	1091		10.1001/jama.282.11.1087	http://dx.doi.org/10.1001/jama.282.11.1087			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493210				2022-12-28	WOS:000082512300036
J	Harlan, DM; Kirk, AD				Harlan, DM; Kirk, AD			The future of organ and tissue transplantation - Can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC ALLOGRAFT-REJECTION; LONG-TERM ACCEPTANCE; ISLET ALLOGRAFTS; CD40 LIGAND; LYMPHOPROLIFERATIVE DISORDERS; ACTIVATION ANTIGEN-B7; DENDRITIC CELL; BLOCKADE; CTLA-4; EXPRESSION	Transplantation therapies have revolutionized care for patients with endstage organ (kidney, liver, heart, lung, and pancreatic g-cell) failure, yet significant problems persist with treatments designed to prevent graft rejection. Antirejection therapies are not always effective, must be taken daily, and are both expensive and associated with well-known toxic effects; Recent advances have suggested that the immune system has more self-regulatory capability than previously appreciated. In this review, we discuss immune system function and new therapeutic agents that modify so-called costimulatory receptor signaling to support transplant function without generally suppressing the immune system.	NIDDK, USN, Med Res Ctr, Transplantat & Autoimmun Branch, Bethesda, MD 20889 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Organ Transplant Serv, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Harlan, DM (corresponding author), NIDDK, USN, Med Res Ctr, Transplantat & Autoimmun Branch, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.		Kirk, Allan D./B-6905-2012	Kirk, Allan/0000-0003-2004-5962				Alejandro R, 1997, DIABETES, V46, P1983, DOI 10.2337/diabetes.46.12.1983; Azuma H, 1996, P NATL ACAD SCI USA, V93, P12439, DOI 10.1073/pnas.93.22.12439; Becker BN, 1997, SEMIN NEPHROL, V17, P176; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Blazar BR, 1997, J IMMUNOL, V158, P29; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Boubenider S, 1997, J NEPHROL, V10, P136; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRETSCHER P, 1992, IMMUNOL TODAY, V13, P74, DOI 10.1016/0167-5699(92)90138-W; BUCKELS JAC, 1995, J ANTIMICROB CHEMOTH, V36, P39, DOI 10.1093/jac/36.suppl_B.39; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; Cecka J M, 1998, Clin Transpl, P1; Chandraker A, 1998, J CLIN INVEST, V101, P2309, DOI 10.1172/JCI2299; Chaparro C, 1997, CLIN CHEST MED, V18, P339, DOI 10.1016/S0272-5231(05)70383-X; DeChristopher PJ, 1997, AM J CLIN PATHOL, V107, pS2; Early GS, 1996, J IMMUNOL, V157, P3159; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; Glysing-Jensen T, 1997, TRANSPLANTATION, V64, P1641, DOI 10.1097/00007890-199712270-00002; Halloran PF, 1999, J AM SOC NEPHROL, V10, P167; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; HARLAN DM, 1998, GRAFT, V1, P60; HARPER K, 1991, J IMMUNOL, V147, P1037; Hayry P, 1998, TRANSPLANT P, V30, P3989, DOI 10.1016/S0041-1345(98)01314-1; Hilbrands LB, 1996, TRANSPLANTATION, V61, P1038, DOI 10.1097/00007890-199604150-00009; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Kendall DM, 1997, ENDOCRIN METAB CLIN, V26, P611, DOI 10.1016/S0889-8529(05)70270-X; Kenyon NS, 1999, P NATL ACAD SCI USA, V96, P8132, DOI 10.1073/pnas.96.14.8132; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; Lanzavecchia A, 1998, NATURE, V393, P413, DOI 10.1038/30845; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; Larsen CP, 1997, CURR OPIN IMMUNOL, V9, P641, DOI 10.1016/S0952-7915(97)80043-X; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LENSCHOW DJ, 1995, TRANSPLANTATION, V60, P1171, DOI 10.1097/00007890-199511270-00019; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Levisetti MG, 1997, J IMMUNOL, V159, P5187; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; Lu LN, 1997, TRANSPLANTATION, V64, P1808, DOI 10.1097/00007890-199712270-00031; MOHAN C, 1995, J IMMUNOL, V154, P1470; Monaco AP, 1999, AM J KIDNEY DIS, V33, P150, DOI 10.1016/S0272-6386(99)70273-8; Mutimer D, 1996, J HEPATOL, V25, P259, DOI 10.1016/S0168-8278(96)80083-3; Nagano H, 1997, AM J MED SCI, V313, P305, DOI 10.1097/00000441-199705000-00010; *NAT CTR HLTH STAT, 1988, DHHS PUBL S; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; PIRSCH JD, 1997, CURR OPIN ORGAN TRAN, V2, P76; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rossini AA, 1996, CELL TRANSPLANT, V5, P49, DOI 10.1016/0963-6897(95)02010-1; Russell ME, 1996, J CLIN INVEST, V97, P833, DOI 10.1172/JCI118483; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tibell A, 1997, TRANSPLANT P, V29, P3124, DOI 10.1016/S0041-1345(97)00809-9; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Vanderhoof JA, 1997, GASTROENTEROLOGY, V113, P1767, DOI 10.1053/gast.1997.v113.pm9352883; Vogel G, 1998, SCIENCE, V281, P1942, DOI 10.1126/science.281.5385.1942; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Zheng XX, 1997, J IMMUNOL, V159, P1169	67	52	56	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1076	1082		10.1001/jama.282.11.1076	http://dx.doi.org/10.1001/jama.282.11.1076			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493208				2022-12-28	WOS:000082512300033
J	Chatal, JF; Hoefnagel, CA				Chatal, JF; Hoefnagel, CA			Radionuclide therapy	LANCET			English	Article							THYROID-CARCINOMA; METASTASES; TUMORS; PAIN; RADIOIMMUNOTHERAPY; RADIOTHERAPY; PALLIATION; ANTIBODY; LYMPHOMA; TRIAL	Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment. In cancer treatment, it often combines the advantage of target selectivity (like brachytherapy or external beam radiotherapy) with that of being systemic, as with chemotherapy, and it may be used as part of a therapeutic strategy with curative intent or for disease control and palliation. Toxicity is generally limited to the haematopoietic tissue and few side-effects are observed. When cure is feasible, the long-term consequences of radionuclide therapy (eg, fertility disorders and leukaemia or other secondary cancers) do compare favourably with the risks associated with and accepted for chemotherapy and radiotherapy.	Ctr Rene Gauducheau, Dept Nucl Med, F-44000 Nantes, France; Netherlands Canc Inst, Dept Nucl Med, Amsterdam, Netherlands	UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Netherlands Cancer Institute	Chatal, JF (corresponding author), Ctr Rene Gauducheau, Dept Nucl Med, F-44000 Nantes, France.							Chatal J. F., 1998, NUCL MED CLIN DIAGNO, P1101; DEKRAKER J, 1995, EUR J CANCER, V31A, P600, DOI 10.1016/0959-8049(95)00063-O; Hnatowich DJ, 1999, J NUCL MED, V40, P693; Hoefnagel CA, 1999, EUR J NUCL MED, V26, P277, DOI 10.1007/s002590050389; HUMM JL, 1990, J NUCL MED, V31, P75; LUI SY, 1998, J CLIN ONCOL, V16, P3270; Maloney DG, 1997, BLOOD, V90, P2188; McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306; Otte A, 1998, LANCET, V351, P417, DOI 10.1016/S0140-6736(05)78355-0; Quirijnen JMSP, 1996, J NUCL MED, V37, P1511; RAOUL JL, 1994, J NUCL MED, V35, P1782; Reubi J C, 1997, Q J Nucl Med, V41, P63; ROBINSON RG, 1995, JAMA-J AM MED ASSOC, V274, P420, DOI 10.1001/jama.274.5.420; Schlumberger M, 1996, J NUCL MED, V37, P598; SCHLUMBERGER M, 1988, J NUCL MED, V29, P1790; Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574; Stolz B, 1998, EUR J NUCL MED, V25, P668, DOI 10.1007/s002590050268; Taal BG, 1996, J CLIN ONCOL, V14, P1829, DOI 10.1200/JCO.1996.14.6.1829; Troncone L, 1991, J NUCL BIOL MED, V35, P177; Wahl RL, 1998, J NUCL MED, V39, p21S; WHELDON TE, 1991, RADIOTHER ONCOL, V21, P91, DOI 10.1016/0167-8140(91)90080-Z	21	71	75	2	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					931	935		10.1016/S0140-6736(99)06002-X	http://dx.doi.org/10.1016/S0140-6736(99)06002-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489968				2022-12-28	WOS:000082511800041
J	Lambert, HP				Lambert, HP			Don't keep taking the tablets?	LANCET			English	Editorial Material							ACUTE MAXILLARY SINUSITIS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; BACTERIAL-MENINGITIS; ANTIBIOTIC-TREATMENT; TRACT INFECTIONS; OTITIS-MEDIA; THERAPY; ADULTS		Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; London Sch Hyg & Trop Med, London WC1, England	St Georges University London; University of London; London School of Hygiene & Tropical Medicine	Lambert, HP (corresponding author), 69 Christ Church Rd, London SW14 7AN, England.							BENNISH ML, 1992, ANN INTERN MED, V117, P727, DOI 10.7326/0003-4819-117-9-727; Bevan V M, 1999, Commun Dis Public Health, V2, P14; Brewis RL, 1995, RESP MED; CAMPBELL H, 1995, ARCH DIS CHILD, V73, P281, DOI 10.1136/adc.73.4.281; Carbon C, 1998, BRIT MED J, V317, P663, DOI 10.1136/bmj.317.7159.663; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; DELMAR C, 1997, BMJ-BRIT MED J, V314, P1516; FISH DN, 1995, PHARMACOTHERAPY, V15, P279; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Gris P, 1996, J ANTIMICROB CHEMOTH, V37, P93, DOI 10.1093/jac/37.suppl_C.93; HAWKEY PM, 1986, J ANTIMICROB CHEMOTH, V18, P133, DOI 10.1093/jac/18.Supplement_C.133; Hirschmann JV, 1998, LANCET, V352, P672, DOI 10.1016/S0140-6736(05)60818-5; KROBER MS, 1985, JAMA-J AM MED ASSOC, V253, P1271, DOI 10.1001/jama.253.9.1271; LEVY SB, 1997, CIBA FDN S, V308; Lewis RF, 1998, LANCET, V352, P823, DOI 10.1016/S0140-6736(05)60723-4; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; NORRBY SR, 1990, REV INFECT DIS, V12, P458; RADETSKY M, 1990, PEDIATR INFECT DIS J, V9, P2, DOI 10.1097/00006454-199001000-00002; SCHAAD UB, 1981, PEDIATRICS, V67, P188; Seaton A, 1989, CROFTON DOUGLASS RES, V4th; SIBELLAS M, 1966, TROP MED HYG, V69, P94; *STAND MED ADV COM, 1998, SUBGR ANT RES PATH L; STOKER DJ, 1962, BMJ-BRIT MED J, P1179, DOI 10.1136/bmj.1.5286.1179; SUTTON DR, 1970, THORAX, V25, P241, DOI 10.1136/thx.25.2.241; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; WALD ER, 1986, PEDIATRICS, V77, P795; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706	29	24	24	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					943	945		10.1016/S0140-6736(99)01139-3	http://dx.doi.org/10.1016/S0140-6736(99)01139-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489971				2022-12-28	WOS:000082511800044
J	McKenzie, R; Conner, B; Bodeker, G				McKenzie, R; Conner, B; Bodeker, G			Increased summertime UV radiation in New Zealand in response to ozone loss	SCIENCE			English	Article							ULTRAVIOLET-RADIATION; IRRADIANCE; SURFACE	Long-term decreases in summertime ozone over Lauder, New Zealand (45 degrees S), are shown to have Led to substantial increases in peak ultraviolet (UV) radiation intensities. In the summer of 1998-99, the peak sunburning UV radiation was about 12 percent more than in the first years of the decade. Larger increases were seen for DNA-damaging UV radiation and plant-damaging UV radiation, whereas UV-A (315 to 400 nanometers) radiation, which is insensitive to ozone, showed no increase, in agreement with model calculations. These results provide strong evidence of human-induced increases in UV radiation, in a region where baseline levels of UV radiation were already relatively high.	Natl Inst Water & Atmospher Res, NIWA Lauder, Cent Otago, New Zealand	National Institute of Water & Atmospheric Research (NIWA) - New Zealand	McKenzie, R (corresponding author), Natl Inst Water & Atmospher Res, NIWA Lauder, PB 50061 Omakau, Cent Otago, New Zealand.			Bodeker, Gregory/0000-0003-1094-5852; McKenzie, Richard Lloyd/0000-0002-4484-7057				ALBRITTON DL, 1998, SCI ASSESSMENT OZONE; BULLIARD JL, 1996, NZ PUBLIC HLTH REP, V3, P73; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; Connor BJ, 1999, GEOPHYS RES LETT, V26, P189, DOI 10.1029/1998GL900250; FORGAN BW, 1997, MISCELLANEOUS SERIES, V49, P51; MADRONICH S, 1995, AMBIO, V24, P143; McKenzie R, 1996, WEATHER CLIM, V16, P17; MCKENZIE RL, 1992, APPL OPTICS, V31, P6501, DOI 10.1364/AO.31.006501; McKenzie RL, 1998, J GEOPHYS RES-ATMOS, V103, P28785, DOI 10.1029/98JD02704; MCKENZIE RL, 1994, OZONE TROPOSPHERE ST, P627; McKinlay AF., 1987, EXCERPTA MED INT C S, V744, P83; Relethford JH, 1998, AM J PHYS ANTHROPOL, V107, P223, DOI 10.1002/(SICI)1096-8644(199810)107:2<223::AID-AJPA9>3.0.CO;2-V; SECKMEYER G, 1992, NATURE, V359, P135, DOI 10.1038/359135a0; SECKMEYER G, 1995, GEOPHYS RES LETT, V22, P1889, DOI 10.1029/95GL01352; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Shindell DT, 1998, NATURE, V392, P589, DOI 10.1038/33385; STAMNES K, 1991, APPL OPTICS, V30, P4418, DOI 10.1364/AO.30.004418; *UN ENV PROGR UNEP, 1998, ENV EFF OZ DEPL 1998; WMO, 1995, SCI ASS OZ DEPL 1994; *WMO, 1994, WMO M EXP UVB MEAS D	20	264	280	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1709	1711		10.1126/science.285.5434.1709	http://dx.doi.org/10.1126/science.285.5434.1709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481002				2022-12-28	WOS:000082472600028
J	Henney, JE				Henney, JE			New type 2 diabetes drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-28	WOS:000082335900005
J	Simoes, EAF				Simoes, EAF			Respiratory syncytial virus infection	LANCET			English	Article							AEROSOLIZED RIBAVIRIN; IMMUNE GLOBULIN; TRACT INFECTION; DOUBLE-BLIND; SEROPOSITIVE CHILDREN; RANDOMIZED TRIAL; VIRAL-INFECTION; INFANTS; BRONCHIOLITIS; DISEASE	Respiratory syncytial virus (RSV), long recognised as the major viral pathogen of the lower respiratory tract of infants, has also been implicated in severe lung disease in adults, especially the elderly. This fact, and the demonstration that passive prophylaxis with either polyclonal or monoclonal antibody to RSV prevents severe lung disease in high-risk infants and children, has led to renewed interest in the immune mechanisms surrounding protection, and the development of vaccines.	Univ Colorado, Sch Med, Dept Pediat, Infect Dis Sect, Denver, CO 80218 USA; Childrens Hosp, Denver, CO 80218 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	Simoes, EAF (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Infect Dis Sect, 1056 E 19th Ave, Denver, CO 80218 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037271] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR0069] Funding Source: Medline; NIAID NIH HHS [AI-37271] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Brandenburg AH, 1997, ARCH DIS CHILD, V77, P410, DOI 10.1136/adc.77.5.410; BREESE JS, 1996, PEDIATR INFECT DIS J, V15, P777; CHANOCK R, 1957, AM J HYG, V66, P281, DOI 10.1093/oxfordjournals.aje.a119901; CHERIAN T, 1990, AM J DIS CHILD, V144, P1026, DOI 10.1001/archpedi.1990.02150330086028; COLLINS PL, 1995, P NATL ACAD SCI USA, V92, P11563, DOI 10.1073/pnas.92.25.11563; Connor E, 1997, PEDIATRICS, V99, P93; CRANAGE MP, 1980, J MED VIROL, V5, P161, DOI 10.1002/jmv.1890050210; Crowe JE, 1996, J INFECT DIS, V173, P829, DOI 10.1093/infdis/173.4.829; De Boeck K, 1997, J PEDIATR-US, V131, P919, DOI 10.1016/S0022-3476(97)70044-1; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Dudas RA, 1998, CLIN MICROBIOL REV, V11, P430, DOI 10.1128/CMR.11.3.430; Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GRAHAM BS, 1995, AM J RESP CRIT CARE, V152, pS63, DOI 10.1164/ajrccm/152.4_Pt_2.S63; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; Groothuis JR, 1998, J INFECT DIS, V177, P467, DOI 10.1086/517377; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; Hammer J, 1997, PEDIATR PULM, V23, P176, DOI 10.1002/(SICI)1099-0496(199703)23:3<176::AID-PPUL2>3.0.CO;2-M; Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; Kellner JD, 1996, ARCH PEDIAT ADOL MED, V150, P1166, DOI 10.1001/archpedi.1996.02170360056009; Kim KK, 1997, J INVEST MED, V45, P469; Kneyber MCJ, 1998, EUR J PEDIATR, V157, P331, DOI 10.1007/s004310050822; Law BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.3.e7; MEERT KL, 1994, CRIT CARE MED, V22, P566, DOI 10.1097/00003246-199404000-00010; MENON K, 1995, J PEDIATR-US, V126, P1004, DOI 10.1016/S0022-3476(95)70234-2; Moler FW, 1996, J PEDIATR-US, V128, P422, DOI 10.1016/S0022-3476(96)70294-9; MORRIS JA, 1956, P SOC EXP BIOL MED, V92, P544, DOI 10.3181/00379727-92-22538; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Piedra PA, 1998, PEDIATR INFECT DIS J, V17, P217, DOI 10.1097/00006454-199803000-00009; PRINGLE CR, 1993, VACCINE, V11, P473, DOI 10.1016/0264-410X(93)90290-E; Randolph AG, 1996, ARCH PEDIAT ADOL MED, V150, P942, DOI 10.1001/archpedi.1996.02170340056011; Rimensberger PC, 1996, PEDIATR INFECT DIS J, V15, P209, DOI 10.1097/00006454-199603000-00007; Rodriguez WJ, 1997, PEDIATRICS, V100, P937, DOI 10.1542/peds.100.6.937; Roosevelt G, 1996, LANCET, V348, P292, DOI 10.1016/S0140-6736(96)02285-4; SANCHEZ I, 1993, J PEDIATR-US, V122, P145, DOI 10.1016/S0022-3476(05)83508-5; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; Simoes EAF, 1998, J PEDIATR-US, V133, P492, DOI 10.1016/S0022-3476(98)70056-3; Simoes EAF, 1996, J PEDIATR-US, V129, P214, DOI 10.1016/S0022-3476(96)70245-7; SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105; TRISTRAM DA, 1993, J INFECT DIS, V167, P191, DOI 10.1093/infdis/167.1.191; UKKONEN P, 1984, J MED VIROL, V13, P131, DOI 10.1002/jmv.1890130204; Walsh EE, 1997, J INFECT DIS, V175, P814, DOI 10.1086/513976; Wang EEL, 1996, J PEDIATR-US, V129, P390, DOI 10.1016/S0022-3476(96)70071-9; Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x; Weber MW, 1998, PEDIATR INFECT DIS J, V17, P224, DOI 10.1097/00006454-199803000-00010; WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393	52	410	435	0	28	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					847	852		10.1016/S0140-6736(99)80040-3	http://dx.doi.org/10.1016/S0140-6736(99)80040-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485741				2022-12-28	WOS:000082400700040
J	Bowers, J; Boursiquot, JM; This, P; Chu, K; Johansson, H; Meredith, C				Bowers, J; Boursiquot, JM; This, P; Chu, K; Johansson, H; Meredith, C			Historical genetics: The parentage of chardonnay, gamay, and other wine grapes of northeastern France	SCIENCE			English	Article							DNA	The origins of the classic European wine grapes (Vitis vinifera) have been the subject of much speculation. In a search for parental relationships, microsatellite Loci were analyzed in more than 300 grape cultivars. Sixteen wine grapes that have Long been grown in northeastern France, including 'Chardonnay', 'Gamay noir', 'Aligote', and 'Melon', have microsatellite genotypes consistent with their being the progeny of a single pair of parents, 'Pinot' and 'Gouais blanc', both of which were widespread in this region in the Middle Ages. Parentage analysis at 32 microsatellite loci provides statistical support for these relationships.	Univ Calif Davis, Dept Viticulture & Enol, Davis, CA 95616 USA; Ecole Natl Super Agron Montpellier, Unite Format & Rech Viticulture, F-34060 Montpellier, France; INRA, Unite Rech Genet & Ameliorat Plantes Viticulture, F-34060 Montpellier, France	University of California System; University of California Davis; Institut Agro; Montpellier SupAgro; INRAE	Meredith, C (corresponding author), Univ Calif Davis, Dept Viticulture & Enol, Davis, CA 95616 USA.		Bowers, John/AAD-7601-2019; Bowers, John/B-9245-2009	Bowers, John/0000-0001-8984-9796; Bowers, John/0000-0001-5693-2796				Bisson J., 1995, Journal International des Sciences de la Vigne et du Vin, V29, P63; BOURSIQUOT JM, UNPUB; Bowers JE, 1999, AM J ENOL VITICULT, V50, P243; Bowers JE, 1996, GENOME, V39, P628, DOI 10.1139/g96-080; Bowers JE, 1997, NAT GENET, V16, P84, DOI 10.1038/ng0597-84; BOWERS JE, 1993, AM J ENOL VITICULT, V44, P266; HAGELBERG E, 1991, NATURE, V352, P427, DOI 10.1038/352427a0; LEVADOUX L., 1956, Annales de l'Amelioration des Plantes, V6, P59; Negrul AM, 1938, CR ACAD SCI URSS, V18, P585; PAREY P, 1887, HDB AMPELOGRAPHIE; Sefc KM, 1999, GENOME, V42, P367, DOI 10.1139/gen-42-3-367; THOMAS M, COMMUNICATION; THOMAS MR, 1993, THEOR APPL GENET, V86, P985, DOI 10.1007/BF00211051; Viala P., 1901, AMPELOGRAPHIE, VI; Weir BS, 1996, GENETIC DATA ANAL, P209	15	282	298	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1562	1565		10.1126/science.285.5433.1562	http://dx.doi.org/10.1126/science.285.5433.1562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477519				2022-12-28	WOS:000082359500064
J	Kleiman, FE; Manley, JL				Kleiman, FE; Manley, JL			Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50	SCIENCE			English	Article							PRE-MESSENGER-RNA; POLYMERASE-II; POLY(A) POLYMERASE; SPECIFICITY FACTOR; IN-VITRO; 3'-END CLEAVAGE; BINDING DOMAIN; GLOBIN GENE; DNA-DAMAGE; BRCA1	Polyadenylation of messenger RNA precursors requires a complex protein machinery that is closely integrated with the even more complex transcriptional apparatus. Here a polyadenylation factor, CstF-50 (cleavage stimulation factor), is shown to interact in vitro and in intact cells with a nuclear protein of previously unknown function, BRCA1-associated RING domain protein (BARD1). The BARD1-CstF-50 interaction inhibits polyadenylation in vitro. BARD1, like CstF-50, also interacts with RNA polymerase II. These results indicate that BARD1-mediated inhibition of polyadenylation may prevent inappropriate RNA processing during transcription, perhaps at sites of DNA repair, and they reveal an unanticipated integration of diverse nuclear events.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jlm2@columbia.edu		Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28983] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beyer K, 1997, J BIOL CHEM, V272, P26769, DOI 10.1074/jbc.272.42.26769; Chen J., COMMUNICATION; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1997, J BIOL CHEM, V272, P29636, DOI 10.1074/jbc.272.47.29636; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KLEIMAN FE, UNPUB; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907	44	139	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1576	1579		10.1126/science.285.5433.1576	http://dx.doi.org/10.1126/science.285.5433.1576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477523				2022-12-28	WOS:000082359500068
J	Cairns, J				Cairns, J			Last days in Arcadia	NATURE			English	Editorial Material											Cairns, J (corresponding author), Hollygrove House, Wilcote OX7 3EA, Charlbury, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					19	19		10.1038/43320	http://dx.doi.org/10.1038/43320			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485696				2022-12-28	WOS:000082374400016
J	Hopker, VH; Shewan, D; Tessier-Lavigne, M; Poo, MM; Holt, C				Hopker, VH; Shewan, D; Tessier-Lavigne, M; Poo, MM; Holt, C			Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1	NATURE			English	Article							FIBRONECTIN RECEPTOR COMPLEX; AXON GUIDANCE; CYCLIC-AMP; CELLS; OUTGROWTH; RETINA; ADULT; DCC	Growing axons are guided by both diffusible and substrate-bound factors(1-3). Growth cones of retinal neurons exhibit chemoattractive turning towards the diffusible factor netrin-1 in vitro(4) and are guided into the optic nerve head (ONH) by localized netrin-1 (ref. 5). Here we report that, in Xenopus, laminin-1 from the extracellular matrix (ECM), converts netrin-mediated attraction into repulsion. A soluble peptide fragment of laminin-1 (YIGSR) mimics this laminin-induced conversion. Low levels of cyclic AMP in growth cones also lead to the conversion of netrin-induced attraction into repulsion(6), and we show that the amount of cAMP decreases in the presence of laminin-1 or YIGSR, suggesting a possible mechanism for laminin's effect. At the netrin-1-rich ONH, where axons turn sharply to leave the eye, laminin-1 is confined to the retinal surface. Repulsion from the region in which laminin and netrin are coexpressed may help to drive axons into the region where only netrin is present, providing a mechanism for their escape from the retinal surface. Consistent with this idea, YIGSR peptides applied to the developing retina cause axons to be misdirected at the ONH. These findings indicate that ECM molecules not only promote axon outgrowth, but also modify the behaviour of growth cones in response to diffusible guidance cues.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Cambridge; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Holt, C (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Holt, Christine Elizabeth/0000-0003-2829-121X				Ardini E, 1997, J BIOL CHEM, V272, P2342; Bates CA, 1996, BRAIN RES, V714, P65, DOI 10.1016/0006-8993(95)01468-3; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; DECURTIS I, 1993, DEVELOPMENT, V118, P377; Deiner MS, 1997, NEURON, V19, P575, DOI 10.1016/S0896-6273(00)80373-6; Hanson MG, 1998, J NEUROSCI, V18, P7361; HARRIS WA, 1985, J NEUROSCI RES, V13, P101, DOI 10.1002/jnr.490130108; HAUZENBERGER D, 1994, J IMMUNOL, V153, P960; HOLT CE, 1989, J NEUROSCI, V9, P3123; LIESI P, 1988, DEV BIOL, V130, P774, DOI 10.1016/0012-1606(88)90366-1; LILIENBAUM A, 1995, MOL CELL NEUROSCI, V6, P139, DOI 10.1006/mcne.1995.1013; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SONG HJ, 1997, NATURE, V389, P413; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; WEEKS BS, 1991, AM J PHYSIOL, V261, pF688, DOI 10.1152/ajprenal.1991.261.4.F688; Wiemelt AP, 1997, J BIOL CHEM, V272, P31489, DOI 10.1074/jbc.272.50.31489	30	393	394	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					69	73		10.1038/43441	http://dx.doi.org/10.1038/43441			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485706				2022-12-28	WOS:000082374400042
J	Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL				Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL			Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy	NATURE			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; DIFFERENTIATION; METABOLISM; MOUSE; FAT	Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a paucity of adipose (fat) tissue which is evident at birth and is accompanied by a severe resistance to insulin, leading to hyperinsulinaemia, hyperglycaemia and enlarged fatty liver(1). We have developed a mouse model that mimics these features of CGL(2): the syndrome occurs in transgenic mice expressing a truncated version of a nuclear protein known as nSREBP-1c (for sterol-regulatory-element-binding protein-1c) under the control of the adipose-specific aP2 enhancer. Adipose tissue from these mice was markedly deficient in messenger RNAs encoding several fat-specific proteins, including leptin(2), a fat-derived hormone that regulates food intake and energy metabolism(3). Here we show that insulin resistance in our lipodystrophic mice can be overcome by a continuous systemic infusion of low doses of recombinant leptin, an effect that is not mimicked by chronic food restriction. Our results support the idea that leptin modulates insulin sensitivity and glucose disposal independently of its effect on food intake, and that leptin deficiency accounts for the insulin resistance found in CGL.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.	mbrowl@mednet.swmed.edu; jgolds@mednet.swmed.edu		Ikemoto, Shinji/0000-0002-2291-2735; Hammer, Robert E./0000-0001-5487-7551				Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Pardini VC, 1998, J CLIN ENDOCR METAB, V83, P503, DOI 10.1210/jc.83.2.503; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	775	812	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1999	401	6748					73	76		10.1038/43448	http://dx.doi.org/10.1038/43448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485707				2022-12-28	WOS:000082374400043
J	Weber-Ban, EU; Reid, BG; Miranker, AD; Horwich, AL				Weber-Ban, EU; Reid, BG; Miranker, AD; Horwich, AL			Global unfolding of a substrate protein by the Hsp100 chaperone ClpA	NATURE			English	Article							REGULATORY SUBUNITS; TAGGING SYSTEM; PROTEASES; BINDING; FAMILY; DEGRADATION	The bacterial protein ClpA, a member of the Hsp100 chaperone family, forms hexameric rings that bind to the free ends of the double-ring serine protease ClpP (refs 1, 2). ClpA directs the ATP-dependent degradation of substrate proteins bearing specific sequences(3-5), much as the 19S ATPase 'cap' of eukaryotic proteasomes functions in the degradation of ubiquitinated proteins(6-8). In isolation, ClpA and its relative ClpX can mediate the disassembly of oligomeric proteinsg(9,10); another similar eukaryotic protein, Hsp104, can dissociate low-order aggregates(11). ClpA has been proposed to destabilize protein structure, allowing passage of proteolysis substrates through a central channel into the ClpP proteolytic cylinder(12-14). Here we test the action of ClpA on a stable monomeric protein, the green fluorescent protein GFP, onto which has been added an Il-amino-acid carboxy-terminal recognition peptide, which is responsible for recruiting truncated proteins to ClpAP for degradation(5,15). Fluorescence studies both with and without a 'trap' version of the chaperonin GroEL, which binds non-native forms of GFP(16), and hydrogen-exchange experiments directly demonstrate that ClpA can unfold stable, native proteins in the presence of ATP.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Horwich, AL (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, 295 Congress Ave, New Haven, CT 06510 USA.			Weber-Ban, Eilika/0000-0002-5773-9274				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	20	353	357	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					90	93		10.1038/43481	http://dx.doi.org/10.1038/43481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485712				2022-12-28	WOS:000082374400048
J	Miller, RS; Dunn, MR; Richter, T				Miller, RS; Dunn, MR; Richter, T			Graduate medical education, 1998-1999 - A closer look	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Despite the ever-present risk of a critical imbalance in the physician workforce total numbers and specialty distribution, no systematic planning mechanism is in place. Furthermore, the length of training for graduate medical education (GME) precludes timely rectification of imbalances. We report GME activities collected in the American Medical Association Annual Survey of Graduate Medical Education Programs for 1998-1999, along with trends during the last 3 to 6 years. These data initially suggest that little has changed during the past several years; however, on closer examination, small but significant changes during the past 2 years may have serious consequences if continued. The total number of resident physicians, which has been constant during the last several years, decreased in 1998 by 760 from the previous year, while the number of programs continues to increase (6.1% since 1993), The number of US medical graduates entering GME programs remained stable during the last 6 years, the number of osteopathic graduates entering GME increased by 55.7%, and the number of international medical graduates (IMGs) entering GME continued to drop (down 13.2% since 1993). More IMGs tend to pursue additional training than do US graduates (in 1997, 32.9% vs 23.6%), Because IMCs are remaining in GME programs for longer periods, the total number of IMGs has not yet reflected significant change. About 62% of IMCs now entering GME training are either US citizens or permanent residents; ethnic minority residents are not decreasing in numbers as some predicted; and for the first time in the past 5 years, the primary care specialties have ceased their persistent growth. Toward the end of GME, the number of residents leaving programs before completion increased by 5.7% during the last 3 years. White some of these changes may be ascribed to reduced GME funding through the Balanced Budget Act of 1997, other factors clearly are at play. To anticipate future changes in the physician workforce, these factors should be identified to permit them to be monitored and modified as needed.	Accreditat Council Grad Med Educ, Operat & Data Anal, Chicago, IL 60610 USA; Amer Med Assoc, Div Grad Med Educ, Chicago, IL USA	American Medical Association	Miller, RS (corresponding author), Accreditat Council Grad Med Educ, Operat & Data Anal, 515 N State St,20th Floor, Chicago, IL 60610 USA.	rmiller@acgme.org						Barzansky B, 1998, JAMA-J AM MED ASSOC, V280, P803, DOI 10.1001/jama.280.9.803; *COUNC GRAD MED ED, 1999, 14 COGME US DEP HLTH; *COUNC GRAD MED ED, 1994, 4 US DEP HLTH HUM SE; Council on Graduate Medical Education, 1998, 10 US DEP HLTH HUM S; Dunn MR, 1996, JAMA-J AM MED ASSOC, V276, P710, DOI 10.1001/jama.276.9.710; Dunn MR, 1997, JAMA-J AM MED ASSOC, V278, P750, DOI 10.1001/jama.278.9.750; Dunn MR, 1998, JAMA-J AM MED ASSOC, V280, P809, DOI 10.1001/jama.280.9.809; MITKA M, 1997, AM MED NEWS     0224, V40, P1	8	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					855	860		10.1001/jama.282.9.855	http://dx.doi.org/10.1001/jama.282.9.855			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478692				2022-12-28	WOS:000082272200011
J	Knoll, AH				Knoll, AH			Paleontology - A new molecular window on early life	SCIENCE			English	Editorial Material							ATMOSPHERIC OXYGEN; EARLY EVOLUTION; PALEOSOLS; GA		Harvard Univ, Bot Museum, Cambridge, MA 02138 USA	Harvard University	Knoll, AH (corresponding author), Harvard Univ, Bot Museum, Cambridge, MA 02138 USA.	aknoll@oeb.harvard.edu						Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; Buick R, 1998, AAPG BULL, V82, P50; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Golubic S, 1995, LETHAIA, V28, P285, DOI 10.1111/j.1502-3931.1995.tb01817.x; Hayes J. M., 1994, EARLY LIFE EARTH, P220; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Ohmoto H, 1996, GEOLOGY, V24, P1135, DOI 10.1130/0091-7613(1996)024<1135:EIPGPF>2.3.CO;2; OURLSSON G, 1987, MICROBIOL, V41, P301; Peters K.E., 1993, BIOMARKER GUIDE; Rasmussen B, 1999, GEOLOGY, V27, P115, DOI 10.1130/0091-7613(1999)027<0115:RSOTAA>2.3.CO;2; Rye R, 1998, AM J SCI, V298, P621, DOI 10.2475/ajs.298.8.621; Schopf JW, 1994, EARLY LIFE EARTH, P193; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	16	54	59	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1025	1026		10.1126/science.285.5430.1025	http://dx.doi.org/10.1126/science.285.5430.1025			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10475845				2022-12-28	WOS:000082033100032
